data_2l8l_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2l8l _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.601 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.1 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.3 mt -99.47 141.8 31.79 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.356 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.66 162.46 17.1 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.758 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 20' ' ' GLU . 41.3 tt0 -64.51 140.77 58.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.443 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.91 -17.72 29.64 Favored Glycine 0 C--N 1.338 0.693 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.5 m -70.63 122.81 20.48 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.419 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.6 mtp180 -82.65 147.99 28.21 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.043 0.449 . . . . 0.0 110.429 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 84.7 mt -133.94 107.67 10.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.26 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -77.97 129.69 35.61 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -101.49 132.02 22.3 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.45 -31.2 9.25 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.857 1.705 . . . . 0.0 112.449 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.2 t -69.99 -53.61 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.049 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -80.19 -39.76 28.59 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.858 0.361 . . . . 0.0 110.24 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.61 74.61 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.8 -168.32 1.43 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 117.363 0.582 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.419 HG21 ' HE ' ' A' ' 7' ' ' ARG . 72.8 m -117.34 119.79 36.2 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.346 0.593 . . . . 0.0 110.397 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 63.9 m170 -109.75 148.07 32.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.089 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -98.87 130.24 45.27 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.6 tp -51.93 -40.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.632 0.253 . . . . 0.0 111.109 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 4' ' ' GLU . 8.6 pt-20 -58.87 -34.57 71.77 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.113 0.482 . . . . 0.0 110.901 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -84.51 -37.49 21.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.432 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 75.4 t -68.09 -41.54 84.39 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.937 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 53.5 t -77.42 -46.33 28.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.2 t0 -55.65 -35.48 65.99 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 120.764 0.316 . . . . 0.0 110.829 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.564 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.77 26.49 14.13 Favored Glycine 0 N--CA 1.46 0.238 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.564 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.2 OUTLIER 15.37 68.77 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.225 0 O-C-N 124.042 0.496 . . . . 0.0 109.71 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 29' ' ' ILE . 83.4 mttt -83.8 114.46 54.05 Favored Pre-proline 0 N--CA 1.45 -0.449 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.87 -175.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -57.16 83.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 CA-C-N 119.78 0.957 . . . . 0.0 111.294 178.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.47 ' N ' ' O ' ' A' ' 27' ' ' LYS . 49.1 pt -119.11 -170.12 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 CA-C-O 121.063 0.459 . . . . 0.0 110.973 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.449 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 67.6 m80 -126.37 161.66 27.34 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.432 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.05 170.56 3.9 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.357 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 97.3 t -88.86 133.68 30.44 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.36 155.64 24.84 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.549 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -127.22 145.71 50.67 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.395 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.73 -176.55 2.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.63 -12.75 61.5 Favored 'General case' 0 CA--C 1.523 -0.092 0 CA-C-O 120.868 0.366 . . . . 0.0 110.686 179.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.491 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 32.3 p30 -76.28 -20.2 57.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.565 179.513 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.491 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 93.95 -8.25 73.34 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.699 ' HG1' ' HE2' ' A' ' 41' ' ' HIS . 33.6 p -82.31 151.09 26.88 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 121.946 0.879 . . . . 0.0 111.783 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.0 mt -100.94 132.21 46.45 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.258 -1.337 . . . . 0.0 111.877 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . 0.699 ' HE2' ' HG1' ' A' ' 39' ' ' THR . 5.7 m80 -137.88 137.39 38.02 Favored 'General case' 0 C--O 1.221 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.375 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.62 143.69 49.7 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.454 -178.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.523 HH21 ' CD ' ' A' ' 125' ' ' GLU . 8.9 mtp85 -149.21 138.61 12.7 Favored Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.991 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -74.85 157.17 43.55 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.239 1.959 . . . . 0.0 112.677 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 99.1 t -96.24 136.67 26.38 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.9 m -123.7 1.39 5.69 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.618 0 CA-C-O 119.202 -0.428 . . . . 0.0 111.856 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.5 p -151.04 144.87 25.13 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 118.987 0.812 . . . . 0.0 109.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.478 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.1 OUTLIER -142.12 123.07 14.47 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.373 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -141.57 145.32 34.93 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -86.88 136.55 32.92 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.442 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -99.14 1.84 45.4 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.806 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.6 -175.44 53.41 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.375 -0.917 . . . . 0.0 111.613 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 70.0 m -95.14 126.66 40.62 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -148.21 168.3 22.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.433 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -73.1 138.36 45.78 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.607 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -139.22 155.11 25.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-O 120.752 0.31 . . . . 0.0 110.181 -179.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 39.0 pt -110.45 153.17 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 110.179 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.28 125.47 7.7 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.5 mt -106.93 112.46 25.44 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 56.8 ttp180 -96.17 123.36 39.77 Favored 'General case' 0 C--O 1.219 -0.521 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.416 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 24.1 mm . . . . . 0 N--CA 1.468 0.427 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 -179.556 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.315 0 CA-C-O 121.543 0.687 . . . . 0.0 109.213 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -132.01 154.67 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.408 -178.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.2 tp -143.69 125.84 15.5 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -105.87 123.52 48.1 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.85 170.77 17.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 6.5 p -78.49 156.7 78.16 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.982 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -59.25 -22.92 67.32 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 121.872 1.715 . . . . 0.0 111.995 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -87.09 -8.9 56.59 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.743 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.775 ' CG ' ' HE2' ' A' ' 138' ' ' HIS . 8.2 t60 -68.7 126.76 30.71 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.72 ' H ' ' CE1' ' A' ' 138' ' ' HIS . 69.0 mttm -86.22 130.88 34.37 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 121.509 0.671 . . . . 0.0 111.418 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -104.66 139.27 26.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.83 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 59.6 tp -77.81 95.96 4.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.955 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.2 p -99.32 178.04 5.01 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.698 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.7 pm0 -64.91 -16.93 63.87 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.556 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 -109.73 26.24 10.88 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.08 -138.38 13.87 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -98.72 132.44 44.09 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.451 -0.374 . . . . 0.0 110.746 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -140.3 132.41 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.266 178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.36 144.81 23.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.902 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.45 -38.24 86.47 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.569 -179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.07 -2.12 6.29 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 120.537 -0.84 . . . . 0.0 111.713 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.67 25.69 11.5 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.95 0.405 . . . . 0.0 110.433 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 77.5 mt -110.18 130.34 55.56 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.608 0.718 . . . . 0.0 111.126 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.522 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.1 mmt180 -130.4 147.53 52.11 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.744 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -45.01 90.35 0.0 OUTLIER 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.888 0.375 . . . . 0.0 110.454 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -13.78 0.33 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -84.48 130.16 34.78 Favored 'General case' 0 C--O 1.225 -0.223 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.43 ' O ' ' OE1' ' A' ' 78' ' ' GLU . 89.1 mtm180 -90.26 136.72 32.88 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 -178.219 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.2 m -125.24 151.52 31.11 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.209 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -84.92 128.59 34.69 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.457 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.3 135.14 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.898 0.38 . . . . 0.0 110.441 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -66.74 133.66 50.62 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.055 0.455 . . . . 0.0 111.344 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -98.54 122.67 42.03 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-N 115.872 -0.603 . . . . 0.0 109.562 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.0 t -75.02 -17.23 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 118.401 0.546 . . . . 0.0 110.649 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.77 -59.25 3.06 Favored 'General case' 0 CA--C 1.522 -0.096 0 C-N-CA 120.197 -0.601 . . . . 0.0 109.964 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.522 ' C ' ' H ' ' A' ' 102' ' ' GLU . 73.6 p -93.88 -11.34 31.31 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 110.435 -0.209 . . . . 0.0 110.435 179.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 72.89 -12.04 4.12 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.522 ' H ' ' C ' ' A' ' 100' ' ' THR . 41.8 mt-10 -88.49 164.57 15.39 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 121.036 0.446 . . . . 0.0 111.24 -177.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.12 142.06 50.77 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.589 -179.459 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.481 ' NH2' ' OG ' ' A' ' 106' ' ' SER . 6.0 ptt85 -136.89 158.76 43.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.611 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.698 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -112.32 135.8 52.56 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.926 -179.746 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' SER . . . . . 0.481 ' OG ' ' NH2' ' A' ' 104' ' ' ARG . 6.7 m -142.55 161.84 37.01 Favored 'General case' 0 C--N 1.344 0.329 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.1 p -94.43 156.48 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 111.33 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.459 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.3 mt -71.1 159.35 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.459 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 43.2 ttm180 -106.57 -46.36 4.02 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.759 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 81.4 tt0 -165.01 143.72 6.55 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 10.7 p -93.95 133.14 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.407 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.3 mm? -101.11 125.4 38.24 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-O 119.674 -0.203 . . . . 0.0 110.977 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.39 165.93 0.1 Allowed 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.225 1.95 . . . . 0.0 112.0 179.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 19.9 p -66.69 151.47 47.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 121.276 0.56 . . . . 0.0 110.776 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -133.06 -142.05 0.21 Allowed 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.678 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.5 mtt85 -156.79 130.93 8.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.285 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.53 169.83 5.03 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.943 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -72.89 148.25 44.56 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.241 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 42.0 p -131.1 143.36 50.6 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -115.65 174.55 5.96 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.753 -179.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -145.28 137.48 25.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.109 -0.95 . . . . 0.0 111.074 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 97.2 mt -130.23 170.8 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.449 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -138.01 106.99 5.98 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.926 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 125' ' ' GLU . 8.5 t -86.04 115.14 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.863 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.523 ' CD ' HH21 ' A' ' 43' ' ' ARG . 81.4 tt0 18.52 -95.65 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.729 0 O-C-N 123.762 0.664 . . . . 0.0 112.327 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -128.03 -33.11 2.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.154 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.439 ' O ' ' N ' ' A' ' 129' ' ' THR . 54.3 mt -78.02 67.93 3.96 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -42.7 97.81 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.229 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 175.14 143.48 0.06 Allowed 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.82 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 3.9 pp -151.47 154.5 36.68 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.415 0.626 . . . . 0.0 111.676 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.7 t -89.76 123.54 42.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.872 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.86 122.87 22.62 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.137 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.489 ' C ' ' H ' ' A' ' 135' ' ' VAL . 13.8 mm-40 55.83 43.54 27.48 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.021 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.51 -15.81 0.8 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.176 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.489 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.7 t -90.53 146.87 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 117.268 0.534 . . . . 0.0 110.456 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.19 115.12 47.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.792 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.416 ' O ' ' C ' ' A' ' 138' ' ' HIS . 21.6 m -147.65 142.19 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.226 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.775 ' HE2' ' CG ' ' A' ' 73' ' ' HIS . 0.3 OUTLIER -37.37 153.48 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.206 0.457 . . . . 0.0 111.681 -179.816 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.9 p30 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.382 179.745 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.62 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 24.5 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -109.34 136.51 48.67 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.845 0.355 . . . . 0.0 110.527 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.04 162.66 21.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.518 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 44.6 tt0 -63.27 143.18 58.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.961 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.83 -20.83 23.96 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.3 m -67.48 123.56 20.74 Favored 'General case' 0 C--N 1.331 -0.218 0 O-C-N 122.768 -0.254 . . . . 0.0 111.244 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.435 ' HE ' HG23 ' A' ' 16' ' ' THR . 72.6 mtp180 -82.72 147.63 28.35 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.781 0.324 . . . . 0.0 110.162 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -134.79 107.3 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.497 179.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -76.95 129.8 36.64 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.474 ' O ' ' N ' ' A' ' 14' ' ' GLY . 50.8 t0 -109.91 110.24 59.06 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-O 119.53 -0.272 . . . . 0.0 110.377 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_exo -51.96 -36.8 65.84 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 121.765 1.643 . . . . 0.0 112.561 178.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.2 t -62.11 -58.25 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.037 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.674 ' HG1' ' H ' ' A' ' 15' ' ' THR . 24.8 p -77.49 -33.93 54.35 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.365 0.602 . . . . 0.0 109.834 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 81.31 6.47 89.27 Favored Glycine 0 N--CA 1.449 -0.465 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.175 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.674 ' H ' ' HG1' ' A' ' 13' ' ' THR . 50.6 m -113.83 159.91 19.3 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 117.719 0.759 . . . . 0.0 109.926 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.435 HG23 ' HE ' ' A' ' 7' ' ' ARG . 13.9 m -80.4 117.05 20.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.17 0.51 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -98.94 139.92 33.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.041 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -95.66 127.47 41.71 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.791 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 3.2 tp -53.98 -40.8 46.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.861 0.362 . . . . 0.0 111.429 -178.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.453 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 8.7 tt0 -58.88 -36.64 74.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.135 0.493 . . . . 0.0 110.729 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -81.5 -36.64 29.0 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.567 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.6 t -66.96 -41.71 87.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.22 -43.56 57.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -58.85 -37.87 77.46 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 121.084 -0.247 . . . . 0.0 111.3 -177.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.87 29.54 10.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.512 ' C ' ' O ' ' A' ' 25' ' ' GLY . 96.3 mtt-85 22.61 56.49 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.088 0 CA-C-O 121.27 0.557 . . . . 0.0 110.266 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.648 ' C ' ' H ' ' A' ' 29' ' ' ILE . 31.1 mmtt -75.41 115.68 47.67 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.917 -177.45 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.558 ' O ' ' O ' ' A' ' 29' ' ' ILE . 32.6 Cg_exo -58.1 12.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.505 2.191 0 C-N-CA 122.001 1.801 . . . . 0.0 112.843 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.648 ' H ' ' C ' ' A' ' 27' ' ' LYS . 2.1 pp -40.23 175.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.713 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.478 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 2.8 m80 -121.71 167.51 12.86 Favored 'General case' 0 N--CA 1.467 0.401 0 O-C-N 122.22 -0.3 . . . . 0.0 110.611 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -148.28 170.08 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.1 t -87.59 137.2 21.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 121.896 -0.502 . . . . 0.0 109.772 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.78 168.03 9.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.138 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.22 140.23 37.69 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.29 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.57 176.02 5.21 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -70.71 -14.07 62.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.803 0.335 . . . . 0.0 110.837 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -79.37 -17.64 54.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.38 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.81 22.1 40.54 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.2 p -101.6 136.64 41.1 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.076 178.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.94 134.1 42.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.848 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -144.4 141.66 29.81 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.781 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.17 141.82 52.57 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.533 -178.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -142.39 140.67 19.31 Favored Pre-proline 0 CA--C 1.542 0.653 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.272 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 157.57 30.53 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.771 2.314 . . . . 0.0 112.52 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -102.96 138.25 27.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.7 m -128.3 4.67 3.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.046 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.431 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 1.2 t -151.91 145.11 24.64 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 119.05 0.841 . . . . 0.0 109.19 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.86 124.66 15.06 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 178.703 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -141.62 146.27 36.02 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -88.68 133.08 34.32 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 176.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.431 ' OE1' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -92.8 -0.23 57.3 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.6 177.44 51.16 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.307 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 39.2 m -89.43 123.85 33.94 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.025 0.44 . . . . 0.0 109.974 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -148.63 173.7 12.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.257 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -77.1 140.86 40.37 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.259 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 m -139.35 154.87 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 30.8 pt -112.05 151.34 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.024 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.88 144.82 15.9 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 27.4 mt -123.33 112.93 18.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.322 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -86.98 107.49 18.42 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.36 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.55 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.8 mp . . . . . 0 N--CA 1.467 0.387 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.936 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.129 0 CA-C-O 120.832 0.349 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.4 ' CG2' ' N ' ' A' ' 67' ' ' LEU . 96.0 mt -125.48 157.29 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.392 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.4 ' N ' ' CG2' ' A' ' 66' ' ' ILE . 49.8 tp -132.74 116.62 16.81 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.064 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.3 m95 -102.8 125.42 49.54 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.76 171.52 17.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.214 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.21 156.9 73.8 Favored Pre-proline 0 CA--C 1.533 0.323 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.586 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.74 -19.98 69.8 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.562 2.175 . . . . 0.0 112.066 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -93.26 -7.04 46.18 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.031 0.444 . . . . 0.0 110.189 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 9.6 t60 -73.42 131.36 41.74 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -88.04 130.63 34.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 110.271 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 76' ' ' LEU . 95.2 t -108.95 90.63 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.847 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' VAL . 49.0 tp -31.21 99.12 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 O-C-N 123.244 0.34 . . . . 0.0 111.707 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.436 ' N ' ' O ' ' A' ' 80' ' ' GLY . 61.4 p -98.22 176.08 5.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -63.37 -19.04 64.31 Favored 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.166 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 -106.86 23.77 13.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.428 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 77' ' ' THR . . . 105.55 -141.47 15.38 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 96.8 m95 -96.11 130.31 43.18 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.732 -0.234 . . . . 0.0 110.766 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -142.35 132.32 24.44 Favored 'General case' 0 C--O 1.232 0.157 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.65 143.8 19.37 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.398 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.426 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -63.52 -37.91 89.13 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.488 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.5 0.09 3.19 Favored Glycine 0 CA--C 1.529 0.965 0 C-N-CA 120.44 -0.886 . . . . 0.0 111.833 -179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 84' ' ' ALA . 97.2 mt-10 -109.19 -2.28 18.11 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.989 0.423 . . . . 0.0 110.426 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 83.7 mt -74.67 129.52 37.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.472 ' O ' ' N ' ' A' ' 90' ' ' GLY . 36.2 mmt180 -133.12 147.99 52.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.435 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -46.37 92.59 0.01 OUTLIER 'General case' 0 C--O 1.233 0.192 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.474 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.85 -20.38 0.78 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -83.63 130.12 34.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.805 0.336 . . . . 0.0 110.694 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.406 ' NH2' ' O ' ' A' ' 105' ' ' TYR . 79.1 mtp85 -91.18 138.66 31.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.518 -179.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 33.2 m -126.36 151.46 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.285 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.14 134.98 52.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.443 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.77 158.45 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.555 179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -104.64 127.95 52.53 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.149 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -100.06 124.51 45.52 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.247 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 12.5 p -75.2 -15.46 15.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.352 0.524 . . . . 0.0 111.087 178.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -69.55 -58.3 4.13 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.224 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.482 ' H ' ' HG1' ' A' ' 100' ' ' THR . 15.6 p -99.18 -12.06 20.79 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.739 -0.21 . . . . 0.0 110.473 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.77 -13.26 8.85 Favored Glycine 0 C--N 1.329 0.187 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.471 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.4 mt-10 -82.05 155.32 25.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.975 0.417 . . . . 0.0 111.222 -177.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.5 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -75.74 139.94 42.13 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.195 179.41 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -139.17 169.61 17.46 Favored 'General case' 0 CA--C 1.51 -0.589 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.406 ' O ' ' NH2' ' A' ' 92' ' ' ARG . 8.2 m-30 -108.1 141.88 39.13 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.197 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.1 m -136.99 159.59 41.42 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 85.0 t -98.32 156.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 29.4 mm -84.66 131.33 34.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.184 178.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.3 mmm180 -82.44 -34.13 28.29 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.765 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -166.21 145.41 5.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -95.38 135.42 29.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.416 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.4 mm? -98.35 123.92 48.73 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 120.626 -0.429 . . . . 0.0 111.149 -179.471 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.5 162.91 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.039 1.826 . . . . 0.0 111.711 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 74.7 p -65.35 152.95 42.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.409 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 41.2 ttt180 -135.18 -139.15 0.17 Allowed 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.691 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.409 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 13.0 tpt180 -157.99 129.77 6.86 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.402 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.39 171.09 4.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.179 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.518 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 88.1 mtm180 -74.68 146.97 41.9 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.62 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 6.6 p -126.22 143.3 51.19 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -115.6 173.1 6.71 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.819 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -152.33 127.02 9.48 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.528 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.3 mt -116.24 171.9 7.53 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.233 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -134.95 107.2 7.21 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.352 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.9 t -91.94 119.86 40.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -60.87 144.42 52.86 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.76 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 69.21 -67.78 0.21 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.662 179.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.36 89.7 4.54 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 116.695 -0.23 . . . . 0.0 110.838 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -62.08 96.83 0.08 Allowed 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER 165.4 155.06 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 178.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 130' ' ' LEU . 2.9 pp -150.94 151.84 32.73 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.307 -0.557 . . . . 0.0 111.544 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 40.0 t -93.14 127.69 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.151 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.49 133.54 42.35 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.006 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 81.1 mm-40 55.29 42.31 30.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.531 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.0 27.47 67.19 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.623 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 23.3 t -130.17 150.75 34.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 118.135 0.968 . . . . 0.0 108.391 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 3.5 t -105.12 111.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-N 118.329 0.513 . . . . 0.0 111.038 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' ' C ' ' A' ' 138' ' ' HIS . 16.9 m -145.88 134.67 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.627 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 51.8 t-80 -34.42 148.06 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.676 0.274 . . . . 0.0 111.649 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.733 ' N ' HD21 ' A' ' 139' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.369 -179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 75.0 mt -96.5 143.63 27.33 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.316 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.3 163.91 16.57 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.701 0.286 . . . . 0.0 110.841 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.433 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 48.3 tt0 -64.78 142.12 58.54 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.523 178.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.66 -22.06 17.67 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.5 m -66.68 121.67 15.92 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.59 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.4 mtt85 -80.57 147.17 30.9 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 6.4 mm -134.77 106.3 7.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.014 0.435 . . . . 0.0 111.212 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -77.82 130.46 36.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -111.68 110.46 54.97 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.713 -0.221 . . . . 0.0 110.547 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.08 -35.58 62.42 Favored 'Trans proline' 0 N--CA 1.497 1.686 0 C-N-CA 122.171 1.914 . . . . 0.0 112.409 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.5 t -61.88 -57.8 10.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.767 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.485 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 43.5 p -79.53 -36.63 38.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.305 0.574 . . . . 0.0 109.905 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.485 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 84.78 6.9 84.87 Favored Glycine 0 N--CA 1.451 -0.362 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.205 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 52.4 m -113.78 157.97 21.58 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 117.769 0.784 . . . . 0.0 109.918 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.6 m -80.47 117.71 21.44 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.121 0.486 . . . . 0.0 110.87 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 18.4 m80 -100.52 143.51 30.62 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.011 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -97.34 128.22 43.97 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.222 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.444 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 8.3 tp -52.9 -40.8 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.252 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.444 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 7.3 tt0 -58.48 -35.96 73.0 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -81.91 -38.05 25.87 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.605 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.8 t -67.45 -42.33 87.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.04 -45.24 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.63 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -57.38 -37.19 72.28 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 120.728 0.299 . . . . 0.0 110.971 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.57 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.38 29.66 9.33 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-O 118.944 -0.92 . . . . 0.0 110.848 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.57 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.7 ptt180 15.15 67.68 0.01 OUTLIER 'General case' 0 C--N 1.363 1.16 0 CA-C-N 117.313 0.557 . . . . 0.0 110.123 179.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.648 ' C ' ' H ' ' A' ' 29' ' ' ILE . 71.3 mttt -86.52 118.01 69.57 Favored Pre-proline 0 N--CA 1.44 -0.965 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.615 ' O ' ' O ' ' A' ' 29' ' ' ILE . 44.2 Cg_exo -53.83 9.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.498 1.762 0 C-N-CA 122.189 1.926 . . . . 0.0 113.383 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.648 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.9 pp -38.01 176.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 123.703 0.627 . . . . 0.0 110.843 -178.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.453 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 4.0 m80 -122.48 166.73 14.31 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 121.837 -0.539 . . . . 0.0 110.795 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.8 m -148.57 171.17 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.27 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.01 135.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.59 166.87 11.1 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.571 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.48 142.4 43.55 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.091 0.472 . . . . 0.0 110.25 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.76 178.67 4.2 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -66.8 -15.53 63.65 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.192 -0.318 . . . . 0.0 110.906 179.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -75.94 -22.0 56.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.685 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.9 -7.01 67.33 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.7 p -77.2 145.12 37.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.187 0.517 . . . . 0.0 111.291 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 64.9 mt -100.4 132.89 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.857 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -141.37 138.96 33.4 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.795 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.06 143.03 52.6 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.673 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NH1' ' OE1' ' A' ' 125' ' ' GLU . 0.9 OUTLIER -142.72 138.34 16.02 Favored Pre-proline 0 CA--C 1.54 0.584 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.187 -179.594 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.67 158.58 31.92 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.916 2.411 . . . . 0.0 112.729 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.4 t -100.73 136.07 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.359 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.95 2.06 3.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.589 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 t -146.33 137.07 24.19 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 118.922 0.783 . . . . 0.0 109.149 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -139.32 124.17 18.64 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -138.23 146.84 43.07 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -179.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 52.7 p-10 -113.14 140.62 47.75 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 122.027 0.918 . . . . 0.0 108.593 176.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 -105.5 0.35 Allowed 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.602 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -165.58 -156.43 9.24 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.332 -1.304 . . . . 0.0 112.918 -176.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -88.51 127.89 35.54 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.983 0.421 . . . . 0.0 111.482 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -145.8 158.65 43.84 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -76.17 140.88 41.93 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.253 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.1 143.72 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.121 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 18.9 pt -96.13 152.36 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.408 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.94 132.66 11.15 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.0 mt -110.76 112.26 24.01 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -85.81 113.24 21.81 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.972 -179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.478 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.467 0.418 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.806 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.265 0 CA-C-O 121.347 0.594 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -130.76 155.96 42.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.671 -179.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.4 tp -142.79 124.0 14.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.851 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -104.52 125.19 50.46 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.9 171.11 18.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.144 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -78.7 155.52 78.26 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-O 120.71 0.291 . . . . 0.0 111.035 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.48 -20.51 70.76 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.675 2.25 . . . . 0.0 112.085 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -89.36 -7.97 54.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.008 0.432 . . . . 0.0 110.178 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.598 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 11.5 t60 -72.66 131.17 42.06 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -87.93 132.04 34.37 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 121.153 0.501 . . . . 0.0 111.142 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.87 140.38 22.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.728 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 53.1 tp -80.99 94.7 6.6 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.776 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.8 p -99.2 178.0 5.04 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -178.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -67.03 -17.88 65.11 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.498 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 79' ' ' TYR . 33.3 t80 -106.25 24.31 12.7 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 120.655 0.264 . . . . 0.0 111.35 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.33 -142.63 15.96 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -92.78 128.85 38.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.85 0.357 . . . . 0.0 110.85 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 82.8 mtp180 -140.91 130.85 24.5 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.903 179.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.73 142.7 22.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.111 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.82 -38.28 87.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.065 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.51 -1.23 4.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.195 -1.002 . . . . 0.0 111.902 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.7 tt0 -107.72 -4.04 18.56 Favored 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 121.446 0.641 . . . . 0.0 110.003 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.2 mt -77.4 128.78 34.84 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.535 0.683 . . . . 0.0 111.259 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.523 ' O ' ' N ' ' A' ' 90' ' ' GLY . 2.3 mmm180 -129.14 147.1 50.96 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.955 -1.02 . . . . 0.0 111.1 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -43.55 91.46 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 121.08 0.467 . . . . 0.0 110.527 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.71 -13.4 0.67 Allowed Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -86.46 130.38 34.52 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.858 0.361 . . . . 0.0 110.32 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -92.7 134.91 34.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.65 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.2 m -120.53 153.54 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.835 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -69.57 125.64 27.31 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.986 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.3 m -124.1 160.43 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.76 178.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -105.2 128.88 53.62 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.784 0.325 . . . . 0.0 110.543 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 104' ' ' ARG . 43.0 t0 -100.11 123.3 44.19 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 178.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.3 p -75.16 -15.41 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 118.47 0.577 . . . . 0.0 111.223 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.7 mm-40 -69.43 -59.13 3.19 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 120.616 -0.434 . . . . 0.0 109.956 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.455 ' C ' ' H ' ' A' ' 102' ' ' GLU . 44.1 p -97.09 -11.54 24.26 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.83 -12.51 8.5 Favored Glycine 0 C--N 1.332 0.355 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.455 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -84.45 159.69 20.72 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.947 0.403 . . . . 0.0 110.892 -177.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -80.31 140.29 36.22 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.865 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.481 ' CZ ' ' OD2' ' A' ' 97' ' ' ASP . 32.5 mtm180 -137.83 168.79 18.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.962 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -109.32 141.17 42.03 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.633 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.4 m -138.03 158.69 43.81 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 65.1 t -92.1 154.3 3.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.554 0.216 . . . . 0.0 110.49 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 79.1 mt -74.15 155.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.03 0.443 . . . . 0.0 110.437 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -101.68 -45.64 5.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.038 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -167.44 149.88 5.95 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 80.6 t -94.1 133.41 35.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.466 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -100.15 148.33 34.73 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.239 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.14 156.12 66.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 122.51 2.14 . . . . 0.0 111.095 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.1 p -63.63 154.74 31.9 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -148.41 144.66 27.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 82.0 mtm-85 -77.38 132.02 38.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.184 0.516 . . . . 0.0 110.612 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -165.34 164.12 19.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.066 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 1.1 tpp85 -74.36 145.21 44.0 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.845 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 22.3 p -129.41 143.78 50.98 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -116.88 175.87 5.38 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.085 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -144.29 129.14 18.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.817 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 97.7 mt -122.24 171.09 9.28 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.619 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -137.94 107.17 6.07 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.623 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.521 ' O ' ' C ' ' A' ' 125' ' ' GLU . 23.7 t -88.03 115.55 28.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.068 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.533 ' OE1' ' NH1' ' A' ' 43' ' ' ARG . 28.1 tt0 15.54 -118.3 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 O-C-N 124.011 0.82 . . . . 0.0 111.212 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -98.64 -27.2 14.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.027 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 81.2 mt -84.99 87.25 7.35 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.448 ' CD2' ' N ' ' A' ' 128' ' ' HIS . 6.5 m170 -60.44 98.05 0.06 Allowed 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 167.44 152.71 0.03 OUTLIER 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.442 ' CD2' ' N ' ' A' ' 130' ' ' LEU . 1.4 pt? -156.04 157.85 36.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.542 0.686 . . . . 0.0 112.095 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.9 p -89.08 125.47 42.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.03 123.31 24.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.665 -179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.473 ' C ' ' H ' ' A' ' 135' ' ' VAL . 77.6 mm-40 56.94 45.3 21.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.2 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.6 -19.67 0.88 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.386 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.473 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.4 t -90.08 152.43 3.34 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.33 0 CA-C-N 117.212 0.506 . . . . 0.0 110.773 -179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.5 t -112.93 117.75 56.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 138' ' ' HIS . 19.1 m -147.28 139.49 18.83 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.601 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.598 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 59.8 t-80 -36.17 157.5 0.01 OUTLIER 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 118.043 0.383 . . . . 0.0 111.93 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.506 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 25.5 p30 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.447 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.645 ' H1 ' ' HG1' ' A' ' 70' ' ' THR . 22.2 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 62.3 mt -110.59 134.82 52.06 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.459 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.14 161.57 25.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.833 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.42 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 49.3 tt0 -63.41 144.54 56.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.125 178.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.53 -16.45 31.63 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 24.7 m -68.44 122.54 18.63 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -95.99 115.67 27.78 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-O 120.858 0.361 . . . . 0.0 110.35 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.4 mt -100.53 113.31 35.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -76.47 136.8 39.39 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 12.0 t0 -104.08 130.81 22.7 Favored Pre-proline 0 CA--C 1.539 0.522 0 N-CA-C 110.28 -0.267 . . . . 0.0 110.28 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.56 -29.57 13.12 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.018 1.812 . . . . 0.0 112.431 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.513 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.9 t -71.18 -55.17 14.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.042 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.442 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 23.1 p -77.33 -33.58 55.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 120.902 0.382 . . . . 0.0 110.236 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.442 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 80.25 11.4 84.34 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.52 -168.68 1.38 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 117.498 0.649 . . . . 0.0 109.858 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.2 m -112.79 115.87 29.19 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.198 0.523 . . . . 0.0 110.24 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.5 m170 -105.64 145.6 30.82 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.061 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -99.47 129.67 45.67 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.982 -0.287 . . . . 0.0 110.315 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -53.5 -38.64 33.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-O 120.885 0.374 . . . . 0.0 111.121 -178.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.42 ' OE1' ' OE2' ' A' ' 4' ' ' GLU . 12.8 pt-20 -60.39 -35.13 75.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.883 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -83.74 -40.22 19.1 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.167 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.4 t -67.53 -42.08 86.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.614 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 53.4 t -74.96 -45.38 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.807 -178.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 62.8 t0 -60.87 -35.52 76.81 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 120.775 0.321 . . . . 0.0 111.088 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.47 26.23 24.26 Favored Glycine 0 C--O 1.229 -0.157 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 81.3 mtt85 17.63 60.95 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.121 0 O-C-N 123.907 0.416 . . . . 0.0 109.892 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.5 mttt -86.26 133.6 40.29 Favored Pre-proline 0 N--CA 1.447 -0.619 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.959 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -75.48 86.06 1.51 Allowed 'Trans proline' 0 C--N 1.313 -1.295 0 C-N-CA 121.499 1.466 . . . . 0.0 110.56 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.419 ' CD1' ' C ' ' A' ' 29' ' ' ILE . 2.4 pp -116.91 -172.81 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 120.778 0.323 . . . . 0.0 110.776 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.407 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 38.2 m80 -128.37 162.57 26.79 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.449 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -146.52 170.5 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.8 t -90.05 134.18 29.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.99 167.43 10.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.71 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.76 142.78 43.01 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.04 0.448 . . . . 0.0 110.521 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.96 176.78 4.89 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.406 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.631 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 73.4 mmtt -71.41 -13.73 61.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.634 0.254 . . . . 0.0 110.531 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.13 -16.1 57.16 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.333 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.43 18.89 56.28 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.8 p -100.44 137.38 38.93 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.759 0.314 . . . . 0.0 111.139 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -93.95 130.43 40.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.683 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -139.05 138.61 37.3 Favored 'General case' 0 C--O 1.223 -0.298 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.743 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.52 142.18 51.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.635 -178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.535 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 11.1 mmp_? -144.06 138.26 14.83 Favored Pre-proline 0 CA--C 1.537 0.458 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.645 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.07 156.5 33.99 Favored 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 122.393 2.062 . . . . 0.0 112.732 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.9 t -98.72 136.26 30.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.502 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 178.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 18.6 m -127.62 3.24 3.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.855 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.7 OUTLIER -151.64 145.33 25.01 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.345 179.089 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.583 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.92 124.23 14.65 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.148 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -139.56 145.66 38.89 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.431 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 49.0 p-10 -90.52 137.36 32.41 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.436 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -96.95 -0.97 46.65 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.479 -179.669 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.24 -178.39 53.49 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.416 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.3 m -85.11 121.99 28.66 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.907 0.384 . . . . 0.0 110.214 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 -145.14 165.48 28.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.551 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -76.94 140.79 40.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.073 179.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.4 m -146.59 154.49 12.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.3 pt -107.62 160.72 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.463 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -115.67 139.71 15.63 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 179.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 67.0 mt -114.23 108.53 17.07 Favored 'General case' 0 C--O 1.219 -0.526 0 CA-C-O 120.801 0.334 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.418 HH11 ' CG2' ' A' ' 66' ' ' ILE . 10.9 tpt180 -78.67 108.28 11.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.449 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.457 ' CD1' ' O ' ' A' ' 59' ' ' LEU . 1.9 mp . . . . . 0 CA--C 1.512 -0.518 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.248 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.441 ' H ' ' CD1' ' A' ' 66' ' ' ILE . 0.0 OUTLIER -129.19 168.75 21.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 120.846 0.355 . . . . 0.0 110.547 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.9 tp -130.79 115.55 16.77 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.621 0.248 . . . . 0.0 110.545 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.2 m95 -101.64 105.36 16.28 Favored 'General case' 0 N--CA 1.463 0.209 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 178.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.44 171.22 14.81 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.144 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.645 ' HG1' ' H1 ' ' A' ' 1' ' ' CYS . 0.6 OUTLIER -76.99 157.66 81.19 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.571 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 85' ' ' GLY . 33.8 Cg_endo -62.46 -17.07 55.97 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.603 2.202 . . . . 0.0 111.869 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 23.6 p30 -98.07 -5.64 33.41 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.861 0.362 . . . . 0.0 110.527 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.555 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 9.0 t60 -72.56 131.98 43.19 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -86.01 123.2 31.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.273 0.559 . . . . 0.0 111.082 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' LEU . 91.4 t -102.4 91.4 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.366 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' VAL . 35.2 tp -32.22 95.84 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.366 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.478 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -99.75 173.62 6.61 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -177.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -63.37 -20.0 65.15 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.042 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.413 ' CD2' ' NH2' ' A' ' 82' ' ' ARG . 63.9 m-85 -104.94 22.79 14.62 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.847 -0.16 . . . . 0.0 111.046 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.69 -144.64 16.16 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.631 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 89.2 m95 -90.75 124.74 35.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.509 0.195 . . . . 0.0 111.157 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.413 ' NH2' ' CD2' ' A' ' 79' ' ' TYR . 88.7 mtt180 -130.23 130.03 44.1 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.13 141.91 54.52 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -72.34 2.0 6.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.485 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -83.67 -14.52 73.0 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -129.37 19.23 5.82 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 122.829 -0.218 . . . . 0.0 111.44 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 28.3 mt -82.41 136.23 34.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.308 0.575 . . . . 0.0 110.797 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 58.0 mmt-85 -132.79 148.84 52.32 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.709 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -45.41 103.0 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.593 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.41 -15.59 1.11 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -82.31 130.28 35.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.791 0.329 . . . . 0.0 110.913 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -91.32 129.17 37.35 Favored 'General case' 0 C--O 1.224 -0.264 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.686 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.4 m -109.52 143.37 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.986 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.63 125.79 25.44 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.579 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.02 155.47 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.72 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.2 ttt85 -102.54 130.27 49.33 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.607 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -100.34 123.03 44.06 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.17 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.76 -16.65 16.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 118.056 0.389 . . . . 0.0 110.906 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -70.46 -58.87 3.24 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.09 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.47 ' C ' ' H ' ' A' ' 102' ' ' GLU . 30.0 p -96.48 -13.62 22.94 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.539 0.209 . . . . 0.0 110.62 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.33 -14.43 8.7 Favored Glycine 0 C--N 1.331 0.303 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.47 ' H ' ' C ' ' A' ' 100' ' ' THR . 76.7 mt-10 -79.44 153.09 29.91 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.906 0.384 . . . . 0.0 111.185 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -81.08 139.33 35.74 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.764 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -138.51 174.27 10.72 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.968 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.478 ' OH ' ' C ' ' A' ' 77' ' ' THR . 2.4 m-85 -113.01 149.67 33.0 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.182 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.6 m -143.25 164.55 29.89 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.0 m -97.08 155.06 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.695 0.225 . . . . 0.0 110.8 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 95.7 mt -86.99 121.75 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.211 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 67.2 mtp180 -68.55 -33.9 74.9 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -168.24 150.45 5.32 Favored 'General case' 0 N--CA 1.456 -0.163 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.8 t -97.15 136.38 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.443 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.2 mm? -96.22 122.38 58.06 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.082 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.64 166.0 0.16 Allowed 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.266 1.977 . . . . 0.0 111.607 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 4.5 p -66.93 151.32 47.83 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.166 0.508 . . . . 0.0 110.949 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.5 mtp85 -134.89 -143.28 0.2 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.81 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 36.4 mtm-85 -154.01 131.1 11.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.848 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.58 171.98 3.18 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.26 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 81.3 mtp180 -74.42 145.09 43.98 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.954 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.1 p -123.14 142.47 50.86 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.659 -0.496 . . . . 0.0 109.659 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -113.62 171.98 7.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.66 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -151.85 125.8 9.13 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.896 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -114.6 170.16 8.52 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.207 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.4 tp10 -137.61 105.28 5.57 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.33 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.61 118.62 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -61.85 146.04 50.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.523 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 69.24 -69.9 0.15 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.288 178.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 90.5 mt -100.44 95.8 6.98 Favored 'General case' 0 CA--C 1.514 -0.424 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.535 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 4.8 p80 -65.83 99.73 0.5 Allowed 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 166.6 145.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.435 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 2.5 pp -145.62 154.05 41.7 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.437 0.637 . . . . 0.0 111.619 -179.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 68.7 t -89.92 125.69 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.738 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.73 135.35 43.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.249 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.2 mm-40 49.73 45.59 24.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.123 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.14 22.51 55.72 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.916 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.99 152.07 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.8 t -105.25 110.84 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 O-C-N 122.065 -0.397 . . . . 0.0 110.536 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 138' ' ' HIS . 13.4 m -146.99 138.52 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.555 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 56.2 t-80 -33.93 153.73 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.752 0.311 . . . . 0.0 111.793 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.287 -179.571 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.554 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 30.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 89.0 mt -107.11 134.55 50.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.912 0.387 . . . . 0.0 110.406 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.32 163.61 23.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.089 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -64.14 139.69 58.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.615 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.17 -18.66 25.67 Favored Glycine 0 C--N 1.334 0.454 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.6 m -69.78 123.93 22.69 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -97.85 116.64 30.46 Favored 'General case' 0 C--O 1.231 0.088 0 CA-C-O 120.982 0.42 . . . . 0.0 110.7 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.0 mt -101.53 115.23 42.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.756 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -76.57 135.9 39.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 5.0 t70 -104.15 132.42 21.01 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 110.571 -0.159 . . . . 0.0 110.571 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.23 -31.84 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 121.838 1.692 . . . . 0.0 112.462 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 74.9 t -69.89 -55.25 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.047 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.6 p -77.54 -35.6 53.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.973 0.415 . . . . 0.0 110.182 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 10.45 85.46 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 88.2 m -114.09 157.51 22.47 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 117.276 0.538 . . . . 0.0 110.09 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.2 m -78.97 116.13 19.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.555 0.693 . . . . 0.0 110.897 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . 0.459 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 61.8 m-70 -104.89 144.87 31.19 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.848 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -98.75 128.32 44.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.304 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.1 tp -52.8 -38.83 29.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 CA-C-O 120.704 0.287 . . . . 0.0 111.012 -178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.03 -32.62 66.36 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.295 0.569 . . . . 0.0 110.806 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -83.57 -37.87 22.41 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.033 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.75 -42.4 86.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 87.5 t -73.08 -46.9 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 65.2 t0 -57.67 -36.0 71.32 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.836 0.351 . . . . 0.0 110.831 -178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -108.31 29.12 10.46 Favored Glycine 0 C--O 1.228 -0.254 0 CA-C-O 118.829 -0.984 . . . . 0.0 111.147 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.1 ptm180 13.08 67.91 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.488 0.644 . . . . 0.0 110.836 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.446 ' C ' ' H ' ' A' ' 29' ' ' ILE . 82.7 mttt -87.56 144.62 35.74 Favored Pre-proline 0 N--CA 1.45 -0.431 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.31 -177.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.587 ' O ' ' O ' ' A' ' 29' ' ' ILE . 57.4 Cg_endo -70.87 8.22 1.08 Allowed 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 122.057 1.838 . . . . 0.0 111.744 179.292 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.587 ' O ' ' O ' ' A' ' 28' ' ' PRO . 15.1 tt -37.1 172.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.847 -178.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.585 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 9.5 m80 -124.83 162.97 23.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.7 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 34.7 m -146.2 169.87 5.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.2 t -87.3 134.13 28.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.455 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.36 166.17 10.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.704 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.87 141.6 40.71 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.184 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.36 178.19 4.37 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -72.82 -12.78 61.12 Favored 'General case' 0 C--O 1.233 0.186 0 O-C-N 122.248 -0.283 . . . . 0.0 110.676 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -78.59 -17.71 55.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.366 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.92 18.59 55.85 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.1 p -100.01 137.29 38.66 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.983 0.42 . . . . 0.0 111.001 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.7 mt -94.34 131.05 40.37 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.714 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 4.9 t-80 -139.55 138.99 36.74 Favored 'General case' 0 C--O 1.221 -0.425 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.791 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.56 142.59 51.76 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -145.64 137.46 13.11 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.869 -179.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_endo -75.79 157.65 39.36 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.644 2.229 . . . . 0.0 112.401 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.6 t -90.91 127.44 43.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.8 -4.8 11.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.782 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.41 ' HG ' ' H ' ' A' ' 123' ' ' GLU . 5.0 p -151.79 143.08 23.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 O-C-N 121.756 -0.59 . . . . 0.0 109.445 178.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -137.6 117.28 13.06 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.189 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -144.8 146.29 32.05 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 45.7 p-10 -90.61 138.41 31.59 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.746 ' OE1' ' O ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -103.74 7.04 37.21 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.771 -179.826 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.746 ' O ' ' OE1' ' A' ' 51' ' ' GLN . . . 92.02 -175.65 38.43 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-O 121.552 0.529 . . . . 0.0 112.802 177.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.3 m -100.84 131.73 46.58 Favored 'General case' 0 N--CA 1.468 0.457 0 O-C-N 121.296 -1.12 . . . . 0.0 108.981 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 80.5 mtp180 -148.32 172.94 13.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.32 0.581 . . . . 0.0 110.382 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -75.54 140.34 42.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.622 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.6 m -140.92 158.13 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.6 pt -112.7 151.56 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 CA-C-O 120.848 0.356 . . . . 0.0 110.809 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.86 132.17 10.99 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.7 mt -111.84 106.27 14.96 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.259 0.552 . . . . 0.0 109.781 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -86.16 117.37 24.94 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.278 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.4 mm . . . . . 0 N--CA 1.47 0.556 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.461 -179.549 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.377 0 CA-C-O 121.396 0.617 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 8.9 tp -123.36 144.03 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.892 -178.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 36.5 tp -136.74 118.97 15.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.862 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.05 127.66 50.23 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.36 170.27 20.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.886 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.87 155.9 82.76 Favored Pre-proline 0 CA--C 1.536 0.439 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.767 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 -18.92 64.18 Favored 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.68 2.254 . . . . 0.0 111.989 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -95.46 -5.0 44.0 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.025 0.441 . . . . 0.0 110.022 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.561 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -69.8 130.13 41.45 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.215 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -86.31 128.66 34.95 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.459 0.647 . . . . 0.0 111.446 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.56 144.44 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.185 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.409 ' CD1' ' C ' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -82.55 94.47 7.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.512 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 17.0 p -100.82 175.89 5.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.83 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.654 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 0.7 OUTLIER -60.41 -21.06 61.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.524 -179.32 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.98 24.25 13.1 Favored 'General case' 0 CA--C 1.516 -0.33 0 C-N-CA 121.303 -0.159 . . . . 0.0 111.095 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.62 -169.39 34.08 Favored Glycine 0 CA--C 1.523 0.583 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.509 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -60.84 123.78 18.55 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.925 -0.638 . . . . 0.0 110.775 -178.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -140.01 134.15 31.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.028 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.81 139.24 40.42 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.04 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.46 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -63.21 -37.29 86.66 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.28 1.87 1.85 Allowed Glycine 0 C--N 1.336 0.573 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.015 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.46 ' H ' ' C ' ' A' ' 84' ' ' ALA . 75.8 mt-10 -110.01 3.4 20.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.272 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.68 133.76 34.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.334 0.588 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.533 ' O ' ' N ' ' A' ' 90' ' ' GLY . 10.2 tpt180 -127.88 148.66 50.48 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.599 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -49.72 86.76 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.232 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 159.27 -18.37 0.26 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -77.94 134.75 37.81 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 88.8 mtm180 -92.36 139.59 30.45 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.927 -178.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.52 154.2 39.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.285 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -83.52 133.87 34.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.904 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.9 m -129.0 165.46 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.224 179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.54 128.62 44.43 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.816 0.341 . . . . 0.0 111.0 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -99.64 122.64 42.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.982 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.6 p -75.33 -16.43 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 CA-C-N 118.425 0.557 . . . . 0.0 110.69 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -69.15 -58.59 3.86 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 120.524 -0.471 . . . . 0.0 109.877 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 102' ' ' GLU . 72.5 p -95.99 -10.78 27.75 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.98 -12.34 6.61 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.496 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.0 mt-10 -89.13 161.23 16.61 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.269 0.557 . . . . 0.0 111.605 -177.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.485 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -74.56 139.26 43.61 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.052 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 37.6 ptt180 -130.98 158.05 41.31 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.654 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -104.15 135.98 44.62 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 42.8 m -144.07 166.19 25.68 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 94.1 t -94.84 154.44 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 110.417 -0.216 . . . . 0.0 110.417 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.471 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.9 mt -67.42 160.2 4.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.471 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 74.3 ttt180 -105.64 -48.91 3.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.648 179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -164.82 142.36 6.3 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.3 t -94.37 134.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.8 mm? -101.8 147.16 33.48 Favored Pre-proline 0 CA--C 1.538 0.501 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.855 -179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.17 165.27 30.87 Favored 'Trans proline' 0 N--CA 1.499 1.805 0 C-N-CA 122.967 2.445 . . . . 0.0 110.938 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -69.38 157.1 37.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.794 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 30.9 ttp180 -141.92 -141.75 0.13 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.377 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.3 mtm-85 -151.89 135.23 15.99 Favored 'General case' 0 C--N 1.33 -0.243 0 O-C-N 123.471 0.482 . . . . 0.0 110.272 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 169.45 4.56 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.141 0.496 . . . . 0.0 110.952 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 18.5 tpp180 -74.59 146.46 42.5 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.592 ' OG1' ' NE2' ' A' ' 51' ' ' GLN . 0.6 OUTLIER -136.47 154.14 50.84 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -131.53 -178.53 4.9 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.677 -175.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -153.74 121.56 5.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.192 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.13 127.9 54.59 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.783 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.41 ' H ' ' HG ' ' A' ' 47' ' ' SER . 80.4 tt0 -88.52 108.18 19.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.815 0.341 . . . . 0.0 110.36 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' A' ' 126' ' ' GLU . 18.1 t -80.6 111.84 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.993 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 124' ' ' VAL . 2.8 tm-20 25.1 -87.63 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.498 ' N ' ' O ' ' A' ' 124' ' ' VAL . 44.2 tp10 -139.25 -27.86 0.79 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.545 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.499 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.1 mt -80.58 66.0 5.93 Favored 'General case' 0 CA--C 1.506 -0.732 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 127' ' ' LEU . 48.3 m170 -38.9 94.96 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.423 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 172.07 141.05 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.612 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.439 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 2.8 pp -147.56 154.79 41.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.46 0.648 . . . . 0.0 111.858 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 72.7 t -91.01 126.38 43.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.77 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.91 134.09 42.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.0 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 50.68 45.06 27.41 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.933 179.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.36 24.72 59.49 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.162 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 20.7 t -129.69 152.47 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -106.49 111.31 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 118.203 0.456 . . . . 0.0 110.75 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' A' ' 138' ' ' HIS . 5.9 m -146.54 140.52 20.54 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.561 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 11.1 t60 -31.35 152.86 0.0 OUTLIER 'General case' 0 C--O 1.226 -0.149 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 17.9 p30 . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.429 -179.406 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.51 ' HG ' ' HG1' ' A' ' 70' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.4 mt -117.04 132.13 56.77 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.887 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.93 161.95 26.34 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -63.8 147.1 52.63 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.968 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.31 -15.18 39.3 Favored Glycine 0 C--N 1.336 0.581 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 m -67.13 121.59 15.96 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 80.9 mtm-85 -97.39 116.66 30.02 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 120.764 0.316 . . . . 0.0 110.272 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.416 HD11 HG23 ' A' ' 8' ' ' ILE . 9.0 mt -103.68 116.03 46.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.761 -179.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -76.13 136.04 39.82 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 11.9 t0 -103.19 130.41 23.68 Favored Pre-proline 0 CA--C 1.54 0.56 0 C-N-CA 121.187 -0.205 . . . . 0.0 110.52 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.05 -30.54 10.68 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.356 2.037 . . . . 0.0 112.196 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.544 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 57.8 t -72.05 -55.1 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.767 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 m -77.4 -39.98 45.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.175 0.512 . . . . 0.0 110.36 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 10.61 80.83 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.299 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.1 m -112.91 154.87 25.68 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-N 117.612 0.706 . . . . 0.0 109.636 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.8 m -79.05 117.15 19.83 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.265 0.555 . . . . 0.0 110.827 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -106.93 148.55 28.48 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.43 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -100.37 127.54 46.66 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.657 178.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tt -54.09 -38.01 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 CA-C-O 120.923 0.392 . . . . 0.0 111.523 -179.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.03 -33.12 71.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.078 0.466 . . . . 0.0 110.984 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -83.79 -38.2 21.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.713 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.7 -41.26 85.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.245 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.99 -45.62 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -58.1 -34.85 70.64 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 120.696 0.284 . . . . 0.0 110.619 -178.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.76 27.34 11.26 Favored Glycine 0 C--O 1.226 -0.363 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.9 ptt-85 15.01 68.06 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.129 0.49 . . . . 0.0 109.82 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -89.8 135.27 30.69 Favored Pre-proline 0 N--CA 1.446 -0.655 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.984 -176.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.9 85.14 1.54 Allowed 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.848 1.699 . . . . 0.0 110.427 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 16.4 pt -111.92 -171.44 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 110.963 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.423 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 65.7 m80 -130.44 159.62 36.49 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.454 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.55 170.49 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.5 t -86.61 131.52 34.56 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.6 146.66 37.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.396 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.02 143.45 45.73 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.938 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.79 176.71 4.94 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.468 ' CB ' ' HZ2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -69.87 -14.43 62.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.772 0.32 . . . . 0.0 110.749 179.523 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 56.0 t0 -80.44 -18.34 49.08 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.177 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.8 21.23 43.86 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 22.3 p -101.62 137.38 40.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.116 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.6 mt -91.35 126.68 36.51 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.745 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -136.76 136.71 39.14 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.579 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.548 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.51 142.02 51.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.487 -178.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.554 HH11 ' CD ' ' A' ' 125' ' ' GLU . 4.2 mmp_? -143.87 137.11 13.98 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.672 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.89 156.47 34.72 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 122.769 2.313 . . . . 0.0 112.962 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -96.64 134.93 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.37 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.34 -0.46 4.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.768 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.7 t -146.65 136.32 23.1 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 118.535 0.607 . . . . 0.0 109.513 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.56 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.62 118.42 15.12 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.291 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -140.74 147.13 38.67 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -96.93 134.04 40.79 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 176.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.571 HE21 ' C ' ' A' ' 119' ' ' THR . 2.2 mt-30 -96.64 3.77 52.32 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.315 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.29 -178.0 49.1 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.724 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -87.67 124.97 34.1 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-O 120.836 0.351 . . . . 0.0 110.17 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 48.2 mmt-85 -143.35 165.04 28.61 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.727 -179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -76.05 142.45 41.79 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.784 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.57 149.8 16.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 84' ' ' ALA . 46.7 pt -98.87 149.44 5.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.577 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.32 125.8 8.41 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 78.0 mt -108.58 113.37 26.32 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.201 0.524 . . . . 0.0 110.199 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.435 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 53.4 ttp180 -87.46 115.45 24.89 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.481 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.6 mm . . . . . 0 N--CA 1.467 0.411 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.441 -179.66 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 -0.204 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.9 tt -118.91 143.65 29.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.11 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.7 tt -118.49 115.38 24.49 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.363 -179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -102.68 125.51 49.44 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.78 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.02 170.97 19.12 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.879 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.51 ' HG1' ' HG ' ' A' ' 1' ' ' CYS . 0.6 OUTLIER -83.53 157.06 65.1 Favored Pre-proline 0 CA--C 1.535 0.372 0 C-N-CA 120.739 -0.385 . . . . 0.0 110.551 179.695 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 85' ' ' GLY . 38.3 Cg_endo -66.24 -18.7 56.17 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.549 2.166 . . . . 0.0 111.985 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -95.39 -6.29 41.32 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.368 . . . . 0.0 110.395 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.543 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 41.4 t60 -72.01 132.2 43.96 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -85.12 123.76 31.0 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.381 0.61 . . . . 0.0 111.629 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.83 140.92 16.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.061 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 47.9 tp -81.4 92.33 6.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.076 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.471 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 39.3 p -98.86 173.15 7.0 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 92' ' ' ARG . 17.3 pt-20 -64.49 -17.05 63.5 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.291 -179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -105.95 24.85 11.7 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.691 0.281 . . . . 0.0 110.787 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.03 -143.5 16.64 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 79.5 m95 -89.1 123.29 33.24 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.729 0.3 . . . . 0.0 111.14 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -122.88 126.06 46.57 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.026 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.45 132.0 46.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.784 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.417 ' O ' ' CD1' ' A' ' 57' ' ' ILE . . . -69.36 -1.07 7.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.029 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -76.37 -12.93 83.85 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -134.76 27.76 3.61 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.3 mt -83.03 133.25 35.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.373 0.606 . . . . 0.0 111.02 179.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -133.38 148.02 51.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.615 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.444 ' HZ2' ' CB ' ' A' ' 89' ' ' LYS . 7.3 ttpm? -47.59 106.59 0.09 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.551 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 147.12 -17.89 1.55 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -82.7 132.94 35.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.643 0.258 . . . . 0.0 110.695 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 85.2 mtm180 -90.04 130.21 36.25 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.364 -0.535 . . . . 0.0 110.302 -179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.9 m -113.49 144.77 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.66 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.15 124.72 26.88 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.708 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.6 m -121.66 165.02 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.146 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.1 tpt180 -101.64 128.91 47.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.61 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.433 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 34.8 t0 -101.13 124.03 46.21 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.534 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.1 t -74.37 -16.2 16.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 118.29 0.495 . . . . 0.0 111.065 178.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -70.3 -59.29 2.96 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.405 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.463 ' C ' ' H ' ' A' ' 102' ' ' GLU . 19.5 p -98.84 -13.93 19.88 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.627 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.38 -14.26 6.92 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.463 ' H ' ' C ' ' A' ' 100' ' ' THR . 46.0 mt-10 -82.09 157.46 24.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 111.175 -177.22 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 7.8 mp -77.22 134.86 38.5 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-O 121.228 0.537 . . . . 0.0 110.153 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.433 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 38.9 ptt180 -132.62 165.4 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.592 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.471 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.1 m-85 -112.04 148.55 33.61 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.048 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 65.1 m -145.15 165.84 27.14 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 57.7 t -91.81 152.31 3.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.62 0.248 . . . . 0.0 110.69 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.477 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 71.9 mt -70.49 162.26 4.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.304 178.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.477 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 37.4 mtp85 -106.04 -48.47 3.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.817 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.435 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 85.3 tt0 -167.53 149.14 5.62 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.963 -0.461 . . . . 0.0 109.853 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.16 134.35 34.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -102.59 151.22 38.22 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.168 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.22 159.85 50.26 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.664 2.243 . . . . 0.0 111.301 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -65.75 154.19 39.69 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 120.886 -0.326 . . . . 0.0 110.431 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -149.8 153.36 36.67 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.804 0.811 . . . . 0.0 110.307 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.0 mmm180 -82.55 132.42 35.2 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.634 -179.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.81 167.63 12.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.973 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.1 ttm180 -80.53 145.12 31.98 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.708 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.571 ' C ' HE21 ' A' ' 51' ' ' GLN . 41.9 p -125.95 145.01 50.46 Favored 'General case' 0 CA--C 1.521 -0.142 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.558 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 59.6 m-85 -120.5 175.09 6.16 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.42 -178.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -151.77 123.84 8.14 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 89.8 mt -122.46 124.59 43.95 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.629 0.252 . . . . 0.0 110.508 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tp10 -89.25 109.56 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.989 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.504 ' O ' ' C ' ' A' ' 125' ' ' GLU . 18.6 t -83.6 115.78 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.918 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.554 ' CD ' HH11 ' A' ' 43' ' ' ARG . 43.7 tt0 20.7 -92.01 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.519 0 O-C-N 123.733 0.645 . . . . 0.0 111.749 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.4 ' N ' ' O ' ' A' ' 124' ' ' VAL . 40.8 tp10 -133.22 -32.46 1.19 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.882 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.508 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.8 mt -74.03 63.04 0.92 Allowed 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.315 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' O ' ' A' ' 127' ' ' LEU . 30.8 m170 -38.48 95.04 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.508 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.33 140.84 0.02 OUTLIER 'General case' 0 C--O 1.233 0.191 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.1 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.42 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.6 pp -149.29 156.89 42.81 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.321 0.582 . . . . 0.0 111.796 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.9 121.44 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 135' ' ' VAL . . . -133.5 145.77 50.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.558 -178.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.534 ' C ' ' H ' ' A' ' 135' ' ' VAL . 40.0 mt-10 40.8 46.5 2.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.155 179.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.32 -22.24 0.29 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.658 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.534 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.4 t -90.91 152.01 3.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 C-N-CA 122.596 0.358 . . . . 0.0 110.701 179.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.3 t -108.8 115.84 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 120.757 0.313 . . . . 0.0 110.416 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 33.5 m -149.94 144.18 17.62 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.057 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.543 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 52.2 t-80 -30.01 149.95 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 179.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.429 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 22.2 p30 . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.415 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.542 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 16.0 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.9 mt -108.25 135.31 49.79 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.599 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.85 163.22 23.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.732 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 65.2 tt0 -63.19 141.5 58.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.053 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.19 -19.73 31.74 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.3 m -67.68 124.55 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.261 0.077 . . . . 0.0 111.169 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -85.32 150.1 25.0 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.992 0.425 . . . . 0.0 109.989 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 12.9 mt -134.47 108.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.191 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -76.01 125.83 29.86 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 178.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.9 129.85 25.66 Favored Pre-proline 0 CA--C 1.536 0.429 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.12 -30.12 16.62 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.703 1.602 . . . . 0.0 112.433 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 72.2 t -73.73 -55.18 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 32.4 m -74.7 -40.34 61.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.472 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.32 6.64 83.85 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 85.3 m -116.92 162.0 18.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.512 0.656 . . . . 0.0 109.794 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -81.02 116.15 20.83 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.609 0.719 . . . . 0.0 111.301 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 13.4 m80 -97.32 138.6 34.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.22 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -95.64 126.67 41.07 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.695 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 3.9 tp -53.07 -40.44 37.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 111.388 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.45 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 6.0 pt-20 -57.12 -36.59 70.86 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.371 0.605 . . . . 0.0 110.968 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.2 t0 -81.85 -36.89 27.77 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.63 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.2 t -67.38 -42.24 87.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.252 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 91.5 t -72.2 -46.52 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -55.04 -37.9 67.28 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 120.96 0.41 . . . . 0.0 110.472 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.579 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -111.99 33.32 5.8 Favored Glycine 0 CA--C 1.52 0.374 0 CA-C-O 118.688 -1.062 . . . . 0.0 110.873 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.579 ' C ' ' O ' ' A' ' 25' ' ' GLY . 26.2 ptt180 8.97 74.63 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 117.576 0.688 . . . . 0.0 110.588 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.457 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.4 mttt -89.04 142.03 29.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.944 -177.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.514 ' O ' ' O ' ' A' ' 29' ' ' ILE . 58.4 Cg_endo -70.87 11.22 0.53 Allowed 'Trans proline' 0 N--CA 1.491 1.338 0 C-N-CA 121.832 1.688 . . . . 0.0 111.534 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.514 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.3 pp -39.78 171.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.237 -177.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.427 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 4.2 m80 -120.99 166.08 14.35 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.425 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.9 m -148.12 170.01 3.23 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 99.5 t -85.75 137.64 20.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.59 165.47 11.51 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.46 138.66 41.67 Favored 'General case' 0 N--CA 1.462 0.161 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.21 178.0 4.43 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.13 -14.9 61.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.883 0.373 . . . . 0.0 110.885 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -77.93 -18.32 56.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.331 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.38 24.97 34.76 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.7 p -102.87 136.4 42.77 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.649 0.262 . . . . 0.0 110.808 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.97 130.84 44.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.954 0.407 . . . . 0.0 110.532 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -141.64 140.05 33.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.734 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -68.9 142.97 54.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.4 mmp_? -146.24 137.57 12.9 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.428 -179.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -74.6 158.32 43.78 Favored 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.611 2.208 . . . . 0.0 112.695 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.2 t -100.03 136.53 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 177.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.1 m -127.83 2.59 3.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 119.032 -0.508 . . . . 0.0 112.159 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.8 t -145.85 134.79 22.55 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 119.349 0.977 . . . . 0.0 108.915 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -132.89 117.6 17.91 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 177.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.504 ' O ' ' OE1' ' A' ' 51' ' ' GLN . 68.4 m-85 -142.81 148.73 37.61 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 48.6 p-10 -97.61 135.8 38.92 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.504 ' OE1' ' O ' ' A' ' 49' ' ' PHE . 0.6 OUTLIER -97.27 8.27 44.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.41 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.47 177.92 50.52 Favored Glycine 0 CA--C 1.527 0.825 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.488 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.549 ' OG1' ' NH1' ' A' ' 118' ' ' ARG . 4.3 m -87.51 127.68 35.24 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.337 -0.432 . . . . 0.0 109.87 179.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.2 mmm180 -148.51 167.49 25.24 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.049 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -73.95 141.79 45.92 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.509 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.7 m -128.88 141.22 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 110.491 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.581 ' H ' ' CD1' ' A' ' 57' ' ' ILE . 0.1 OUTLIER -100.9 139.78 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.87 179.794 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.48 140.95 15.31 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.103 -0.57 . . . . 0.0 111.846 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 27.6 mt -129.0 115.86 18.43 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-O 121.197 0.522 . . . . 0.0 109.972 -179.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.611 ' NH2' ' NH1' ' A' ' 109' ' ' ARG . 62.9 ttt180 -97.02 114.55 26.18 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.729 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm . . . . . 0 N--CA 1.465 0.31 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.287 -178.52 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.067 0 CA-C-O 121.215 0.531 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -132.07 156.81 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.579 -178.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.9 tp -146.21 123.75 11.76 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.427 -0.352 . . . . 0.0 111.723 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 2.1 m95 -99.42 107.85 20.19 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -127.51 177.14 6.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.158 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.9 155.27 52.87 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.225 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -60.44 -27.38 84.74 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.909 2.406 . . . . 0.0 112.08 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' A' ' 74' ' ' LYS . 38.7 t70 -85.9 -6.93 58.99 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.476 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.8 t60 -70.53 126.37 29.45 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' A' ' 72' ' ' ASP . 14.3 mptt -89.55 137.4 32.36 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.352 0.596 . . . . 0.0 110.517 -179.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.5 t -105.09 135.85 41.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.151 -0.932 . . . . 0.0 109.586 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.5 tp -76.54 100.37 5.27 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.671 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.492 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 81.8 p -98.81 174.78 6.22 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -178.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.431 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 10.0 pt-20 -67.11 -12.75 60.84 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.674 -0.411 . . . . 0.0 111.438 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.431 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 60.2 m-85 -112.89 22.13 14.76 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.473 0.175 . . . . 0.0 111.473 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.88 -138.01 14.67 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -107.12 138.32 43.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.716 0.293 . . . . 0.0 110.387 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 tpt180 -137.82 130.33 29.51 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.66 141.9 36.07 Favored 'General case' 0 CA--C 1.516 -0.33 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.03 -40.06 88.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.92 -179.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.29 -3.74 20.05 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 119.808 -1.187 . . . . 0.0 111.893 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.83 -6.14 20.51 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 117.139 0.469 . . . . 0.0 110.382 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.25 128.74 35.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.622 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.4 mmt85 -134.02 148.44 51.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.383 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.8 ttmt -43.42 92.71 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.002 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.1 -17.58 0.53 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -89.67 128.95 36.16 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.895 0.378 . . . . 0.0 111.059 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -89.63 133.31 34.7 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -178.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.4 m -114.32 144.58 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.791 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.59 130.55 43.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.072 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.5 m -128.92 161.04 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.416 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -107.51 130.59 54.84 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -100.27 123.17 44.17 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.359 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.0 m -75.19 -14.68 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-N 118.534 0.606 . . . . 0.0 110.638 177.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -70.07 -58.38 3.88 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.604 -0.438 . . . . 0.0 109.952 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.7 p -98.12 -10.68 23.82 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.93 -12.61 6.23 Favored Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.504 ' H ' ' C ' ' A' ' 100' ' ' THR . 93.3 mt-10 -82.32 155.62 24.69 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 120.926 0.393 . . . . 0.0 111.578 -176.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.504 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 2.0 pt? -81.56 139.83 34.85 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.513 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.419 HH12 ' HG ' ' A' ' 106' ' ' SER . 9.4 ptm180 -140.01 178.39 7.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.17 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.492 ' OH ' ' C ' ' A' ' 77' ' ' THR . 3.6 m-85 -117.36 147.9 42.21 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.028 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' SER . . . . . 0.419 ' HG ' HH12 ' A' ' 104' ' ' ARG . 18.7 m -138.28 161.35 37.13 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.4 p -91.93 154.57 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 50.1 mt -75.89 151.59 6.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 178.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.611 ' NH1' ' NH2' ' A' ' 60' ' ' ARG . 68.7 ttt180 -104.11 -42.39 5.55 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.579 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.46 147.85 5.34 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 73.4 t -94.92 133.37 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.0 mp -100.91 151.24 37.57 Favored Pre-proline 0 CA--C 1.537 0.475 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.1 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.47 158.42 56.07 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.804 2.336 . . . . 0.0 111.57 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.6 p -67.57 156.9 35.66 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.101 0.477 . . . . 0.0 110.478 -179.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -133.77 -141.28 0.19 Allowed 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.431 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.1 mtt85 -157.59 130.1 7.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.041 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.7 170.54 4.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.274 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.549 ' NH1' ' OG1' ' A' ' 53' ' ' THR . 64.7 mmt-85 -74.15 151.38 40.07 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.372 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.3 p -131.2 146.52 52.36 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.172 0.511 . . . . 0.0 109.861 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.46 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 68.6 m-85 -123.3 174.07 7.55 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.275 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 120' ' ' PHE . 78.5 m-20 -153.62 123.26 6.73 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.71 177.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 65.5 mt -118.52 126.13 51.34 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -86.59 112.02 21.19 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 120.951 0.405 . . . . 0.0 110.399 -178.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.471 ' O ' ' C ' ' A' ' 125' ' ' GLU . 62.7 t -86.52 114.14 25.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.895 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.471 ' C ' ' O ' ' A' ' 124' ' ' VAL . 40.4 tp10 22.14 -115.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 O-C-N 123.811 0.694 . . . . 0.0 111.936 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.9 tp10 -109.8 -25.64 10.24 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.316 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 129' ' ' THR . 86.3 mt -82.83 66.68 8.56 Favored 'General case' 0 CA--C 1.505 -0.781 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.415 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 2.0 p80 -41.21 98.42 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.77 142.98 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.688 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.436 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 1.9 pp -149.02 152.78 36.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.396 0.617 . . . . 0.0 111.961 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -90.96 126.58 43.67 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.04 -179.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.39 132.91 41.74 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.067 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 52.01 43.71 30.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.542 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.62 28.13 62.23 Favored Glycine 0 CA--C 1.524 0.648 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.175 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 20.8 t -129.6 151.91 36.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -104.38 109.6 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.551 0.614 . . . . 0.0 110.722 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.431 ' O ' ' C ' ' A' ' 138' ' ' HIS . 28.8 m -147.28 139.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 62.7 t-80 -33.54 149.65 0.01 OUTLIER 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.751 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.349 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.445 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 4.8 m . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 85.4 mt -115.57 134.05 55.43 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.76 162.04 23.07 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.605 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.47 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 25.8 tt0 -62.62 144.42 56.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.939 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.13 -14.6 36.88 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.2 m -69.22 121.46 16.85 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 121.104 -0.239 . . . . 0.0 110.785 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 86.8 mtm180 -84.55 149.89 25.6 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.284 179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 73.5 mt -133.49 107.21 10.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.301 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -78.42 131.84 37.08 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -108.83 124.72 33.45 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.97 -25.53 32.23 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.248 1.966 . . . . 0.0 111.841 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.1 t -69.95 -56.23 12.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.539 ' HG1' ' H ' ' A' ' 15' ' ' THR . 7.1 p -83.55 -38.2 22.01 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.056 0.455 . . . . 0.0 109.887 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.47 12.1 70.46 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.539 ' H ' ' HG1' ' A' ' 13' ' ' THR . 41.9 m -114.75 155.37 26.82 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 117.963 0.882 . . . . 0.0 109.769 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.8 m -80.59 120.65 24.81 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.311 0.577 . . . . 0.0 110.971 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -105.36 145.85 30.21 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.34 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -97.31 123.05 41.0 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.1 tt -53.99 -40.07 43.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.619 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -60.42 -32.71 71.6 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.945 0.402 . . . . 0.0 111.202 -179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -83.7 -39.07 20.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.672 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 92.8 t -67.53 -40.67 84.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.11 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.8 t -72.43 -46.72 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.619 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.11 -34.76 70.55 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-O 120.65 0.262 . . . . 0.0 110.866 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.556 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.81 26.7 18.66 Favored Glycine 0 CA--C 1.518 0.224 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.556 ' C ' ' O ' ' A' ' 25' ' ' GLY . 94.1 mtt-85 17.47 64.55 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.409 ' O ' ' N ' ' A' ' 29' ' ' ILE . 78.8 mttt -90.14 114.22 60.12 Favored Pre-proline 0 N--CA 1.448 -0.568 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.058 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -55.88 86.5 0.04 OUTLIER 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.836 1.69 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' A' ' 27' ' ' LYS . 12.5 pt -109.24 -172.68 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-O 120.752 0.31 . . . . 0.0 110.707 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.669 ' HE2' ' CB ' ' A' ' 42' ' ' ALA . 6.3 t-80 -127.02 156.86 40.96 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.712 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.64 ' O ' ' CE1' ' A' ' 30' ' ' HIS . 29.2 m -148.46 169.7 3.05 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.87 134.91 27.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 O-C-N 122.115 -0.365 . . . . 0.0 110.36 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.1 167.18 10.19 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.799 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.44 145.3 40.75 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.261 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.12 178.22 4.37 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.577 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.705 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 69.7 mmtt -71.4 -11.6 60.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.024 0.44 . . . . 0.0 110.458 179.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.0 p30 -80.22 -13.41 59.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.29 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.3 19.74 61.87 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 47.4 p -102.18 138.83 38.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 111.594 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.3 mt -92.29 131.0 37.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.181 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -137.3 138.24 39.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.669 ' CB ' ' HE2' ' A' ' 30' ' ' HIS . . . -69.26 136.12 51.48 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.662 ' N ' ' NE2' ' A' ' 30' ' ' HIS . 4.6 mmp_? -146.13 136.53 12.16 Favored Pre-proline 0 CA--C 1.537 0.454 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.178 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.88 159.85 30.87 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.865 2.377 . . . . 0.0 113.118 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.9 t -101.42 139.02 23.66 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 177.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.6 m -130.68 4.56 2.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.06 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 p -149.34 145.2 26.89 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.175 0.898 . . . . 0.0 109.025 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.612 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.26 123.76 13.98 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.51 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -136.41 145.12 44.94 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -91.88 140.32 29.79 Favored 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.445 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 46.8 mm-40 -89.84 -4.19 57.72 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.338 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 77.46 21.62 72.18 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.657 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ARG . 0.4 OUTLIER 64.53 135.3 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.836 0.35 . . . . 0.0 110.087 -179.945 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . 0.419 ' CG ' ' O ' ' A' ' 53' ' ' THR . 72.0 mtp180 -157.27 174.92 14.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.404 178.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . 0.498 ' CG ' ' HG1' ' A' ' 114' ' ' THR . 50.3 t0 -73.93 139.67 45.07 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -142.13 152.73 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.09 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 44.6 pt -104.86 152.05 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.177 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.79 138.1 14.26 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.6 mt -121.32 114.57 21.53 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 121.111 0.481 . . . . 0.0 110.365 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -87.0 113.78 23.05 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.888 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 15.7 mm . . . . . 0 CA--C 1.511 -0.523 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 110.441 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.47 150.77 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.212 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 57.9 tp -123.99 113.55 18.58 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.823 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . 0.556 ' CG ' ' NH2' ' A' ' 115' ' ' ARG . 95.3 m95 -104.5 121.28 43.14 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.95 171.94 15.53 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.318 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.426 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 40.2 p -78.56 154.41 78.79 Favored Pre-proline 0 C--N 1.329 -0.294 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.109 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.66 -22.15 59.23 Favored 'Trans proline' 0 N--CA 1.495 1.578 0 C-N-CA 122.027 1.818 . . . . 0.0 112.113 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -93.15 -7.71 44.6 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.79 0.328 . . . . 0.0 110.364 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.8 t60 -66.81 126.83 30.29 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mptt -82.72 123.42 29.28 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.219 0.533 . . . . 0.0 111.395 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.5 t -99.73 139.68 20.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.732 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.66 95.02 5.16 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.867 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 13.9 p -98.7 174.67 6.3 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -66.78 -14.9 63.15 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.29 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 68.4 m-85 -108.05 25.22 11.86 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.483 0.183 . . . . 0.0 110.744 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.59 -141.15 15.35 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.705 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 92.5 m95 -94.47 129.31 41.29 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.966 0.412 . . . . 0.0 111.172 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.9 tpt180 -138.7 131.42 29.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.441 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.62 144.49 26.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.012 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.07 -37.94 84.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 120.936 -0.306 . . . . 0.0 111.613 -179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.77 -5.33 24.16 Favored Glycine 0 CA--C 1.528 0.9 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.795 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -103.38 4.9 36.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.962 0.411 . . . . 0.0 110.432 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.5 mt -90.67 131.05 36.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.404 0.621 . . . . 0.0 111.122 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.517 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.4 mmt180 -129.2 148.96 51.18 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.705 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -45.27 90.83 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 153.72 -12.33 0.55 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -84.09 130.77 34.84 Favored 'General case' 0 C--O 1.228 -0.079 0 CA-C-O 120.936 0.398 . . . . 0.0 110.672 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -92.48 141.55 28.39 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.724 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.51 158.98 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.282 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.6 130.35 43.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.105 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.87 132.79 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.434 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -84.29 125.61 32.42 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.742 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 37.5 t0 -99.81 122.62 43.04 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.999 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 -17.8 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 118.35 0.523 . . . . 0.0 111.303 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 -69.64 -59.74 2.77 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 120.517 -0.473 . . . . 0.0 109.898 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.471 ' C ' ' H ' ' A' ' 102' ' ' GLU . 33.8 p -93.1 -12.85 29.46 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.12 -14.27 6.52 Favored Glycine 0 C--N 1.331 0.278 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.471 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.5 mt-10 -83.38 157.95 22.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.841 0.353 . . . . 0.0 110.824 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -82.39 133.71 35.23 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.22 0.533 . . . . 0.0 109.852 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.4 ptt85 -138.18 137.14 37.32 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.408 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -78.55 147.32 33.83 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -177.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.2 m -134.98 160.44 38.31 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.575 178.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 17.0 m -91.73 153.67 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.5 mm -70.23 156.33 7.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.084 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.443 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt85 -107.61 -46.63 3.79 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.989 178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -166.3 145.95 6.0 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 19.3 t -93.33 131.84 39.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -99.57 148.48 34.79 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.047 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.88 160.34 50.16 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.408 2.072 . . . . 0.0 111.126 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.498 ' HG1' ' CG ' ' A' ' 55' ' ' ASP . 0.1 OUTLIER -69.26 156.67 38.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 120.999 0.428 . . . . 0.0 110.585 -179.387 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.556 ' NH2' ' CG ' ' A' ' 68' ' ' TRP . 39.3 ptt180 -139.87 -144.41 0.17 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.964 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -154.03 134.75 13.66 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.69 172.12 3.64 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.983 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.47 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 91.4 mtm-85 -71.45 140.54 50.07 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.519 178.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 143.01 51.28 Favored 'General case' 0 C--O 1.231 0.126 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -120.61 178.02 4.84 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.719 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.444 ' HB2' HE21 ' A' ' 51' ' ' GLN . 51.0 t0 -153.49 120.75 5.81 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.269 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 84.8 mt -119.57 123.53 44.15 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.744 0.307 . . . . 0.0 110.443 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -88.51 111.51 21.91 Favored 'General case' 0 CA--C 1.514 -0.441 0 C-N-CA 120.612 -0.435 . . . . 0.0 109.899 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 59.8 t -86.49 119.74 35.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.464 -0.495 . . . . 0.0 109.849 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 33.2 tp10 21.71 -121.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.961 0.788 . . . . 0.0 111.148 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -104.17 -26.81 12.39 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.916 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.431 ' O ' ' N ' ' A' ' 129' ' ' THR . 66.9 mt -81.86 70.54 8.78 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.421 ' O ' HG21 ' A' ' 129' ' ' THR . 31.2 m170 -41.57 98.83 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 179.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.431 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.46 141.49 0.02 OUTLIER 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.997 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.421 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.3 pp -146.65 155.85 42.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.377 0.608 . . . . 0.0 111.614 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 8.4 p -89.8 125.48 42.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.875 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -132.62 132.36 42.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.784 -179.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.507 ' C ' ' H ' ' A' ' 135' ' ' VAL . 80.8 mm-40 49.7 46.49 23.8 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.22 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.39 -13.35 0.58 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.431 -0.667 . . . . 0.0 111.431 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.507 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.2 t -95.18 150.64 4.08 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.27 0 CA-C-N 117.061 0.43 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.6 t -107.97 113.52 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.65 0.262 . . . . 0.0 110.531 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' HIS . 22.9 m -148.28 141.05 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.109 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.546 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 15.8 t60 -30.25 151.5 0.0 OUTLIER 'General case' 0 C--O 1.224 -0.254 0 CA-C-O 120.989 0.424 . . . . 0.0 112.05 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 p30 . . . . . 0 C--N 1.32 -0.683 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.674 -179.342 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 39.4 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.5 mt -109.34 136.42 48.8 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.906 0.384 . . . . 0.0 110.338 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.32 162.75 21.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.519 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.74 141.1 58.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.115 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.87 -17.67 22.5 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.4 m -68.91 120.43 14.8 Favored 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.534 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -94.6 114.59 26.57 Favored 'General case' 0 N--CA 1.456 -0.141 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.47 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.6 mp -102.37 114.87 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 4.6 t80 -77.16 135.41 38.53 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 9.7 t0 -102.79 132.62 21.05 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.647 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.22 -30.95 9.94 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.672 2.248 . . . . 0.0 112.37 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.512 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 47.1 t -71.31 -55.02 15.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.737 -179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.0 p -78.19 -37.0 46.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.043 0.449 . . . . 0.0 110.271 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.29 82.68 Favored Glycine 0 CA--C 1.52 0.389 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.23 -168.73 1.43 Allowed 'General case' 0 C--N 1.34 0.171 0 CA-C-N 117.621 0.71 . . . . 0.0 109.501 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 63.7 m -113.6 117.34 31.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.259 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 58.9 m170 -103.46 143.59 32.51 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.341 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 23.2 mmt85 -96.59 126.08 41.52 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.64 179.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.457 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -51.4 -42.54 28.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.213 0.53 . . . . 0.0 111.19 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 4.5 pt-20 -58.72 -32.08 68.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.823 -177.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.5 t0 -83.81 -38.49 21.19 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.29 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 86.6 t -64.65 -40.8 90.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.337 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 50.3 t -73.51 -44.58 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -57.52 -37.94 73.86 Favored 'General case' 0 CA--C 1.513 -0.472 0 C-N-CA 120.823 -0.351 . . . . 0.0 111.227 -177.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.568 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.2 29.37 9.27 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.568 ' C ' ' O ' ' A' ' 25' ' ' GLY . 89.1 mtt-85 16.12 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -87.31 113.99 56.5 Favored Pre-proline 0 N--CA 1.449 -0.491 0 O-C-N 123.434 0.459 . . . . 0.0 111.177 -176.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.6 89.43 0.06 OUTLIER 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.159 1.906 . . . . 0.0 110.414 178.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.51 -172.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 120.867 0.365 . . . . 0.0 110.497 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.425 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 52.4 m80 -127.94 160.63 31.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.598 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -149.41 172.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.2 t -90.93 136.05 25.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.406 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.7 167.77 10.34 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.763 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.0 143.24 44.69 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.325 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.01 177.7 4.55 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.653 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -70.0 -13.63 62.32 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 110.658 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -80.13 -18.21 50.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.453 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.89 24.16 39.14 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.6 p -103.06 136.83 42.15 Favored 'General case' 0 N--CA 1.463 0.207 0 O-C-N 122.724 -0.28 . . . . 0.0 111.281 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.3 mt -94.22 130.67 40.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.819 0.343 . . . . 0.0 110.648 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 7.1 t-160 -142.36 139.24 31.69 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.838 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.91 139.95 53.04 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.555 -178.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.487 ' CZ ' ' OE1' ' A' ' 126' ' ' GLU . 14.5 mmt180 -142.92 140.35 17.99 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.376 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -78.37 157.03 29.28 Favored 'Trans proline' 0 N--CA 1.491 1.324 0 C-N-CA 122.757 2.305 . . . . 0.0 113.019 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.57 134.87 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.8 m -125.6 0.23 4.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.645 -179.06 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.1 141.99 25.8 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 119.144 0.884 . . . . 0.0 108.912 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.592 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -139.39 120.74 14.93 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 178.398 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -139.22 145.86 39.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.318 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -89.95 133.52 34.74 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.491 HE21 ' HB2' ' A' ' 121' ' ' ASP . 27.3 mm-40 -92.75 -1.98 56.36 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.653 -0.249 . . . . 0.0 111.298 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.428 ' O ' ' OG1' ' A' ' 119' ' ' THR . . . 87.66 175.76 48.35 Favored Glycine 0 C--N 1.339 0.698 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.376 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.0 m -90.44 118.67 30.1 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -141.95 172.6 12.46 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.939 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 99.5 m-20 -75.32 141.57 43.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.889 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.1 m -141.85 157.67 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.5 pt -112.79 153.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.206 179.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.32 139.26 14.5 Favored Glycine 0 N--CA 1.465 0.577 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.2 mt -120.41 112.35 18.88 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.143 0.497 . . . . 0.0 110.464 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -89.39 111.43 22.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.555 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.4 HG22 HD12 ' A' ' 61' ' ' ILE . 16.8 mm . . . . . 0 N--CA 1.468 0.433 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.737 -179.066 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.948 0.404 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.6 mt -124.89 155.01 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.462 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 47.1 tp -132.08 116.5 17.13 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.118 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -104.63 115.54 30.52 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.18 172.49 12.62 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.62 156.87 80.41 Favored Pre-proline 0 C--N 1.327 -0.401 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -61.68 -21.65 72.59 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.649 2.233 . . . . 0.0 111.826 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 24.5 p30 -93.09 -4.83 51.66 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.248 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.5 t60 -72.27 129.56 38.72 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -86.19 127.47 34.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-O 121.277 0.56 . . . . 0.0 110.251 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.2 t -108.26 92.39 2.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.117 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 75' ' ' VAL . 9.6 tp -31.01 93.59 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.644 0.59 . . . . 0.0 111.442 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.458 ' N ' ' O ' ' A' ' 75' ' ' VAL . 29.9 p -98.34 177.19 5.44 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.747 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.524 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 6.0 pt-20 -65.05 -21.36 66.82 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.232 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.524 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 57.8 m-85 -104.47 25.09 10.64 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 120.459 0.171 . . . . 0.0 110.905 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.445 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.22 -176.07 41.73 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -58.62 129.68 43.24 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.696 -177.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 73.4 mtm180 -145.9 134.55 22.21 Favored 'General case' 0 C--N 1.339 0.118 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.063 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.27 141.11 24.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.04 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.444 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.5 -36.98 84.27 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.143 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.73 -1.44 2.7 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.672 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.444 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.7 mt-10 -108.16 6.58 26.92 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 88.9 mt -85.1 125.95 33.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.262 0.553 . . . . 0.0 110.975 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.553 ' O ' ' N ' ' A' ' 90' ' ' GLY . 25.2 mmt85 -130.5 147.53 52.2 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.584 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -45.89 88.22 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 120.897 0.38 . . . . 0.0 110.632 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.0 -16.82 0.37 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -86.23 130.88 34.37 Favored 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.885 0.374 . . . . 0.0 110.419 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.67 135.25 34.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.0 m -120.43 152.02 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.3 139.64 58.79 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.164 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 26.9 m -138.55 156.7 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.391 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -106.09 130.65 53.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.679 0.276 . . . . 0.0 110.317 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -101.63 125.86 48.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.581 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.94 -14.74 16.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 118.203 0.456 . . . . 0.0 111.279 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -67.85 -60.38 2.56 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.822 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.535 ' HB ' ' OE1' ' A' ' 102' ' ' GLU . 53.3 m -103.39 -12.9 16.89 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.251 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 80.39 -11.19 39.35 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.995 177.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.703 ' N ' ' OE1' ' A' ' 102' ' ' GLU . 0.0 OUTLIER -77.18 158.8 30.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-O 121.558 0.694 . . . . 0.0 112.161 -179.149 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 5.9 tp -83.07 133.08 35.09 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.824 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.424 ' CD ' ' OE2' ' A' ' 102' ' ' GLU . 85.0 mtp180 -133.9 172.87 12.2 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.3 m-30 -109.46 142.25 40.74 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.389 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 6.7 m -134.43 154.39 51.41 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.37 155.15 3.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 110.864 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 63.1 mt -73.44 153.05 7.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.836 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.8 mmm180 -108.29 -43.24 4.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.021 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -164.69 141.82 6.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 16.5 t -95.13 134.09 33.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.412 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.3 mm? -101.97 125.46 36.78 Favored Pre-proline 0 CA--C 1.538 0.509 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.88 163.72 0.2 Allowed 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.217 1.945 . . . . 0.0 111.831 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 61.4 p -68.04 156.78 36.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.089 0.471 . . . . 0.0 110.812 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' O ' ' OD1' ' A' ' 55' ' ' ASP . 42.4 ttm-85 -139.64 -136.94 0.12 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.974 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -158.97 131.16 6.66 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.411 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.33 172.8 3.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.071 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -76.18 145.75 39.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.871 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.428 ' OG1' ' O ' ' A' ' 52' ' ' GLY . 3.9 p -122.63 141.49 51.67 Favored 'General case' 0 N--CA 1.463 0.175 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -119.66 174.04 6.65 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.215 -178.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.491 ' HB2' HE21 ' A' ' 51' ' ' GLN . 43.2 t0 -156.18 125.72 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.389 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 76.5 mt -119.54 121.7 39.98 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -86.73 115.28 24.06 Favored 'General case' 0 CA--C 1.512 -0.491 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.127 -177.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.53 117.89 33.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.542 ' O ' ' N ' ' A' ' 127' ' ' LEU . 40.0 tt0 -58.26 156.05 10.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.505 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.487 ' OE1' ' CZ ' ' A' ' 43' ' ' ARG . 91.0 mt-10 56.24 -69.16 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.395 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.542 ' N ' ' O ' ' A' ' 125' ' ' GLU . 95.9 mt -98.27 101.23 12.62 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.413 ' C ' ' OG1' ' A' ' 129' ' ' THR . 39.6 m80 -72.3 99.61 2.44 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.413 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.04 143.86 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.969 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.413 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.2 pp -144.38 152.86 41.3 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 121.182 0.515 . . . . 0.0 111.293 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.0 p -87.67 128.15 40.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.32 128.28 35.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.935 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' A' ' 135' ' ' VAL . 72.9 mm-40 52.46 47.23 25.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.204 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.87 -18.43 0.47 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.513 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.7 t -90.59 151.02 3.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 CA-C-N 117.169 0.485 . . . . 0.0 110.287 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 62.1 t -106.41 112.98 41.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 138' ' ' HIS . 17.4 m -147.77 138.23 17.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.366 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.424 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.533 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 7.7 t60 -35.46 155.67 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.152 0 CA-C-O 120.747 0.308 . . . . 0.0 111.62 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 14.1 p30 . . . . . 0 C--N 1.322 -0.629 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.659 -179.415 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.714 ' CB ' HE22 ' A' ' 51' ' ' GLN . 11.9 m . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.72 131.85 53.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.837 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.78 162.72 18.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.525 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -62.18 141.46 58.18 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.442 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.94 -15.45 21.23 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.6 m -71.24 120.02 16.21 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.632 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -93.27 115.96 28.54 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 120.908 0.385 . . . . 0.0 110.322 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 57.5 mt -99.9 112.49 32.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.77 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 3.5 t80 -77.76 135.77 38.05 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.555 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.7 t0 -102.32 131.71 22.24 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.046 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.43 -32.5 7.94 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.577 2.184 . . . . 0.0 112.136 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.555 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.0 t -69.7 -52.88 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.222 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 m -79.02 -40.01 32.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.003 0.43 . . . . 0.0 110.385 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.77 82.17 Favored Glycine 0 N--CA 1.453 -0.205 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.599 ' CG2' ' H ' ' A' ' 16' ' ' THR . 12.7 m -104.19 -174.5 2.56 Favored 'General case' 0 C--N 1.338 0.086 0 CA-C-N 117.68 0.74 . . . . 0.0 109.613 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.599 ' H ' ' CG2' ' A' ' 15' ' ' THR . 88.1 m -112.23 118.97 36.76 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.068 179.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -113.43 151.8 30.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.477 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 66.3 mtt85 -100.27 128.77 46.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.607 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 4.0 tt -52.28 -38.96 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 120.924 0.392 . . . . 0.0 111.2 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -60.78 -34.14 74.04 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.167 0.508 . . . . 0.0 110.771 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.575 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 7.1 t70 -85.31 -38.29 18.99 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.352 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.0 t -69.71 -42.71 80.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.9 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 34.1 t -76.14 -47.83 30.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.578 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 33.1 p-10 -56.53 -30.77 63.45 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 120.987 0.423 . . . . 0.0 110.603 -177.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' N ' ' OD1' ' A' ' 24' ' ' ASP . . . -109.64 21.49 25.71 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.52 ' C ' ' O ' ' A' ' 25' ' ' GLY . 43.1 ptt85 21.79 61.65 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.202 0 O-C-N 124.309 0.652 . . . . 0.0 109.324 179.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -79.02 134.65 59.52 Favored Pre-proline 0 N--CA 1.446 -0.658 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.049 -177.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -76.04 81.35 2.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.305 2.003 . . . . 0.0 111.247 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.6 pt -118.33 -169.72 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.499 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.444 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 54.3 m80 -128.35 164.53 22.44 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.826 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.6 m -148.47 171.79 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.401 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 74.6 t -90.81 131.6 37.55 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.11 167.83 9.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.205 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.62 141.81 39.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.912 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.76 177.73 4.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.909 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -70.43 -12.62 61.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 120.93 0.395 . . . . 0.0 110.609 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 64.6 t0 -81.32 -18.77 44.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.88 23.07 43.24 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.2 p -102.59 136.5 42.3 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.81 0.338 . . . . 0.0 111.012 178.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 77.9 mt -91.24 128.64 37.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.835 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -138.98 137.84 36.73 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.596 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.486 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -70.16 140.56 52.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.777 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.486 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.4 mmp_? -144.04 138.8 15.31 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.665 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -77.56 158.21 32.31 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 123.001 2.468 . . . . 0.0 113.142 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.3 t -101.34 136.46 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.4 m -127.89 3.01 3.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.554 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.464 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -152.5 149.54 28.64 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 119.426 1.012 . . . . 0.0 108.585 179.732 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.503 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -149.31 127.04 11.72 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.355 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 -140.02 148.43 41.83 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.708 0.632 . . . . 0.0 112.708 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -105.84 138.58 41.8 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.714 HE22 ' CB ' ' A' ' 1' ' ' CYS . 1.4 mt-30 -101.77 2.97 39.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.489 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.15 -165.05 39.13 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.415 178.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 20.9 m -87.16 127.72 35.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -148.82 160.79 42.9 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.821 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.79 139.73 41.95 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.05 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.77 156.07 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.4 pt -107.8 149.37 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.359 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.38 142.68 15.67 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 75.8 mt -127.9 114.73 17.56 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.2 0.524 . . . . 0.0 110.654 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 56.6 ttp180 -96.66 122.45 39.6 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 55.1 mt . . . . . 0 N--CA 1.467 0.403 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.232 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.1 mt -122.65 151.06 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.236 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -126.56 115.69 19.91 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.931 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -105.41 116.34 31.77 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -143.04 171.78 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.397 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.529 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 1.0 OUTLIER -79.41 156.2 76.1 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.616 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -62.26 -17.48 57.27 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.597 2.198 . . . . 0.0 111.882 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -95.9 -6.71 38.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.742 0.306 . . . . 0.0 110.38 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.4 t60 -69.03 127.46 33.23 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.7 mmtp -85.97 128.19 34.79 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.902 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.6 t -103.31 141.29 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.341 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 56.3 tp -78.0 93.29 4.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.886 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.494 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 76.1 p -98.33 173.66 6.87 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -178.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -63.7 -16.24 60.54 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.367 -179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -108.06 25.65 11.34 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.82 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.58 -176.1 46.1 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -58.64 133.12 55.61 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.206 0.527 . . . . 0.0 110.478 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -146.11 134.73 22.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.666 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.99 137.98 31.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.08 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.442 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.3 -37.9 87.32 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.222 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.32 -2.42 3.02 Favored Glycine 0 C--N 1.335 0.503 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.734 -179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.8 mm-40 -108.17 11.51 27.41 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.918 0.389 . . . . 0.0 110.321 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.0 mt -92.93 128.15 38.7 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.465 0.65 . . . . 0.0 111.072 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.572 ' O ' ' N ' ' A' ' 90' ' ' GLY . 14.8 tpt180 -130.51 149.52 52.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.976 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -45.76 86.57 0.0 OUTLIER 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.557 179.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.77 -14.83 0.29 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -85.02 131.78 34.42 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.707 -0.29 . . . . 0.0 110.29 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -89.21 130.74 35.58 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.434 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.0 m -116.64 146.35 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.584 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.64 137.55 47.98 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.704 0.288 . . . . 0.0 111.073 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.17 161.92 38.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.004 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -103.5 130.98 50.99 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.508 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.543 ' OD2' ' NH2' ' A' ' 104' ' ' ARG . 42.5 t0 -100.62 123.96 45.54 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.33 -16.65 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 CA-C-N 118.297 0.499 . . . . 0.0 111.261 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -71.26 -58.27 3.7 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.139 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.478 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.8 p -95.18 -15.02 23.61 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.651 -0.25 . . . . 0.0 110.34 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.99 -13.98 5.07 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.478 ' H ' ' C ' ' A' ' 100' ' ' THR . 98.2 mt-10 -81.49 159.87 24.09 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-O 120.755 0.312 . . . . 0.0 110.758 -177.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 7.7 tp -85.32 128.79 34.83 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.163 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.543 ' NH2' ' OD2' ' A' ' 97' ' ' ASP . 16.5 ptp180 -127.24 175.81 7.88 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.33 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.494 ' OH ' ' C ' ' A' ' 77' ' ' THR . 0.8 OUTLIER -114.68 147.26 39.88 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.835 179.877 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -144.23 163.06 34.76 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.4 m -94.79 155.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-O 120.674 0.273 . . . . 0.0 110.483 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.446 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 68.1 mt -73.08 159.43 5.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 120.97 0.414 . . . . 0.0 110.303 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.446 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 24.9 mmt180 -105.26 -44.97 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.192 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -165.23 143.55 6.27 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.19 134.86 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.467 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.6 mm? -104.06 147.69 34.71 Favored Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.34 166.66 27.57 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 122.533 2.155 . . . . 0.0 111.357 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 21.8 p -66.12 151.56 46.65 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.21 0.528 . . . . 0.0 110.689 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -133.86 -148.48 0.33 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.092 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -148.88 127.62 12.52 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.147 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.61 175.52 2.48 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.756 -178.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -79.48 147.03 32.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.928 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.2 p -121.12 140.81 51.48 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.1 0.476 . . . . 0.0 109.747 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.542 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 58.3 m-85 -114.9 168.02 10.28 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.921 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 122' ' ' LEU . 66.4 t0 -147.47 131.16 16.91 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.219 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . 0.443 ' N ' ' OD1' ' A' ' 121' ' ' ASP . 4.5 mm? -114.62 163.88 14.81 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.486 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -135.1 104.84 6.08 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.017 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 17.4 t -91.93 120.7 41.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.418 ' O ' ' N ' ' A' ' 127' ' ' LEU . 75.7 tt0 -62.69 152.9 34.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.5 tt0 62.17 -70.57 0.05 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.81 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.418 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -99.96 104.45 16.07 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.473 ' C ' ' HG1' ' A' ' 129' ' ' THR . 62.3 m80 -73.99 100.2 3.49 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.473 ' HG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 165.89 144.67 0.02 OUTLIER 'General case' 0 C--N 1.344 0.35 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.44 ' H ' HD21 ' A' ' 130' ' ' LEU . 1.7 pt? -144.43 155.5 43.77 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-O 121.759 0.79 . . . . 0.0 111.566 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.88 125.14 40.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -131.88 125.73 32.45 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.052 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 50.36 46.47 25.11 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.939 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.17 -17.24 0.43 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 12.1 t -92.34 150.94 3.68 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 O-C-N 122.285 -0.538 . . . . 0.0 110.727 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.19 114.35 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' A' ' 138' ' ' HIS . 18.0 m -146.74 132.14 12.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.315 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.517 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 50.2 t-80 -37.21 159.86 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.74 0.305 . . . . 0.0 111.74 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.485 ' N ' ' CG ' ' A' ' 138' ' ' HIS . 21.1 p30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.388 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.607 ' H2 ' ' HG1' ' A' ' 70' ' ' THR . 61.9 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 73.0 mt -106.9 138.44 43.07 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.415 -179.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.87 164.13 20.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.85 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -64.02 145.41 55.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.233 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.03 -17.6 44.43 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.6 m -67.67 123.93 21.86 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.435 ' HE ' HG23 ' A' ' 16' ' ' THR . 61.0 mtp180 -81.62 147.78 29.4 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.829 0.347 . . . . 0.0 110.263 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.416 HG21 HD11 ' A' ' 8' ' ' ILE . 90.3 mt -134.46 106.4 7.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.857 179.182 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.4 t80 -77.52 133.5 38.52 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.238 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 17.1 t0 -106.49 129.62 24.2 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.44 -26.4 24.42 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.119 1.88 . . . . 0.0 112.512 -179.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.509 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 38.9 t -78.34 -53.1 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.016 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.8 p -79.97 -34.63 38.5 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 120.975 0.417 . . . . 0.0 110.134 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.94 9.5 86.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.427 ' CG2' ' N ' ' A' ' 16' ' ' THR . 87.8 m -113.17 166.73 11.16 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 117.873 0.836 . . . . 0.0 109.65 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.435 HG23 ' HE ' ' A' ' 7' ' ' ARG . 38.5 m -90.26 116.09 27.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.316 0.579 . . . . 0.0 111.321 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -102.12 144.47 30.65 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.153 -0.931 . . . . 0.0 110.147 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 92.2 mtt-85 -98.77 129.84 45.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.606 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.6 tp -52.79 -40.03 33.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.721 0.296 . . . . 0.0 111.154 -179.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -60.56 -34.98 74.95 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.263 0.554 . . . . 0.0 110.11 -179.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.76 -40.45 22.64 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.741 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 83.4 t -68.47 -42.58 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.4 t -72.21 -46.19 58.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.014 0.375 . . . . 0.0 112.014 -178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 66.8 t0 -58.56 -35.17 71.94 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.157 0.503 . . . . 0.0 110.549 -177.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.3 25.45 12.45 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-O 118.853 -0.971 . . . . 0.0 111.049 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.566 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.2 ptt180 14.03 72.74 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 CA-C-N 117.427 0.614 . . . . 0.0 109.523 179.219 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -87.45 137.61 32.33 Favored Pre-proline 0 N--CA 1.445 -0.705 0 O-C-N 121.673 -0.642 . . . . 0.0 110.925 -175.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -74.52 83.33 1.74 Allowed 'Trans proline' 0 C--N 1.31 -1.465 0 C-N-CA 121.311 1.341 . . . . 0.0 110.618 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.7 pt -119.51 -170.53 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.811 0.339 . . . . 0.0 110.097 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.426 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 26.3 m80 -131.35 163.55 27.61 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.621 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.42 170.96 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 85.9 t -87.16 130.88 36.31 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.563 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.23 166.54 10.34 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.599 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.12 141.99 40.18 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.848 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.72 179.31 3.99 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -72.03 -13.63 61.65 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.91 0.386 . . . . 0.0 110.814 179.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -79.51 -21.55 45.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.402 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 91.46 19.55 41.12 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.4 p -99.22 135.61 40.38 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 121.098 0.475 . . . . 0.0 111.01 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.5 mt -91.65 127.72 37.21 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.269 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -137.95 138.94 39.46 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.73 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.06 142.42 50.86 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.384 -0.526 . . . . 0.0 109.85 -178.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -144.06 137.47 14.15 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.046 179.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.35 157.18 33.09 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 122.631 2.221 . . . . 0.0 112.73 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.0 135.7 31.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.57 2.88 3.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.647 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -150.69 144.84 25.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 119.173 0.897 . . . . 0.0 108.844 178.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -144.95 128.97 17.53 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -136.41 145.03 44.83 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.242 0.544 . . . . 0.0 112.255 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 53.2 p-10 -114.43 141.22 47.95 Favored 'General case' 0 CA--C 1.5 -0.959 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -110.27 -101.15 0.39 Allowed 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.002 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -173.82 -153.13 9.47 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 114.408 -1.269 . . . . 0.0 112.951 -177.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.1 m -86.32 129.3 34.9 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.1 0.476 . . . . 0.0 111.549 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -150.48 162.25 40.95 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.498 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -78.53 138.61 38.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.21 141.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 120.828 0.347 . . . . 0.0 110.281 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 41.1 pt -90.41 145.64 7.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.795 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.97 140.53 14.91 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 15.1 mt -125.12 114.09 18.57 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.102 0.477 . . . . 0.0 110.559 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -91.53 112.85 24.94 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.275 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.512 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.469 0.489 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.412 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.093 0 CA-C-O 120.889 0.376 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.7 mt -119.13 142.0 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.24 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.409 ' CD2' ' C ' ' A' ' 67' ' ' LEU . 4.2 tt -120.41 113.08 19.8 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.197 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.02 127.6 50.19 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.27 172.22 14.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.317 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.607 ' HG1' ' H2 ' ' A' ' 1' ' ' CYS . 0.7 OUTLIER -85.19 155.34 60.43 Favored Pre-proline 0 CA--C 1.535 0.38 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.353 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -63.62 -22.21 70.3 Favored 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.566 2.177 . . . . 0.0 112.012 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -91.24 -8.1 49.36 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 120.977 0.418 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.584 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.7 t60 -70.52 127.52 33.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.559 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.7 mtmm -86.11 132.62 33.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.135 0.493 . . . . 0.0 111.159 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.94 148.82 17.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.22 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 25.9 tp -85.37 92.07 8.37 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.794 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' TYR . 0.1 OUTLIER -107.73 139.92 41.56 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.16 0.505 . . . . 0.0 110.434 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.54 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 67.5 mm-40 60.02 -64.66 0.05 Allowed 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.134 -1.394 . . . . 0.0 111.262 178.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' THR . 0.3 OUTLIER 179.15 55.71 0.01 OUTLIER 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 174.32 175.81 42.21 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 119.56 -1.305 . . . . 0.0 111.976 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -91.71 129.31 37.71 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.874 0.368 . . . . 0.0 110.815 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 -145.46 138.53 26.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.365 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.89 142.74 23.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.144 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.548 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -65.24 -37.82 88.45 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 120.885 -0.326 . . . . 0.0 111.724 -179.573 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.41 5.22 0.17 Allowed Glycine 0 CA--C 1.527 0.839 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.863 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.548 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.9 mt-10 -110.57 1.96 18.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.888 0.344 . . . . 0.0 110.259 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 61.3 mt -80.49 130.6 35.25 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.484 0.659 . . . . 0.0 111.127 -179.274 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.506 ' O ' ' N ' ' A' ' 90' ' ' GLY . 32.5 mmt180 -129.46 151.2 50.35 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.944 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -51.91 87.19 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.27 -21.32 0.49 Allowed Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -73.5 135.93 44.08 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.491 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -90.2 132.21 35.61 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 120.96 0.41 . . . . 0.0 110.248 -178.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.1 143.74 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.502 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.55 138.07 57.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.734 0.302 . . . . 0.0 110.52 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.2 m -135.18 158.14 40.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.622 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -101.93 129.0 48.09 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.581 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -99.84 120.22 39.41 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.18 179.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 42.4 t -74.62 -15.1 16.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.387 0.539 . . . . 0.0 110.821 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.37 -60.09 2.56 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 120.447 -0.501 . . . . 0.0 109.923 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.48 ' C ' ' H ' ' A' ' 102' ' ' GLU . 74.5 p -96.2 -10.47 28.02 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.78 -12.66 5.99 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.48 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -83.21 158.13 22.43 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 120.792 0.33 . . . . 0.0 110.748 -177.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 5.2 tt -86.79 130.5 34.45 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.3 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.7 ptt85 -127.81 173.16 10.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.729 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.54 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.41 143.5 37.25 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.164 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.2 m -141.22 164.15 31.04 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 98.2 t -98.1 154.91 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.423 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -70.78 157.1 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.875 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.423 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 59.8 ttt85 -101.43 -47.34 4.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.749 179.274 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -164.62 144.43 7.42 Favored 'General case' 0 C--N 1.341 0.197 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 9.7 p -93.0 132.34 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.6 mm? -102.85 148.03 34.96 Favored Pre-proline 0 N--CA 1.469 0.491 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.426 -178.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.71 160.2 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.606 2.204 . . . . 0.0 110.992 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -65.96 155.01 37.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.061 0.458 . . . . 0.0 110.318 -178.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -147.99 143.69 27.44 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.002 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -71.92 131.01 42.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.964 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.69 168.21 14.58 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.723 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -81.46 149.72 28.63 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.669 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 50.6 p -133.12 144.38 49.89 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 2.8 m-85 -121.5 177.95 5.01 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.475 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.492 ' OD1' ' SG ' ' A' ' 1' ' ' CYS . 10.5 m-20 -144.22 149.21 36.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.947 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 97.3 mt -138.97 170.14 16.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.616 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -137.29 106.66 6.09 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.926 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.48 ' O ' ' C ' ' A' ' 125' ' ' GLU . 48.9 t -85.72 113.55 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 124' ' ' VAL . 0.3 OUTLIER 21.4 -91.11 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 123.816 0.698 . . . . 0.0 111.771 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 124' ' ' VAL . 9.0 tp10 -135.23 -27.97 1.18 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.658 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.451 ' O ' ' N ' ' A' ' 129' ' ' THR . 83.0 mt -82.13 67.59 8.21 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.416 ' C ' ' O ' ' A' ' 127' ' ' LEU . 20.6 m170 -39.61 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 170.89 140.89 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.117 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.4 ' N ' ' CD2' ' A' ' 130' ' ' LEU . 1.1 pt? -151.15 160.88 43.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.69 0.757 . . . . 0.0 112.386 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 25.2 t -90.27 124.65 43.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -135.28 124.72 24.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.941 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.5 mm-40 53.12 42.53 32.19 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.04 28.07 68.24 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.652 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.58 152.12 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 97.6 t -106.67 111.06 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 O-C-N 122.11 -0.369 . . . . 0.0 110.308 179.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 138' ' ' HIS . 6.5 m -146.14 137.1 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.638 -0.256 . . . . 0.0 110.48 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.584 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 50.4 t-80 -33.57 156.72 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.565 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 139' ' ' ASN . 7.7 p-10 . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.363 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.585 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 53.9 m . . . . . 0 N--CA 1.487 1.405 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.2 mt -118.38 134.68 54.85 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.728 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.59 161.7 24.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.503 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.45 145.98 54.53 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.55 -14.38 50.4 Favored Glycine 0 C--N 1.338 0.686 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.7 m -68.96 123.75 21.87 Favored 'General case' 0 C--O 1.234 0.278 0 O-C-N 122.652 -0.322 . . . . 0.0 110.587 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 18' ' ' ARG . 10.6 mpt_? -83.67 150.62 25.75 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.238 0.542 . . . . 0.0 109.857 178.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.402 HG22 HD12 ' A' ' 8' ' ' ILE . 99.1 mt -133.89 107.74 10.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.691 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -77.25 126.57 31.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.1 t0 -104.91 129.76 24.3 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.982 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.79 -31.03 13.54 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.51 2.14 . . . . 0.0 111.989 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 71.1 t -69.13 -55.95 13.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.31 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.723 ' HG1' ' H ' ' A' ' 15' ' ' THR . 15.3 p -78.85 -37.58 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 110.059 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.432 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 83.27 7.99 85.92 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.723 ' H ' ' HG1' ' A' ' 13' ' ' THR . 91.6 m -115.61 157.63 23.88 Favored 'General case' 0 C--N 1.341 0.196 0 O-C-N 121.937 -0.743 . . . . 0.0 109.756 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 15.2 m -78.91 116.95 19.56 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.05 0.452 . . . . 0.0 110.982 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -102.24 144.16 31.11 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.371 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 7' ' ' ARG . 39.1 ttm180 -96.53 124.07 40.41 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.324 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -52.67 -40.37 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 O-C-N 121.992 -0.443 . . . . 0.0 111.426 -178.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -56.82 -35.23 68.54 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.984 0.421 . . . . 0.0 110.666 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -83.22 -39.44 20.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.125 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.8 t -66.93 -41.73 87.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.563 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.1 -46.29 59.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.513 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -57.87 -36.34 72.21 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 120.948 -0.301 . . . . 0.0 110.866 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.537 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.85 30.13 10.84 Favored Glycine 0 N--CA 1.452 -0.292 0 N-CA-C 110.536 -1.026 . . . . 0.0 110.536 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.537 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtt85 15.79 64.33 0.01 OUTLIER 'General case' 0 C--N 1.364 1.207 0 CA-C-N 117.418 0.609 . . . . 0.0 110.254 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.42 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.0 mttt -89.78 144.2 31.36 Favored Pre-proline 0 N--CA 1.444 -0.732 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.294 -178.074 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.541 ' O ' ' O ' ' A' ' 29' ' ' ILE . 45.7 Cg_endo -70.21 10.11 0.59 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.236 1.957 . . . . 0.0 112.33 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' O ' ' O ' ' A' ' 28' ' ' PRO . 3.7 mm -37.37 168.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 O-C-N 123.718 0.636 . . . . 0.0 110.124 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.502 ' N ' ' CG2' ' A' ' 29' ' ' ILE . 3.7 m80 -122.68 167.27 13.65 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.953 0.406 . . . . 0.0 110.707 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.9 m -148.63 170.73 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -89.52 134.65 28.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.246 0 O-C-N 121.675 -0.64 . . . . 0.0 109.624 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.48 166.91 10.61 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.785 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.27 144.99 42.99 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.068 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.12 179.0 4.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.642 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.03 -12.57 61.05 Favored 'General case' 0 C--O 1.235 0.322 0 O-C-N 121.821 -0.549 . . . . 0.0 110.767 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -76.81 -19.41 57.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.346 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.04 -7.57 76.34 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.9 p -80.08 150.21 30.37 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.262 0.553 . . . . 0.0 111.203 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.9 mt -103.77 135.66 44.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.934 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -141.11 139.72 34.03 Favored 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.701 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.36 140.74 52.22 Favored 'General case' 0 CA--C 1.506 -0.736 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.657 -178.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.405 HH11 ' CD ' ' A' ' 125' ' ' GLU . 1.0 OUTLIER -143.51 137.66 14.73 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.231 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -74.78 158.27 43.13 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 123.105 2.537 . . . . 0.0 112.711 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 70.3 t -98.29 133.59 39.96 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 177.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.6 m -125.73 0.14 4.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.215 -179.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.416 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -150.16 145.04 26.05 Favored 'General case' 0 N--CA 1.448 -0.563 0 O-C-N 121.026 -1.046 . . . . 0.0 108.676 179.411 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.584 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.06 123.2 13.68 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 178.095 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -140.94 146.73 37.76 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -87.58 133.24 33.83 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.505 HE21 ' CB ' ' A' ' 121' ' ' ASP . 33.6 mm-40 -89.79 -0.49 57.58 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.86 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.73 174.28 50.06 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 97.4 m -91.67 127.43 37.12 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.031 0.443 . . . . 0.0 110.354 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -154.92 176.2 12.82 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.715 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 55' ' ' ASP . 0.6 OUTLIER -74.19 136.57 42.81 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.163 -179.539 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.868 ' CG2' ' HE1' ' A' ' 68' ' ' TRP . 1.5 m -145.4 156.59 13.3 Favored 'Isoleucine or valine' 0 C--N 1.34 0.153 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.45 HD11 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -109.14 155.79 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.845 -178.782 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.77 121.07 5.45 Favored Glycine 0 CA--C 1.521 0.455 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 20.7 mt -102.55 116.77 33.28 Favored 'General case' 0 C--O 1.225 -0.219 0 O-C-N 122.381 -0.482 . . . . 0.0 110.133 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.525 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 55.7 ttp180 -101.09 128.58 47.09 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.161 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 91.6 mt . . . . . 0 N--CA 1.465 0.297 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.575 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.1 tt -121.12 138.79 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.82 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 42.6 tp -126.4 112.5 15.71 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.099 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . 0.868 ' HE1' ' CG2' ' A' ' 56' ' ' VAL . 4.3 t-105 -107.71 125.79 51.81 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -154.85 175.44 13.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.233 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.422 ' OG1' ' OD1' ' A' ' 72' ' ' ASP . 71.3 p -77.06 154.0 82.64 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.16 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.12 -22.21 73.97 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.649 2.233 . . . . 0.0 111.889 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . 0.422 ' OD1' ' OG1' ' A' ' 70' ' ' THR . 10.1 p30 -91.07 -6.0 54.41 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.585 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 13.1 t60 -70.96 128.7 36.87 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -85.34 128.42 34.7 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.01 0.433 . . . . 0.0 111.304 -179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -102.8 139.79 22.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.59 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.9 tp -79.37 93.41 5.33 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.955 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 44.7 p -99.22 175.89 5.73 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.763 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.0 pt-20 -64.94 -17.53 64.46 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.284 -0.567 . . . . 0.0 111.268 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -105.77 25.97 10.18 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 121.125 -0.23 . . . . 0.0 110.811 -178.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.72 -141.13 15.43 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 87.7 m95 -93.64 129.99 39.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.452 -0.374 . . . . 0.0 111.142 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 77.4 mtm180 -142.01 131.78 24.22 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.274 179.201 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.76 17.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.024 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.42 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.84 -37.67 87.76 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.124 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.1 -2.72 2.97 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.619 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.42 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.9 mm-40 -107.64 10.87 28.95 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.93 0.395 . . . . 0.0 110.378 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.1 mt -93.51 126.94 38.94 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.378 0.608 . . . . 0.0 111.638 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.589 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.6 mmt180 -132.14 151.63 51.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.469 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -47.88 85.52 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.242 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 160.28 -15.97 0.2 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -84.91 130.32 34.66 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 116.748 0.274 . . . . 0.0 110.304 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -93.37 143.21 26.5 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.275 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.4 m -135.08 158.97 41.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.593 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -75.2 131.62 40.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.635 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 m -129.21 132.88 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -74.13 125.62 28.75 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.927 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -99.7 123.84 44.36 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.182 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 16.1 t -75.39 -16.84 15.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 121.653 -0.654 . . . . 0.0 111.43 178.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -68.97 -59.03 3.33 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 102' ' ' GLU . 23.1 p -95.43 -11.97 26.72 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.56 -13.2 6.73 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.473 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.8 mt-10 -87.15 162.81 17.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.942 0.401 . . . . 0.0 110.639 -177.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.548 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.8 pt? -76.35 140.08 41.28 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -133.18 164.32 27.32 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.763 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.38 137.36 46.48 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.114 -178.373 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -144.04 163.03 34.7 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.93 154.03 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.605 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -67.94 160.31 4.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.913 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 37.9 ttm180 -106.87 -51.71 2.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.973 179.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.525 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 83.1 tt0 -166.93 147.3 5.67 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.796 -0.565 . . . . 0.0 109.739 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -96.77 134.46 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.422 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.1 mm? -101.64 131.27 23.13 Favored Pre-proline 0 CA--C 1.538 0.504 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.555 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.76 158.53 0.74 Allowed 'Trans proline' 0 N--CA 1.489 1.22 0 C-N-CA 121.956 1.771 . . . . 0.0 111.587 178.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.7 p -69.67 157.38 37.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.462 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.6 mtp85 -154.71 161.62 41.46 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.789 0.804 . . . . 0.0 111.11 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 83.7 mtt180 -85.01 130.21 34.66 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.354 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.54 167.38 13.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.164 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 87.0 mtm180 -81.17 149.92 28.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.143 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 1.4 p -127.61 143.32 51.18 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.288 0.566 . . . . 0.0 109.931 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -114.64 171.32 7.71 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.846 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.505 ' CB ' HE21 ' A' ' 51' ' ' GLN . 45.5 t0 -156.24 128.06 7.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.977 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.0 125.75 43.18 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.751 0.31 . . . . 0.0 110.375 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 tp10 -86.67 112.62 21.81 Favored 'General case' 0 CA--C 1.513 -0.468 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.957 -178.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.4 t -85.24 112.41 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.55 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 124' ' ' VAL . 52.8 tt0 24.55 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.47 0 O-C-N 123.7 0.625 . . . . 0.0 111.578 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -130.77 -27.97 2.05 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.161 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 129' ' ' THR . 88.2 mt -77.01 66.9 2.92 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.428 ' C ' ' O ' ' A' ' 127' ' ' LEU . 47.7 m170 -38.27 95.84 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.62 139.32 0.02 OUTLIER 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.464 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.447 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 2.3 pp -147.29 155.61 42.19 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.659 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.416 ' O ' ' CG1' ' A' ' 131' ' ' VAL . 9.2 p -88.66 123.19 40.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.016 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -131.58 128.78 39.93 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.75 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.534 ' C ' ' H ' ' A' ' 135' ' ' VAL . 69.7 mm-40 53.87 45.79 27.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.037 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.81 -17.68 0.5 Allowed Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.22 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.534 ' H ' ' C ' ' A' ' 133' ' ' GLU . 5.0 t -90.55 150.41 3.75 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.293 0 O-C-N 122.267 -0.549 . . . . 0.0 110.346 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 66.6 t -109.35 113.63 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.671 0.272 . . . . 0.0 110.423 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 138' ' ' HIS . 34.0 m -149.1 143.85 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.998 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.577 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 47.7 t-80 -27.53 148.86 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.087 0.403 . . . . 0.0 112.087 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.319 -0.751 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.721 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.454 ' N ' ' OG1' ' A' ' 70' ' ' THR . 7.9 m . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -112.25 136.32 51.82 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.392 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.49 161.03 22.52 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.688 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 -62.82 146.22 53.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.832 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.66 -15.82 37.67 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 m -69.07 121.95 17.74 Favored 'General case' 0 C--O 1.233 0.237 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.653 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -83.87 149.86 26.1 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.851 0.358 . . . . 0.0 110.108 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 94.4 mt -134.7 107.4 8.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.34 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -77.41 129.95 36.45 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.634 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -103.49 133.2 20.43 Favored Pre-proline 0 CA--C 1.541 0.626 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.594 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.32 -32.64 7.97 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.7 2.267 . . . . 0.0 112.236 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.634 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 68.9 t -69.22 -52.61 31.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.538 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.59 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 7.6 p -80.88 -37.74 29.26 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.59 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 83.03 9.74 83.85 Favored Glycine 0 C--N 1.331 0.293 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.425 ' H ' ' HG1' ' A' ' 13' ' ' THR . 0.2 OUTLIER -108.22 -168.17 1.33 Allowed 'General case' 0 C--N 1.341 0.229 0 CA-C-N 117.725 0.763 . . . . 0.0 109.653 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.9 m -113.98 116.12 28.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.151 0.501 . . . . 0.0 110.283 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -105.27 147.41 28.11 Favored 'General case' 0 C--O 1.223 -0.335 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.413 -179.585 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.2 mmt85 -99.1 127.26 45.02 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.443 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 1.4 tt -53.02 -40.61 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.146 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -59.39 -33.83 71.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.672 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.6 t0 -84.35 -39.81 18.65 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.968 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 71.0 t -67.9 -43.01 86.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 65.2 t -73.57 -46.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.908 -0.317 . . . . 0.0 111.647 -178.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -60.43 -35.78 76.62 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.929 0.395 . . . . 0.0 111.013 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -100.25 25.17 29.3 Favored Glycine 0 C--N 1.322 -0.22 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.547 ' C ' ' O ' ' A' ' 25' ' ' GLY . 66.0 mtp180 17.14 59.73 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 25' ' ' GLY . 80.2 mttt -86.94 135.06 35.74 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.754 -177.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -75.36 84.89 1.64 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.222 1.948 . . . . 0.0 110.234 178.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.695 ' CG1' ' H ' ' A' ' 30' ' ' HIS . 5.2 tt -115.4 -174.5 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.994 0.426 . . . . 0.0 110.243 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.695 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 46.7 m80 -126.43 161.82 27.02 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.08 171.21 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.435 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.2 t -89.58 133.0 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.12 166.51 11.01 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.695 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.45 145.0 42.58 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.228 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.9 177.94 4.46 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -70.8 -14.0 62.25 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 120.848 0.356 . . . . 0.0 110.637 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 54.5 t0 -80.03 -18.97 48.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.28 179.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.56 23.34 34.01 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.8 p -102.31 136.11 42.72 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.854 0.359 . . . . 0.0 111.168 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' A' ' 41' ' ' HIS . 81.2 mt -92.5 128.59 38.41 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.017 0.437 . . . . 0.0 110.607 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . 0.447 ' CD2' ' O ' ' A' ' 40' ' ' LEU . 32.7 m170 -140.01 138.49 35.49 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.772 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.07 142.19 52.7 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.779 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -143.07 138.56 15.86 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.148 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.87 157.28 34.97 Favored 'Trans proline' 0 N--CA 1.489 1.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.822 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -98.99 133.7 40.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 20.0 m -124.98 -0.27 5.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.37 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -151.22 146.75 26.3 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.174 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.575 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.45 127.51 17.47 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 178.254 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -131.22 144.6 51.45 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.97 0.414 . . . . 0.0 111.643 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -116.08 139.62 50.11 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 178.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -109.2 -110.82 0.32 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.704 -1.134 . . . . 0.0 109.889 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -162.09 -156.81 8.59 Favored Glycine 0 C--N 1.303 -1.277 0 CA-C-N 114.233 -1.348 . . . . 0.0 112.482 -177.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.408 ' O ' ' CG2' ' A' ' 53' ' ' THR . 4.5 t -98.1 126.75 43.68 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.868 0.366 . . . . 0.0 111.178 -179.104 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -145.74 172.04 13.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.614 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -76.3 136.38 39.6 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.126 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.9 m -140.23 135.88 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.942 0.401 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 39.3 pt -87.86 148.79 4.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.717 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.47 126.8 8.35 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.0 mt -108.58 115.84 30.85 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.219 0.533 . . . . 0.0 110.938 -179.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -83.03 104.74 13.46 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.881 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.0 mm . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.242 -178.263 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.87 155.64 37.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.332 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.0 tp -133.39 118.24 18.2 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.153 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.8 m95 -104.34 114.16 28.21 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -139.45 171.2 14.6 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.484 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.7 OUTLIER -80.65 157.02 72.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.361 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -63.42 -18.13 63.17 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.645 2.23 . . . . 0.0 111.9 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -94.46 -9.99 33.78 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.876 0.37 . . . . 0.0 110.309 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.545 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.8 t60 -71.01 130.77 42.42 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -87.03 130.61 34.39 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.148 0.499 . . . . 0.0 111.144 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.36 142.29 18.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.875 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 52.9 tp -79.91 93.17 5.63 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.691 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.616 ' HG1' ' H ' ' A' ' 79' ' ' TYR . 12.1 p -99.02 177.67 5.17 Favored 'General case' 0 CA--C 1.52 -0.19 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -178.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -68.09 -19.15 64.83 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.236 -179.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.616 ' H ' ' HG1' ' A' ' 77' ' ' THR . 6.0 t80 -104.63 24.1 12.28 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-O 120.733 0.302 . . . . 0.0 110.632 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.69 -176.03 42.56 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 81.2 m95 -57.91 127.76 33.68 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.014 0.435 . . . . 0.0 110.12 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 -142.36 133.54 26.11 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.888 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.44 140.01 29.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.675 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.15 -37.87 86.83 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.243 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.01 -2.42 4.92 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.526 -179.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -106.0 -0.65 24.77 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.02 0.438 . . . . 0.0 110.418 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -81.55 127.79 33.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.151 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.548 ' O ' ' N ' ' A' ' 90' ' ' GLY . 8.9 tpp180 -131.01 149.75 52.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.179 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -45.5 89.04 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.644 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.05 -15.72 0.43 Allowed Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -86.39 130.15 34.61 Favored 'General case' 0 CA--C 1.523 -0.085 0 CA-C-O 121.023 0.44 . . . . 0.0 110.381 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -90.73 131.3 36.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.37 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 26.8 m -116.93 150.35 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.227 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.39 136.09 47.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.004 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.1 m -133.85 161.77 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.33 179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 67.9 ttt-85 -104.67 128.37 52.7 Favored 'General case' 0 N--CA 1.462 0.14 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -100.92 123.49 45.2 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.082 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 28.1 m -75.9 -15.4 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 118.179 0.445 . . . . 0.0 110.906 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -69.59 -58.45 3.93 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.06 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.441 ' C ' ' H ' ' A' ' 102' ' ' GLU . 1.5 t -97.87 -12.4 22.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.269 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.35 -12.84 8.85 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.441 ' H ' ' C ' ' A' ' 100' ' ' THR . 43.2 mt-10 -83.25 159.44 21.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.79 0.329 . . . . 0.0 110.749 -178.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.02 140.06 32.11 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.231 0.538 . . . . 0.0 109.934 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 59.4 mtp180 -137.07 171.91 13.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.218 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.8 m-30 -105.56 139.14 40.63 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.954 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 7.9 m -135.96 155.31 50.45 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.7 p -95.2 157.21 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 122.573 0.349 . . . . 0.0 111.116 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 42.7 mm -82.18 136.68 22.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.003 178.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.1 mmt85 -84.88 -38.44 19.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.694 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -169.45 151.85 4.61 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 84.6 t -95.31 132.08 40.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.113 0.483 . . . . 0.0 110.176 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.421 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.0 mm? -100.37 131.48 23.91 Favored Pre-proline 0 N--CA 1.467 0.394 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.61 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.37 154.63 2.5 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.129 1.886 . . . . 0.0 111.662 178.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.3 p -68.39 158.88 32.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.022 0.439 . . . . 0.0 110.518 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -151.46 149.12 28.89 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.047 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 57.0 mtm180 -78.33 132.58 37.49 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.197 0.522 . . . . 0.0 110.354 179.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.75 158.13 12.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.43 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -67.16 142.59 56.98 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 71.4 p -124.25 141.34 52.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.206 0.527 . . . . 0.0 109.899 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -116.67 174.84 5.86 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.82 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -152.63 128.96 10.56 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 82.2 mt -116.1 170.79 8.24 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.667 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -137.88 107.74 6.3 Favored 'General case' 0 CA--C 1.516 -0.346 0 C-N-CA 120.604 -0.439 . . . . 0.0 110.576 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.43 116.81 31.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 127' ' ' LEU . 38.8 tt0 -58.39 149.88 23.69 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.757 -179.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 61.64 -69.13 0.05 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.254 -0.885 . . . . 0.0 112.159 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -98.0 95.06 7.21 Favored 'General case' 0 CA--C 1.519 -0.23 0 O-C-N 122.285 -0.259 . . . . 0.0 110.413 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.403 ' O ' ' OG1' ' A' ' 129' ' ' THR . 75.5 m80 -67.04 99.84 0.69 Allowed 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.55 144.62 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.432 ' H ' HD21 ' A' ' 130' ' ' LEU . 1.7 pt? -144.68 154.45 42.79 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 121.635 0.731 . . . . 0.0 111.788 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.76 127.25 41.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 179.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.93 129.74 36.74 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.401 -179.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 51.73 46.78 26.0 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.033 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.14 -21.01 0.39 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 8.1 t -90.4 152.42 3.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.172 0 O-C-N 122.27 -0.547 . . . . 0.0 110.588 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -106.53 114.64 46.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.358 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 10.1 m -147.15 136.16 15.99 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.467 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 3.2 t60 -38.54 162.91 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.833 0.349 . . . . 0.0 111.621 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.434 ' H ' ' CD2' ' A' ' 138' ' ' HIS . 12.6 p30 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.271 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.638 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.5 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -118.02 134.56 54.86 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 120.89 0.376 . . . . 0.0 110.391 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -86.38 163.61 17.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.396 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.409 ' OE2' ' CD ' ' A' ' 20' ' ' GLU . 57.7 tt0 -63.02 142.16 58.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.506 178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.85 -21.09 30.43 Favored Glycine 0 C--N 1.334 0.458 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.8 m -66.04 123.48 19.96 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.01 148.88 28.41 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.838 0.352 . . . . 0.0 110.068 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.52 107.31 8.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -77.4 125.19 28.94 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.625 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 4.7 t70 -101.99 132.79 21.19 Favored Pre-proline 0 CA--C 1.538 0.501 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.846 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.95 -31.61 7.94 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.619 2.213 . . . . 0.0 112.166 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.625 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 66.2 t -71.47 -54.47 17.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.694 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.479 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 6.9 p -77.32 -38.94 49.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.961 0.41 . . . . 0.0 110.171 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.479 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 84.31 4.62 87.91 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.5 m -114.18 157.63 22.39 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 117.435 0.617 . . . . 0.0 109.85 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 40.2 m -78.47 116.65 19.01 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.28 0.562 . . . . 0.0 110.794 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . 0.485 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-70 -103.1 146.7 27.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.452 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -98.52 128.12 44.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.971 179.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 2.6 tp -52.2 -40.87 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.613 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.417 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 7.4 tt0 -57.56 -36.16 71.31 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.976 0.417 . . . . 0.0 110.852 -179.486 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.519 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 49.4 t0 -81.73 -35.7 29.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.47 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -67.32 -42.17 87.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.642 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.5 t -74.11 -46.79 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -177.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 0.6 OUTLIER -56.05 -37.57 69.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.824 -177.869 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.07 32.17 7.63 Favored Glycine 0 C--O 1.227 -0.287 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.6 ptm180 12.45 65.72 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.005 0 CA-C-O 121.189 0.518 . . . . 0.0 110.307 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.402 ' N ' ' O ' ' A' ' 25' ' ' GLY . 78.2 mttt -85.88 141.55 35.84 Favored Pre-proline 0 N--CA 1.447 -0.579 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.811 -177.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.548 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.4 Cg_endo -71.3 7.62 1.4 Allowed 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.23 1.953 . . . . 0.0 112.224 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' PRO . 12.8 tt -38.05 169.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 O-C-N 123.505 0.503 . . . . 0.0 110.597 -178.308 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.521 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 2.2 m80 -120.16 170.61 9.16 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.341 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.08 172.76 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.9 t -88.16 135.03 26.5 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.53 167.53 10.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.845 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.6 140.41 40.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.855 0.359 . . . . 0.0 110.373 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.23 179.06 4.06 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.564 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -68.44 -16.06 63.77 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-O 120.754 0.312 . . . . 0.0 110.764 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -74.8 -19.56 60.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.618 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.22 -11.89 69.84 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.0 p -74.8 148.74 40.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.141 0.496 . . . . 0.0 110.961 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 56.6 mt -104.78 135.09 46.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.802 -179.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -141.13 138.63 33.62 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.625 -179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -68.7 143.0 54.86 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.759 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.467 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.3 mmp_? -143.83 138.26 15.01 Favored Pre-proline 0 CA--C 1.538 0.483 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.829 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 160.06 37.42 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 123.058 2.505 . . . . 0.0 112.754 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.88 136.92 34.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.045 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.512 ' C ' ' HG ' ' A' ' 47' ' ' SER . 22.2 m -128.26 3.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.877 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.512 ' HG ' ' C ' ' A' ' 46' ' ' VAL . 1.4 m -148.43 142.5 25.96 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.889 0.768 . . . . 0.0 109.239 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -144.09 123.26 12.93 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 178.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -143.91 149.13 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.822 0.675 . . . . 0.0 112.822 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -96.51 131.85 42.7 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.355 -0.979 . . . . 0.0 108.355 176.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.652 HE21 ' C ' ' A' ' 119' ' ' THR . 1.9 mt-30 -95.41 4.29 53.48 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.655 -0.248 . . . . 0.0 111.075 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.11 -172.09 47.11 Favored Glycine 0 C--N 1.336 0.576 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.821 179.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.463 ' OG1' ' CZ ' ' A' ' 118' ' ' ARG . 67.8 m -86.82 127.44 35.01 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 120.76 0.314 . . . . 0.0 110.308 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -148.18 159.6 43.78 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.605 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.0 143.24 43.67 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.873 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.01 147.11 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.117 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . 0.418 HD11 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -100.86 148.13 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.944 -179.693 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.98 135.5 12.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -119.24 114.96 23.22 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.254 0.549 . . . . 0.0 110.346 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -95.95 116.81 29.5 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.776 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.538 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.9 mp . . . . . 0 N--CA 1.466 0.358 0 CA-C-O 120.987 0.422 . . . . 0.0 111.009 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.194 0 CA-C-O 121.084 0.469 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.5 tt -126.18 158.21 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.681 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.1 tp -138.61 121.73 16.85 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.429 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.1 m95 -106.06 128.96 54.21 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.96 172.39 16.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.411 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -82.65 155.98 68.21 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.793 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.31 -24.0 75.61 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.706 2.271 . . . . 0.0 111.918 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -87.6 -7.38 57.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.181 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.638 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 8.2 t60 -73.81 128.65 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -87.88 133.99 33.79 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.134 0.492 . . . . 0.0 111.034 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -105.44 140.44 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.061 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.427 ' C ' ' CD1' ' A' ' 76' ' ' LEU . 0.6 OUTLIER -83.39 95.29 8.18 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.176 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.454 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 50.1 p -98.72 179.37 4.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.493 -179.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.447 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 17.6 pt-20 -65.26 -17.61 64.64 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.303 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . 0.447 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 50.2 m-85 -107.32 25.48 11.37 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.193 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.47 -139.2 14.32 Favored Glycine 0 C--N 1.335 0.482 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.716 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.5 m95 -94.47 130.13 40.96 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.329 -0.436 . . . . 0.0 111.784 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -138.13 125.92 22.41 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.95 140.81 29.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.95 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.493 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -59.97 -40.7 89.99 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 121.023 -0.271 . . . . 0.0 111.616 -178.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.21 -1.72 0.78 Allowed Glycine 0 CA--C 1.524 0.626 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.075 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.595 ' OE1' ' N ' ' A' ' 86' ' ' GLU . 57.4 mp0 -118.94 36.75 4.33 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.026 0.441 . . . . 0.0 110.612 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.4 mt -110.73 124.95 52.95 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.955 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.7 mmt180 -131.87 145.65 51.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.567 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -40.94 90.63 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 121.01 0.433 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.12 -13.71 0.38 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -89.99 127.75 36.11 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 120.974 0.416 . . . . 0.0 110.358 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -92.21 133.6 35.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.599 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.4 m -114.57 149.24 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.63 128.46 36.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.918 0.39 . . . . 0.0 110.997 -179.297 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.7 m -130.8 161.74 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.348 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -110.29 132.9 53.77 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.57 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -100.98 126.11 47.61 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.251 178.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 85.3 t -74.96 -15.44 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 O-C-N 121.891 -0.506 . . . . 0.0 111.367 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -70.01 -57.41 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.145 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.425 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.1 m -100.51 -14.4 18.26 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.501 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.16 -11.93 14.5 Favored Glycine 0 C--N 1.331 0.261 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.528 ' OE1' ' NH2' ' A' ' 104' ' ' ARG . 95.4 mt-10 -79.14 156.05 28.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 0.0 110.897 -178.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.17 132.52 35.36 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 121.605 0.716 . . . . 0.0 110.038 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.528 ' NH2' ' OE1' ' A' ' 102' ' ' GLU . 35.9 mmt180 -132.28 -179.54 5.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.342 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.454 ' OH ' ' C ' ' A' ' 77' ' ' THR . 4.1 m-85 -118.63 147.28 43.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.681 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 28.6 m -138.57 159.0 43.19 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.6 p -89.55 153.09 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.726 0.298 . . . . 0.0 110.72 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.431 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.8 mm -72.64 156.78 6.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.179 0.514 . . . . 0.0 109.963 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.431 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 2.5 tpm_? -106.69 -47.37 3.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.106 179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -166.56 145.56 5.57 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.63 133.77 35.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.929 0.395 . . . . 0.0 110.072 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.56 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -102.06 148.21 35.04 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.357 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.99 158.52 57.01 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 122.496 2.131 . . . . 0.0 111.549 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 2.0 p -68.49 158.2 34.3 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.009 0.433 . . . . 0.0 110.66 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.402 ' CG ' ' N ' ' A' ' 116' ' ' ARG . 45.2 ttp180 -153.55 153.86 33.18 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.507 179.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.402 ' N ' ' CG ' ' A' ' 115' ' ' ARG . 18.5 mmm180 -77.31 125.71 29.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.506 179.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -162.89 159.18 23.45 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.701 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.463 ' CZ ' ' OG1' ' A' ' 53' ' ' THR . 11.0 mpt_? -76.26 149.11 37.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.815 179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.652 ' C ' HE21 ' A' ' 51' ' ' GLN . 62.1 p -132.03 145.77 51.65 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.588 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 63.8 m-85 -114.74 173.06 6.66 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.627 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -143.37 130.7 20.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.69 170.91 10.01 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.417 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -135.32 106.49 6.72 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 17.4 t -85.42 109.55 18.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.28 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 41.4 tp10 21.86 -108.13 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.9 0.75 . . . . 0.0 111.359 179.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -114.41 -26.68 7.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.039 179.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 129' ' ' THR . 91.4 mt -84.52 68.53 10.34 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' OG1' ' A' ' 129' ' ' THR . 9.7 m170 -41.94 99.94 0.02 OUTLIER 'General case' 0 CA--C 1.507 -0.683 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.486 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.435 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.32 137.26 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.248 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 130' ' ' LEU . 2.2 pp -145.34 150.6 36.9 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.157 0.504 . . . . 0.0 111.237 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.423 ' O ' ' CG1' ' A' ' 131' ' ' VAL . 5.4 p -87.55 127.9 40.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.351 -0.841 . . . . 0.0 108.935 -179.127 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.9 124.86 27.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.734 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.503 ' C ' ' H ' ' A' ' 135' ' ' VAL . 76.2 mm-40 59.21 44.63 15.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.287 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.0 -19.49 0.75 Allowed Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.503 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.6 t -88.76 150.78 3.61 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 117.033 0.416 . . . . 0.0 110.622 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 48.6 t -106.43 113.56 43.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.31 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 138' ' ' HIS . 15.0 m -148.37 140.87 18.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.548 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 60.6 t-80 -32.37 155.6 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.438 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 23.2 p30 . . . . . 0 C--N 1.324 -0.523 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.45 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.632 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 28.2 m . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -111.46 139.12 47.15 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.832 0.349 . . . . 0.0 110.193 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.91 162.45 16.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -60.5 143.11 54.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.489 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.14 -16.12 32.82 Favored Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 m -71.8 122.58 20.94 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.707 -0.29 . . . . 0.0 111.014 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.6 mtt85 -82.04 148.49 28.58 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 120.781 0.324 . . . . 0.0 110.247 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.4 HD11 HG23 ' A' ' 8' ' ' ILE . 71.0 mt -135.62 108.21 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.289 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -79.72 129.66 34.67 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.413 ' O ' ' N ' ' A' ' 14' ' ' GLY . 55.3 t0 -109.94 113.41 57.23 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.813 -0.176 . . . . 0.0 110.755 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.11 -36.93 78.68 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.625 2.217 . . . . 0.0 112.082 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -61.8 -57.8 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.613 -178.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.734 ' HG1' ' H ' ' A' ' 15' ' ' THR . 29.9 p -78.27 -37.96 43.76 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.179 0.514 . . . . 0.0 110.126 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 85.16 5.71 85.35 Favored Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.734 ' H ' ' HG1' ' A' ' 13' ' ' THR . 96.5 m -114.33 157.29 23.0 Favored 'General case' 0 C--N 1.346 0.449 0 CA-C-N 117.658 0.729 . . . . 0.0 109.837 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 26.0 m -79.67 119.66 22.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.35 0.595 . . . . 0.0 110.61 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 19.9 m-70 -103.31 145.34 30.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.385 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 29.0 ttm-85 -96.92 124.37 40.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.03 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.466 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 1.6 tp -51.75 -44.14 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.724 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.466 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 10.8 pt-20 -57.98 -34.9 70.47 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.131 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -82.25 -37.56 25.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.326 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 67.7 t -66.92 -43.24 89.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.517 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.3 t -72.5 -47.23 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -57.18 -38.11 73.15 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.146 -178.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.08 29.52 12.34 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.548 ' C ' ' O ' ' A' ' 25' ' ' GLY . 90.7 mtm180 15.78 62.5 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 O-C-N 124.037 0.492 . . . . 0.0 110.045 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.2 mttt -87.64 126.13 62.85 Favored Pre-proline 0 N--CA 1.44 -0.97 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.944 -177.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -75.23 93.43 0.97 Allowed 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.469 2.113 . . . . 0.0 110.316 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.3 pt -121.21 -170.16 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.87 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -125.97 164.49 20.7 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.307 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.1 m -150.65 173.68 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.2 t -86.55 125.28 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.17 150.85 25.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.626 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.22 144.12 49.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.411 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.26 178.26 4.39 Favored 'General case' 0 N--CA 1.472 0.664 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.8 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp -68.45 -15.25 63.48 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.693 0.283 . . . . 0.0 110.396 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -78.43 -20.3 51.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.083 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.45 -9.67 71.56 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.5 p -73.1 139.01 46.17 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.363 0.601 . . . . 0.0 111.297 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.403 ' CD1' ' NH2' ' A' ' 96' ' ' ARG . 50.6 mt -95.7 135.33 37.54 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.558 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -145.98 141.48 27.75 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.39 147.54 44.2 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.663 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 6.5 mtp180 -152.81 148.98 21.15 Favored Pre-proline 0 N--CA 1.457 -0.124 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.231 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.6 149.55 61.71 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.557 2.172 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.7 t -112.87 146.53 17.44 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.847 0 CA-C-O 121.502 0.668 . . . . 0.0 109.312 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.705 ' O ' ' CE2' ' A' ' 48' ' ' TRP . 2.1 m -139.49 -100.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.497 ' H ' ' CG2' ' A' ' 46' ' ' VAL . 9.3 t -19.0 113.84 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 114.164 -1.38 . . . . 0.0 111.542 -175.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.705 ' CE2' ' O ' ' A' ' 46' ' ' VAL . 1.5 m-90 -120.3 110.89 17.1 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.7 m-85 -138.43 147.02 42.86 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.304 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 46.4 p-10 -91.65 134.98 34.22 Favored 'General case' 0 C--N 1.334 -0.069 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.524 HE21 ' HB2' ' A' ' 121' ' ' ASP . 29.8 mm-40 -92.67 -4.83 52.6 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.715 -0.22 . . . . 0.0 111.219 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 -179.11 48.68 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 79.9 m -94.24 122.66 37.01 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.8 mtp85 -146.54 171.38 15.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.435 0.636 . . . . 0.0 110.656 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -74.42 139.63 44.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.219 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -139.36 153.3 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 pt -108.88 155.83 9.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.183 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.03 128.73 8.71 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 28.4 mt -108.94 115.3 29.82 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.205 0.526 . . . . 0.0 110.413 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.6 tpp180 -85.81 109.29 18.57 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.055 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 12.8 mm . . . . . 0 N--CA 1.469 0.478 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.041 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.369 0 CA-C-O 120.949 0.404 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.4 tt -124.94 153.47 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.357 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 43.9 tp -132.75 118.72 19.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.337 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -105.8 118.21 36.01 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.96 170.97 15.12 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.534 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 37.6 p -79.5 153.56 76.24 Favored Pre-proline 0 N--CA 1.45 -0.432 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.128 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.78 -30.25 88.6 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 122.534 2.156 . . . . 0.0 112.146 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -80.97 -9.46 59.84 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.428 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.632 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.7 t60 -70.46 129.04 38.2 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -86.75 131.61 34.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.399 0.619 . . . . 0.0 111.154 -179.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -103.62 139.21 25.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.783 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 58.7 tp -78.35 91.95 4.51 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.856 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.9 p -97.38 -179.34 4.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -178.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -69.87 -16.41 63.24 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.196 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -106.27 26.31 9.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.933 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.88 -138.54 13.97 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -95.67 130.61 42.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.537 -0.331 . . . . 0.0 111.138 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . 0.511 ' NH1' ' OD1' ' A' ' 91' ' ' ASP . 84.0 mtp180 -140.56 129.89 23.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.246 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.38 145.29 18.42 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.011 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.418 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.48 -40.14 95.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 121.249 -0.18 . . . . 0.0 111.473 -179.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.3 -3.46 3.89 Favored Glycine 0 C--N 1.337 0.614 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.757 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.418 ' H ' ' C ' ' A' ' 84' ' ' ALA . 50.9 mt-10 -113.24 32.73 5.54 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.732 0.301 . . . . 0.0 110.56 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.9 mt -112.7 126.81 55.8 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 121.38 0.61 . . . . 0.0 111.226 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 37.5 mmt180 -130.89 147.19 52.51 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.884 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -42.66 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.876 0.369 . . . . 0.0 110.741 -179.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.25 -12.68 0.43 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.511 ' OD1' ' NH1' ' A' ' 82' ' ' ARG . 17.8 t70 -87.85 128.57 35.35 Favored 'General case' 0 C--O 1.227 -0.102 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -89.84 131.74 35.62 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.393 -179.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -118.32 150.91 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.121 -0.49 . . . . 0.0 109.797 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -66.76 134.98 53.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.955 0.407 . . . . 0.0 111.015 -179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 21.4 m -134.22 159.68 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.013 179.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.403 ' NH2' ' CD1' ' A' ' 40' ' ' LEU . 52.6 ttm-85 -107.02 130.24 54.68 Favored 'General case' 0 C--N 1.334 -0.098 0 CA-C-O 120.677 0.275 . . . . 0.0 110.333 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.36 122.9 43.86 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.365 178.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 62.3 t -76.28 -16.19 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 118.133 0.424 . . . . 0.0 110.749 179.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 99' ' ' GLU . 0.5 OUTLIER -72.02 -57.26 4.44 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.849 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.3 p -94.45 -13.81 25.83 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.13 -14.76 3.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.473 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.5 mt-10 -83.56 163.53 20.34 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 120.981 0.42 . . . . 0.0 110.764 -177.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 4.6 tt -80.51 136.88 36.38 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 45.9 mtp85 -134.42 168.81 18.25 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.099 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -110.87 140.6 45.2 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.672 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.3 m -136.49 155.39 50.05 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.409 179.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 58.1 t -91.33 156.68 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.008 0.432 . . . . 0.0 110.555 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 3.5 mm -72.66 153.13 7.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.237 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -106.0 -45.93 4.23 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -166.05 145.36 6.08 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 83.5 t -96.46 132.88 39.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.137 0.494 . . . . 0.0 110.163 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.457 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.1 mm? -98.57 128.73 32.0 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.288 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.63 157.99 2.11 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 122.384 2.056 . . . . 0.0 111.743 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.2 p -66.94 156.93 34.56 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.49 0.662 . . . . 0.0 110.685 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -139.04 -140.1 0.14 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.915 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 80.7 mtm180 -153.66 132.6 12.46 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.902 0.382 . . . . 0.0 110.115 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.7 173.67 3.86 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.651 -179.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 -83.51 154.27 23.96 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.144 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -132.64 143.47 49.69 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.95 174.83 5.7 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.483 -0.78 . . . . 0.0 111.5 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.524 ' HB2' HE21 ' A' ' 51' ' ' GLN . 26.4 t0 -148.03 128.79 14.26 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.164 -179.572 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.2 mt -132.15 123.39 27.0 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.852 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -87.51 115.67 25.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.144 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 125' ' ' GLU . 98.5 t -85.48 114.09 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 127' ' ' LEU . 39.7 tp10 -28.2 111.92 0.06 Allowed 'General case' 0 N--CA 1.466 0.367 0 O-C-N 123.574 0.546 . . . . 0.0 111.762 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 60.49 -65.87 0.05 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 178.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.477 ' N ' ' O ' ' A' ' 125' ' ' GLU . 86.0 mt -72.76 75.17 1.13 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.041 0.448 . . . . 0.0 111.005 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.428 ' C ' ' OG1' ' A' ' 129' ' ' THR . 31.5 m170 -56.01 98.96 0.03 OUTLIER 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.45 143.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 O-C-N 123.712 0.632 . . . . 0.0 109.439 178.936 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.493 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 1.8 pp -149.23 154.1 38.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.542 0.687 . . . . 0.0 111.446 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 85.6 t -90.01 123.69 42.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.033 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.08 129.16 37.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -178.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.525 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.2 mm-40 58.77 43.23 18.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.897 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.76 -20.89 0.48 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.525 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.9 t -89.18 151.13 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-O 120.943 0.402 . . . . 0.0 110.821 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -104.69 112.78 39.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.548 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 11.5 m -148.3 138.65 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 CA-C-O 118.988 -0.529 . . . . 0.0 110.29 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.578 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 14.4 t-80 -28.41 147.63 0.0 OUTLIER 'General case' 0 C--N 1.342 0.259 0 O-C-N 123.571 0.544 . . . . 0.0 111.956 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.616 ' C ' HD21 ' A' ' 139' ' ' ASN . 0.2 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.895 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -91.45 139.01 31.13 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.839 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.52 161.7 28.95 Favored 'General case' 0 CA--C 1.529 0.135 0 CA-C-O 120.978 0.418 . . . . 0.0 111.262 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 77.5 tt0 -66.62 143.27 57.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.826 178.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.97 -18.85 33.58 Favored Glycine 0 C--N 1.336 0.561 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 m -66.05 124.97 24.01 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.441 ' HE ' ' CD ' ' A' ' 18' ' ' ARG . 1.6 mpt_? -97.25 116.39 29.36 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 121.014 0.435 . . . . 0.0 110.214 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 15.4 mt -100.41 113.06 34.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.209 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -75.47 133.93 40.96 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.07 129.97 26.02 Favored Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 121.145 -0.222 . . . . 0.0 110.678 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.72 -27.47 18.2 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.91 1.74 . . . . 0.0 112.277 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 42.7 t -76.42 -53.81 14.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.19 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.9 p -76.94 -35.88 56.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.983 0.42 . . . . 0.0 110.251 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.64 10.5 85.13 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.406 ' CG2' ' N ' ' A' ' 16' ' ' THR . 54.8 m -115.56 160.42 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 117.564 0.682 . . . . 0.0 109.694 -179.689 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.406 ' N ' ' CG2' ' A' ' 15' ' ' THR . 12.5 m -79.54 115.0 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.194 0.521 . . . . 0.0 110.911 -179.229 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -101.3 143.46 31.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.866 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.441 ' CD ' ' HE ' ' A' ' 7' ' ' ARG . 69.3 mtm180 -99.65 128.38 45.75 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.753 -0.203 . . . . 0.0 110.574 178.247 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.1 tp -53.1 -38.42 29.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.561 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -58.17 -35.34 71.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.318 0.58 . . . . 0.0 110.969 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -85.18 -38.38 19.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.63 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 94.2 t -69.04 -42.39 81.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.838 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 75.2 t -75.36 -45.89 39.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.833 -178.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -57.67 -34.5 69.45 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.681 -178.332 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.577 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.25 29.31 9.3 Favored Glycine 0 CA--C 1.519 0.298 0 CA-C-O 119.108 -0.829 . . . . 0.0 111.033 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.577 ' C ' ' O ' ' A' ' 25' ' ' GLY . 44.6 ptt85 13.62 64.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.45 0.643 . . . . 0.0 110.054 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 25' ' ' GLY . 81.6 mttt -84.86 139.49 37.36 Favored Pre-proline 0 N--CA 1.449 -0.503 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.369 -176.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.9 83.27 2.14 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.352 1.368 . . . . 0.0 110.164 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.419 ' CD1' ' C ' ' A' ' 29' ' ' ILE . 1.9 pp -116.27 -174.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.811 0.338 . . . . 0.0 110.486 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.422 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 34.7 m80 -128.65 161.95 28.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.511 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.9 m -146.96 170.47 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.97 134.98 26.56 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.358 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -107.78 166.55 10.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.534 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.2 137.59 39.29 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.914 0.387 . . . . 0.0 110.23 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -112.28 175.42 5.44 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -73.02 -13.34 61.2 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.865 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -78.32 -11.44 59.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.429 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.46 17.37 64.38 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.2 p -100.81 139.34 36.64 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.024 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.9 mt -98.54 131.61 44.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.655 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -139.52 138.3 36.21 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.965 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.87 142.7 52.99 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.465 -0.494 . . . . 0.0 109.959 -178.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -145.04 138.6 14.36 Favored Pre-proline 0 N--CA 1.468 0.461 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.297 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.12 157.2 33.96 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 122.555 2.17 . . . . 0.0 112.424 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -98.84 138.17 24.14 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 177.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.99 2.66 3.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.183 -178.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.431 ' OG ' ' OE1' ' A' ' 123' ' ' GLU . 1.5 m -146.97 133.99 20.33 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 120.038 -0.665 . . . . 0.0 110.006 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.508 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.77 121.71 18.85 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.003 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -138.14 143.59 40.39 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.599 ' O ' ' HG2' ' A' ' 51' ' ' GLN . 29.3 t70 -88.42 125.77 34.89 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.599 ' HG2' ' O ' ' A' ' 50' ' ' ASP . 8.2 mt-30 -160.86 60.08 0.31 Allowed 'General case' 0 CA--C 1.498 -1.042 0 O-C-N 124.158 0.911 . . . . 0.0 108.55 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . 0.759 ' CA ' ' H ' ' A' ' 119' ' ' THR . . . -118.62 167.06 12.98 Favored Glycine 0 C--N 1.314 -0.684 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.398 -178.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.562 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 33.3 m 113.99 63.53 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 O-C-N 125.436 1.315 . . . . 0.0 111.261 177.788 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.6 mtt-85 -148.78 175.72 10.99 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.634 0.254 . . . . 0.0 110.794 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -77.47 139.56 39.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.61 151.81 19.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.41 144.77 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 109.963 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.93 134.7 12.15 Favored Glycine 0 N--CA 1.462 0.39 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 71.6 mt -116.78 116.34 27.3 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-O 121.064 0.459 . . . . 0.0 110.313 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.75 107.73 17.09 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.103 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.562 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.6 mp . . . . . 0 C--N 1.325 -0.461 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 179.007 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.163 0 CA-C-O 120.811 0.338 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.0 mt -124.7 154.72 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.123 179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 61.9 tp -128.79 114.73 16.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.814 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -103.83 109.96 21.9 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -134.2 172.32 13.02 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.198 -179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.14 156.8 69.13 Favored Pre-proline 0 CA--C 1.535 0.401 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.435 179.487 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -63.15 -17.72 61.5 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.734 2.29 . . . . 0.0 112.169 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 49.3 p-10 -97.62 -6.67 32.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.992 0.425 . . . . 0.0 110.185 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.4 t60 -71.85 129.68 39.21 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -83.57 124.07 30.4 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.375 0.607 . . . . 0.0 111.631 -179.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 73.5 t -98.14 138.35 23.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.058 -0.973 . . . . 0.0 109.889 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 37.9 tp -81.67 95.64 7.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.036 -179.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 p -100.28 175.87 5.57 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -67.67 -18.14 64.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.459 -178.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -105.97 21.07 17.93 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.647 0.26 . . . . 0.0 110.642 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.89 -144.63 15.88 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -91.95 126.54 37.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.527 0.204 . . . . 0.0 110.97 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -127.83 126.75 42.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.79 136.9 54.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.949 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -69.78 -0.88 7.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.683 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.71 -13.78 77.22 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -132.22 15.44 4.61 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.758 0.313 . . . . 0.0 111.46 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.5 mt -80.32 141.41 35.47 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.233 0.54 . . . . 0.0 110.877 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.0 tpp85 -142.08 155.21 45.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.014 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -48.51 113.86 0.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.334 179.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 141.77 -22.33 2.5 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -83.09 130.56 35.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.706 0.289 . . . . 0.0 110.766 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -88.84 136.62 32.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.128 0.49 . . . . 0.0 110.795 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.0 m -122.02 144.05 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.5 -179.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.52 131.53 42.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.912 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.4 m -127.06 163.11 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.98 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -100.5 128.14 46.65 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.671 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -100.54 124.28 45.88 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.8 t -75.63 -15.81 15.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 118.24 0.473 . . . . 0.0 110.909 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 37.7 tp10 -69.35 -58.66 3.72 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.097 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.475 ' C ' ' H ' ' A' ' 102' ' ' GLU . 70.3 p -99.73 -12.18 20.2 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.772 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.32 -13.87 9.78 Favored Glycine 0 C--N 1.332 0.312 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.475 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.6 mt-10 -82.05 153.84 25.93 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.953 0.406 . . . . 0.0 111.622 -177.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 139.92 36.59 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 179.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.0 ptt85 -142.64 138.47 30.7 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.702 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.9 m-30 -78.28 147.8 34.16 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.38 -0.528 . . . . 0.0 109.998 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -139.34 162.68 34.43 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.7 t -95.32 154.29 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 61.6 mt -73.54 154.61 6.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.0 ttm180 -104.75 -42.72 5.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.16 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -167.23 147.82 5.53 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 23.1 t -92.81 130.85 41.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.6 mp -98.99 124.93 43.69 Favored Pre-proline 0 CA--C 1.543 0.709 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.973 -179.519 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -48.45 162.73 0.31 Allowed 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.228 1.952 . . . . 0.0 111.998 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.1 p -73.02 160.44 32.07 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.28 0.562 . . . . 0.0 110.823 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.459 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 10.0 tpt180 -144.89 -132.47 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.195 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.459 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 1.5 tmm_? -155.39 134.83 12.47 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.983 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 170.77 4.27 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.072 -178.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 84.2 mtm-85 -83.87 140.36 32.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.843 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' THR . . . . . 0.759 ' H ' ' CA ' ' A' ' 52' ' ' GLY . 4.2 p -128.39 148.78 50.72 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.559 177.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -122.75 179.76 4.51 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.971 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -147.64 124.83 11.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.368 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.84 173.08 6.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.444 -179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . 0.431 ' OE1' ' OG ' ' A' ' 47' ' ' SER . 38.5 tt0 -136.38 105.36 5.92 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.241 178.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 125' ' ' GLU . 16.4 t -83.56 108.64 16.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.0 tt0 20.37 -89.14 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.639 0.587 . . . . 0.0 112.322 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 124' ' ' VAL . 81.6 mt-10 -129.27 -39.94 1.49 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.392 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.515 ' O ' ' N ' ' A' ' 129' ' ' THR . 84.3 mt -71.04 64.86 0.35 Allowed 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.183 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.402 ' N ' ' O ' ' A' ' 126' ' ' GLU . 39.3 m80 -41.78 94.82 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 179.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.515 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 171.63 141.28 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.189 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.43 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.0 pp -147.79 155.96 42.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.425 0.631 . . . . 0.0 111.885 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -89.12 126.78 42.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.18 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.582 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.23 132.62 39.9 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.219 -179.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.8 mm-40 50.64 46.23 25.95 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.156 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.99 23.26 56.82 Favored Glycine 0 CA--C 1.522 0.523 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.802 178.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.75 153.69 39.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -105.32 111.9 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 O-C-N 121.944 -0.473 . . . . 0.0 110.611 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 26.8 m -147.38 139.33 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 55.6 t-80 -31.25 151.53 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.201 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.264 -179.635 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.681 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 6.2 m . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 80.5 mt -123.22 132.69 54.13 Favored 'General case' 0 C--N 1.34 0.189 0 CA-C-O 121.182 0.515 . . . . 0.0 110.72 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.09 162.26 24.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.39 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.76 146.52 52.25 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.45 -17.34 40.13 Favored Glycine 0 C--N 1.34 0.754 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.7 m -67.03 124.76 23.95 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.08 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -83.98 149.35 26.35 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.238 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 8' ' ' ILE . 75.2 mt -134.6 107.42 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.81 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -77.0 127.22 32.3 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 14' ' ' GLY . 61.6 t0 -107.32 111.44 63.17 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.07 -37.3 68.24 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 122.508 2.139 . . . . 0.0 111.969 178.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -61.21 -58.41 7.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.518 -179.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.746 ' HG1' ' H ' ' A' ' 15' ' ' THR . 30.5 p -74.88 -33.07 62.01 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.181 0.515 . . . . 0.0 109.788 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 80.47 7.74 88.24 Favored Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.746 ' H ' ' HG1' ' A' ' 13' ' ' THR . 0.2 OUTLIER -110.87 -163.82 0.88 Allowed 'General case' 0 C--N 1.347 0.471 0 CA-C-N 117.727 0.764 . . . . 0.0 109.507 -179.248 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.4 m -114.71 115.7 27.49 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.516 0.674 . . . . 0.0 110.511 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -100.18 141.72 32.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.206 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -97.65 125.99 42.72 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.969 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.42 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -52.92 -41.01 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.217 -179.333 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.42 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 2.8 pt-20 -55.31 -35.23 64.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.355 0.598 . . . . 0.0 110.646 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 50.9 t0 -83.1 -36.18 25.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.972 . . . . 0.0 111.62 -178.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 54.1 t -66.65 -43.83 90.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.408 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 72.2 t -69.52 -46.11 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.721 -179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -56.04 -36.9 68.53 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 120.946 -0.302 . . . . 0.0 110.596 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.558 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.71 32.64 6.09 Favored Glycine 0 C--O 1.228 -0.257 0 CA-C-O 118.222 -1.321 . . . . 0.0 110.563 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.558 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.0 ptt-85 10.37 72.55 0.01 OUTLIER 'General case' 0 C--N 1.367 1.341 0 O-C-N 124.437 0.728 . . . . 0.0 110.004 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.422 ' C ' ' H ' ' A' ' 29' ' ' ILE . 74.1 mttt -90.06 144.71 31.7 Favored Pre-proline 0 N--CA 1.443 -0.791 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.716 -177.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.561 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.2 Cg_endo -71.77 9.83 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.581 2.187 . . . . 0.0 112.464 179.517 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.561 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.1 pp -38.19 171.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 124.087 0.867 . . . . 0.0 110.374 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 1.2 m80 -123.05 166.74 14.62 Favored 'General case' 0 CA--C 1.509 -0.622 0 O-C-N 122.103 -0.373 . . . . 0.0 111.057 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -150.42 173.96 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.385 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 3.8 t -87.3 132.51 32.46 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.152 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -102.38 166.93 10.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.79 137.08 36.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.074 0.464 . . . . 0.0 110.315 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.5 177.46 4.64 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -72.76 -14.73 61.6 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.615 0.245 . . . . 0.0 110.677 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -78.98 -14.66 59.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.7 20.46 56.1 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.6 p -100.82 135.29 42.49 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 120.76 0.314 . . . . 0.0 110.691 178.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 53.2 mt -99.78 137.63 37.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.561 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -147.72 143.56 27.67 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.795 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.86 145.01 48.86 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.452 ' HE ' HD13 ' A' ' 127' ' ' LEU . 86.6 mtt-85 -153.25 142.44 14.67 Favored Pre-proline 0 CA--C 1.54 0.587 0 O-C-N 123.813 0.696 . . . . 0.0 111.097 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.36 160.0 39.46 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 123.094 2.529 . . . . 0.0 113.267 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -97.89 135.76 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 177.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.3 m -122.24 -1.33 7.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 118.803 -0.618 . . . . 0.0 111.167 -178.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.8 p -148.79 141.33 24.35 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 119.203 0.91 . . . . 0.0 108.717 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.509 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.23 121.32 12.93 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.047 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -142.1 148.23 38.03 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -99.74 135.06 41.73 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.659 HE22 ' CB ' ' A' ' 1' ' ' CYS . 2.0 mt-30 -97.75 4.56 49.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 119.412 -0.327 . . . . 0.0 111.53 178.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.05 -169.73 42.49 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 98.0 m -88.26 128.33 35.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.397 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.5 mtt-85 -147.17 161.59 40.6 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.544 -179.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -77.18 142.8 39.46 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.489 179.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.8 m -141.12 160.27 22.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.8 pt -111.89 147.29 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.257 179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.59 137.53 13.32 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.409 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 43.6 mt -120.63 111.99 18.34 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.403 0.62 . . . . 0.0 110.276 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -87.21 109.24 19.34 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.189 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.558 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.7 mp . . . . . 0 N--CA 1.473 0.715 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.079 -179.238 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.747 0.308 . . . . 0.0 110.376 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.2 tt -125.21 154.75 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.346 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 54.1 tp -130.97 116.82 18.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -104.4 115.17 29.9 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.73 172.69 12.35 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.261 -179.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.34 156.28 78.79 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.689 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.29 -21.44 72.63 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 122.794 2.33 . . . . 0.0 111.931 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -92.95 -4.69 52.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.28 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.681 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.7 t60 -72.02 129.98 39.86 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 48.9 mttp -86.86 127.58 35.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 121.51 0.672 . . . . 0.0 110.493 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 93.8 t -105.16 91.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.602 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 15.3 tp -31.01 95.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 O-C-N 123.924 0.765 . . . . 0.0 111.123 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.446 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -98.92 176.93 5.42 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 -177.973 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.478 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 12.8 pt-20 -63.85 -18.35 64.06 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.291 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.73 24.3 13.13 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.432 0.158 . . . . 0.0 110.965 -179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.81 -141.37 15.26 Favored Glycine 0 C--N 1.321 -0.253 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -94.05 127.24 39.74 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.633 -0.283 . . . . 0.0 111.264 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -137.61 129.04 28.08 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.25 141.39 29.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.807 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.11 -38.58 83.41 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.164 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.27 -3.2 4.86 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.678 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -105.49 0.46 26.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.923 0.392 . . . . 0.0 110.179 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 93.3 mt -80.95 127.63 32.78 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.554 0.693 . . . . 0.0 111.245 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.583 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.6 mmt85 -131.64 149.26 52.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.788 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -44.57 86.33 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 123.465 0.478 . . . . 0.0 110.845 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 158.08 -15.85 0.29 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -85.39 130.1 34.67 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 117.209 0.505 . . . . 0.0 110.394 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.478 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 90.1 mtm180 -88.94 131.17 35.26 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.408 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.7 m -114.42 142.69 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.1 131.52 45.98 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.72 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.36 160.72 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.408 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.534 ' NH1' ' O ' ' A' ' 101' ' ' GLY . 9.0 tpt180 -104.6 129.63 52.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.59 -179.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 42.1 t0 -101.33 123.67 45.78 Favored 'General case' 0 C--O 1.22 -0.49 0 CA-C-O 118.996 -0.526 . . . . 0.0 110.468 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 61.4 t -77.21 -16.72 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 118.474 0.579 . . . . 0.0 111.12 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -69.65 -58.43 3.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.486 ' C ' ' H ' ' A' ' 102' ' ' GLU . 80.8 p -95.86 -12.65 24.88 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.534 ' O ' ' NH1' ' A' ' 96' ' ' ARG . . . 76.13 -16.05 4.88 Favored Glycine 0 C--O 1.223 -0.583 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.2 mt-10 -80.78 158.05 25.59 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.614 0.245 . . . . 0.0 110.606 -177.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -86.68 141.12 29.16 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.359 0.6 . . . . 0.0 110.059 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.45 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 37.6 ptt180 -139.81 178.65 7.09 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.214 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.446 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.8 m-85 -113.31 147.74 37.03 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.801 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -139.63 160.17 40.48 Favored 'General case' 0 C--O 1.222 -0.366 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.6 m -90.63 153.02 3.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-O 121.015 0.436 . . . . 0.0 110.842 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.41 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.6 mm -70.31 155.39 7.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.094 179.297 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.41 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt180 -106.01 -48.31 3.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.704 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -166.07 145.74 6.19 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.78 134.38 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 mt -102.68 145.22 30.15 Favored Pre-proline 0 N--CA 1.466 0.358 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.367 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -67.16 164.06 31.75 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.408 2.072 . . . . 0.0 111.534 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.3 p -67.03 156.42 36.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 121.388 0.613 . . . . 0.0 110.873 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 79.3 mtp180 -139.98 -137.35 0.12 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.757 -179.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -158.04 131.31 7.58 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.079 0.466 . . . . 0.0 110.254 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.79 173.26 3.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.13 -179.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.3 mtp85 -78.39 145.48 35.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 2.9 p -119.5 141.08 49.51 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.155 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.62 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 57.2 m-85 -118.5 168.55 10.56 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.199 -179.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -157.79 120.33 3.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.989 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 67.1 mt -118.04 129.52 55.62 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -87.5 109.63 19.75 Favored 'General case' 0 CA--C 1.516 -0.338 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.6 t -83.0 113.09 21.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.97 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.7 tt0 29.96 -98.38 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 O-C-N 123.775 0.672 . . . . 0.0 111.1 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -123.62 -25.92 4.26 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.271 179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.452 HD13 ' HE ' ' A' ' 43' ' ' ARG . 96.4 mt -84.85 94.55 8.76 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.7 m170 -60.6 98.24 0.06 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 167.1 154.77 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 1.2 pt? -162.83 161.49 26.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.796 0.808 . . . . 0.0 112.369 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.3 t -86.2 126.15 40.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.88 123.78 25.32 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.757 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 54.29 44.66 28.68 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.682 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.0 28.1 69.88 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.2 t -132.67 151.3 34.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 CA-C-N 118.155 0.977 . . . . 0.0 108.681 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 89.9 t -108.9 112.34 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 118.232 0.469 . . . . 0.0 110.239 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 138' ' ' HIS . 29.4 m -146.63 136.72 17.51 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-O 119.086 -0.483 . . . . 0.0 110.021 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 37.4 t-80 -31.54 152.08 0.0 OUTLIER 'General case' 0 C--O 1.223 -0.295 0 O-C-N 123.577 0.548 . . . . 0.0 111.36 179.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.521 ' OD1' ' CE1' ' A' ' 138' ' ' HIS . 49.2 p30 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.74 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -101.16 143.72 30.91 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.365 -179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -88.18 162.41 16.71 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.637 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . 0.431 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 59.8 tt0 -60.37 142.69 54.54 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 120.786 0.327 . . . . 0.0 110.466 178.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 115.98 -21.66 12.08 Favored Glycine 0 C--N 1.333 0.376 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.0 m -69.01 120.03 14.24 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.11 179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.7 mtp85 -95.15 112.63 24.31 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.91 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.6 mt -99.17 113.29 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.621 -179.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -76.48 137.79 39.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 10.2 t0 -106.31 132.64 20.73 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 121.25 -0.18 . . . . 0.0 110.622 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.03 -30.88 10.36 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.187 1.925 . . . . 0.0 112.433 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.533 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 24.9 t -72.98 -53.89 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.868 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.8 p -77.64 -36.79 51.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.136 0.493 . . . . 0.0 110.159 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 6.9 89.01 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 48.1 m -111.55 156.53 21.6 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.769 0.785 . . . . 0.0 109.717 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 27.0 m -80.49 116.77 20.71 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.146 0.498 . . . . 0.0 110.976 -179.154 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -107.32 150.29 26.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.302 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -101.43 132.74 46.86 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.914 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.403 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 2.8 tp -52.69 -40.21 33.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.764 0.316 . . . . 0.0 111.077 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.431 ' OE1' ' OE2' ' A' ' 4' ' ' GLU . 6.9 tt0 -58.51 -36.25 73.51 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.191 0.519 . . . . 0.0 110.483 -179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -82.18 -38.36 24.76 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.615 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -69.51 -43.76 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 72.5 t -73.82 -46.73 46.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.9 t0 -60.85 -36.4 79.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.019 0.437 . . . . 0.0 110.813 -178.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.36 24.55 31.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtm180 17.22 62.73 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 79.2 mttt -86.57 131.96 44.11 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.869 -176.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -75.07 87.21 1.35 Allowed 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.491 1.461 . . . . 0.0 110.41 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 30.1 pt -120.67 -172.01 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.917 0.389 . . . . 0.0 110.491 -179.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.43 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 16.5 m80 -127.21 162.88 25.13 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.747 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.46 171.24 2.44 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.237 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.01 136.33 23.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -115.27 164.33 14.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.67 -0.241 . . . . 0.0 110.414 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.97 50.42 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.36 177.66 4.55 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -72.74 -16.33 61.66 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 122.101 -0.375 . . . . 0.0 111.105 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -78.71 -16.46 57.22 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.336 179.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 22.85 40.45 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.1 p -102.11 133.84 46.31 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.676 0.274 . . . . 0.0 111.052 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.621 ' CD2' ' N ' ' A' ' 40' ' ' LEU . 2.2 mm? -94.57 133.05 38.63 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 121.069 0.461 . . . . 0.0 111.128 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -143.66 139.87 29.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.569 -179.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.2 144.86 49.99 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.969 -178.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.439 ' HE ' ' HB3' ' A' ' 125' ' ' GLU . 15.7 mtp85 -147.81 138.91 13.36 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.181 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -74.94 158.1 42.64 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.7 2.267 . . . . 0.0 112.831 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.9 t -93.82 131.85 39.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.0 t -119.24 -3.1 9.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.387 -177.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' SER . . . . . 0.442 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.3 OUTLIER -155.06 149.01 25.7 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.612 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.571 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -144.84 131.02 19.48 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.701 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -134.64 144.56 47.92 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.379 0.609 . . . . 0.0 111.899 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.414 ' OD1' ' N ' ' A' ' 51' ' ' GLN . 58.1 t0 -112.76 139.21 48.57 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.224 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.414 ' N ' ' OD1' ' A' ' 50' ' ' ASP . 2.8 mm-40 -105.15 -106.46 0.3 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.328 -1.305 . . . . 0.0 108.854 -178.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.24 -156.1 9.59 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 114.457 -1.247 . . . . 0.0 112.354 -177.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -94.58 119.56 33.45 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.077 0.465 . . . . 0.0 111.2 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -138.31 164.66 28.7 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.51 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -76.98 140.9 40.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.12 159.61 26.1 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.164 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 32.7 pt -112.58 151.26 14.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.966 0.412 . . . . 0.0 109.991 179.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.16 131.68 10.76 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 32.2 mt -113.16 113.19 25.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 0.0 110.044 -179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 12.6 tpt180 -87.75 107.06 18.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.355 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.552 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.7 mp . . . . . 0 N--CA 1.467 0.417 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.929 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.189 0 CA-C-O 121.105 0.479 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.1 tt -125.38 152.06 31.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.34 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.404 ' C ' ' CD2' ' A' ' 67' ' ' LEU . 2.2 tt -127.63 114.91 17.98 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.496 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.3 m95 -102.93 120.04 39.92 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.85 171.09 18.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.158 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 20.4 p -76.91 154.71 83.04 Favored Pre-proline 0 CA--C 1.531 0.232 0 C-N-CA 120.584 -0.447 . . . . 0.0 111.227 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 -24.09 70.8 Favored 'Trans proline' 0 N--CA 1.499 1.849 0 C-N-CA 122.096 1.864 . . . . 0.0 112.211 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -84.75 -8.64 58.76 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.853 0.359 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.573 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.2 t60 -72.8 132.66 43.86 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -90.44 131.73 36.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.183 0.516 . . . . 0.0 110.348 -178.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 92.5 t -107.37 89.59 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.117 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 55.7 tp -29.12 97.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.508 0.505 . . . . 0.0 111.717 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.47 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 38.5 p -98.68 177.21 5.37 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.531 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.548 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.8 pt-20 -66.45 -17.56 64.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.341 -179.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.07 22.22 16.25 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.745 0.307 . . . . 0.0 111.117 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.76 -141.09 15.34 Favored Glycine 0 N--CA 1.462 0.431 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.0 m95 -97.38 130.91 44.47 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.724 -0.238 . . . . 0.0 110.924 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.8 mtp85 -139.7 131.12 26.9 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.43 144.73 20.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.084 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.434 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -63.11 -38.88 92.93 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.576 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.7 -1.75 2.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.622 -0.799 . . . . 0.0 111.428 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 84' ' ' ALA . 72.3 mm-40 -107.49 -2.99 19.9 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.941 0.4 . . . . 0.0 110.184 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 85.7 mt -76.88 125.59 29.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.917 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.558 ' O ' ' N ' ' A' ' 90' ' ' GLY . 7.1 tpt180 -132.1 148.42 52.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.501 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -43.34 88.83 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.932 0.396 . . . . 0.0 110.693 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.97 -16.57 0.45 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -87.21 129.79 34.82 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.728 0.299 . . . . 0.0 110.771 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 87.1 mtm180 -90.19 131.06 36.23 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 121.083 0.468 . . . . 0.0 110.586 -178.617 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.15 143.32 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.391 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.13 131.78 49.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.8 m -129.57 157.81 42.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.368 179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 71.7 ttt180 -106.98 130.28 54.65 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.458 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.53 121.9 42.34 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.373 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 57.6 t -75.01 -15.44 15.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 O-C-N 122.081 -0.387 . . . . 0.0 110.648 178.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -70.75 -58.03 4.06 Favored 'General case' 0 C--O 1.232 0.154 0 C-N-CA 120.485 -0.486 . . . . 0.0 109.927 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.483 ' C ' ' H ' ' A' ' 102' ' ' GLU . 45.9 p -96.79 -12.56 23.48 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 116.751 -0.204 . . . . 0.0 110.562 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.53 -13.72 6.17 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.483 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.4 mt-10 -81.74 157.1 24.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.972 0.415 . . . . 0.0 111.078 -177.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.531 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -78.48 140.4 38.61 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 179.393 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -139.55 174.51 10.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.47 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.9 m-85 -115.3 146.09 41.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.222 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 14.8 m -139.78 161.44 37.54 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.3 t -94.35 154.75 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.667 0.27 . . . . 0.0 110.467 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.403 HG22 HD11 ' A' ' 108' ' ' ILE . 97.0 mt -76.38 149.96 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 178.735 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 74.1 ttt-85 -99.16 -41.77 7.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.613 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -165.74 146.81 6.97 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.9 t -97.63 134.43 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -98.67 148.78 35.02 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.074 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.79 162.03 44.03 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.796 2.331 . . . . 0.0 111.436 179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 2.9 p -62.49 149.38 43.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.981 0.419 . . . . 0.0 110.742 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.401 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttt85 -132.3 -141.24 0.21 Allowed 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.663 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . 0.401 ' H ' ' HG2' ' A' ' 115' ' ' ARG . 12.8 tpt180 -157.06 129.98 7.71 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.322 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.19 170.5 5.16 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.087 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -75.57 149.29 38.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.868 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 59.2 p -128.78 142.7 50.9 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.069 0.461 . . . . 0.0 109.764 179.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 9.2 m-85 -120.85 176.4 5.56 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.897 -178.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -148.76 153.54 38.31 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.855 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 90.8 mt -140.18 171.14 14.59 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.681 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -135.17 106.11 6.61 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' C ' ' A' ' 125' ' ' GLU . 7.9 t -86.89 111.74 22.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.498 ' C ' ' O ' ' A' ' 124' ' ' VAL . 5.2 tp10 20.79 -116.57 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 O-C-N 123.657 0.598 . . . . 0.0 111.685 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -106.74 -26.14 11.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.277 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.9 mt -89.21 69.84 8.26 Favored 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.409 ' O ' HG21 ' A' ' 129' ' ' THR . 28.9 m170 -42.92 104.88 0.04 OUTLIER 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.409 HG21 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.4 139.59 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.675 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -147.14 156.73 43.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 121.509 0.671 . . . . 0.0 112.122 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.02 125.35 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.8 126.59 30.9 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.947 -179.011 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.502 ' C ' ' H ' ' A' ' 135' ' ' VAL . 15.4 mm-40 53.81 46.78 25.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.982 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.33 -22.06 0.51 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.502 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.1 t -89.01 152.56 3.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 117.121 0.461 . . . . 0.0 110.66 -179.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -110.44 115.55 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.416 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 138' ' ' HIS . 12.3 m -147.31 137.69 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.528 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.573 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 53.1 t-80 -36.52 156.79 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.529 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 16.1 p30 . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.468 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.5 mt -105.12 141.49 36.58 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-O 120.938 0.399 . . . . 0.0 110.543 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -84.35 161.42 20.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.463 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 63.8 tt0 -61.68 146.03 50.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.381 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.57 -16.4 40.81 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.3 m -68.47 124.16 22.81 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.789 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . 0.422 ' HE ' HG22 ' A' ' 16' ' ' THR . 81.0 mtp180 -85.03 149.82 25.31 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.162 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . 0.4 HG21 HD12 ' A' ' 8' ' ' ILE . 56.2 mt -134.13 108.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.271 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -76.94 126.7 31.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 178.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -96.06 131.2 29.37 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.094 -179.335 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.05 -33.17 4.73 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.33 2.02 . . . . 0.0 111.8 179.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.6 t -73.31 -54.27 16.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.64 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.5 m -75.17 -38.09 61.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.163 0.506 . . . . 0.0 110.065 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.23 7.36 85.18 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.059 -0.816 . . . . 0.0 111.059 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.0 t -106.9 -167.22 1.25 Allowed 'General case' 0 C--N 1.338 0.09 0 CA-C-N 117.652 0.726 . . . . 0.0 109.895 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' THR . . . . . 0.422 HG22 ' HE ' ' A' ' 7' ' ' ARG . 93.3 m -115.0 115.28 26.6 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.547 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -100.68 140.75 34.51 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.744 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.7 tpp85 -97.27 127.2 43.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.538 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 3.1 tp -51.57 -40.3 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.771 -178.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.426 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 14.3 tt0 -53.74 -35.29 61.06 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.961 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.72 -34.13 40.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.695 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.662 ' O ' ' O ' ' A' ' 26' ' ' ARG . 85.1 t -64.83 -45.61 94.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.807 0.337 . . . . 0.0 111.122 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 87.9 t -66.54 -45.16 89.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 O-C-N 121.186 -0.946 . . . . 0.0 111.951 -178.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -55.41 -42.41 74.04 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.741 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.75 33.49 3.72 Favored Glycine 0 CA--C 1.529 0.95 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.662 ' O ' ' O ' ' A' ' 22' ' ' VAL . 82.4 mtp180 58.14 -100.58 0.11 Allowed 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.216 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.65 ' C ' ' H ' ' A' ' 29' ' ' ILE . 40.7 mttt 79.94 82.65 0.09 OUTLIER Pre-proline 0 C--N 1.299 -1.604 0 C-N-CA 122.898 0.479 . . . . 0.0 110.388 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.7 ' O ' ' O ' ' A' ' 29' ' ' ILE . 34.1 Cg_exo -59.52 19.76 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.745 2.297 . . . . 0.0 112.577 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.7 ' O ' ' O ' ' A' ' 28' ' ' PRO . 20.3 pt -35.41 -178.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 O-C-N 124.041 0.838 . . . . 0.0 111.189 -178.258 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -119.78 163.33 17.63 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 121.43 -0.794 . . . . 0.0 110.891 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.1 171.33 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.9 t -91.03 135.13 27.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.47 168.09 9.81 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.82 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.06 142.67 46.39 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.216 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.39 177.93 4.48 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.785 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -70.54 -13.9 62.29 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.92 0.39 . . . . 0.0 110.656 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -81.34 -18.53 45.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.279 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.9 24.91 36.28 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.6 p -103.11 135.18 45.25 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.7 0.286 . . . . 0.0 111.203 178.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 65.4 mt -92.59 131.24 37.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.654 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 8.2 t-160 -142.82 139.82 31.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.483 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.55 141.95 51.82 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.794 -178.51 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.1 mmp_? -143.85 138.21 14.95 Favored Pre-proline 0 CA--C 1.535 0.398 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.8 158.81 31.46 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.86 2.373 . . . . 0.0 112.727 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.32 135.42 36.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.9 m -124.9 1.05 5.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.543 -178.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.9 t -144.34 133.68 23.16 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.548 0.613 . . . . 0.0 109.792 179.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.531 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -132.68 117.26 17.65 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 178.106 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -141.24 146.55 37.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -89.2 132.83 34.67 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 176.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.431 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -92.17 -0.64 57.42 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.186 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.36 -179.6 51.66 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.31 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.8 m -91.74 126.6 36.89 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 120.945 0.402 . . . . 0.0 110.39 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 78.1 mtp85 -150.25 170.48 18.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.798 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -75.45 141.83 43.07 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.041 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -142.44 156.46 18.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 37.7 pt -110.75 154.4 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.978 0.418 . . . . 0.0 110.258 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.84 132.73 11.26 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 21.0 mt -115.26 114.29 25.0 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.104 0.478 . . . . 0.0 110.222 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -99.19 122.75 42.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.968 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 94.4 mt . . . . . 0 CA--C 1.513 -0.465 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.692 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 120.994 0.426 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . 0.465 ' O ' ' OE1' ' A' ' 133' ' ' GLU . 97.1 mt -125.89 158.64 34.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.524 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.44 ' N ' ' CG2' ' A' ' 66' ' ' ILE . 42.5 tp -132.68 117.43 17.85 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.582 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -102.79 115.74 31.19 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.13 171.74 14.86 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.368 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 75.9 p -77.09 152.52 82.19 Favored Pre-proline 0 C--N 1.327 -0.394 0 C-N-CA 120.457 -0.497 . . . . 0.0 111.35 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.19 -28.8 81.01 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 122.214 1.943 . . . . 0.0 112.336 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -83.21 -5.66 59.2 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.899 0.38 . . . . 0.0 110.563 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.9 t60 -71.64 130.02 40.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.43 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.64 127.26 34.43 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.236 0.541 . . . . 0.0 110.737 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.5 t -109.6 93.75 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.619 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.117 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' VAL . 6.4 tp -31.42 93.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.677 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 75' ' ' VAL . 0.9 OUTLIER -97.25 177.86 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -178.236 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.411 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.2 pt-20 -64.68 -22.84 67.07 Favored 'General case' 0 N--CA 1.448 -0.573 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.262 -179.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -104.59 26.39 9.11 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 121.235 -0.186 . . . . 0.0 110.99 -179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.426 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.18 -177.88 43.01 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -57.01 130.74 47.38 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.977 0.418 . . . . 0.0 110.335 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -146.38 135.26 22.42 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.78 144.5 14.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.917 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.494 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -64.25 -38.76 92.21 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.488 -179.014 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.51 1.02 0.52 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.449 -0.881 . . . . 0.0 111.76 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.494 ' H ' ' C ' ' A' ' 84' ' ' ALA . 19.9 tp10 -107.66 5.43 26.83 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.159 0.504 . . . . 0.0 110.049 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.29 123.19 29.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.226 0.536 . . . . 0.0 111.018 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 90' ' ' GLY . 33.1 mmt180 -132.47 149.76 52.28 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.803 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -48.02 87.89 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.977 0.418 . . . . 0.0 110.657 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -20.0 0.44 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.911 -0.875 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -84.18 129.48 34.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.83 0.348 . . . . 0.0 110.582 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.411 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 88.2 mtm180 -90.68 132.38 35.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.142 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 m -119.93 152.14 22.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.823 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -68.69 137.36 54.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.491 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.19 162.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.465 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.554 HH21 ' CG1' ' A' ' 131' ' ' VAL . 12.2 ttm180 -106.58 129.45 54.51 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.535 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 101' ' ' GLY . 45.9 t0 -100.97 123.77 45.67 Favored 'General case' 0 C--O 1.224 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.426 178.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -74.24 -15.73 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 118.184 0.447 . . . . 0.0 111.12 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -72.45 -55.18 7.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.01 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.2 m -99.44 -16.27 18.43 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.735 -0.211 . . . . 0.0 110.632 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 97' ' ' ASP . . . 73.84 -14.32 3.67 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.506 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.3 mt-10 -80.71 160.4 24.97 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-O 120.781 0.324 . . . . 0.0 110.64 -177.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 7.5 tp -79.03 126.59 30.9 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.027 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 65.8 mtp85 -126.81 168.17 14.8 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.956 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -110.32 142.72 41.58 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.5 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 12.7 m -137.94 158.44 44.33 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.331 178.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.85 152.82 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.737 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.43 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.9 mm -67.46 156.7 6.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.844 179.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.43 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 17.2 tpt180 -108.39 -52.33 2.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.01 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -165.56 144.47 6.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 70.0 t -95.09 133.29 36.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.087 0.47 . . . . 0.0 110.037 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.62 127.02 32.39 Favored Pre-proline 0 CA--C 1.536 0.432 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.518 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -47.88 161.64 0.33 Allowed 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 122.206 1.937 . . . . 0.0 112.021 179.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 80.6 p -64.99 153.82 39.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.0 0.429 . . . . 0.0 110.699 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.8 ttp180 -134.98 -140.8 0.17 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.586 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.8 mtm-85 -156.79 130.44 8.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.11 172.82 3.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.979 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 22.6 mmt85 -77.51 147.03 36.03 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.971 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 18.5 p -125.13 142.9 51.21 Favored 'General case' 0 CA--C 1.52 -0.181 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -118.93 175.54 5.71 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.821 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -153.47 120.51 5.74 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.553 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 75.1 mt -120.03 123.95 44.7 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -87.58 118.41 27.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.209 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 50.5 t -90.42 115.23 29.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -58.1 149.28 24.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.715 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.9 tt0 63.85 -69.73 0.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.295 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.82 100.79 11.78 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 110.43 -0.211 . . . . 0.0 110.43 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.414 ' O ' ' OG1' ' A' ' 129' ' ' THR . 72.4 m-70 -69.73 100.28 1.47 Allowed 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.161 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 164.15 144.37 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -145.33 157.02 44.13 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.636 0.732 . . . . 0.0 112.011 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . 0.554 ' CG1' HH21 ' A' ' 96' ' ' ARG . 8.9 p -92.35 120.56 41.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.832 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.89 126.45 30.46 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.891 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.535 ' C ' ' H ' ' A' ' 135' ' ' VAL . 8.9 mt-10 59.86 45.33 12.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.222 0.534 . . . . 0.0 110.029 -179.475 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.41 -24.7 0.35 Allowed Glycine 0 CA--C 1.522 0.524 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.28 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.535 ' H ' ' C ' ' A' ' 133' ' ' GLU . 10.3 t -90.25 151.21 3.53 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 O-C-N 122.485 -0.42 . . . . 0.0 110.68 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.89 115.84 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.68 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 138' ' ' HIS . 20.9 m -147.28 136.67 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.434 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 17.9 t-80 -34.99 154.36 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.089 0.403 . . . . 0.0 112.089 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.277 -179.861 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.6 mt -108.97 137.53 46.74 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.341 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 161.46 23.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.687 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -62.36 145.91 52.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.092 179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.56 -17.65 33.3 Favored Glycine 0 C--N 1.337 0.63 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.8 m -66.89 122.4 17.63 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.224 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -98.35 115.72 29.06 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.143 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.6 mt -102.59 117.33 47.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.734 -179.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -75.84 133.23 40.66 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASP . . . . . 0.506 ' OD2' ' O ' ' A' ' 30' ' ' HIS . 4.1 t70 -104.0 134.93 19.45 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.526 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.52 -32.51 3.71 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.512 2.142 . . . . 0.0 112.321 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.07 -59.6 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.417 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.425 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 1.9 t -76.9 -34.21 57.74 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.97 12.84 76.11 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 75.5 m -116.94 161.6 19.1 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 117.977 0.888 . . . . 0.0 109.753 -179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 43.0 m -79.71 115.83 19.54 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.278 0.561 . . . . 0.0 110.713 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 24.8 m-70 -101.84 147.07 26.94 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.206 -179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -101.23 125.53 47.87 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.004 178.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -53.46 -39.32 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.265 -179.234 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -58.55 -33.72 70.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 68.4 t0 -83.97 -37.22 22.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.596 179.611 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 78.4 t -66.39 -42.74 91.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.27 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 75.9 t -69.51 -44.81 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 121.093 -0.243 . . . . 0.0 111.428 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -54.15 -36.32 63.19 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 121.036 -0.266 . . . . 0.0 110.761 -178.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -117.25 33.31 5.07 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER 12.42 74.95 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 124.056 0.504 . . . . 0.0 109.9 179.859 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LYS . . . . . 0.68 ' C ' ' H ' ' A' ' 29' ' ' ILE . 64.0 mttt -91.29 117.74 68.04 Favored Pre-proline 0 N--CA 1.442 -0.862 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -178.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.68 ' O ' ' O ' ' A' ' 29' ' ' ILE . 52.5 Cg_exo -52.67 7.54 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.964 2.442 . . . . 0.0 113.005 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.68 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.3 pp -37.05 -178.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 O-C-N 123.949 0.781 . . . . 0.0 110.722 -178.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' HIS . . . . . 0.506 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 2.4 m80 -126.49 168.14 14.65 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 121.404 -0.81 . . . . 0.0 111.247 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.1 m -148.12 171.78 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.264 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 62.9 t -88.11 131.11 36.53 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.641 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -109.07 149.72 28.86 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.055 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.69 140.79 50.1 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.933 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.69 174.31 5.99 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.771 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -68.42 -14.62 63.13 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.651 0.263 . . . . 0.0 110.648 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 38.4 p30 -81.79 -15.71 53.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.488 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 87.04 22.64 44.45 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.42 ' OG1' ' OD1' ' A' ' 37' ' ' ASP . 22.0 p -102.87 137.29 41.27 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.622 0.249 . . . . 0.0 111.108 178.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.7 mt -94.79 130.18 41.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.884 0.374 . . . . 0.0 110.47 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.48 138.7 33.01 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.404 -179.073 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.74 139.9 53.4 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.609 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.7 mmt-85 -143.38 137.97 15.1 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.897 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.73 156.34 35.37 Favored 'Trans proline' 0 C--N 1.316 -1.177 0 C-N-CA 122.783 2.322 . . . . 0.0 112.969 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.9 t -93.86 130.75 42.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -118.11 -5.02 11.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.527 -178.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.1 t -145.97 134.73 22.35 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.203 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' TRP . . . . . 0.557 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -134.02 116.28 15.32 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.359 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PHE . . . . . 0.514 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 47.5 m-85 -140.94 150.71 43.48 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.063 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -93.54 133.16 37.13 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 176.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.642 HE21 ' CB ' ' A' ' 121' ' ' ASP . 26.1 mm-40 -92.17 -0.35 57.43 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.202 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.5 179.73 51.48 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 32.0 m -91.41 123.07 34.55 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -143.79 169.97 16.76 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.915 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -76.99 142.71 39.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.971 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.7 m -147.15 157.59 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.113 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.9 pt -108.12 159.05 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.238 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.83 139.55 15.75 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.7 mt -118.53 112.04 19.39 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.148 0.499 . . . . 0.0 109.689 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.695 ' NE ' ' HE ' ' A' ' 109' ' ' ARG . 56.8 ttp180 -98.94 126.17 44.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.001 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.516 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.469 0.52 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.472 0 CA-C-O 120.797 0.332 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 93.5 mt -120.89 135.55 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.222 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.7 tp -112.53 111.0 21.51 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.798 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' TRP . . . . . 0.515 ' CE3' ' NH2' ' A' ' 115' ' ' ARG . 97.9 m95 -103.73 105.71 16.0 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.25 172.47 12.87 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.549 -179.059 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -72.76 156.24 90.11 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.759 -179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 85' ' ' GLY . 31.4 Cg_endo -64.3 -19.36 65.59 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.644 2.229 . . . . 0.0 111.866 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 39.6 p-10 -90.99 -4.98 56.0 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' HIS . . . . . 0.534 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.6 t60 -71.88 132.09 43.91 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.19 124.65 32.09 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.442 0.639 . . . . 0.0 111.386 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.8 t -99.03 143.01 13.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.159 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.4 tp -82.83 89.87 6.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.699 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.473 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 30.0 p -97.86 176.25 5.86 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -67.39 -20.03 65.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.117 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -101.73 24.35 9.98 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-O 120.656 0.265 . . . . 0.0 110.825 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.09 -144.71 17.5 Favored Glycine 0 C--N 1.332 0.306 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -86.88 121.88 29.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.732 0.301 . . . . 0.0 111.289 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.7 mmt85 -122.56 125.8 46.45 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.089 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ALA . . . . . 0.425 ' C ' ' H ' ' A' ' 85' ' ' GLY . . . -68.54 129.84 41.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.507 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -66.83 -0.03 2.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.799 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 83' ' ' ALA . . . -75.55 -13.13 83.22 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -136.97 30.84 2.74 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.914 0.387 . . . . 0.0 111.378 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.9 mt -82.88 131.81 35.18 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.403 0.62 . . . . 0.0 111.007 179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 83.2 mmt-85 -133.62 148.38 51.55 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.082 -0.963 . . . . 0.0 111.346 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -46.37 97.92 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.547 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 158.48 -16.52 0.28 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -88.29 129.91 35.25 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -88.57 129.74 35.41 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.36 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.9 m -108.9 141.86 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.046 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.08 120.71 18.06 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.722 -179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -121.85 131.28 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.945 0.402 . . . . 0.0 110.07 179.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -67.73 132.05 46.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.848 -179.413 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 48.7 t0 -101.77 122.9 44.81 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 119.297 -0.382 . . . . 0.0 110.443 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.5 p -75.22 -16.87 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 CA-C-N 118.427 0.558 . . . . 0.0 111.323 179.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.75 -58.49 3.59 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.436 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' THR . . . . . 0.472 ' C ' ' H ' ' A' ' 102' ' ' GLU . 48.8 p -98.58 -14.89 19.72 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.456 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.37 -17.22 4.26 Favored Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.472 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.4 mt-10 -78.38 157.75 28.97 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -177.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.1 tp -75.06 135.18 41.24 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.314 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 32.5 ptt180 -135.04 167.46 20.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.216 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . 0.473 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.0 m-85 -117.12 152.83 33.9 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.029 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.1 m -146.2 165.21 29.85 Favored 'General case' 0 CA--C 1.516 -0.348 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.8 t -89.2 150.37 3.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 120.775 0.321 . . . . 0.0 110.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ILE . . . . . 0.491 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.2 mm -69.83 160.75 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.211 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . 0.695 ' HE ' ' NE ' ' A' ' 60' ' ' ARG . 12.6 ttp85 -107.67 -49.32 3.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.533 179.252 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLU . . . . . 0.527 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 74.8 tt0 -166.78 146.66 5.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -94.09 134.58 31.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.238 0.542 . . . . 0.0 110.019 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 3.0 mm? -97.86 145.48 29.82 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.157 -179.208 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.47 160.18 50.78 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 122.568 2.179 . . . . 0.0 111.468 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -64.88 154.12 38.22 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.146 0.498 . . . . 0.0 110.655 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.515 ' NH2' ' CE3' ' A' ' 68' ' ' TRP . 74.4 mtm180 -140.95 -138.82 0.12 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.657 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -155.58 132.01 10.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.236 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -171.13 173.03 5.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.764 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -77.77 140.24 39.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.779 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 3.1 p -114.98 140.46 49.01 Favored 'General case' 0 CA--C 1.522 -0.117 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -119.59 171.59 8.26 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.24 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.642 ' CB ' HE21 ' A' ' 51' ' ' GLN . 43.6 p-10 -160.72 120.31 2.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.089 179.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 69.9 mt -117.38 131.67 56.73 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 120.72 0.295 . . . . 0.0 110.63 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -87.71 110.18 20.25 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.568 ' O ' ' N ' ' A' ' 126' ' ' GLU . 21.6 t -81.04 109.49 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.467 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.074 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.488 ' C ' ' O ' ' A' ' 124' ' ' VAL . 1.6 tm-20 24.14 -85.53 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.815 0.697 . . . . 0.0 111.435 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . 0.568 ' N ' ' O ' ' A' ' 124' ' ' VAL . 79.8 tt0 -136.87 -36.44 0.68 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.157 -0.928 . . . . 0.0 111.141 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.481 ' O ' ' N ' ' A' ' 129' ' ' THR . 74.0 mt -72.4 67.69 0.74 Allowed 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' HIS . . . . . 0.454 ' O ' HG22 ' A' ' 129' ' ' THR . 35.4 m80 -40.82 95.92 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' THR . . . . . 0.598 ' C ' HD22 ' A' ' 139' ' ' ASN . 0.0 OUTLIER 166.5 136.36 0.01 OUTLIER 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.442 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.5 pp -144.99 154.37 42.47 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.449 0.642 . . . . 0.0 111.679 -178.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.81 123.99 40.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 135' ' ' VAL . . . -133.51 142.22 48.13 Favored 'General case' 0 C--O 1.227 -0.106 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.444 -178.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.55 ' C ' ' H ' ' A' ' 135' ' ' VAL . 71.1 mm-40 40.23 49.79 2.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.196 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.45 -25.32 0.27 Allowed Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.446 -0.662 . . . . 0.0 111.446 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.55 ' H ' ' C ' ' A' ' 133' ' ' GLU . 2.7 t -89.12 152.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.394 0 O-C-N 122.48 -0.423 . . . . 0.0 110.689 -179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -109.87 117.64 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.437 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 138' ' ' HIS . 20.5 m -149.87 141.01 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.531 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.492 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 54.3 t-80 -31.42 150.31 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.173 0 O-C-N 123.209 0.318 . . . . 0.0 111.741 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.598 HD22 ' C ' ' A' ' 129' ' ' THR . 1.5 m120 . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 118.056 -0.973 . . . . 0.0 110.628 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.601 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.1 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.3 mt -99.47 141.8 31.79 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.356 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.66 162.46 17.1 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.758 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 20' ' ' GLU . 41.3 tt0 -64.51 140.77 58.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.443 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.91 -17.72 29.64 Favored Glycine 0 C--N 1.338 0.693 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.5 m -70.63 122.81 20.48 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.419 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.6 mtp180 -82.65 147.99 28.21 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.043 0.449 . . . . 0.0 110.429 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 84.7 mt -133.94 107.67 10.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.26 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -77.97 129.69 35.61 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -101.49 132.02 22.3 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.45 -31.2 9.25 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.857 1.705 . . . . 0.0 112.449 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.2 t -69.99 -53.61 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.049 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -80.19 -39.76 28.59 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.858 0.361 . . . . 0.0 110.24 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.61 74.61 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -105.8 -168.32 1.43 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 117.363 0.582 . . . . 0.0 109.855 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.419 HG21 ' HE ' ' A' ' 7' ' ' ARG . 72.8 m -117.34 119.79 36.2 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.346 0.593 . . . . 0.0 110.397 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 63.9 m170 -109.75 148.07 32.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.089 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -98.87 130.24 45.27 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 5.6 tp -51.93 -40.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.632 0.253 . . . . 0.0 111.109 -179.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 4' ' ' GLU . 8.6 pt-20 -58.87 -34.57 71.77 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.113 0.482 . . . . 0.0 110.901 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -84.51 -37.49 21.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.432 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 75.4 t -68.09 -41.54 84.39 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.937 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 53.5 t -77.42 -46.33 28.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.651 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.2 t0 -55.65 -35.48 65.99 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 120.764 0.316 . . . . 0.0 110.829 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.564 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.77 26.49 14.13 Favored Glycine 0 N--CA 1.46 0.238 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.564 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.2 OUTLIER 15.37 68.77 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.225 0 O-C-N 124.042 0.496 . . . . 0.0 109.71 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 29' ' ' ILE . 83.4 mttt -83.8 114.46 54.05 Favored Pre-proline 0 N--CA 1.45 -0.449 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.87 -175.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -57.16 83.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 CA-C-N 119.78 0.957 . . . . 0.0 111.294 178.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.47 ' N ' ' O ' ' A' ' 27' ' ' LYS . 49.1 pt -119.11 -170.12 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 CA-C-O 121.063 0.459 . . . . 0.0 110.973 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.449 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 67.6 m80 -126.37 161.66 27.34 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.432 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.05 170.56 3.9 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.357 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 97.3 t -88.86 133.68 30.44 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.36 155.64 24.84 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.549 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -127.22 145.71 50.67 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.395 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.73 -176.55 2.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.63 -12.75 61.5 Favored 'General case' 0 CA--C 1.523 -0.092 0 CA-C-O 120.868 0.366 . . . . 0.0 110.686 179.561 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.491 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 32.3 p30 -76.28 -20.2 57.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.565 179.513 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.491 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 93.95 -8.25 73.34 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.699 ' HG1' ' HE2' ' A' ' 41' ' ' HIS . 33.6 p -82.31 151.09 26.88 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 121.946 0.879 . . . . 0.0 111.783 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.0 mt -100.94 132.21 46.45 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.258 -1.337 . . . . 0.0 111.877 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . 0.699 ' HE2' ' HG1' ' A' ' 39' ' ' THR . 5.7 m80 -137.88 137.39 38.02 Favored 'General case' 0 C--O 1.221 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.375 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.62 143.69 49.7 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.454 -178.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.523 HH21 ' CD ' ' A' ' 125' ' ' GLU . 8.9 mtp85 -149.21 138.61 12.7 Favored Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.991 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -74.85 157.17 43.55 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.239 1.959 . . . . 0.0 112.677 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 99.1 t -96.24 136.67 26.38 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.9 m -123.7 1.39 5.69 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.618 0 CA-C-O 119.202 -0.428 . . . . 0.0 111.856 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.5 p -151.04 144.87 25.13 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 118.987 0.812 . . . . 0.0 109.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.478 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.1 OUTLIER -142.12 123.07 14.47 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.373 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -141.57 145.32 34.93 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -86.88 136.55 32.92 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.442 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -99.14 1.84 45.4 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.806 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.6 -175.44 53.41 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.375 -0.917 . . . . 0.0 111.613 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 70.0 m -95.14 126.66 40.62 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -148.21 168.3 22.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.433 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -73.1 138.36 45.78 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.607 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -139.22 155.11 25.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-O 120.752 0.31 . . . . 0.0 110.181 -179.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 39.0 pt -110.45 153.17 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 110.179 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.28 125.47 7.7 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.5 mt -106.93 112.46 25.44 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 56.8 ttp180 -96.17 123.36 39.77 Favored 'General case' 0 C--O 1.219 -0.521 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.416 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 24.1 mm -111.36 157.83 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.12 138.14 26.25 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.697 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.678 ' H ' ' NH2' ' A' ' 109' ' ' ARG . . . 101.69 -3.57 53.19 Favored Glycine 0 CA--C 1.525 0.717 0 CA-C-N 115.938 -0.573 . . . . 0.0 111.915 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 96.52 -19.8 53.09 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -53.25 125.35 17.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.543 0.687 . . . . 0.0 109.213 -177.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -132.01 154.67 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.408 -178.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.2 tp -143.69 125.84 15.5 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -105.87 123.52 48.1 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.85 170.77 17.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 6.5 p -78.49 156.7 78.16 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.982 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -59.25 -22.92 67.32 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 121.872 1.715 . . . . 0.0 111.995 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -87.09 -8.9 56.59 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.743 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.775 ' CG ' ' HE2' ' A' ' 138' ' ' HIS . 8.2 t60 -68.7 126.76 30.71 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.72 ' H ' ' CE1' ' A' ' 138' ' ' HIS . 69.0 mttm -86.22 130.88 34.37 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 121.509 0.671 . . . . 0.0 111.418 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -104.66 139.27 26.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.83 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 59.6 tp -77.81 95.96 4.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.955 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.2 p -99.32 178.04 5.01 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.698 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.7 pm0 -64.91 -16.93 63.87 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.556 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 -109.73 26.24 10.88 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.08 -138.38 13.87 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -98.72 132.44 44.09 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.451 -0.374 . . . . 0.0 110.746 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -140.3 132.41 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.266 178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.36 144.81 23.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.902 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.45 -38.24 86.47 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.569 -179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.07 -2.12 6.29 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 120.537 -0.84 . . . . 0.0 111.713 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.67 25.69 11.5 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.95 0.405 . . . . 0.0 110.433 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 77.5 mt -110.18 130.34 55.56 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.608 0.718 . . . . 0.0 111.126 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.522 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.1 mmt180 -130.4 147.53 52.11 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.744 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -45.01 90.35 0.0 OUTLIER 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.888 0.375 . . . . 0.0 110.454 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -13.78 0.33 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -84.48 130.16 34.78 Favored 'General case' 0 C--O 1.225 -0.223 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.43 ' O ' ' OE1' ' A' ' 78' ' ' GLU . 89.1 mtm180 -90.26 136.72 32.88 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 -178.219 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.2 m -125.24 151.52 31.11 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.209 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -84.92 128.59 34.69 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.457 -179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.3 135.14 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.898 0.38 . . . . 0.0 110.441 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -66.74 133.66 50.62 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.055 0.455 . . . . 0.0 111.344 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -98.54 122.67 42.03 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-N 115.872 -0.603 . . . . 0.0 109.562 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.0 t -75.02 -17.23 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 118.401 0.546 . . . . 0.0 110.649 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.77 -59.25 3.06 Favored 'General case' 0 CA--C 1.522 -0.096 0 C-N-CA 120.197 -0.601 . . . . 0.0 109.964 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.522 ' C ' ' H ' ' A' ' 102' ' ' GLU . 73.6 p -93.88 -11.34 31.31 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 110.435 -0.209 . . . . 0.0 110.435 179.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 72.89 -12.04 4.12 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.522 ' H ' ' C ' ' A' ' 100' ' ' THR . 41.8 mt-10 -88.49 164.57 15.39 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 121.036 0.446 . . . . 0.0 111.24 -177.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.12 142.06 50.77 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.589 -179.459 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.481 ' NH2' ' OG ' ' A' ' 106' ' ' SER . 6.0 ptt85 -136.89 158.76 43.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.611 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.698 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -112.32 135.8 52.56 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.926 -179.746 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' SER . . . . . 0.481 ' OG ' ' NH2' ' A' ' 104' ' ' ARG . 6.7 m -142.55 161.84 37.01 Favored 'General case' 0 C--N 1.344 0.329 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.1 p -94.43 156.48 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 111.33 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.459 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.3 mt -71.1 159.35 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.678 ' NH2' ' H ' ' A' ' 63' ' ' GLY . 43.2 ttm180 -106.57 -46.36 4.02 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.759 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 81.4 tt0 -165.01 143.72 6.55 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 10.7 p -93.95 133.14 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.407 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.3 mm? -101.11 125.4 38.24 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-O 119.674 -0.203 . . . . 0.0 110.977 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.39 165.93 0.1 Allowed 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.225 1.95 . . . . 0.0 112.0 179.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 19.9 p -66.69 151.47 47.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 121.276 0.56 . . . . 0.0 110.776 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -133.06 -142.05 0.21 Allowed 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.678 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.5 mtt85 -156.79 130.93 8.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.285 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.53 169.83 5.03 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.943 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -72.89 148.25 44.56 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.241 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 42.0 p -131.1 143.36 50.6 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -115.65 174.55 5.96 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.753 -179.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -145.28 137.48 25.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.109 -0.95 . . . . 0.0 111.074 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 97.2 mt -130.23 170.8 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.449 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -138.01 106.99 5.98 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.926 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 125' ' ' GLU . 8.5 t -86.04 115.14 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.863 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.523 ' CD ' HH21 ' A' ' 43' ' ' ARG . 81.4 tt0 18.52 -95.65 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.729 0 O-C-N 123.762 0.664 . . . . 0.0 112.327 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -128.03 -33.11 2.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.154 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.439 ' O ' ' N ' ' A' ' 129' ' ' THR . 54.3 mt -78.02 67.93 3.96 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -42.7 97.81 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.229 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 175.14 143.48 0.06 Allowed 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.82 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 3.9 pp -151.47 154.5 36.68 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.415 0.626 . . . . 0.0 111.676 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.7 t -89.76 123.54 42.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.872 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.86 122.87 22.62 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.137 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.489 ' C ' ' H ' ' A' ' 135' ' ' VAL . 13.8 mm-40 55.83 43.54 27.48 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.021 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.51 -15.81 0.8 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.176 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.489 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.7 t -90.53 146.87 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 117.268 0.534 . . . . 0.0 110.456 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.19 115.12 47.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.792 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.416 ' O ' ' C ' ' A' ' 138' ' ' HIS . 21.6 m -147.65 142.19 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.226 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.775 ' HE2' ' CG ' ' A' ' 73' ' ' HIS . 0.3 OUTLIER -37.37 153.48 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.206 0.457 . . . . 0.0 111.681 -179.816 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.9 p30 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.382 179.745 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.62 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 24.5 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -109.34 136.51 48.67 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.845 0.355 . . . . 0.0 110.527 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.04 162.66 21.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.518 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 44.6 tt0 -63.27 143.18 58.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.961 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.83 -20.83 23.96 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.3 m -67.48 123.56 20.74 Favored 'General case' 0 C--N 1.331 -0.218 0 O-C-N 122.768 -0.254 . . . . 0.0 111.244 -179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.435 ' HE ' HG23 ' A' ' 16' ' ' THR . 72.6 mtp180 -82.72 147.63 28.35 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.781 0.324 . . . . 0.0 110.162 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -134.79 107.3 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.497 179.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -76.95 129.8 36.64 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.474 ' O ' ' N ' ' A' ' 14' ' ' GLY . 50.8 t0 -109.91 110.24 59.06 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-O 119.53 -0.272 . . . . 0.0 110.377 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_exo -51.96 -36.8 65.84 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 121.765 1.643 . . . . 0.0 112.561 178.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.2 t -62.11 -58.25 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.037 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.674 ' HG1' ' H ' ' A' ' 15' ' ' THR . 24.8 p -77.49 -33.93 54.35 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.365 0.602 . . . . 0.0 109.834 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 81.31 6.47 89.27 Favored Glycine 0 N--CA 1.449 -0.465 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.175 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.674 ' H ' ' HG1' ' A' ' 13' ' ' THR . 50.6 m -113.83 159.91 19.3 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 117.719 0.759 . . . . 0.0 109.926 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.435 HG23 ' HE ' ' A' ' 7' ' ' ARG . 13.9 m -80.4 117.05 20.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.17 0.51 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -98.94 139.92 33.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.041 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -95.66 127.47 41.71 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.791 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.453 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 3.2 tp -53.98 -40.8 46.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.861 0.362 . . . . 0.0 111.429 -178.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.453 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 8.7 tt0 -58.88 -36.64 74.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.135 0.493 . . . . 0.0 110.729 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -81.5 -36.64 29.0 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.567 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.6 t -66.96 -41.71 87.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.22 -43.56 57.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -58.85 -37.87 77.46 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 121.084 -0.247 . . . . 0.0 111.3 -177.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.87 29.54 10.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.512 ' C ' ' O ' ' A' ' 25' ' ' GLY . 96.3 mtt-85 22.61 56.49 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.088 0 CA-C-O 121.27 0.557 . . . . 0.0 110.266 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.648 ' C ' ' H ' ' A' ' 29' ' ' ILE . 31.1 mmtt -75.41 115.68 47.67 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.917 -177.45 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.558 ' O ' ' O ' ' A' ' 29' ' ' ILE . 32.6 Cg_exo -58.1 12.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.505 2.191 0 C-N-CA 122.001 1.801 . . . . 0.0 112.843 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.648 ' H ' ' C ' ' A' ' 27' ' ' LYS . 2.1 pp -40.23 175.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.713 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.478 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 2.8 m80 -121.71 167.51 12.86 Favored 'General case' 0 N--CA 1.467 0.401 0 O-C-N 122.22 -0.3 . . . . 0.0 110.611 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -148.28 170.08 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.1 t -87.59 137.2 21.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 121.896 -0.502 . . . . 0.0 109.772 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.78 168.03 9.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.138 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.22 140.23 37.69 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.29 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.57 176.02 5.21 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -70.71 -14.07 62.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.803 0.335 . . . . 0.0 110.837 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -79.37 -17.64 54.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.38 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.81 22.1 40.54 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.2 p -101.6 136.64 41.1 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.076 178.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.94 134.1 42.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.848 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -144.4 141.66 29.81 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.781 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.17 141.82 52.57 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.533 -178.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -142.39 140.67 19.31 Favored Pre-proline 0 CA--C 1.542 0.653 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.272 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 157.57 30.53 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.771 2.314 . . . . 0.0 112.52 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -102.96 138.25 27.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.7 m -128.3 4.67 3.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.046 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.431 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 1.2 t -151.91 145.11 24.64 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 119.05 0.841 . . . . 0.0 109.19 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.86 124.66 15.06 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 178.703 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -141.62 146.27 36.02 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -88.68 133.08 34.32 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 176.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.431 ' OE1' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -92.8 -0.23 57.3 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.6 177.44 51.16 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.307 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 39.2 m -89.43 123.85 33.94 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.025 0.44 . . . . 0.0 109.974 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -148.63 173.7 12.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.257 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -77.1 140.86 40.37 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.259 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 m -139.35 154.87 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 30.8 pt -112.05 151.34 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.024 179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.88 144.82 15.9 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 27.4 mt -123.33 112.93 18.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.322 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -86.98 107.49 18.42 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.36 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.555 ' O ' ' N ' ' A' ' 63' ' ' GLY . 1.8 mp -96.51 124.8 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.936 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.566 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 36.97 24.43 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.723 -179.291 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 71.98 -25.38 0.67 Allowed Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.566 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.18 -105.82 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.96 171.2 9.45 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.246 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.4 ' CG2' ' N ' ' A' ' 67' ' ' LEU . 96.0 mt -125.48 157.29 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.392 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.4 ' N ' ' CG2' ' A' ' 66' ' ' ILE . 49.8 tp -132.74 116.62 16.81 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.064 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.3 m95 -102.8 125.42 49.54 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.76 171.52 17.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.214 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.21 156.9 73.8 Favored Pre-proline 0 CA--C 1.533 0.323 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.586 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.74 -19.98 69.8 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.562 2.175 . . . . 0.0 112.066 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -93.26 -7.04 46.18 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.031 0.444 . . . . 0.0 110.189 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 9.6 t60 -73.42 131.36 41.74 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -88.04 130.63 34.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 110.271 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 76' ' ' LEU . 95.2 t -108.95 90.63 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.847 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' VAL . 49.0 tp -31.21 99.12 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 O-C-N 123.244 0.34 . . . . 0.0 111.707 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.436 ' N ' ' O ' ' A' ' 80' ' ' GLY . 61.4 p -98.22 176.08 5.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -63.37 -19.04 64.31 Favored 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.166 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 -106.86 23.77 13.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.428 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 77' ' ' THR . . . 105.55 -141.47 15.38 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 96.8 m95 -96.11 130.31 43.18 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.732 -0.234 . . . . 0.0 110.766 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -142.35 132.32 24.44 Favored 'General case' 0 C--O 1.232 0.157 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.65 143.8 19.37 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.398 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.426 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -63.52 -37.91 89.13 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.488 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.5 0.09 3.19 Favored Glycine 0 CA--C 1.529 0.965 0 C-N-CA 120.44 -0.886 . . . . 0.0 111.833 -179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 84' ' ' ALA . 97.2 mt-10 -109.19 -2.28 18.11 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.989 0.423 . . . . 0.0 110.426 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 83.7 mt -74.67 129.52 37.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.472 ' O ' ' N ' ' A' ' 90' ' ' GLY . 36.2 mmt180 -133.12 147.99 52.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.435 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -46.37 92.59 0.01 OUTLIER 'General case' 0 C--O 1.233 0.192 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.474 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.85 -20.38 0.78 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -83.63 130.12 34.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.805 0.336 . . . . 0.0 110.694 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.406 ' NH2' ' O ' ' A' ' 105' ' ' TYR . 79.1 mtp85 -91.18 138.66 31.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.518 -179.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 33.2 m -126.36 151.46 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.285 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.14 134.98 52.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.443 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.77 158.45 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.555 179.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -104.64 127.95 52.53 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.149 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -100.06 124.51 45.52 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.247 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 12.5 p -75.2 -15.46 15.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.352 0.524 . . . . 0.0 111.087 178.232 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -69.55 -58.3 4.13 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.224 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.482 ' H ' ' HG1' ' A' ' 100' ' ' THR . 15.6 p -99.18 -12.06 20.79 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.739 -0.21 . . . . 0.0 110.473 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.77 -13.26 8.85 Favored Glycine 0 C--N 1.329 0.187 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.471 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.4 mt-10 -82.05 155.32 25.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.975 0.417 . . . . 0.0 111.222 -177.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.5 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -75.74 139.94 42.13 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.195 179.41 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 98.8 mtt180 -139.17 169.61 17.46 Favored 'General case' 0 CA--C 1.51 -0.589 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.406 ' O ' ' NH2' ' A' ' 92' ' ' ARG . 8.2 m-30 -108.1 141.88 39.13 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.197 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 4.1 m -136.99 159.59 41.42 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 85.0 t -98.32 156.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 29.4 mm -84.66 131.33 34.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.184 178.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.3 mmm180 -82.44 -34.13 28.29 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.765 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -166.21 145.41 5.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -95.38 135.42 29.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.416 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.4 mm? -98.35 123.92 48.73 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 120.626 -0.429 . . . . 0.0 111.149 -179.471 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.5 162.91 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.039 1.826 . . . . 0.0 111.711 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 74.7 p -65.35 152.95 42.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.409 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 41.2 ttt180 -135.18 -139.15 0.17 Allowed 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.691 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.409 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 13.0 tpt180 -157.99 129.77 6.86 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.402 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.39 171.09 4.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.179 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.518 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 88.1 mtm180 -74.68 146.97 41.9 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.62 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 6.6 p -126.22 143.3 51.19 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -115.6 173.1 6.71 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.819 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -152.33 127.02 9.48 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.528 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.3 mt -116.24 171.9 7.53 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.233 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -134.95 107.2 7.21 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.352 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.9 t -91.94 119.86 40.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -60.87 144.42 52.86 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.76 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 69.21 -67.78 0.21 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.662 179.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.36 89.7 4.54 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 116.695 -0.23 . . . . 0.0 110.838 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -62.08 96.83 0.08 Allowed 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER 165.4 155.06 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 178.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 130' ' ' LEU . 2.9 pp -150.94 151.84 32.73 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.307 -0.557 . . . . 0.0 111.544 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 40.0 t -93.14 127.69 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.151 -179.405 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.49 133.54 42.35 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.006 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 81.1 mm-40 55.29 42.31 30.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.531 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.0 27.47 67.19 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.623 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 23.3 t -130.17 150.75 34.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 118.135 0.968 . . . . 0.0 108.391 179.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 3.5 t -105.12 111.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-N 118.329 0.513 . . . . 0.0 111.038 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' ' C ' ' A' ' 138' ' ' HIS . 16.9 m -145.88 134.67 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.627 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 51.8 t-80 -34.42 148.06 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.676 0.274 . . . . 0.0 111.649 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.733 ' N ' HD21 ' A' ' 139' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.369 -179.695 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 75.0 mt -96.5 143.63 27.33 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.316 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.3 163.91 16.57 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.701 0.286 . . . . 0.0 110.841 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.433 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 48.3 tt0 -64.78 142.12 58.54 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.523 178.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.66 -22.06 17.67 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.5 m -66.68 121.67 15.92 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.59 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.4 mtt85 -80.57 147.17 30.9 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 6.4 mm -134.77 106.3 7.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.014 0.435 . . . . 0.0 111.212 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -77.82 130.46 36.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -111.68 110.46 54.97 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.713 -0.221 . . . . 0.0 110.547 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.08 -35.58 62.42 Favored 'Trans proline' 0 N--CA 1.497 1.686 0 C-N-CA 122.171 1.914 . . . . 0.0 112.409 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.5 t -61.88 -57.8 10.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.767 -178.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.485 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 43.5 p -79.53 -36.63 38.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.305 0.574 . . . . 0.0 109.905 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.485 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 84.78 6.9 84.87 Favored Glycine 0 N--CA 1.451 -0.362 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.205 -179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 52.4 m -113.78 157.97 21.58 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 117.769 0.784 . . . . 0.0 109.918 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 30.6 m -80.47 117.71 21.44 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.121 0.486 . . . . 0.0 110.87 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 18.4 m80 -100.52 143.51 30.62 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.011 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -97.34 128.22 43.97 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.222 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.444 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 8.3 tp -52.9 -40.8 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.252 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.444 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 7.3 tt0 -58.48 -35.96 73.0 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -81.91 -38.05 25.87 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.605 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.8 t -67.45 -42.33 87.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.04 -45.24 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.63 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -57.38 -37.19 72.28 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 120.728 0.299 . . . . 0.0 110.971 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.57 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.38 29.66 9.33 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-O 118.944 -0.92 . . . . 0.0 110.848 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.57 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.7 ptt180 15.15 67.68 0.01 OUTLIER 'General case' 0 C--N 1.363 1.16 0 CA-C-N 117.313 0.557 . . . . 0.0 110.123 179.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.648 ' C ' ' H ' ' A' ' 29' ' ' ILE . 71.3 mttt -86.52 118.01 69.57 Favored Pre-proline 0 N--CA 1.44 -0.965 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.615 ' O ' ' O ' ' A' ' 29' ' ' ILE . 44.2 Cg_exo -53.83 9.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.498 1.762 0 C-N-CA 122.189 1.926 . . . . 0.0 113.383 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.648 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.9 pp -38.01 176.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 123.703 0.627 . . . . 0.0 110.843 -178.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.453 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 4.0 m80 -122.48 166.73 14.31 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 121.837 -0.539 . . . . 0.0 110.795 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.8 m -148.57 171.17 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.27 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.01 135.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.59 166.87 11.1 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.571 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.48 142.4 43.55 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.091 0.472 . . . . 0.0 110.25 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.76 178.67 4.2 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -66.8 -15.53 63.65 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.192 -0.318 . . . . 0.0 110.906 179.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -75.94 -22.0 56.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.685 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.9 -7.01 67.33 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.7 p -77.2 145.12 37.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.187 0.517 . . . . 0.0 111.291 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 64.9 mt -100.4 132.89 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.857 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -141.37 138.96 33.4 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.795 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.06 143.03 52.6 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.673 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NH1' ' OE1' ' A' ' 125' ' ' GLU . 0.9 OUTLIER -142.72 138.34 16.02 Favored Pre-proline 0 CA--C 1.54 0.584 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.187 -179.594 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.67 158.58 31.92 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.916 2.411 . . . . 0.0 112.729 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.4 t -100.73 136.07 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.359 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.95 2.06 3.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.589 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 t -146.33 137.07 24.19 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 118.922 0.783 . . . . 0.0 109.149 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -139.32 124.17 18.64 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -138.23 146.84 43.07 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -179.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 52.7 p-10 -113.14 140.62 47.75 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 122.027 0.918 . . . . 0.0 108.593 176.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 -105.5 0.35 Allowed 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.602 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -165.58 -156.43 9.24 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.332 -1.304 . . . . 0.0 112.918 -176.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -88.51 127.89 35.54 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.983 0.421 . . . . 0.0 111.482 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -145.8 158.65 43.84 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -76.17 140.88 41.93 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.253 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.1 143.72 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.121 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 18.9 pt -96.13 152.36 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.408 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.94 132.66 11.15 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.0 mt -110.76 112.26 24.01 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -85.81 113.24 21.81 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.972 -179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.478 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -104.46 149.83 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.806 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.78 139.8 16.05 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.734 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.78 -3.31 60.72 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 96.41 -17.93 58.39 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.16 125.75 20.27 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.347 0.594 . . . . 0.0 109.589 -178.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -130.76 155.96 42.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.671 -179.174 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.4 tp -142.79 124.0 14.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.851 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -104.52 125.19 50.46 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.9 171.11 18.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.144 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -78.7 155.52 78.26 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-O 120.71 0.291 . . . . 0.0 111.035 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.48 -20.51 70.76 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.675 2.25 . . . . 0.0 112.085 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -89.36 -7.97 54.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.008 0.432 . . . . 0.0 110.178 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.598 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 11.5 t60 -72.66 131.17 42.06 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -87.93 132.04 34.37 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 121.153 0.501 . . . . 0.0 111.142 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.87 140.38 22.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.728 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 53.1 tp -80.99 94.7 6.6 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.776 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.8 p -99.2 178.0 5.04 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -178.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -67.03 -17.88 65.11 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.498 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 79' ' ' TYR . 33.3 t80 -106.25 24.31 12.7 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 120.655 0.264 . . . . 0.0 111.35 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.33 -142.63 15.96 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -92.78 128.85 38.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.85 0.357 . . . . 0.0 110.85 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 82.8 mtp180 -140.91 130.85 24.5 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.903 179.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.73 142.7 22.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.111 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.82 -38.28 87.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.065 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.51 -1.23 4.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.195 -1.002 . . . . 0.0 111.902 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.7 tt0 -107.72 -4.04 18.56 Favored 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 121.446 0.641 . . . . 0.0 110.003 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.2 mt -77.4 128.78 34.84 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.535 0.683 . . . . 0.0 111.259 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.523 ' O ' ' N ' ' A' ' 90' ' ' GLY . 2.3 mmm180 -129.14 147.1 50.96 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.955 -1.02 . . . . 0.0 111.1 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -43.55 91.46 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 121.08 0.467 . . . . 0.0 110.527 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.71 -13.4 0.67 Allowed Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -86.46 130.38 34.52 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.858 0.361 . . . . 0.0 110.32 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -92.7 134.91 34.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.65 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.2 m -120.53 153.54 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.835 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -69.57 125.64 27.31 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.986 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 17.3 m -124.1 160.43 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.76 178.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -105.2 128.88 53.62 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.784 0.325 . . . . 0.0 110.543 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 104' ' ' ARG . 43.0 t0 -100.11 123.3 44.19 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 178.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.3 p -75.16 -15.41 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 118.47 0.577 . . . . 0.0 111.223 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.7 mm-40 -69.43 -59.13 3.19 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 120.616 -0.434 . . . . 0.0 109.956 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.455 ' C ' ' H ' ' A' ' 102' ' ' GLU . 44.1 p -97.09 -11.54 24.26 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.83 -12.51 8.5 Favored Glycine 0 C--N 1.332 0.355 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.455 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -84.45 159.69 20.72 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.947 0.403 . . . . 0.0 110.892 -177.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -80.31 140.29 36.22 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.865 179.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.481 ' CZ ' ' OD2' ' A' ' 97' ' ' ASP . 32.5 mtm180 -137.83 168.79 18.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.962 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -109.32 141.17 42.03 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.633 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.4 m -138.03 158.69 43.81 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 65.1 t -92.1 154.3 3.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.554 0.216 . . . . 0.0 110.49 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 79.1 mt -74.15 155.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.03 0.443 . . . . 0.0 110.437 178.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -101.68 -45.64 5.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.038 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -167.44 149.88 5.95 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 80.6 t -94.1 133.41 35.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.457 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.466 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -100.15 148.33 34.73 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.239 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.14 156.12 66.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 122.51 2.14 . . . . 0.0 111.095 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.1 p -63.63 154.74 31.9 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -148.41 144.66 27.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 82.0 mtm-85 -77.38 132.02 38.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.184 0.516 . . . . 0.0 110.612 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -165.34 164.12 19.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.066 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 1.1 tpp85 -74.36 145.21 44.0 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.845 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 22.3 p -129.41 143.78 50.98 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -116.88 175.87 5.38 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.085 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -144.29 129.14 18.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.817 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 97.7 mt -122.24 171.09 9.28 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.619 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -137.94 107.17 6.07 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.623 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.521 ' O ' ' C ' ' A' ' 125' ' ' GLU . 23.7 t -88.03 115.55 28.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.068 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.533 ' OE1' ' NH1' ' A' ' 43' ' ' ARG . 28.1 tt0 15.54 -118.3 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 O-C-N 124.011 0.82 . . . . 0.0 111.212 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -98.64 -27.2 14.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.027 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 81.2 mt -84.99 87.25 7.35 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.448 ' CD2' ' N ' ' A' ' 128' ' ' HIS . 6.5 m170 -60.44 98.05 0.06 Allowed 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 167.44 152.71 0.03 OUTLIER 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.442 ' CD2' ' N ' ' A' ' 130' ' ' LEU . 1.4 pt? -156.04 157.85 36.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.542 0.686 . . . . 0.0 112.095 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.9 p -89.08 125.47 42.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.03 123.31 24.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.665 -179.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.473 ' C ' ' H ' ' A' ' 135' ' ' VAL . 77.6 mm-40 56.94 45.3 21.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.2 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.6 -19.67 0.88 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.386 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.473 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.4 t -90.08 152.43 3.34 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.33 0 CA-C-N 117.212 0.506 . . . . 0.0 110.773 -179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.5 t -112.93 117.75 56.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 138' ' ' HIS . 19.1 m -147.28 139.49 18.83 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.601 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.598 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 59.8 t-80 -36.17 157.5 0.01 OUTLIER 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 118.043 0.383 . . . . 0.0 111.93 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.506 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 25.5 p30 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.447 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.645 ' H1 ' ' HG1' ' A' ' 70' ' ' THR . 22.2 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 62.3 mt -110.59 134.82 52.06 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.459 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.14 161.57 25.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.833 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.42 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 49.3 tt0 -63.41 144.54 56.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.125 178.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.53 -16.45 31.63 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 24.7 m -68.44 122.54 18.63 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -95.99 115.67 27.78 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-O 120.858 0.361 . . . . 0.0 110.35 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.4 mt -100.53 113.31 35.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -76.47 136.8 39.39 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 12.0 t0 -104.08 130.81 22.7 Favored Pre-proline 0 CA--C 1.539 0.522 0 N-CA-C 110.28 -0.267 . . . . 0.0 110.28 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.56 -29.57 13.12 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.018 1.812 . . . . 0.0 112.431 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.513 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.9 t -71.18 -55.17 14.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.042 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.442 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 23.1 p -77.33 -33.58 55.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 120.902 0.382 . . . . 0.0 110.236 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.442 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 80.25 11.4 84.34 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.52 -168.68 1.38 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 117.498 0.649 . . . . 0.0 109.858 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.2 m -112.79 115.87 29.19 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.198 0.523 . . . . 0.0 110.24 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.5 m170 -105.64 145.6 30.82 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.061 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -99.47 129.67 45.67 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.982 -0.287 . . . . 0.0 110.315 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -53.5 -38.64 33.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-O 120.885 0.374 . . . . 0.0 111.121 -178.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.42 ' OE1' ' OE2' ' A' ' 4' ' ' GLU . 12.8 pt-20 -60.39 -35.13 75.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.883 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -83.74 -40.22 19.1 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.167 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.4 t -67.53 -42.08 86.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.614 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 53.4 t -74.96 -45.38 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.807 -178.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 62.8 t0 -60.87 -35.52 76.81 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 120.775 0.321 . . . . 0.0 111.088 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.47 26.23 24.26 Favored Glycine 0 C--O 1.229 -0.157 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 81.3 mtt85 17.63 60.95 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.121 0 O-C-N 123.907 0.416 . . . . 0.0 109.892 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.5 mttt -86.26 133.6 40.29 Favored Pre-proline 0 N--CA 1.447 -0.619 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.959 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -75.48 86.06 1.51 Allowed 'Trans proline' 0 C--N 1.313 -1.295 0 C-N-CA 121.499 1.466 . . . . 0.0 110.56 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.419 ' CD1' ' C ' ' A' ' 29' ' ' ILE . 2.4 pp -116.91 -172.81 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 120.778 0.323 . . . . 0.0 110.776 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.407 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 38.2 m80 -128.37 162.57 26.79 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.449 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -146.52 170.5 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.8 t -90.05 134.18 29.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.99 167.43 10.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.71 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.76 142.78 43.01 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.04 0.448 . . . . 0.0 110.521 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.96 176.78 4.89 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.406 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.631 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 73.4 mmtt -71.41 -13.73 61.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.634 0.254 . . . . 0.0 110.531 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.13 -16.1 57.16 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.333 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.43 18.89 56.28 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.8 p -100.44 137.38 38.93 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.759 0.314 . . . . 0.0 111.139 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -93.95 130.43 40.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.683 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -139.05 138.61 37.3 Favored 'General case' 0 C--O 1.223 -0.298 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.743 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.52 142.18 51.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.635 -178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.535 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 11.1 mmp_? -144.06 138.26 14.83 Favored Pre-proline 0 CA--C 1.537 0.458 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.645 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.07 156.5 33.99 Favored 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 122.393 2.062 . . . . 0.0 112.732 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.9 t -98.72 136.26 30.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.502 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 178.06 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 18.6 m -127.62 3.24 3.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.855 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.7 OUTLIER -151.64 145.33 25.01 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.345 179.089 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.583 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.92 124.23 14.65 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.148 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -139.56 145.66 38.89 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.431 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 49.0 p-10 -90.52 137.36 32.41 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.436 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -96.95 -0.97 46.65 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.479 -179.669 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.24 -178.39 53.49 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.416 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.3 m -85.11 121.99 28.66 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.907 0.384 . . . . 0.0 110.214 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 -145.14 165.48 28.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.551 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -76.94 140.79 40.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.073 179.105 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.4 m -146.59 154.49 12.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.3 pt -107.62 160.72 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.463 179.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -115.67 139.71 15.63 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 179.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 67.0 mt -114.23 108.53 17.07 Favored 'General case' 0 C--O 1.219 -0.526 0 CA-C-O 120.801 0.334 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.418 HH11 ' CG2' ' A' ' 66' ' ' ILE . 10.9 tpt180 -78.67 108.28 11.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.449 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.662 ' O ' ' N ' ' A' ' 63' ' ' GLY . 1.9 mp -94.37 132.55 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.518 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.654 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 23.89 33.97 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.818 0.699 . . . . 0.0 112.539 178.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.662 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 66.82 -21.24 0.19 Allowed Glycine 0 CA--C 1.531 1.088 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.202 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.654 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -52.47 -106.41 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.679 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.58 171.69 7.97 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.441 ' H ' ' CD1' ' A' ' 66' ' ' ILE . 0.0 OUTLIER -129.19 168.75 21.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 120.846 0.355 . . . . 0.0 110.547 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.9 tp -130.79 115.55 16.77 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.621 0.248 . . . . 0.0 110.545 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.2 m95 -101.64 105.36 16.28 Favored 'General case' 0 N--CA 1.463 0.209 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 178.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.44 171.22 14.81 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.144 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.645 ' HG1' ' H1 ' ' A' ' 1' ' ' CYS . 0.6 OUTLIER -76.99 157.66 81.19 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.571 -179.992 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 85' ' ' GLY . 33.8 Cg_endo -62.46 -17.07 55.97 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.603 2.202 . . . . 0.0 111.869 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 23.6 p30 -98.07 -5.64 33.41 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.861 0.362 . . . . 0.0 110.527 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.555 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 9.0 t60 -72.56 131.98 43.19 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -86.01 123.2 31.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.273 0.559 . . . . 0.0 111.082 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' LEU . 91.4 t -102.4 91.4 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.366 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' VAL . 35.2 tp -32.22 95.84 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.366 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.478 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -99.75 173.62 6.61 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -177.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -63.37 -20.0 65.15 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.042 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.413 ' CD2' ' NH2' ' A' ' 82' ' ' ARG . 63.9 m-85 -104.94 22.79 14.62 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.847 -0.16 . . . . 0.0 111.046 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.69 -144.64 16.16 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.631 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 89.2 m95 -90.75 124.74 35.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.509 0.195 . . . . 0.0 111.157 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.413 ' NH2' ' CD2' ' A' ' 79' ' ' TYR . 88.7 mtt180 -130.23 130.03 44.1 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.13 141.91 54.52 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -72.34 2.0 6.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.485 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -83.67 -14.52 73.0 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -129.37 19.23 5.82 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 122.829 -0.218 . . . . 0.0 111.44 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 28.3 mt -82.41 136.23 34.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.308 0.575 . . . . 0.0 110.797 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 58.0 mmt-85 -132.79 148.84 52.32 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.709 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -45.41 103.0 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.593 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.41 -15.59 1.11 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -82.31 130.28 35.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.791 0.329 . . . . 0.0 110.913 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -91.32 129.17 37.35 Favored 'General case' 0 C--O 1.224 -0.264 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.686 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.4 m -109.52 143.37 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.986 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.63 125.79 25.44 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.579 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.3 m -122.02 155.47 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.72 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.2 ttt85 -102.54 130.27 49.33 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.607 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -100.34 123.03 44.06 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.17 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.76 -16.65 16.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 118.056 0.389 . . . . 0.0 110.906 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -70.46 -58.87 3.24 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.09 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.47 ' C ' ' H ' ' A' ' 102' ' ' GLU . 30.0 p -96.48 -13.62 22.94 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.539 0.209 . . . . 0.0 110.62 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.33 -14.43 8.7 Favored Glycine 0 C--N 1.331 0.303 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.47 ' H ' ' C ' ' A' ' 100' ' ' THR . 76.7 mt-10 -79.44 153.09 29.91 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.906 0.384 . . . . 0.0 111.185 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -81.08 139.33 35.74 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.764 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.2 mtp180 -138.51 174.27 10.72 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.968 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.478 ' OH ' ' C ' ' A' ' 77' ' ' THR . 2.4 m-85 -113.01 149.67 33.0 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.182 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.6 m -143.25 164.55 29.89 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.0 m -97.08 155.06 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.695 0.225 . . . . 0.0 110.8 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 95.7 mt -86.99 121.75 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.211 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 67.2 mtp180 -68.55 -33.9 74.9 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -168.24 150.45 5.32 Favored 'General case' 0 N--CA 1.456 -0.163 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.8 t -97.15 136.38 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.443 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.2 mm? -96.22 122.38 58.06 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.082 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.64 166.0 0.16 Allowed 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.266 1.977 . . . . 0.0 111.607 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 4.5 p -66.93 151.32 47.83 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.166 0.508 . . . . 0.0 110.949 -179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.5 mtp85 -134.89 -143.28 0.2 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.81 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 36.4 mtm-85 -154.01 131.1 11.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.848 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.58 171.98 3.18 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.26 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 81.3 mtp180 -74.42 145.09 43.98 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.954 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.1 p -123.14 142.47 50.86 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.659 -0.496 . . . . 0.0 109.659 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -113.62 171.98 7.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.66 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -151.85 125.8 9.13 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.896 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -114.6 170.16 8.52 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.207 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.4 tp10 -137.61 105.28 5.57 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.33 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.61 118.62 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -61.85 146.04 50.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.523 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 69.24 -69.9 0.15 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.288 178.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 90.5 mt -100.44 95.8 6.98 Favored 'General case' 0 CA--C 1.514 -0.424 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.535 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 4.8 p80 -65.83 99.73 0.5 Allowed 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 166.6 145.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.578 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.435 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 2.5 pp -145.62 154.05 41.7 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.437 0.637 . . . . 0.0 111.619 -179.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 68.7 t -89.92 125.69 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.738 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.73 135.35 43.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.249 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 69.2 mm-40 49.73 45.59 24.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.123 179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.14 22.51 55.72 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.916 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.99 152.07 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.8 t -105.25 110.84 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 O-C-N 122.065 -0.397 . . . . 0.0 110.536 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 138' ' ' HIS . 13.4 m -146.99 138.52 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.555 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 56.2 t-80 -33.93 153.73 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.752 0.311 . . . . 0.0 111.793 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.287 -179.571 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.554 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 30.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 89.0 mt -107.11 134.55 50.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.912 0.387 . . . . 0.0 110.406 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.32 163.61 23.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.089 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -64.14 139.69 58.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.615 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.17 -18.66 25.67 Favored Glycine 0 C--N 1.334 0.454 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.6 m -69.78 123.93 22.69 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -97.85 116.64 30.46 Favored 'General case' 0 C--O 1.231 0.088 0 CA-C-O 120.982 0.42 . . . . 0.0 110.7 -179.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.0 mt -101.53 115.23 42.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.756 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -76.57 135.9 39.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 5.0 t70 -104.15 132.42 21.01 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 110.571 -0.159 . . . . 0.0 110.571 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.23 -31.84 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 121.838 1.692 . . . . 0.0 112.462 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 74.9 t -69.89 -55.25 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.047 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.6 p -77.54 -35.6 53.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.973 0.415 . . . . 0.0 110.182 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 10.45 85.46 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 88.2 m -114.09 157.51 22.47 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 117.276 0.538 . . . . 0.0 110.09 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 28.2 m -78.97 116.13 19.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.555 0.693 . . . . 0.0 110.897 -179.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . 0.459 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 61.8 m-70 -104.89 144.87 31.19 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.848 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -98.75 128.32 44.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.304 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.1 tp -52.8 -38.83 29.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 CA-C-O 120.704 0.287 . . . . 0.0 111.012 -178.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -57.03 -32.62 66.36 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.295 0.569 . . . . 0.0 110.806 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -83.57 -37.87 22.41 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.033 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.75 -42.4 86.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 87.5 t -73.08 -46.9 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 65.2 t0 -57.67 -36.0 71.32 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.836 0.351 . . . . 0.0 110.831 -178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -108.31 29.12 10.46 Favored Glycine 0 C--O 1.228 -0.254 0 CA-C-O 118.829 -0.984 . . . . 0.0 111.147 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.1 ptm180 13.08 67.91 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.488 0.644 . . . . 0.0 110.836 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.446 ' C ' ' H ' ' A' ' 29' ' ' ILE . 82.7 mttt -87.56 144.62 35.74 Favored Pre-proline 0 N--CA 1.45 -0.431 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.31 -177.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.587 ' O ' ' O ' ' A' ' 29' ' ' ILE . 57.4 Cg_endo -70.87 8.22 1.08 Allowed 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 122.057 1.838 . . . . 0.0 111.744 179.292 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.587 ' O ' ' O ' ' A' ' 28' ' ' PRO . 15.1 tt -37.1 172.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.847 -178.179 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.585 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 9.5 m80 -124.83 162.97 23.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.7 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 34.7 m -146.2 169.87 5.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.2 t -87.3 134.13 28.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.455 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.36 166.17 10.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.704 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.87 141.6 40.71 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.184 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.36 178.19 4.37 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -72.82 -12.78 61.12 Favored 'General case' 0 C--O 1.233 0.186 0 O-C-N 122.248 -0.283 . . . . 0.0 110.676 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -78.59 -17.71 55.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.366 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.92 18.59 55.85 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.1 p -100.01 137.29 38.66 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.983 0.42 . . . . 0.0 111.001 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.7 mt -94.34 131.05 40.37 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.714 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 4.9 t-80 -139.55 138.99 36.74 Favored 'General case' 0 C--O 1.221 -0.425 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.791 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.56 142.59 51.76 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -145.64 137.46 13.11 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.869 -179.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_endo -75.79 157.65 39.36 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.644 2.229 . . . . 0.0 112.401 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.6 t -90.91 127.44 43.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.8 -4.8 11.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.782 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.41 ' HG ' ' H ' ' A' ' 123' ' ' GLU . 5.0 p -151.79 143.08 23.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 O-C-N 121.756 -0.59 . . . . 0.0 109.445 178.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -137.6 117.28 13.06 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.189 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -144.8 146.29 32.05 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 45.7 p-10 -90.61 138.41 31.59 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.746 ' OE1' ' O ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -103.74 7.04 37.21 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.771 -179.826 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.746 ' O ' ' OE1' ' A' ' 51' ' ' GLN . . . 92.02 -175.65 38.43 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-O 121.552 0.529 . . . . 0.0 112.802 177.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.3 m -100.84 131.73 46.58 Favored 'General case' 0 N--CA 1.468 0.457 0 O-C-N 121.296 -1.12 . . . . 0.0 108.981 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 80.5 mtp180 -148.32 172.94 13.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.32 0.581 . . . . 0.0 110.382 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -75.54 140.34 42.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.622 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.6 m -140.92 158.13 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.6 pt -112.7 151.56 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 CA-C-O 120.848 0.356 . . . . 0.0 110.809 179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.86 132.17 10.99 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.7 mt -111.84 106.27 14.96 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.259 0.552 . . . . 0.0 109.781 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -86.16 117.37 24.94 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.278 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.4 mm -110.05 156.7 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.461 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -47.49 138.65 7.55 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.712 -179.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.47 -1.49 58.66 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 90.52 -9.99 75.91 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.2 129.13 33.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.14 -0.624 . . . . 0.0 109.371 -177.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 8.9 tp -123.36 144.03 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.892 -178.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 36.5 tp -136.74 118.97 15.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.862 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.05 127.66 50.23 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.36 170.27 20.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.886 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.87 155.9 82.76 Favored Pre-proline 0 CA--C 1.536 0.439 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.767 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 -18.92 64.18 Favored 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.68 2.254 . . . . 0.0 111.989 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -95.46 -5.0 44.0 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.025 0.441 . . . . 0.0 110.022 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.561 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -69.8 130.13 41.45 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.215 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -86.31 128.66 34.95 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.459 0.647 . . . . 0.0 111.446 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.56 144.44 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.185 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.409 ' CD1' ' C ' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -82.55 94.47 7.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.512 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 17.0 p -100.82 175.89 5.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.83 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.654 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 0.7 OUTLIER -60.41 -21.06 61.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.524 -179.32 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.98 24.25 13.1 Favored 'General case' 0 CA--C 1.516 -0.33 0 C-N-CA 121.303 -0.159 . . . . 0.0 111.095 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.62 -169.39 34.08 Favored Glycine 0 CA--C 1.523 0.583 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.509 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -60.84 123.78 18.55 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.925 -0.638 . . . . 0.0 110.775 -178.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -140.01 134.15 31.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.028 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.81 139.24 40.42 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.04 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.46 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -63.21 -37.29 86.66 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.28 1.87 1.85 Allowed Glycine 0 C--N 1.336 0.573 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.015 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.46 ' H ' ' C ' ' A' ' 84' ' ' ALA . 75.8 mt-10 -110.01 3.4 20.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.272 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.68 133.76 34.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.334 0.588 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.533 ' O ' ' N ' ' A' ' 90' ' ' GLY . 10.2 tpt180 -127.88 148.66 50.48 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.599 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -49.72 86.76 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.232 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 159.27 -18.37 0.26 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -77.94 134.75 37.81 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 88.8 mtm180 -92.36 139.59 30.45 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.927 -178.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.52 154.2 39.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.285 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -83.52 133.87 34.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.904 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.9 m -129.0 165.46 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.224 179.491 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.54 128.62 44.43 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.816 0.341 . . . . 0.0 111.0 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -99.64 122.64 42.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.982 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.6 p -75.33 -16.43 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 CA-C-N 118.425 0.557 . . . . 0.0 110.69 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -69.15 -58.59 3.86 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 120.524 -0.471 . . . . 0.0 109.877 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.496 ' C ' ' H ' ' A' ' 102' ' ' GLU . 72.5 p -95.99 -10.78 27.75 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.98 -12.34 6.61 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.496 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.0 mt-10 -89.13 161.23 16.61 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.269 0.557 . . . . 0.0 111.605 -177.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.485 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -74.56 139.26 43.61 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.052 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 37.6 ptt180 -130.98 158.05 41.31 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.654 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -104.15 135.98 44.62 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 42.8 m -144.07 166.19 25.68 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 94.1 t -94.84 154.44 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 110.417 -0.216 . . . . 0.0 110.417 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.471 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.9 mt -67.42 160.2 4.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.087 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.471 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 74.3 ttt180 -105.64 -48.91 3.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.648 179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -164.82 142.36 6.3 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.3 t -94.37 134.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.8 mm? -101.8 147.16 33.48 Favored Pre-proline 0 CA--C 1.538 0.501 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.855 -179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.17 165.27 30.87 Favored 'Trans proline' 0 N--CA 1.499 1.805 0 C-N-CA 122.967 2.445 . . . . 0.0 110.938 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -69.38 157.1 37.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.794 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 30.9 ttp180 -141.92 -141.75 0.13 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.377 179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.3 mtm-85 -151.89 135.23 15.99 Favored 'General case' 0 C--N 1.33 -0.243 0 O-C-N 123.471 0.482 . . . . 0.0 110.272 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 169.45 4.56 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.141 0.496 . . . . 0.0 110.952 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 18.5 tpp180 -74.59 146.46 42.5 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.592 ' OG1' ' NE2' ' A' ' 51' ' ' GLN . 0.6 OUTLIER -136.47 154.14 50.84 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -131.53 -178.53 4.9 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.677 -175.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -153.74 121.56 5.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.192 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 85.4 mt -117.13 127.9 54.59 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.783 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.41 ' H ' ' HG ' ' A' ' 47' ' ' SER . 80.4 tt0 -88.52 108.18 19.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.815 0.341 . . . . 0.0 110.36 -179.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' A' ' 126' ' ' GLU . 18.1 t -80.6 111.84 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.993 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 124' ' ' VAL . 2.8 tm-20 25.1 -87.63 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.498 ' N ' ' O ' ' A' ' 124' ' ' VAL . 44.2 tp10 -139.25 -27.86 0.79 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.545 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.499 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.1 mt -80.58 66.0 5.93 Favored 'General case' 0 CA--C 1.506 -0.732 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 127' ' ' LEU . 48.3 m170 -38.9 94.96 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.423 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 172.07 141.05 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.612 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.439 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 2.8 pp -147.56 154.79 41.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.46 0.648 . . . . 0.0 111.858 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 72.7 t -91.01 126.38 43.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.77 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.91 134.09 42.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.0 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 50.68 45.06 27.41 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.933 179.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.36 24.72 59.49 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.162 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 20.7 t -129.69 152.47 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -106.49 111.31 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 118.203 0.456 . . . . 0.0 110.75 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' A' ' 138' ' ' HIS . 5.9 m -146.54 140.52 20.54 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.561 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 11.1 t60 -31.35 152.86 0.0 OUTLIER 'General case' 0 C--O 1.226 -0.149 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 17.9 p30 . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.429 -179.406 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.51 ' HG ' ' HG1' ' A' ' 70' ' ' THR . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.4 mt -117.04 132.13 56.77 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.887 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.93 161.95 26.34 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -63.8 147.1 52.63 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.968 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.31 -15.18 39.3 Favored Glycine 0 C--N 1.336 0.581 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 18.5 m -67.13 121.59 15.96 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.611 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 80.9 mtm-85 -97.39 116.66 30.02 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 120.764 0.316 . . . . 0.0 110.272 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.416 HD11 HG23 ' A' ' 8' ' ' ILE . 9.0 mt -103.68 116.03 46.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.761 -179.228 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -76.13 136.04 39.82 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 11.9 t0 -103.19 130.41 23.68 Favored Pre-proline 0 CA--C 1.54 0.56 0 C-N-CA 121.187 -0.205 . . . . 0.0 110.52 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.05 -30.54 10.68 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.356 2.037 . . . . 0.0 112.196 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.544 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 57.8 t -72.05 -55.1 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.767 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 m -77.4 -39.98 45.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.175 0.512 . . . . 0.0 110.36 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 10.61 80.83 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.299 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.1 m -112.91 154.87 25.68 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-N 117.612 0.706 . . . . 0.0 109.636 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.8 m -79.05 117.15 19.83 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.265 0.555 . . . . 0.0 110.827 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -106.93 148.55 28.48 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.43 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -100.37 127.54 46.66 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.657 178.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.5 tt -54.09 -38.01 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 CA-C-O 120.923 0.392 . . . . 0.0 111.523 -179.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -60.03 -33.12 71.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.078 0.466 . . . . 0.0 110.984 -179.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -83.79 -38.2 21.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.713 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.7 -41.26 85.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.245 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.7 t -72.99 -45.62 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.037 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -58.1 -34.85 70.64 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 120.696 0.284 . . . . 0.0 110.619 -178.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.76 27.34 11.26 Favored Glycine 0 C--O 1.226 -0.363 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.9 ptt-85 15.01 68.06 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.129 0.49 . . . . 0.0 109.82 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -89.8 135.27 30.69 Favored Pre-proline 0 N--CA 1.446 -0.655 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.984 -176.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.9 85.14 1.54 Allowed 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.848 1.699 . . . . 0.0 110.427 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 16.4 pt -111.92 -171.44 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 110.963 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.423 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 65.7 m80 -130.44 159.62 36.49 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.454 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.55 170.49 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.5 t -86.61 131.52 34.56 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.6 146.66 37.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.396 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.02 143.45 45.73 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.938 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.79 176.71 4.94 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.468 ' CB ' ' HZ2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -69.87 -14.43 62.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.772 0.32 . . . . 0.0 110.749 179.523 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 56.0 t0 -80.44 -18.34 49.08 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.177 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.8 21.23 43.86 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 22.3 p -101.62 137.38 40.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.116 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 62.6 mt -91.35 126.68 36.51 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.745 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -136.76 136.71 39.14 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.579 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.548 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.51 142.02 51.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.487 -178.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.554 HH11 ' CD ' ' A' ' 125' ' ' GLU . 4.2 mmp_? -143.87 137.11 13.98 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.672 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.89 156.47 34.72 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 122.769 2.313 . . . . 0.0 112.962 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -96.64 134.93 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.37 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.34 -0.46 4.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.768 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.7 t -146.65 136.32 23.1 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 118.535 0.607 . . . . 0.0 109.513 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.56 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.62 118.42 15.12 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.291 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -140.74 147.13 38.67 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -96.93 134.04 40.79 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 176.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.571 HE21 ' C ' ' A' ' 119' ' ' THR . 2.2 mt-30 -96.64 3.77 52.32 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.315 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.29 -178.0 49.1 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.724 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -87.67 124.97 34.1 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-O 120.836 0.351 . . . . 0.0 110.17 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 48.2 mmt-85 -143.35 165.04 28.61 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.727 -179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -76.05 142.45 41.79 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.784 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.57 149.8 16.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.417 ' CD1' ' O ' ' A' ' 84' ' ' ALA . 46.7 pt -98.87 149.44 5.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.577 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.32 125.8 8.41 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 78.0 mt -108.58 113.37 26.32 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.201 0.524 . . . . 0.0 110.199 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.435 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 53.4 ttp180 -87.46 115.45 24.89 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.481 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.422 ' C ' ' H ' ' A' ' 63' ' ' GLY . 22.6 mm -106.09 152.47 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.441 -179.66 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.05 -10.1 0.75 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.715 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.422 ' H ' ' C ' ' A' ' 61' ' ' ILE . . . -61.87 -12.21 34.45 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 89.32 -20.72 32.3 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.17 172.47 8.2 Favored 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.9 tt -118.91 143.65 29.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.11 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.7 tt -118.49 115.38 24.49 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.363 -179.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -102.68 125.51 49.44 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.78 179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.02 170.97 19.12 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.879 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.51 ' HG1' ' HG ' ' A' ' 1' ' ' CYS . 0.6 OUTLIER -83.53 157.06 65.1 Favored Pre-proline 0 CA--C 1.535 0.372 0 C-N-CA 120.739 -0.385 . . . . 0.0 110.551 179.695 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 85' ' ' GLY . 38.3 Cg_endo -66.24 -18.7 56.17 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.549 2.166 . . . . 0.0 111.985 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -95.39 -6.29 41.32 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.368 . . . . 0.0 110.395 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.543 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 41.4 t60 -72.01 132.2 43.96 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -85.12 123.76 31.0 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.381 0.61 . . . . 0.0 111.629 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.83 140.92 16.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.061 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 47.9 tp -81.4 92.33 6.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.076 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.471 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 39.3 p -98.86 173.15 7.0 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 92' ' ' ARG . 17.3 pt-20 -64.49 -17.05 63.5 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.291 -179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -105.95 24.85 11.7 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.691 0.281 . . . . 0.0 110.787 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.03 -143.5 16.64 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 79.5 m95 -89.1 123.29 33.24 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.729 0.3 . . . . 0.0 111.14 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -122.88 126.06 46.57 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.026 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.45 132.0 46.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.784 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.417 ' O ' ' CD1' ' A' ' 57' ' ' ILE . . . -69.36 -1.07 7.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.029 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -76.37 -12.93 83.85 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -134.76 27.76 3.61 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 13.3 mt -83.03 133.25 35.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.373 0.606 . . . . 0.0 111.02 179.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -133.38 148.02 51.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.615 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.444 ' HZ2' ' CB ' ' A' ' 89' ' ' LYS . 7.3 ttpm? -47.59 106.59 0.09 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.551 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 147.12 -17.89 1.55 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -82.7 132.94 35.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.643 0.258 . . . . 0.0 110.695 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 85.2 mtm180 -90.04 130.21 36.25 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.364 -0.535 . . . . 0.0 110.302 -179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.9 m -113.49 144.77 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.66 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.15 124.72 26.88 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.708 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.6 m -121.66 165.02 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.146 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.1 tpt180 -101.64 128.91 47.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.61 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.433 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 34.8 t0 -101.13 124.03 46.21 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.534 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 97.1 t -74.37 -16.2 16.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 118.29 0.495 . . . . 0.0 111.065 178.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -70.3 -59.29 2.96 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.405 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.463 ' C ' ' H ' ' A' ' 102' ' ' GLU . 19.5 p -98.84 -13.93 19.88 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.627 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.38 -14.26 6.92 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.463 ' H ' ' C ' ' A' ' 100' ' ' THR . 46.0 mt-10 -82.09 157.46 24.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 111.175 -177.22 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 7.8 mp -77.22 134.86 38.5 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-O 121.228 0.537 . . . . 0.0 110.153 179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.433 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 38.9 ptt180 -132.62 165.4 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.592 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.471 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.1 m-85 -112.04 148.55 33.61 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.048 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 65.1 m -145.15 165.84 27.14 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 57.7 t -91.81 152.31 3.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.62 0.248 . . . . 0.0 110.69 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.477 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 71.9 mt -70.49 162.26 4.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.304 178.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.477 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 37.4 mtp85 -106.04 -48.47 3.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.817 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.435 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 85.3 tt0 -167.53 149.14 5.62 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.963 -0.461 . . . . 0.0 109.853 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.16 134.35 34.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -102.59 151.22 38.22 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.168 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.22 159.85 50.26 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.664 2.243 . . . . 0.0 111.301 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -65.75 154.19 39.69 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 120.886 -0.326 . . . . 0.0 110.431 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -149.8 153.36 36.67 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.804 0.811 . . . . 0.0 110.307 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.0 mmm180 -82.55 132.42 35.2 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.634 -179.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.81 167.63 12.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.973 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.1 ttm180 -80.53 145.12 31.98 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.708 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.571 ' C ' HE21 ' A' ' 51' ' ' GLN . 41.9 p -125.95 145.01 50.46 Favored 'General case' 0 CA--C 1.521 -0.142 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.558 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 59.6 m-85 -120.5 175.09 6.16 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.42 -178.438 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -151.77 123.84 8.14 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 89.8 mt -122.46 124.59 43.95 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.629 0.252 . . . . 0.0 110.508 179.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tp10 -89.25 109.56 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.989 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.504 ' O ' ' C ' ' A' ' 125' ' ' GLU . 18.6 t -83.6 115.78 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.918 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.554 ' CD ' HH11 ' A' ' 43' ' ' ARG . 43.7 tt0 20.7 -92.01 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.519 0 O-C-N 123.733 0.645 . . . . 0.0 111.749 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.4 ' N ' ' O ' ' A' ' 124' ' ' VAL . 40.8 tp10 -133.22 -32.46 1.19 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.882 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.508 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.8 mt -74.03 63.04 0.92 Allowed 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.315 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' O ' ' A' ' 127' ' ' LEU . 30.8 m170 -38.48 95.04 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.508 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.33 140.84 0.02 OUTLIER 'General case' 0 C--O 1.233 0.191 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.1 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.42 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.6 pp -149.29 156.89 42.81 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.321 0.582 . . . . 0.0 111.796 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.9 121.44 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.424 ' O ' ' N ' ' A' ' 135' ' ' VAL . . . -133.5 145.77 50.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.558 -178.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.534 ' C ' ' H ' ' A' ' 135' ' ' VAL . 40.0 mt-10 40.8 46.5 2.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.155 179.063 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.32 -22.24 0.29 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.658 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.534 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.4 t -90.91 152.01 3.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 C-N-CA 122.596 0.358 . . . . 0.0 110.701 179.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.3 t -108.8 115.84 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 120.757 0.313 . . . . 0.0 110.416 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 33.5 m -149.94 144.18 17.62 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.057 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.543 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 52.2 t-80 -30.01 149.95 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 179.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.429 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 22.2 p30 . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.415 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.542 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 16.0 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 68.9 mt -108.25 135.31 49.79 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.599 -179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.85 163.22 23.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.732 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 65.2 tt0 -63.19 141.5 58.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.053 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.19 -19.73 31.74 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.3 m -67.68 124.55 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.261 0.077 . . . . 0.0 111.169 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -85.32 150.1 25.0 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.992 0.425 . . . . 0.0 109.989 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 12.9 mt -134.47 108.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.191 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -76.01 125.83 29.86 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 178.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.9 129.85 25.66 Favored Pre-proline 0 CA--C 1.536 0.429 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.12 -30.12 16.62 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.703 1.602 . . . . 0.0 112.433 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 72.2 t -73.73 -55.18 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 32.4 m -74.7 -40.34 61.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.472 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.32 6.64 83.85 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 85.3 m -116.92 162.0 18.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.512 0.656 . . . . 0.0 109.794 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 1.9 p -81.02 116.15 20.83 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.609 0.719 . . . . 0.0 111.301 -179.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 13.4 m80 -97.32 138.6 34.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.22 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -95.64 126.67 41.07 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.695 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 3.9 tp -53.07 -40.44 37.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 111.388 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.45 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 6.0 pt-20 -57.12 -36.59 70.86 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.371 0.605 . . . . 0.0 110.968 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.2 t0 -81.85 -36.89 27.77 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.63 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.2 t -67.38 -42.24 87.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.252 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 91.5 t -72.2 -46.52 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -55.04 -37.9 67.28 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 120.96 0.41 . . . . 0.0 110.472 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.579 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -111.99 33.32 5.8 Favored Glycine 0 CA--C 1.52 0.374 0 CA-C-O 118.688 -1.062 . . . . 0.0 110.873 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.579 ' C ' ' O ' ' A' ' 25' ' ' GLY . 26.2 ptt180 8.97 74.63 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 117.576 0.688 . . . . 0.0 110.588 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.457 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.4 mttt -89.04 142.03 29.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.944 -177.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.514 ' O ' ' O ' ' A' ' 29' ' ' ILE . 58.4 Cg_endo -70.87 11.22 0.53 Allowed 'Trans proline' 0 N--CA 1.491 1.338 0 C-N-CA 121.832 1.688 . . . . 0.0 111.534 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.514 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.3 pp -39.78 171.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.237 -177.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.427 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 4.2 m80 -120.99 166.08 14.35 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.425 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.9 m -148.12 170.01 3.23 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 99.5 t -85.75 137.64 20.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.59 165.47 11.51 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.46 138.66 41.67 Favored 'General case' 0 N--CA 1.462 0.161 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.21 178.0 4.43 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.13 -14.9 61.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.883 0.373 . . . . 0.0 110.885 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -77.93 -18.32 56.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.331 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.38 24.97 34.76 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.7 p -102.87 136.4 42.77 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.649 0.262 . . . . 0.0 110.808 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.97 130.84 44.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.954 0.407 . . . . 0.0 110.532 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -141.64 140.05 33.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.734 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -68.9 142.97 54.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.4 mmp_? -146.24 137.57 12.9 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.428 -179.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -74.6 158.32 43.78 Favored 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.611 2.208 . . . . 0.0 112.695 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.2 t -100.03 136.53 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 177.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.1 m -127.83 2.59 3.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 119.032 -0.508 . . . . 0.0 112.159 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.8 t -145.85 134.79 22.55 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 119.349 0.977 . . . . 0.0 108.915 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -132.89 117.6 17.91 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 177.86 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.504 ' O ' ' OE1' ' A' ' 51' ' ' GLN . 68.4 m-85 -142.81 148.73 37.61 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 48.6 p-10 -97.61 135.8 38.92 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.504 ' OE1' ' O ' ' A' ' 49' ' ' PHE . 0.6 OUTLIER -97.27 8.27 44.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.41 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.47 177.92 50.52 Favored Glycine 0 CA--C 1.527 0.825 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.488 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.549 ' OG1' ' NH1' ' A' ' 118' ' ' ARG . 4.3 m -87.51 127.68 35.24 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.337 -0.432 . . . . 0.0 109.87 179.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.2 mmm180 -148.51 167.49 25.24 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.049 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -73.95 141.79 45.92 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.509 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.7 m -128.88 141.22 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 110.491 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.581 ' H ' ' CD1' ' A' ' 57' ' ' ILE . 0.1 OUTLIER -100.9 139.78 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.87 179.794 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.48 140.95 15.31 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.103 -0.57 . . . . 0.0 111.846 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 27.6 mt -129.0 115.86 18.43 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-O 121.197 0.522 . . . . 0.0 109.972 -179.036 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.611 ' NH2' ' NH1' ' A' ' 109' ' ' ARG . 62.9 ttt180 -97.02 114.55 26.18 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.729 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.542 ' O ' ' N ' ' A' ' 63' ' ' GLY . 16.4 mm -100.76 123.9 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.287 -178.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.493 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 39.92 20.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.001 -178.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 75.82 -29.91 1.3 Allowed Glycine 0 CA--C 1.52 0.354 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 63' ' ' GLY . . . -45.77 -108.77 0.01 OUTLIER Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -177.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -81.78 167.89 18.6 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.215 0.531 . . . . 0.0 111.174 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -132.07 156.81 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.579 -178.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.9 tp -146.21 123.75 11.76 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.427 -0.352 . . . . 0.0 111.723 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 2.1 m95 -99.42 107.85 20.19 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 175.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -127.51 177.14 6.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.158 -177.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.9 155.27 52.87 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.225 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -60.44 -27.38 84.74 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.909 2.406 . . . . 0.0 112.08 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' A' ' 74' ' ' LYS . 38.7 t70 -85.9 -6.93 58.99 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.476 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.8 t60 -70.53 126.37 29.45 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' A' ' 72' ' ' ASP . 14.3 mptt -89.55 137.4 32.36 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.352 0.596 . . . . 0.0 110.517 -179.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.5 t -105.09 135.85 41.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.151 -0.932 . . . . 0.0 109.586 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.5 tp -76.54 100.37 5.27 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.671 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.492 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 81.8 p -98.81 174.78 6.22 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -178.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.431 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 10.0 pt-20 -67.11 -12.75 60.84 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.674 -0.411 . . . . 0.0 111.438 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.431 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 60.2 m-85 -112.89 22.13 14.76 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.473 0.175 . . . . 0.0 111.473 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.88 -138.01 14.67 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -107.12 138.32 43.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.716 0.293 . . . . 0.0 110.387 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 tpt180 -137.82 130.33 29.51 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.66 141.9 36.07 Favored 'General case' 0 CA--C 1.516 -0.33 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.03 -40.06 88.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.92 -179.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.29 -3.74 20.05 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 119.808 -1.187 . . . . 0.0 111.893 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.83 -6.14 20.51 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 117.139 0.469 . . . . 0.0 110.382 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.25 128.74 35.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.622 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.4 mmt85 -134.02 148.44 51.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.383 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.8 ttmt -43.42 92.71 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.002 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.1 -17.58 0.53 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -89.67 128.95 36.16 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.895 0.378 . . . . 0.0 111.059 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -89.63 133.31 34.7 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -178.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.4 m -114.32 144.58 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.791 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.59 130.55 43.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.072 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.5 m -128.92 161.04 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.416 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -107.51 130.59 54.84 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -100.27 123.17 44.17 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.359 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.0 m -75.19 -14.68 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-N 118.534 0.606 . . . . 0.0 110.638 177.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -70.07 -58.38 3.88 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.604 -0.438 . . . . 0.0 109.952 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.504 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.7 p -98.12 -10.68 23.82 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.93 -12.61 6.23 Favored Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.504 ' H ' ' C ' ' A' ' 100' ' ' THR . 93.3 mt-10 -82.32 155.62 24.69 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 120.926 0.393 . . . . 0.0 111.578 -176.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.504 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 2.0 pt? -81.56 139.83 34.85 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.513 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.419 HH12 ' HG ' ' A' ' 106' ' ' SER . 9.4 ptm180 -140.01 178.39 7.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.17 179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.492 ' OH ' ' C ' ' A' ' 77' ' ' THR . 3.6 m-85 -117.36 147.9 42.21 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.028 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' SER . . . . . 0.419 ' HG ' HH12 ' A' ' 104' ' ' ARG . 18.7 m -138.28 161.35 37.13 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.696 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 10.4 p -91.93 154.57 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 50.1 mt -75.89 151.59 6.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 178.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.611 ' NH1' ' NH2' ' A' ' 60' ' ' ARG . 68.7 ttt180 -104.11 -42.39 5.55 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.579 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.46 147.85 5.34 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 73.4 t -94.92 133.37 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.0 mp -100.91 151.24 37.57 Favored Pre-proline 0 CA--C 1.537 0.475 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.1 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.47 158.42 56.07 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.804 2.336 . . . . 0.0 111.57 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.6 p -67.57 156.9 35.66 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.101 0.477 . . . . 0.0 110.478 -179.035 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -133.77 -141.28 0.19 Allowed 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.431 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.1 mtt85 -157.59 130.1 7.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.041 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.7 170.54 4.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.274 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.549 ' NH1' ' OG1' ' A' ' 53' ' ' THR . 64.7 mmt-85 -74.15 151.38 40.07 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.372 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.3 p -131.2 146.52 52.36 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.172 0.511 . . . . 0.0 109.861 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.46 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 68.6 m-85 -123.3 174.07 7.55 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.275 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 120' ' ' PHE . 78.5 m-20 -153.62 123.26 6.73 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.71 177.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 65.5 mt -118.52 126.13 51.34 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -86.59 112.02 21.19 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 120.951 0.405 . . . . 0.0 110.399 -178.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.471 ' O ' ' C ' ' A' ' 125' ' ' GLU . 62.7 t -86.52 114.14 25.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.895 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.471 ' C ' ' O ' ' A' ' 124' ' ' VAL . 40.4 tp10 22.14 -115.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 O-C-N 123.811 0.694 . . . . 0.0 111.936 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.9 tp10 -109.8 -25.64 10.24 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.316 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 129' ' ' THR . 86.3 mt -82.83 66.68 8.56 Favored 'General case' 0 CA--C 1.505 -0.781 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.415 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 2.0 p80 -41.21 98.42 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.77 142.98 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.688 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.436 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 1.9 pp -149.02 152.78 36.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.396 0.617 . . . . 0.0 111.961 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -90.96 126.58 43.67 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.04 -179.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.39 132.91 41.74 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.067 -179.025 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 52.01 43.71 30.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.542 -179.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.62 28.13 62.23 Favored Glycine 0 CA--C 1.524 0.648 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.175 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 20.8 t -129.6 151.91 36.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -104.38 109.6 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.551 0.614 . . . . 0.0 110.722 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.431 ' O ' ' C ' ' A' ' 138' ' ' HIS . 28.8 m -147.28 139.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 62.7 t-80 -33.54 149.65 0.01 OUTLIER 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.751 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.349 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.445 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 4.8 m . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 85.4 mt -115.57 134.05 55.43 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.76 162.04 23.07 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.605 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.47 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 25.8 tt0 -62.62 144.42 56.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.939 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.13 -14.6 36.88 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.2 m -69.22 121.46 16.85 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 121.104 -0.239 . . . . 0.0 110.785 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 86.8 mtm180 -84.55 149.89 25.6 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.284 179.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 73.5 mt -133.49 107.21 10.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.301 179.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -78.42 131.84 37.08 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -108.83 124.72 33.45 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -68.97 -25.53 32.23 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.248 1.966 . . . . 0.0 111.841 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.1 t -69.95 -56.23 12.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.539 ' HG1' ' H ' ' A' ' 15' ' ' THR . 7.1 p -83.55 -38.2 22.01 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.056 0.455 . . . . 0.0 109.887 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.47 12.1 70.46 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.539 ' H ' ' HG1' ' A' ' 13' ' ' THR . 41.9 m -114.75 155.37 26.82 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 117.963 0.882 . . . . 0.0 109.769 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.8 m -80.59 120.65 24.81 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.311 0.577 . . . . 0.0 110.971 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -105.36 145.85 30.21 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.34 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 6.6 ttm180 -97.31 123.05 41.0 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.1 tt -53.99 -40.07 43.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.619 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -60.42 -32.71 71.6 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.945 0.402 . . . . 0.0 111.202 -179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -83.7 -39.07 20.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.672 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 92.8 t -67.53 -40.67 84.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.11 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.8 t -72.43 -46.72 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.619 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.11 -34.76 70.55 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-O 120.65 0.262 . . . . 0.0 110.866 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.556 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.81 26.7 18.66 Favored Glycine 0 CA--C 1.518 0.224 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.556 ' C ' ' O ' ' A' ' 25' ' ' GLY . 94.1 mtt-85 17.47 64.55 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.409 ' O ' ' N ' ' A' ' 29' ' ' ILE . 78.8 mttt -90.14 114.22 60.12 Favored Pre-proline 0 N--CA 1.448 -0.568 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.058 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -55.88 86.5 0.04 OUTLIER 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.836 1.69 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' A' ' 27' ' ' LYS . 12.5 pt -109.24 -172.68 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-O 120.752 0.31 . . . . 0.0 110.707 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.669 ' HE2' ' CB ' ' A' ' 42' ' ' ALA . 6.3 t-80 -127.02 156.86 40.96 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.712 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.64 ' O ' ' CE1' ' A' ' 30' ' ' HIS . 29.2 m -148.46 169.7 3.05 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.87 134.91 27.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 O-C-N 122.115 -0.365 . . . . 0.0 110.36 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.1 167.18 10.19 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.799 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.44 145.3 40.75 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.261 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.12 178.22 4.37 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.577 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.705 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 69.7 mmtt -71.4 -11.6 60.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.024 0.44 . . . . 0.0 110.458 179.568 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.0 p30 -80.22 -13.41 59.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.29 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.3 19.74 61.87 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 47.4 p -102.18 138.83 38.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 111.594 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.3 mt -92.29 131.0 37.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.181 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -137.3 138.24 39.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.669 ' CB ' ' HE2' ' A' ' 30' ' ' HIS . . . -69.26 136.12 51.48 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.662 ' N ' ' NE2' ' A' ' 30' ' ' HIS . 4.6 mmp_? -146.13 136.53 12.16 Favored Pre-proline 0 CA--C 1.537 0.454 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.178 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.88 159.85 30.87 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.865 2.377 . . . . 0.0 113.118 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.9 t -101.42 139.02 23.66 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 177.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.6 m -130.68 4.56 2.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.06 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 p -149.34 145.2 26.89 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.175 0.898 . . . . 0.0 109.025 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.612 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.26 123.76 13.98 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.51 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -136.41 145.12 44.94 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -91.88 140.32 29.79 Favored 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.445 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 46.8 mm-40 -89.84 -4.19 57.72 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.338 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 77.46 21.62 72.18 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.657 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ARG . 0.4 OUTLIER 64.53 135.3 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.836 0.35 . . . . 0.0 110.087 -179.945 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . 0.419 ' CG ' ' O ' ' A' ' 53' ' ' THR . 72.0 mtp180 -157.27 174.92 14.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.404 178.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . 0.498 ' CG ' ' HG1' ' A' ' 114' ' ' THR . 50.3 t0 -73.93 139.67 45.07 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -142.13 152.73 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.09 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 44.6 pt -104.86 152.05 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.177 179.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.79 138.1 14.26 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.6 mt -121.32 114.57 21.53 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 121.111 0.481 . . . . 0.0 110.365 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -87.0 113.78 23.05 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.888 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.662 ' O ' ' N ' ' A' ' 63' ' ' GLY . 15.7 mm -98.54 134.09 38.51 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.523 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.691 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 24.13 34.25 0.0 OUTLIER 'General case' 0 C--N 1.35 0.607 0 O-C-N 123.848 0.718 . . . . 0.0 112.038 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.662 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 62.72 -18.3 0.07 OUTLIER Glycine 0 CA--C 1.535 1.281 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.691 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -52.9 -107.84 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 110.079 -1.208 . . . . 0.0 110.079 -178.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.23 168.91 11.01 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 120.887 0.375 . . . . 0.0 110.441 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.47 150.77 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.212 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 57.9 tp -123.99 113.55 18.58 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.823 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . 0.556 ' CG ' ' NH2' ' A' ' 115' ' ' ARG . 95.3 m95 -104.5 121.28 43.14 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.95 171.94 15.53 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.318 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.426 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 40.2 p -78.56 154.41 78.79 Favored Pre-proline 0 C--N 1.329 -0.294 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.109 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.66 -22.15 59.23 Favored 'Trans proline' 0 N--CA 1.495 1.578 0 C-N-CA 122.027 1.818 . . . . 0.0 112.113 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -93.15 -7.71 44.6 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.79 0.328 . . . . 0.0 110.364 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.8 t60 -66.81 126.83 30.29 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mptt -82.72 123.42 29.28 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.219 0.533 . . . . 0.0 111.395 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.5 t -99.73 139.68 20.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.732 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.66 95.02 5.16 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.867 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 13.9 p -98.7 174.67 6.3 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -66.78 -14.9 63.15 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.29 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 68.4 m-85 -108.05 25.22 11.86 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.483 0.183 . . . . 0.0 110.744 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.59 -141.15 15.35 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.705 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 92.5 m95 -94.47 129.31 41.29 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.966 0.412 . . . . 0.0 111.172 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.9 tpt180 -138.7 131.42 29.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.441 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.62 144.49 26.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.012 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -61.07 -37.94 84.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 120.936 -0.306 . . . . 0.0 111.613 -179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.77 -5.33 24.16 Favored Glycine 0 CA--C 1.528 0.9 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.795 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -103.38 4.9 36.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.962 0.411 . . . . 0.0 110.432 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.5 mt -90.67 131.05 36.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.404 0.621 . . . . 0.0 111.122 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.517 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.4 mmt180 -129.2 148.96 51.18 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.705 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -45.27 90.83 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 153.72 -12.33 0.55 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -84.09 130.77 34.84 Favored 'General case' 0 C--O 1.228 -0.079 0 CA-C-O 120.936 0.398 . . . . 0.0 110.672 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -92.48 141.55 28.39 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.724 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.51 158.98 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.282 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.6 130.35 43.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.105 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.87 132.79 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.434 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -84.29 125.61 32.42 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.742 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 37.5 t0 -99.81 122.62 43.04 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.999 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 -17.8 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 118.35 0.523 . . . . 0.0 111.303 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 -69.64 -59.74 2.77 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 120.517 -0.473 . . . . 0.0 109.898 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.471 ' C ' ' H ' ' A' ' 102' ' ' GLU . 33.8 p -93.1 -12.85 29.46 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.12 -14.27 6.52 Favored Glycine 0 C--N 1.331 0.278 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.471 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.5 mt-10 -83.38 157.95 22.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.841 0.353 . . . . 0.0 110.824 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -82.39 133.71 35.23 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.22 0.533 . . . . 0.0 109.852 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.4 ptt85 -138.18 137.14 37.32 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.408 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -78.55 147.32 33.83 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -177.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 3.2 m -134.98 160.44 38.31 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.575 178.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 17.0 m -91.73 153.67 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.5 mm -70.23 156.33 7.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.084 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.443 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt85 -107.61 -46.63 3.79 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.989 178.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -166.3 145.95 6.0 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 19.3 t -93.33 131.84 39.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -99.57 148.48 34.79 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.047 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.88 160.34 50.16 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.408 2.072 . . . . 0.0 111.126 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.498 ' HG1' ' CG ' ' A' ' 55' ' ' ASP . 0.1 OUTLIER -69.26 156.67 38.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 120.999 0.428 . . . . 0.0 110.585 -179.387 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.556 ' NH2' ' CG ' ' A' ' 68' ' ' TRP . 39.3 ptt180 -139.87 -144.41 0.17 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.964 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -154.03 134.75 13.66 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.69 172.12 3.64 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.983 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.47 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 91.4 mtm-85 -71.45 140.54 50.07 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.519 178.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 143.01 51.28 Favored 'General case' 0 C--O 1.231 0.126 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 52.2 m-85 -120.61 178.02 4.84 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.719 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.444 ' HB2' HE21 ' A' ' 51' ' ' GLN . 51.0 t0 -153.49 120.75 5.81 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.269 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 84.8 mt -119.57 123.53 44.15 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.744 0.307 . . . . 0.0 110.443 179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -88.51 111.51 21.91 Favored 'General case' 0 CA--C 1.514 -0.441 0 C-N-CA 120.612 -0.435 . . . . 0.0 109.899 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 59.8 t -86.49 119.74 35.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.464 -0.495 . . . . 0.0 109.849 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 33.2 tp10 21.71 -121.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.961 0.788 . . . . 0.0 111.148 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -104.17 -26.81 12.39 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.916 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.431 ' O ' ' N ' ' A' ' 129' ' ' THR . 66.9 mt -81.86 70.54 8.78 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.421 ' O ' HG21 ' A' ' 129' ' ' THR . 31.2 m170 -41.57 98.83 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 179.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.431 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.46 141.49 0.02 OUTLIER 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.997 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.421 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.3 pp -146.65 155.85 42.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.377 0.608 . . . . 0.0 111.614 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 8.4 p -89.8 125.48 42.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.875 -179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -132.62 132.36 42.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.784 -179.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.507 ' C ' ' H ' ' A' ' 135' ' ' VAL . 80.8 mm-40 49.7 46.49 23.8 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.22 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.39 -13.35 0.58 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.431 -0.667 . . . . 0.0 111.431 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.507 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.2 t -95.18 150.64 4.08 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.27 0 CA-C-N 117.061 0.43 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.6 t -107.97 113.52 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.65 0.262 . . . . 0.0 110.531 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' HIS . 22.9 m -148.28 141.05 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.109 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.546 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 15.8 t60 -30.25 151.5 0.0 OUTLIER 'General case' 0 C--O 1.224 -0.254 0 CA-C-O 120.989 0.424 . . . . 0.0 112.05 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 p30 . . . . . 0 C--N 1.32 -0.683 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.674 -179.342 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 39.4 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.5 mt -109.34 136.42 48.8 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.906 0.384 . . . . 0.0 110.338 -179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.32 162.75 21.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.519 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.74 141.1 58.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.115 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.87 -17.67 22.5 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 14.4 m -68.91 120.43 14.8 Favored 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.534 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -94.6 114.59 26.57 Favored 'General case' 0 N--CA 1.456 -0.141 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.47 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.6 mp -102.37 114.87 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 4.6 t80 -77.16 135.41 38.53 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 9.7 t0 -102.79 132.62 21.05 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.647 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.22 -30.95 9.94 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.672 2.248 . . . . 0.0 112.37 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.512 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 47.1 t -71.31 -55.02 15.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.737 -179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.0 p -78.19 -37.0 46.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.043 0.449 . . . . 0.0 110.271 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.29 82.68 Favored Glycine 0 CA--C 1.52 0.389 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.23 -168.73 1.43 Allowed 'General case' 0 C--N 1.34 0.171 0 CA-C-N 117.621 0.71 . . . . 0.0 109.501 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 63.7 m -113.6 117.34 31.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.259 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 58.9 m170 -103.46 143.59 32.51 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.341 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 23.2 mmt85 -96.59 126.08 41.52 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.64 179.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.457 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -51.4 -42.54 28.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.213 0.53 . . . . 0.0 111.19 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 4.5 pt-20 -58.72 -32.08 68.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.823 -177.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.5 t0 -83.81 -38.49 21.19 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.29 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 86.6 t -64.65 -40.8 90.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.337 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 50.3 t -73.51 -44.58 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -57.52 -37.94 73.86 Favored 'General case' 0 CA--C 1.513 -0.472 0 C-N-CA 120.823 -0.351 . . . . 0.0 111.227 -177.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.568 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.2 29.37 9.27 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.568 ' C ' ' O ' ' A' ' 25' ' ' GLY . 89.1 mtt-85 16.12 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -87.31 113.99 56.5 Favored Pre-proline 0 N--CA 1.449 -0.491 0 O-C-N 123.434 0.459 . . . . 0.0 111.177 -176.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.6 89.43 0.06 OUTLIER 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.159 1.906 . . . . 0.0 110.414 178.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.51 -172.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 120.867 0.365 . . . . 0.0 110.497 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.425 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 52.4 m80 -127.94 160.63 31.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.598 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -149.41 172.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.2 t -90.93 136.05 25.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.406 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.7 167.77 10.34 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.763 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.0 143.24 44.69 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.325 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.01 177.7 4.55 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.653 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -70.0 -13.63 62.32 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 110.658 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -80.13 -18.21 50.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.453 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.89 24.16 39.14 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.6 p -103.06 136.83 42.15 Favored 'General case' 0 N--CA 1.463 0.207 0 O-C-N 122.724 -0.28 . . . . 0.0 111.281 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.3 mt -94.22 130.67 40.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.819 0.343 . . . . 0.0 110.648 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 7.1 t-160 -142.36 139.24 31.69 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.838 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.91 139.95 53.04 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.555 -178.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.487 ' CZ ' ' OE1' ' A' ' 126' ' ' GLU . 14.5 mmt180 -142.92 140.35 17.99 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.376 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -78.37 157.03 29.28 Favored 'Trans proline' 0 N--CA 1.491 1.324 0 C-N-CA 122.757 2.305 . . . . 0.0 113.019 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.57 134.87 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.8 m -125.6 0.23 4.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.645 -179.06 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.1 141.99 25.8 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 119.144 0.884 . . . . 0.0 108.912 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.592 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -139.39 120.74 14.93 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 178.398 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -139.22 145.86 39.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.318 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -89.95 133.52 34.74 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.491 HE21 ' HB2' ' A' ' 121' ' ' ASP . 27.3 mm-40 -92.75 -1.98 56.36 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.653 -0.249 . . . . 0.0 111.298 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.428 ' O ' ' OG1' ' A' ' 119' ' ' THR . . . 87.66 175.76 48.35 Favored Glycine 0 C--N 1.339 0.698 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.376 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.0 m -90.44 118.67 30.1 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -141.95 172.6 12.46 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.939 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 99.5 m-20 -75.32 141.57 43.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.889 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.1 m -141.85 157.67 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.5 pt -112.79 153.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.206 179.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.32 139.26 14.5 Favored Glycine 0 N--CA 1.465 0.577 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.2 mt -120.41 112.35 18.88 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.143 0.497 . . . . 0.0 110.464 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -89.39 111.43 22.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.555 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 63' ' ' GLY . 16.8 mm -99.95 126.3 53.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.737 -179.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.566 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 35.98 25.6 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.879 0.737 . . . . 0.0 110.782 -178.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 70.86 -23.83 0.53 Allowed Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.084 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.566 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.24 -106.71 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.37 170.49 10.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 120.948 0.404 . . . . 0.0 110.311 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.6 mt -124.89 155.01 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.462 179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 47.1 tp -132.08 116.5 17.13 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.118 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -104.63 115.54 30.52 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.18 172.49 12.62 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.62 156.87 80.41 Favored Pre-proline 0 C--N 1.327 -0.401 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -61.68 -21.65 72.59 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.649 2.233 . . . . 0.0 111.826 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 24.5 p30 -93.09 -4.83 51.66 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.248 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.5 t60 -72.27 129.56 38.72 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -86.19 127.47 34.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-O 121.277 0.56 . . . . 0.0 110.251 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.2 t -108.26 92.39 2.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.117 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 75' ' ' VAL . 9.6 tp -31.01 93.59 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.644 0.59 . . . . 0.0 111.442 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.458 ' N ' ' O ' ' A' ' 75' ' ' VAL . 29.9 p -98.34 177.19 5.44 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.747 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.524 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 6.0 pt-20 -65.05 -21.36 66.82 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.232 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.524 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 57.8 m-85 -104.47 25.09 10.64 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 120.459 0.171 . . . . 0.0 110.905 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.445 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.22 -176.07 41.73 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -58.62 129.68 43.24 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.696 -177.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 73.4 mtm180 -145.9 134.55 22.21 Favored 'General case' 0 C--N 1.339 0.118 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.063 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.27 141.11 24.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.04 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.444 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.5 -36.98 84.27 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.143 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.73 -1.44 2.7 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.672 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.444 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.7 mt-10 -108.16 6.58 26.92 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 88.9 mt -85.1 125.95 33.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.262 0.553 . . . . 0.0 110.975 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.553 ' O ' ' N ' ' A' ' 90' ' ' GLY . 25.2 mmt85 -130.5 147.53 52.2 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.584 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -45.89 88.22 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 120.897 0.38 . . . . 0.0 110.632 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.0 -16.82 0.37 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -86.23 130.88 34.37 Favored 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.885 0.374 . . . . 0.0 110.419 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.67 135.25 34.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.0 m -120.43 152.02 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.3 139.64 58.79 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.164 -179.567 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 26.9 m -138.55 156.7 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.391 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -106.09 130.65 53.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.679 0.276 . . . . 0.0 110.317 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -101.63 125.86 48.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.581 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.4 p -73.94 -14.74 16.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 118.203 0.456 . . . . 0.0 111.279 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -67.85 -60.38 2.56 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.822 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.535 ' HB ' ' OE1' ' A' ' 102' ' ' GLU . 53.3 m -103.39 -12.9 16.89 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.251 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 80.39 -11.19 39.35 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.995 177.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.703 ' N ' ' OE1' ' A' ' 102' ' ' GLU . 0.0 OUTLIER -77.18 158.8 30.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-O 121.558 0.694 . . . . 0.0 112.161 -179.149 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 5.9 tp -83.07 133.08 35.09 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.824 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.424 ' CD ' ' OE2' ' A' ' 102' ' ' GLU . 85.0 mtp180 -133.9 172.87 12.2 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.3 m-30 -109.46 142.25 40.74 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.389 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 6.7 m -134.43 154.39 51.41 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.37 155.15 3.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 110.864 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 63.1 mt -73.44 153.05 7.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.836 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.8 mmm180 -108.29 -43.24 4.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.021 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -164.69 141.82 6.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 16.5 t -95.13 134.09 33.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.034 179.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.412 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.3 mm? -101.97 125.46 36.78 Favored Pre-proline 0 CA--C 1.538 0.509 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.88 163.72 0.2 Allowed 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.217 1.945 . . . . 0.0 111.831 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 61.4 p -68.04 156.78 36.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.089 0.471 . . . . 0.0 110.812 -179.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' O ' ' OD1' ' A' ' 55' ' ' ASP . 42.4 ttm-85 -139.64 -136.94 0.12 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.974 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -158.97 131.16 6.66 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.411 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.33 172.8 3.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.071 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -76.18 145.75 39.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.871 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.428 ' OG1' ' O ' ' A' ' 52' ' ' GLY . 3.9 p -122.63 141.49 51.67 Favored 'General case' 0 N--CA 1.463 0.175 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -119.66 174.04 6.65 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.215 -178.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.491 ' HB2' HE21 ' A' ' 51' ' ' GLN . 43.2 t0 -156.18 125.72 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.389 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 76.5 mt -119.54 121.7 39.98 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -86.73 115.28 24.06 Favored 'General case' 0 CA--C 1.512 -0.491 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.127 -177.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.53 117.89 33.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.542 ' O ' ' N ' ' A' ' 127' ' ' LEU . 40.0 tt0 -58.26 156.05 10.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.505 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.487 ' OE1' ' CZ ' ' A' ' 43' ' ' ARG . 91.0 mt-10 56.24 -69.16 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.395 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.542 ' N ' ' O ' ' A' ' 125' ' ' GLU . 95.9 mt -98.27 101.23 12.62 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.413 ' C ' ' OG1' ' A' ' 129' ' ' THR . 39.6 m80 -72.3 99.61 2.44 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.413 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.04 143.86 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.969 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.413 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.2 pp -144.38 152.86 41.3 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 121.182 0.515 . . . . 0.0 111.293 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.0 p -87.67 128.15 40.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.32 128.28 35.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.935 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' A' ' 135' ' ' VAL . 72.9 mm-40 52.46 47.23 25.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.204 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.87 -18.43 0.47 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.513 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.7 t -90.59 151.02 3.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 CA-C-N 117.169 0.485 . . . . 0.0 110.287 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 62.1 t -106.41 112.98 41.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 138' ' ' HIS . 17.4 m -147.77 138.23 17.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.366 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.424 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.533 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 7.7 t60 -35.46 155.67 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.152 0 CA-C-O 120.747 0.308 . . . . 0.0 111.62 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 14.1 p30 . . . . . 0 C--N 1.322 -0.629 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.659 -179.415 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.714 ' CB ' HE22 ' A' ' 51' ' ' GLN . 11.9 m . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.72 131.85 53.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.837 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.78 162.72 18.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.525 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -62.18 141.46 58.18 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.442 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.94 -15.45 21.23 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.6 m -71.24 120.02 16.21 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.632 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -93.27 115.96 28.54 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 120.908 0.385 . . . . 0.0 110.322 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 57.5 mt -99.9 112.49 32.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.77 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 3.5 t80 -77.76 135.77 38.05 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.555 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.7 t0 -102.32 131.71 22.24 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.046 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.43 -32.5 7.94 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.577 2.184 . . . . 0.0 112.136 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.555 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.0 t -69.7 -52.88 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.222 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 m -79.02 -40.01 32.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.003 0.43 . . . . 0.0 110.385 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.77 82.17 Favored Glycine 0 N--CA 1.453 -0.205 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.599 ' CG2' ' H ' ' A' ' 16' ' ' THR . 12.7 m -104.19 -174.5 2.56 Favored 'General case' 0 C--N 1.338 0.086 0 CA-C-N 117.68 0.74 . . . . 0.0 109.613 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.599 ' H ' ' CG2' ' A' ' 15' ' ' THR . 88.1 m -112.23 118.97 36.76 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.068 179.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -113.43 151.8 30.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.477 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 66.3 mtt85 -100.27 128.77 46.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.607 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 4.0 tt -52.28 -38.96 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 120.924 0.392 . . . . 0.0 111.2 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -60.78 -34.14 74.04 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.167 0.508 . . . . 0.0 110.771 -179.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.575 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 7.1 t70 -85.31 -38.29 18.99 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.352 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.0 t -69.71 -42.71 80.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.9 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 34.1 t -76.14 -47.83 30.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.578 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 33.1 p-10 -56.53 -30.77 63.45 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 120.987 0.423 . . . . 0.0 110.603 -177.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' N ' ' OD1' ' A' ' 24' ' ' ASP . . . -109.64 21.49 25.71 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.52 ' C ' ' O ' ' A' ' 25' ' ' GLY . 43.1 ptt85 21.79 61.65 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.202 0 O-C-N 124.309 0.652 . . . . 0.0 109.324 179.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -79.02 134.65 59.52 Favored Pre-proline 0 N--CA 1.446 -0.658 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.049 -177.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -76.04 81.35 2.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.305 2.003 . . . . 0.0 111.247 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.6 pt -118.33 -169.72 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.499 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.444 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 54.3 m80 -128.35 164.53 22.44 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.826 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.6 m -148.47 171.79 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.401 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 74.6 t -90.81 131.6 37.55 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.11 167.83 9.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.205 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.62 141.81 39.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.912 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.76 177.73 4.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.909 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -70.43 -12.62 61.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 120.93 0.395 . . . . 0.0 110.609 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 64.6 t0 -81.32 -18.77 44.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.88 23.07 43.24 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.2 p -102.59 136.5 42.3 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.81 0.338 . . . . 0.0 111.012 178.526 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 77.9 mt -91.24 128.64 37.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.835 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -138.98 137.84 36.73 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.596 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.486 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -70.16 140.56 52.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.777 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.486 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.4 mmp_? -144.04 138.8 15.31 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.665 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -77.56 158.21 32.31 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 123.001 2.468 . . . . 0.0 113.142 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.3 t -101.34 136.46 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.4 m -127.89 3.01 3.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.554 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.464 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -152.5 149.54 28.64 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 119.426 1.012 . . . . 0.0 108.585 179.732 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.503 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -149.31 127.04 11.72 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.355 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 -140.02 148.43 41.83 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.708 0.632 . . . . 0.0 112.708 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -105.84 138.58 41.8 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.714 HE22 ' CB ' ' A' ' 1' ' ' CYS . 1.4 mt-30 -101.77 2.97 39.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.489 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.15 -165.05 39.13 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.415 178.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 20.9 m -87.16 127.72 35.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -148.82 160.79 42.9 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.821 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.79 139.73 41.95 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.05 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.77 156.07 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.4 pt -107.8 149.37 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.359 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.38 142.68 15.67 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 75.8 mt -127.9 114.73 17.56 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.2 0.524 . . . . 0.0 110.654 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 56.6 ttp180 -96.66 122.45 39.6 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 55.1 mt -117.91 160.97 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.449 ' C ' ' N ' ' A' ' 64' ' ' GLY . . . -53.14 -27.04 19.0 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.777 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.49 -15.43 0.46 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.449 ' N ' ' C ' ' A' ' 62' ' ' ALA . . . 87.28 -18.39 37.32 Favored Glycine 0 C--N 1.335 0.48 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.89 170.48 9.65 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 110.117 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.1 mt -122.65 151.06 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.236 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -126.56 115.69 19.91 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.931 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -105.41 116.34 31.77 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -143.04 171.78 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.397 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.529 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 1.0 OUTLIER -79.41 156.2 76.1 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.616 -179.973 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -62.26 -17.48 57.27 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.597 2.198 . . . . 0.0 111.882 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -95.9 -6.71 38.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.742 0.306 . . . . 0.0 110.38 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.649 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.4 t60 -69.03 127.46 33.23 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.7 mmtp -85.97 128.19 34.79 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.902 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.6 t -103.31 141.29 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.341 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 56.3 tp -78.0 93.29 4.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.886 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.494 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 76.1 p -98.33 173.66 6.87 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -178.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -63.7 -16.24 60.54 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.367 -179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -108.06 25.65 11.34 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.82 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.58 -176.1 46.1 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -58.64 133.12 55.61 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.206 0.527 . . . . 0.0 110.478 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -146.11 134.73 22.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.666 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.99 137.98 31.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.08 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.442 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.3 -37.9 87.32 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.222 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.32 -2.42 3.02 Favored Glycine 0 C--N 1.335 0.503 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.734 -179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.8 mm-40 -108.17 11.51 27.41 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.918 0.389 . . . . 0.0 110.321 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.0 mt -92.93 128.15 38.7 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.465 0.65 . . . . 0.0 111.072 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.572 ' O ' ' N ' ' A' ' 90' ' ' GLY . 14.8 tpt180 -130.51 149.52 52.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.976 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -45.76 86.57 0.0 OUTLIER 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.557 179.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.77 -14.83 0.29 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -85.02 131.78 34.42 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.707 -0.29 . . . . 0.0 110.29 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -89.21 130.74 35.58 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.434 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.0 m -116.64 146.35 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.584 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.64 137.55 47.98 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.704 0.288 . . . . 0.0 111.073 -179.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.17 161.92 38.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.004 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -103.5 130.98 50.99 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.508 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.543 ' OD2' ' NH2' ' A' ' 104' ' ' ARG . 42.5 t0 -100.62 123.96 45.54 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.33 -16.65 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 CA-C-N 118.297 0.499 . . . . 0.0 111.261 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -71.26 -58.27 3.7 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.139 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.478 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.8 p -95.18 -15.02 23.61 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.651 -0.25 . . . . 0.0 110.34 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.99 -13.98 5.07 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.478 ' H ' ' C ' ' A' ' 100' ' ' THR . 98.2 mt-10 -81.49 159.87 24.09 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-O 120.755 0.312 . . . . 0.0 110.758 -177.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 7.7 tp -85.32 128.79 34.83 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.163 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.543 ' NH2' ' OD2' ' A' ' 97' ' ' ASP . 16.5 ptp180 -127.24 175.81 7.88 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.33 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.494 ' OH ' ' C ' ' A' ' 77' ' ' THR . 0.8 OUTLIER -114.68 147.26 39.88 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.835 179.877 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -144.23 163.06 34.76 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.4 m -94.79 155.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-O 120.674 0.273 . . . . 0.0 110.483 -179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.446 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 68.1 mt -73.08 159.43 5.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 120.97 0.414 . . . . 0.0 110.303 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.446 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 24.9 mmt180 -105.26 -44.97 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.192 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -165.23 143.55 6.27 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 9.9 p -96.19 134.86 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.467 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.6 mm? -104.06 147.69 34.71 Favored Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.34 166.66 27.57 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 122.533 2.155 . . . . 0.0 111.357 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 21.8 p -66.12 151.56 46.65 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.21 0.528 . . . . 0.0 110.689 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -133.86 -148.48 0.33 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.092 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 25.7 mmm180 -148.88 127.62 12.52 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.147 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.61 175.52 2.48 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.756 -178.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -79.48 147.03 32.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.928 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.2 p -121.12 140.81 51.48 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.1 0.476 . . . . 0.0 109.747 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.542 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 58.3 m-85 -114.9 168.02 10.28 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.921 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 122' ' ' LEU . 66.4 t0 -147.47 131.16 16.91 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.219 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.443 ' N ' ' OD1' ' A' ' 121' ' ' ASP . 4.5 mm? -114.62 163.88 14.81 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.486 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -135.1 104.84 6.08 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.017 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 17.4 t -91.93 120.7 41.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.418 ' O ' ' N ' ' A' ' 127' ' ' LEU . 75.7 tt0 -62.69 152.9 34.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.5 tt0 62.17 -70.57 0.05 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.81 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.418 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -99.96 104.45 16.07 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.473 ' C ' ' HG1' ' A' ' 129' ' ' THR . 62.3 m80 -73.99 100.2 3.49 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.675 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.473 ' HG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 165.89 144.67 0.02 OUTLIER 'General case' 0 C--N 1.344 0.35 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.44 ' H ' HD21 ' A' ' 130' ' ' LEU . 1.7 pt? -144.43 155.5 43.77 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-O 121.759 0.79 . . . . 0.0 111.566 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.88 125.14 40.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -131.88 125.73 32.45 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.052 -179.338 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 50.36 46.47 25.11 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.939 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.17 -17.24 0.43 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 12.1 t -92.34 150.94 3.68 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 O-C-N 122.285 -0.538 . . . . 0.0 110.727 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.19 114.35 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.436 ' O ' ' O ' ' A' ' 138' ' ' HIS . 18.0 m -146.74 132.14 12.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.315 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.517 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 50.2 t-80 -37.21 159.86 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.74 0.305 . . . . 0.0 111.74 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.485 ' N ' ' CG ' ' A' ' 138' ' ' HIS . 21.1 p30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.388 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.607 ' H2 ' ' HG1' ' A' ' 70' ' ' THR . 61.9 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 73.0 mt -106.9 138.44 43.07 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.415 -179.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.87 164.13 20.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.85 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -64.02 145.41 55.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.233 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.03 -17.6 44.43 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.6 m -67.67 123.93 21.86 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.435 ' HE ' HG23 ' A' ' 16' ' ' THR . 61.0 mtp180 -81.62 147.78 29.4 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.829 0.347 . . . . 0.0 110.263 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.416 HG21 HD11 ' A' ' 8' ' ' ILE . 90.3 mt -134.46 106.4 7.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.857 179.182 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.4 t80 -77.52 133.5 38.52 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.238 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 17.1 t0 -106.49 129.62 24.2 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.44 -26.4 24.42 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.119 1.88 . . . . 0.0 112.512 -179.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.509 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 38.9 t -78.34 -53.1 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.016 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.8 p -79.97 -34.63 38.5 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 120.975 0.417 . . . . 0.0 110.134 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.94 9.5 86.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.427 ' CG2' ' N ' ' A' ' 16' ' ' THR . 87.8 m -113.17 166.73 11.16 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 117.873 0.836 . . . . 0.0 109.65 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.435 HG23 ' HE ' ' A' ' 7' ' ' ARG . 38.5 m -90.26 116.09 27.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.316 0.579 . . . . 0.0 111.321 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -102.12 144.47 30.65 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.153 -0.931 . . . . 0.0 110.147 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 92.2 mtt-85 -98.77 129.84 45.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.606 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.6 tp -52.79 -40.03 33.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.721 0.296 . . . . 0.0 111.154 -179.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -60.56 -34.98 74.95 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.263 0.554 . . . . 0.0 110.11 -179.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.76 -40.45 22.64 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.741 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 83.4 t -68.47 -42.58 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.4 t -72.21 -46.19 58.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.014 0.375 . . . . 0.0 112.014 -178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 66.8 t0 -58.56 -35.17 71.94 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.157 0.503 . . . . 0.0 110.549 -177.938 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.3 25.45 12.45 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-O 118.853 -0.971 . . . . 0.0 111.049 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.566 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.2 ptt180 14.03 72.74 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 CA-C-N 117.427 0.614 . . . . 0.0 109.523 179.219 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -87.45 137.61 32.33 Favored Pre-proline 0 N--CA 1.445 -0.705 0 O-C-N 121.673 -0.642 . . . . 0.0 110.925 -175.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -74.52 83.33 1.74 Allowed 'Trans proline' 0 C--N 1.31 -1.465 0 C-N-CA 121.311 1.341 . . . . 0.0 110.618 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.7 pt -119.51 -170.53 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.811 0.339 . . . . 0.0 110.097 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.426 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 26.3 m80 -131.35 163.55 27.61 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.621 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.42 170.96 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 85.9 t -87.16 130.88 36.31 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.563 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.23 166.54 10.34 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.599 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.12 141.99 40.18 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.848 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.72 179.31 3.99 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -72.03 -13.63 61.65 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.91 0.386 . . . . 0.0 110.814 179.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -79.51 -21.55 45.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.402 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 91.46 19.55 41.12 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.4 p -99.22 135.61 40.38 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 121.098 0.475 . . . . 0.0 111.01 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.5 mt -91.65 127.72 37.21 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.269 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -137.95 138.94 39.46 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.73 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.06 142.42 50.86 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.384 -0.526 . . . . 0.0 109.85 -178.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -144.06 137.47 14.15 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.046 179.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.35 157.18 33.09 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 122.631 2.221 . . . . 0.0 112.73 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.0 135.7 31.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.57 2.88 3.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.647 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -150.69 144.84 25.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 119.173 0.897 . . . . 0.0 108.844 178.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -144.95 128.97 17.53 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -136.41 145.03 44.83 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.242 0.544 . . . . 0.0 112.255 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 53.2 p-10 -114.43 141.22 47.95 Favored 'General case' 0 CA--C 1.5 -0.959 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -110.27 -101.15 0.39 Allowed 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.002 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -173.82 -153.13 9.47 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 114.408 -1.269 . . . . 0.0 112.951 -177.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.1 m -86.32 129.3 34.9 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.1 0.476 . . . . 0.0 111.549 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -150.48 162.25 40.95 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.498 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -78.53 138.61 38.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.21 141.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 120.828 0.347 . . . . 0.0 110.281 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 41.1 pt -90.41 145.64 7.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.795 179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.97 140.53 14.91 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 15.1 mt -125.12 114.09 18.57 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.102 0.477 . . . . 0.0 110.559 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -91.53 112.85 24.94 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.275 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.539 ' C ' ' H ' ' A' ' 63' ' ' GLY . 2.2 mp -105.36 154.06 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.412 -179.487 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -54.89 -4.22 0.06 Allowed 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.826 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 61' ' ' ILE . . . -70.87 -12.75 71.44 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 86.87 -19.43 29.74 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.93 171.62 9.16 Favored 'General case' 0 CA--C 1.523 -0.093 0 CA-C-O 120.889 0.376 . . . . 0.0 110.25 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.7 mt -119.13 142.0 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.24 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.409 ' CD2' ' C ' ' A' ' 67' ' ' LEU . 4.2 tt -120.41 113.08 19.8 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.197 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.02 127.6 50.19 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.27 172.22 14.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.317 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.607 ' HG1' ' H2 ' ' A' ' 1' ' ' CYS . 0.7 OUTLIER -85.19 155.34 60.43 Favored Pre-proline 0 CA--C 1.535 0.38 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.353 179.696 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -63.62 -22.21 70.3 Favored 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.566 2.177 . . . . 0.0 112.012 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -91.24 -8.1 49.36 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 120.977 0.418 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.584 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.7 t60 -70.52 127.52 33.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.559 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.7 mtmm -86.11 132.62 33.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.135 0.493 . . . . 0.0 111.159 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.94 148.82 17.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.22 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 25.9 tp -85.37 92.07 8.37 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.794 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.545 ' O ' ' N ' ' A' ' 79' ' ' TYR . 0.1 OUTLIER -107.73 139.92 41.56 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.16 0.505 . . . . 0.0 110.434 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.54 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 67.5 mm-40 60.02 -64.66 0.05 Allowed 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.134 -1.394 . . . . 0.0 111.262 178.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.545 ' N ' ' O ' ' A' ' 77' ' ' THR . 0.3 OUTLIER 179.15 55.71 0.01 OUTLIER 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 174.32 175.81 42.21 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 119.56 -1.305 . . . . 0.0 111.976 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -91.71 129.31 37.71 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.874 0.368 . . . . 0.0 110.815 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 -145.46 138.53 26.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.365 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.89 142.74 23.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.144 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.548 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -65.24 -37.82 88.45 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 120.885 -0.326 . . . . 0.0 111.724 -179.573 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.41 5.22 0.17 Allowed Glycine 0 CA--C 1.527 0.839 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.863 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.548 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.9 mt-10 -110.57 1.96 18.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.888 0.344 . . . . 0.0 110.259 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 61.3 mt -80.49 130.6 35.25 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.484 0.659 . . . . 0.0 111.127 -179.274 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.506 ' O ' ' N ' ' A' ' 90' ' ' GLY . 32.5 mmt180 -129.46 151.2 50.35 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.944 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -51.91 87.19 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.27 -21.32 0.49 Allowed Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -73.5 135.93 44.08 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.491 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -90.2 132.21 35.61 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 120.96 0.41 . . . . 0.0 110.248 -178.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.1 143.74 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.502 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.55 138.07 57.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.734 0.302 . . . . 0.0 110.52 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.2 m -135.18 158.14 40.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.622 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -101.93 129.0 48.09 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.581 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -99.84 120.22 39.41 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.18 179.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 42.4 t -74.62 -15.1 16.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.387 0.539 . . . . 0.0 110.821 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.37 -60.09 2.56 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 120.447 -0.501 . . . . 0.0 109.923 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.48 ' C ' ' H ' ' A' ' 102' ' ' GLU . 74.5 p -96.2 -10.47 28.02 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.78 -12.66 5.99 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.48 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -83.21 158.13 22.43 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 120.792 0.33 . . . . 0.0 110.748 -177.622 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 5.2 tt -86.79 130.5 34.45 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.3 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.7 ptt85 -127.81 173.16 10.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.729 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.54 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.41 143.5 37.25 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.164 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.2 m -141.22 164.15 31.04 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 98.2 t -98.1 154.91 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.423 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -70.78 157.1 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.875 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.423 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 59.8 ttt85 -101.43 -47.34 4.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.749 179.274 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -164.62 144.43 7.42 Favored 'General case' 0 C--N 1.341 0.197 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 9.7 p -93.0 132.34 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.6 mm? -102.85 148.03 34.96 Favored Pre-proline 0 N--CA 1.469 0.491 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.426 -178.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.71 160.2 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.606 2.204 . . . . 0.0 110.992 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -65.96 155.01 37.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.061 0.458 . . . . 0.0 110.318 -178.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -147.99 143.69 27.44 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.002 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -71.92 131.01 42.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.964 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.69 168.21 14.58 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.723 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -81.46 149.72 28.63 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.669 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 50.6 p -133.12 144.38 49.89 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 2.8 m-85 -121.5 177.95 5.01 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.475 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.492 ' OD1' ' SG ' ' A' ' 1' ' ' CYS . 10.5 m-20 -144.22 149.21 36.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.947 179.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 97.3 mt -138.97 170.14 16.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.616 -179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -137.29 106.66 6.09 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.926 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.48 ' O ' ' C ' ' A' ' 125' ' ' GLU . 48.9 t -85.72 113.55 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 124' ' ' VAL . 0.3 OUTLIER 21.4 -91.11 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 123.816 0.698 . . . . 0.0 111.771 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 124' ' ' VAL . 9.0 tp10 -135.23 -27.97 1.18 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.658 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.451 ' O ' ' N ' ' A' ' 129' ' ' THR . 83.0 mt -82.13 67.59 8.21 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.416 ' C ' ' O ' ' A' ' 127' ' ' LEU . 20.6 m170 -39.61 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 170.89 140.89 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.117 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.4 ' N ' ' CD2' ' A' ' 130' ' ' LEU . 1.1 pt? -151.15 160.88 43.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.69 0.757 . . . . 0.0 112.386 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 25.2 t -90.27 124.65 43.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -135.28 124.72 24.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.941 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.5 mm-40 53.12 42.53 32.19 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -179.663 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.04 28.07 68.24 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.652 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 21.9 t -131.58 152.12 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 97.6 t -106.67 111.06 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 O-C-N 122.11 -0.369 . . . . 0.0 110.308 179.146 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 138' ' ' HIS . 6.5 m -146.14 137.1 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.638 -0.256 . . . . 0.0 110.48 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.584 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 50.4 t-80 -33.57 156.72 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.565 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.5 ' OD1' ' N ' ' A' ' 139' ' ' ASN . 7.7 p-10 . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.363 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.585 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 53.9 m . . . . . 0 N--CA 1.487 1.405 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.2 mt -118.38 134.68 54.85 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.728 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.59 161.7 24.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.503 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.45 145.98 54.53 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.55 -14.38 50.4 Favored Glycine 0 C--N 1.338 0.686 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.7 m -68.96 123.75 21.87 Favored 'General case' 0 C--O 1.234 0.278 0 O-C-N 122.652 -0.322 . . . . 0.0 110.587 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 18' ' ' ARG . 10.6 mpt_? -83.67 150.62 25.75 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.238 0.542 . . . . 0.0 109.857 178.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.402 HG22 HD12 ' A' ' 8' ' ' ILE . 99.1 mt -133.89 107.74 10.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.691 179.252 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -77.25 126.57 31.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.1 t0 -104.91 129.76 24.3 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.982 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.79 -31.03 13.54 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.51 2.14 . . . . 0.0 111.989 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 71.1 t -69.13 -55.95 13.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.31 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.723 ' HG1' ' H ' ' A' ' 15' ' ' THR . 15.3 p -78.85 -37.58 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 110.059 179.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.432 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 83.27 7.99 85.92 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.723 ' H ' ' HG1' ' A' ' 13' ' ' THR . 91.6 m -115.61 157.63 23.88 Favored 'General case' 0 C--N 1.341 0.196 0 O-C-N 121.937 -0.743 . . . . 0.0 109.756 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 15.2 m -78.91 116.95 19.56 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.05 0.452 . . . . 0.0 110.982 -179.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -102.24 144.16 31.11 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.371 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 7' ' ' ARG . 39.1 ttm180 -96.53 124.07 40.41 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.324 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -52.67 -40.37 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 O-C-N 121.992 -0.443 . . . . 0.0 111.426 -178.433 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -56.82 -35.23 68.54 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.984 0.421 . . . . 0.0 110.666 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -83.22 -39.44 20.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.125 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.8 t -66.93 -41.73 87.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.563 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.1 -46.29 59.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.513 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -57.87 -36.34 72.21 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 120.948 -0.301 . . . . 0.0 110.866 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.537 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.85 30.13 10.84 Favored Glycine 0 N--CA 1.452 -0.292 0 N-CA-C 110.536 -1.026 . . . . 0.0 110.536 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.537 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtt85 15.79 64.33 0.01 OUTLIER 'General case' 0 C--N 1.364 1.207 0 CA-C-N 117.418 0.609 . . . . 0.0 110.254 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.42 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.0 mttt -89.78 144.2 31.36 Favored Pre-proline 0 N--CA 1.444 -0.732 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.294 -178.074 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.541 ' O ' ' O ' ' A' ' 29' ' ' ILE . 45.7 Cg_endo -70.21 10.11 0.59 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.236 1.957 . . . . 0.0 112.33 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' O ' ' O ' ' A' ' 28' ' ' PRO . 3.7 mm -37.37 168.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 O-C-N 123.718 0.636 . . . . 0.0 110.124 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.502 ' N ' ' CG2' ' A' ' 29' ' ' ILE . 3.7 m80 -122.68 167.27 13.65 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.953 0.406 . . . . 0.0 110.707 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.9 m -148.63 170.73 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -89.52 134.65 28.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.246 0 O-C-N 121.675 -0.64 . . . . 0.0 109.624 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.48 166.91 10.61 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.785 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.27 144.99 42.99 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.068 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.12 179.0 4.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.642 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.5 mmtt -68.03 -12.57 61.05 Favored 'General case' 0 C--O 1.235 0.322 0 O-C-N 121.821 -0.549 . . . . 0.0 110.767 179.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -76.81 -19.41 57.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.346 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.04 -7.57 76.34 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.9 p -80.08 150.21 30.37 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.262 0.553 . . . . 0.0 111.203 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.9 mt -103.77 135.66 44.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.934 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -141.11 139.72 34.03 Favored 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.701 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.36 140.74 52.22 Favored 'General case' 0 CA--C 1.506 -0.736 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.657 -178.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.405 HH11 ' CD ' ' A' ' 125' ' ' GLU . 1.0 OUTLIER -143.51 137.66 14.73 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.231 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -74.78 158.27 43.13 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 123.105 2.537 . . . . 0.0 112.711 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 70.3 t -98.29 133.59 39.96 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 177.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.6 m -125.73 0.14 4.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.215 -179.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.416 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -150.16 145.04 26.05 Favored 'General case' 0 N--CA 1.448 -0.563 0 O-C-N 121.026 -1.046 . . . . 0.0 108.676 179.411 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.584 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.06 123.2 13.68 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 178.095 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -140.94 146.73 37.76 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -87.58 133.24 33.83 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.505 HE21 ' CB ' ' A' ' 121' ' ' ASP . 33.6 mm-40 -89.79 -0.49 57.58 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.86 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.73 174.28 50.06 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 97.4 m -91.67 127.43 37.12 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.031 0.443 . . . . 0.0 110.354 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -154.92 176.2 12.82 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.715 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . 0.445 ' N ' ' OD1' ' A' ' 55' ' ' ASP . 0.6 OUTLIER -74.19 136.57 42.81 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.163 -179.539 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.868 ' CG2' ' HE1' ' A' ' 68' ' ' TRP . 1.5 m -145.4 156.59 13.3 Favored 'Isoleucine or valine' 0 C--N 1.34 0.153 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.45 HD11 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -109.14 155.79 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.845 -178.782 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.77 121.07 5.45 Favored Glycine 0 CA--C 1.521 0.455 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 20.7 mt -102.55 116.77 33.28 Favored 'General case' 0 C--O 1.225 -0.219 0 O-C-N 122.381 -0.482 . . . . 0.0 110.133 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.525 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 55.7 ttp180 -101.09 128.58 47.09 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.161 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.458 ' CG2' ' N ' ' A' ' 62' ' ' ALA . 91.6 mt -117.63 164.22 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.458 ' N ' ' CG2' ' A' ' 61' ' ' ILE . . . -60.34 139.82 57.44 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.759 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.505 ' H ' ' NH2' ' A' ' 109' ' ' ARG . . . 99.99 -9.29 59.81 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 102.49 -19.3 48.43 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.65 119.95 6.03 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.087 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.1 tt -121.12 138.79 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.82 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 42.6 tp -126.4 112.5 15.71 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.099 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . 0.868 ' HE1' ' CG2' ' A' ' 56' ' ' VAL . 4.3 t-105 -107.71 125.79 51.81 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -154.85 175.44 13.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.233 -178.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.422 ' OG1' ' OD1' ' A' ' 72' ' ' ASP . 71.3 p -77.06 154.0 82.64 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.16 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.12 -22.21 73.97 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.649 2.233 . . . . 0.0 111.889 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . 0.422 ' OD1' ' OG1' ' A' ' 70' ' ' THR . 10.1 p30 -91.07 -6.0 54.41 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.585 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 13.1 t60 -70.96 128.7 36.87 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -85.34 128.42 34.7 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.01 0.433 . . . . 0.0 111.304 -179.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -102.8 139.79 22.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.59 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.9 tp -79.37 93.41 5.33 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.955 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 44.7 p -99.22 175.89 5.73 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.763 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.0 pt-20 -64.94 -17.53 64.46 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.284 -0.567 . . . . 0.0 111.268 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -105.77 25.97 10.18 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 121.125 -0.23 . . . . 0.0 110.811 -178.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.72 -141.13 15.43 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 87.7 m95 -93.64 129.99 39.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.452 -0.374 . . . . 0.0 111.142 -179.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 77.4 mtm180 -142.01 131.78 24.22 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.274 179.201 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.76 17.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.024 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.42 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.84 -37.67 87.76 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.124 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.1 -2.72 2.97 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.619 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.42 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.9 mm-40 -107.64 10.87 28.95 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.93 0.395 . . . . 0.0 110.378 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.1 mt -93.51 126.94 38.94 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.378 0.608 . . . . 0.0 111.638 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.589 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.6 mmt180 -132.14 151.63 51.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.469 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -47.88 85.52 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.242 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 160.28 -15.97 0.2 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -84.91 130.32 34.66 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 116.748 0.274 . . . . 0.0 110.304 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -93.37 143.21 26.5 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.275 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.4 m -135.08 158.97 41.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.593 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -75.2 131.62 40.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.635 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 m -129.21 132.88 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -74.13 125.62 28.75 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.927 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -99.7 123.84 44.36 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.182 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 16.1 t -75.39 -16.84 15.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 121.653 -0.654 . . . . 0.0 111.43 178.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -68.97 -59.03 3.33 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 102' ' ' GLU . 23.1 p -95.43 -11.97 26.72 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.56 -13.2 6.73 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.473 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.8 mt-10 -87.15 162.81 17.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.942 0.401 . . . . 0.0 110.639 -177.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.548 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.8 pt? -76.35 140.08 41.28 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -133.18 164.32 27.32 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.763 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.38 137.36 46.48 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.114 -178.373 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -144.04 163.03 34.7 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 16.9 m -90.93 154.03 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.605 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -67.94 160.31 4.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.913 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.505 ' NH2' ' H ' ' A' ' 63' ' ' GLY . 37.9 ttm180 -106.87 -51.71 2.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.973 179.304 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.525 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 83.1 tt0 -166.93 147.3 5.67 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.796 -0.565 . . . . 0.0 109.739 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 91.8 t -96.77 134.46 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.337 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.422 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.1 mm? -101.64 131.27 23.13 Favored Pre-proline 0 CA--C 1.538 0.504 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.555 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.76 158.53 0.74 Allowed 'Trans proline' 0 N--CA 1.489 1.22 0 C-N-CA 121.956 1.771 . . . . 0.0 111.587 178.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.7 p -69.67 157.38 37.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.462 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.6 mtp85 -154.71 161.62 41.46 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.789 0.804 . . . . 0.0 111.11 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 83.7 mtt180 -85.01 130.21 34.66 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.354 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.54 167.38 13.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.164 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 87.0 mtm180 -81.17 149.92 28.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.143 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 1.4 p -127.61 143.32 51.18 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.288 0.566 . . . . 0.0 109.931 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -114.64 171.32 7.71 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.846 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.505 ' CB ' HE21 ' A' ' 51' ' ' GLN . 45.5 t0 -156.24 128.06 7.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.977 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 94.4 mt -126.0 125.75 43.18 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.751 0.31 . . . . 0.0 110.375 179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 tp10 -86.67 112.62 21.81 Favored 'General case' 0 CA--C 1.513 -0.468 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.957 -178.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.4 t -85.24 112.41 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.55 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 124' ' ' VAL . 52.8 tt0 24.55 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.47 0 O-C-N 123.7 0.625 . . . . 0.0 111.578 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -130.77 -27.97 2.05 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.161 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 129' ' ' THR . 88.2 mt -77.01 66.9 2.92 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.428 ' C ' ' O ' ' A' ' 127' ' ' LEU . 47.7 m170 -38.27 95.84 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.62 139.32 0.02 OUTLIER 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.464 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.447 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 2.3 pp -147.29 155.61 42.19 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.659 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.416 ' O ' ' CG1' ' A' ' 131' ' ' VAL . 9.2 p -88.66 123.19 40.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.016 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -131.58 128.78 39.93 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.75 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.534 ' C ' ' H ' ' A' ' 135' ' ' VAL . 69.7 mm-40 53.87 45.79 27.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.037 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.81 -17.68 0.5 Allowed Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.22 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.534 ' H ' ' C ' ' A' ' 133' ' ' GLU . 5.0 t -90.55 150.41 3.75 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.293 0 O-C-N 122.267 -0.549 . . . . 0.0 110.346 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 66.6 t -109.35 113.63 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.671 0.272 . . . . 0.0 110.423 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 138' ' ' HIS . 34.0 m -149.1 143.85 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.998 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.577 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 47.7 t-80 -27.53 148.86 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.087 0.403 . . . . 0.0 112.087 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.319 -0.751 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.721 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.454 ' N ' ' OG1' ' A' ' 70' ' ' THR . 7.9 m . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -112.25 136.32 51.82 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.392 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.49 161.03 22.52 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.688 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 -62.82 146.22 53.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.832 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.66 -15.82 37.67 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 m -69.07 121.95 17.74 Favored 'General case' 0 C--O 1.233 0.237 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.653 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -83.87 149.86 26.1 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.851 0.358 . . . . 0.0 110.108 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 94.4 mt -134.7 107.4 8.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.34 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -77.41 129.95 36.45 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.634 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -103.49 133.2 20.43 Favored Pre-proline 0 CA--C 1.541 0.626 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.594 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.32 -32.64 7.97 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.7 2.267 . . . . 0.0 112.236 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.634 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 68.9 t -69.22 -52.61 31.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.538 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.59 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 7.6 p -80.88 -37.74 29.26 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.59 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 83.03 9.74 83.85 Favored Glycine 0 C--N 1.331 0.293 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.425 ' H ' ' HG1' ' A' ' 13' ' ' THR . 0.2 OUTLIER -108.22 -168.17 1.33 Allowed 'General case' 0 C--N 1.341 0.229 0 CA-C-N 117.725 0.763 . . . . 0.0 109.653 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.9 m -113.98 116.12 28.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.151 0.501 . . . . 0.0 110.283 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -105.27 147.41 28.11 Favored 'General case' 0 C--O 1.223 -0.335 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.413 -179.585 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.2 mmt85 -99.1 127.26 45.02 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.443 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 1.4 tt -53.02 -40.61 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.146 -179.036 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -59.39 -33.83 71.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.672 -179.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.6 t0 -84.35 -39.81 18.65 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.968 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 71.0 t -67.9 -43.01 86.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 65.2 t -73.57 -46.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.908 -0.317 . . . . 0.0 111.647 -178.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -60.43 -35.78 76.62 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.929 0.395 . . . . 0.0 111.013 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -100.25 25.17 29.3 Favored Glycine 0 C--N 1.322 -0.22 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.547 ' C ' ' O ' ' A' ' 25' ' ' GLY . 66.0 mtp180 17.14 59.73 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 25' ' ' GLY . 80.2 mttt -86.94 135.06 35.74 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.754 -177.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -75.36 84.89 1.64 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.222 1.948 . . . . 0.0 110.234 178.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.695 ' CG1' ' H ' ' A' ' 30' ' ' HIS . 5.2 tt -115.4 -174.5 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.994 0.426 . . . . 0.0 110.243 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.695 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 46.7 m80 -126.43 161.82 27.02 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.08 171.21 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.435 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.2 t -89.58 133.0 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.12 166.51 11.01 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.695 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.45 145.0 42.58 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.228 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.9 177.94 4.46 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -70.8 -14.0 62.25 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 120.848 0.356 . . . . 0.0 110.637 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 54.5 t0 -80.03 -18.97 48.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.28 179.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.56 23.34 34.01 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.8 p -102.31 136.11 42.72 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.854 0.359 . . . . 0.0 111.168 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' A' ' 41' ' ' HIS . 81.2 mt -92.5 128.59 38.41 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.017 0.437 . . . . 0.0 110.607 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . 0.447 ' CD2' ' O ' ' A' ' 40' ' ' LEU . 32.7 m170 -140.01 138.49 35.49 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.772 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.07 142.19 52.7 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.779 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -143.07 138.56 15.86 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.148 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.87 157.28 34.97 Favored 'Trans proline' 0 N--CA 1.489 1.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.822 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -98.99 133.7 40.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 20.0 m -124.98 -0.27 5.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.37 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -151.22 146.75 26.3 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.174 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.575 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.45 127.51 17.47 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 178.254 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -131.22 144.6 51.45 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.97 0.414 . . . . 0.0 111.643 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -116.08 139.62 50.11 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 178.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 2.3 mm-40 -109.2 -110.82 0.32 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.704 -1.134 . . . . 0.0 109.889 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -162.09 -156.81 8.59 Favored Glycine 0 C--N 1.303 -1.277 0 CA-C-N 114.233 -1.348 . . . . 0.0 112.482 -177.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.408 ' O ' ' CG2' ' A' ' 53' ' ' THR . 4.5 t -98.1 126.75 43.68 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.868 0.366 . . . . 0.0 111.178 -179.104 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -145.74 172.04 13.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.614 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -76.3 136.38 39.6 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.126 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.9 m -140.23 135.88 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.942 0.401 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 39.3 pt -87.86 148.79 4.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.717 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.47 126.8 8.35 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.0 mt -108.58 115.84 30.85 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.219 0.533 . . . . 0.0 110.938 -179.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -83.03 104.74 13.46 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.881 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 63' ' ' GLY . 6.0 mm -89.93 116.31 31.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.242 -178.263 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.563 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 36.36 28.59 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.726 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 72.36 -27.71 0.7 Allowed Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.74 -106.51 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -178.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.64 170.71 9.93 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.883 0.373 . . . . 0.0 110.382 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.87 155.64 37.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.332 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.0 tp -133.39 118.24 18.2 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.153 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.8 m95 -104.34 114.16 28.21 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -139.45 171.2 14.6 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.484 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.454 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.7 OUTLIER -80.65 157.02 72.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.361 -179.645 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -63.42 -18.13 63.17 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.645 2.23 . . . . 0.0 111.9 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -94.46 -9.99 33.78 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.876 0.37 . . . . 0.0 110.309 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.545 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.8 t60 -71.01 130.77 42.42 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -87.03 130.61 34.39 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.148 0.499 . . . . 0.0 111.144 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.36 142.29 18.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.875 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 52.9 tp -79.91 93.17 5.63 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.691 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.616 ' HG1' ' H ' ' A' ' 79' ' ' TYR . 12.1 p -99.02 177.67 5.17 Favored 'General case' 0 CA--C 1.52 -0.19 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -178.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -68.09 -19.15 64.83 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.236 -179.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.616 ' H ' ' HG1' ' A' ' 77' ' ' THR . 6.0 t80 -104.63 24.1 12.28 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-O 120.733 0.302 . . . . 0.0 110.632 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.69 -176.03 42.56 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 81.2 m95 -57.91 127.76 33.68 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.014 0.435 . . . . 0.0 110.12 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 -142.36 133.54 26.11 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.888 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.44 140.01 29.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.675 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.15 -37.87 86.83 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.243 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.01 -2.42 4.92 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.526 -179.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -106.0 -0.65 24.77 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.02 0.438 . . . . 0.0 110.418 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -81.55 127.79 33.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.151 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.548 ' O ' ' N ' ' A' ' 90' ' ' GLY . 8.9 tpp180 -131.01 149.75 52.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.179 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -45.5 89.04 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.644 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.05 -15.72 0.43 Allowed Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -86.39 130.15 34.61 Favored 'General case' 0 CA--C 1.523 -0.085 0 CA-C-O 121.023 0.44 . . . . 0.0 110.381 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -90.73 131.3 36.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.37 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 26.8 m -116.93 150.35 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.227 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.39 136.09 47.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.004 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.1 m -133.85 161.77 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.33 179.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 67.9 ttt-85 -104.67 128.37 52.7 Favored 'General case' 0 N--CA 1.462 0.14 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -100.92 123.49 45.2 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.082 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 28.1 m -75.9 -15.4 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 118.179 0.445 . . . . 0.0 110.906 179.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -69.59 -58.45 3.93 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.06 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.441 ' C ' ' H ' ' A' ' 102' ' ' GLU . 1.5 t -97.87 -12.4 22.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.269 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.35 -12.84 8.85 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.441 ' H ' ' C ' ' A' ' 100' ' ' THR . 43.2 mt-10 -83.25 159.44 21.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.79 0.329 . . . . 0.0 110.749 -178.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -84.02 140.06 32.11 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.231 0.538 . . . . 0.0 109.934 179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 59.4 mtp180 -137.07 171.91 13.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.218 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.8 m-30 -105.56 139.14 40.63 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.954 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 7.9 m -135.96 155.31 50.45 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.7 p -95.2 157.21 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 122.573 0.349 . . . . 0.0 111.116 -179.83 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 42.7 mm -82.18 136.68 22.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.003 178.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.1 mmt85 -84.88 -38.44 19.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.694 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -169.45 151.85 4.61 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 84.6 t -95.31 132.08 40.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.113 0.483 . . . . 0.0 110.176 178.901 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.421 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.0 mm? -100.37 131.48 23.91 Favored Pre-proline 0 N--CA 1.467 0.394 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.61 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.37 154.63 2.5 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.129 1.886 . . . . 0.0 111.662 178.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.3 p -68.39 158.88 32.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.022 0.439 . . . . 0.0 110.518 -179.263 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -151.46 149.12 28.89 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.047 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 57.0 mtm180 -78.33 132.58 37.49 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.197 0.522 . . . . 0.0 110.354 179.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.75 158.13 12.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.43 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -67.16 142.59 56.98 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 71.4 p -124.25 141.34 52.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.206 0.527 . . . . 0.0 109.899 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -116.67 174.84 5.86 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.82 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -152.63 128.96 10.56 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 82.2 mt -116.1 170.79 8.24 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.667 -179.84 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -137.88 107.74 6.3 Favored 'General case' 0 CA--C 1.516 -0.346 0 C-N-CA 120.604 -0.439 . . . . 0.0 110.576 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.43 116.81 31.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 127' ' ' LEU . 38.8 tt0 -58.39 149.88 23.69 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.757 -179.207 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 61.64 -69.13 0.05 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.254 -0.885 . . . . 0.0 112.159 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -98.0 95.06 7.21 Favored 'General case' 0 CA--C 1.519 -0.23 0 O-C-N 122.285 -0.259 . . . . 0.0 110.413 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.403 ' O ' ' OG1' ' A' ' 129' ' ' THR . 75.5 m80 -67.04 99.84 0.69 Allowed 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.403 ' OG1' ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.55 144.62 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.937 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.432 ' H ' HD21 ' A' ' 130' ' ' LEU . 1.7 pt? -144.68 154.45 42.79 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 121.635 0.731 . . . . 0.0 111.788 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.76 127.25 41.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 179.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.93 129.74 36.74 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.401 -179.076 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 51.73 46.78 26.0 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.033 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.14 -21.01 0.39 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 8.1 t -90.4 152.42 3.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.172 0 O-C-N 122.27 -0.547 . . . . 0.0 110.588 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -106.53 114.64 46.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.358 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 10.1 m -147.15 136.16 15.99 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.467 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 3.2 t60 -38.54 162.91 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.833 0.349 . . . . 0.0 111.621 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.434 ' H ' ' CD2' ' A' ' 138' ' ' HIS . 12.6 p30 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.271 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.638 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.5 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -118.02 134.56 54.86 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 120.89 0.376 . . . . 0.0 110.391 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -86.38 163.61 17.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.396 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.409 ' OE2' ' CD ' ' A' ' 20' ' ' GLU . 57.7 tt0 -63.02 142.16 58.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.506 178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.85 -21.09 30.43 Favored Glycine 0 C--N 1.334 0.458 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.8 m -66.04 123.48 19.96 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.01 148.88 28.41 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.838 0.352 . . . . 0.0 110.068 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.52 107.31 8.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -77.4 125.19 28.94 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.625 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 4.7 t70 -101.99 132.79 21.19 Favored Pre-proline 0 CA--C 1.538 0.501 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.846 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.95 -31.61 7.94 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.619 2.213 . . . . 0.0 112.166 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.625 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 66.2 t -71.47 -54.47 17.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.694 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.479 ' HG1' ' N ' ' A' ' 14' ' ' GLY . 6.9 p -77.32 -38.94 49.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.961 0.41 . . . . 0.0 110.171 -179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.479 ' N ' ' HG1' ' A' ' 13' ' ' THR . . . 84.31 4.62 87.91 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.887 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 55.5 m -114.18 157.63 22.39 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 117.435 0.617 . . . . 0.0 109.85 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 40.2 m -78.47 116.65 19.01 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.28 0.562 . . . . 0.0 110.794 -179.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . 0.485 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 87.0 m-70 -103.1 146.7 27.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.452 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -98.52 128.12 44.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.971 179.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.417 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 2.6 tp -52.2 -40.87 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.613 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.417 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 7.4 tt0 -57.56 -36.16 71.31 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.976 0.417 . . . . 0.0 110.852 -179.486 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.519 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 49.4 t0 -81.73 -35.7 29.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.47 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -67.32 -42.17 87.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.642 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.5 t -74.11 -46.79 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -177.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 0.6 OUTLIER -56.05 -37.57 69.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.824 -177.869 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.07 32.17 7.63 Favored Glycine 0 C--O 1.227 -0.287 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.6 ptm180 12.45 65.72 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.005 0 CA-C-O 121.189 0.518 . . . . 0.0 110.307 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.402 ' N ' ' O ' ' A' ' 25' ' ' GLY . 78.2 mttt -85.88 141.55 35.84 Favored Pre-proline 0 N--CA 1.447 -0.579 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.811 -177.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.548 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.4 Cg_endo -71.3 7.62 1.4 Allowed 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.23 1.953 . . . . 0.0 112.224 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' PRO . 12.8 tt -38.05 169.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 O-C-N 123.505 0.503 . . . . 0.0 110.597 -178.308 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.521 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 2.2 m80 -120.16 170.61 9.16 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.341 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.08 172.76 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.9 t -88.16 135.03 26.5 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.53 167.53 10.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.845 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.6 140.41 40.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.855 0.359 . . . . 0.0 110.373 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.23 179.06 4.06 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.564 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -68.44 -16.06 63.77 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-O 120.754 0.312 . . . . 0.0 110.764 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -74.8 -19.56 60.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.618 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.22 -11.89 69.84 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.0 p -74.8 148.74 40.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.141 0.496 . . . . 0.0 110.961 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 56.6 mt -104.78 135.09 46.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.802 -179.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -141.13 138.63 33.62 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.625 -179.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -68.7 143.0 54.86 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.759 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.467 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.3 mmp_? -143.83 138.26 15.01 Favored Pre-proline 0 CA--C 1.538 0.483 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.829 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 160.06 37.42 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 123.058 2.505 . . . . 0.0 112.754 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.88 136.92 34.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.045 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.512 ' C ' ' HG ' ' A' ' 47' ' ' SER . 22.2 m -128.26 3.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.877 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.512 ' HG ' ' C ' ' A' ' 46' ' ' VAL . 1.4 m -148.43 142.5 25.96 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.889 0.768 . . . . 0.0 109.239 179.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -144.09 123.26 12.93 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 178.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -143.91 149.13 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.822 0.675 . . . . 0.0 112.822 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -96.51 131.85 42.7 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.355 -0.979 . . . . 0.0 108.355 176.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.652 HE21 ' C ' ' A' ' 119' ' ' THR . 1.9 mt-30 -95.41 4.29 53.48 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.655 -0.248 . . . . 0.0 111.075 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.11 -172.09 47.11 Favored Glycine 0 C--N 1.336 0.576 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.821 179.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.463 ' OG1' ' CZ ' ' A' ' 118' ' ' ARG . 67.8 m -86.82 127.44 35.01 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 120.76 0.314 . . . . 0.0 110.308 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -148.18 159.6 43.78 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.605 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.0 143.24 43.67 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.873 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.01 147.11 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.117 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . 0.418 HD11 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -100.86 148.13 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.944 -179.693 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.98 135.5 12.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -119.24 114.96 23.22 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.254 0.549 . . . . 0.0 110.346 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -95.95 116.81 29.5 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.776 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.538 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.9 mp -104.18 129.83 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-O 120.987 0.422 . . . . 0.0 111.009 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.558 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 39.93 23.25 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.561 -178.862 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 71.02 -23.81 0.55 Allowed Glycine 0 CA--C 1.53 1.002 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.558 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -46.85 -103.73 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 -178.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.63 173.93 7.53 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.084 0.469 . . . . 0.0 110.516 -179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.5 tt -126.18 158.21 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.681 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.1 tp -138.61 121.73 16.85 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.429 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.1 m95 -106.06 128.96 54.21 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.96 172.39 16.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.411 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' THR . . . . . 0.519 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -82.65 155.98 68.21 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.793 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.31 -24.0 75.61 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.706 2.271 . . . . 0.0 111.918 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -87.6 -7.38 57.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.181 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.638 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 8.2 t60 -73.81 128.65 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -87.88 133.99 33.79 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.134 0.492 . . . . 0.0 111.034 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -105.44 140.44 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.061 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.427 ' C ' ' CD1' ' A' ' 76' ' ' LEU . 0.6 OUTLIER -83.39 95.29 8.18 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.176 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.454 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 50.1 p -98.72 179.37 4.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.493 -179.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.447 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 17.6 pt-20 -65.26 -17.61 64.64 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.303 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . 0.447 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 50.2 m-85 -107.32 25.48 11.37 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.193 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.47 -139.2 14.32 Favored Glycine 0 C--N 1.335 0.482 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.716 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.5 m95 -94.47 130.13 40.96 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.329 -0.436 . . . . 0.0 111.784 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -138.13 125.92 22.41 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.95 140.81 29.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.95 -179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.493 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -59.97 -40.7 89.99 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 121.023 -0.271 . . . . 0.0 111.616 -178.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.21 -1.72 0.78 Allowed Glycine 0 CA--C 1.524 0.626 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.075 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.595 ' OE1' ' N ' ' A' ' 86' ' ' GLU . 57.4 mp0 -118.94 36.75 4.33 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.026 0.441 . . . . 0.0 110.612 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.4 mt -110.73 124.95 52.95 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.955 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.7 mmt180 -131.87 145.65 51.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.567 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -40.94 90.63 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 121.01 0.433 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.12 -13.71 0.38 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -89.99 127.75 36.11 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 120.974 0.416 . . . . 0.0 110.358 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -92.21 133.6 35.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.599 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.4 m -114.57 149.24 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.63 128.46 36.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.918 0.39 . . . . 0.0 110.997 -179.297 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.7 m -130.8 161.74 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.348 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 25.8 ttm180 -110.29 132.9 53.77 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.57 179.539 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -100.98 126.11 47.61 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.251 178.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 85.3 t -74.96 -15.44 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 O-C-N 121.891 -0.506 . . . . 0.0 111.367 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -70.01 -57.41 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.145 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.425 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.1 m -100.51 -14.4 18.26 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.501 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.16 -11.93 14.5 Favored Glycine 0 C--N 1.331 0.261 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.528 ' OE1' ' NH2' ' A' ' 104' ' ' ARG . 95.4 mt-10 -79.14 156.05 28.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 0.0 110.897 -178.144 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.17 132.52 35.36 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 121.605 0.716 . . . . 0.0 110.038 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.528 ' NH2' ' OE1' ' A' ' 102' ' ' GLU . 35.9 mmt180 -132.28 -179.54 5.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.342 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.454 ' OH ' ' C ' ' A' ' 77' ' ' THR . 4.1 m-85 -118.63 147.28 43.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.681 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 28.6 m -138.57 159.0 43.19 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.6 p -89.55 153.09 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.726 0.298 . . . . 0.0 110.72 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.431 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.8 mm -72.64 156.78 6.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.179 0.514 . . . . 0.0 109.963 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.431 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 2.5 tpm_? -106.69 -47.37 3.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.106 179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -166.56 145.56 5.57 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.63 133.77 35.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.929 0.395 . . . . 0.0 110.072 179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.56 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -102.06 148.21 35.04 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.357 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.99 158.52 57.01 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 122.496 2.131 . . . . 0.0 111.549 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 2.0 p -68.49 158.2 34.3 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.009 0.433 . . . . 0.0 110.66 -179.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.402 ' CG ' ' N ' ' A' ' 116' ' ' ARG . 45.2 ttp180 -153.55 153.86 33.18 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.507 179.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.402 ' N ' ' CG ' ' A' ' 115' ' ' ARG . 18.5 mmm180 -77.31 125.71 29.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.506 179.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -162.89 159.18 23.45 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.701 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.463 ' CZ ' ' OG1' ' A' ' 53' ' ' THR . 11.0 mpt_? -76.26 149.11 37.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.815 179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.652 ' C ' HE21 ' A' ' 51' ' ' GLN . 62.1 p -132.03 145.77 51.65 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.588 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 63.8 m-85 -114.74 173.06 6.66 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.627 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -143.37 130.7 20.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.9 mt -123.69 170.91 10.01 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.417 179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -135.32 106.49 6.72 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.085 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 17.4 t -85.42 109.55 18.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.28 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 41.4 tp10 21.86 -108.13 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.9 0.75 . . . . 0.0 111.359 179.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -114.41 -26.68 7.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.039 179.526 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 129' ' ' THR . 91.4 mt -84.52 68.53 10.34 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' OG1' ' A' ' 129' ' ' THR . 9.7 m170 -41.94 99.94 0.02 OUTLIER 'General case' 0 CA--C 1.507 -0.683 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.486 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.435 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.32 137.26 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.248 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.422 ' CD1' ' C ' ' A' ' 130' ' ' LEU . 2.2 pp -145.34 150.6 36.9 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.157 0.504 . . . . 0.0 111.237 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.423 ' O ' ' CG1' ' A' ' 131' ' ' VAL . 5.4 p -87.55 127.9 40.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.351 -0.841 . . . . 0.0 108.935 -179.127 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.9 124.86 27.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.734 -179.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.503 ' C ' ' H ' ' A' ' 135' ' ' VAL . 76.2 mm-40 59.21 44.63 15.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.287 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.0 -19.49 0.75 Allowed Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.503 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.6 t -88.76 150.78 3.61 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 117.033 0.416 . . . . 0.0 110.622 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 48.6 t -106.43 113.56 43.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.31 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 138' ' ' HIS . 15.0 m -148.37 140.87 18.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.548 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 60.6 t-80 -32.37 155.6 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.438 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 23.2 p30 . . . . . 0 C--N 1.324 -0.523 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.45 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.632 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 28.2 m . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -111.46 139.12 47.15 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.832 0.349 . . . . 0.0 110.193 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.91 162.45 16.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -60.5 143.11 54.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.489 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.14 -16.12 32.82 Favored Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 21.3 m -71.8 122.58 20.94 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.707 -0.29 . . . . 0.0 111.014 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.6 mtt85 -82.04 148.49 28.58 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 120.781 0.324 . . . . 0.0 110.247 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.4 HD11 HG23 ' A' ' 8' ' ' ILE . 71.0 mt -135.62 108.21 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.289 -179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -79.72 129.66 34.67 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.413 ' O ' ' N ' ' A' ' 14' ' ' GLY . 55.3 t0 -109.94 113.41 57.23 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.813 -0.176 . . . . 0.0 110.755 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.11 -36.93 78.68 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.625 2.217 . . . . 0.0 112.082 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 49.1 t -61.8 -57.8 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.613 -178.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.734 ' HG1' ' H ' ' A' ' 15' ' ' THR . 29.9 p -78.27 -37.96 43.76 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.179 0.514 . . . . 0.0 110.126 -179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 85.16 5.71 85.35 Favored Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.734 ' H ' ' HG1' ' A' ' 13' ' ' THR . 96.5 m -114.33 157.29 23.0 Favored 'General case' 0 C--N 1.346 0.449 0 CA-C-N 117.658 0.729 . . . . 0.0 109.837 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 26.0 m -79.67 119.66 22.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.35 0.595 . . . . 0.0 110.61 -179.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 19.9 m-70 -103.31 145.34 30.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.385 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 29.0 ttm-85 -96.92 124.37 40.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.03 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.466 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 1.6 tp -51.75 -44.14 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.724 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.466 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 10.8 pt-20 -57.98 -34.9 70.47 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.131 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -82.25 -37.56 25.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.326 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 67.7 t -66.92 -43.24 89.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.517 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.3 t -72.5 -47.23 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -57.18 -38.11 73.15 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.146 -178.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.08 29.52 12.34 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.548 ' C ' ' O ' ' A' ' 25' ' ' GLY . 90.7 mtm180 15.78 62.5 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 O-C-N 124.037 0.492 . . . . 0.0 110.045 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.2 mttt -87.64 126.13 62.85 Favored Pre-proline 0 N--CA 1.44 -0.97 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.944 -177.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -75.23 93.43 0.97 Allowed 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.469 2.113 . . . . 0.0 110.316 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.3 pt -121.21 -170.16 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.87 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -125.97 164.49 20.7 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.307 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.1 m -150.65 173.68 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 5.2 t -86.55 125.28 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.17 150.85 25.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.626 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.22 144.12 49.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.411 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.26 178.26 4.39 Favored 'General case' 0 N--CA 1.472 0.664 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.8 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp -68.45 -15.25 63.48 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.693 0.283 . . . . 0.0 110.396 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -78.43 -20.3 51.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.083 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.45 -9.67 71.56 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.5 p -73.1 139.01 46.17 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.363 0.601 . . . . 0.0 111.297 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.403 ' CD1' ' NH2' ' A' ' 96' ' ' ARG . 50.6 mt -95.7 135.33 37.54 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.558 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -145.98 141.48 27.75 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.39 147.54 44.2 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.663 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 6.5 mtp180 -152.81 148.98 21.15 Favored Pre-proline 0 N--CA 1.457 -0.124 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.231 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.6 149.55 61.71 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.557 2.172 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.7 t -112.87 146.53 17.44 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.847 0 CA-C-O 121.502 0.668 . . . . 0.0 109.312 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.705 ' O ' ' CE2' ' A' ' 48' ' ' TRP . 2.1 m -139.49 -100.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.497 ' H ' ' CG2' ' A' ' 46' ' ' VAL . 9.3 t -19.0 113.84 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 114.164 -1.38 . . . . 0.0 111.542 -175.525 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.705 ' CE2' ' O ' ' A' ' 46' ' ' VAL . 1.5 m-90 -120.3 110.89 17.1 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.7 m-85 -138.43 147.02 42.86 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.304 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 46.4 p-10 -91.65 134.98 34.22 Favored 'General case' 0 C--N 1.334 -0.069 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.524 HE21 ' HB2' ' A' ' 121' ' ' ASP . 29.8 mm-40 -92.67 -4.83 52.6 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.715 -0.22 . . . . 0.0 111.219 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 -179.11 48.68 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 79.9 m -94.24 122.66 37.01 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.8 mtp85 -146.54 171.38 15.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.435 0.636 . . . . 0.0 110.656 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -74.42 139.63 44.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.219 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -139.36 153.3 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 14.4 pt -108.88 155.83 9.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.183 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.03 128.73 8.71 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 28.4 mt -108.94 115.3 29.82 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.205 0.526 . . . . 0.0 110.413 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.6 tpp180 -85.81 109.29 18.57 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.055 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' A' ' 63' ' ' GLY . 12.8 mm -97.47 125.76 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.639 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 33.73 29.16 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.815 0.697 . . . . 0.0 110.852 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 65.03 -22.62 0.11 Allowed Glycine 0 CA--C 1.532 1.139 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.639 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.76 -104.22 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.46 171.39 9.07 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.949 0.404 . . . . 0.0 110.462 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.4 tt -124.94 153.47 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.357 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 43.9 tp -132.75 118.72 19.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.337 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -105.8 118.21 36.01 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.96 170.97 15.12 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.534 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 37.6 p -79.5 153.56 76.24 Favored Pre-proline 0 N--CA 1.45 -0.432 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.128 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.78 -30.25 88.6 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 122.534 2.156 . . . . 0.0 112.146 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -80.97 -9.46 59.84 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.428 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.632 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.7 t60 -70.46 129.04 38.2 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -86.75 131.61 34.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.399 0.619 . . . . 0.0 111.154 -179.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -103.62 139.21 25.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.783 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 58.7 tp -78.35 91.95 4.51 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.856 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.9 p -97.38 -179.34 4.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -178.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -69.87 -16.41 63.24 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.196 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -106.27 26.31 9.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.933 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.88 -138.54 13.97 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -95.67 130.61 42.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.537 -0.331 . . . . 0.0 111.138 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . 0.511 ' NH1' ' OD1' ' A' ' 91' ' ' ASP . 84.0 mtp180 -140.56 129.89 23.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.246 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.38 145.29 18.42 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.011 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.418 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.48 -40.14 95.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 121.249 -0.18 . . . . 0.0 111.473 -179.0 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.3 -3.46 3.89 Favored Glycine 0 C--N 1.337 0.614 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.757 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.418 ' H ' ' C ' ' A' ' 84' ' ' ALA . 50.9 mt-10 -113.24 32.73 5.54 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.732 0.301 . . . . 0.0 110.56 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.9 mt -112.7 126.81 55.8 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 121.38 0.61 . . . . 0.0 111.226 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 37.5 mmt180 -130.89 147.19 52.51 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.884 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -42.66 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.876 0.369 . . . . 0.0 110.741 -179.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.25 -12.68 0.43 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.511 ' OD1' ' NH1' ' A' ' 82' ' ' ARG . 17.8 t70 -87.85 128.57 35.35 Favored 'General case' 0 C--O 1.227 -0.102 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -89.84 131.74 35.62 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.393 -179.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -118.32 150.91 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.121 -0.49 . . . . 0.0 109.797 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -66.76 134.98 53.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.955 0.407 . . . . 0.0 111.015 -179.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 21.4 m -134.22 159.68 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.013 179.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.403 ' NH2' ' CD1' ' A' ' 40' ' ' LEU . 52.6 ttm-85 -107.02 130.24 54.68 Favored 'General case' 0 C--N 1.334 -0.098 0 CA-C-O 120.677 0.275 . . . . 0.0 110.333 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.36 122.9 43.86 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.365 178.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 62.3 t -76.28 -16.19 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 118.133 0.424 . . . . 0.0 110.749 179.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 99' ' ' GLU . 0.5 OUTLIER -72.02 -57.26 4.44 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.849 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.473 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.3 p -94.45 -13.81 25.83 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.13 -14.76 3.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.473 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.5 mt-10 -83.56 163.53 20.34 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 120.981 0.42 . . . . 0.0 110.764 -177.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 4.6 tt -80.51 136.88 36.38 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 45.9 mtp85 -134.42 168.81 18.25 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.099 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -110.87 140.6 45.2 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.672 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 23.3 m -136.49 155.39 50.05 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.409 179.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 58.1 t -91.33 156.68 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.008 0.432 . . . . 0.0 110.555 -179.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 3.5 mm -72.66 153.13 7.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.237 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -106.0 -45.93 4.23 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.454 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -166.05 145.36 6.08 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 83.5 t -96.46 132.88 39.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.137 0.494 . . . . 0.0 110.163 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.457 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 4.1 mm? -98.57 128.73 32.0 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.288 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.63 157.99 2.11 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 122.384 2.056 . . . . 0.0 111.743 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.2 p -66.94 156.93 34.56 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.49 0.662 . . . . 0.0 110.685 -179.303 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -139.04 -140.1 0.14 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.915 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 80.7 mtm180 -153.66 132.6 12.46 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.902 0.382 . . . . 0.0 110.115 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.7 173.67 3.86 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.651 -179.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 -83.51 154.27 23.96 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.144 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -132.64 143.47 49.69 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.95 174.83 5.7 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.483 -0.78 . . . . 0.0 111.5 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.524 ' HB2' HE21 ' A' ' 51' ' ' GLN . 26.4 t0 -148.03 128.79 14.26 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.164 -179.572 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.2 mt -132.15 123.39 27.0 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.852 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -87.51 115.67 25.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.144 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 125' ' ' GLU . 98.5 t -85.48 114.09 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 127' ' ' LEU . 39.7 tp10 -28.2 111.92 0.06 Allowed 'General case' 0 N--CA 1.466 0.367 0 O-C-N 123.574 0.546 . . . . 0.0 111.762 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 60.49 -65.87 0.05 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 178.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.477 ' N ' ' O ' ' A' ' 125' ' ' GLU . 86.0 mt -72.76 75.17 1.13 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.041 0.448 . . . . 0.0 111.005 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.428 ' C ' ' OG1' ' A' ' 129' ' ' THR . 31.5 m170 -56.01 98.96 0.03 OUTLIER 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.45 143.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 O-C-N 123.712 0.632 . . . . 0.0 109.439 178.936 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.493 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 1.8 pp -149.23 154.1 38.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.542 0.687 . . . . 0.0 111.446 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 85.6 t -90.01 123.69 42.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.033 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.08 129.16 37.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -178.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.525 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.2 mm-40 58.77 43.23 18.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.897 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.76 -20.89 0.48 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.525 ' H ' ' C ' ' A' ' 133' ' ' GLU . 3.9 t -89.18 151.13 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-O 120.943 0.402 . . . . 0.0 110.821 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -104.69 112.78 39.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.548 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 11.5 m -148.3 138.65 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 CA-C-O 118.988 -0.529 . . . . 0.0 110.29 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.578 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 14.4 t-80 -28.41 147.63 0.0 OUTLIER 'General case' 0 C--N 1.342 0.259 0 O-C-N 123.571 0.544 . . . . 0.0 111.956 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.616 ' C ' HD21 ' A' ' 139' ' ' ASN . 0.2 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.895 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -91.45 139.01 31.13 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.839 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.52 161.7 28.95 Favored 'General case' 0 CA--C 1.529 0.135 0 CA-C-O 120.978 0.418 . . . . 0.0 111.262 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 77.5 tt0 -66.62 143.27 57.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.826 178.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.97 -18.85 33.58 Favored Glycine 0 C--N 1.336 0.561 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.9 m -66.05 124.97 24.01 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.441 ' HE ' ' CD ' ' A' ' 18' ' ' ARG . 1.6 mpt_? -97.25 116.39 29.36 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 121.014 0.435 . . . . 0.0 110.214 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 15.4 mt -100.41 113.06 34.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.209 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -75.47 133.93 40.96 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.07 129.97 26.02 Favored Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 121.145 -0.222 . . . . 0.0 110.678 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.72 -27.47 18.2 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.91 1.74 . . . . 0.0 112.277 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 42.7 t -76.42 -53.81 14.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.19 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.9 p -76.94 -35.88 56.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.983 0.42 . . . . 0.0 110.251 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.64 10.5 85.13 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.406 ' CG2' ' N ' ' A' ' 16' ' ' THR . 54.8 m -115.56 160.42 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 117.564 0.682 . . . . 0.0 109.694 -179.689 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.406 ' N ' ' CG2' ' A' ' 15' ' ' THR . 12.5 m -79.54 115.0 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.194 0.521 . . . . 0.0 110.911 -179.229 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -101.3 143.46 31.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.866 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.441 ' CD ' ' HE ' ' A' ' 7' ' ' ARG . 69.3 mtm180 -99.65 128.38 45.75 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.753 -0.203 . . . . 0.0 110.574 178.247 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 3.1 tp -53.1 -38.42 29.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.561 -179.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.3 pt-20 -58.17 -35.34 71.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.318 0.58 . . . . 0.0 110.969 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -85.18 -38.38 19.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.63 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 94.2 t -69.04 -42.39 81.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.838 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 75.2 t -75.36 -45.89 39.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.833 -178.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -57.67 -34.5 69.45 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.681 -178.332 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.577 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.25 29.31 9.3 Favored Glycine 0 CA--C 1.519 0.298 0 CA-C-O 119.108 -0.829 . . . . 0.0 111.033 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.577 ' C ' ' O ' ' A' ' 25' ' ' GLY . 44.6 ptt85 13.62 64.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.45 0.643 . . . . 0.0 110.054 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 25' ' ' GLY . 81.6 mttt -84.86 139.49 37.36 Favored Pre-proline 0 N--CA 1.449 -0.503 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.369 -176.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.9 83.27 2.14 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.352 1.368 . . . . 0.0 110.164 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.419 ' CD1' ' C ' ' A' ' 29' ' ' ILE . 1.9 pp -116.27 -174.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.811 0.338 . . . . 0.0 110.486 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.422 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 34.7 m80 -128.65 161.95 28.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.511 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.9 m -146.96 170.47 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.97 134.98 26.56 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.358 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -107.78 166.55 10.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.534 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.2 137.59 39.29 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.914 0.387 . . . . 0.0 110.23 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -112.28 175.42 5.44 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -73.02 -13.34 61.2 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.865 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -78.32 -11.44 59.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.429 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.46 17.37 64.38 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.2 p -100.81 139.34 36.64 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.024 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.9 mt -98.54 131.61 44.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.655 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -139.52 138.3 36.21 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.965 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.87 142.7 52.99 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.465 -0.494 . . . . 0.0 109.959 -178.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 31.7 mmt180 -145.04 138.6 14.36 Favored Pre-proline 0 N--CA 1.468 0.461 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.297 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.12 157.2 33.96 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 122.555 2.17 . . . . 0.0 112.424 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -98.84 138.17 24.14 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 177.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.99 2.66 3.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.183 -178.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.431 ' OG ' ' OE1' ' A' ' 123' ' ' GLU . 1.5 m -146.97 133.99 20.33 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 120.038 -0.665 . . . . 0.0 110.006 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.508 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.77 121.71 18.85 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.003 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -138.14 143.59 40.39 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.599 ' O ' ' HG2' ' A' ' 51' ' ' GLN . 29.3 t70 -88.42 125.77 34.89 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.599 ' HG2' ' O ' ' A' ' 50' ' ' ASP . 8.2 mt-30 -160.86 60.08 0.31 Allowed 'General case' 0 CA--C 1.498 -1.042 0 O-C-N 124.158 0.911 . . . . 0.0 108.55 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . 0.759 ' CA ' ' H ' ' A' ' 119' ' ' THR . . . -118.62 167.06 12.98 Favored Glycine 0 C--N 1.314 -0.684 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.398 -178.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.562 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 33.3 m 113.99 63.53 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 O-C-N 125.436 1.315 . . . . 0.0 111.261 177.788 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.6 mtt-85 -148.78 175.72 10.99 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.634 0.254 . . . . 0.0 110.794 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -77.47 139.56 39.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.481 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.61 151.81 19.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.41 144.77 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 109.963 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.93 134.7 12.15 Favored Glycine 0 N--CA 1.462 0.39 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 71.6 mt -116.78 116.34 27.3 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-O 121.064 0.459 . . . . 0.0 110.313 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.75 107.73 17.09 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.103 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.696 ' O ' ' N ' ' A' ' 63' ' ' GLY . 1.6 mp -93.86 133.49 34.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 179.007 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.657 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 24.11 31.43 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.743 0.652 . . . . 0.0 112.756 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.696 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 65.81 -23.92 0.14 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.657 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.4 -107.47 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -178.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.71 170.24 10.3 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.811 0.338 . . . . 0.0 110.503 -179.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.0 mt -124.7 154.72 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.123 179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 61.9 tp -128.79 114.73 16.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.814 179.654 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -103.83 109.96 21.9 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -134.2 172.32 13.02 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.198 -179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.14 156.8 69.13 Favored Pre-proline 0 CA--C 1.535 0.401 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.435 179.487 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -63.15 -17.72 61.5 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.734 2.29 . . . . 0.0 112.169 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 49.3 p-10 -97.62 -6.67 32.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.992 0.425 . . . . 0.0 110.185 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.4 t60 -71.85 129.68 39.21 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -83.57 124.07 30.4 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.375 0.607 . . . . 0.0 111.631 -179.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 73.5 t -98.14 138.35 23.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.058 -0.973 . . . . 0.0 109.889 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 37.9 tp -81.67 95.64 7.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.036 -179.524 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 p -100.28 175.87 5.57 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -67.67 -18.14 64.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.459 -178.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -105.97 21.07 17.93 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.647 0.26 . . . . 0.0 110.642 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.89 -144.63 15.88 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -91.95 126.54 37.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.527 0.204 . . . . 0.0 110.97 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -127.83 126.75 42.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.79 136.9 54.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.949 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -69.78 -0.88 7.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.683 179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.71 -13.78 77.22 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -132.22 15.44 4.61 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.758 0.313 . . . . 0.0 111.46 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 20.5 mt -80.32 141.41 35.47 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.233 0.54 . . . . 0.0 110.877 179.374 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.0 tpp85 -142.08 155.21 45.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.014 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -48.51 113.86 0.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.334 179.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 141.77 -22.33 2.5 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -83.09 130.56 35.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.706 0.289 . . . . 0.0 110.766 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -88.84 136.62 32.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.128 0.49 . . . . 0.0 110.795 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.0 m -122.02 144.05 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.5 -179.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.52 131.53 42.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.912 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 1.4 m -127.06 163.11 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.98 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -100.5 128.14 46.65 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.671 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -100.54 124.28 45.88 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.8 t -75.63 -15.81 15.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 118.24 0.473 . . . . 0.0 110.909 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 37.7 tp10 -69.35 -58.66 3.72 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.097 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.475 ' C ' ' H ' ' A' ' 102' ' ' GLU . 70.3 p -99.73 -12.18 20.2 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.772 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.32 -13.87 9.78 Favored Glycine 0 C--N 1.332 0.312 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.475 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.6 mt-10 -82.05 153.84 25.93 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.953 0.406 . . . . 0.0 111.622 -177.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -80.16 139.92 36.59 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 179.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.0 ptt85 -142.64 138.47 30.7 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.702 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.9 m-30 -78.28 147.8 34.16 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.38 -0.528 . . . . 0.0 109.998 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -139.34 162.68 34.43 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.7 t -95.32 154.29 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 61.6 mt -73.54 154.61 6.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.0 ttm180 -104.75 -42.72 5.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.16 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -167.23 147.82 5.53 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 23.1 t -92.81 130.85 41.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.6 mp -98.99 124.93 43.69 Favored Pre-proline 0 CA--C 1.543 0.709 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.973 -179.519 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -48.45 162.73 0.31 Allowed 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.228 1.952 . . . . 0.0 111.998 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.1 p -73.02 160.44 32.07 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.28 0.562 . . . . 0.0 110.823 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.459 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 10.0 tpt180 -144.89 -132.47 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.195 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.459 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 1.5 tmm_? -155.39 134.83 12.47 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.983 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 170.77 4.27 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.072 -178.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 84.2 mtm-85 -83.87 140.36 32.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.843 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' THR . . . . . 0.759 ' H ' ' CA ' ' A' ' 52' ' ' GLY . 4.2 p -128.39 148.78 50.72 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.559 177.834 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -122.75 179.76 4.51 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.971 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -147.64 124.83 11.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.368 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 95.6 mt -115.84 173.08 6.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.444 -179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . 0.431 ' OE1' ' OG ' ' A' ' 47' ' ' SER . 38.5 tt0 -136.38 105.36 5.92 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.241 178.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 125' ' ' GLU . 16.4 t -83.56 108.64 16.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.0 tt0 20.37 -89.14 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.639 0.587 . . . . 0.0 112.322 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 124' ' ' VAL . 81.6 mt-10 -129.27 -39.94 1.49 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.392 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.515 ' O ' ' N ' ' A' ' 129' ' ' THR . 84.3 mt -71.04 64.86 0.35 Allowed 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.183 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.402 ' N ' ' O ' ' A' ' 126' ' ' GLU . 39.3 m80 -41.78 94.82 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 179.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.515 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 171.63 141.28 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.189 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.43 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.0 pp -147.79 155.96 42.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.425 0.631 . . . . 0.0 111.885 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -89.12 126.78 42.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.18 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.582 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.23 132.62 39.9 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.219 -179.099 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.8 mm-40 50.64 46.23 25.95 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.156 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.99 23.26 56.82 Favored Glycine 0 CA--C 1.522 0.523 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.802 178.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 21.9 t -129.75 153.69 39.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -105.32 111.9 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 O-C-N 121.944 -0.473 . . . . 0.0 110.611 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 26.8 m -147.38 139.33 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 55.6 t-80 -31.25 151.53 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.201 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.264 -179.635 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.681 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 6.2 m . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 80.5 mt -123.22 132.69 54.13 Favored 'General case' 0 C--N 1.34 0.189 0 CA-C-O 121.182 0.515 . . . . 0.0 110.72 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.09 162.26 24.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.39 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.76 146.52 52.25 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.45 -17.34 40.13 Favored Glycine 0 C--N 1.34 0.754 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.7 m -67.03 124.76 23.95 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.08 -179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 81.1 mtp180 -83.98 149.35 26.35 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.238 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.414 HG23 HD13 ' A' ' 8' ' ' ILE . 75.2 mt -134.6 107.42 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.81 179.923 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -77.0 127.22 32.3 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 14' ' ' GLY . 61.6 t0 -107.32 111.44 63.17 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.07 -37.3 68.24 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 122.508 2.139 . . . . 0.0 111.969 178.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -61.21 -58.41 7.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.518 -179.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.746 ' HG1' ' H ' ' A' ' 15' ' ' THR . 30.5 p -74.88 -33.07 62.01 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.181 0.515 . . . . 0.0 109.788 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 80.47 7.74 88.24 Favored Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.746 ' H ' ' HG1' ' A' ' 13' ' ' THR . 0.2 OUTLIER -110.87 -163.82 0.88 Allowed 'General case' 0 C--N 1.347 0.471 0 CA-C-N 117.727 0.764 . . . . 0.0 109.507 -179.248 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 87.4 m -114.71 115.7 27.49 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.516 0.674 . . . . 0.0 110.511 179.4 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -100.18 141.72 32.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.206 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -97.65 125.99 42.72 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.969 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.42 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -52.92 -41.01 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.217 -179.333 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.42 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 2.8 pt-20 -55.31 -35.23 64.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.355 0.598 . . . . 0.0 110.646 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 50.9 t0 -83.1 -36.18 25.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.972 . . . . 0.0 111.62 -178.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 54.1 t -66.65 -43.83 90.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.408 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 72.2 t -69.52 -46.11 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.721 -179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -56.04 -36.9 68.53 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 120.946 -0.302 . . . . 0.0 110.596 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.558 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.71 32.64 6.09 Favored Glycine 0 C--O 1.228 -0.257 0 CA-C-O 118.222 -1.321 . . . . 0.0 110.563 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.558 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.0 ptt-85 10.37 72.55 0.01 OUTLIER 'General case' 0 C--N 1.367 1.341 0 O-C-N 124.437 0.728 . . . . 0.0 110.004 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.422 ' C ' ' H ' ' A' ' 29' ' ' ILE . 74.1 mttt -90.06 144.71 31.7 Favored Pre-proline 0 N--CA 1.443 -0.791 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.716 -177.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.561 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.2 Cg_endo -71.77 9.83 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.581 2.187 . . . . 0.0 112.464 179.517 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.561 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.1 pp -38.19 171.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 124.087 0.867 . . . . 0.0 110.374 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 1.2 m80 -123.05 166.74 14.62 Favored 'General case' 0 CA--C 1.509 -0.622 0 O-C-N 122.103 -0.373 . . . . 0.0 111.057 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -150.42 173.96 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.385 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.499 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 3.8 t -87.3 132.51 32.46 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.152 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -102.38 166.93 10.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.79 137.08 36.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.074 0.464 . . . . 0.0 110.315 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.5 177.46 4.64 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -72.76 -14.73 61.6 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.615 0.245 . . . . 0.0 110.677 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -78.98 -14.66 59.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.7 20.46 56.1 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.6 p -100.82 135.29 42.49 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 120.76 0.314 . . . . 0.0 110.691 178.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 53.2 mt -99.78 137.63 37.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.561 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -147.72 143.56 27.67 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.795 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.86 145.01 48.86 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.452 ' HE ' HD13 ' A' ' 127' ' ' LEU . 86.6 mtt-85 -153.25 142.44 14.67 Favored Pre-proline 0 CA--C 1.54 0.587 0 O-C-N 123.813 0.696 . . . . 0.0 111.097 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.36 160.0 39.46 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 123.094 2.529 . . . . 0.0 113.267 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -97.89 135.76 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 177.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.3 m -122.24 -1.33 7.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 118.803 -0.618 . . . . 0.0 111.167 -178.705 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.8 p -148.79 141.33 24.35 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 119.203 0.91 . . . . 0.0 108.717 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.509 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.23 121.32 12.93 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.047 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -142.1 148.23 38.03 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -99.74 135.06 41.73 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.659 HE22 ' CB ' ' A' ' 1' ' ' CYS . 2.0 mt-30 -97.75 4.56 49.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 119.412 -0.327 . . . . 0.0 111.53 178.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.05 -169.73 42.49 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 98.0 m -88.26 128.33 35.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.397 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.5 mtt-85 -147.17 161.59 40.6 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.544 -179.575 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -77.18 142.8 39.46 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.489 179.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.8 m -141.12 160.27 22.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 43.8 pt -111.89 147.29 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.257 179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.59 137.53 13.32 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.409 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 43.6 mt -120.63 111.99 18.34 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.403 0.62 . . . . 0.0 110.276 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -87.21 109.24 19.34 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.189 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.582 ' O ' ' N ' ' A' ' 63' ' ' GLY . 1.7 mp -98.99 132.61 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.079 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.659 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 32.19 28.42 0.0 OUTLIER 'General case' 0 C--N 1.343 0.303 0 O-C-N 124.052 0.845 . . . . 0.0 111.0 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 64.43 -25.88 0.1 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 -178.393 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.659 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -47.53 -104.91 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 -178.293 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.22 171.93 9.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 120.747 0.308 . . . . 0.0 110.376 -179.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.2 tt -125.21 154.75 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.346 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 54.1 tp -130.97 116.82 18.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -104.4 115.17 29.9 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.73 172.69 12.35 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.261 -179.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.34 156.28 78.79 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.689 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.29 -21.44 72.63 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 122.794 2.33 . . . . 0.0 111.931 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -92.95 -4.69 52.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.28 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.681 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.7 t60 -72.02 129.98 39.86 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 48.9 mttp -86.86 127.58 35.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 121.51 0.672 . . . . 0.0 110.493 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 93.8 t -105.16 91.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.602 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 15.3 tp -31.01 95.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 O-C-N 123.924 0.765 . . . . 0.0 111.123 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.446 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -98.92 176.93 5.42 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 -177.973 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.478 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 12.8 pt-20 -63.85 -18.35 64.06 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.291 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.73 24.3 13.13 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.432 0.158 . . . . 0.0 110.965 -179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.81 -141.37 15.26 Favored Glycine 0 C--N 1.321 -0.253 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -94.05 127.24 39.74 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.633 -0.283 . . . . 0.0 111.264 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -137.61 129.04 28.08 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.25 141.39 29.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.807 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.11 -38.58 83.41 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.164 -179.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.27 -3.2 4.86 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.678 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -105.49 0.46 26.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.923 0.392 . . . . 0.0 110.179 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 93.3 mt -80.95 127.63 32.78 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.554 0.693 . . . . 0.0 111.245 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.583 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.6 mmt85 -131.64 149.26 52.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.788 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -44.57 86.33 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 123.465 0.478 . . . . 0.0 110.845 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 158.08 -15.85 0.29 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -85.39 130.1 34.67 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 117.209 0.505 . . . . 0.0 110.394 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.478 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 90.1 mtm180 -88.94 131.17 35.26 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.408 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.7 m -114.42 142.69 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.1 131.52 45.98 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.72 -179.141 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.36 160.72 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.408 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.534 ' NH1' ' O ' ' A' ' 101' ' ' GLY . 9.0 tpt180 -104.6 129.63 52.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.59 -179.592 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 42.1 t0 -101.33 123.67 45.78 Favored 'General case' 0 C--O 1.22 -0.49 0 CA-C-O 118.996 -0.526 . . . . 0.0 110.468 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 61.4 t -77.21 -16.72 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 118.474 0.579 . . . . 0.0 111.12 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -69.65 -58.43 3.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.486 ' C ' ' H ' ' A' ' 102' ' ' GLU . 80.8 p -95.86 -12.65 24.88 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.303 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.534 ' O ' ' NH1' ' A' ' 96' ' ' ARG . . . 76.13 -16.05 4.88 Favored Glycine 0 C--O 1.223 -0.583 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.2 mt-10 -80.78 158.05 25.59 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.614 0.245 . . . . 0.0 110.606 -177.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -86.68 141.12 29.16 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.359 0.6 . . . . 0.0 110.059 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.45 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 37.6 ptt180 -139.81 178.65 7.09 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.214 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.446 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.8 m-85 -113.31 147.74 37.03 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.801 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -139.63 160.17 40.48 Favored 'General case' 0 C--O 1.222 -0.366 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.6 m -90.63 153.02 3.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-O 121.015 0.436 . . . . 0.0 110.842 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.41 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.6 mm -70.31 155.39 7.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.094 179.297 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.41 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt180 -106.01 -48.31 3.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.704 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -166.07 145.74 6.19 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.78 134.38 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 mt -102.68 145.22 30.15 Favored Pre-proline 0 N--CA 1.466 0.358 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.367 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -67.16 164.06 31.75 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.408 2.072 . . . . 0.0 111.534 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.3 p -67.03 156.42 36.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 121.388 0.613 . . . . 0.0 110.873 179.782 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 79.3 mtp180 -139.98 -137.35 0.12 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.757 -179.689 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -158.04 131.31 7.58 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.079 0.466 . . . . 0.0 110.254 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.79 173.26 3.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.13 -179.07 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.3 mtp85 -78.39 145.48 35.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 2.9 p -119.5 141.08 49.51 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.155 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.62 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 57.2 m-85 -118.5 168.55 10.56 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.199 -179.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -157.79 120.33 3.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.989 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 67.1 mt -118.04 129.52 55.62 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -87.5 109.63 19.75 Favored 'General case' 0 CA--C 1.516 -0.338 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.6 t -83.0 113.09 21.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.97 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.7 tt0 29.96 -98.38 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 O-C-N 123.775 0.672 . . . . 0.0 111.1 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -123.62 -25.92 4.26 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.271 179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.452 HD13 ' HE ' ' A' ' 43' ' ' ARG . 96.4 mt -84.85 94.55 8.76 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 29.7 m170 -60.6 98.24 0.06 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.682 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 167.1 154.77 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 32' ' ' VAL . 1.2 pt? -162.83 161.49 26.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.796 0.808 . . . . 0.0 112.369 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.3 t -86.2 126.15 40.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.42 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.88 123.78 25.32 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.757 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 54.29 44.66 28.68 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.682 179.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.0 28.1 69.88 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.2 t -132.67 151.3 34.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 CA-C-N 118.155 0.977 . . . . 0.0 108.681 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 89.9 t -108.9 112.34 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 118.232 0.469 . . . . 0.0 110.239 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 138' ' ' HIS . 29.4 m -146.63 136.72 17.51 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-O 119.086 -0.483 . . . . 0.0 110.021 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 37.4 t-80 -31.54 152.08 0.0 OUTLIER 'General case' 0 C--O 1.223 -0.295 0 O-C-N 123.577 0.548 . . . . 0.0 111.36 179.597 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.521 ' OD1' ' CE1' ' A' ' 138' ' ' HIS . 49.2 p30 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.74 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -101.16 143.72 30.91 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.365 -179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -88.18 162.41 16.71 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.637 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.431 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 59.8 tt0 -60.37 142.69 54.54 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 120.786 0.327 . . . . 0.0 110.466 178.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 115.98 -21.66 12.08 Favored Glycine 0 C--N 1.333 0.376 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.0 m -69.01 120.03 14.24 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.11 179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.7 mtp85 -95.15 112.63 24.31 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.91 -179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.6 mt -99.17 113.29 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.621 -179.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -76.48 137.79 39.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 10.2 t0 -106.31 132.64 20.73 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 121.25 -0.18 . . . . 0.0 110.622 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.03 -30.88 10.36 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.187 1.925 . . . . 0.0 112.433 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.533 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 24.9 t -72.98 -53.89 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.868 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.8 p -77.64 -36.79 51.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.136 0.493 . . . . 0.0 110.159 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 6.9 89.01 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 48.1 m -111.55 156.53 21.6 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.769 0.785 . . . . 0.0 109.717 -179.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 27.0 m -80.49 116.77 20.71 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.146 0.498 . . . . 0.0 110.976 -179.154 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -107.32 150.29 26.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.302 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -101.43 132.74 46.86 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.914 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.403 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 2.8 tp -52.69 -40.21 33.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.764 0.316 . . . . 0.0 111.077 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.431 ' OE1' ' OE2' ' A' ' 4' ' ' GLU . 6.9 tt0 -58.51 -36.25 73.51 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.191 0.519 . . . . 0.0 110.483 -179.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -82.18 -38.36 24.76 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.615 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -69.51 -43.76 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 72.5 t -73.82 -46.73 46.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.9 t0 -60.85 -36.4 79.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.019 0.437 . . . . 0.0 110.813 -178.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.36 24.55 31.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtm180 17.22 62.73 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 79.2 mttt -86.57 131.96 44.11 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.869 -176.438 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -75.07 87.21 1.35 Allowed 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.491 1.461 . . . . 0.0 110.41 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 30.1 pt -120.67 -172.01 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.917 0.389 . . . . 0.0 110.491 -179.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.43 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 16.5 m80 -127.21 162.88 25.13 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.747 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.46 171.24 2.44 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.237 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.01 136.33 23.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -115.27 164.33 14.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.67 -0.241 . . . . 0.0 110.414 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.97 50.42 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.36 177.66 4.55 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -72.74 -16.33 61.66 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 122.101 -0.375 . . . . 0.0 111.105 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -78.71 -16.46 57.22 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.336 179.288 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 22.85 40.45 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 33.1 p -102.11 133.84 46.31 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.676 0.274 . . . . 0.0 111.052 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.621 ' CD2' ' N ' ' A' ' 40' ' ' LEU . 2.2 mm? -94.57 133.05 38.63 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 121.069 0.461 . . . . 0.0 111.128 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -143.66 139.87 29.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.569 -179.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.2 144.86 49.99 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.969 -178.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.439 ' HE ' ' HB3' ' A' ' 125' ' ' GLU . 15.7 mtp85 -147.81 138.91 13.36 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.181 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -74.94 158.1 42.64 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.7 2.267 . . . . 0.0 112.831 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.9 t -93.82 131.85 39.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.0 t -119.24 -3.1 9.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.387 -177.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' SER . . . . . 0.442 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.3 OUTLIER -155.06 149.01 25.7 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.612 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.571 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -144.84 131.02 19.48 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.701 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -134.64 144.56 47.92 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.379 0.609 . . . . 0.0 111.899 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.414 ' OD1' ' N ' ' A' ' 51' ' ' GLN . 58.1 t0 -112.76 139.21 48.57 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.224 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.414 ' N ' ' OD1' ' A' ' 50' ' ' ASP . 2.8 mm-40 -105.15 -106.46 0.3 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.328 -1.305 . . . . 0.0 108.854 -178.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -167.24 -156.1 9.59 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 114.457 -1.247 . . . . 0.0 112.354 -177.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -94.58 119.56 33.45 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.077 0.465 . . . . 0.0 111.2 -179.264 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -138.31 164.66 28.7 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.51 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -76.98 140.9 40.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.12 159.61 26.1 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.164 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 32.7 pt -112.58 151.26 14.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.966 0.412 . . . . 0.0 109.991 179.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.16 131.68 10.76 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 32.2 mt -113.16 113.19 25.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 0.0 110.044 -179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 12.6 tpt180 -87.75 107.06 18.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.355 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.552 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -96.69 127.79 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.929 -179.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.597 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 35.02 27.2 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.072 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.546 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 68.22 -26.31 0.26 Allowed Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.597 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -47.51 -104.78 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -178.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.95 171.82 9.02 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.105 0.479 . . . . 0.0 110.726 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.1 tt -125.38 152.06 31.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.34 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.404 ' C ' ' CD2' ' A' ' 67' ' ' LEU . 2.2 tt -127.63 114.91 17.98 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.496 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.3 m95 -102.93 120.04 39.92 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.85 171.09 18.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.158 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 20.4 p -76.91 154.71 83.04 Favored Pre-proline 0 CA--C 1.531 0.232 0 C-N-CA 120.584 -0.447 . . . . 0.0 111.227 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 -24.09 70.8 Favored 'Trans proline' 0 N--CA 1.499 1.849 0 C-N-CA 122.096 1.864 . . . . 0.0 112.211 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -84.75 -8.64 58.76 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.853 0.359 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.573 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.2 t60 -72.8 132.66 43.86 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -90.44 131.73 36.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.183 0.516 . . . . 0.0 110.348 -178.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 92.5 t -107.37 89.59 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.117 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 55.7 tp -29.12 97.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.508 0.505 . . . . 0.0 111.717 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.47 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 38.5 p -98.68 177.21 5.37 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.531 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.548 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.8 pt-20 -66.45 -17.56 64.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.341 -179.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.07 22.22 16.25 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.745 0.307 . . . . 0.0 111.117 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.76 -141.09 15.34 Favored Glycine 0 N--CA 1.462 0.431 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.0 m95 -97.38 130.91 44.47 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.724 -0.238 . . . . 0.0 110.924 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.8 mtp85 -139.7 131.12 26.9 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.43 144.73 20.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.084 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.434 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -63.11 -38.88 92.93 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.576 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.7 -1.75 2.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.622 -0.799 . . . . 0.0 111.428 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 84' ' ' ALA . 72.3 mm-40 -107.49 -2.99 19.9 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.941 0.4 . . . . 0.0 110.184 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 85.7 mt -76.88 125.59 29.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.917 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.558 ' O ' ' N ' ' A' ' 90' ' ' GLY . 7.1 tpt180 -132.1 148.42 52.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.501 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -43.34 88.83 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.932 0.396 . . . . 0.0 110.693 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.97 -16.57 0.45 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -87.21 129.79 34.82 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.728 0.299 . . . . 0.0 110.771 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 87.1 mtm180 -90.19 131.06 36.23 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 121.083 0.468 . . . . 0.0 110.586 -178.617 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.15 143.32 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.391 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.13 131.78 49.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.8 m -129.57 157.81 42.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.368 179.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 71.7 ttt180 -106.98 130.28 54.65 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.458 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.53 121.9 42.34 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.373 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 57.6 t -75.01 -15.44 15.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 O-C-N 122.081 -0.387 . . . . 0.0 110.648 178.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -70.75 -58.03 4.06 Favored 'General case' 0 C--O 1.232 0.154 0 C-N-CA 120.485 -0.486 . . . . 0.0 109.927 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.483 ' C ' ' H ' ' A' ' 102' ' ' GLU . 45.9 p -96.79 -12.56 23.48 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 116.751 -0.204 . . . . 0.0 110.562 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.53 -13.72 6.17 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.483 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.4 mt-10 -81.74 157.1 24.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.972 0.415 . . . . 0.0 111.078 -177.794 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.531 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -78.48 140.4 38.61 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 179.393 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.5 mtm180 -139.55 174.51 10.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.47 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.9 m-85 -115.3 146.09 41.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.222 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 14.8 m -139.78 161.44 37.54 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.033 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.3 t -94.35 154.75 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.667 0.27 . . . . 0.0 110.467 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.403 HG22 HD11 ' A' ' 108' ' ' ILE . 97.0 mt -76.38 149.96 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 178.735 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 74.1 ttt-85 -99.16 -41.77 7.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.613 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -165.74 146.81 6.97 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.9 t -97.63 134.43 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -98.67 148.78 35.02 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.074 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.79 162.03 44.03 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.796 2.331 . . . . 0.0 111.436 179.398 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 2.9 p -62.49 149.38 43.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.981 0.419 . . . . 0.0 110.742 -179.694 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.401 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttt85 -132.3 -141.24 0.21 Allowed 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.663 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . 0.401 ' H ' ' HG2' ' A' ' 115' ' ' ARG . 12.8 tpt180 -157.06 129.98 7.71 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.322 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.19 170.5 5.16 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.087 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -75.57 149.29 38.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.868 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 59.2 p -128.78 142.7 50.9 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.069 0.461 . . . . 0.0 109.764 179.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 9.2 m-85 -120.85 176.4 5.56 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.897 -178.663 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -148.76 153.54 38.31 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.855 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 90.8 mt -140.18 171.14 14.59 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.681 -179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -135.17 106.11 6.61 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' C ' ' A' ' 125' ' ' GLU . 7.9 t -86.89 111.74 22.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.498 ' C ' ' O ' ' A' ' 124' ' ' VAL . 5.2 tp10 20.79 -116.57 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 O-C-N 123.657 0.598 . . . . 0.0 111.685 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -106.74 -26.14 11.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.277 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.9 mt -89.21 69.84 8.26 Favored 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.409 ' O ' HG21 ' A' ' 129' ' ' THR . 28.9 m170 -42.92 104.88 0.04 OUTLIER 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.409 HG21 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.4 139.59 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.675 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -147.14 156.73 43.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 121.509 0.671 . . . . 0.0 112.122 179.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.02 125.35 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.8 126.59 30.9 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.947 -179.011 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.502 ' C ' ' H ' ' A' ' 135' ' ' VAL . 15.4 mm-40 53.81 46.78 25.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.982 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.33 -22.06 0.51 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.502 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.1 t -89.01 152.56 3.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 117.121 0.461 . . . . 0.0 110.66 -179.411 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -110.44 115.55 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.416 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 138' ' ' HIS . 12.3 m -147.31 137.69 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.528 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.573 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 53.1 t-80 -36.52 156.79 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.529 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 16.1 p30 . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.468 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.5 mt -105.12 141.49 36.58 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-O 120.938 0.399 . . . . 0.0 110.543 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -84.35 161.42 20.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.463 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 63.8 tt0 -61.68 146.03 50.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.381 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.57 -16.4 40.81 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 26.3 m -68.47 124.16 22.81 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.789 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.422 ' HE ' HG22 ' A' ' 16' ' ' THR . 81.0 mtp180 -85.03 149.82 25.31 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.162 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . 0.4 HG21 HD12 ' A' ' 8' ' ' ILE . 56.2 mt -134.13 108.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.271 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -76.94 126.7 31.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 178.205 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -96.06 131.2 29.37 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.094 -179.335 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.05 -33.17 4.73 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.33 2.02 . . . . 0.0 111.8 179.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.6 t -73.31 -54.27 16.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.64 -179.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.5 m -75.17 -38.09 61.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.163 0.506 . . . . 0.0 110.065 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.23 7.36 85.18 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.059 -0.816 . . . . 0.0 111.059 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.0 t -106.9 -167.22 1.25 Allowed 'General case' 0 C--N 1.338 0.09 0 CA-C-N 117.652 0.726 . . . . 0.0 109.895 -179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' THR . . . . . 0.422 HG22 ' HE ' ' A' ' 7' ' ' ARG . 93.3 m -115.0 115.28 26.6 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.547 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -100.68 140.75 34.51 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.744 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.7 tpp85 -97.27 127.2 43.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.538 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.426 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 3.1 tp -51.57 -40.3 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.771 -178.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.426 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 14.3 tt0 -53.74 -35.29 61.06 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.961 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.72 -34.13 40.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.695 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.662 ' O ' ' O ' ' A' ' 26' ' ' ARG . 85.1 t -64.83 -45.61 94.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.807 0.337 . . . . 0.0 111.122 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 87.9 t -66.54 -45.16 89.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 O-C-N 121.186 -0.946 . . . . 0.0 111.951 -178.512 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -55.41 -42.41 74.04 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.741 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.75 33.49 3.72 Favored Glycine 0 CA--C 1.529 0.95 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.662 ' O ' ' O ' ' A' ' 22' ' ' VAL . 82.4 mtp180 58.14 -100.58 0.11 Allowed 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.216 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.65 ' C ' ' H ' ' A' ' 29' ' ' ILE . 40.7 mttt 79.94 82.65 0.09 OUTLIER Pre-proline 0 C--N 1.299 -1.604 0 C-N-CA 122.898 0.479 . . . . 0.0 110.388 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.7 ' O ' ' O ' ' A' ' 29' ' ' ILE . 34.1 Cg_exo -59.52 19.76 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.745 2.297 . . . . 0.0 112.577 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.7 ' O ' ' O ' ' A' ' 28' ' ' PRO . 20.3 pt -35.41 -178.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 O-C-N 124.041 0.838 . . . . 0.0 111.189 -178.258 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . . . . . . . . . 56.6 m80 -119.78 163.33 17.63 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 121.43 -0.794 . . . . 0.0 110.891 179.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.1 171.33 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.9 t -91.03 135.13 27.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.47 168.09 9.81 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.82 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.06 142.67 46.39 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.216 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.39 177.93 4.48 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.785 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -70.54 -13.9 62.29 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.92 0.39 . . . . 0.0 110.656 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -81.34 -18.53 45.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.279 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.9 24.91 36.28 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.6 p -103.11 135.18 45.25 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.7 0.286 . . . . 0.0 111.203 178.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 65.4 mt -92.59 131.24 37.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.654 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 8.2 t-160 -142.82 139.82 31.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.483 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.55 141.95 51.82 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.794 -178.51 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.1 mmp_? -143.85 138.21 14.95 Favored Pre-proline 0 CA--C 1.535 0.398 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.8 158.81 31.46 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.86 2.373 . . . . 0.0 112.727 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.32 135.42 36.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.243 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.9 m -124.9 1.05 5.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.543 -178.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.9 t -144.34 133.68 23.16 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.548 0.613 . . . . 0.0 109.792 179.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.531 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -132.68 117.26 17.65 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 178.106 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -141.24 146.55 37.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -89.2 132.83 34.67 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 176.642 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.431 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -92.17 -0.64 57.42 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.186 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.36 -179.6 51.66 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.31 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.8 m -91.74 126.6 36.89 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 120.945 0.402 . . . . 0.0 110.39 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 78.1 mtp85 -150.25 170.48 18.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.798 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -75.45 141.83 43.07 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.041 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -142.44 156.46 18.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 37.7 pt -110.75 154.4 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.978 0.418 . . . . 0.0 110.258 179.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.84 132.73 11.26 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 21.0 mt -115.26 114.29 25.0 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.104 0.478 . . . . 0.0 110.222 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -99.19 122.75 42.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.968 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 63' ' ' GLY . 94.4 mt -111.37 143.56 20.98 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.657 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 29.04 30.62 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 O-C-N 123.831 0.707 . . . . 0.0 111.517 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.629 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 64.1 -20.26 0.09 OUTLIER Glycine 0 CA--C 1.533 1.184 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.672 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.657 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.38 -109.13 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -178.094 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.28 172.89 8.11 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.994 0.426 . . . . 0.0 110.553 -178.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . 0.465 ' O ' ' OE1' ' A' ' 133' ' ' GLU . 97.1 mt -125.89 158.64 34.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.524 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.44 ' N ' ' CG2' ' A' ' 66' ' ' ILE . 42.5 tp -132.68 117.43 17.85 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.582 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -102.79 115.74 31.19 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.13 171.74 14.86 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.368 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 75.9 p -77.09 152.52 82.19 Favored Pre-proline 0 C--N 1.327 -0.394 0 C-N-CA 120.457 -0.497 . . . . 0.0 111.35 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.19 -28.8 81.01 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 122.214 1.943 . . . . 0.0 112.336 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -83.21 -5.66 59.2 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.899 0.38 . . . . 0.0 110.563 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.9 t60 -71.64 130.02 40.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.43 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.64 127.26 34.43 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.236 0.541 . . . . 0.0 110.737 -179.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.5 t -109.6 93.75 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.619 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.117 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 75' ' ' VAL . 6.4 tp -31.42 93.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.677 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 75' ' ' VAL . 0.9 OUTLIER -97.25 177.86 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -178.236 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.2 pt-20 -64.68 -22.84 67.07 Favored 'General case' 0 N--CA 1.448 -0.573 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.262 -179.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -104.59 26.39 9.11 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 121.235 -0.186 . . . . 0.0 110.99 -179.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.426 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.18 -177.88 43.01 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 83.1 m95 -57.01 130.74 47.38 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.977 0.418 . . . . 0.0 110.335 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -146.38 135.26 22.42 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.78 144.5 14.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.917 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.494 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -64.25 -38.76 92.21 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.488 -179.014 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.51 1.02 0.52 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.449 -0.881 . . . . 0.0 111.76 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.494 ' H ' ' C ' ' A' ' 84' ' ' ALA . 19.9 tp10 -107.66 5.43 26.83 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.159 0.504 . . . . 0.0 110.049 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.29 123.19 29.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.226 0.536 . . . . 0.0 111.018 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 90' ' ' GLY . 33.1 mmt180 -132.47 149.76 52.28 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.803 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -48.02 87.89 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.977 0.418 . . . . 0.0 110.657 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -20.0 0.44 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.911 -0.875 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -84.18 129.48 34.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.83 0.348 . . . . 0.0 110.582 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.411 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 88.2 mtm180 -90.68 132.38 35.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.142 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 m -119.93 152.14 22.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.823 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -68.69 137.36 54.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.491 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 30.0 m -137.19 162.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.465 178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.554 HH21 ' CG1' ' A' ' 131' ' ' VAL . 12.2 ttm180 -106.58 129.45 54.51 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.535 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.455 ' O ' ' N ' ' A' ' 101' ' ' GLY . 45.9 t0 -100.97 123.77 45.67 Favored 'General case' 0 C--O 1.224 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.426 178.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -74.24 -15.73 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 118.184 0.447 . . . . 0.0 111.12 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -72.45 -55.18 7.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.01 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.506 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.2 m -99.44 -16.27 18.43 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.735 -0.211 . . . . 0.0 110.632 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' A' ' 97' ' ' ASP . . . 73.84 -14.32 3.67 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.506 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.3 mt-10 -80.71 160.4 24.97 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-O 120.781 0.324 . . . . 0.0 110.64 -177.651 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 7.5 tp -79.03 126.59 30.9 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.027 -179.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 65.8 mtp85 -126.81 168.17 14.8 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.956 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -110.32 142.72 41.58 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.5 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 12.7 m -137.94 158.44 44.33 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.331 178.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.85 152.82 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.737 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.43 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.9 mm -67.46 156.7 6.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.844 179.502 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.43 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 17.2 tpt180 -108.39 -52.33 2.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.01 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -165.56 144.47 6.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 70.0 t -95.09 133.29 36.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.087 0.47 . . . . 0.0 110.037 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.62 127.02 32.39 Favored Pre-proline 0 CA--C 1.536 0.432 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.518 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -47.88 161.64 0.33 Allowed 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 122.206 1.937 . . . . 0.0 112.021 179.274 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 80.6 p -64.99 153.82 39.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.0 0.429 . . . . 0.0 110.699 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.8 ttp180 -134.98 -140.8 0.17 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.586 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.8 mtm-85 -156.79 130.44 8.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.11 172.82 3.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.979 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 22.6 mmt85 -77.51 147.03 36.03 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.971 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 18.5 p -125.13 142.9 51.21 Favored 'General case' 0 CA--C 1.52 -0.181 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -118.93 175.54 5.71 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.821 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -153.47 120.51 5.74 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.553 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 75.1 mt -120.03 123.95 44.7 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.066 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -87.58 118.41 27.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.209 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 50.5 t -90.42 115.23 29.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -58.1 149.28 24.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.715 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.9 tt0 63.85 -69.73 0.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.295 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.82 100.79 11.78 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 110.43 -0.211 . . . . 0.0 110.43 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.414 ' O ' ' OG1' ' A' ' 129' ' ' THR . 72.4 m-70 -69.73 100.28 1.47 Allowed 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.161 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.414 ' OG1' ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 164.15 144.37 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -145.33 157.02 44.13 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.636 0.732 . . . . 0.0 112.011 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . 0.554 ' CG1' HH21 ' A' ' 96' ' ' ARG . 8.9 p -92.35 120.56 41.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.832 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.89 126.45 30.46 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.891 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.535 ' C ' ' H ' ' A' ' 135' ' ' VAL . 8.9 mt-10 59.86 45.33 12.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.222 0.534 . . . . 0.0 110.029 -179.475 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.41 -24.7 0.35 Allowed Glycine 0 CA--C 1.522 0.524 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.28 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.535 ' H ' ' C ' ' A' ' 133' ' ' GLU . 10.3 t -90.25 151.21 3.53 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 O-C-N 122.485 -0.42 . . . . 0.0 110.68 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.89 115.84 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.68 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 138' ' ' HIS . 20.9 m -147.28 136.67 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.434 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 17.9 t-80 -34.99 154.36 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.089 0.403 . . . . 0.0 112.089 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.277 -179.861 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.6 mt -108.97 137.53 46.74 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.341 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 161.46 23.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.687 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -62.36 145.91 52.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.092 179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.56 -17.65 33.3 Favored Glycine 0 C--N 1.337 0.63 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 20.8 m -66.89 122.4 17.63 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.224 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -98.35 115.72 29.06 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.143 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 3.6 mt -102.59 117.33 47.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.734 -179.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -75.84 133.23 40.66 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASP . . . . . 0.506 ' OD2' ' O ' ' A' ' 30' ' ' HIS . 4.1 t70 -104.0 134.93 19.45 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.526 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.52 -32.51 3.71 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.512 2.142 . . . . 0.0 112.321 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.07 -59.6 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.417 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.425 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 1.9 t -76.9 -34.21 57.74 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.97 12.84 76.11 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 75.5 m -116.94 161.6 19.1 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 117.977 0.888 . . . . 0.0 109.753 -179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 43.0 m -79.71 115.83 19.54 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.278 0.561 . . . . 0.0 110.713 -179.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 24.8 m-70 -101.84 147.07 26.94 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.206 -179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -101.23 125.53 47.87 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.004 178.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -53.46 -39.32 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.265 -179.234 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -58.55 -33.72 70.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 68.4 t0 -83.97 -37.22 22.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.596 179.611 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 78.4 t -66.39 -42.74 91.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.27 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 75.9 t -69.51 -44.81 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 121.093 -0.243 . . . . 0.0 111.428 -179.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -54.15 -36.32 63.19 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 121.036 -0.266 . . . . 0.0 110.761 -178.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -117.25 33.31 5.07 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER 12.42 74.95 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 124.056 0.504 . . . . 0.0 109.9 179.859 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LYS . . . . . 0.68 ' C ' ' H ' ' A' ' 29' ' ' ILE . 64.0 mttt -91.29 117.74 68.04 Favored Pre-proline 0 N--CA 1.442 -0.862 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -178.201 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.68 ' O ' ' O ' ' A' ' 29' ' ' ILE . 52.5 Cg_exo -52.67 7.54 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.964 2.442 . . . . 0.0 113.005 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.68 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.3 pp -37.05 -178.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 O-C-N 123.949 0.781 . . . . 0.0 110.722 -178.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' HIS . . . . . 0.506 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 2.4 m80 -126.49 168.14 14.65 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 121.404 -0.81 . . . . 0.0 111.247 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.1 m -148.12 171.78 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.264 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 62.9 t -88.11 131.11 36.53 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.641 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -109.07 149.72 28.86 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.055 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.69 140.79 50.1 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.933 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.69 174.31 5.99 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.771 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -68.42 -14.62 63.13 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.651 0.263 . . . . 0.0 110.648 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.43 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 38.4 p30 -81.79 -15.71 53.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.488 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 87.04 22.64 44.45 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.42 ' OG1' ' OD1' ' A' ' 37' ' ' ASP . 22.0 p -102.87 137.29 41.27 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.622 0.249 . . . . 0.0 111.108 178.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.7 mt -94.79 130.18 41.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.884 0.374 . . . . 0.0 110.47 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.48 138.7 33.01 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.404 -179.073 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.74 139.9 53.4 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.609 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.7 mmt-85 -143.38 137.97 15.1 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.897 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.73 156.34 35.37 Favored 'Trans proline' 0 C--N 1.316 -1.177 0 C-N-CA 122.783 2.322 . . . . 0.0 112.969 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.9 t -93.86 130.75 42.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -118.11 -5.02 11.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.527 -178.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.1 t -145.97 134.73 22.35 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.203 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' TRP . . . . . 0.557 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -134.02 116.28 15.32 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.359 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.514 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 47.5 m-85 -140.94 150.71 43.48 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.063 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -93.54 133.16 37.13 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 176.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.642 HE21 ' CB ' ' A' ' 121' ' ' ASP . 26.1 mm-40 -92.17 -0.35 57.43 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.202 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.5 179.73 51.48 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 32.0 m -91.41 123.07 34.55 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -143.79 169.97 16.76 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.915 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -76.99 142.71 39.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.971 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.7 m -147.15 157.59 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.113 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 45.9 pt -108.12 159.05 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.238 179.55 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.83 139.55 15.75 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.7 mt -118.53 112.04 19.39 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.148 0.499 . . . . 0.0 109.689 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.695 ' NE ' ' HE ' ' A' ' 109' ' ' ARG . 56.8 ttp180 -98.94 126.17 44.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.001 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.516 ' CD1' ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -106.28 160.79 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.448 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.522 ' O ' ' N ' ' A' ' 64' ' ' GLY . . . -34.84 92.85 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.303 0.377 . . . . 0.0 111.256 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 40.46 20.84 0.03 OUTLIER Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.774 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 62' ' ' ALA . . . -89.61 -149.1 20.59 Favored Glycine 0 N--CA 1.439 -1.15 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 -179.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.17 169.21 16.05 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.069 -0.565 . . . . 0.0 110.556 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 93.5 mt -120.89 135.55 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.222 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.7 tp -112.53 111.0 21.51 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.798 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' TRP . . . . . 0.515 ' CE3' ' NH2' ' A' ' 115' ' ' ARG . 97.9 m95 -103.73 105.71 16.0 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.25 172.47 12.87 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.549 -179.059 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -72.76 156.24 90.11 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.759 -179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 85' ' ' GLY . 31.4 Cg_endo -64.3 -19.36 65.59 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.644 2.229 . . . . 0.0 111.866 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 39.6 p-10 -90.99 -4.98 56.0 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' HIS . . . . . 0.534 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.6 t60 -71.88 132.09 43.91 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.19 124.65 32.09 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.442 0.639 . . . . 0.0 111.386 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.8 t -99.03 143.01 13.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.159 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.4 tp -82.83 89.87 6.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.699 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.473 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 30.0 p -97.86 176.25 5.86 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -67.39 -20.03 65.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.117 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -101.73 24.35 9.98 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-O 120.656 0.265 . . . . 0.0 110.825 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.09 -144.71 17.5 Favored Glycine 0 C--N 1.332 0.306 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -86.88 121.88 29.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.732 0.301 . . . . 0.0 111.289 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.7 mmt85 -122.56 125.8 46.45 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.089 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ALA . . . . . 0.425 ' C ' ' H ' ' A' ' 85' ' ' GLY . . . -68.54 129.84 41.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.507 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -66.83 -0.03 2.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.799 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 83' ' ' ALA . . . -75.55 -13.13 83.22 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -136.97 30.84 2.74 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.914 0.387 . . . . 0.0 111.378 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 10.9 mt -82.88 131.81 35.18 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.403 0.62 . . . . 0.0 111.007 179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 83.2 mmt-85 -133.62 148.38 51.55 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.082 -0.963 . . . . 0.0 111.346 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -46.37 97.92 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.547 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 158.48 -16.52 0.28 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -88.29 129.91 35.25 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -88.57 129.74 35.41 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.36 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.9 m -108.9 141.86 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.046 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.08 120.71 18.06 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.722 -179.167 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -121.85 131.28 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.945 0.402 . . . . 0.0 110.07 179.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -67.73 132.05 46.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.848 -179.413 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 48.7 t0 -101.77 122.9 44.81 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 119.297 -0.382 . . . . 0.0 110.443 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.5 p -75.22 -16.87 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 CA-C-N 118.427 0.558 . . . . 0.0 111.323 179.101 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.75 -58.49 3.59 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.436 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' THR . . . . . 0.472 ' C ' ' H ' ' A' ' 102' ' ' GLU . 48.8 p -98.58 -14.89 19.72 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.456 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.37 -17.22 4.26 Favored Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.472 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.4 mt-10 -78.38 157.75 28.97 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -177.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.1 tp -75.06 135.18 41.24 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.314 -179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 32.5 ptt180 -135.04 167.46 20.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.216 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . 0.473 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.0 m-85 -117.12 152.83 33.9 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.029 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.1 m -146.2 165.21 29.85 Favored 'General case' 0 CA--C 1.516 -0.348 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.8 t -89.2 150.37 3.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 120.775 0.321 . . . . 0.0 110.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ILE . . . . . 0.491 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.2 mm -69.83 160.75 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.211 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.695 ' HE ' ' NE ' ' A' ' 60' ' ' ARG . 12.6 ttp85 -107.67 -49.32 3.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.533 179.252 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLU . . . . . 0.527 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 74.8 tt0 -166.78 146.66 5.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -94.09 134.58 31.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.238 0.542 . . . . 0.0 110.019 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 3.0 mm? -97.86 145.48 29.82 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.157 -179.208 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.47 160.18 50.78 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 122.568 2.179 . . . . 0.0 111.468 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -64.88 154.12 38.22 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.146 0.498 . . . . 0.0 110.655 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.515 ' NH2' ' CE3' ' A' ' 68' ' ' TRP . 74.4 mtm180 -140.95 -138.82 0.12 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.657 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -155.58 132.01 10.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.236 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -171.13 173.03 5.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.764 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -77.77 140.24 39.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.779 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 3.1 p -114.98 140.46 49.01 Favored 'General case' 0 CA--C 1.522 -0.117 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -119.59 171.59 8.26 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.24 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.642 ' CB ' HE21 ' A' ' 51' ' ' GLN . 43.6 p-10 -160.72 120.31 2.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.089 179.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 69.9 mt -117.38 131.67 56.73 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 120.72 0.295 . . . . 0.0 110.63 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -87.71 110.18 20.25 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.568 ' O ' ' N ' ' A' ' 126' ' ' GLU . 21.6 t -81.04 109.49 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.467 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.074 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.488 ' C ' ' O ' ' A' ' 124' ' ' VAL . 1.6 tm-20 24.14 -85.53 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.815 0.697 . . . . 0.0 111.435 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . 0.568 ' N ' ' O ' ' A' ' 124' ' ' VAL . 79.8 tt0 -136.87 -36.44 0.68 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.157 -0.928 . . . . 0.0 111.141 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.481 ' O ' ' N ' ' A' ' 129' ' ' THR . 74.0 mt -72.4 67.69 0.74 Allowed 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.019 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' HIS . . . . . 0.454 ' O ' HG22 ' A' ' 129' ' ' THR . 35.4 m80 -40.82 95.92 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' THR . . . . . 0.598 ' C ' HD22 ' A' ' 139' ' ' ASN . 0.0 OUTLIER 166.5 136.36 0.01 OUTLIER 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.442 ' C ' ' CD1' ' A' ' 130' ' ' LEU . 3.5 pp -144.99 154.37 42.47 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.449 0.642 . . . . 0.0 111.679 -178.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.2 t -87.81 123.99 40.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 135' ' ' VAL . . . -133.51 142.22 48.13 Favored 'General case' 0 C--O 1.227 -0.106 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.444 -178.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.55 ' C ' ' H ' ' A' ' 135' ' ' VAL . 71.1 mm-40 40.23 49.79 2.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.196 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.45 -25.32 0.27 Allowed Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.446 -0.662 . . . . 0.0 111.446 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.55 ' H ' ' C ' ' A' ' 133' ' ' GLU . 2.7 t -89.12 152.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.394 0 O-C-N 122.48 -0.423 . . . . 0.0 110.689 -179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -109.87 117.64 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.437 179.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 138' ' ' HIS . 20.5 m -149.87 141.01 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.531 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.492 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 54.3 t-80 -31.42 150.31 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.173 0 O-C-N 123.209 0.318 . . . . 0.0 111.741 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.598 HD22 ' C ' ' A' ' 129' ' ' THR . 1.5 m120 . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 118.056 -0.973 . . . . 0.0 110.628 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.543 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.1 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.3 mt -99.47 141.8 31.79 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.356 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.66 162.46 17.1 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.758 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 20' ' ' GLU . 41.3 tt0 -64.51 140.77 58.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.443 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.91 -17.72 29.64 Favored Glycine 0 C--N 1.338 0.693 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.5 m -70.63 122.81 20.48 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.607 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.6 mtp180 -82.65 147.99 28.21 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.043 0.449 . . . . 0.0 110.429 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 84.7 mt -133.94 107.67 10.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.26 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -77.97 129.69 35.61 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -101.49 132.02 22.3 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.45 -31.2 9.25 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.857 1.705 . . . . 0.0 112.449 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.2 t -69.99 -53.61 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.049 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -80.19 -39.76 28.59 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.858 0.361 . . . . 0.0 110.24 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.61 74.61 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.416 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -105.8 -168.32 1.43 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 117.363 0.582 . . . . 0.0 109.855 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.607 HG21 ' HE ' ' A' ' 7' ' ' ARG . 72.8 m -117.34 119.79 36.2 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.346 0.593 . . . . 0.0 110.397 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 63.9 m170 -109.75 148.07 32.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.089 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -98.87 130.24 45.27 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.502 HG23 ' N ' ' A' ' 20' ' ' GLU . 5.6 tp -51.93 -40.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.632 0.253 . . . . 0.0 111.109 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.502 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.6 pt-20 -58.87 -34.57 71.77 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.113 0.482 . . . . 0.0 110.901 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -84.51 -37.49 21.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.432 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 75.4 t -68.09 -41.54 84.39 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.937 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.67 HG22 HD21 ' A' ' 122' ' ' LEU . 53.5 t -77.42 -46.33 28.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.2 t0 -55.65 -35.48 65.99 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 120.764 0.316 . . . . 0.0 110.829 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.564 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.77 26.49 14.13 Favored Glycine 0 N--CA 1.46 0.238 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.564 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.2 OUTLIER 15.37 68.77 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.225 0 O-C-N 124.042 0.496 . . . . 0.0 109.71 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 29' ' ' ILE . 83.4 mttt -83.8 114.46 54.05 Favored Pre-proline 0 N--CA 1.45 -0.449 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.87 -175.384 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -57.16 83.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 CA-C-N 119.78 0.957 . . . . 0.0 111.294 178.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.47 ' N ' ' O ' ' A' ' 27' ' ' LYS . 49.1 pt -119.11 -170.12 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 CA-C-O 121.063 0.459 . . . . 0.0 110.973 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.449 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 67.6 m80 -126.37 161.66 27.34 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.432 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.05 170.56 3.9 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.357 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 97.3 t -88.86 133.68 30.44 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.36 155.64 24.84 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.549 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -127.22 145.71 50.67 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.395 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.73 -176.55 2.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.428 ' H ' ' HD2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -71.63 -12.75 61.5 Favored 'General case' 0 CA--C 1.523 -0.092 0 CA-C-O 120.868 0.366 . . . . 0.0 110.686 179.561 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.491 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 32.3 p30 -76.28 -20.2 57.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.565 179.513 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.491 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 93.95 -8.25 73.34 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.457 ' HG1' ' CE1' ' A' ' 41' ' ' HIS . 33.6 p -82.31 151.09 26.88 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 121.946 0.879 . . . . 0.0 111.783 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.0 mt -100.94 132.21 46.45 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.258 -1.337 . . . . 0.0 111.877 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' HIS . . . . . 0.457 ' CE1' ' HG1' ' A' ' 39' ' ' THR . 5.7 m80 -137.88 137.39 38.02 Favored 'General case' 0 C--O 1.221 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.375 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.62 143.69 49.7 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.454 -178.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.537 HH21 ' CD ' ' A' ' 125' ' ' GLU . 8.9 mtp85 -149.21 138.61 12.7 Favored Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.991 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -74.85 157.17 43.55 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.239 1.959 . . . . 0.0 112.677 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 99.1 t -96.24 136.67 26.38 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.9 m -123.7 1.39 5.69 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.618 0 CA-C-O 119.202 -0.428 . . . . 0.0 111.856 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.5 p -151.04 144.87 25.13 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 118.987 0.812 . . . . 0.0 109.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.478 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.1 OUTLIER -142.12 123.07 14.47 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.373 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -141.57 145.32 34.93 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -86.88 136.55 32.92 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.437 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -99.14 1.84 45.4 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.806 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.6 -175.44 53.41 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.375 -0.917 . . . . 0.0 111.613 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 70.0 m -95.14 126.66 40.62 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -148.21 168.3 22.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.433 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -73.1 138.36 45.78 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.607 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -139.22 155.11 25.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-O 120.752 0.31 . . . . 0.0 110.181 -179.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.791 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.0 pt -110.45 153.17 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 110.179 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.28 125.47 7.7 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.5 mt -106.93 112.46 25.44 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 56.8 ttp180 -96.17 123.36 39.77 Favored 'General case' 0 C--O 1.219 -0.521 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.416 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 24.1 mm . . . . . 0 N--CA 1.468 0.427 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 -179.556 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.315 0 CA-C-O 121.543 0.687 . . . . 0.0 109.213 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -132.01 154.67 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.408 -178.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.2 tp -143.69 125.84 15.5 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -105.87 123.52 48.1 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.85 170.77 17.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 6.5 p -78.49 156.7 78.16 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.982 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -59.25 -22.92 67.32 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 121.872 1.715 . . . . 0.0 111.995 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -87.09 -8.9 56.59 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.743 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 8.2 t60 -68.7 126.76 30.71 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.751 ' H ' ' CE1' ' A' ' 138' ' ' HIS . 69.0 mttm -86.22 130.88 34.37 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 121.509 0.671 . . . . 0.0 111.418 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -104.66 139.27 26.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.83 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 59.6 tp -77.81 95.96 4.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.955 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.2 p -99.32 178.04 5.01 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.698 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.7 pm0 -64.91 -16.93 63.87 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.556 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.456 ' HB2' ' HE ' ' A' ' 82' ' ' ARG . 77.3 m-85 -109.73 26.24 10.88 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.08 -138.38 13.87 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -98.72 132.44 44.09 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.451 -0.374 . . . . 0.0 110.746 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.456 ' HE ' ' HB2' ' A' ' 79' ' ' TYR . 90.8 mtt-85 -140.3 132.41 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.266 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.36 144.81 23.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.902 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.791 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.45 -38.24 86.47 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.569 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.07 -2.12 6.29 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 120.537 -0.84 . . . . 0.0 111.713 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.67 25.69 11.5 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.95 0.405 . . . . 0.0 110.433 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 77.5 mt -110.18 130.34 55.56 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.608 0.718 . . . . 0.0 111.126 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.522 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.1 mmt180 -130.4 147.53 52.11 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.744 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -45.01 90.35 0.0 OUTLIER 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.888 0.375 . . . . 0.0 110.454 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -13.78 0.33 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -84.48 130.16 34.78 Favored 'General case' 0 C--O 1.225 -0.223 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.43 ' O ' ' OE1' ' A' ' 78' ' ' GLU . 89.1 mtm180 -90.26 136.72 32.88 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 -178.219 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.2 m -125.24 151.52 31.11 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.209 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.494 ' HB1' ' CD1' ' A' ' 103' ' ' LEU . . . -84.92 128.59 34.69 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.457 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.3 135.14 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.898 0.38 . . . . 0.0 110.441 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -66.74 133.66 50.62 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.055 0.455 . . . . 0.0 111.344 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -98.54 122.67 42.03 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-N 115.872 -0.603 . . . . 0.0 109.562 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.0 t -75.02 -17.23 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 118.401 0.546 . . . . 0.0 110.649 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.77 -59.25 3.06 Favored 'General case' 0 CA--C 1.522 -0.096 0 C-N-CA 120.197 -0.601 . . . . 0.0 109.964 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.494 ' C ' ' H ' ' A' ' 102' ' ' GLU . 73.6 p -93.88 -11.34 31.31 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 110.435 -0.209 . . . . 0.0 110.435 179.47 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 72.89 -12.04 4.12 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.494 ' H ' ' C ' ' A' ' 100' ' ' THR . 41.8 mt-10 -88.49 164.57 15.39 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 121.036 0.446 . . . . 0.0 111.24 -177.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.513 HD13 ' H ' ' A' ' 104' ' ' ARG . 0.2 OUTLIER -71.12 142.06 50.77 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.589 -179.459 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.513 ' H ' HD13 ' A' ' 103' ' ' LEU . 6.0 ptt85 -136.89 158.76 43.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.611 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.698 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -112.32 135.8 52.56 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.926 -179.746 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.481 ' OG ' ' NH2' ' A' ' 104' ' ' ARG . 6.7 m -142.55 161.84 37.01 Favored 'General case' 0 C--N 1.344 0.329 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.1 p -94.43 156.48 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 111.33 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.459 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.3 mt -71.1 159.35 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.459 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 43.2 ttm180 -106.57 -46.36 4.02 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.759 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 81.4 tt0 -165.01 143.72 6.55 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.424 ' C ' HD22 ' A' ' 112' ' ' LEU . 10.7 p -93.95 133.14 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.433 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.3 mm? -101.11 125.4 38.24 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-O 119.674 -0.203 . . . . 0.0 110.977 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.39 165.93 0.1 Allowed 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.225 1.95 . . . . 0.0 112.0 179.065 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 19.9 p -66.69 151.47 47.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 121.276 0.56 . . . . 0.0 110.776 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -133.06 -142.05 0.21 Allowed 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.678 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.5 mtt85 -156.79 130.93 8.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.285 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.53 169.83 5.03 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.943 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -72.89 148.25 44.56 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.241 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 42.0 p -131.1 143.36 50.6 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.49 ' HB3' HG21 ' A' ' 23' ' ' VAL . 68.3 m-85 -115.65 174.55 5.96 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.753 -179.04 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -145.28 137.48 25.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.109 -0.95 . . . . 0.0 111.074 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.67 HD21 HG22 ' A' ' 23' ' ' VAL . 97.2 mt -130.23 170.8 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.449 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -138.01 106.99 5.98 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.926 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 125' ' ' GLU . 8.5 t -86.04 115.14 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.863 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.537 ' CD ' HH21 ' A' ' 43' ' ' ARG . 81.4 tt0 18.52 -95.65 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.729 0 O-C-N 123.762 0.664 . . . . 0.0 112.327 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -128.03 -33.11 2.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.154 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.439 ' O ' ' N ' ' A' ' 129' ' ' THR . 54.3 mt -78.02 67.93 3.96 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -42.7 97.81 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.229 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 175.14 143.48 0.06 Allowed 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.82 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.634 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.9 pp -151.47 154.5 36.68 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.415 0.626 . . . . 0.0 111.676 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.7 t -89.76 123.54 42.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.872 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.86 122.87 22.62 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.137 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.8 mm-40 55.83 43.54 27.48 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.021 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.51 -15.81 0.8 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.176 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.7 t -90.53 146.87 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 117.268 0.534 . . . . 0.0 110.456 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.19 115.12 47.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.792 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.416 ' O ' ' C ' ' A' ' 138' ' ' HIS . 21.6 m -147.65 142.19 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.226 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.751 ' CE1' ' H ' ' A' ' 74' ' ' LYS . 0.3 OUTLIER -37.37 153.48 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.206 0.457 . . . . 0.0 111.681 -179.816 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.9 p30 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.382 179.745 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.431 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 24.5 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -109.34 136.51 48.67 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.845 0.355 . . . . 0.0 110.527 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.04 162.66 21.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.518 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 44.6 tt0 -63.27 143.18 58.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.961 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.83 -20.83 23.96 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.619 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.3 m -67.48 123.56 20.74 Favored 'General case' 0 C--N 1.331 -0.218 0 O-C-N 122.768 -0.254 . . . . 0.0 111.244 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.817 ' HE ' HG21 ' A' ' 16' ' ' THR . 72.6 mtp180 -82.72 147.63 28.35 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.781 0.324 . . . . 0.0 110.162 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -134.79 107.3 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.497 179.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -76.95 129.8 36.64 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' A' ' 10' ' ' ASP . 50.8 t0 -109.91 110.24 59.06 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-O 119.53 -0.272 . . . . 0.0 110.377 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_exo -51.96 -36.8 65.84 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 121.765 1.643 . . . . 0.0 112.561 178.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.2 t -62.11 -58.25 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.037 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 24.8 p -77.49 -33.93 54.35 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.365 0.602 . . . . 0.0 109.834 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.31 6.47 89.27 Favored Glycine 0 N--CA 1.449 -0.465 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.175 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.494 HG22 ' N ' ' A' ' 16' ' ' THR . 50.6 m -113.83 159.91 19.3 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 117.719 0.759 . . . . 0.0 109.926 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.817 HG21 ' HE ' ' A' ' 7' ' ' ARG . 13.9 m -80.4 117.05 20.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.17 0.51 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -98.94 139.92 33.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.041 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -95.66 127.47 41.71 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.791 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.561 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.2 tp -53.98 -40.8 46.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.861 0.362 . . . . 0.0 111.429 -178.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.561 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.7 tt0 -58.88 -36.64 74.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.135 0.493 . . . . 0.0 110.729 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -81.5 -36.64 29.0 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.567 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.6 t -66.96 -41.71 87.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.22 -43.56 57.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -58.85 -37.87 77.46 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 121.084 -0.247 . . . . 0.0 111.3 -177.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.87 29.54 10.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.512 ' C ' ' O ' ' A' ' 25' ' ' GLY . 96.3 mtt-85 22.61 56.49 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.088 0 CA-C-O 121.27 0.557 . . . . 0.0 110.266 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.626 ' C ' ' H ' ' A' ' 29' ' ' ILE . 31.1 mmtt -75.41 115.68 47.67 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.917 -177.45 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.558 ' O ' ' O ' ' A' ' 29' ' ' ILE . 32.6 Cg_exo -58.1 12.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.505 2.191 0 C-N-CA 122.001 1.801 . . . . 0.0 112.843 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.626 ' H ' ' C ' ' A' ' 27' ' ' LYS . 2.1 pp -40.23 175.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.713 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.478 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 2.8 m80 -121.71 167.51 12.86 Favored 'General case' 0 N--CA 1.467 0.401 0 O-C-N 122.22 -0.3 . . . . 0.0 110.611 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -148.28 170.08 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.1 t -87.59 137.2 21.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 121.896 -0.502 . . . . 0.0 109.772 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.78 168.03 9.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.138 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.22 140.23 37.69 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.29 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.57 176.02 5.21 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -70.71 -14.07 62.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.803 0.335 . . . . 0.0 110.837 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -79.37 -17.64 54.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.38 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.81 22.1 40.54 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.2 p -101.6 136.64 41.1 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.076 178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.94 134.1 42.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.848 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -144.4 141.66 29.81 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.781 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.17 141.82 52.57 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.533 -178.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -142.39 140.67 19.31 Favored Pre-proline 0 CA--C 1.542 0.653 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.272 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 157.57 30.53 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.771 2.314 . . . . 0.0 112.52 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -102.96 138.25 27.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.7 m -128.3 4.67 3.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.046 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.431 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 1.2 t -151.91 145.11 24.64 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 119.05 0.841 . . . . 0.0 109.19 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.86 124.66 15.06 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 178.703 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -141.62 146.27 36.02 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -88.68 133.08 34.32 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 176.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.431 ' OE1' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -92.8 -0.23 57.3 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.6 177.44 51.16 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.307 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 39.2 m -89.43 123.85 33.94 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.025 0.44 . . . . 0.0 109.974 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -148.63 173.7 12.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.257 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -77.1 140.86 40.37 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.259 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 m -139.35 154.87 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.558 HD11 ' CB ' ' A' ' 84' ' ' ALA . 30.8 pt -112.05 151.34 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.024 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.88 144.82 15.9 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 27.4 mt -123.33 112.93 18.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.322 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.426 ' C ' HD12 ' A' ' 61' ' ' ILE . 67.1 ttt180 -86.98 107.49 18.42 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.36 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.755 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.8 mp . . . . . 0 N--CA 1.467 0.387 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.936 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.129 0 CA-C-O 120.832 0.349 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.0 mt -125.48 157.29 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.392 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.501 ' N ' HG22 ' A' ' 66' ' ' ILE . 49.8 tp -132.74 116.62 16.81 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.064 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.3 m95 -102.8 125.42 49.54 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.76 171.52 17.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.214 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.21 156.9 73.8 Favored Pre-proline 0 CA--C 1.533 0.323 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.586 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.74 -19.98 69.8 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.562 2.175 . . . . 0.0 112.066 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -93.26 -7.04 46.18 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.031 0.444 . . . . 0.0 110.189 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 9.6 t60 -73.42 131.36 41.74 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -88.04 130.63 34.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 110.271 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' THR . 95.2 t -108.95 90.63 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.847 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' VAL . 49.0 tp -31.21 99.12 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 O-C-N 123.244 0.34 . . . . 0.0 111.707 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 75' ' ' VAL . 61.4 p -98.22 176.08 5.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -63.37 -19.04 64.31 Favored 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.166 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 -106.86 23.77 13.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.428 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 77' ' ' THR . . . 105.55 -141.47 15.38 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 96.8 m95 -96.11 130.31 43.18 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.732 -0.234 . . . . 0.0 110.766 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -142.35 132.32 24.44 Favored 'General case' 0 C--O 1.232 0.157 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.65 143.8 19.37 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.398 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.558 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.52 -37.91 89.13 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.488 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.5 0.09 3.19 Favored Glycine 0 CA--C 1.529 0.965 0 C-N-CA 120.44 -0.886 . . . . 0.0 111.833 -179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -109.19 -2.28 18.11 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.989 0.423 . . . . 0.0 110.426 179.511 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 83.7 mt -74.67 129.52 37.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.472 ' O ' ' N ' ' A' ' 90' ' ' GLY . 36.2 mmt180 -133.12 147.99 52.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.435 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -46.37 92.59 0.01 OUTLIER 'General case' 0 C--O 1.233 0.192 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.474 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.85 -20.38 0.78 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -83.63 130.12 34.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.805 0.336 . . . . 0.0 110.694 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.406 ' NH2' ' O ' ' A' ' 105' ' ' TYR . 79.1 mtp85 -91.18 138.66 31.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.518 -179.073 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 33.2 m -126.36 151.46 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.285 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.14 134.98 52.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.443 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.632 HG21 ' OG ' ' A' ' 106' ' ' SER . 27.3 m -133.77 158.45 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.555 179.345 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -104.64 127.95 52.53 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.149 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -100.06 124.51 45.52 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.247 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 12.5 p -75.2 -15.46 15.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.352 0.524 . . . . 0.0 111.087 178.232 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -69.55 -58.3 4.13 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.224 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.429 ' C ' ' H ' ' A' ' 102' ' ' GLU . 15.6 p -99.18 -12.06 20.79 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.739 -0.21 . . . . 0.0 110.473 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.77 -13.26 8.85 Favored Glycine 0 C--N 1.329 0.187 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.429 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.4 mt-10 -82.05 155.32 25.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.975 0.417 . . . . 0.0 111.222 -177.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.576 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -75.74 139.94 42.13 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.195 179.41 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.62 ' O ' HG22 ' A' ' 95' ' ' VAL . 98.8 mtt180 -139.17 169.61 17.46 Favored 'General case' 0 CA--C 1.51 -0.589 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.406 ' O ' ' NH2' ' A' ' 92' ' ' ARG . 8.2 m-30 -108.1 141.88 39.13 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.197 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.632 ' OG ' HG21 ' A' ' 95' ' ' VAL . 4.1 m -136.99 159.59 41.42 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.196 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 108' ' ' ILE . 85.0 t -98.32 156.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 107' ' ' VAL . 29.4 mm -84.66 131.33 34.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.184 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.3 mmm180 -82.44 -34.13 28.29 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.765 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -166.21 145.41 5.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.408 ' C ' HD22 ' A' ' 112' ' ' LEU . 0.8 OUTLIER -95.38 135.42 29.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.441 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.444 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.4 mm? -98.35 123.92 48.73 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 120.626 -0.429 . . . . 0.0 111.149 -179.471 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.5 162.91 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.039 1.826 . . . . 0.0 111.711 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 57' ' ' ILE . 74.7 p -65.35 152.95 42.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 ttt180 -135.18 -139.15 0.17 Allowed 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.691 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 13.0 tpt180 -157.99 129.77 6.86 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.402 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.39 171.09 4.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.179 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.518 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 88.1 mtm180 -74.68 146.97 41.9 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.62 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 6.6 p -126.22 143.3 51.19 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -115.6 173.1 6.71 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.819 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -152.33 127.02 9.48 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.528 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.415 HD11 HD12 ' A' ' 19' ' ' ILE . 87.3 mt -116.24 171.9 7.53 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.233 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -134.95 107.2 7.21 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.352 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 129' ' ' THR . 20.9 t -91.94 119.86 40.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -60.87 144.42 52.86 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.76 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 69.21 -67.78 0.21 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.662 179.016 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.36 89.7 4.54 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 116.695 -0.23 . . . . 0.0 110.838 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.624 ' C ' HG22 ' A' ' 129' ' ' THR . 97.6 m-70 -62.08 96.83 0.08 Allowed 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.624 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 165.4 155.06 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 178.584 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.9 pp -150.94 151.84 32.73 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.307 -0.557 . . . . 0.0 111.544 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 135' ' ' VAL . 40.0 t -93.14 127.69 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.151 -179.405 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.49 133.54 42.35 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.006 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.535 ' O ' HG23 ' A' ' 135' ' ' VAL . 81.1 mm-40 55.29 42.31 30.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.531 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.0 27.47 67.19 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.623 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 133' ' ' GLU . 23.3 t -130.17 150.75 34.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 118.135 0.968 . . . . 0.0 108.391 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 3.5 t -105.12 111.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-N 118.329 0.513 . . . . 0.0 111.038 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' ' C ' ' A' ' 138' ' ' HIS . 16.9 m -145.88 134.67 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.516 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 51.8 t-80 -34.42 148.06 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.676 0.274 . . . . 0.0 111.649 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.477 ' OD1' ' NE2' ' A' ' 138' ' ' HIS . 28.2 p-10 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.369 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 75.0 mt -96.5 143.63 27.33 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.316 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.3 163.91 16.57 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.701 0.286 . . . . 0.0 110.841 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.433 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 48.3 tt0 -64.78 142.12 58.54 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.523 178.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.66 -22.06 17.67 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.568 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.5 m -66.68 121.67 15.92 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.59 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.4 mtt85 -80.57 147.17 30.9 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 6.4 mm -134.77 106.3 7.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.014 0.435 . . . . 0.0 111.212 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -77.82 130.46 36.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -111.68 110.46 54.97 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.713 -0.221 . . . . 0.0 110.547 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.08 -35.58 62.42 Favored 'Trans proline' 0 N--CA 1.497 1.686 0 C-N-CA 122.171 1.914 . . . . 0.0 112.409 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 56.5 t -61.88 -57.8 10.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.767 -178.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 43.5 p -79.53 -36.63 38.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.305 0.574 . . . . 0.0 109.905 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.78 6.9 84.87 Favored Glycine 0 N--CA 1.451 -0.362 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.472 HG22 ' N ' ' A' ' 16' ' ' THR . 52.4 m -113.78 157.97 21.58 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 117.769 0.784 . . . . 0.0 109.918 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.472 ' N ' HG22 ' A' ' 15' ' ' THR . 30.6 m -80.47 117.71 21.44 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.121 0.486 . . . . 0.0 110.87 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -100.52 143.51 30.62 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.011 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -97.34 128.22 43.97 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.222 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.536 HG23 ' N ' ' A' ' 20' ' ' GLU . 8.3 tp -52.9 -40.8 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.252 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.3 tt0 -58.48 -35.96 73.0 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -81.91 -38.05 25.87 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.605 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.8 t -67.45 -42.33 87.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.04 -45.24 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.63 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -57.38 -37.19 72.28 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 120.728 0.299 . . . . 0.0 110.971 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.57 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.38 29.66 9.33 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-O 118.944 -0.92 . . . . 0.0 110.848 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.57 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.7 ptt180 15.15 67.68 0.01 OUTLIER 'General case' 0 C--N 1.363 1.16 0 CA-C-N 117.313 0.557 . . . . 0.0 110.123 179.231 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.636 ' C ' ' H ' ' A' ' 29' ' ' ILE . 71.3 mttt -86.52 118.01 69.57 Favored Pre-proline 0 N--CA 1.44 -0.965 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.615 ' O ' ' O ' ' A' ' 29' ' ' ILE . 44.2 Cg_exo -53.83 9.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.498 1.762 0 C-N-CA 122.189 1.926 . . . . 0.0 113.383 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.636 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.9 pp -38.01 176.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 123.703 0.627 . . . . 0.0 110.843 -178.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.453 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 4.0 m80 -122.48 166.73 14.31 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 121.837 -0.539 . . . . 0.0 110.795 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.8 m -148.57 171.17 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.27 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.01 135.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.59 166.87 11.1 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.571 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.48 142.4 43.55 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.091 0.472 . . . . 0.0 110.25 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.76 178.67 4.2 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -66.8 -15.53 63.65 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.192 -0.318 . . . . 0.0 110.906 179.261 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -75.94 -22.0 56.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.685 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.9 -7.01 67.33 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.7 p -77.2 145.12 37.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.187 0.517 . . . . 0.0 111.291 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 64.9 mt -100.4 132.89 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.857 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -141.37 138.96 33.4 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.795 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.06 143.03 52.6 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.673 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NH1' ' OE1' ' A' ' 125' ' ' GLU . 0.9 OUTLIER -142.72 138.34 16.02 Favored Pre-proline 0 CA--C 1.54 0.584 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.187 -179.594 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.67 158.58 31.92 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.916 2.411 . . . . 0.0 112.729 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.4 t -100.73 136.07 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.359 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.95 2.06 3.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.589 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 t -146.33 137.07 24.19 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 118.922 0.783 . . . . 0.0 109.149 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -139.32 124.17 18.64 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -138.23 146.84 43.07 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -179.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 52.7 p-10 -113.14 140.62 47.75 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 122.027 0.918 . . . . 0.0 108.593 176.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 -105.5 0.35 Allowed 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.602 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -165.58 -156.43 9.24 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.332 -1.304 . . . . 0.0 112.918 -176.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -88.51 127.89 35.54 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.983 0.421 . . . . 0.0 111.482 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -145.8 158.65 43.84 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -76.17 140.88 41.93 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.253 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.1 143.72 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.121 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.56 HD11 ' CB ' ' A' ' 84' ' ' ALA . 18.9 pt -96.13 152.36 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.408 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.94 132.66 11.15 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.0 mt -110.76 112.26 24.01 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.493 ' C ' HD12 ' A' ' 61' ' ' ILE . 60.0 ttm-85 -85.81 113.24 21.81 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.972 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.694 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.467 0.418 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.806 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.265 0 CA-C-O 121.347 0.594 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -130.76 155.96 42.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.671 -179.174 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.4 tp -142.79 124.0 14.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.851 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -104.52 125.19 50.46 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.9 171.11 18.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.144 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -78.7 155.52 78.26 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-O 120.71 0.291 . . . . 0.0 111.035 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.48 -20.51 70.76 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.675 2.25 . . . . 0.0 112.085 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -89.36 -7.97 54.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.008 0.432 . . . . 0.0 110.178 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.598 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 11.5 t60 -72.66 131.17 42.06 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -87.93 132.04 34.37 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 121.153 0.501 . . . . 0.0 111.142 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.87 140.38 22.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.728 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 53.1 tp -80.99 94.7 6.6 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.776 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.8 p -99.2 178.0 5.04 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -178.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -67.03 -17.88 65.11 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.498 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 79' ' ' TYR . 33.3 t80 -106.25 24.31 12.7 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 120.655 0.264 . . . . 0.0 111.35 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.33 -142.63 15.96 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -92.78 128.85 38.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.85 0.357 . . . . 0.0 110.85 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 82.8 mtp180 -140.91 130.85 24.5 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.903 179.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.73 142.7 22.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.111 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.56 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -61.82 -38.28 87.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.065 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.51 -1.23 4.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.195 -1.002 . . . . 0.0 111.902 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.7 tt0 -107.72 -4.04 18.56 Favored 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 121.446 0.641 . . . . 0.0 110.003 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.2 mt -77.4 128.78 34.84 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.535 0.683 . . . . 0.0 111.259 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.523 ' O ' ' N ' ' A' ' 90' ' ' GLY . 2.3 mmm180 -129.14 147.1 50.96 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.955 -1.02 . . . . 0.0 111.1 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -43.55 91.46 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 121.08 0.467 . . . . 0.0 110.527 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.71 -13.4 0.67 Allowed Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -86.46 130.38 34.52 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.858 0.361 . . . . 0.0 110.32 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.43 ' HE ' HG22 ' A' ' 107' ' ' VAL . 99.5 mtt180 -92.7 134.91 34.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.65 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.2 m -120.53 153.54 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.835 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -69.57 125.64 27.31 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.986 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 104' ' ' ARG . 17.3 m -124.1 160.43 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.76 178.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -105.2 128.88 53.62 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.784 0.325 . . . . 0.0 110.543 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 104' ' ' ARG . 43.0 t0 -100.11 123.3 44.19 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 178.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.3 p -75.16 -15.41 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 118.47 0.577 . . . . 0.0 111.223 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.7 mm-40 -69.43 -59.13 3.19 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 120.616 -0.434 . . . . 0.0 109.956 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.419 ' C ' ' H ' ' A' ' 102' ' ' GLU . 44.1 p -97.09 -11.54 24.26 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.83 -12.51 8.5 Favored Glycine 0 C--N 1.332 0.355 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.419 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -84.45 159.69 20.72 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.947 0.403 . . . . 0.0 110.892 -177.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.569 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.31 140.29 36.22 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.865 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.481 ' CZ ' ' OD2' ' A' ' 97' ' ' ASP . 32.5 mtm180 -137.83 168.79 18.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.962 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -109.32 141.17 42.03 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.633 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.402 ' OG ' HG21 ' A' ' 95' ' ' VAL . 11.4 m -138.03 158.69 43.81 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' HE ' ' A' ' 92' ' ' ARG . 65.1 t -92.1 154.3 3.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.554 0.216 . . . . 0.0 110.49 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.403 ' N ' HG12 ' A' ' 107' ' ' VAL . 79.1 mt -74.15 155.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.03 0.443 . . . . 0.0 110.437 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.4 ' N ' HG22 ' A' ' 108' ' ' ILE . 14.2 mmt180 -101.68 -45.64 5.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.038 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -167.44 149.88 5.95 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.427 ' C ' HD22 ' A' ' 112' ' ' LEU . 80.6 t -94.1 133.41 35.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.466 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -100.15 148.33 34.73 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.239 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.14 156.12 66.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 122.51 2.14 . . . . 0.0 111.095 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.461 HG23 ' H ' ' A' ' 114' ' ' THR . 1.1 p -63.63 154.74 31.9 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -148.41 144.66 27.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 82.0 mtm-85 -77.38 132.02 38.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.184 0.516 . . . . 0.0 110.612 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -165.34 164.12 19.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.066 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 1.1 tpp85 -74.36 145.21 44.0 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.845 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 22.3 p -129.41 143.78 50.98 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -116.88 175.87 5.38 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.085 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -144.29 129.14 18.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.817 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.459 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.7 mt -122.24 171.09 9.28 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.619 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -137.94 107.17 6.07 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.623 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.521 ' O ' ' C ' ' A' ' 125' ' ' GLU . 23.7 t -88.03 115.55 28.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.068 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.533 ' OE1' ' NH1' ' A' ' 43' ' ' ARG . 28.1 tt0 15.54 -118.3 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 O-C-N 124.011 0.82 . . . . 0.0 111.212 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -98.64 -27.2 14.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.027 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 81.2 mt -84.99 87.25 7.35 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.594 ' C ' HG22 ' A' ' 129' ' ' THR . 2.9 m-70 -60.44 98.05 0.06 Allowed 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.594 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.44 152.71 0.03 OUTLIER 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.566 ' N ' HD23 ' A' ' 130' ' ' LEU . 1.4 pt? -156.04 157.85 36.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.542 0.686 . . . . 0.0 112.095 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.471 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.9 p -89.08 125.47 42.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.568 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.03 123.31 24.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.665 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.472 ' C ' ' H ' ' A' ' 135' ' ' VAL . 77.6 mm-40 56.94 45.3 21.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.2 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.6 -19.67 0.88 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.386 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.472 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.4 t -90.08 152.43 3.34 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.33 0 CA-C-N 117.212 0.506 . . . . 0.0 110.773 -179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.5 t -112.93 117.75 56.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 138' ' ' HIS . 19.1 m -147.28 139.49 18.83 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.601 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.598 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 59.8 t-80 -36.17 157.5 0.01 OUTLIER 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 118.043 0.383 . . . . 0.0 111.93 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.484 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 25.5 p30 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.447 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.402 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 22.2 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 62.3 mt -110.59 134.82 52.06 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.459 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.14 161.57 25.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.833 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.42 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 49.3 tt0 -63.41 144.54 56.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.125 178.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.53 -16.45 31.63 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.615 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 24.7 m -68.44 122.54 18.63 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -95.99 115.67 27.78 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-O 120.858 0.361 . . . . 0.0 110.35 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.4 mt -100.53 113.31 35.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -76.47 136.8 39.39 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 12.0 t0 -104.08 130.81 22.7 Favored Pre-proline 0 CA--C 1.539 0.522 0 N-CA-C 110.28 -0.267 . . . . 0.0 110.28 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.56 -29.57 13.12 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.018 1.812 . . . . 0.0 112.431 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.513 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.9 t -71.18 -55.17 14.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.042 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.1 p -77.33 -33.58 55.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 120.902 0.382 . . . . 0.0 110.236 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.25 11.4 84.34 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.52 -168.68 1.38 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 117.498 0.649 . . . . 0.0 109.858 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.2 m -112.79 115.87 29.19 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.198 0.523 . . . . 0.0 110.24 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.5 m170 -105.64 145.6 30.82 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.061 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -99.47 129.67 45.67 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.982 -0.287 . . . . 0.0 110.315 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.449 HD11 HD23 ' A' ' 122' ' ' LEU . 1.0 OUTLIER -53.5 -38.64 33.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-O 120.885 0.374 . . . . 0.0 111.121 -178.918 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.8 pt-20 -60.39 -35.13 75.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.883 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -83.74 -40.22 19.1 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.167 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.4 t -67.53 -42.08 86.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.614 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.538 ' CG2' HD21 ' A' ' 122' ' ' LEU . 53.4 t -74.96 -45.38 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.807 -178.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 62.8 t0 -60.87 -35.52 76.81 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 120.775 0.321 . . . . 0.0 111.088 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.47 26.23 24.26 Favored Glycine 0 C--O 1.229 -0.157 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 81.3 mtt85 17.63 60.95 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.121 0 O-C-N 123.907 0.416 . . . . 0.0 109.892 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.5 mttt -86.26 133.6 40.29 Favored Pre-proline 0 N--CA 1.447 -0.619 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.959 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -75.48 86.06 1.51 Allowed 'Trans proline' 0 C--N 1.313 -1.295 0 C-N-CA 121.499 1.466 . . . . 0.0 110.56 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.613 ' C ' HD12 ' A' ' 29' ' ' ILE . 2.4 pp -116.91 -172.81 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 120.778 0.323 . . . . 0.0 110.776 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.407 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 38.2 m80 -128.37 162.57 26.79 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.449 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -146.52 170.5 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.8 t -90.05 134.18 29.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.99 167.43 10.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.71 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.76 142.78 43.01 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.04 0.448 . . . . 0.0 110.521 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.96 176.78 4.89 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.406 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.673 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 73.4 mmtt -71.41 -13.73 61.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.634 0.254 . . . . 0.0 110.531 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.13 -16.1 57.16 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.333 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.43 18.89 56.28 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.8 p -100.44 137.38 38.93 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.759 0.314 . . . . 0.0 111.139 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -93.95 130.43 40.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.683 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -139.05 138.61 37.3 Favored 'General case' 0 C--O 1.223 -0.298 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.743 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.52 142.18 51.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.635 -178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.535 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 11.1 mmp_? -144.06 138.26 14.83 Favored Pre-proline 0 CA--C 1.537 0.458 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.645 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.07 156.5 33.99 Favored 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 122.393 2.062 . . . . 0.0 112.732 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.9 t -98.72 136.26 30.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.502 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 178.06 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 18.6 m -127.62 3.24 3.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.855 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.7 OUTLIER -151.64 145.33 25.01 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.345 179.089 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.583 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.92 124.23 14.65 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.148 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -139.56 145.66 38.89 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.431 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 49.0 p-10 -90.52 137.36 32.41 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.438 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -96.95 -0.97 46.65 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.479 -179.669 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.24 -178.39 53.49 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.416 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.3 m -85.11 121.99 28.66 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.907 0.384 . . . . 0.0 110.214 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 -145.14 165.48 28.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.551 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -76.94 140.79 40.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.073 179.105 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.4 m -146.59 154.49 12.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.65 HD11 ' HB1' ' A' ' 84' ' ' ALA . 47.3 pt -107.62 160.72 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.463 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -115.67 139.71 15.63 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 179.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 67.0 mt -114.23 108.53 17.07 Favored 'General case' 0 C--O 1.219 -0.526 0 CA-C-O 120.801 0.334 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.436 HH11 ' CG2' ' A' ' 66' ' ' ILE . 10.9 tpt180 -78.67 108.28 11.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.449 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.627 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.9 mp . . . . . 0 CA--C 1.512 -0.518 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.248 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.665 HD13 ' H ' ' A' ' 66' ' ' ILE . 0.0 OUTLIER -129.19 168.75 21.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 120.846 0.355 . . . . 0.0 110.547 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.9 tp -130.79 115.55 16.77 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.621 0.248 . . . . 0.0 110.545 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.2 m95 -101.64 105.36 16.28 Favored 'General case' 0 N--CA 1.463 0.209 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 178.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.44 171.22 14.81 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.144 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -76.99 157.66 81.19 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.571 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 85' ' ' GLY . 33.8 Cg_endo -62.46 -17.07 55.97 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.603 2.202 . . . . 0.0 111.869 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 23.6 p30 -98.07 -5.64 33.41 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.861 0.362 . . . . 0.0 110.527 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.555 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 9.0 t60 -72.56 131.98 43.19 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -86.01 123.2 31.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.273 0.559 . . . . 0.0 111.082 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' LEU . 91.4 t -102.4 91.4 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.366 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' VAL . 35.2 tp -32.22 95.84 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.366 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.478 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -99.75 173.62 6.61 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -177.979 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -63.37 -20.0 65.15 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.042 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.413 ' CD2' ' NH2' ' A' ' 82' ' ' ARG . 63.9 m-85 -104.94 22.79 14.62 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.847 -0.16 . . . . 0.0 111.046 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.69 -144.64 16.16 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.673 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 89.2 m95 -90.75 124.74 35.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.509 0.195 . . . . 0.0 111.157 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.413 ' NH2' ' CD2' ' A' ' 79' ' ' TYR . 88.7 mtt180 -130.23 130.03 44.1 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.563 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.13 141.91 54.52 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.65 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -72.34 2.0 6.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.485 179.588 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -83.67 -14.52 73.0 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -129.37 19.23 5.82 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 122.829 -0.218 . . . . 0.0 111.44 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.476 HD12 ' HA ' ' A' ' 84' ' ' ALA . 28.3 mt -82.41 136.23 34.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.308 0.575 . . . . 0.0 110.797 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 58.0 mmt-85 -132.79 148.84 52.32 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.709 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -45.41 103.0 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.593 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.41 -15.59 1.11 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -82.31 130.28 35.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.791 0.329 . . . . 0.0 110.913 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HE ' ' CG1' ' A' ' 107' ' ' VAL . 99.5 mtt180 -91.32 129.17 37.35 Favored 'General case' 0 C--O 1.224 -0.264 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.686 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.4 m -109.52 143.37 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.986 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -63.63 125.79 25.44 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.579 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 104' ' ' ARG . 30.3 m -122.02 155.47 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.72 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.2 ttt85 -102.54 130.27 49.33 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.607 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -100.34 123.03 44.06 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.17 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.76 -16.65 16.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 118.056 0.389 . . . . 0.0 110.906 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -70.46 -58.87 3.24 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.09 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.431 ' C ' ' H ' ' A' ' 102' ' ' GLU . 30.0 p -96.48 -13.62 22.94 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.539 0.209 . . . . 0.0 110.62 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.33 -14.43 8.7 Favored Glycine 0 C--N 1.331 0.303 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.431 ' H ' ' C ' ' A' ' 100' ' ' THR . 76.7 mt-10 -79.44 153.09 29.91 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.906 0.384 . . . . 0.0 111.185 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.595 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -81.08 139.33 35.74 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.764 179.497 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.434 ' O ' HG22 ' A' ' 95' ' ' VAL . 75.2 mtp180 -138.51 174.27 10.72 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.968 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.478 ' OH ' ' C ' ' A' ' 77' ' ' THR . 2.4 m-85 -113.01 149.67 33.0 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.182 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.6 m -143.25 164.55 29.89 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.4 ' CG1' ' HE ' ' A' ' 92' ' ' ARG . 18.0 m -97.08 155.06 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.695 0.225 . . . . 0.0 110.8 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 95.7 mt -86.99 121.75 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.211 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 67.2 mtp180 -68.55 -33.9 74.9 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -168.24 150.45 5.32 Favored 'General case' 0 N--CA 1.456 -0.163 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.8 t -97.15 136.38 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.474 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.2 mm? -96.22 122.38 58.06 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.082 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.64 166.0 0.16 Allowed 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.266 1.977 . . . . 0.0 111.607 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.408 ' H ' HG23 ' A' ' 114' ' ' THR . 4.5 p -66.93 151.32 47.83 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.166 0.508 . . . . 0.0 110.949 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.5 mtp85 -134.89 -143.28 0.2 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.81 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 36.4 mtm-85 -154.01 131.1 11.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.848 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.58 171.98 3.18 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.26 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 81.3 mtp180 -74.42 145.09 43.98 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.954 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.1 p -123.14 142.47 50.86 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.659 -0.496 . . . . 0.0 109.659 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -113.62 171.98 7.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.66 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.577 ' C ' HD22 ' A' ' 122' ' ' LEU . 49.6 t0 -151.85 125.8 9.13 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.896 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.6 170.16 8.52 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.207 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.4 tp10 -137.61 105.28 5.57 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.33 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.61 118.62 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -61.85 146.04 50.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.523 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 69.24 -69.9 0.15 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.288 178.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 90.5 mt -100.44 95.8 6.98 Favored 'General case' 0 CA--C 1.514 -0.424 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.524 ' O ' HG23 ' A' ' 129' ' ' THR . 9.2 p-80 -65.83 99.73 0.5 Allowed 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.6 145.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.578 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.661 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.5 pp -145.62 154.05 41.7 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.437 0.637 . . . . 0.0 111.619 -179.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 130' ' ' LEU . 68.7 t -89.92 125.69 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.738 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.615 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.73 135.35 43.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.249 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.621 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.2 mm-40 49.73 45.59 24.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.123 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.14 22.51 55.72 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.916 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.6 t -128.99 152.07 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.8 t -105.25 110.84 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 O-C-N 122.065 -0.397 . . . . 0.0 110.536 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 138' ' ' HIS . 13.4 m -146.99 138.52 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.555 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 56.2 t-80 -33.93 153.73 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.752 0.311 . . . . 0.0 111.793 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.287 -179.571 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.471 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 30.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 89.0 mt -107.11 134.55 50.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.912 0.387 . . . . 0.0 110.406 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.32 163.61 23.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.089 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -64.14 139.69 58.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.615 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.17 -18.66 25.67 Favored Glycine 0 C--N 1.334 0.454 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.459 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.6 m -69.78 123.93 22.69 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.505 ' NE ' HG21 ' A' ' 16' ' ' THR . 77.5 mtp85 -97.85 116.64 30.46 Favored 'General case' 0 C--O 1.231 0.088 0 CA-C-O 120.982 0.42 . . . . 0.0 110.7 -179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.462 HD11 HD13 ' A' ' 19' ' ' ILE . 18.0 mt -101.53 115.23 42.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.756 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -76.57 135.9 39.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 5.0 t70 -104.15 132.42 21.01 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 110.571 -0.159 . . . . 0.0 110.571 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.23 -31.84 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 121.838 1.692 . . . . 0.0 112.462 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 74.9 t -69.89 -55.25 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.047 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.6 p -77.54 -35.6 53.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.973 0.415 . . . . 0.0 110.182 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 10.45 85.46 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.458 HG22 ' N ' ' A' ' 16' ' ' THR . 88.2 m -114.09 157.51 22.47 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 117.276 0.538 . . . . 0.0 110.09 -179.659 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.505 HG21 ' NE ' ' A' ' 7' ' ' ARG . 28.2 m -78.97 116.13 19.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.555 0.693 . . . . 0.0 110.897 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' HIS . . . . . 0.459 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 61.8 m-70 -104.89 144.87 31.19 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.848 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -98.75 128.32 44.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.304 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.523 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -52.8 -38.83 29.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 CA-C-O 120.704 0.287 . . . . 0.0 111.012 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.497 ' N ' HG23 ' A' ' 19' ' ' ILE . 9.1 pt-20 -57.03 -32.62 66.36 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.295 0.569 . . . . 0.0 110.806 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -83.57 -37.87 22.41 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.033 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.75 -42.4 86.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.719 HG22 HD21 ' A' ' 122' ' ' LEU . 87.5 t -73.08 -46.9 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 65.2 t0 -57.67 -36.0 71.32 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.836 0.351 . . . . 0.0 110.831 -178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -108.31 29.12 10.46 Favored Glycine 0 C--O 1.228 -0.254 0 CA-C-O 118.829 -0.984 . . . . 0.0 111.147 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.1 ptm180 13.08 67.91 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.488 0.644 . . . . 0.0 110.836 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.436 ' C ' ' H ' ' A' ' 29' ' ' ILE . 82.7 mttt -87.56 144.62 35.74 Favored Pre-proline 0 N--CA 1.45 -0.431 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.31 -177.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.587 ' O ' ' O ' ' A' ' 29' ' ' ILE . 57.4 Cg_endo -70.87 8.22 1.08 Allowed 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 122.057 1.838 . . . . 0.0 111.744 179.292 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.587 ' O ' ' O ' ' A' ' 28' ' ' PRO . 15.1 tt -37.1 172.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.847 -178.179 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.527 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 9.5 m80 -124.83 162.97 23.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.7 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 34.7 m -146.2 169.87 5.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.2 t -87.3 134.13 28.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.455 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.36 166.17 10.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.704 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.87 141.6 40.71 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.184 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.36 178.19 4.37 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -72.82 -12.78 61.12 Favored 'General case' 0 C--O 1.233 0.186 0 O-C-N 122.248 -0.283 . . . . 0.0 110.676 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -78.59 -17.71 55.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.366 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.92 18.59 55.85 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.1 p -100.01 137.29 38.66 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.983 0.42 . . . . 0.0 111.001 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.7 mt -94.34 131.05 40.37 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.714 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 23.9 t60 -139.55 138.99 36.74 Favored 'General case' 0 C--O 1.221 -0.425 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.791 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.56 142.59 51.76 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -145.64 137.46 13.11 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.869 -179.4 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_endo -75.79 157.65 39.36 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.644 2.229 . . . . 0.0 112.401 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.6 t -90.91 127.44 43.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.8 -4.8 11.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.782 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.0 p -151.79 143.08 23.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 O-C-N 121.756 -0.59 . . . . 0.0 109.445 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -137.6 117.28 13.06 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.189 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -144.8 146.29 32.05 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 45.7 p-10 -90.61 138.41 31.59 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.746 ' OE1' ' O ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -103.74 7.04 37.21 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.771 -179.826 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.746 ' O ' ' OE1' ' A' ' 51' ' ' GLN . . . 92.02 -175.65 38.43 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-O 121.552 0.529 . . . . 0.0 112.802 177.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.581 HG23 ' C ' ' A' ' 117' ' ' ALA . 61.3 m -100.84 131.73 46.58 Favored 'General case' 0 N--CA 1.468 0.457 0 O-C-N 121.296 -1.12 . . . . 0.0 108.981 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 80.5 mtp180 -148.32 172.94 13.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.32 0.581 . . . . 0.0 110.382 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -75.54 140.34 42.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.622 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.6 m -140.92 158.13 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.542 HD11 ' CB ' ' A' ' 84' ' ' ALA . 46.6 pt -112.7 151.56 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 CA-C-O 120.848 0.356 . . . . 0.0 110.809 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.86 132.17 10.99 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.7 mt -111.84 106.27 14.96 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.259 0.552 . . . . 0.0 109.781 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -86.16 117.37 24.94 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.278 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.4 mm . . . . . 0 N--CA 1.47 0.556 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.461 -179.549 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.377 0 CA-C-O 121.396 0.617 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 8.9 tp -123.36 144.03 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.892 -178.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 36.5 tp -136.74 118.97 15.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.862 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.05 127.66 50.23 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.36 170.27 20.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.886 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.87 155.9 82.76 Favored Pre-proline 0 CA--C 1.536 0.439 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.767 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 -18.92 64.18 Favored 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.68 2.254 . . . . 0.0 111.989 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -95.46 -5.0 44.0 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.025 0.441 . . . . 0.0 110.022 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.561 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -69.8 130.13 41.45 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.215 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -86.31 128.66 34.95 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.459 0.647 . . . . 0.0 111.446 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.56 144.44 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.185 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.469 HD13 ' C ' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -82.55 94.47 7.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.512 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 17.0 p -100.82 175.89 5.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.83 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.654 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 0.7 OUTLIER -60.41 -21.06 61.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.524 -179.32 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.98 24.25 13.1 Favored 'General case' 0 CA--C 1.516 -0.33 0 C-N-CA 121.303 -0.159 . . . . 0.0 111.095 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.62 -169.39 34.08 Favored Glycine 0 CA--C 1.523 0.583 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.509 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -60.84 123.78 18.55 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.925 -0.638 . . . . 0.0 110.775 -178.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -140.01 134.15 31.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.028 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.81 139.24 40.42 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.04 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.542 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.21 -37.29 86.66 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.28 1.87 1.85 Allowed Glycine 0 C--N 1.336 0.573 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.015 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.421 ' H ' ' C ' ' A' ' 84' ' ' ALA . 75.8 mt-10 -110.01 3.4 20.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.272 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.68 133.76 34.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.334 0.588 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.533 ' O ' ' N ' ' A' ' 90' ' ' GLY . 10.2 tpt180 -127.88 148.66 50.48 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.599 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -49.72 86.76 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.232 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 159.27 -18.37 0.26 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -77.94 134.75 37.81 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 88.8 mtm180 -92.36 139.59 30.45 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.927 -178.686 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.52 154.2 39.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.285 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -83.52 133.87 34.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.904 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.514 HG12 HG22 ' A' ' 135' ' ' VAL . 30.9 m -129.0 165.46 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.224 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.54 128.62 44.43 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.816 0.341 . . . . 0.0 111.0 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -99.64 122.64 42.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.982 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.6 p -75.33 -16.43 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 CA-C-N 118.425 0.557 . . . . 0.0 110.69 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -69.15 -58.59 3.86 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 120.524 -0.471 . . . . 0.0 109.877 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.469 ' C ' ' H ' ' A' ' 102' ' ' GLU . 72.5 p -95.99 -10.78 27.75 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.98 -12.34 6.61 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.469 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.0 mt-10 -89.13 161.23 16.61 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.269 0.557 . . . . 0.0 111.605 -177.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.552 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -74.56 139.26 43.61 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.052 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 37.6 ptt180 -130.98 158.05 41.31 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.654 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -104.15 135.98 44.62 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 42.8 m -144.07 166.19 25.68 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 108' ' ' ILE . 94.1 t -94.84 154.44 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 110.417 -0.216 . . . . 0.0 110.417 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.471 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.9 mt -67.42 160.2 4.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.087 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.471 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 74.3 ttt180 -105.64 -48.91 3.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.648 179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -164.82 142.36 6.3 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.3 t -94.37 134.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.8 mm? -101.8 147.16 33.48 Favored Pre-proline 0 CA--C 1.538 0.501 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.855 -179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.17 165.27 30.87 Favored 'Trans proline' 0 N--CA 1.499 1.805 0 C-N-CA 122.967 2.445 . . . . 0.0 110.938 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -69.38 157.1 37.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.794 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttp180 -141.92 -141.75 0.13 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.377 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.405 ' H ' ' HG2' ' A' ' 115' ' ' ARG . 78.3 mtm-85 -151.89 135.23 15.99 Favored 'General case' 0 C--N 1.33 -0.243 0 O-C-N 123.471 0.482 . . . . 0.0 110.272 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ALA . . . . . 0.581 ' C ' HG23 ' A' ' 53' ' ' THR . . . -173.17 169.45 4.56 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.141 0.496 . . . . 0.0 110.952 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 18.5 tpp180 -74.59 146.46 42.5 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.592 ' OG1' ' NE2' ' A' ' 51' ' ' GLN . 0.6 OUTLIER -136.47 154.14 50.84 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -131.53 -178.53 4.9 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.677 -175.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -153.74 121.56 5.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.192 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.719 HD21 HG22 ' A' ' 23' ' ' VAL . 85.4 mt -117.13 127.9 54.59 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.783 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -88.52 108.18 19.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.815 0.341 . . . . 0.0 110.36 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' A' ' 126' ' ' GLU . 18.1 t -80.6 111.84 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.993 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 124' ' ' VAL . 2.8 tm-20 25.1 -87.63 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.498 ' N ' ' O ' ' A' ' 124' ' ' VAL . 44.2 tp10 -139.25 -27.86 0.79 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.545 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.499 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.1 mt -80.58 66.0 5.93 Favored 'General case' 0 CA--C 1.506 -0.732 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 127' ' ' LEU . 48.3 m170 -38.9 94.96 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.423 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 172.07 141.05 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.612 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.668 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.8 pp -147.56 154.79 41.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.46 0.648 . . . . 0.0 111.858 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 8' ' ' ILE . 72.7 t -91.01 126.38 43.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.77 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.459 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.91 134.09 42.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.0 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.573 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 50.68 45.06 27.41 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.933 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.36 24.72 59.49 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.162 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.7 t -129.69 152.47 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -106.49 111.31 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 118.203 0.456 . . . . 0.0 110.75 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' A' ' 138' ' ' HIS . 5.9 m -146.54 140.52 20.54 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.561 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 11.1 t60 -31.35 152.86 0.0 OUTLIER 'General case' 0 C--O 1.226 -0.149 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 17.9 p30 . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.429 -179.406 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.4 mt -117.04 132.13 56.77 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.887 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.93 161.95 26.34 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -63.8 147.1 52.63 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.968 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.31 -15.18 39.3 Favored Glycine 0 C--N 1.336 0.581 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.559 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.5 m -67.13 121.59 15.96 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 80.9 mtm-85 -97.39 116.66 30.02 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 120.764 0.316 . . . . 0.0 110.272 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.422 HD11 ' HB ' ' A' ' 19' ' ' ILE . 9.0 mt -103.68 116.03 46.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.761 -179.228 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -76.13 136.04 39.82 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 11.9 t0 -103.19 130.41 23.68 Favored Pre-proline 0 CA--C 1.54 0.56 0 C-N-CA 121.187 -0.205 . . . . 0.0 110.52 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.05 -30.54 10.68 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.356 2.037 . . . . 0.0 112.196 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.544 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 57.8 t -72.05 -55.1 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.767 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 m -77.4 -39.98 45.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.175 0.512 . . . . 0.0 110.36 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 10.61 80.83 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.299 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.1 m -112.91 154.87 25.68 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-N 117.612 0.706 . . . . 0.0 109.636 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.8 m -79.05 117.15 19.83 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.265 0.555 . . . . 0.0 110.827 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -106.93 148.55 28.48 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.43 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -100.37 127.54 46.66 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.657 178.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.49 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.5 tt -54.09 -38.01 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 CA-C-O 120.923 0.392 . . . . 0.0 111.523 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.421 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.8 pt-20 -60.03 -33.12 71.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.078 0.466 . . . . 0.0 110.984 -179.378 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -83.79 -38.2 21.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.713 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.7 -41.26 85.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.245 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.697 HG22 HD21 ' A' ' 122' ' ' LEU . 60.7 t -72.99 -45.62 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -58.1 -34.85 70.64 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 120.696 0.284 . . . . 0.0 110.619 -178.187 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.76 27.34 11.26 Favored Glycine 0 C--O 1.226 -0.363 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.9 ptt-85 15.01 68.06 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.129 0.49 . . . . 0.0 109.82 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -89.8 135.27 30.69 Favored Pre-proline 0 N--CA 1.446 -0.655 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.984 -176.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.9 85.14 1.54 Allowed 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.848 1.699 . . . . 0.0 110.427 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 16.4 pt -111.92 -171.44 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 110.963 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.45 ' CG ' HG21 ' A' ' 12' ' ' VAL . 65.7 m80 -130.44 159.62 36.49 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.454 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.55 170.49 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.5 t -86.61 131.52 34.56 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.6 146.66 37.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.396 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.02 143.45 45.73 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.938 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.79 176.71 4.94 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.506 ' HD3' ' H ' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -69.87 -14.43 62.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.772 0.32 . . . . 0.0 110.749 179.523 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 56.0 t0 -80.44 -18.34 49.08 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.177 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.8 21.23 43.86 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 22.3 p -101.62 137.38 40.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.116 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.58 HD11 ' CD1' ' A' ' 103' ' ' LEU . 62.6 mt -91.35 126.68 36.51 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.745 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -136.76 136.71 39.14 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.579 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.548 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.51 142.02 51.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.487 -178.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.572 HH11 ' CD ' ' A' ' 125' ' ' GLU . 4.2 mmp_? -143.87 137.11 13.98 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.672 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.89 156.47 34.72 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 122.769 2.313 . . . . 0.0 112.962 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -96.64 134.93 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.37 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.34 -0.46 4.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.768 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.7 t -146.65 136.32 23.1 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 118.535 0.607 . . . . 0.0 109.513 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.56 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.62 118.42 15.12 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.291 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -140.74 147.13 38.67 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -96.93 134.04 40.79 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 176.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.408 ' OE1' ' O ' ' A' ' 120' ' ' PHE . 9.1 mt-30 -96.64 3.77 52.32 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.315 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.29 -178.0 49.1 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.724 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -87.67 124.97 34.1 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-O 120.836 0.351 . . . . 0.0 110.17 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 48.2 mmt-85 -143.35 165.04 28.61 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.727 -179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -76.05 142.45 41.79 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.784 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.57 149.8 16.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.61 HD11 ' HB1' ' A' ' 84' ' ' ALA . 46.7 pt -98.87 149.44 5.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.577 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.32 125.8 8.41 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 78.0 mt -108.58 113.37 26.32 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.201 0.524 . . . . 0.0 110.199 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.435 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 53.4 ttp180 -87.46 115.45 24.89 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.481 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.6 mm . . . . . 0 N--CA 1.467 0.411 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.441 -179.66 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 -0.204 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.441 HD11 ' CZ2' ' A' ' 68' ' ' TRP . 20.9 tt -118.91 143.65 29.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.11 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.7 tt -118.49 115.38 24.49 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.363 -179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.441 ' CZ2' HD11 ' A' ' 66' ' ' ILE . 98.0 m95 -102.68 125.51 49.44 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.78 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.02 170.97 19.12 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.879 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.53 157.06 65.1 Favored Pre-proline 0 CA--C 1.535 0.372 0 C-N-CA 120.739 -0.385 . . . . 0.0 110.551 179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 85' ' ' GLY . 38.3 Cg_endo -66.24 -18.7 56.17 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.549 2.166 . . . . 0.0 111.985 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -95.39 -6.29 41.32 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.368 . . . . 0.0 110.395 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.543 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 41.4 t60 -72.01 132.2 43.96 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -85.12 123.76 31.0 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.381 0.61 . . . . 0.0 111.629 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.83 140.92 16.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.061 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 47.9 tp -81.4 92.33 6.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.076 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.471 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 39.3 p -98.86 173.15 7.0 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 92' ' ' ARG . 17.3 pt-20 -64.49 -17.05 63.5 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.291 -179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -105.95 24.85 11.7 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.691 0.281 . . . . 0.0 110.787 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.03 -143.5 16.64 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 79.5 m95 -89.1 123.29 33.24 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.729 0.3 . . . . 0.0 111.14 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -122.88 126.06 46.57 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.026 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.45 132.0 46.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.784 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.61 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -69.36 -1.07 7.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.029 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -76.37 -12.93 83.85 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -134.76 27.76 3.61 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.451 HD12 ' HA ' ' A' ' 84' ' ' ALA . 13.3 mt -83.03 133.25 35.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.373 0.606 . . . . 0.0 111.02 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -133.38 148.02 51.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.615 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -47.59 106.59 0.09 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.551 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 147.12 -17.89 1.55 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -82.7 132.94 35.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.643 0.258 . . . . 0.0 110.695 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 85.2 mtm180 -90.04 130.21 36.25 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.364 -0.535 . . . . 0.0 110.302 -179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.9 m -113.49 144.77 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.66 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.15 124.72 26.88 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.708 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.6 m -121.66 165.02 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.146 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.1 tpt180 -101.64 128.91 47.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.61 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.433 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 34.8 t0 -101.13 124.03 46.21 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.534 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG12 ' A' ' 98' ' ' VAL . 97.1 t -74.37 -16.2 16.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 118.29 0.495 . . . . 0.0 111.065 178.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -70.3 -59.29 2.96 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.405 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.426 ' C ' ' H ' ' A' ' 102' ' ' GLU . 19.5 p -98.84 -13.93 19.88 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.627 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.38 -14.26 6.92 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 100' ' ' THR . 46.0 mt-10 -82.09 157.46 24.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 111.175 -177.22 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.58 ' CD1' HD11 ' A' ' 40' ' ' LEU . 7.8 mp -77.22 134.86 38.5 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-O 121.228 0.537 . . . . 0.0 110.153 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.433 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 38.9 ptt180 -132.62 165.4 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.592 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.471 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.1 m-85 -112.04 148.55 33.61 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.048 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 65.1 m -145.15 165.84 27.14 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 57.7 t -91.81 152.31 3.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.62 0.248 . . . . 0.0 110.69 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.516 HG22 ' N ' ' A' ' 109' ' ' ARG . 71.9 mt -70.49 162.26 4.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.304 178.72 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.516 ' N ' HG22 ' A' ' 108' ' ' ILE . 37.4 mtp85 -106.04 -48.47 3.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.817 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.435 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 85.3 tt0 -167.53 149.14 5.62 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.963 -0.461 . . . . 0.0 109.853 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 112' ' ' LEU . 72.0 t -96.16 134.35 34.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -102.59 151.22 38.22 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.168 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.22 159.85 50.26 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.664 2.243 . . . . 0.0 111.301 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 57' ' ' ILE . 81.7 p -65.75 154.19 39.69 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 120.886 -0.326 . . . . 0.0 110.431 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -149.8 153.36 36.67 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.804 0.811 . . . . 0.0 110.307 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.0 mmm180 -82.55 132.42 35.2 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.634 -179.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.81 167.63 12.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.973 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.1 ttm180 -80.53 145.12 31.98 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.708 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.9 p -125.95 145.01 50.46 Favored 'General case' 0 CA--C 1.521 -0.142 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.427 ' HB3' HG21 ' A' ' 23' ' ' VAL . 59.6 m-85 -120.5 175.09 6.16 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.42 -178.438 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -151.77 123.84 8.14 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.697 HD21 HG22 ' A' ' 23' ' ' VAL . 89.8 mt -122.46 124.59 43.95 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.629 0.252 . . . . 0.0 110.508 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tp10 -89.25 109.56 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.989 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.504 ' O ' ' C ' ' A' ' 125' ' ' GLU . 18.6 t -83.6 115.78 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.918 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.572 ' CD ' HH11 ' A' ' 43' ' ' ARG . 43.7 tt0 20.7 -92.01 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.519 0 O-C-N 123.733 0.645 . . . . 0.0 111.749 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.4 ' N ' ' O ' ' A' ' 124' ' ' VAL . 40.8 tp10 -133.22 -32.46 1.19 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.882 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.508 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.8 mt -74.03 63.04 0.92 Allowed 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.315 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.528 ' O ' HG23 ' A' ' 129' ' ' THR . 30.8 m170 -38.48 95.04 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.528 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.33 140.84 0.02 OUTLIER 'General case' 0 C--O 1.233 0.191 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.1 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.6 pp -149.29 156.89 42.81 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.321 0.582 . . . . 0.0 111.796 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.9 121.44 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.607 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.5 145.77 50.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.558 -178.429 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 135' ' ' VAL . 40.0 mt-10 40.8 46.5 2.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.155 179.063 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.32 -22.24 0.29 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.658 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.4 t -90.91 152.01 3.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 C-N-CA 122.596 0.358 . . . . 0.0 110.701 179.706 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.3 t -108.8 115.84 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 120.757 0.313 . . . . 0.0 110.416 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 33.5 m -149.94 144.18 17.62 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.057 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.543 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 52.2 t-80 -30.01 149.95 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 179.428 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.429 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 22.2 p30 . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.415 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.0 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.415 HD11 HD11 ' A' ' 130' ' ' LEU . 68.9 mt -108.25 135.31 49.79 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.599 -179.489 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.85 163.22 23.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.732 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 65.2 tt0 -63.19 141.5 58.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.053 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.19 -19.73 31.74 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.3 m -67.68 124.55 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.261 0.077 . . . . 0.0 111.169 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -85.32 150.1 25.0 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.992 0.425 . . . . 0.0 109.989 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 12.9 mt -134.47 108.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.191 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -76.01 125.83 29.86 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 178.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.9 129.85 25.66 Favored Pre-proline 0 CA--C 1.536 0.429 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.12 -30.12 16.62 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.703 1.602 . . . . 0.0 112.433 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 72.2 t -73.73 -55.18 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 32.4 m -74.7 -40.34 61.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.472 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.32 6.64 83.85 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 85.3 m -116.92 162.0 18.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.512 0.656 . . . . 0.0 109.794 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 1.9 p -81.02 116.15 20.83 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.609 0.719 . . . . 0.0 111.301 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 13.4 m80 -97.32 138.6 34.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.22 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -95.64 126.67 41.07 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.695 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.9 tp -53.07 -40.44 37.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 111.388 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.0 pt-20 -57.12 -36.59 70.86 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.371 0.605 . . . . 0.0 110.968 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.2 t0 -81.85 -36.89 27.77 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.63 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.2 t -67.38 -42.24 87.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.252 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 91.5 t -72.2 -46.52 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -55.04 -37.9 67.28 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 120.96 0.41 . . . . 0.0 110.472 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.579 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -111.99 33.32 5.8 Favored Glycine 0 CA--C 1.52 0.374 0 CA-C-O 118.688 -1.062 . . . . 0.0 110.873 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.579 ' C ' ' O ' ' A' ' 25' ' ' GLY . 26.2 ptt180 8.97 74.63 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 117.576 0.688 . . . . 0.0 110.588 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.453 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.4 mttt -89.04 142.03 29.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.944 -177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.514 ' O ' ' O ' ' A' ' 29' ' ' ILE . 58.4 Cg_endo -70.87 11.22 0.53 Allowed 'Trans proline' 0 N--CA 1.491 1.338 0 C-N-CA 121.832 1.688 . . . . 0.0 111.534 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.514 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.3 pp -39.78 171.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.237 -177.411 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.427 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 4.2 m80 -120.99 166.08 14.35 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.425 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.9 m -148.12 170.01 3.23 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 99.5 t -85.75 137.64 20.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.59 165.47 11.51 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.46 138.66 41.67 Favored 'General case' 0 N--CA 1.462 0.161 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.21 178.0 4.43 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.13 -14.9 61.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.883 0.373 . . . . 0.0 110.885 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -77.93 -18.32 56.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.331 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.38 24.97 34.76 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.7 p -102.87 136.4 42.77 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.649 0.262 . . . . 0.0 110.808 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.97 130.84 44.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.954 0.407 . . . . 0.0 110.532 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.9 t60 -141.64 140.05 33.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.734 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -68.9 142.97 54.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.4 mmp_? -146.24 137.57 12.9 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.428 -179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -74.6 158.32 43.78 Favored 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.611 2.208 . . . . 0.0 112.695 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.2 t -100.03 136.53 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 177.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.1 m -127.83 2.59 3.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 119.032 -0.508 . . . . 0.0 112.159 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.8 t -145.85 134.79 22.55 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 119.349 0.977 . . . . 0.0 108.915 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -132.89 117.6 17.91 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 177.86 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.504 ' O ' ' OE1' ' A' ' 51' ' ' GLN . 68.4 m-85 -142.81 148.73 37.61 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 48.6 p-10 -97.61 135.8 38.92 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.504 ' OE1' ' O ' ' A' ' 49' ' ' PHE . 0.6 OUTLIER -97.27 8.27 44.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.41 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.47 177.92 50.52 Favored Glycine 0 CA--C 1.527 0.825 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.488 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.549 ' OG1' ' NH1' ' A' ' 118' ' ' ARG . 4.3 m -87.51 127.68 35.24 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.337 -0.432 . . . . 0.0 109.87 179.007 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.2 mmm180 -148.51 167.49 25.24 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.049 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -73.95 141.79 45.92 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.509 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.7 m -128.88 141.22 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 110.491 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.788 ' H ' HD13 ' A' ' 57' ' ' ILE . 0.1 OUTLIER -100.9 139.78 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.87 179.794 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.48 140.95 15.31 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.103 -0.57 . . . . 0.0 111.846 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 27.6 mt -129.0 115.86 18.43 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-O 121.197 0.522 . . . . 0.0 109.972 -179.036 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.611 ' NH2' ' NH1' ' A' ' 109' ' ' ARG . 62.9 ttt180 -97.02 114.55 26.18 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.729 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm . . . . . 0 N--CA 1.465 0.31 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.287 -178.52 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.067 0 CA-C-O 121.215 0.531 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.425 HG21 ' CZ2' ' A' ' 68' ' ' TRP . 0.1 OUTLIER -132.07 156.81 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.579 -178.729 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.9 tp -146.21 123.75 11.76 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.427 -0.352 . . . . 0.0 111.723 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.425 ' CZ2' HG21 ' A' ' 66' ' ' ILE . 2.1 m95 -99.42 107.85 20.19 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 175.961 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.451 ' O ' HD13 ' A' ' 57' ' ' ILE . . . -127.51 177.14 6.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.158 -177.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.9 155.27 52.87 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.225 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -60.44 -27.38 84.74 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.909 2.406 . . . . 0.0 112.08 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' A' ' 74' ' ' LYS . 38.7 t70 -85.9 -6.93 58.99 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.476 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 6.8 t60 -70.53 126.37 29.45 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' A' ' 72' ' ' ASP . 14.3 mptt -89.55 137.4 32.36 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.352 0.596 . . . . 0.0 110.517 -179.202 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.5 t -105.09 135.85 41.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.151 -0.932 . . . . 0.0 109.586 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.5 tp -76.54 100.37 5.27 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.671 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.492 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 81.8 p -98.81 174.78 6.22 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -178.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.431 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 10.0 pt-20 -67.11 -12.75 60.84 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.674 -0.411 . . . . 0.0 111.438 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.431 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 60.2 m-85 -112.89 22.13 14.76 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.473 0.175 . . . . 0.0 111.473 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.88 -138.01 14.67 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -107.12 138.32 43.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.716 0.293 . . . . 0.0 110.387 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 tpt180 -137.82 130.33 29.51 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.66 141.9 36.07 Favored 'General case' 0 CA--C 1.516 -0.33 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.03 -40.06 88.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.92 -179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.29 -3.74 20.05 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 119.808 -1.187 . . . . 0.0 111.893 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.83 -6.14 20.51 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 117.139 0.469 . . . . 0.0 110.382 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.25 128.74 35.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.622 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.4 mmt85 -134.02 148.44 51.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.383 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.8 ttmt -43.42 92.71 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.002 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.1 -17.58 0.53 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -89.67 128.95 36.16 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.895 0.378 . . . . 0.0 111.059 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -89.63 133.31 34.7 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -178.101 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.4 m -114.32 144.58 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.791 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.59 130.55 43.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.072 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.5 m -128.92 161.04 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.416 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -107.51 130.59 54.84 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -100.27 123.17 44.17 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.359 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.0 m -75.19 -14.68 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-N 118.534 0.606 . . . . 0.0 110.638 177.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -70.07 -58.38 3.88 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.604 -0.438 . . . . 0.0 109.952 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.7 p -98.12 -10.68 23.82 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.93 -12.61 6.23 Favored Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 93.3 mt-10 -82.32 155.62 24.69 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 120.926 0.393 . . . . 0.0 111.578 -176.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.609 ' H ' HD23 ' A' ' 103' ' ' LEU . 2.0 pt? -81.56 139.83 34.85 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.513 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -140.01 178.39 7.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.17 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.492 ' OH ' ' C ' ' A' ' 77' ' ' THR . 3.6 m-85 -117.36 147.9 42.21 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.028 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.7 m -138.28 161.35 37.13 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.413 HG22 ' N ' ' A' ' 108' ' ' ILE . 10.4 p -91.93 154.57 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.413 ' N ' HG22 ' A' ' 107' ' ' VAL . 50.1 mt -75.89 151.59 6.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 178.684 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.611 ' NH1' ' NH2' ' A' ' 60' ' ' ARG . 68.7 ttt180 -104.11 -42.39 5.55 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.579 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.46 147.85 5.34 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.404 ' C ' HD12 ' A' ' 112' ' ' LEU . 73.4 t -94.92 133.37 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.0 mp -100.91 151.24 37.57 Favored Pre-proline 0 CA--C 1.537 0.475 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.1 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.47 158.42 56.07 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.804 2.336 . . . . 0.0 111.57 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.6 p -67.57 156.9 35.66 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.101 0.477 . . . . 0.0 110.478 -179.035 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -133.77 -141.28 0.19 Allowed 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.431 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.1 mtt85 -157.59 130.1 7.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.041 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.7 170.54 4.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.274 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.549 ' NH1' ' OG1' ' A' ' 53' ' ' THR . 64.7 mmt-85 -74.15 151.38 40.07 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.372 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.3 p -131.2 146.52 52.36 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.172 0.511 . . . . 0.0 109.861 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.46 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 68.6 m-85 -123.3 174.07 7.55 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.275 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 120' ' ' PHE . 78.5 m-20 -153.62 123.26 6.73 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.71 177.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 65.5 mt -118.52 126.13 51.34 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -86.59 112.02 21.19 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 120.951 0.405 . . . . 0.0 110.399 -178.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.471 ' O ' ' C ' ' A' ' 125' ' ' GLU . 62.7 t -86.52 114.14 25.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.895 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.471 ' C ' ' O ' ' A' ' 124' ' ' VAL . 40.4 tp10 22.14 -115.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 O-C-N 123.811 0.694 . . . . 0.0 111.936 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.9 tp10 -109.8 -25.64 10.24 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.316 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 129' ' ' THR . 86.3 mt -82.83 66.68 8.56 Favored 'General case' 0 CA--C 1.505 -0.781 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.444 ' O ' HG23 ' A' ' 129' ' ' THR . 2.5 p-80 -41.21 98.42 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.122 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.77 142.98 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.688 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.663 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.9 pp -149.02 152.78 36.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.396 0.617 . . . . 0.0 111.961 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.411 ' N ' HD12 ' A' ' 130' ' ' LEU . 97.7 t -90.96 126.58 43.67 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.04 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.441 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.39 132.91 41.74 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.067 -179.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.557 ' O ' HG23 ' A' ' 135' ' ' VAL . 14.2 mm-40 52.01 43.71 30.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.542 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.62 28.13 62.23 Favored Glycine 0 CA--C 1.524 0.648 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.175 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.8 t -129.6 151.91 36.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -104.38 109.6 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.551 0.614 . . . . 0.0 110.722 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.431 ' O ' ' C ' ' A' ' 138' ' ' HIS . 28.8 m -147.28 139.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 62.7 t-80 -33.54 149.65 0.01 OUTLIER 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.751 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.3 p30 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.349 -179.419 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.445 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 4.8 m . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 85.4 mt -115.57 134.05 55.43 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.76 162.04 23.07 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.605 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.47 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 25.8 tt0 -62.62 144.42 56.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.939 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.13 -14.6 36.88 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.518 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.2 m -69.22 121.46 16.85 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 121.104 -0.239 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 86.8 mtm180 -84.55 149.89 25.6 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.284 179.322 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' A' ' 19' ' ' ILE . 73.5 mt -133.49 107.21 10.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.301 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -78.42 131.84 37.08 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -108.83 124.72 33.45 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' HD1' ' A' ' 30' ' ' HIS . 42.4 Cg_endo -68.97 -25.53 32.23 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.248 1.966 . . . . 0.0 111.841 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.1 t -69.95 -56.23 12.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 p -83.55 -38.2 22.01 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.056 0.455 . . . . 0.0 109.887 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.47 12.1 70.46 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.9 m -114.75 155.37 26.82 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 117.963 0.882 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.8 m -80.59 120.65 24.81 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.311 0.577 . . . . 0.0 110.971 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -105.36 145.85 30.21 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.34 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.414 ' O ' HG23 ' A' ' 22' ' ' VAL . 6.6 ttm180 -97.31 123.05 41.0 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.603 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.1 tt -53.99 -40.07 43.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.619 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.7 pt-20 -60.42 -32.71 71.6 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.945 0.402 . . . . 0.0 111.202 -179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -83.7 -39.07 20.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.672 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.488 HG11 ' CD1' ' A' ' 29' ' ' ILE . 92.8 t -67.53 -40.67 84.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.11 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.639 HG22 HD21 ' A' ' 122' ' ' LEU . 61.8 t -72.43 -46.72 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.619 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.11 -34.76 70.55 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-O 120.65 0.262 . . . . 0.0 110.866 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.556 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.81 26.7 18.66 Favored Glycine 0 CA--C 1.518 0.224 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.556 ' C ' ' O ' ' A' ' 25' ' ' GLY . 94.1 mtt-85 17.47 64.55 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.419 ' O ' HG23 ' A' ' 29' ' ' ILE . 78.8 mttt -90.14 114.22 60.12 Favored Pre-proline 0 N--CA 1.448 -0.568 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.058 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -55.88 86.5 0.04 OUTLIER 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.836 1.69 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.488 ' CD1' HG11 ' A' ' 22' ' ' VAL . 12.5 pt -109.24 -172.68 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-O 120.752 0.31 . . . . 0.0 110.707 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.873 ' NE2' ' HB1' ' A' ' 42' ' ' ALA . 6.3 t-80 -127.02 156.86 40.96 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.712 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.64 ' O ' ' CE1' ' A' ' 30' ' ' HIS . 29.2 m -148.46 169.7 3.05 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.87 134.91 27.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 O-C-N 122.115 -0.365 . . . . 0.0 110.36 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.1 167.18 10.19 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.799 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.44 145.3 40.75 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.261 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.12 178.22 4.37 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.577 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.74 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 69.7 mmtt -71.4 -11.6 60.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.024 0.44 . . . . 0.0 110.458 179.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.0 p30 -80.22 -13.41 59.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.29 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.3 19.74 61.87 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 47.4 p -102.18 138.83 38.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 111.594 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.3 mt -92.29 131.0 37.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.181 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -137.3 138.24 39.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.873 ' HB1' ' NE2' ' A' ' 30' ' ' HIS . . . -69.26 136.12 51.48 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.297 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.662 ' N ' ' NE2' ' A' ' 30' ' ' HIS . 4.6 mmp_? -146.13 136.53 12.16 Favored Pre-proline 0 CA--C 1.537 0.454 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.178 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.88 159.85 30.87 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.865 2.377 . . . . 0.0 113.118 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.9 t -101.42 139.02 23.66 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 177.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.6 m -130.68 4.56 2.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.06 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 p -149.34 145.2 26.89 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.175 0.898 . . . . 0.0 109.025 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.612 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.26 123.76 13.98 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.51 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -136.41 145.12 44.94 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -91.88 140.32 29.79 Favored 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.445 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 3.9 mm100 -89.84 -4.19 57.72 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.338 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 77.46 21.62 72.18 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.657 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ARG . 0.4 OUTLIER 64.53 135.3 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.836 0.35 . . . . 0.0 110.087 -179.945 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ARG . . . . . 0.419 ' CG ' ' O ' ' A' ' 53' ' ' THR . 72.0 mtp180 -157.27 174.92 14.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.404 178.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASP . . . . . 0.443 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 50.3 t0 -73.93 139.67 45.07 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -142.13 152.73 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.09 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.726 HD11 ' HB1' ' A' ' 84' ' ' ALA . 44.6 pt -104.86 152.05 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.177 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.79 138.1 14.26 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.6 mt -121.32 114.57 21.53 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 121.111 0.481 . . . . 0.0 110.365 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -87.0 113.78 23.05 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.888 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 15.7 mm . . . . . 0 CA--C 1.511 -0.523 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 110.441 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.47 150.77 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.212 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 57.9 tp -123.99 113.55 18.58 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.823 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.556 ' CG ' ' NH2' ' A' ' 115' ' ' ARG . 95.3 m95 -104.5 121.28 43.14 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.95 171.94 15.53 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.318 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' THR . . . . . 0.418 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 40.2 p -78.56 154.41 78.79 Favored Pre-proline 0 C--N 1.329 -0.294 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.109 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.66 -22.15 59.23 Favored 'Trans proline' 0 N--CA 1.495 1.578 0 C-N-CA 122.027 1.818 . . . . 0.0 112.113 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -93.15 -7.71 44.6 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.79 0.328 . . . . 0.0 110.364 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.8 t60 -66.81 126.83 30.29 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mptt -82.72 123.42 29.28 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.219 0.533 . . . . 0.0 111.395 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.5 t -99.73 139.68 20.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.732 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.66 95.02 5.16 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.867 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 13.9 p -98.7 174.67 6.3 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -66.78 -14.9 63.15 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.29 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 68.4 m-85 -108.05 25.22 11.86 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.483 0.183 . . . . 0.0 110.744 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.59 -141.15 15.35 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.74 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 92.5 m95 -94.47 129.31 41.29 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.966 0.412 . . . . 0.0 111.172 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.9 tpt180 -138.7 131.42 29.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.441 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.62 144.49 26.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.012 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.726 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.07 -37.94 84.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 120.936 -0.306 . . . . 0.0 111.613 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.77 -5.33 24.16 Favored Glycine 0 CA--C 1.528 0.9 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.795 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -103.38 4.9 36.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.962 0.411 . . . . 0.0 110.432 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.5 mt -90.67 131.05 36.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.404 0.621 . . . . 0.0 111.122 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.517 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.4 mmt180 -129.2 148.96 51.18 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.705 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -45.27 90.83 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 153.72 -12.33 0.55 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -84.09 130.77 34.84 Favored 'General case' 0 C--O 1.228 -0.079 0 CA-C-O 120.936 0.398 . . . . 0.0 110.672 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.411 ' HE ' HG12 ' A' ' 107' ' ' VAL . 93.9 mtt180 -92.48 141.55 28.39 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.724 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.51 158.98 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.282 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.6 130.35 43.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.105 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.452 HG21 ' OG ' ' A' ' 106' ' ' SER . 1.4 t -130.87 132.79 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.434 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -84.29 125.61 32.42 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.742 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 37.5 t0 -99.81 122.62 43.04 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.999 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 -17.8 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 118.35 0.523 . . . . 0.0 111.303 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 -69.64 -59.74 2.77 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 120.517 -0.473 . . . . 0.0 109.898 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.438 ' C ' ' H ' ' A' ' 102' ' ' GLU . 33.8 p -93.1 -12.85 29.46 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.12 -14.27 6.52 Favored Glycine 0 C--N 1.331 0.278 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.438 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.5 mt-10 -83.38 157.95 22.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.841 0.353 . . . . 0.0 110.824 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.604 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -82.39 133.71 35.23 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.22 0.533 . . . . 0.0 109.852 179.755 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.4 ptt85 -138.18 137.14 37.32 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.408 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -78.55 147.32 33.83 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -177.538 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.452 ' OG ' HG21 ' A' ' 95' ' ' VAL . 3.2 m -134.98 160.44 38.31 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.575 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.431 HG22 ' H ' ' A' ' 107' ' ' VAL . 17.0 m -91.73 153.67 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.5 mm -70.23 156.33 7.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.084 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.443 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt85 -107.61 -46.63 3.79 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.989 178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -166.3 145.95 6.0 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.436 ' C ' HD22 ' A' ' 112' ' ' LEU . 19.3 t -93.33 131.84 39.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -99.57 148.48 34.79 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.047 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.88 160.34 50.16 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.408 2.072 . . . . 0.0 111.126 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.425 HG23 ' H ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -69.26 156.67 38.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 120.999 0.428 . . . . 0.0 110.585 -179.387 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.556 ' NH2' ' CG ' ' A' ' 68' ' ' TRP . 39.3 ptt180 -139.87 -144.41 0.17 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.964 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -154.03 134.75 13.66 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.69 172.12 3.64 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.983 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.47 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 91.4 mtm-85 -71.45 140.54 50.07 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.519 178.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 143.01 51.28 Favored 'General case' 0 C--O 1.231 0.126 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.455 ' HB3' HG21 ' A' ' 23' ' ' VAL . 52.2 m-85 -120.61 178.02 4.84 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.719 -177.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -153.49 120.75 5.81 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.269 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.639 HD21 HG22 ' A' ' 23' ' ' VAL . 84.8 mt -119.57 123.53 44.15 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.744 0.307 . . . . 0.0 110.443 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -88.51 111.51 21.91 Favored 'General case' 0 CA--C 1.514 -0.441 0 C-N-CA 120.612 -0.435 . . . . 0.0 109.899 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 59.8 t -86.49 119.74 35.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.464 -0.495 . . . . 0.0 109.849 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 33.2 tp10 21.71 -121.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.961 0.788 . . . . 0.0 111.148 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -104.17 -26.81 12.39 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.916 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.431 ' O ' ' N ' ' A' ' 129' ' ' THR . 66.9 mt -81.86 70.54 8.78 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.527 ' O ' HG23 ' A' ' 129' ' ' THR . 1.7 m-70 -41.57 98.83 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 179.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.46 141.49 0.02 OUTLIER 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.997 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.3 pp -146.65 155.85 42.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.377 0.608 . . . . 0.0 111.614 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 131' ' ' VAL . 8.4 p -89.8 125.48 42.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.875 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.518 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -132.62 132.36 42.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.784 -179.222 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.618 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 49.7 46.49 23.8 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.22 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.39 -13.35 0.58 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.431 -0.667 . . . . 0.0 111.431 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.2 t -95.18 150.64 4.08 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.27 0 CA-C-N 117.061 0.43 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.6 t -107.97 113.52 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.65 0.262 . . . . 0.0 110.531 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' HIS . 22.9 m -148.28 141.05 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.109 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.546 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 57.2 t-80 -30.25 151.5 0.0 OUTLIER 'General case' 0 C--O 1.224 -0.254 0 CA-C-O 120.989 0.424 . . . . 0.0 112.05 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 p30 . . . . . 0 C--N 1.32 -0.683 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.674 -179.342 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 39.4 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LEU . . . . . 0.464 HD11 HD11 ' A' ' 130' ' ' LEU . 76.5 mt -109.34 136.42 48.8 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.906 0.384 . . . . 0.0 110.338 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.32 162.75 21.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.519 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.74 141.1 58.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.115 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.87 -17.67 22.5 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 14.4 m -68.91 120.43 14.8 Favored 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.534 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.424 ' HG2' ' HE ' ' A' ' 18' ' ' ARG . 85.9 mtm180 -94.6 114.59 26.57 Favored 'General case' 0 N--CA 1.456 -0.141 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.6 mp -102.37 114.87 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 4.6 t80 -77.16 135.41 38.53 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 9.7 t0 -102.79 132.62 21.05 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.647 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.22 -30.95 9.94 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.672 2.248 . . . . 0.0 112.37 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.512 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 47.1 t -71.31 -55.02 15.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.737 -179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.0 p -78.19 -37.0 46.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.043 0.449 . . . . 0.0 110.271 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.29 82.68 Favored Glycine 0 CA--C 1.52 0.389 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.23 -168.73 1.43 Allowed 'General case' 0 C--N 1.34 0.171 0 CA-C-N 117.621 0.71 . . . . 0.0 109.501 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 63.7 m -113.6 117.34 31.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.259 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 58.9 m170 -103.46 143.59 32.51 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.341 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.424 ' HE ' ' HG2' ' A' ' 7' ' ' ARG . 23.2 mmt85 -96.59 126.08 41.52 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.64 179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.457 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -51.4 -42.54 28.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.213 0.53 . . . . 0.0 111.19 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 4.5 pt-20 -58.72 -32.08 68.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.823 -177.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.5 t0 -83.81 -38.49 21.19 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.29 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 86.6 t -64.65 -40.8 90.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.337 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 50.3 t -73.51 -44.58 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -57.52 -37.94 73.86 Favored 'General case' 0 CA--C 1.513 -0.472 0 C-N-CA 120.823 -0.351 . . . . 0.0 111.227 -177.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.568 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.2 29.37 9.27 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.568 ' C ' ' O ' ' A' ' 25' ' ' GLY . 89.1 mtt-85 16.12 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -87.31 113.99 56.5 Favored Pre-proline 0 N--CA 1.449 -0.491 0 O-C-N 123.434 0.459 . . . . 0.0 111.177 -176.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.6 89.43 0.06 OUTLIER 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.159 1.906 . . . . 0.0 110.414 178.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.51 -172.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 120.867 0.365 . . . . 0.0 110.497 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.425 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 52.4 m80 -127.94 160.63 31.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.598 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -149.41 172.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.2 t -90.93 136.05 25.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.406 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.7 167.77 10.34 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.763 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.0 143.24 44.69 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.325 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.01 177.7 4.55 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.653 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -70.0 -13.63 62.32 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 110.658 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -80.13 -18.21 50.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.453 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.89 24.16 39.14 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.6 p -103.06 136.83 42.15 Favored 'General case' 0 N--CA 1.463 0.207 0 O-C-N 122.724 -0.28 . . . . 0.0 111.281 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.3 mt -94.22 130.67 40.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.819 0.343 . . . . 0.0 110.648 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 7.1 t-160 -142.36 139.24 31.69 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.838 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.91 139.95 53.04 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.555 -178.257 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.487 ' CZ ' ' OE1' ' A' ' 126' ' ' GLU . 14.5 mmt180 -142.92 140.35 17.99 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.376 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -78.37 157.03 29.28 Favored 'Trans proline' 0 N--CA 1.491 1.324 0 C-N-CA 122.757 2.305 . . . . 0.0 113.019 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.57 134.87 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.067 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.8 m -125.6 0.23 4.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.645 -179.06 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.1 141.99 25.8 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 119.144 0.884 . . . . 0.0 108.912 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.592 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -139.39 120.74 14.93 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 178.398 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -139.22 145.86 39.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.318 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -89.95 133.52 34.74 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.446 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -92.75 -1.98 56.36 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.653 -0.249 . . . . 0.0 111.298 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 119' ' ' THR . . . 87.66 175.76 48.35 Favored Glycine 0 C--N 1.339 0.698 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.376 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.0 m -90.44 118.67 30.1 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -141.95 172.6 12.46 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.939 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 99.5 m-20 -75.32 141.57 43.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.889 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.1 m -141.85 157.67 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.494 ' CG2' HG22 ' A' ' 114' ' ' THR . 45.5 pt -112.79 153.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.206 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.32 139.26 14.5 Favored Glycine 0 N--CA 1.465 0.577 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.2 mt -120.41 112.35 18.88 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.143 0.497 . . . . 0.0 110.464 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -89.39 111.43 22.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.555 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm . . . . . 0 N--CA 1.468 0.433 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.737 -179.066 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.948 0.404 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.453 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.6 mt -124.89 155.01 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.462 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.453 ' N ' HG22 ' A' ' 66' ' ' ILE . 47.1 tp -132.08 116.5 17.13 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.118 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -104.63 115.54 30.52 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.18 172.49 12.62 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.62 156.87 80.41 Favored Pre-proline 0 C--N 1.327 -0.401 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -61.68 -21.65 72.59 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.649 2.233 . . . . 0.0 111.826 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 24.5 p30 -93.09 -4.83 51.66 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.248 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.533 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.5 t60 -72.27 129.56 38.72 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -86.19 127.47 34.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-O 121.277 0.56 . . . . 0.0 110.251 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.827 ' O ' HG23 ' A' ' 77' ' ' THR . 91.2 t -108.26 92.39 2.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.117 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 75' ' ' VAL . 9.6 tp -31.01 93.59 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.644 0.59 . . . . 0.0 111.442 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.827 HG23 ' O ' ' A' ' 75' ' ' VAL . 29.9 p -98.34 177.19 5.44 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.747 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.524 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 6.0 pt-20 -65.05 -21.36 66.82 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.232 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.524 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 57.8 m-85 -104.47 25.09 10.64 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 120.459 0.171 . . . . 0.0 110.905 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.445 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.22 -176.07 41.73 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -58.62 129.68 43.24 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.696 -177.142 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 73.4 mtm180 -145.9 134.55 22.21 Favored 'General case' 0 C--N 1.339 0.118 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.063 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.27 141.11 24.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.04 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.5 -36.98 84.27 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.143 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.73 -1.44 2.7 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.672 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.7 mt-10 -108.16 6.58 26.92 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 88.9 mt -85.1 125.95 33.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.262 0.553 . . . . 0.0 110.975 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.553 ' O ' ' N ' ' A' ' 90' ' ' GLY . 25.2 mmt85 -130.5 147.53 52.2 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.584 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -45.89 88.22 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 120.897 0.38 . . . . 0.0 110.632 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.0 -16.82 0.37 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -86.23 130.88 34.37 Favored 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.885 0.374 . . . . 0.0 110.419 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.67 135.25 34.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.0 m -120.43 152.02 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.52 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -64.3 139.64 58.79 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.164 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.73 HG21 ' OG ' ' A' ' 106' ' ' SER . 26.9 m -138.55 156.7 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.391 178.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -106.09 130.65 53.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.679 0.276 . . . . 0.0 110.317 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -101.63 125.86 48.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.581 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 98' ' ' VAL . 7.4 p -73.94 -14.74 16.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 118.203 0.456 . . . . 0.0 111.279 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -67.85 -60.38 2.56 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.822 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.571 ' HB ' ' OE1' ' A' ' 102' ' ' GLU . 53.3 m -103.39 -12.9 16.89 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.251 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 80.39 -11.19 39.35 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.995 177.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.703 ' N ' ' OE1' ' A' ' 102' ' ' GLU . 0.0 OUTLIER -77.18 158.8 30.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-O 121.558 0.694 . . . . 0.0 112.161 -179.149 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.52 HD21 ' HB1' ' A' ' 94' ' ' ALA . 5.9 tp -83.07 133.08 35.09 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.824 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.514 ' O ' HG22 ' A' ' 95' ' ' VAL . 85.0 mtp180 -133.9 172.87 12.2 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.3 m-30 -109.46 142.25 40.74 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.389 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.73 ' OG ' HG21 ' A' ' 95' ' ' VAL . 6.7 m -134.43 154.39 51.41 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.37 155.15 3.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 110.864 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 63.1 mt -73.44 153.05 7.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.836 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.8 mmm180 -108.29 -43.24 4.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.021 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -164.69 141.82 6.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.472 ' C ' HD22 ' A' ' 112' ' ' LEU . 16.5 t -95.13 134.09 33.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.034 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.472 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.3 mm? -101.97 125.46 36.78 Favored Pre-proline 0 CA--C 1.538 0.509 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.88 163.72 0.2 Allowed 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.217 1.945 . . . . 0.0 111.831 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.494 HG22 ' CG2' ' A' ' 57' ' ' ILE . 61.4 p -68.04 156.78 36.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.089 0.471 . . . . 0.0 110.812 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' O ' ' OD1' ' A' ' 55' ' ' ASP . 42.4 ttm-85 -139.64 -136.94 0.12 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.974 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -158.97 131.16 6.66 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.411 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.33 172.8 3.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.071 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -76.18 145.75 39.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.871 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 52' ' ' GLY . 3.9 p -122.63 141.49 51.67 Favored 'General case' 0 N--CA 1.463 0.175 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CB ' HD12 ' A' ' 19' ' ' ILE . 83.5 m-85 -119.66 174.04 6.65 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.215 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -156.18 125.72 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.389 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 76.5 mt -119.54 121.7 39.98 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -86.73 115.28 24.06 Favored 'General case' 0 CA--C 1.512 -0.491 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.127 -177.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.53 117.89 33.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.542 ' O ' ' N ' ' A' ' 127' ' ' LEU . 40.0 tt0 -58.26 156.05 10.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.505 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.487 ' OE1' ' CZ ' ' A' ' 43' ' ' ARG . 91.0 mt-10 56.24 -69.16 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.395 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.542 ' N ' ' O ' ' A' ' 125' ' ' GLU . 95.9 mt -98.27 101.23 12.62 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.532 ' O ' HG23 ' A' ' 129' ' ' THR . 39.6 m80 -72.3 99.61 2.44 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.04 143.86 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.969 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.641 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.2 pp -144.38 152.86 41.3 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 121.182 0.515 . . . . 0.0 111.293 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.0 p -87.67 128.15 40.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.545 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.32 128.28 35.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.935 -179.308 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 72.9 mm-40 52.46 47.23 25.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.204 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.87 -18.43 0.47 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.7 t -90.59 151.02 3.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 CA-C-N 117.169 0.485 . . . . 0.0 110.287 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 62.1 t -106.41 112.98 41.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 138' ' ' HIS . 17.4 m -147.77 138.23 17.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.366 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.424 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.533 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 7.7 t60 -35.46 155.67 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.152 0 CA-C-O 120.747 0.308 . . . . 0.0 111.62 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 14.1 p30 . . . . . 0 C--N 1.322 -0.629 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.659 -179.415 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.625 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 11.9 m . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.72 131.85 53.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.837 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.78 162.72 18.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.525 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -62.18 141.46 58.18 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.442 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.94 -15.45 21.23 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.495 HG23 ' HG2' ' A' ' 133' ' ' GLU . 22.6 m -71.24 120.02 16.21 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.632 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -93.27 115.96 28.54 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 120.908 0.385 . . . . 0.0 110.322 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 57.5 mt -99.9 112.49 32.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.77 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 3.5 t80 -77.76 135.77 38.05 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.269 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.555 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.7 t0 -102.32 131.71 22.24 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.046 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.43 -32.5 7.94 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.577 2.184 . . . . 0.0 112.136 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.555 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.0 t -69.7 -52.88 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.222 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 m -79.02 -40.01 32.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.003 0.43 . . . . 0.0 110.385 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.77 82.17 Favored Glycine 0 N--CA 1.453 -0.205 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.896 HG22 ' H ' ' A' ' 16' ' ' THR . 12.7 m -104.19 -174.5 2.56 Favored 'General case' 0 C--N 1.338 0.086 0 CA-C-N 117.68 0.74 . . . . 0.0 109.613 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.896 ' H ' HG22 ' A' ' 15' ' ' THR . 88.1 m -112.23 118.97 36.76 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.068 179.142 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -113.43 151.8 30.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.477 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 66.3 mtt85 -100.27 128.77 46.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.607 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.423 HG23 ' N ' ' A' ' 20' ' ' GLU . 4.0 tt -52.28 -38.96 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 120.924 0.392 . . . . 0.0 111.2 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.2 pt-20 -60.78 -34.14 74.04 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.167 0.508 . . . . 0.0 110.771 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.575 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 7.1 t70 -85.31 -38.29 18.99 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.352 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.0 t -69.71 -42.71 80.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.9 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.512 ' CG2' HD21 ' A' ' 122' ' ' LEU . 34.1 t -76.14 -47.83 30.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.578 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 33.1 p-10 -56.53 -30.77 63.45 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 120.987 0.423 . . . . 0.0 110.603 -177.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' N ' ' OD1' ' A' ' 24' ' ' ASP . . . -109.64 21.49 25.71 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.52 ' C ' ' O ' ' A' ' 25' ' ' GLY . 43.1 ptt85 21.79 61.65 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.202 0 O-C-N 124.309 0.652 . . . . 0.0 109.324 179.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -79.02 134.65 59.52 Favored Pre-proline 0 N--CA 1.446 -0.658 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.049 -177.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -76.04 81.35 2.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.305 2.003 . . . . 0.0 111.247 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.6 pt -118.33 -169.72 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.499 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.444 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 54.3 m80 -128.35 164.53 22.44 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.826 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.6 m -148.47 171.79 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.401 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 74.6 t -90.81 131.6 37.55 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.11 167.83 9.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.205 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.62 141.81 39.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.912 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.76 177.73 4.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.909 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -70.43 -12.62 61.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 120.93 0.395 . . . . 0.0 110.609 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 64.6 t0 -81.32 -18.77 44.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.88 23.07 43.24 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.2 p -102.59 136.5 42.3 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.81 0.338 . . . . 0.0 111.012 178.526 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 77.9 mt -91.24 128.64 37.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.835 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -138.98 137.84 36.73 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.596 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.486 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -70.16 140.56 52.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.777 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.486 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.4 mmp_? -144.04 138.8 15.31 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.665 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -77.56 158.21 32.31 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 123.001 2.468 . . . . 0.0 113.142 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.3 t -101.34 136.46 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.4 m -127.89 3.01 3.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.554 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.464 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -152.5 149.54 28.64 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 119.426 1.012 . . . . 0.0 108.585 179.732 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.503 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -149.31 127.04 11.72 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.355 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 -140.02 148.43 41.83 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.708 0.632 . . . . 0.0 112.708 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.446 ' OD2' ' N ' ' A' ' 52' ' ' GLY . 15.1 t70 -105.84 138.58 41.8 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.685 ' NE2' ' C ' ' A' ' 120' ' ' PHE . 4.0 mt-30 -101.77 2.97 39.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.489 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.446 ' N ' ' OD2' ' A' ' 50' ' ' ASP . . . 85.15 -165.05 39.13 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.415 178.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.439 HG22 ' NH2' ' A' ' 116' ' ' ARG . 20.9 m -87.16 127.72 35.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -148.82 160.79 42.9 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.821 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.79 139.73 41.95 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.05 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.77 156.07 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.4 pt -107.8 149.37 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.359 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.38 142.68 15.67 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 75.8 mt -127.9 114.73 17.56 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.2 0.524 . . . . 0.0 110.654 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 56.6 ttp180 -96.66 122.45 39.6 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 55.1 mt . . . . . 0 N--CA 1.467 0.403 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.232 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.1 mt -122.65 151.06 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.236 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -126.56 115.69 19.91 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.931 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -105.41 116.34 31.77 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -143.04 171.78 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.397 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -79.41 156.2 76.1 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.616 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -62.26 -17.48 57.27 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.597 2.198 . . . . 0.0 111.882 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -95.9 -6.71 38.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.742 0.306 . . . . 0.0 110.38 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.4 t60 -69.03 127.46 33.23 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.7 mmtp -85.97 128.19 34.79 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.902 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.6 t -103.31 141.29 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.341 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 56.3 tp -78.0 93.29 4.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.886 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.494 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 76.1 p -98.33 173.66 6.87 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -178.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -63.7 -16.24 60.54 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.367 -179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -108.06 25.65 11.34 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.82 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.58 -176.1 46.1 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -58.64 133.12 55.61 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.206 0.527 . . . . 0.0 110.478 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -146.11 134.73 22.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.666 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.99 137.98 31.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.08 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.402 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.3 -37.9 87.32 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.222 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.32 -2.42 3.02 Favored Glycine 0 C--N 1.335 0.503 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.734 -179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.402 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.8 mm-40 -108.17 11.51 27.41 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.918 0.389 . . . . 0.0 110.321 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.0 mt -92.93 128.15 38.7 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.465 0.65 . . . . 0.0 111.072 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.572 ' O ' ' N ' ' A' ' 90' ' ' GLY . 14.8 tpt180 -130.51 149.52 52.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.976 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -45.76 86.57 0.0 OUTLIER 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.557 179.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.77 -14.83 0.29 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -85.02 131.78 34.42 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.707 -0.29 . . . . 0.0 110.29 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -89.21 130.74 35.58 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.434 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.0 m -116.64 146.35 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.584 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.452 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -71.64 137.55 47.98 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.704 0.288 . . . . 0.0 111.073 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.17 161.92 38.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.004 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -103.5 130.98 50.99 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.508 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.543 ' OD2' ' NH2' ' A' ' 104' ' ' ARG . 42.5 t0 -100.62 123.96 45.54 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.33 -16.65 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 CA-C-N 118.297 0.499 . . . . 0.0 111.261 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -71.26 -58.27 3.7 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.139 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.8 p -95.18 -15.02 23.61 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.651 -0.25 . . . . 0.0 110.34 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.99 -13.98 5.07 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 98.2 mt-10 -81.49 159.87 24.09 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-O 120.755 0.312 . . . . 0.0 110.758 -177.767 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.452 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.7 tp -85.32 128.79 34.83 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.163 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.543 ' NH2' ' OD2' ' A' ' 97' ' ' ASP . 16.5 ptp180 -127.24 175.81 7.88 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.33 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.494 ' OH ' ' C ' ' A' ' 77' ' ' THR . 0.8 OUTLIER -114.68 147.26 39.88 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.835 179.877 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -144.23 163.06 34.76 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.413 ' H ' HG22 ' A' ' 107' ' ' VAL . 9.4 m -94.79 155.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-O 120.674 0.273 . . . . 0.0 110.483 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.468 HG22 ' N ' ' A' ' 109' ' ' ARG . 68.1 mt -73.08 159.43 5.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 120.97 0.414 . . . . 0.0 110.303 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.468 ' N ' HG22 ' A' ' 108' ' ' ILE . 24.9 mmt180 -105.26 -44.97 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.192 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -165.23 143.55 6.27 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.497 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.9 p -96.19 134.86 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.497 HD22 ' C ' ' A' ' 111' ' ' VAL . 2.6 mm? -104.06 147.69 34.71 Favored Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.34 166.66 27.57 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 122.533 2.155 . . . . 0.0 111.357 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 21.8 p -66.12 151.56 46.65 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.21 0.528 . . . . 0.0 110.689 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -133.86 -148.48 0.33 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.092 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.439 ' NH2' HG22 ' A' ' 53' ' ' THR . 25.7 mmm180 -148.88 127.62 12.52 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.147 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.61 175.52 2.48 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.756 -178.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -79.48 147.03 32.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.928 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.2 p -121.12 140.81 51.48 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.1 0.476 . . . . 0.0 109.747 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.685 ' C ' ' NE2' ' A' ' 51' ' ' GLN . 58.3 m-85 -114.9 168.02 10.28 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.921 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.599 ' C ' HD22 ' A' ' 122' ' ' LEU . 66.4 t0 -147.47 131.16 16.91 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.219 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.599 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.62 163.88 14.81 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.486 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -135.1 104.84 6.08 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.017 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 17.4 t -91.93 120.7 41.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.418 ' O ' ' N ' ' A' ' 127' ' ' LEU . 75.7 tt0 -62.69 152.9 34.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.5 tt0 62.17 -70.57 0.05 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.81 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.418 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -99.96 104.45 16.07 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.548 ' O ' HG23 ' A' ' 129' ' ' THR . 62.3 m80 -73.99 100.2 3.49 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.675 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 165.89 144.67 0.02 OUTLIER 'General case' 0 C--N 1.344 0.35 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.964 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.634 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.43 155.5 43.77 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-O 121.759 0.79 . . . . 0.0 111.566 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.88 125.14 40.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.473 ' HB1' HG21 ' A' ' 6' ' ' THR . . . -131.88 125.73 32.45 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.052 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.525 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 50.36 46.47 25.11 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.939 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.17 -17.24 0.43 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.525 ' H ' ' C ' ' A' ' 133' ' ' GLU . 12.1 t -92.34 150.94 3.68 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 O-C-N 122.285 -0.538 . . . . 0.0 110.727 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.19 114.35 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 137' ' ' VAL . 18.0 m -146.74 132.14 12.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.315 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.517 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 50.2 t-80 -37.21 159.86 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.74 0.305 . . . . 0.0 111.74 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.485 ' N ' ' CG ' ' A' ' 138' ' ' HIS . 21.1 p30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.388 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 73.0 mt -106.9 138.44 43.07 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.415 -179.289 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.87 164.13 20.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.85 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -64.02 145.41 55.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.233 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.03 -17.6 44.43 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.6 m -67.67 123.93 21.86 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.437 ' HE ' HG21 ' A' ' 16' ' ' THR . 61.0 mtp180 -81.62 147.78 29.4 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.829 0.347 . . . . 0.0 110.263 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 19' ' ' ILE . 90.3 mt -134.46 106.4 7.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.857 179.182 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.4 t80 -77.52 133.5 38.52 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.238 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 17.1 t0 -106.49 129.62 24.2 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.44 -26.4 24.42 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.119 1.88 . . . . 0.0 112.512 -179.546 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.509 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 38.9 t -78.34 -53.1 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.016 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.8 p -79.97 -34.63 38.5 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 120.975 0.417 . . . . 0.0 110.134 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.94 9.5 86.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.595 HG22 ' N ' ' A' ' 16' ' ' THR . 87.8 m -113.17 166.73 11.16 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 117.873 0.836 . . . . 0.0 109.65 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.595 ' N ' HG22 ' A' ' 15' ' ' THR . 38.5 m -90.26 116.09 27.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.316 0.579 . . . . 0.0 111.321 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -102.12 144.47 30.65 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.153 -0.931 . . . . 0.0 110.147 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 92.2 mtt-85 -98.77 129.84 45.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.606 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.492 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.6 tp -52.79 -40.03 33.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.721 0.296 . . . . 0.0 111.154 -179.104 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.492 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -60.56 -34.98 74.95 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.263 0.554 . . . . 0.0 110.11 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.76 -40.45 22.64 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.741 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 83.4 t -68.47 -42.58 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.4 t -72.21 -46.19 58.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.014 0.375 . . . . 0.0 112.014 -178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 66.8 t0 -58.56 -35.17 71.94 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.157 0.503 . . . . 0.0 110.549 -177.938 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.3 25.45 12.45 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-O 118.853 -0.971 . . . . 0.0 111.049 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.566 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.2 ptt180 14.03 72.74 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 CA-C-N 117.427 0.614 . . . . 0.0 109.523 179.219 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -87.45 137.61 32.33 Favored Pre-proline 0 N--CA 1.445 -0.705 0 O-C-N 121.673 -0.642 . . . . 0.0 110.925 -175.623 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -74.52 83.33 1.74 Allowed 'Trans proline' 0 C--N 1.31 -1.465 0 C-N-CA 121.311 1.341 . . . . 0.0 110.618 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.7 pt -119.51 -170.53 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.811 0.339 . . . . 0.0 110.097 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.426 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 26.3 m80 -131.35 163.55 27.61 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.621 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.42 170.96 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 85.9 t -87.16 130.88 36.31 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.563 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.23 166.54 10.34 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.599 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.12 141.99 40.18 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.848 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.72 179.31 3.99 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -72.03 -13.63 61.65 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.91 0.386 . . . . 0.0 110.814 179.365 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -79.51 -21.55 45.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.402 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 91.46 19.55 41.12 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.4 p -99.22 135.61 40.38 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 121.098 0.475 . . . . 0.0 111.01 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.5 mt -91.65 127.72 37.21 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.269 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -137.95 138.94 39.46 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.73 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.06 142.42 50.86 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.384 -0.526 . . . . 0.0 109.85 -178.625 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.597 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.6 mmt180 -144.06 137.47 14.15 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.046 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.35 157.18 33.09 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 122.631 2.221 . . . . 0.0 112.73 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.0 135.7 31.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.57 2.88 3.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.647 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -150.69 144.84 25.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 119.173 0.897 . . . . 0.0 108.844 178.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -144.95 128.97 17.53 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -136.41 145.03 44.83 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.242 0.544 . . . . 0.0 112.255 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 53.2 p-10 -114.43 141.22 47.95 Favored 'General case' 0 CA--C 1.5 -0.959 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -110.27 -101.15 0.39 Allowed 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.002 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -173.82 -153.13 9.47 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 114.408 -1.269 . . . . 0.0 112.951 -177.126 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.1 m -86.32 129.3 34.9 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.1 0.476 . . . . 0.0 111.549 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -150.48 162.25 40.95 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.498 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -78.53 138.61 38.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.21 141.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 120.828 0.347 . . . . 0.0 110.281 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.657 HD11 ' HB1' ' A' ' 84' ' ' ALA . 41.1 pt -90.41 145.64 7.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.795 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.97 140.53 14.91 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 15.1 mt -125.12 114.09 18.57 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.102 0.477 . . . . 0.0 110.559 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.522 ' C ' HD12 ' A' ' 61' ' ' ILE . 36.0 ttm180 -91.53 112.85 24.94 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.275 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.726 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.469 0.489 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.412 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.093 0 CA-C-O 120.889 0.376 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.7 mt -119.13 142.0 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.24 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.566 HD23 ' C ' ' A' ' 67' ' ' LEU . 4.2 tt -120.41 113.08 19.8 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.197 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.555 ' N ' HD23 ' A' ' 67' ' ' LEU . 99.5 m95 -103.02 127.6 50.19 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.472 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.27 172.22 14.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.317 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.19 155.34 60.43 Favored Pre-proline 0 CA--C 1.535 0.38 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.353 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -63.62 -22.21 70.3 Favored 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.566 2.177 . . . . 0.0 112.012 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -91.24 -8.1 49.36 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 120.977 0.418 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.584 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.7 t60 -70.52 127.52 33.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.559 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.7 mtmm -86.11 132.62 33.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.135 0.493 . . . . 0.0 111.159 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.94 148.82 17.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.22 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 25.9 tp -85.37 92.07 8.37 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.794 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 79' ' ' TYR . 0.1 OUTLIER -107.73 139.92 41.56 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.16 0.505 . . . . 0.0 110.434 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.54 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 67.5 mm-40 60.02 -64.66 0.05 Allowed 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.134 -1.394 . . . . 0.0 111.262 178.433 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.582 ' N ' ' O ' ' A' ' 77' ' ' THR . 0.3 OUTLIER 179.15 55.71 0.01 OUTLIER 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 174.32 175.81 42.21 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 119.56 -1.305 . . . . 0.0 111.976 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -91.71 129.31 37.71 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.874 0.368 . . . . 0.0 110.815 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 -145.46 138.53 26.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.365 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.89 142.74 23.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.144 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.657 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -65.24 -37.82 88.45 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 120.885 -0.326 . . . . 0.0 111.724 -179.573 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.41 5.22 0.17 Allowed Glycine 0 CA--C 1.527 0.839 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.863 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.9 mt-10 -110.57 1.96 18.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.888 0.344 . . . . 0.0 110.259 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 61.3 mt -80.49 130.6 35.25 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.484 0.659 . . . . 0.0 111.127 -179.274 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.506 ' O ' ' N ' ' A' ' 90' ' ' GLY . 32.5 mmt180 -129.46 151.2 50.35 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.944 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -51.91 87.19 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.27 -21.32 0.49 Allowed Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -73.5 135.93 44.08 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.491 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -90.2 132.21 35.61 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 120.96 0.41 . . . . 0.0 110.248 -178.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.1 143.74 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.502 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.584 ' HB1' HD11 ' A' ' 103' ' ' LEU . . . -65.55 138.07 57.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.734 0.302 . . . . 0.0 110.52 -179.393 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.2 m -135.18 158.14 40.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.622 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -101.93 129.0 48.09 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.581 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -99.84 120.22 39.41 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.18 179.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 42.4 t -74.62 -15.1 16.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.387 0.539 . . . . 0.0 110.821 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.37 -60.09 2.56 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 120.447 -0.501 . . . . 0.0 109.923 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 74.5 p -96.2 -10.47 28.02 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.78 -12.66 5.99 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -83.21 158.13 22.43 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 120.792 0.33 . . . . 0.0 110.748 -177.622 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.584 HD11 ' HB1' ' A' ' 94' ' ' ALA . 5.2 tt -86.79 130.5 34.45 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.3 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.7 ptt85 -127.81 173.16 10.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.729 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.54 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.41 143.5 37.25 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.164 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.2 m -141.22 164.15 31.04 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.419 HG12 ' N ' ' A' ' 108' ' ' ILE . 98.2 t -98.1 154.91 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.423 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -70.78 157.1 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.875 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.423 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 59.8 ttt85 -101.43 -47.34 4.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.749 179.274 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -164.62 144.43 7.42 Favored 'General case' 0 C--N 1.341 0.197 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.425 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.7 p -93.0 132.34 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.425 HD22 ' C ' ' A' ' 111' ' ' VAL . 2.6 mm? -102.85 148.03 34.96 Favored Pre-proline 0 N--CA 1.469 0.491 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.426 -178.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.71 160.2 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.606 2.204 . . . . 0.0 110.992 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 114' ' ' THR . 1.4 p -65.96 155.01 37.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.061 0.458 . . . . 0.0 110.318 -178.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -147.99 143.69 27.44 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.002 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -71.92 131.01 42.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.964 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.69 168.21 14.58 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.723 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -81.46 149.72 28.63 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.669 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 50.6 p -133.12 144.38 49.89 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.375 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 2.8 m-85 -121.5 177.95 5.01 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.475 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -144.22 149.21 36.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.947 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.408 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.3 mt -138.97 170.14 16.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.616 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -137.29 106.66 6.09 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.926 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.48 ' O ' ' C ' ' A' ' 125' ' ' GLU . 48.9 t -85.72 113.55 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 124' ' ' VAL . 0.3 OUTLIER 21.4 -91.11 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 123.816 0.698 . . . . 0.0 111.771 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 124' ' ' VAL . 9.0 tp10 -135.23 -27.97 1.18 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.658 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.597 HD12 ' HE ' ' A' ' 43' ' ' ARG . 83.0 mt -82.13 67.59 8.21 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.416 ' C ' ' O ' ' A' ' 127' ' ' LEU . 20.6 m170 -39.61 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 170.89 140.89 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.117 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.533 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.1 pt? -151.15 160.88 43.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.69 0.757 . . . . 0.0 112.386 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 25.2 t -90.27 124.65 43.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -135.28 124.72 24.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.941 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.5 mm-40 53.12 42.53 32.19 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.04 28.07 68.24 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.652 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -131.58 152.12 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 97.6 t -106.67 111.06 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 O-C-N 122.11 -0.369 . . . . 0.0 110.308 179.146 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 138' ' ' HIS . 6.5 m -146.14 137.1 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.638 -0.256 . . . . 0.0 110.48 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.584 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 50.4 t-80 -33.57 156.72 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.565 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.436 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 7.7 p-10 . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.363 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.443 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 53.9 m . . . . . 0 N--CA 1.487 1.405 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.2 mt -118.38 134.68 54.85 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.728 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.4 ' HB2' ' CD1' ' A' ' 68' ' ' TRP . . . -80.59 161.7 24.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.503 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.45 145.98 54.53 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.55 -14.38 50.4 Favored Glycine 0 C--N 1.338 0.686 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.442 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.7 m -68.96 123.75 21.87 Favored 'General case' 0 C--O 1.234 0.278 0 O-C-N 122.652 -0.322 . . . . 0.0 110.587 -179.562 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 18' ' ' ARG . 10.6 mpt_? -83.67 150.62 25.75 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.238 0.542 . . . . 0.0 109.857 178.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 99.1 mt -133.89 107.74 10.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.691 179.252 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -77.25 126.57 31.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.1 t0 -104.91 129.76 24.3 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.982 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.79 -31.03 13.54 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.51 2.14 . . . . 0.0 111.989 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 71.1 t -69.13 -55.95 13.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.31 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 p -78.85 -37.58 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 110.059 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.27 7.99 85.92 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.461 HG22 ' N ' ' A' ' 16' ' ' THR . 91.6 m -115.61 157.63 23.88 Favored 'General case' 0 C--N 1.341 0.196 0 O-C-N 121.937 -0.743 . . . . 0.0 109.756 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.461 ' N ' HG22 ' A' ' 15' ' ' THR . 15.2 m -78.91 116.95 19.56 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.05 0.452 . . . . 0.0 110.982 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -102.24 144.16 31.11 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.371 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 7' ' ' ARG . 39.1 ttm180 -96.53 124.07 40.41 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.324 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -52.67 -40.37 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 O-C-N 121.992 -0.443 . . . . 0.0 111.426 -178.433 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 4.0 pt-20 -56.82 -35.23 68.54 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.984 0.421 . . . . 0.0 110.666 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -83.22 -39.44 20.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.125 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.8 t -66.93 -41.73 87.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.563 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.75 HG22 HD21 ' A' ' 122' ' ' LEU . 71.9 t -72.1 -46.29 59.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.513 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -57.87 -36.34 72.21 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 120.948 -0.301 . . . . 0.0 110.866 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.537 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.85 30.13 10.84 Favored Glycine 0 N--CA 1.452 -0.292 0 N-CA-C 110.536 -1.026 . . . . 0.0 110.536 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.537 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtt85 15.79 64.33 0.01 OUTLIER 'General case' 0 C--N 1.364 1.207 0 CA-C-N 117.418 0.609 . . . . 0.0 110.254 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.429 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.0 mttt -89.78 144.2 31.36 Favored Pre-proline 0 N--CA 1.444 -0.732 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.294 -178.074 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.541 ' O ' ' O ' ' A' ' 29' ' ' ILE . 45.7 Cg_endo -70.21 10.11 0.59 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.236 1.957 . . . . 0.0 112.33 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.616 HG22 ' N ' ' A' ' 30' ' ' HIS . 3.7 mm -37.37 168.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 O-C-N 123.718 0.636 . . . . 0.0 110.124 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.616 ' N ' HG22 ' A' ' 29' ' ' ILE . 3.7 m80 -122.68 167.27 13.65 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.953 0.406 . . . . 0.0 110.707 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.9 m -148.63 170.73 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -89.52 134.65 28.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.246 0 O-C-N 121.675 -0.64 . . . . 0.0 109.624 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.48 166.91 10.61 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.785 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.27 144.99 42.99 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.068 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.12 179.0 4.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.642 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.431 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 68.5 mmtt -68.03 -12.57 61.05 Favored 'General case' 0 C--O 1.235 0.322 0 O-C-N 121.821 -0.549 . . . . 0.0 110.767 179.289 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -76.81 -19.41 57.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.346 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.04 -7.57 76.34 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.9 p -80.08 150.21 30.37 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.262 0.553 . . . . 0.0 111.203 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.9 mt -103.77 135.66 44.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.934 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -141.11 139.72 34.03 Favored 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.701 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.36 140.74 52.22 Favored 'General case' 0 CA--C 1.506 -0.736 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.657 -178.175 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.452 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.0 OUTLIER -143.51 137.66 14.73 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.231 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 43' ' ' ARG . 2.9 Cg_exo -74.78 158.27 43.13 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 123.105 2.537 . . . . 0.0 112.711 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 70.3 t -98.29 133.59 39.96 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 177.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.6 m -125.73 0.14 4.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.215 -179.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.416 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -150.16 145.04 26.05 Favored 'General case' 0 N--CA 1.448 -0.563 0 O-C-N 121.026 -1.046 . . . . 0.0 108.676 179.411 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.584 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.06 123.2 13.68 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 178.095 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -140.94 146.73 37.76 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -87.58 133.24 33.83 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.415 ' HB3' HE21 ' A' ' 51' ' ' GLN . 1.8 mm100 -89.79 -0.49 57.58 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.86 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.73 174.28 50.06 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 97.4 m -91.67 127.43 37.12 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.031 0.443 . . . . 0.0 110.354 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -154.92 176.2 12.82 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.715 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 55' ' ' ASP . 0.6 OUTLIER -74.19 136.57 42.81 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.163 -179.539 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.959 ' CG2' ' HE1' ' A' ' 68' ' ' TRP . 1.5 m -145.4 156.59 13.3 Favored 'Isoleucine or valine' 0 C--N 1.34 0.153 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.536 HD13 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -109.14 155.79 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.845 -178.782 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.77 121.07 5.45 Favored Glycine 0 CA--C 1.521 0.455 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 20.7 mt -102.55 116.77 33.28 Favored 'General case' 0 C--O 1.225 -0.219 0 O-C-N 122.381 -0.482 . . . . 0.0 110.133 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.525 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 55.7 ttp180 -101.09 128.58 47.09 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.161 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 91.6 mt . . . . . 0 N--CA 1.465 0.297 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.575 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.1 tt -121.12 138.79 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.82 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 42.6 tp -126.4 112.5 15.71 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.099 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.959 ' HE1' ' CG2' ' A' ' 56' ' ' VAL . 4.3 t-105 -107.71 125.79 51.81 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HB1' ' O ' ' A' ' 1' ' ' CYS . . . -154.85 175.44 13.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.233 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' THR . . . . . 0.736 ' HA ' HG12 ' A' ' 56' ' ' VAL . 71.3 p -77.06 154.0 82.64 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.16 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.12 -22.21 73.97 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.649 2.233 . . . . 0.0 111.889 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -91.07 -6.0 54.41 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.1 t60 -70.96 128.7 36.87 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -85.34 128.42 34.7 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.01 0.433 . . . . 0.0 111.304 -179.125 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -102.8 139.79 22.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.59 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.9 tp -79.37 93.41 5.33 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.955 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.46 HG21 ' HE ' ' A' ' 82' ' ' ARG . 44.7 p -99.22 175.89 5.73 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.278 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.763 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.0 pt-20 -64.94 -17.53 64.46 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.284 -0.567 . . . . 0.0 111.268 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -105.77 25.97 10.18 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 121.125 -0.23 . . . . 0.0 110.811 -178.728 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.72 -141.13 15.43 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.431 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 87.7 m95 -93.64 129.99 39.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.452 -0.374 . . . . 0.0 111.142 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.46 ' HE ' HG21 ' A' ' 77' ' ' THR . 77.4 mtm180 -142.01 131.78 24.22 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.274 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.76 17.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.024 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.84 -37.67 87.76 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.124 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.1 -2.72 2.97 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.619 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.64 10.87 28.95 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.93 0.395 . . . . 0.0 110.378 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.1 mt -93.51 126.94 38.94 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.378 0.608 . . . . 0.0 111.638 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.589 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.6 mmt180 -132.14 151.63 51.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.469 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -47.88 85.52 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.242 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 160.28 -15.97 0.2 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -84.91 130.32 34.66 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 116.748 0.274 . . . . 0.0 110.304 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -93.37 143.21 26.5 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.275 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.4 m -135.08 158.97 41.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.593 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -75.2 131.62 40.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.635 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 m -129.21 132.88 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -74.13 125.62 28.75 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.927 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -99.7 123.84 44.36 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.182 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 16.1 t -75.39 -16.84 15.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 121.653 -0.654 . . . . 0.0 111.43 178.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -68.97 -59.03 3.33 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 23.1 p -95.43 -11.97 26.72 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.56 -13.2 6.73 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.8 mt-10 -87.15 162.81 17.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.942 0.401 . . . . 0.0 110.639 -177.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.623 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.8 pt? -76.35 140.08 41.28 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -133.18 164.32 27.32 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.763 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.38 137.36 46.48 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.114 -178.373 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -144.04 163.03 34.7 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 107' ' ' VAL . 16.9 m -90.93 154.03 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.605 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -67.94 160.31 4.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.913 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 37.9 ttm180 -106.87 -51.71 2.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.973 179.304 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.525 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 83.1 tt0 -166.93 147.3 5.67 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.796 -0.565 . . . . 0.0 109.739 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.471 ' C ' HD22 ' A' ' 112' ' ' LEU . 91.8 t -96.77 134.46 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.471 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.1 mm? -101.64 131.27 23.13 Favored Pre-proline 0 CA--C 1.538 0.504 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.555 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.76 158.53 0.74 Allowed 'Trans proline' 0 N--CA 1.489 1.22 0 C-N-CA 121.956 1.771 . . . . 0.0 111.587 178.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.467 ' H ' HG23 ' A' ' 114' ' ' THR . 1.7 p -69.67 157.38 37.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.462 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.6 mtp85 -154.71 161.62 41.46 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.789 0.804 . . . . 0.0 111.11 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 83.7 mtt180 -85.01 130.21 34.66 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.354 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.54 167.38 13.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.164 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 87.0 mtm180 -81.17 149.92 28.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.143 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 1.4 p -127.61 143.32 51.18 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.288 0.566 . . . . 0.0 109.931 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -114.64 171.32 7.71 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.846 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -156.24 128.06 7.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.977 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.75 HD21 HG22 ' A' ' 23' ' ' VAL . 94.4 mt -126.0 125.75 43.18 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.751 0.31 . . . . 0.0 110.375 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 tp10 -86.67 112.62 21.81 Favored 'General case' 0 CA--C 1.513 -0.468 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.957 -178.703 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.4 t -85.24 112.41 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.55 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 124' ' ' VAL . 52.8 tt0 24.55 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.47 0 O-C-N 123.7 0.625 . . . . 0.0 111.578 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -130.77 -27.97 2.05 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.161 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 129' ' ' THR . 88.2 mt -77.01 66.9 2.92 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.448 ' O ' HG23 ' A' ' 129' ' ' THR . 47.7 m170 -38.27 95.84 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.62 139.32 0.02 OUTLIER 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.464 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.678 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.3 pp -147.29 155.61 42.19 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.659 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.2 p -88.66 123.19 40.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.016 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -131.58 128.78 39.93 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.75 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.537 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.7 mm-40 53.87 45.79 27.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.037 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.81 -17.68 0.5 Allowed Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.22 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.0 t -90.55 150.41 3.75 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.293 0 O-C-N 122.267 -0.549 . . . . 0.0 110.346 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 66.6 t -109.35 113.63 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.671 0.272 . . . . 0.0 110.423 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 138' ' ' HIS . 34.0 m -149.1 143.85 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.998 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.577 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 47.7 t-80 -27.53 148.86 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.087 0.403 . . . . 0.0 112.087 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.319 -0.751 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.721 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -112.25 136.32 51.82 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.392 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.49 161.03 22.52 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.688 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 -62.82 146.22 53.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.832 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.66 -15.82 37.67 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.544 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 m -69.07 121.95 17.74 Favored 'General case' 0 C--O 1.233 0.237 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.653 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -83.87 149.86 26.1 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.851 0.358 . . . . 0.0 110.108 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 94.4 mt -134.7 107.4 8.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.34 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -77.41 129.95 36.45 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.634 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -103.49 133.2 20.43 Favored Pre-proline 0 CA--C 1.541 0.626 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.594 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.32 -32.64 7.97 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.7 2.267 . . . . 0.0 112.236 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.634 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 68.9 t -69.22 -52.61 31.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.538 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 p -80.88 -37.74 29.26 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.03 9.74 83.85 Favored Glycine 0 C--N 1.331 0.293 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.22 -168.17 1.33 Allowed 'General case' 0 C--N 1.341 0.229 0 CA-C-N 117.725 0.763 . . . . 0.0 109.653 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.9 m -113.98 116.12 28.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.151 0.501 . . . . 0.0 110.283 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -105.27 147.41 28.11 Favored 'General case' 0 C--O 1.223 -0.335 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.413 -179.585 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.2 mmt85 -99.1 127.26 45.02 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.443 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.471 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.4 tt -53.02 -40.61 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.471 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -59.39 -33.83 71.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.672 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.6 t0 -84.35 -39.81 18.65 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.968 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 71.0 t -67.9 -43.01 86.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 65.2 t -73.57 -46.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.908 -0.317 . . . . 0.0 111.647 -178.797 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -60.43 -35.78 76.62 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.929 0.395 . . . . 0.0 111.013 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -100.25 25.17 29.3 Favored Glycine 0 C--N 1.322 -0.22 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.547 ' C ' ' O ' ' A' ' 25' ' ' GLY . 66.0 mtp180 17.14 59.73 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 25' ' ' GLY . 80.2 mttt -86.94 135.06 35.74 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.754 -177.058 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -75.36 84.89 1.64 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.222 1.948 . . . . 0.0 110.234 178.468 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.655 ' CG1' ' H ' ' A' ' 30' ' ' HIS . 5.2 tt -115.4 -174.5 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.994 0.426 . . . . 0.0 110.243 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.655 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 46.7 m80 -126.43 161.82 27.02 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.08 171.21 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.435 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.2 t -89.58 133.0 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.12 166.51 11.01 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.695 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.45 145.0 42.58 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.228 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.9 177.94 4.46 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -70.8 -14.0 62.25 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 120.848 0.356 . . . . 0.0 110.637 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 54.5 t0 -80.03 -18.97 48.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.28 179.721 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.56 23.34 34.01 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.8 p -102.31 136.11 42.72 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.854 0.359 . . . . 0.0 111.168 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 81.2 mt -92.5 128.59 38.41 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.017 0.437 . . . . 0.0 110.607 179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 34.5 m-70 -140.01 138.49 35.49 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.772 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.07 142.19 52.7 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.779 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -143.07 138.56 15.86 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.148 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.87 157.28 34.97 Favored 'Trans proline' 0 N--CA 1.489 1.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.822 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -98.99 133.7 40.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 20.0 m -124.98 -0.27 5.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.37 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -151.22 146.75 26.3 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.174 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.575 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.45 127.51 17.47 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 178.254 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -131.22 144.6 51.45 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.97 0.414 . . . . 0.0 111.643 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -116.08 139.62 50.11 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 178.713 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.449 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.3 mm-40 -109.2 -110.82 0.32 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.704 -1.134 . . . . 0.0 109.889 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -162.09 -156.81 8.59 Favored Glycine 0 C--N 1.303 -1.277 0 CA-C-N 114.233 -1.348 . . . . 0.0 112.482 -177.307 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 53' ' ' THR . 4.5 t -98.1 126.75 43.68 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.868 0.366 . . . . 0.0 111.178 -179.104 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -145.74 172.04 13.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.614 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -76.3 136.38 39.6 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.126 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.9 m -140.23 135.88 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.942 0.401 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.676 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.3 pt -87.86 148.79 4.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.717 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.47 126.8 8.35 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.0 mt -108.58 115.84 30.85 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.219 0.533 . . . . 0.0 110.938 -179.275 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -83.03 104.74 13.46 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.881 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.0 mm . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.242 -178.263 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.87 155.64 37.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.332 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.0 tp -133.39 118.24 18.2 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.153 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.8 m95 -104.34 114.16 28.21 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -139.45 171.2 14.6 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.484 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.65 157.02 72.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.361 -179.645 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -63.42 -18.13 63.17 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.645 2.23 . . . . 0.0 111.9 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -94.46 -9.99 33.78 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.876 0.37 . . . . 0.0 110.309 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.545 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.8 t60 -71.01 130.77 42.42 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -87.03 130.61 34.39 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.148 0.499 . . . . 0.0 111.144 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.36 142.29 18.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.875 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 52.9 tp -79.91 93.17 5.63 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.691 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 12.1 p -99.02 177.67 5.17 Favored 'General case' 0 CA--C 1.52 -0.19 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -178.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -68.09 -19.15 64.83 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.236 -179.137 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -104.63 24.1 12.28 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-O 120.733 0.302 . . . . 0.0 110.632 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.69 -176.03 42.56 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 81.2 m95 -57.91 127.76 33.68 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.014 0.435 . . . . 0.0 110.12 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 -142.36 133.54 26.11 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.888 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.44 140.01 29.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.675 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.676 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.15 -37.87 86.83 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.243 -179.287 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.01 -2.42 4.92 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.526 -179.618 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -106.0 -0.65 24.77 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.02 0.438 . . . . 0.0 110.418 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -81.55 127.79 33.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.151 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.548 ' O ' ' N ' ' A' ' 90' ' ' GLY . 8.9 tpp180 -131.01 149.75 52.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.179 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -45.5 89.04 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.644 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.05 -15.72 0.43 Allowed Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -86.39 130.15 34.61 Favored 'General case' 0 CA--C 1.523 -0.085 0 CA-C-O 121.023 0.44 . . . . 0.0 110.381 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -90.73 131.3 36.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.37 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 26.8 m -116.93 150.35 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.227 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.39 136.09 47.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.004 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.559 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.1 m -133.85 161.77 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.33 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 67.9 ttt-85 -104.67 128.37 52.7 Favored 'General case' 0 N--CA 1.462 0.14 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -100.92 123.49 45.2 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.082 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.401 ' H ' HG22 ' A' ' 98' ' ' VAL . 28.1 m -75.9 -15.4 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 118.179 0.445 . . . . 0.0 110.906 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -69.59 -58.45 3.93 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.06 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.437 HG23 ' H ' ' A' ' 102' ' ' GLU . 1.5 t -97.87 -12.4 22.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.269 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.35 -12.84 8.85 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.437 ' H ' HG23 ' A' ' 100' ' ' THR . 43.2 mt-10 -83.25 159.44 21.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.79 0.329 . . . . 0.0 110.749 -178.062 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.589 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -84.02 140.06 32.11 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.231 0.538 . . . . 0.0 109.934 179.642 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 59.4 mtp180 -137.07 171.91 13.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.218 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.8 m-30 -105.56 139.14 40.63 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.954 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.559 ' OG ' HG21 ' A' ' 95' ' ' VAL . 7.9 m -135.96 155.31 50.45 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.125 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 108' ' ' ILE . 9.7 p -95.2 157.21 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 122.573 0.349 . . . . 0.0 111.116 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.406 ' N ' HG22 ' A' ' 107' ' ' VAL . 42.7 mm -82.18 136.68 22.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.003 178.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.1 mmt85 -84.88 -38.44 19.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.694 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -169.45 151.85 4.61 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.459 ' C ' HD22 ' A' ' 112' ' ' LEU . 84.6 t -95.31 132.08 40.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.113 0.483 . . . . 0.0 110.176 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.459 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.0 mm? -100.37 131.48 23.91 Favored Pre-proline 0 N--CA 1.467 0.394 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.61 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.37 154.63 2.5 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.129 1.886 . . . . 0.0 111.662 178.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 57' ' ' ILE . 1.3 p -68.39 158.88 32.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.022 0.439 . . . . 0.0 110.518 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -151.46 149.12 28.89 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.047 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 57.0 mtm180 -78.33 132.58 37.49 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.197 0.522 . . . . 0.0 110.354 179.466 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.75 158.13 12.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.43 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -67.16 142.59 56.98 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 71.4 p -124.25 141.34 52.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.206 0.527 . . . . 0.0 109.899 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -116.67 174.84 5.86 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.82 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -152.63 128.96 10.56 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 82.2 mt -116.1 170.79 8.24 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.667 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -137.88 107.74 6.3 Favored 'General case' 0 CA--C 1.516 -0.346 0 C-N-CA 120.604 -0.439 . . . . 0.0 110.576 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.43 116.81 31.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 127' ' ' LEU . 38.8 tt0 -58.39 149.88 23.69 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.757 -179.207 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 61.64 -69.13 0.05 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.254 -0.885 . . . . 0.0 112.159 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -98.0 95.06 7.21 Favored 'General case' 0 CA--C 1.519 -0.23 0 O-C-N 122.285 -0.259 . . . . 0.0 110.413 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.614 ' O ' HG23 ' A' ' 129' ' ' THR . 75.5 m80 -67.04 99.84 0.69 Allowed 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.614 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.55 144.62 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.937 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.573 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.68 154.45 42.79 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 121.635 0.731 . . . . 0.0 111.788 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.76 127.25 41.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 179.253 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.93 129.74 36.74 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.401 -179.076 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 51.73 46.78 26.0 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.033 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.14 -21.01 0.39 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 8.1 t -90.4 152.42 3.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.172 0 O-C-N 122.27 -0.547 . . . . 0.0 110.588 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -106.53 114.64 46.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.358 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 10.1 m -147.15 136.16 15.99 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.467 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 21.7 t-80 -38.54 162.91 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.833 0.349 . . . . 0.0 111.621 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 12.6 p30 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.271 -179.838 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.572 ' HB3' HE22 ' A' ' 51' ' ' GLN . 5.5 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -118.02 134.56 54.86 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 120.89 0.376 . . . . 0.0 110.391 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -86.38 163.61 17.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.396 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.409 ' OE2' ' CD ' ' A' ' 20' ' ' GLU . 57.7 tt0 -63.02 142.16 58.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.506 178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.85 -21.09 30.43 Favored Glycine 0 C--N 1.334 0.458 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.8 m -66.04 123.48 19.96 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.01 148.88 28.41 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.838 0.352 . . . . 0.0 110.068 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.52 107.31 8.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -77.4 125.19 28.94 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.625 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 4.7 t70 -101.99 132.79 21.19 Favored Pre-proline 0 CA--C 1.538 0.501 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.846 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.95 -31.61 7.94 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.619 2.213 . . . . 0.0 112.166 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.625 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 66.2 t -71.47 -54.47 17.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.694 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.9 p -77.32 -38.94 49.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.961 0.41 . . . . 0.0 110.171 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.31 4.62 87.91 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.474 HG22 ' N ' ' A' ' 16' ' ' THR . 55.5 m -114.18 157.63 22.39 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 117.435 0.617 . . . . 0.0 109.85 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.474 ' N ' HG22 ' A' ' 15' ' ' THR . 40.2 m -78.47 116.65 19.01 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.28 0.562 . . . . 0.0 110.794 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' HIS . . . . . 0.541 ' CD2' HD11 ' A' ' 29' ' ' ILE . 87.0 m-70 -103.1 146.7 27.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.452 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -98.52 128.12 44.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.971 179.197 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.6 tp -52.2 -40.87 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.613 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.535 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.4 tt0 -57.56 -36.16 71.31 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.976 0.417 . . . . 0.0 110.852 -179.486 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.519 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 49.4 t0 -81.73 -35.7 29.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.47 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -67.32 -42.17 87.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.642 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.567 HG21 ' HB3' ' A' ' 120' ' ' PHE . 48.5 t -74.11 -46.79 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -177.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 0.6 OUTLIER -56.05 -37.57 69.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.824 -177.869 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.07 32.17 7.63 Favored Glycine 0 C--O 1.227 -0.287 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.6 ptm180 12.45 65.72 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.005 0 CA-C-O 121.189 0.518 . . . . 0.0 110.307 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.402 ' N ' ' O ' ' A' ' 25' ' ' GLY . 78.2 mttt -85.88 141.55 35.84 Favored Pre-proline 0 N--CA 1.447 -0.579 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.811 -177.724 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.548 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.4 Cg_endo -71.3 7.62 1.4 Allowed 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.23 1.953 . . . . 0.0 112.224 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' PRO . 12.8 tt -38.05 169.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 O-C-N 123.505 0.503 . . . . 0.0 110.597 -178.308 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.521 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 2.2 m80 -120.16 170.61 9.16 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.341 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.08 172.76 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.9 t -88.16 135.03 26.5 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.53 167.53 10.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.845 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.6 140.41 40.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.855 0.359 . . . . 0.0 110.373 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.23 179.06 4.06 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.564 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -68.44 -16.06 63.77 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-O 120.754 0.312 . . . . 0.0 110.764 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -74.8 -19.56 60.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.618 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.22 -11.89 69.84 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.0 p -74.8 148.74 40.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.141 0.496 . . . . 0.0 110.961 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 56.6 mt -104.78 135.09 46.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.802 -179.381 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -141.13 138.63 33.62 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.625 -179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -68.7 143.0 54.86 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.759 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.467 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.3 mmp_? -143.83 138.26 15.01 Favored Pre-proline 0 CA--C 1.538 0.483 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.829 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 160.06 37.42 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 123.058 2.505 . . . . 0.0 112.754 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.88 136.92 34.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.045 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.2 m -128.26 3.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.877 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 m -148.43 142.5 25.96 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.889 0.768 . . . . 0.0 109.239 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -144.09 123.26 12.93 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 178.554 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -143.91 149.13 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.822 0.675 . . . . 0.0 112.822 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -96.51 131.85 42.7 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.355 -0.979 . . . . 0.0 108.355 176.309 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.657 HE21 ' C ' ' A' ' 119' ' ' THR . 1.9 mt-30 -95.41 4.29 53.48 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.655 -0.248 . . . . 0.0 111.075 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.11 -172.09 47.11 Favored Glycine 0 C--N 1.336 0.576 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.821 179.15 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.463 ' OG1' ' CZ ' ' A' ' 118' ' ' ARG . 67.8 m -86.82 127.44 35.01 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 120.76 0.314 . . . . 0.0 110.308 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -148.18 159.6 43.78 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.605 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.0 143.24 43.67 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.873 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.01 147.11 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.117 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.513 HD13 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -100.86 148.13 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.944 -179.693 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.98 135.5 12.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -119.24 114.96 23.22 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.254 0.549 . . . . 0.0 110.346 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.2 tpt180 -95.95 116.81 29.5 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.776 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.9 mp . . . . . 0 N--CA 1.466 0.358 0 CA-C-O 120.987 0.422 . . . . 0.0 111.009 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.194 0 CA-C-O 121.084 0.469 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.5 tt -126.18 158.21 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.681 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.1 tp -138.61 121.73 16.85 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.429 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.1 m95 -106.06 128.96 54.21 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.96 172.39 16.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.411 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' THR . . . . . 0.434 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -82.65 155.98 68.21 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.793 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.31 -24.0 75.61 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.706 2.271 . . . . 0.0 111.918 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -87.6 -7.38 57.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.181 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -73.81 128.65 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -87.88 133.99 33.79 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.134 0.492 . . . . 0.0 111.034 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -105.44 140.44 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.061 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.614 HD23 ' CZ2' ' A' ' 81' ' ' TRP . 0.6 OUTLIER -83.39 95.29 8.18 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.176 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.454 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 50.1 p -98.72 179.37 4.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.493 -179.112 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.447 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 17.6 pt-20 -65.26 -17.61 64.64 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.303 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' TYR . . . . . 0.447 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 50.2 m-85 -107.32 25.48 11.37 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.193 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.47 -139.2 14.32 Favored Glycine 0 C--N 1.335 0.482 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.716 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.614 ' CZ2' HD23 ' A' ' 76' ' ' LEU . 97.5 m95 -94.47 130.13 40.96 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.329 -0.436 . . . . 0.0 111.784 -179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -138.13 125.92 22.41 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.816 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ALA . . . . . 0.64 ' HB3' ' OE1' ' A' ' 86' ' ' GLU . . . -53.95 140.81 29.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.95 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.447 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -59.97 -40.7 89.99 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 121.023 -0.271 . . . . 0.0 111.616 -178.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.21 -1.72 0.78 Allowed Glycine 0 CA--C 1.524 0.626 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.075 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.64 ' OE1' ' HB3' ' A' ' 83' ' ' ALA . 57.4 mp0 -118.94 36.75 4.33 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.026 0.441 . . . . 0.0 110.612 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.4 mt -110.73 124.95 52.95 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.955 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.7 mmt180 -131.87 145.65 51.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.567 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -40.94 90.63 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 121.01 0.433 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.12 -13.71 0.38 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -89.99 127.75 36.11 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 120.974 0.416 . . . . 0.0 110.358 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -92.21 133.6 35.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.599 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.4 m -114.57 149.24 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.63 128.46 36.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.918 0.39 . . . . 0.0 110.997 -179.297 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.7 m -130.8 161.74 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.348 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.512 ' NH2' HG11 ' A' ' 131' ' ' VAL . 25.8 ttm180 -110.29 132.9 53.77 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.57 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -100.98 126.11 47.61 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.251 178.673 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 85.3 t -74.96 -15.44 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 O-C-N 121.891 -0.506 . . . . 0.0 111.367 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -70.01 -57.41 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.145 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.1 m -100.51 -14.4 18.26 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.501 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.16 -11.93 14.5 Favored Glycine 0 C--N 1.331 0.261 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.528 ' OE1' ' NH2' ' A' ' 104' ' ' ARG . 95.4 mt-10 -79.14 156.05 28.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 0.0 110.897 -178.144 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.17 132.52 35.36 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 121.605 0.716 . . . . 0.0 110.038 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.528 ' NH2' ' OE1' ' A' ' 102' ' ' GLU . 35.9 mmt180 -132.28 -179.54 5.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.342 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.454 ' OH ' ' C ' ' A' ' 77' ' ' THR . 4.1 m-85 -118.63 147.28 43.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.681 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 28.6 m -138.57 159.0 43.19 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.6 p -89.55 153.09 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.726 0.298 . . . . 0.0 110.72 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.431 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.8 mm -72.64 156.78 6.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.179 0.514 . . . . 0.0 109.963 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.431 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 2.5 tpm_? -106.69 -47.37 3.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.106 179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -166.56 145.56 5.57 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.562 ' C ' HD22 ' A' ' 112' ' ' LEU . 21.3 t -95.63 133.77 35.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.929 0.395 . . . . 0.0 110.072 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.755 ' N ' HD22 ' A' ' 112' ' ' LEU . 2.7 mm? -102.06 148.21 35.04 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.357 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.99 158.52 57.01 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 122.496 2.131 . . . . 0.0 111.549 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.449 ' H ' HG23 ' A' ' 114' ' ' THR . 2.0 p -68.49 158.2 34.3 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.009 0.433 . . . . 0.0 110.66 -179.36 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.402 ' CG ' ' N ' ' A' ' 116' ' ' ARG . 45.2 ttp180 -153.55 153.86 33.18 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.507 179.501 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.402 ' N ' ' CG ' ' A' ' 115' ' ' ARG . 18.5 mmm180 -77.31 125.71 29.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.506 179.768 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -162.89 159.18 23.45 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.701 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.463 ' CZ ' ' OG1' ' A' ' 53' ' ' THR . 11.0 mpt_? -76.26 149.11 37.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.815 179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.657 ' C ' HE21 ' A' ' 51' ' ' GLN . 62.1 p -132.03 145.77 51.65 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.588 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 63.8 m-85 -114.74 173.06 6.66 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.627 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -143.37 130.7 20.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.459 HD21 HG22 ' A' ' 23' ' ' VAL . 87.9 mt -123.69 170.91 10.01 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.417 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -135.32 106.49 6.72 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.085 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 17.4 t -85.42 109.55 18.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.28 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 41.4 tp10 21.86 -108.13 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.9 0.75 . . . . 0.0 111.359 179.556 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -114.41 -26.68 7.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.039 179.526 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 129' ' ' THR . 91.4 mt -84.52 68.53 10.34 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' OG1' ' A' ' 129' ' ' THR . 5.1 m-70 -41.94 99.94 0.02 OUTLIER 'General case' 0 CA--C 1.507 -0.683 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.486 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.435 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.32 137.26 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.248 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.637 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.2 pp -145.34 150.6 36.9 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.157 0.504 . . . . 0.0 111.237 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.512 HG11 ' NH2' ' A' ' 96' ' ' ARG . 5.4 p -87.55 127.9 40.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.351 -0.841 . . . . 0.0 108.935 -179.127 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.4 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.9 124.86 27.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.734 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.502 ' O ' HG23 ' A' ' 135' ' ' VAL . 76.2 mm-40 59.21 44.63 15.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.287 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.0 -19.49 0.75 Allowed Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.6 t -88.76 150.78 3.61 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 117.033 0.416 . . . . 0.0 110.622 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 48.6 t -106.43 113.56 43.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.31 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 138' ' ' HIS . 15.0 m -148.37 140.87 18.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.548 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 60.6 t-80 -32.37 155.6 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.429 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 23.2 p30 . . . . . 0 C--N 1.324 -0.523 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.45 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.469 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 28.2 m . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -111.46 139.12 47.15 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.832 0.349 . . . . 0.0 110.193 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.91 162.45 16.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -60.5 143.11 54.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.489 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.14 -16.12 32.82 Favored Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.579 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.3 m -71.8 122.58 20.94 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.707 -0.29 . . . . 0.0 111.014 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.6 mtt85 -82.04 148.49 28.58 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 120.781 0.324 . . . . 0.0 110.247 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -135.62 108.21 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.289 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -79.72 129.66 34.67 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.413 ' O ' ' N ' ' A' ' 14' ' ' GLY . 55.3 t0 -109.94 113.41 57.23 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.813 -0.176 . . . . 0.0 110.755 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.11 -36.93 78.68 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.625 2.217 . . . . 0.0 112.082 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.4 HG21 ' CG ' ' A' ' 30' ' ' HIS . 49.1 t -61.8 -57.8 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.613 -178.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 p -78.27 -37.96 43.76 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.179 0.514 . . . . 0.0 110.126 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 85.16 5.71 85.35 Favored Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 16' ' ' THR . 96.5 m -114.33 157.29 23.0 Favored 'General case' 0 C--N 1.346 0.449 0 CA-C-N 117.658 0.729 . . . . 0.0 109.837 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 15' ' ' THR . 26.0 m -79.67 119.66 22.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.35 0.595 . . . . 0.0 110.61 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 19.9 m-70 -103.31 145.34 30.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.385 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 29.0 ttm-85 -96.92 124.37 40.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.03 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.6 tp -51.75 -44.14 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.724 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.617 ' N ' HG23 ' A' ' 19' ' ' ILE . 10.8 pt-20 -57.98 -34.9 70.47 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.131 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -82.25 -37.56 25.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.326 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 67.7 t -66.92 -43.24 89.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.517 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.3 t -72.5 -47.23 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -57.18 -38.11 73.15 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.146 -178.447 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.08 29.52 12.34 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.548 ' C ' ' O ' ' A' ' 25' ' ' GLY . 90.7 mtm180 15.78 62.5 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 O-C-N 124.037 0.492 . . . . 0.0 110.045 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.2 mttt -87.64 126.13 62.85 Favored Pre-proline 0 N--CA 1.44 -0.97 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.944 -177.186 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -75.23 93.43 0.97 Allowed 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.469 2.113 . . . . 0.0 110.316 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.3 pt -121.21 -170.16 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.87 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.4 ' CG ' HG21 ' A' ' 12' ' ' VAL . 38.0 m80 -125.97 164.49 20.7 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.1 m -150.65 173.68 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.447 HG11 HH21 ' A' ' 96' ' ' ARG . 5.2 t -86.55 125.28 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.17 150.85 25.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.626 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.22 144.12 49.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.411 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.26 178.26 4.39 Favored 'General case' 0 N--CA 1.472 0.664 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.8 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp -68.45 -15.25 63.48 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.693 0.283 . . . . 0.0 110.396 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -78.43 -20.3 51.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.083 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.45 -9.67 71.56 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.5 p -73.1 139.01 46.17 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.363 0.601 . . . . 0.0 111.297 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.616 HD13 ' NH2' ' A' ' 96' ' ' ARG . 50.6 mt -95.7 135.33 37.54 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.558 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -145.98 141.48 27.75 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.39 147.54 44.2 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.663 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.512 ' HD2' HD12 ' A' ' 127' ' ' LEU . 6.5 mtp180 -152.81 148.98 21.15 Favored Pre-proline 0 N--CA 1.457 -0.124 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.231 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.6 149.55 61.71 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.557 2.172 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.7 t -112.87 146.53 17.44 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.847 0 CA-C-O 121.502 0.668 . . . . 0.0 109.312 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.705 ' O ' ' CE2' ' A' ' 48' ' ' TRP . 2.1 m -139.49 -100.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.61 ' H ' HG23 ' A' ' 46' ' ' VAL . 9.3 t -19.0 113.84 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 114.164 -1.38 . . . . 0.0 111.542 -175.525 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.705 ' CE2' ' O ' ' A' ' 46' ' ' VAL . 1.5 m-90 -120.3 110.89 17.1 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.7 m-85 -138.43 147.02 42.86 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.304 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 46.4 p-10 -91.65 134.98 34.22 Favored 'General case' 0 C--N 1.334 -0.069 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.465 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -92.67 -4.83 52.6 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.715 -0.22 . . . . 0.0 111.219 179.638 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 -179.11 48.68 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 79.9 m -94.24 122.66 37.01 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.8 mtp85 -146.54 171.38 15.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.435 0.636 . . . . 0.0 110.656 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -74.42 139.63 44.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.219 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -139.36 153.3 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.651 HD11 ' HB1' ' A' ' 84' ' ' ALA . 14.4 pt -108.88 155.83 9.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.183 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.03 128.73 8.71 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 28.4 mt -108.94 115.3 29.82 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.205 0.526 . . . . 0.0 110.413 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.6 tpp180 -85.81 109.29 18.57 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.055 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 12.8 mm . . . . . 0 N--CA 1.469 0.478 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.041 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.369 0 CA-C-O 120.949 0.404 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.4 tt -124.94 153.47 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.357 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 43.9 tp -132.75 118.72 19.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.337 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -105.8 118.21 36.01 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.96 170.97 15.12 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.534 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 37.6 p -79.5 153.56 76.24 Favored Pre-proline 0 N--CA 1.45 -0.432 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.128 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.78 -30.25 88.6 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 122.534 2.156 . . . . 0.0 112.146 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -80.97 -9.46 59.84 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.428 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.7 t60 -70.46 129.04 38.2 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -86.75 131.61 34.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.399 0.619 . . . . 0.0 111.154 -179.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -103.62 139.21 25.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.783 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 58.7 tp -78.35 91.95 4.51 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.856 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.9 p -97.38 -179.34 4.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -178.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -69.87 -16.41 63.24 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.196 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -106.27 26.31 9.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.933 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.88 -138.54 13.97 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -95.67 130.61 42.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.537 -0.331 . . . . 0.0 111.138 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ARG . . . . . 0.511 ' NH1' ' OD1' ' A' ' 91' ' ' ASP . 84.0 mtp180 -140.56 129.89 23.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.246 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.38 145.29 18.42 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.011 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.651 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.48 -40.14 95.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 121.249 -0.18 . . . . 0.0 111.473 -179.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.3 -3.46 3.89 Favored Glycine 0 C--N 1.337 0.614 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.757 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -113.24 32.73 5.54 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.732 0.301 . . . . 0.0 110.56 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.9 mt -112.7 126.81 55.8 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 121.38 0.61 . . . . 0.0 111.226 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 37.5 mmt180 -130.89 147.19 52.51 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.884 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -42.66 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.876 0.369 . . . . 0.0 110.741 -179.516 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.25 -12.68 0.43 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.511 ' OD1' ' NH1' ' A' ' 82' ' ' ARG . 17.8 t70 -87.85 128.57 35.35 Favored 'General case' 0 C--O 1.227 -0.102 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -89.84 131.74 35.62 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.393 -179.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -118.32 150.91 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.121 -0.49 . . . . 0.0 109.797 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -66.76 134.98 53.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.955 0.407 . . . . 0.0 111.015 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 104' ' ' ARG . 21.4 m -134.22 159.68 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.013 179.077 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.616 ' NH2' HD13 ' A' ' 40' ' ' LEU . 52.6 ttm-85 -107.02 130.24 54.68 Favored 'General case' 0 C--N 1.334 -0.098 0 CA-C-O 120.677 0.275 . . . . 0.0 110.333 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.36 122.9 43.86 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.365 178.7 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 62.3 t -76.28 -16.19 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 118.133 0.424 . . . . 0.0 110.749 179.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 99' ' ' GLU . 0.5 OUTLIER -72.02 -57.26 4.44 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.849 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.449 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.3 p -94.45 -13.81 25.83 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.13 -14.76 3.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.449 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.5 mt-10 -83.56 163.53 20.34 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 120.981 0.42 . . . . 0.0 110.764 -177.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.47 HD21 ' HB1' ' A' ' 94' ' ' ALA . 4.6 tt -80.51 136.88 36.38 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.431 ' O ' HG22 ' A' ' 95' ' ' VAL . 45.9 mtp85 -134.42 168.81 18.25 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.099 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -110.87 140.6 45.2 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.672 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.416 ' OG ' HG21 ' A' ' 95' ' ' VAL . 23.3 m -136.49 155.39 50.05 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.409 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 108' ' ' ILE . 58.1 t -91.33 156.68 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.008 0.432 . . . . 0.0 110.555 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.485 ' N ' HG12 ' A' ' 107' ' ' VAL . 3.5 mm -72.66 153.13 7.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.237 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -106.0 -45.93 4.23 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.454 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -166.05 145.36 6.08 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.457 ' C ' HD22 ' A' ' 112' ' ' LEU . 83.5 t -96.46 132.88 39.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.137 0.494 . . . . 0.0 110.163 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.484 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.1 mm? -98.57 128.73 32.0 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.288 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.63 157.99 2.11 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 122.384 2.056 . . . . 0.0 111.743 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.436 HG23 ' H ' ' A' ' 114' ' ' THR . 1.2 p -66.94 156.93 34.56 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.49 0.662 . . . . 0.0 110.685 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -139.04 -140.1 0.14 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.915 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 80.7 mtm180 -153.66 132.6 12.46 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.902 0.382 . . . . 0.0 110.115 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.7 173.67 3.86 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.651 -179.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 -83.51 154.27 23.96 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.144 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -132.64 143.47 49.69 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.95 174.83 5.7 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.483 -0.78 . . . . 0.0 111.5 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -148.03 128.79 14.26 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.164 -179.572 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.2 mt -132.15 123.39 27.0 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.852 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -87.51 115.67 25.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.144 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 125' ' ' GLU . 98.5 t -85.48 114.09 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 127' ' ' LEU . 39.7 tp10 -28.2 111.92 0.06 Allowed 'General case' 0 N--CA 1.466 0.367 0 O-C-N 123.574 0.546 . . . . 0.0 111.762 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 60.49 -65.87 0.05 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 178.905 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.512 HD12 ' HD2' ' A' ' 43' ' ' ARG . 86.0 mt -72.76 75.17 1.13 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.041 0.448 . . . . 0.0 111.005 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.629 ' O ' HG23 ' A' ' 129' ' ' THR . 31.5 m170 -56.01 98.96 0.03 OUTLIER 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.432 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.629 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.45 143.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 O-C-N 123.712 0.632 . . . . 0.0 109.439 178.936 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.723 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.8 pp -149.23 154.1 38.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.542 0.687 . . . . 0.0 111.446 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.513 ' N ' HD12 ' A' ' 130' ' ' LEU . 85.6 t -90.01 123.69 42.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.033 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.649 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.08 129.16 37.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -178.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.551 ' O ' HG23 ' A' ' 135' ' ' VAL . 70.2 mm-40 58.77 43.23 18.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.897 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.76 -20.89 0.48 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.9 t -89.18 151.13 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-O 120.943 0.402 . . . . 0.0 110.821 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.403 HG21 HD11 ' A' ' 103' ' ' LEU . 2.5 t -104.69 112.78 39.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.548 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 11.5 m -148.3 138.65 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 CA-C-O 118.988 -0.529 . . . . 0.0 110.29 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.537 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 14.4 t-80 -28.41 147.63 0.0 OUTLIER 'General case' 0 C--N 1.342 0.259 0 O-C-N 123.571 0.544 . . . . 0.0 111.956 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.428 ' OD1' ' NE2' ' A' ' 138' ' ' HIS . 26.8 p30 . . . . . 0 C--N 1.321 -0.673 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.895 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -91.45 139.01 31.13 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.839 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.52 161.7 28.95 Favored 'General case' 0 CA--C 1.529 0.135 0 CA-C-O 120.978 0.418 . . . . 0.0 111.262 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 77.5 tt0 -66.62 143.27 57.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.826 178.93 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.97 -18.85 33.58 Favored Glycine 0 C--N 1.336 0.561 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.512 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 26.9 m -66.05 124.97 24.01 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.48 ' HE ' ' CD ' ' A' ' 18' ' ' ARG . 1.6 mpt_? -97.25 116.39 29.36 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 121.014 0.435 . . . . 0.0 110.214 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.47 HD11 HD13 ' A' ' 19' ' ' ILE . 15.4 mt -100.41 113.06 34.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.209 179.844 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -75.47 133.93 40.96 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.379 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.07 129.97 26.02 Favored Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 121.145 -0.222 . . . . 0.0 110.678 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.72 -27.47 18.2 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.91 1.74 . . . . 0.0 112.277 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 42.7 t -76.42 -53.81 14.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.19 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.9 p -76.94 -35.88 56.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.983 0.42 . . . . 0.0 110.251 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.64 10.5 85.13 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 54.8 m -115.56 160.42 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 117.564 0.682 . . . . 0.0 109.694 -179.689 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 12.5 m -79.54 115.0 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.194 0.521 . . . . 0.0 110.911 -179.229 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -101.3 143.46 31.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.866 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.48 ' CD ' ' HE ' ' A' ' 7' ' ' ARG . 69.3 mtm180 -99.65 128.38 45.75 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.753 -0.203 . . . . 0.0 110.574 178.247 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.1 tp -53.1 -38.42 29.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.561 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.509 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.3 pt-20 -58.17 -35.34 71.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.318 0.58 . . . . 0.0 110.969 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -85.18 -38.38 19.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.63 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 94.2 t -69.04 -42.39 81.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.838 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.56 HG22 HD21 ' A' ' 122' ' ' LEU . 75.2 t -75.36 -45.89 39.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.833 -178.621 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -57.67 -34.5 69.45 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.681 -178.332 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.577 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.25 29.31 9.3 Favored Glycine 0 CA--C 1.519 0.298 0 CA-C-O 119.108 -0.829 . . . . 0.0 111.033 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.577 ' C ' ' O ' ' A' ' 25' ' ' GLY . 44.6 ptt85 13.62 64.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.45 0.643 . . . . 0.0 110.054 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 25' ' ' GLY . 81.6 mttt -84.86 139.49 37.36 Favored Pre-proline 0 N--CA 1.449 -0.503 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.369 -176.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.9 83.27 2.14 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.352 1.368 . . . . 0.0 110.164 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.563 ' C ' HD12 ' A' ' 29' ' ' ILE . 1.9 pp -116.27 -174.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.811 0.338 . . . . 0.0 110.486 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.422 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 34.7 m80 -128.65 161.95 28.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.511 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.9 m -146.96 170.47 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.97 134.98 26.56 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.358 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -107.78 166.55 10.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.534 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.2 137.59 39.29 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.914 0.387 . . . . 0.0 110.23 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -112.28 175.42 5.44 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -73.02 -13.34 61.2 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.865 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -78.32 -11.44 59.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.429 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.46 17.37 64.38 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.2 p -100.81 139.34 36.64 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.024 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.9 mt -98.54 131.61 44.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.655 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -139.52 138.3 36.21 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.965 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.87 142.7 52.99 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.465 -0.494 . . . . 0.0 109.959 -178.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.526 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.7 mmt180 -145.04 138.6 14.36 Favored Pre-proline 0 N--CA 1.468 0.461 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.297 -179.156 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.12 157.2 33.96 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 122.555 2.17 . . . . 0.0 112.424 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -98.84 138.17 24.14 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 177.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.99 2.66 3.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.183 -178.471 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 m -146.97 133.99 20.33 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 120.038 -0.665 . . . . 0.0 110.006 179.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.508 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.77 121.71 18.85 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.003 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -138.14 143.59 40.39 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.644 ' O ' ' HG2' ' A' ' 51' ' ' GLN . 29.3 t70 -88.42 125.77 34.89 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.644 ' HG2' ' O ' ' A' ' 50' ' ' ASP . 8.2 mt-30 -160.86 60.08 0.31 Allowed 'General case' 0 CA--C 1.498 -1.042 0 O-C-N 124.158 0.911 . . . . 0.0 108.55 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.818 ' CA ' ' H ' ' A' ' 119' ' ' THR . . . -118.62 167.06 12.98 Favored Glycine 0 C--N 1.314 -0.684 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.398 -178.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.562 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 33.3 m 113.99 63.53 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 O-C-N 125.436 1.315 . . . . 0.0 111.261 177.788 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.6 mtt-85 -148.78 175.72 10.99 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.634 0.254 . . . . 0.0 110.794 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -77.47 139.56 39.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.61 151.81 19.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.525 HD13 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -103.41 144.77 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 109.963 179.934 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.93 134.7 12.15 Favored Glycine 0 N--CA 1.462 0.39 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 71.6 mt -116.78 116.34 27.3 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-O 121.064 0.459 . . . . 0.0 110.313 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.449 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.1 tpt180 -84.75 107.73 17.09 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.103 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.754 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.6 mp . . . . . 0 C--N 1.325 -0.461 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 179.007 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.163 0 CA-C-O 120.811 0.338 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.412 HG22 ' N ' ' A' ' 67' ' ' LEU . 95.0 mt -124.7 154.72 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.123 179.689 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.412 ' N ' HG22 ' A' ' 66' ' ' ILE . 61.9 tp -128.79 114.73 16.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.814 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -103.83 109.96 21.9 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -134.2 172.32 13.02 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.198 -179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.14 156.8 69.13 Favored Pre-proline 0 CA--C 1.535 0.401 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.435 179.487 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -63.15 -17.72 61.5 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.734 2.29 . . . . 0.0 112.169 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 49.3 p-10 -97.62 -6.67 32.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.992 0.425 . . . . 0.0 110.185 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.4 t60 -71.85 129.68 39.21 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -83.57 124.07 30.4 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.375 0.607 . . . . 0.0 111.631 -179.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 73.5 t -98.14 138.35 23.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.058 -0.973 . . . . 0.0 109.889 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 37.9 tp -81.67 95.64 7.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.036 -179.524 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 p -100.28 175.87 5.57 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -67.67 -18.14 64.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.459 -178.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -105.97 21.07 17.93 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.647 0.26 . . . . 0.0 110.642 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.89 -144.63 15.88 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -91.95 126.54 37.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.527 0.204 . . . . 0.0 110.97 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -127.83 126.75 42.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.08 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.79 136.9 54.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.949 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.591 ' HA ' HD12 ' A' ' 87' ' ' LEU . . . -69.78 -0.88 7.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.683 179.666 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.71 -13.78 77.22 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.618 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -132.22 15.44 4.61 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.758 0.313 . . . . 0.0 111.46 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 84' ' ' ALA . 20.5 mt -80.32 141.41 35.47 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.233 0.54 . . . . 0.0 110.877 179.374 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.0 tpp85 -142.08 155.21 45.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.014 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -48.51 113.86 0.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.334 179.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 141.77 -22.33 2.5 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -83.09 130.56 35.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.706 0.289 . . . . 0.0 110.766 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -88.84 136.62 32.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.128 0.49 . . . . 0.0 110.795 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.0 m -122.02 144.05 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.5 -179.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.52 131.53 42.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.912 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.4 m -127.06 163.11 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.98 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -100.5 128.14 46.65 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.671 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -100.54 124.28 45.88 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 98' ' ' VAL . 89.8 t -75.63 -15.81 15.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 118.24 0.473 . . . . 0.0 110.909 178.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 37.7 tp10 -69.35 -58.66 3.72 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.097 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 70.3 p -99.73 -12.18 20.2 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.772 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.32 -13.87 9.78 Favored Glycine 0 C--N 1.332 0.312 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.6 mt-10 -82.05 153.84 25.93 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.953 0.406 . . . . 0.0 111.622 -177.423 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.586 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.16 139.92 36.59 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 179.479 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.419 ' O ' HG22 ' A' ' 95' ' ' VAL . 53.0 ptt85 -142.64 138.47 30.7 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.702 -179.292 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.9 m-30 -78.28 147.8 34.16 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.38 -0.528 . . . . 0.0 109.998 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -139.34 162.68 34.43 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.7 t -95.32 154.29 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 61.6 mt -73.54 154.61 6.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.021 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.0 ttm180 -104.75 -42.72 5.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.16 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -167.23 147.82 5.53 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.75 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 112' ' ' LEU . 23.1 t -92.81 130.85 41.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.6 mp -98.99 124.93 43.69 Favored Pre-proline 0 CA--C 1.543 0.709 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.973 -179.519 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -48.45 162.73 0.31 Allowed 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.228 1.952 . . . . 0.0 111.998 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.1 p -73.02 160.44 32.07 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.28 0.562 . . . . 0.0 110.823 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.434 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 10.0 tpt180 -144.89 -132.47 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.195 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.434 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 1.5 tmm_? -155.39 134.83 12.47 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.983 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 170.77 4.27 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.072 -178.45 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 84.2 mtm-85 -83.87 140.36 32.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.843 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' THR . . . . . 0.818 ' H ' ' CA ' ' A' ' 52' ' ' GLY . 4.2 p -128.39 148.78 50.72 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.559 177.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -122.75 179.76 4.51 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.971 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -147.64 124.83 11.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.368 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.56 HD21 HG22 ' A' ' 23' ' ' VAL . 95.6 mt -115.84 173.08 6.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.444 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -136.38 105.36 5.92 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.241 178.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 125' ' ' GLU . 16.4 t -83.56 108.64 16.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.0 tt0 20.37 -89.14 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.639 0.587 . . . . 0.0 112.322 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 124' ' ' VAL . 81.6 mt-10 -129.27 -39.94 1.49 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.392 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.526 HD12 ' HE ' ' A' ' 43' ' ' ARG . 84.3 mt -71.04 64.86 0.35 Allowed 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.183 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.438 ' O ' HG23 ' A' ' 129' ' ' THR . 39.3 m80 -41.78 94.82 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 179.351 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.515 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 171.63 141.28 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.189 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.681 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.0 pp -147.79 155.96 42.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.425 0.631 . . . . 0.0 111.885 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -89.12 126.78 42.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.18 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.582 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.512 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.23 132.62 39.9 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.219 -179.099 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.583 ' O ' HG23 ' A' ' 135' ' ' VAL . 68.8 mm-40 50.64 46.23 25.95 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.156 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.99 23.26 56.82 Favored Glycine 0 CA--C 1.522 0.523 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.802 178.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -129.75 153.69 39.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.436 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -105.32 111.9 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 O-C-N 121.944 -0.473 . . . . 0.0 110.611 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 26.8 m -147.38 139.33 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 55.6 t-80 -31.25 151.53 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.201 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.264 -179.635 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.647 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 6.2 m . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 80.5 mt -123.22 132.69 54.13 Favored 'General case' 0 C--N 1.34 0.189 0 CA-C-O 121.182 0.515 . . . . 0.0 110.72 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.09 162.26 24.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.39 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.76 146.52 52.25 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.45 -17.34 40.13 Favored Glycine 0 C--N 1.34 0.754 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.477 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.7 m -67.03 124.76 23.95 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.08 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.543 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.1 mtp180 -83.98 149.35 26.35 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.238 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 75.2 mt -134.6 107.42 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.81 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -77.0 127.22 32.3 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 14' ' ' GLY . 61.6 t0 -107.32 111.44 63.17 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.07 -37.3 68.24 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 122.508 2.139 . . . . 0.0 111.969 178.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -61.21 -58.41 7.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.518 -179.098 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 30.5 p -74.88 -33.07 62.01 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.181 0.515 . . . . 0.0 109.788 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 80.47 7.74 88.24 Favored Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.479 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -110.87 -163.82 0.88 Allowed 'General case' 0 C--N 1.347 0.471 0 CA-C-N 117.727 0.764 . . . . 0.0 109.507 -179.248 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.543 HG21 ' HE ' ' A' ' 7' ' ' ARG . 87.4 m -114.71 115.7 27.49 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.516 0.674 . . . . 0.0 110.511 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -100.18 141.72 32.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.206 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -97.65 125.99 42.72 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.969 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -52.92 -41.01 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.217 -179.333 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.562 ' N ' HG23 ' A' ' 19' ' ' ILE . 2.8 pt-20 -55.31 -35.23 64.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.355 0.598 . . . . 0.0 110.646 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 50.9 t0 -83.1 -36.18 25.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.972 . . . . 0.0 111.62 -178.33 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 54.1 t -66.65 -43.83 90.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.408 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 72.2 t -69.52 -46.11 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.721 -179.279 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -56.04 -36.9 68.53 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 120.946 -0.302 . . . . 0.0 110.596 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.558 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.71 32.64 6.09 Favored Glycine 0 C--O 1.228 -0.257 0 CA-C-O 118.222 -1.321 . . . . 0.0 110.563 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.558 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.0 ptt-85 10.37 72.55 0.01 OUTLIER 'General case' 0 C--N 1.367 1.341 0 O-C-N 124.437 0.728 . . . . 0.0 110.004 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.406 ' C ' ' H ' ' A' ' 29' ' ' ILE . 74.1 mttt -90.06 144.71 31.7 Favored Pre-proline 0 N--CA 1.443 -0.791 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.716 -177.857 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.561 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.2 Cg_endo -71.77 9.83 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.581 2.187 . . . . 0.0 112.464 179.517 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.561 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.1 pp -38.19 171.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 124.087 0.867 . . . . 0.0 110.374 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 1.2 m80 -123.05 166.74 14.62 Favored 'General case' 0 CA--C 1.509 -0.622 0 O-C-N 122.103 -0.373 . . . . 0.0 111.057 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -150.42 173.96 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.385 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 3.8 t -87.3 132.51 32.46 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.152 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -102.38 166.93 10.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.79 137.08 36.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.074 0.464 . . . . 0.0 110.315 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.5 177.46 4.64 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -72.76 -14.73 61.6 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.615 0.245 . . . . 0.0 110.677 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -78.98 -14.66 59.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.7 20.46 56.1 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.6 p -100.82 135.29 42.49 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 120.76 0.314 . . . . 0.0 110.691 178.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 53.2 mt -99.78 137.63 37.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.561 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -147.72 143.56 27.67 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.795 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.86 145.01 48.86 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.641 ' HE ' HD12 ' A' ' 127' ' ' LEU . 86.6 mtt-85 -153.25 142.44 14.67 Favored Pre-proline 0 CA--C 1.54 0.587 0 O-C-N 123.813 0.696 . . . . 0.0 111.097 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.36 160.0 39.46 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 123.094 2.529 . . . . 0.0 113.267 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -97.89 135.76 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 177.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.3 m -122.24 -1.33 7.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 118.803 -0.618 . . . . 0.0 111.167 -178.705 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.8 p -148.79 141.33 24.35 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 119.203 0.91 . . . . 0.0 108.717 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.509 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.23 121.32 12.93 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.047 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -142.1 148.23 38.03 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -99.74 135.06 41.73 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.026 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.815 HE22 ' C ' ' A' ' 120' ' ' PHE . 4.8 mt-30 -97.75 4.56 49.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 119.412 -0.327 . . . . 0.0 111.53 178.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.05 -169.73 42.49 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 98.0 m -88.26 128.33 35.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.397 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.5 mtt-85 -147.17 161.59 40.6 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.544 -179.575 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -77.18 142.8 39.46 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.489 179.368 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.8 m -141.12 160.27 22.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.528 HD11 ' CB ' ' A' ' 84' ' ' ALA . 43.8 pt -111.89 147.29 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.257 179.491 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.59 137.53 13.32 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.409 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 43.6 mt -120.63 111.99 18.34 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.403 0.62 . . . . 0.0 110.276 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.524 ' C ' HD12 ' A' ' 61' ' ' ILE . 14.4 tpt180 -87.21 109.24 19.34 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.189 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp . . . . . 0 N--CA 1.473 0.715 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.079 -179.238 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.747 0.308 . . . . 0.0 110.376 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.2 tt -125.21 154.75 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.346 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 54.1 tp -130.97 116.82 18.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -104.4 115.17 29.9 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.73 172.69 12.35 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.261 -179.227 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.34 156.28 78.79 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.689 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.29 -21.44 72.63 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 122.794 2.33 . . . . 0.0 111.931 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -92.95 -4.69 52.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.28 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.647 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.7 t60 -72.02 129.98 39.86 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 48.9 mttp -86.86 127.58 35.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 121.51 0.672 . . . . 0.0 110.493 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 93.8 t -105.16 91.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.602 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 15.3 tp -31.01 95.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 O-C-N 123.924 0.765 . . . . 0.0 111.123 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.446 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -98.92 176.93 5.42 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 -177.973 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.478 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 12.8 pt-20 -63.85 -18.35 64.06 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.291 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.73 24.3 13.13 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.432 0.158 . . . . 0.0 110.965 -179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.81 -141.37 15.26 Favored Glycine 0 C--N 1.321 -0.253 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.519 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -94.05 127.24 39.74 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.633 -0.283 . . . . 0.0 111.264 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -137.61 129.04 28.08 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.25 141.39 29.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.807 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.528 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -60.11 -38.58 83.41 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.164 -179.206 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.27 -3.2 4.86 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.678 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -105.49 0.46 26.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.923 0.392 . . . . 0.0 110.179 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 93.3 mt -80.95 127.63 32.78 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.554 0.693 . . . . 0.0 111.245 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.583 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.6 mmt85 -131.64 149.26 52.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.788 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -44.57 86.33 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 123.465 0.478 . . . . 0.0 110.845 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 158.08 -15.85 0.29 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -85.39 130.1 34.67 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 117.209 0.505 . . . . 0.0 110.394 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.478 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 90.1 mtm180 -88.94 131.17 35.26 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.408 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.7 m -114.42 142.69 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.459 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -67.1 131.52 45.98 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.72 -179.141 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.36 160.72 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.408 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.534 ' NH1' ' O ' ' A' ' 101' ' ' GLY . 9.0 tpt180 -104.6 129.63 52.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.59 -179.592 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 42.1 t0 -101.33 123.67 45.78 Favored 'General case' 0 C--O 1.22 -0.49 0 CA-C-O 118.996 -0.526 . . . . 0.0 110.468 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 61.4 t -77.21 -16.72 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 118.474 0.579 . . . . 0.0 111.12 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -69.65 -58.43 3.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.45 ' C ' ' H ' ' A' ' 102' ' ' GLU . 80.8 p -95.86 -12.65 24.88 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.534 ' O ' ' NH1' ' A' ' 96' ' ' ARG . . . 76.13 -16.05 4.88 Favored Glycine 0 C--O 1.223 -0.583 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.555 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.45 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.2 mt-10 -80.78 158.05 25.59 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.614 0.245 . . . . 0.0 110.606 -177.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.572 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -86.68 141.12 29.16 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.359 0.6 . . . . 0.0 110.059 179.77 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.45 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 37.6 ptt180 -139.81 178.65 7.09 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.214 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.446 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.8 m-85 -113.31 147.74 37.03 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.801 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -139.63 160.17 40.48 Favored 'General case' 0 C--O 1.222 -0.366 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.004 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.6 m -90.63 153.02 3.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-O 121.015 0.436 . . . . 0.0 110.842 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.41 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.6 mm -70.31 155.39 7.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.094 179.297 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.41 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt180 -106.01 -48.31 3.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.704 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -166.07 145.74 6.19 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.78 134.38 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 mt -102.68 145.22 30.15 Favored Pre-proline 0 N--CA 1.466 0.358 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.367 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -67.16 164.06 31.75 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.408 2.072 . . . . 0.0 111.534 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.467 HG22 HG22 ' A' ' 57' ' ' ILE . 81.3 p -67.03 156.42 36.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 121.388 0.613 . . . . 0.0 110.873 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 79.3 mtp180 -139.98 -137.35 0.12 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.757 -179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -158.04 131.31 7.58 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.079 0.466 . . . . 0.0 110.254 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.79 173.26 3.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.13 -179.07 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.3 mtp85 -78.39 145.48 35.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 2.9 p -119.5 141.08 49.51 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.155 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.815 ' C ' HE22 ' A' ' 51' ' ' GLN . 57.2 m-85 -118.5 168.55 10.56 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.199 -179.372 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -157.79 120.33 3.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.989 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 67.1 mt -118.04 129.52 55.62 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -87.5 109.63 19.75 Favored 'General case' 0 CA--C 1.516 -0.338 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.463 HG21 ' O ' ' A' ' 129' ' ' THR . 21.6 t -83.0 113.09 21.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.97 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.7 tt0 29.96 -98.38 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 O-C-N 123.775 0.672 . . . . 0.0 111.1 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -123.62 -25.92 4.26 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.271 179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.641 HD12 ' HE ' ' A' ' 43' ' ' ARG . 96.4 mt -84.85 94.55 8.76 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.62 ' C ' HG22 ' A' ' 129' ' ' THR . 29.7 m170 -60.6 98.24 0.06 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.62 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.1 154.77 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.941 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.608 ' N ' HD23 ' A' ' 130' ' ' LEU . 1.2 pt? -162.83 161.49 26.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.796 0.808 . . . . 0.0 112.369 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 136' ' ' VAL . 9.3 t -86.2 126.15 40.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.42 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.477 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.88 123.78 25.32 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.757 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.602 ' O ' HG23 ' A' ' 135' ' ' VAL . 77.8 mm-40 54.29 44.66 28.68 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.682 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.0 28.1 69.88 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.2 t -132.67 151.3 34.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 CA-C-N 118.155 0.977 . . . . 0.0 108.681 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 131' ' ' VAL . 89.9 t -108.9 112.34 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 118.232 0.469 . . . . 0.0 110.239 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 138' ' ' HIS . 29.4 m -146.63 136.72 17.51 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-O 119.086 -0.483 . . . . 0.0 110.021 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 37.4 t-80 -31.54 152.08 0.0 OUTLIER 'General case' 0 C--O 1.223 -0.295 0 O-C-N 123.577 0.548 . . . . 0.0 111.36 179.597 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.521 ' OD1' ' CE1' ' A' ' 138' ' ' HIS . 49.2 p30 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.74 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -101.16 143.72 30.91 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.365 -179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -88.18 162.41 16.71 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.637 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLU . . . . . 0.431 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 59.8 tt0 -60.37 142.69 54.54 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 120.786 0.327 . . . . 0.0 110.466 178.821 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 115.98 -21.66 12.08 Favored Glycine 0 C--N 1.333 0.376 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.577 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 23.0 m -69.01 120.03 14.24 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.11 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.508 ' NE ' HG21 ' A' ' 16' ' ' THR . 74.7 mtp85 -95.15 112.63 24.31 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.91 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.6 mt -99.17 113.29 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.621 -179.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -76.48 137.79 39.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 10.2 t0 -106.31 132.64 20.73 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 121.25 -0.18 . . . . 0.0 110.622 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.03 -30.88 10.36 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.187 1.925 . . . . 0.0 112.433 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.533 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 24.9 t -72.98 -53.89 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.868 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.8 p -77.64 -36.79 51.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.136 0.493 . . . . 0.0 110.159 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 6.9 89.01 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.447 HG22 ' N ' ' A' ' 16' ' ' THR . 48.1 m -111.55 156.53 21.6 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.769 0.785 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.508 HG21 ' NE ' ' A' ' 7' ' ' ARG . 27.0 m -80.49 116.77 20.71 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.146 0.498 . . . . 0.0 110.976 -179.154 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -107.32 150.29 26.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.302 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -101.43 132.74 46.86 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.914 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.8 tp -52.69 -40.21 33.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.764 0.316 . . . . 0.0 111.077 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.548 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.9 tt0 -58.51 -36.25 73.51 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.191 0.519 . . . . 0.0 110.483 -179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -82.18 -38.36 24.76 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.615 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -69.51 -43.76 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.589 HG22 HD21 ' A' ' 122' ' ' LEU . 72.5 t -73.82 -46.73 46.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.9 t0 -60.85 -36.4 79.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.019 0.437 . . . . 0.0 110.813 -178.447 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.36 24.55 31.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtm180 17.22 62.73 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 79.2 mttt -86.57 131.96 44.11 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.869 -176.438 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -75.07 87.21 1.35 Allowed 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.491 1.461 . . . . 0.0 110.41 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 29' ' ' ILE . 30.1 pt -120.67 -172.01 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.917 0.389 . . . . 0.0 110.491 -179.234 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.43 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 16.5 m80 -127.21 162.88 25.13 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.747 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.46 171.24 2.44 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.237 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.01 136.33 23.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -115.27 164.33 14.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.67 -0.241 . . . . 0.0 110.414 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.97 50.42 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.36 177.66 4.55 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -72.74 -16.33 61.66 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 122.101 -0.375 . . . . 0.0 111.105 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -78.71 -16.46 57.22 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.336 179.288 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 22.85 40.45 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.49 ' C ' HD22 ' A' ' 40' ' ' LEU . 33.1 p -102.11 133.84 46.31 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.676 0.274 . . . . 0.0 111.052 178.13 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.776 ' N ' HD22 ' A' ' 40' ' ' LEU . 2.2 mm? -94.57 133.05 38.63 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 121.069 0.461 . . . . 0.0 111.128 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -143.66 139.87 29.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.569 -179.173 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.2 144.86 49.99 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.969 -178.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HE ' ' HB3' ' A' ' 125' ' ' GLU . 15.7 mtp85 -147.81 138.91 13.36 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.181 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -74.94 158.1 42.64 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.7 2.267 . . . . 0.0 112.831 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.9 t -93.82 131.85 39.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.0 t -119.24 -3.1 9.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.387 -177.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' SER . . . . . 0.442 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.3 OUTLIER -155.06 149.01 25.7 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.612 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.571 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -144.84 131.02 19.48 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.701 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -134.64 144.56 47.92 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.379 0.609 . . . . 0.0 111.899 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.414 ' OD1' ' N ' ' A' ' 51' ' ' GLN . 58.1 t0 -112.76 139.21 48.57 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.224 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.448 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.8 mm-40 -105.15 -106.46 0.3 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.328 -1.305 . . . . 0.0 108.854 -178.473 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.448 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -167.24 -156.1 9.59 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 114.457 -1.247 . . . . 0.0 112.354 -177.26 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.457 HG22 ' HG3' ' A' ' 116' ' ' ARG . 0.5 OUTLIER -94.58 119.56 33.45 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.077 0.465 . . . . 0.0 111.2 -179.264 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -138.31 164.66 28.7 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.51 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -76.98 140.9 40.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.12 159.61 26.1 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.164 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.596 HD11 ' HB1' ' A' ' 84' ' ' ALA . 32.7 pt -112.58 151.26 14.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.966 0.412 . . . . 0.0 109.991 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.16 131.68 10.76 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 32.2 mt -113.16 113.19 25.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 0.0 110.044 -179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.467 ' C ' HD12 ' A' ' 61' ' ' ILE . 12.6 tpt180 -87.75 107.06 18.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.355 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.742 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp . . . . . 0 N--CA 1.467 0.417 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.929 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.189 0 CA-C-O 121.105 0.479 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.448 HD13 ' HE1' ' A' ' 68' ' ' TRP . 19.1 tt -125.38 152.06 31.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.34 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 68' ' ' TRP . 2.2 tt -127.63 114.91 17.98 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.496 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.57 ' N ' HD23 ' A' ' 67' ' ' LEU . 81.3 m95 -102.93 120.04 39.92 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.85 171.09 18.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.158 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 20.4 p -76.91 154.71 83.04 Favored Pre-proline 0 CA--C 1.531 0.232 0 C-N-CA 120.584 -0.447 . . . . 0.0 111.227 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 -24.09 70.8 Favored 'Trans proline' 0 N--CA 1.499 1.849 0 C-N-CA 122.096 1.864 . . . . 0.0 112.211 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -84.75 -8.64 58.76 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.853 0.359 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.573 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.2 t60 -72.8 132.66 43.86 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -90.44 131.73 36.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.183 0.516 . . . . 0.0 110.348 -178.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.726 ' O ' HG23 ' A' ' 77' ' ' THR . 92.5 t -107.37 89.59 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.117 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 55.7 tp -29.12 97.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.508 0.505 . . . . 0.0 111.717 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.726 HG23 ' O ' ' A' ' 75' ' ' VAL . 38.5 p -98.68 177.21 5.37 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.531 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.548 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.8 pt-20 -66.45 -17.56 64.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.341 -179.75 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.07 22.22 16.25 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.745 0.307 . . . . 0.0 111.117 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.76 -141.09 15.34 Favored Glycine 0 N--CA 1.462 0.431 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.0 m95 -97.38 130.91 44.47 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.724 -0.238 . . . . 0.0 110.924 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.8 mtp85 -139.7 131.12 26.9 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.43 144.73 20.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.084 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.596 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -63.11 -38.88 92.93 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.576 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.7 -1.75 2.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.622 -0.799 . . . . 0.0 111.428 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.408 ' H ' ' C ' ' A' ' 84' ' ' ALA . 72.3 mm-40 -107.49 -2.99 19.9 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.941 0.4 . . . . 0.0 110.184 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 85.7 mt -76.88 125.59 29.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.917 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.558 ' O ' ' N ' ' A' ' 90' ' ' GLY . 7.1 tpt180 -132.1 148.42 52.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.501 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -43.34 88.83 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.932 0.396 . . . . 0.0 110.693 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.97 -16.57 0.45 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -87.21 129.79 34.82 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.728 0.299 . . . . 0.0 110.771 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 87.1 mtm180 -90.19 131.06 36.23 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 121.083 0.468 . . . . 0.0 110.586 -178.617 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.15 143.32 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.391 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.13 131.78 49.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 104' ' ' ARG . 25.8 m -129.57 157.81 42.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.368 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 71.7 ttt180 -106.98 130.28 54.65 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.458 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.53 121.9 42.34 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.373 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 57.6 t -75.01 -15.44 15.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 O-C-N 122.081 -0.387 . . . . 0.0 110.648 178.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -70.75 -58.03 4.06 Favored 'General case' 0 C--O 1.232 0.154 0 C-N-CA 120.485 -0.486 . . . . 0.0 109.927 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.442 ' C ' ' H ' ' A' ' 102' ' ' GLU . 45.9 p -96.79 -12.56 23.48 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 116.751 -0.204 . . . . 0.0 110.562 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.53 -13.72 6.17 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.4 mt-10 -81.74 157.1 24.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.972 0.415 . . . . 0.0 111.078 -177.794 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.629 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -78.48 140.4 38.61 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 179.393 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.451 ' O ' HG22 ' A' ' 95' ' ' VAL . 52.5 mtm180 -139.55 174.51 10.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.47 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.9 m-85 -115.3 146.09 41.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.222 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.44 ' OG ' HG21 ' A' ' 95' ' ' VAL . 14.8 m -139.78 161.44 37.54 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.033 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.3 t -94.35 154.75 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.667 0.27 . . . . 0.0 110.467 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 97.0 mt -76.38 149.96 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 178.735 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 74.1 ttt-85 -99.16 -41.77 7.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.613 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -165.74 146.81 6.97 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.444 ' C ' HD12 ' A' ' 112' ' ' LEU . 71.9 t -97.63 134.43 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -98.67 148.78 35.02 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.074 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.79 162.03 44.03 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.796 2.331 . . . . 0.0 111.436 179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 114' ' ' THR . 2.9 p -62.49 149.38 43.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.981 0.419 . . . . 0.0 110.742 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttt85 -132.3 -141.24 0.21 Allowed 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.663 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' ARG . . . . . 0.457 ' HG3' HG22 ' A' ' 53' ' ' THR . 12.8 tpt180 -157.06 129.98 7.71 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.322 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.19 170.5 5.16 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.087 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -75.57 149.29 38.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.868 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 59.2 p -128.78 142.7 50.9 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.069 0.461 . . . . 0.0 109.764 179.287 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 9.2 m-85 -120.85 176.4 5.56 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.897 -178.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -148.76 153.54 38.31 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.855 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.589 HD21 HG22 ' A' ' 23' ' ' VAL . 90.8 mt -140.18 171.14 14.59 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.681 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -135.17 106.11 6.61 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' C ' ' A' ' 125' ' ' GLU . 7.9 t -86.89 111.74 22.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.498 ' C ' ' O ' ' A' ' 124' ' ' VAL . 5.2 tp10 20.79 -116.57 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 O-C-N 123.657 0.598 . . . . 0.0 111.685 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -106.74 -26.14 11.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.277 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.9 mt -89.21 69.84 8.26 Favored 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.498 ' O ' HG23 ' A' ' 129' ' ' THR . 28.9 m170 -42.92 104.88 0.04 OUTLIER 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.498 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.4 139.59 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.675 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.569 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.3 pt? -147.14 156.73 43.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 121.509 0.671 . . . . 0.0 112.122 179.542 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.0 p -89.02 125.35 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.577 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.8 126.59 30.9 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.947 -179.011 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.503 ' C ' ' H ' ' A' ' 135' ' ' VAL . 15.4 mm-40 53.81 46.78 25.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.982 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.33 -22.06 0.51 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.503 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.1 t -89.01 152.56 3.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 117.121 0.461 . . . . 0.0 110.66 -179.411 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -110.44 115.55 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.416 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 138' ' ' HIS . 12.3 m -147.31 137.69 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.528 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.573 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 53.1 t-80 -36.52 156.79 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.529 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 16.1 p30 . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.468 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.5 mt -105.12 141.49 36.58 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-O 120.938 0.399 . . . . 0.0 110.543 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -84.35 161.42 20.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.463 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 63.8 tt0 -61.68 146.03 50.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.381 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.57 -16.4 40.81 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.633 HG23 ' HG3' ' A' ' 133' ' ' GLU . 26.3 m -68.47 124.16 22.81 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.789 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ARG . . . . . 0.472 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.0 mtp180 -85.03 149.82 25.31 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.162 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 56.2 mt -134.13 108.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.271 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . 0.413 ' HB3' HH22 ' A' ' 96' ' ' ARG . 43.9 t80 -76.94 126.7 31.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 178.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -96.06 131.2 29.37 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.094 -179.335 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.05 -33.17 4.73 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.33 2.02 . . . . 0.0 111.8 179.02 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 73.6 t -73.31 -54.27 16.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.64 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.5 m -75.17 -38.09 61.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.163 0.506 . . . . 0.0 110.065 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.23 7.36 85.18 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.059 -0.816 . . . . 0.0 111.059 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 16' ' ' THR . 3.0 t -106.9 -167.22 1.25 Allowed 'General case' 0 C--N 1.338 0.09 0 CA-C-N 117.652 0.726 . . . . 0.0 109.895 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.472 HG21 ' HE ' ' A' ' 7' ' ' ARG . 93.3 m -115.0 115.28 26.6 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.547 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -100.68 140.75 34.51 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.744 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.7 tpp85 -97.27 127.2 43.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.538 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.671 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -51.57 -40.3 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.771 -178.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.541 ' N ' HG23 ' A' ' 19' ' ' ILE . 14.3 tt0 -53.74 -35.29 61.06 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.961 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.72 -34.13 40.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.695 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.662 ' O ' ' O ' ' A' ' 26' ' ' ARG . 85.1 t -64.83 -45.61 94.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.807 0.337 . . . . 0.0 111.122 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 120' ' ' PHE . 87.9 t -66.54 -45.16 89.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 O-C-N 121.186 -0.946 . . . . 0.0 111.951 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -55.41 -42.41 74.04 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.741 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.75 33.49 3.72 Favored Glycine 0 CA--C 1.529 0.95 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.662 ' O ' ' O ' ' A' ' 22' ' ' VAL . 82.4 mtp180 58.14 -100.58 0.11 Allowed 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.216 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.638 ' C ' ' H ' ' A' ' 29' ' ' ILE . 40.7 mttt 79.94 82.65 0.09 OUTLIER Pre-proline 0 C--N 1.299 -1.604 0 C-N-CA 122.898 0.479 . . . . 0.0 110.388 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.7 ' O ' ' O ' ' A' ' 29' ' ' ILE . 34.1 Cg_exo -59.52 19.76 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.745 2.297 . . . . 0.0 112.577 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.7 ' O ' ' O ' ' A' ' 28' ' ' PRO . 20.3 pt -35.41 -178.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 O-C-N 124.041 0.838 . . . . 0.0 111.189 -178.258 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.426 ' CG ' HG21 ' A' ' 12' ' ' VAL . 56.6 m80 -119.78 163.33 17.63 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 121.43 -0.794 . . . . 0.0 110.891 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.1 171.33 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.9 t -91.03 135.13 27.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.47 168.09 9.81 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.82 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.06 142.67 46.39 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.216 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.39 177.93 4.48 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.785 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -70.54 -13.9 62.29 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.92 0.39 . . . . 0.0 110.656 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -81.34 -18.53 45.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.279 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.9 24.91 36.28 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.6 p -103.11 135.18 45.25 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.7 0.286 . . . . 0.0 111.203 178.324 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 65.4 mt -92.59 131.24 37.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.654 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 8.2 t-160 -142.82 139.82 31.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.483 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.55 141.95 51.82 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.794 -178.51 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.1 mmp_? -143.85 138.21 14.95 Favored Pre-proline 0 CA--C 1.535 0.398 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.8 158.81 31.46 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.86 2.373 . . . . 0.0 112.727 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.32 135.42 36.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.243 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.9 m -124.9 1.05 5.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.543 -178.957 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.9 t -144.34 133.68 23.16 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.548 0.613 . . . . 0.0 109.792 179.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.531 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -132.68 117.26 17.65 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 178.106 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -141.24 146.55 37.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -89.2 132.83 34.67 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 176.642 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.434 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -92.17 -0.64 57.42 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.186 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.36 -179.6 51.66 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.31 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.8 m -91.74 126.6 36.89 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 120.945 0.402 . . . . 0.0 110.39 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 78.1 mtp85 -150.25 170.48 18.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.798 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -75.45 141.83 43.07 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.041 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -142.44 156.46 18.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.466 ' CG2' HG22 ' A' ' 114' ' ' THR . 37.7 pt -110.75 154.4 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.978 0.418 . . . . 0.0 110.258 179.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.84 132.73 11.26 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 21.0 mt -115.26 114.29 25.0 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.104 0.478 . . . . 0.0 110.222 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -99.19 122.75 42.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.968 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 94.4 mt . . . . . 0 CA--C 1.513 -0.465 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.692 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 120.994 0.426 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 66' ' ' ILE . . . . . 0.508 HG22 ' N ' ' A' ' 67' ' ' LEU . 97.1 mt -125.89 158.64 34.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.524 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.508 ' N ' HG22 ' A' ' 66' ' ' ILE . 42.5 tp -132.68 117.43 17.85 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.582 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -102.79 115.74 31.19 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.13 171.74 14.86 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.368 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 75.9 p -77.09 152.52 82.19 Favored Pre-proline 0 C--N 1.327 -0.394 0 C-N-CA 120.457 -0.497 . . . . 0.0 111.35 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.19 -28.8 81.01 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 122.214 1.943 . . . . 0.0 112.336 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -83.21 -5.66 59.2 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.899 0.38 . . . . 0.0 110.563 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.9 t60 -71.64 130.02 40.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.43 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.422 ' H ' ' HD2' ' A' ' 74' ' ' LYS . 0.0 OUTLIER -85.64 127.26 34.43 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.236 0.541 . . . . 0.0 110.737 -179.464 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.5 t -109.6 93.75 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.619 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.117 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.448 HD13 ' CH2' ' A' ' 81' ' ' TRP . 6.4 tp -31.42 93.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.677 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 75' ' ' VAL . 0.9 OUTLIER -97.25 177.86 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -178.236 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.411 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.2 pt-20 -64.68 -22.84 67.07 Favored 'General case' 0 N--CA 1.448 -0.573 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.262 -179.012 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -104.59 26.39 9.11 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 121.235 -0.186 . . . . 0.0 110.99 -179.388 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.18 -177.88 43.01 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.448 ' CH2' HD13 ' A' ' 76' ' ' LEU . 83.1 m95 -57.01 130.74 47.38 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.977 0.418 . . . . 0.0 110.335 -177.284 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -146.38 135.26 22.42 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.78 144.5 14.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.917 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.462 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -64.25 -38.76 92.21 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.488 -179.014 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.51 1.02 0.52 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.449 -0.881 . . . . 0.0 111.76 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.462 ' H ' ' C ' ' A' ' 84' ' ' ALA . 19.9 tp10 -107.66 5.43 26.83 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.159 0.504 . . . . 0.0 110.049 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.29 123.19 29.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.226 0.536 . . . . 0.0 111.018 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 90' ' ' GLY . 33.1 mmt180 -132.47 149.76 52.28 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.803 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -48.02 87.89 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.977 0.418 . . . . 0.0 110.657 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -20.0 0.44 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.911 -0.875 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -84.18 129.48 34.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.83 0.348 . . . . 0.0 110.582 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.411 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 88.2 mtm180 -90.68 132.38 35.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.142 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 m -119.93 152.14 22.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.823 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -68.69 137.36 54.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.491 -179.422 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.436 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.0 m -137.19 162.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.465 178.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.709 HH21 HG11 ' A' ' 131' ' ' VAL . 12.2 ttm180 -106.58 129.45 54.51 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.535 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 101' ' ' GLY . 45.9 t0 -100.97 123.77 45.67 Favored 'General case' 0 C--O 1.224 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.426 178.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -74.24 -15.73 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 118.184 0.447 . . . . 0.0 111.12 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -72.45 -55.18 7.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.01 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.2 m -99.44 -16.27 18.43 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.735 -0.211 . . . . 0.0 110.632 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 97' ' ' ASP . . . 73.84 -14.32 3.67 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.3 mt-10 -80.71 160.4 24.97 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-O 120.781 0.324 . . . . 0.0 110.64 -177.651 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.442 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.5 tp -79.03 126.59 30.9 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.027 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.408 ' O ' HG22 ' A' ' 95' ' ' VAL . 65.8 mtp85 -126.81 168.17 14.8 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.956 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -110.32 142.72 41.58 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.5 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' SER . . . . . 0.436 ' OG ' HG21 ' A' ' 95' ' ' VAL . 12.7 m -137.94 158.44 44.33 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.85 152.82 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.737 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.43 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.9 mm -67.46 156.7 6.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.844 179.502 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.43 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 17.2 tpt180 -108.39 -52.33 2.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.01 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -165.56 144.47 6.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 70.0 t -95.09 133.29 36.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.087 0.47 . . . . 0.0 110.037 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.62 127.02 32.39 Favored Pre-proline 0 CA--C 1.536 0.432 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.518 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -47.88 161.64 0.33 Allowed 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 122.206 1.937 . . . . 0.0 112.021 179.274 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.466 HG22 ' CG2' ' A' ' 57' ' ' ILE . 80.6 p -64.99 153.82 39.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.0 0.429 . . . . 0.0 110.699 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.8 ttp180 -134.98 -140.8 0.17 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.586 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.8 mtm-85 -156.79 130.44 8.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.11 172.82 3.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.979 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 22.6 mmt85 -77.51 147.03 36.03 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.971 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 18.5 p -125.13 142.9 51.21 Favored 'General case' 0 CA--C 1.52 -0.181 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' PHE . . . . . 0.925 ' CD1' HG21 ' A' ' 23' ' ' VAL . 75.6 m-85 -118.93 175.54 5.71 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.821 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -153.47 120.51 5.74 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.553 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.671 HD11 HD12 ' A' ' 19' ' ' ILE . 75.1 mt -120.03 123.95 44.7 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -87.58 118.41 27.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.209 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 50.5 t -90.42 115.23 29.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -58.1 149.28 24.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.715 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.9 tt0 63.85 -69.73 0.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.295 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.82 100.79 11.78 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 110.43 -0.211 . . . . 0.0 110.43 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.55 ' O ' HG23 ' A' ' 129' ' ' THR . 72.4 m-70 -69.73 100.28 1.47 Allowed 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.161 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.55 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 164.15 144.37 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.962 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.558 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.5 pt? -145.33 157.02 44.13 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.636 0.732 . . . . 0.0 112.011 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.709 HG11 HH21 ' A' ' 96' ' ' ARG . 8.9 p -92.35 120.56 41.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.832 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.604 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.89 126.45 30.46 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.891 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.633 ' HG3' HG23 ' A' ' 6' ' ' THR . 8.9 mt-10 59.86 45.33 12.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.222 0.534 . . . . 0.0 110.029 -179.475 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.41 -24.7 0.35 Allowed Glycine 0 CA--C 1.522 0.524 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.28 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.533 ' H ' ' C ' ' A' ' 133' ' ' GLU . 10.3 t -90.25 151.21 3.53 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 O-C-N 122.485 -0.42 . . . . 0.0 110.68 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.89 115.84 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.68 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 138' ' ' HIS . 20.9 m -147.28 136.67 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.434 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 17.9 t-80 -34.99 154.36 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.089 0.403 . . . . 0.0 112.089 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.277 -179.861 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.6 mt -108.97 137.53 46.74 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.341 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 161.46 23.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.687 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -62.36 145.91 52.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.092 179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.56 -17.65 33.3 Favored Glycine 0 C--N 1.337 0.63 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.8 m -66.89 122.4 17.63 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.224 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -98.35 115.72 29.06 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.143 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 131' ' ' VAL . 3.6 mt -102.59 117.33 47.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.734 -179.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -75.84 133.23 40.66 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASP . . . . . 0.823 ' OD1' HG22 ' A' ' 13' ' ' THR . 4.1 t70 -104.0 134.93 19.45 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.526 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.52 -32.51 3.71 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.512 2.142 . . . . 0.0 112.321 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.07 -59.6 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.417 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.823 HG22 ' OD1' ' A' ' 10' ' ' ASP . 1.9 t -76.9 -34.21 57.74 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.97 12.84 76.11 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.648 ' H ' HG23 ' A' ' 13' ' ' THR . 75.5 m -116.94 161.6 19.1 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 117.977 0.888 . . . . 0.0 109.753 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' THR . . . . . 0.523 ' N ' HG22 ' A' ' 15' ' ' THR . 43.0 m -79.71 115.83 19.54 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.278 0.561 . . . . 0.0 110.713 -179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' HIS . . . . . 0.669 ' NE2' HG21 ' A' ' 13' ' ' THR . 24.8 m-70 -101.84 147.07 26.94 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.206 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -101.23 125.53 47.87 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.004 178.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -53.46 -39.32 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.265 -179.234 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.2 pt-20 -58.55 -33.72 70.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 68.4 t0 -83.97 -37.22 22.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.596 179.611 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 78.4 t -66.39 -42.74 91.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.27 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.447 HG22 HD21 ' A' ' 122' ' ' LEU . 75.9 t -69.51 -44.81 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 121.093 -0.243 . . . . 0.0 111.428 -179.697 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -54.15 -36.32 63.19 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 121.036 -0.266 . . . . 0.0 110.761 -178.222 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -117.25 33.31 5.07 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER 12.42 74.95 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 124.056 0.504 . . . . 0.0 109.9 179.859 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LYS . . . . . 0.652 ' C ' ' H ' ' A' ' 29' ' ' ILE . 64.0 mttt -91.29 117.74 68.04 Favored Pre-proline 0 N--CA 1.442 -0.862 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -178.201 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.68 ' O ' ' O ' ' A' ' 29' ' ' ILE . 52.5 Cg_exo -52.67 7.54 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.964 2.442 . . . . 0.0 113.005 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.68 ' O ' ' O ' ' A' ' 28' ' ' PRO . 1.3 pp -37.05 -178.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 O-C-N 123.949 0.781 . . . . 0.0 110.722 -178.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' HIS . . . . . 0.506 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 2.4 m80 -126.49 168.14 14.65 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 121.404 -0.81 . . . . 0.0 111.247 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.1 m -148.12 171.78 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.264 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 62.9 t -88.11 131.11 36.53 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.641 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -109.07 149.72 28.86 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.055 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.69 140.79 50.1 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.933 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB3' ' OD1' ' A' ' 37' ' ' ASP . . . -113.69 174.31 5.99 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.771 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -68.42 -14.62 63.13 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.651 0.263 . . . . 0.0 110.648 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.485 ' OD1' ' HB3' ' A' ' 35' ' ' ALA . 38.4 p30 -81.79 -15.71 53.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.488 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 87.04 22.64 44.45 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.42 ' OG1' ' OD1' ' A' ' 37' ' ' ASP . 22.0 p -102.87 137.29 41.27 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.622 0.249 . . . . 0.0 111.108 178.783 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.7 mt -94.79 130.18 41.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.884 0.374 . . . . 0.0 110.47 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.48 138.7 33.01 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.404 -179.073 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.74 139.9 53.4 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.609 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.7 mmt-85 -143.38 137.97 15.1 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.897 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.73 156.34 35.37 Favored 'Trans proline' 0 C--N 1.316 -1.177 0 C-N-CA 122.783 2.322 . . . . 0.0 112.969 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.9 t -93.86 130.75 42.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -118.11 -5.02 11.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.527 -178.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.1 t -145.97 134.73 22.35 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.203 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' TRP . . . . . 0.557 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -134.02 116.28 15.32 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.359 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PHE . . . . . 0.514 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 47.5 m-85 -140.94 150.71 43.48 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.063 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -93.54 133.16 37.13 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 176.951 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -92.17 -0.35 57.43 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.202 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.5 179.73 51.48 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 32.0 m -91.41 123.07 34.55 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -143.79 169.97 16.76 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.915 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -76.99 142.71 39.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.971 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.7 m -147.15 157.59 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.113 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.629 HD11 ' HB1' ' A' ' 84' ' ' ALA . 45.9 pt -108.12 159.05 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.238 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.83 139.55 15.75 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.7 mt -118.53 112.04 19.39 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.148 0.499 . . . . 0.0 109.689 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.735 ' NE ' ' HE ' ' A' ' 109' ' ' ARG . 56.8 ttp180 -98.94 126.17 44.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.001 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.733 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.469 0.52 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.472 0 CA-C-O 120.797 0.332 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 93.5 mt -120.89 135.55 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.222 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.7 tp -112.53 111.0 21.51 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.798 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' TRP . . . . . 0.515 ' CE3' ' NH2' ' A' ' 115' ' ' ARG . 97.9 m95 -103.73 105.71 16.0 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.25 172.47 12.87 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.549 -179.059 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -72.76 156.24 90.11 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.759 -179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 85' ' ' GLY . 31.4 Cg_endo -64.3 -19.36 65.59 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.644 2.229 . . . . 0.0 111.866 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 39.6 p-10 -90.99 -4.98 56.0 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' HIS . . . . . 0.534 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.6 t60 -71.88 132.09 43.91 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.19 124.65 32.09 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.442 0.639 . . . . 0.0 111.386 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.8 t -99.03 143.01 13.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.159 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.4 tp -82.83 89.87 6.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.699 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.473 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 30.0 p -97.86 176.25 5.86 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -67.39 -20.03 65.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.117 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -101.73 24.35 9.98 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-O 120.656 0.265 . . . . 0.0 110.825 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.09 -144.71 17.5 Favored Glycine 0 C--N 1.332 0.306 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -86.88 121.88 29.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.732 0.301 . . . . 0.0 111.289 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.7 mmt85 -122.56 125.8 46.45 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.089 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -68.54 129.84 41.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.507 -179.72 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.629 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -66.83 -0.03 2.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.799 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -75.55 -13.13 83.22 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -136.97 30.84 2.74 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.914 0.387 . . . . 0.0 111.378 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LEU . . . . . 0.455 HD12 ' HA ' ' A' ' 84' ' ' ALA . 10.9 mt -82.88 131.81 35.18 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.403 0.62 . . . . 0.0 111.007 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 83.2 mmt-85 -133.62 148.38 51.55 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.082 -0.963 . . . . 0.0 111.346 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -46.37 97.92 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.547 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 158.48 -16.52 0.28 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -88.29 129.91 35.25 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -88.57 129.74 35.41 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.36 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.9 m -108.9 141.86 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.046 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ALA . . . . . 0.465 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -72.08 120.71 18.06 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.722 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' VAL . . . . . 0.406 ' O ' HG23 ' A' ' 95' ' ' VAL . 33.2 m -121.85 131.28 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.945 0.402 . . . . 0.0 110.07 179.09 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -67.73 132.05 46.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.848 -179.413 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 48.7 t0 -101.77 122.9 44.81 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 119.297 -0.382 . . . . 0.0 110.443 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.5 p -75.22 -16.87 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 CA-C-N 118.427 0.558 . . . . 0.0 111.323 179.101 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.75 -58.49 3.59 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.436 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' THR . . . . . 0.439 ' C ' ' H ' ' A' ' 102' ' ' GLU . 48.8 p -98.58 -14.89 19.72 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.456 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.37 -17.22 4.26 Favored Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.439 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.4 mt-10 -78.38 157.75 28.97 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -177.769 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.494 HD11 HG21 ' A' ' 136' ' ' VAL . 2.1 tp -75.06 135.18 41.24 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.314 -179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 32.5 ptt180 -135.04 167.46 20.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.216 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.473 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.0 m-85 -117.12 152.83 33.9 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.029 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.1 m -146.2 165.21 29.85 Favored 'General case' 0 CA--C 1.516 -0.348 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.8 t -89.2 150.37 3.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 120.775 0.321 . . . . 0.0 110.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ILE . . . . . 0.491 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.2 mm -69.83 160.75 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.211 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.735 ' HE ' ' NE ' ' A' ' 60' ' ' ARG . 12.6 ttp85 -107.67 -49.32 3.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.533 179.252 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLU . . . . . 0.527 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 74.8 tt0 -166.78 146.66 5.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.473 ' C ' HD22 ' A' ' 112' ' ' LEU . 1.0 OUTLIER -94.09 134.58 31.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.238 0.542 . . . . 0.0 110.019 179.688 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 3.0 mm? -97.86 145.48 29.82 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.157 -179.208 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.47 160.18 50.78 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 122.568 2.179 . . . . 0.0 111.468 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -64.88 154.12 38.22 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.146 0.498 . . . . 0.0 110.655 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.515 ' NH2' ' CE3' ' A' ' 68' ' ' TRP . 74.4 mtm180 -140.95 -138.82 0.12 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.657 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -155.58 132.01 10.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.236 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -171.13 173.03 5.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.764 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -77.77 140.24 39.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.779 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 3.1 p -114.98 140.46 49.01 Favored 'General case' 0 CA--C 1.522 -0.117 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -119.59 171.59 8.26 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.24 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.514 ' OD1' ' O ' ' A' ' 49' ' ' PHE . 43.6 p-10 -160.72 120.31 2.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.089 179.346 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 23' ' ' VAL . 69.9 mt -117.38 131.67 56.73 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 120.72 0.295 . . . . 0.0 110.63 179.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -87.71 110.18 20.25 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.568 ' O ' ' N ' ' A' ' 126' ' ' GLU . 21.6 t -81.04 109.49 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.467 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.074 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.488 ' C ' ' O ' ' A' ' 124' ' ' VAL . 1.6 tm-20 24.14 -85.53 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.815 0.697 . . . . 0.0 111.435 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.568 ' N ' ' O ' ' A' ' 124' ' ' VAL . 79.8 tt0 -136.87 -36.44 0.68 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.157 -0.928 . . . . 0.0 111.141 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.481 ' O ' ' N ' ' A' ' 129' ' ' THR . 74.0 mt -72.4 67.69 0.74 Allowed 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.019 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' HIS . . . . . 0.602 ' HA ' HD22 ' A' ' 139' ' ' ASN . 35.4 m80 -40.82 95.92 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.58 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.5 136.36 0.01 OUTLIER 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.685 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.5 pp -144.99 154.37 42.47 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.449 0.642 . . . . 0.0 111.679 -178.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 8' ' ' ILE . 97.2 t -87.81 123.99 40.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ALA . . . . . 0.603 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.51 142.22 48.13 Favored 'General case' 0 C--O 1.227 -0.106 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.444 -178.511 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.581 ' O ' HG23 ' A' ' 135' ' ' VAL . 71.1 mm-40 40.23 49.79 2.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.196 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.45 -25.32 0.27 Allowed Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.446 -0.662 . . . . 0.0 111.446 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 133' ' ' GLU . 2.7 t -89.12 152.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.394 0 O-C-N 122.48 -0.423 . . . . 0.0 110.689 -179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' VAL . . . . . 0.494 HG21 HD11 ' A' ' 103' ' ' LEU . 2.7 t -109.87 117.64 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.437 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 138' ' ' HIS . 20.5 m -149.87 141.01 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.531 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.492 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 54.3 t-80 -31.42 150.31 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.173 0 O-C-N 123.209 0.318 . . . . 0.0 111.741 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.602 HD22 ' HA ' ' A' ' 128' ' ' HIS . 3.0 m-20 . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 118.056 -0.973 . . . . 0.0 110.628 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.543 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.1 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.3 mt -99.47 141.8 31.79 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.356 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.66 162.46 17.1 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.758 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 20' ' ' GLU . 41.3 tt0 -64.51 140.77 58.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.443 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.91 -17.72 29.64 Favored Glycine 0 C--N 1.338 0.693 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.5 m -70.63 122.81 20.48 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.607 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.6 mtp180 -82.65 147.99 28.21 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.043 0.449 . . . . 0.0 110.429 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 84.7 mt -133.94 107.67 10.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.26 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -77.97 129.69 35.61 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -101.49 132.02 22.3 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.45 -31.2 9.25 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.857 1.705 . . . . 0.0 112.449 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.2 t -69.99 -53.61 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.049 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -80.19 -39.76 28.59 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.858 0.361 . . . . 0.0 110.24 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.61 74.61 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.416 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -105.8 -168.32 1.43 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 117.363 0.582 . . . . 0.0 109.855 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.607 HG21 ' HE ' ' A' ' 7' ' ' ARG . 72.8 m -117.34 119.79 36.2 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.346 0.593 . . . . 0.0 110.397 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 63.9 m170 -109.75 148.07 32.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.089 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -98.87 130.24 45.27 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.502 HG23 ' N ' ' A' ' 20' ' ' GLU . 5.6 tp -51.93 -40.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.632 0.253 . . . . 0.0 111.109 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.502 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.6 pt-20 -58.87 -34.57 71.77 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.113 0.482 . . . . 0.0 110.901 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -84.51 -37.49 21.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.432 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 75.4 t -68.09 -41.54 84.39 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.937 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.67 HG22 HD21 ' A' ' 122' ' ' LEU . 53.5 t -77.42 -46.33 28.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.2 t0 -55.65 -35.48 65.99 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 120.764 0.316 . . . . 0.0 110.829 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.564 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.77 26.49 14.13 Favored Glycine 0 N--CA 1.46 0.238 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.564 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.2 OUTLIER 15.37 68.77 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.225 0 O-C-N 124.042 0.496 . . . . 0.0 109.71 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 29' ' ' ILE . 83.4 mttt -83.8 114.46 54.05 Favored Pre-proline 0 N--CA 1.45 -0.449 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.87 -175.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -57.16 83.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 CA-C-N 119.78 0.957 . . . . 0.0 111.294 178.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.47 ' N ' ' O ' ' A' ' 27' ' ' LYS . 49.1 pt -119.11 -170.12 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 CA-C-O 121.063 0.459 . . . . 0.0 110.973 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.449 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 67.6 m80 -126.37 161.66 27.34 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.432 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.05 170.56 3.9 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.357 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 97.3 t -88.86 133.68 30.44 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.36 155.64 24.84 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.549 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -127.22 145.71 50.67 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.395 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.73 -176.55 2.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.428 ' H ' ' HD2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -71.63 -12.75 61.5 Favored 'General case' 0 CA--C 1.523 -0.092 0 CA-C-O 120.868 0.366 . . . . 0.0 110.686 179.561 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.491 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 32.3 p30 -76.28 -20.2 57.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.565 179.513 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.491 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 93.95 -8.25 73.34 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.457 ' HG1' ' CE1' ' A' ' 41' ' ' HIS . 33.6 p -82.31 151.09 26.88 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 121.946 0.879 . . . . 0.0 111.783 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.0 mt -100.94 132.21 46.45 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.258 -1.337 . . . . 0.0 111.877 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' HIS . . . . . 0.457 ' CE1' ' HG1' ' A' ' 39' ' ' THR . 5.7 m80 -137.88 137.39 38.02 Favored 'General case' 0 C--O 1.221 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.375 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.62 143.69 49.7 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.454 -178.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.537 HH21 ' CD ' ' A' ' 125' ' ' GLU . 8.9 mtp85 -149.21 138.61 12.7 Favored Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.991 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -74.85 157.17 43.55 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.239 1.959 . . . . 0.0 112.677 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 99.1 t -96.24 136.67 26.38 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.9 m -123.7 1.39 5.69 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.618 0 CA-C-O 119.202 -0.428 . . . . 0.0 111.856 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.5 p -151.04 144.87 25.13 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 118.987 0.812 . . . . 0.0 109.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.478 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.1 OUTLIER -142.12 123.07 14.47 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.373 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -141.57 145.32 34.93 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -86.88 136.55 32.92 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.437 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -99.14 1.84 45.4 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.806 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.6 -175.44 53.41 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.375 -0.917 . . . . 0.0 111.613 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 70.0 m -95.14 126.66 40.62 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -148.21 168.3 22.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.433 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -73.1 138.36 45.78 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.607 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -139.22 155.11 25.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-O 120.752 0.31 . . . . 0.0 110.181 -179.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.791 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.0 pt -110.45 153.17 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 110.179 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.28 125.47 7.7 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.5 mt -106.93 112.46 25.44 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 56.8 ttp180 -96.17 123.36 39.77 Favored 'General case' 0 C--O 1.219 -0.521 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.416 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 24.1 mm -111.36 157.83 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.12 138.14 26.25 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.697 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.712 ' H ' ' NH2' ' A' ' 109' ' ' ARG . . . 101.69 -3.57 53.19 Favored Glycine 0 CA--C 1.525 0.717 0 CA-C-N 115.938 -0.573 . . . . 0.0 111.915 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 96.52 -19.8 53.09 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -53.25 125.35 17.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.543 0.687 . . . . 0.0 109.213 -177.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -132.01 154.67 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.408 -178.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.2 tp -143.69 125.84 15.5 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -105.87 123.52 48.1 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.85 170.77 17.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 6.5 p -78.49 156.7 78.16 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.982 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -59.25 -22.92 67.32 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 121.872 1.715 . . . . 0.0 111.995 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -87.09 -8.9 56.59 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.743 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 8.2 t60 -68.7 126.76 30.71 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.751 ' H ' ' CE1' ' A' ' 138' ' ' HIS . 69.0 mttm -86.22 130.88 34.37 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 121.509 0.671 . . . . 0.0 111.418 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -104.66 139.27 26.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.83 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 59.6 tp -77.81 95.96 4.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.955 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.2 p -99.32 178.04 5.01 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.698 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.7 pm0 -64.91 -16.93 63.87 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.556 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.456 ' HB2' ' HE ' ' A' ' 82' ' ' ARG . 77.3 m-85 -109.73 26.24 10.88 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.08 -138.38 13.87 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -98.72 132.44 44.09 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.451 -0.374 . . . . 0.0 110.746 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.456 ' HE ' ' HB2' ' A' ' 79' ' ' TYR . 90.8 mtt-85 -140.3 132.41 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.266 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.36 144.81 23.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.902 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.791 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.45 -38.24 86.47 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.569 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.07 -2.12 6.29 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 120.537 -0.84 . . . . 0.0 111.713 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.67 25.69 11.5 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.95 0.405 . . . . 0.0 110.433 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 77.5 mt -110.18 130.34 55.56 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.608 0.718 . . . . 0.0 111.126 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.522 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.1 mmt180 -130.4 147.53 52.11 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.744 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -45.01 90.35 0.0 OUTLIER 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.888 0.375 . . . . 0.0 110.454 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -13.78 0.33 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -84.48 130.16 34.78 Favored 'General case' 0 C--O 1.225 -0.223 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.43 ' O ' ' OE1' ' A' ' 78' ' ' GLU . 89.1 mtm180 -90.26 136.72 32.88 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 -178.219 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.2 m -125.24 151.52 31.11 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.209 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.494 ' HB1' ' CD1' ' A' ' 103' ' ' LEU . . . -84.92 128.59 34.69 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.457 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.3 135.14 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.898 0.38 . . . . 0.0 110.441 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -66.74 133.66 50.62 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.055 0.455 . . . . 0.0 111.344 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -98.54 122.67 42.03 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-N 115.872 -0.603 . . . . 0.0 109.562 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.0 t -75.02 -17.23 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 118.401 0.546 . . . . 0.0 110.649 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.77 -59.25 3.06 Favored 'General case' 0 CA--C 1.522 -0.096 0 C-N-CA 120.197 -0.601 . . . . 0.0 109.964 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.494 ' C ' ' H ' ' A' ' 102' ' ' GLU . 73.6 p -93.88 -11.34 31.31 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 110.435 -0.209 . . . . 0.0 110.435 179.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 72.89 -12.04 4.12 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.494 ' H ' ' C ' ' A' ' 100' ' ' THR . 41.8 mt-10 -88.49 164.57 15.39 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 121.036 0.446 . . . . 0.0 111.24 -177.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.513 HD13 ' H ' ' A' ' 104' ' ' ARG . 0.2 OUTLIER -71.12 142.06 50.77 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.589 -179.459 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.513 ' H ' HD13 ' A' ' 103' ' ' LEU . 6.0 ptt85 -136.89 158.76 43.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.611 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.698 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -112.32 135.8 52.56 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.926 -179.746 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.481 ' OG ' ' NH2' ' A' ' 104' ' ' ARG . 6.7 m -142.55 161.84 37.01 Favored 'General case' 0 C--N 1.344 0.329 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.1 p -94.43 156.48 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 111.33 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.459 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.3 mt -71.1 159.35 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.712 ' NH2' ' H ' ' A' ' 63' ' ' GLY . 43.2 ttm180 -106.57 -46.36 4.02 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.759 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 81.4 tt0 -165.01 143.72 6.55 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.424 ' C ' HD22 ' A' ' 112' ' ' LEU . 10.7 p -93.95 133.14 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.433 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.3 mm? -101.11 125.4 38.24 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-O 119.674 -0.203 . . . . 0.0 110.977 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.39 165.93 0.1 Allowed 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.225 1.95 . . . . 0.0 112.0 179.065 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 19.9 p -66.69 151.47 47.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 121.276 0.56 . . . . 0.0 110.776 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -133.06 -142.05 0.21 Allowed 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.678 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.5 mtt85 -156.79 130.93 8.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.285 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.53 169.83 5.03 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.943 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -72.89 148.25 44.56 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.241 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 42.0 p -131.1 143.36 50.6 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.49 ' HB3' HG21 ' A' ' 23' ' ' VAL . 68.3 m-85 -115.65 174.55 5.96 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.753 -179.04 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -145.28 137.48 25.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.109 -0.95 . . . . 0.0 111.074 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.67 HD21 HG22 ' A' ' 23' ' ' VAL . 97.2 mt -130.23 170.8 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.449 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -138.01 106.99 5.98 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.926 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 125' ' ' GLU . 8.5 t -86.04 115.14 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.863 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.537 ' CD ' HH21 ' A' ' 43' ' ' ARG . 81.4 tt0 18.52 -95.65 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.729 0 O-C-N 123.762 0.664 . . . . 0.0 112.327 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -128.03 -33.11 2.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.154 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.439 ' O ' ' N ' ' A' ' 129' ' ' THR . 54.3 mt -78.02 67.93 3.96 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -42.7 97.81 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.229 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 175.14 143.48 0.06 Allowed 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.82 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.634 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.9 pp -151.47 154.5 36.68 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.415 0.626 . . . . 0.0 111.676 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.7 t -89.76 123.54 42.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.872 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.86 122.87 22.62 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.137 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.8 mm-40 55.83 43.54 27.48 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.021 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.51 -15.81 0.8 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.176 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.7 t -90.53 146.87 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 117.268 0.534 . . . . 0.0 110.456 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.19 115.12 47.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.792 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.416 ' O ' ' C ' ' A' ' 138' ' ' HIS . 21.6 m -147.65 142.19 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.226 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.751 ' CE1' ' H ' ' A' ' 74' ' ' LYS . 0.3 OUTLIER -37.37 153.48 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.206 0.457 . . . . 0.0 111.681 -179.816 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.9 p30 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.382 179.745 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.431 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 24.5 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -109.34 136.51 48.67 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.845 0.355 . . . . 0.0 110.527 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.04 162.66 21.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.518 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 44.6 tt0 -63.27 143.18 58.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.961 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.83 -20.83 23.96 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.619 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.3 m -67.48 123.56 20.74 Favored 'General case' 0 C--N 1.331 -0.218 0 O-C-N 122.768 -0.254 . . . . 0.0 111.244 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.817 ' HE ' HG21 ' A' ' 16' ' ' THR . 72.6 mtp180 -82.72 147.63 28.35 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.781 0.324 . . . . 0.0 110.162 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -134.79 107.3 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.497 179.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -76.95 129.8 36.64 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' A' ' 10' ' ' ASP . 50.8 t0 -109.91 110.24 59.06 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-O 119.53 -0.272 . . . . 0.0 110.377 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_exo -51.96 -36.8 65.84 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 121.765 1.643 . . . . 0.0 112.561 178.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.2 t -62.11 -58.25 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.037 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 24.8 p -77.49 -33.93 54.35 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.365 0.602 . . . . 0.0 109.834 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.31 6.47 89.27 Favored Glycine 0 N--CA 1.449 -0.465 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.175 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.494 HG22 ' N ' ' A' ' 16' ' ' THR . 50.6 m -113.83 159.91 19.3 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 117.719 0.759 . . . . 0.0 109.926 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.817 HG21 ' HE ' ' A' ' 7' ' ' ARG . 13.9 m -80.4 117.05 20.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.17 0.51 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -98.94 139.92 33.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.041 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -95.66 127.47 41.71 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.791 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.561 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.2 tp -53.98 -40.8 46.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.861 0.362 . . . . 0.0 111.429 -178.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.561 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.7 tt0 -58.88 -36.64 74.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.135 0.493 . . . . 0.0 110.729 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -81.5 -36.64 29.0 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.567 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.6 t -66.96 -41.71 87.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.22 -43.56 57.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -58.85 -37.87 77.46 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 121.084 -0.247 . . . . 0.0 111.3 -177.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.87 29.54 10.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.512 ' C ' ' O ' ' A' ' 25' ' ' GLY . 96.3 mtt-85 22.61 56.49 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.088 0 CA-C-O 121.27 0.557 . . . . 0.0 110.266 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.626 ' C ' ' H ' ' A' ' 29' ' ' ILE . 31.1 mmtt -75.41 115.68 47.67 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.917 -177.45 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.558 ' O ' ' O ' ' A' ' 29' ' ' ILE . 32.6 Cg_exo -58.1 12.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.505 2.191 0 C-N-CA 122.001 1.801 . . . . 0.0 112.843 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.626 ' H ' ' C ' ' A' ' 27' ' ' LYS . 2.1 pp -40.23 175.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.713 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.478 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 2.8 m80 -121.71 167.51 12.86 Favored 'General case' 0 N--CA 1.467 0.401 0 O-C-N 122.22 -0.3 . . . . 0.0 110.611 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -148.28 170.08 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.1 t -87.59 137.2 21.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 121.896 -0.502 . . . . 0.0 109.772 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.78 168.03 9.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.138 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.22 140.23 37.69 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.29 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.57 176.02 5.21 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -70.71 -14.07 62.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.803 0.335 . . . . 0.0 110.837 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -79.37 -17.64 54.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.38 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.81 22.1 40.54 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.2 p -101.6 136.64 41.1 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.076 178.532 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.94 134.1 42.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.848 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -144.4 141.66 29.81 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.781 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.17 141.82 52.57 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.533 -178.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -142.39 140.67 19.31 Favored Pre-proline 0 CA--C 1.542 0.653 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.272 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 157.57 30.53 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.771 2.314 . . . . 0.0 112.52 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -102.96 138.25 27.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.7 m -128.3 4.67 3.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.046 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.431 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 1.2 t -151.91 145.11 24.64 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 119.05 0.841 . . . . 0.0 109.19 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.86 124.66 15.06 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 178.703 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -141.62 146.27 36.02 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -88.68 133.08 34.32 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 176.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.431 ' OE1' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -92.8 -0.23 57.3 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.6 177.44 51.16 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.307 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 39.2 m -89.43 123.85 33.94 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.025 0.44 . . . . 0.0 109.974 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -148.63 173.7 12.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.257 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -77.1 140.86 40.37 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.259 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 m -139.35 154.87 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.558 HD11 ' CB ' ' A' ' 84' ' ' ALA . 30.8 pt -112.05 151.34 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.024 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.88 144.82 15.9 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 27.4 mt -123.33 112.93 18.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.322 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.437 ' HE ' ' HA2' ' A' ' 63' ' ' GLY . 67.1 ttt180 -86.98 107.49 18.42 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.36 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.755 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.8 mp -96.51 124.8 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.936 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.536 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 36.97 24.43 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.723 -179.291 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 71.98 -25.38 0.67 Allowed Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.18 -105.82 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.636 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.96 171.2 9.45 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.246 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.0 mt -125.48 157.29 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.392 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.501 ' N ' HG22 ' A' ' 66' ' ' ILE . 49.8 tp -132.74 116.62 16.81 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.064 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.3 m95 -102.8 125.42 49.54 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.76 171.52 17.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.214 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.21 156.9 73.8 Favored Pre-proline 0 CA--C 1.533 0.323 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.586 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.74 -19.98 69.8 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.562 2.175 . . . . 0.0 112.066 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -93.26 -7.04 46.18 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.031 0.444 . . . . 0.0 110.189 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 9.6 t60 -73.42 131.36 41.74 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -88.04 130.63 34.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 110.271 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' THR . 95.2 t -108.95 90.63 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.847 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' VAL . 49.0 tp -31.21 99.12 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 O-C-N 123.244 0.34 . . . . 0.0 111.707 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 75' ' ' VAL . 61.4 p -98.22 176.08 5.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -63.37 -19.04 64.31 Favored 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.166 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 -106.86 23.77 13.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.428 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 77' ' ' THR . . . 105.55 -141.47 15.38 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 96.8 m95 -96.11 130.31 43.18 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.732 -0.234 . . . . 0.0 110.766 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -142.35 132.32 24.44 Favored 'General case' 0 C--O 1.232 0.157 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.65 143.8 19.37 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.398 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.558 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.52 -37.91 89.13 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.488 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.5 0.09 3.19 Favored Glycine 0 CA--C 1.529 0.965 0 C-N-CA 120.44 -0.886 . . . . 0.0 111.833 -179.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -109.19 -2.28 18.11 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.989 0.423 . . . . 0.0 110.426 179.511 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 83.7 mt -74.67 129.52 37.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.472 ' O ' ' N ' ' A' ' 90' ' ' GLY . 36.2 mmt180 -133.12 147.99 52.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.435 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -46.37 92.59 0.01 OUTLIER 'General case' 0 C--O 1.233 0.192 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.474 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.85 -20.38 0.78 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -83.63 130.12 34.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.805 0.336 . . . . 0.0 110.694 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.406 ' NH2' ' O ' ' A' ' 105' ' ' TYR . 79.1 mtp85 -91.18 138.66 31.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.518 -179.073 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 33.2 m -126.36 151.46 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.285 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.14 134.98 52.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.443 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.632 HG21 ' OG ' ' A' ' 106' ' ' SER . 27.3 m -133.77 158.45 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.555 179.345 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -104.64 127.95 52.53 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.149 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -100.06 124.51 45.52 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.247 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 12.5 p -75.2 -15.46 15.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.352 0.524 . . . . 0.0 111.087 178.232 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -69.55 -58.3 4.13 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.224 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.429 ' C ' ' H ' ' A' ' 102' ' ' GLU . 15.6 p -99.18 -12.06 20.79 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.739 -0.21 . . . . 0.0 110.473 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.77 -13.26 8.85 Favored Glycine 0 C--N 1.329 0.187 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.429 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.4 mt-10 -82.05 155.32 25.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.975 0.417 . . . . 0.0 111.222 -177.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.576 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -75.74 139.94 42.13 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.195 179.41 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.62 ' O ' HG22 ' A' ' 95' ' ' VAL . 98.8 mtt180 -139.17 169.61 17.46 Favored 'General case' 0 CA--C 1.51 -0.589 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.406 ' O ' ' NH2' ' A' ' 92' ' ' ARG . 8.2 m-30 -108.1 141.88 39.13 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.197 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.632 ' OG ' HG21 ' A' ' 95' ' ' VAL . 4.1 m -136.99 159.59 41.42 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.196 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 108' ' ' ILE . 85.0 t -98.32 156.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 107' ' ' VAL . 29.4 mm -84.66 131.33 34.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.184 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.3 mmm180 -82.44 -34.13 28.29 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.765 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -166.21 145.41 5.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.408 ' C ' HD22 ' A' ' 112' ' ' LEU . 0.8 OUTLIER -95.38 135.42 29.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.441 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.444 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.4 mm? -98.35 123.92 48.73 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 120.626 -0.429 . . . . 0.0 111.149 -179.471 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.5 162.91 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.039 1.826 . . . . 0.0 111.711 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 57' ' ' ILE . 74.7 p -65.35 152.95 42.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 ttt180 -135.18 -139.15 0.17 Allowed 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.691 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 13.0 tpt180 -157.99 129.77 6.86 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.402 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.39 171.09 4.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.179 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.518 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 88.1 mtm180 -74.68 146.97 41.9 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.62 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 6.6 p -126.22 143.3 51.19 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -115.6 173.1 6.71 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.819 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -152.33 127.02 9.48 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.528 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.415 HD11 HD12 ' A' ' 19' ' ' ILE . 87.3 mt -116.24 171.9 7.53 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.233 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -134.95 107.2 7.21 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.352 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 129' ' ' THR . 20.9 t -91.94 119.86 40.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -60.87 144.42 52.86 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.76 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 69.21 -67.78 0.21 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.662 179.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.36 89.7 4.54 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 116.695 -0.23 . . . . 0.0 110.838 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.624 ' C ' HG22 ' A' ' 129' ' ' THR . 97.6 m-70 -62.08 96.83 0.08 Allowed 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.624 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 165.4 155.06 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 178.584 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.9 pp -150.94 151.84 32.73 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.307 -0.557 . . . . 0.0 111.544 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 135' ' ' VAL . 40.0 t -93.14 127.69 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.151 -179.405 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.49 133.54 42.35 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.006 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.535 ' O ' HG23 ' A' ' 135' ' ' VAL . 81.1 mm-40 55.29 42.31 30.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.531 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.0 27.47 67.19 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.623 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 133' ' ' GLU . 23.3 t -130.17 150.75 34.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 118.135 0.968 . . . . 0.0 108.391 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 3.5 t -105.12 111.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-N 118.329 0.513 . . . . 0.0 111.038 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' ' C ' ' A' ' 138' ' ' HIS . 16.9 m -145.88 134.67 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.516 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 51.8 t-80 -34.42 148.06 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.676 0.274 . . . . 0.0 111.649 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.477 ' OD1' ' NE2' ' A' ' 138' ' ' HIS . 28.2 p-10 . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.369 -179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 75.0 mt -96.5 143.63 27.33 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.316 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.3 163.91 16.57 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.701 0.286 . . . . 0.0 110.841 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.433 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 48.3 tt0 -64.78 142.12 58.54 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.523 178.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.66 -22.06 17.67 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.568 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.5 m -66.68 121.67 15.92 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.59 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.4 mtt85 -80.57 147.17 30.9 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 6.4 mm -134.77 106.3 7.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.014 0.435 . . . . 0.0 111.212 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -77.82 130.46 36.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -111.68 110.46 54.97 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.713 -0.221 . . . . 0.0 110.547 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.08 -35.58 62.42 Favored 'Trans proline' 0 N--CA 1.497 1.686 0 C-N-CA 122.171 1.914 . . . . 0.0 112.409 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 56.5 t -61.88 -57.8 10.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.767 -178.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 43.5 p -79.53 -36.63 38.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.305 0.574 . . . . 0.0 109.905 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.78 6.9 84.87 Favored Glycine 0 N--CA 1.451 -0.362 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.472 HG22 ' N ' ' A' ' 16' ' ' THR . 52.4 m -113.78 157.97 21.58 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 117.769 0.784 . . . . 0.0 109.918 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.472 ' N ' HG22 ' A' ' 15' ' ' THR . 30.6 m -80.47 117.71 21.44 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.121 0.486 . . . . 0.0 110.87 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 48.2 m-70 -100.52 143.51 30.62 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.011 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -97.34 128.22 43.97 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.222 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.536 HG23 ' N ' ' A' ' 20' ' ' GLU . 8.3 tp -52.9 -40.8 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.252 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.3 tt0 -58.48 -35.96 73.0 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -81.91 -38.05 25.87 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.605 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.8 t -67.45 -42.33 87.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.04 -45.24 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.63 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -57.38 -37.19 72.28 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 120.728 0.299 . . . . 0.0 110.971 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.57 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.38 29.66 9.33 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-O 118.944 -0.92 . . . . 0.0 110.848 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.57 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.7 ptt180 15.15 67.68 0.01 OUTLIER 'General case' 0 C--N 1.363 1.16 0 CA-C-N 117.313 0.557 . . . . 0.0 110.123 179.231 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.636 ' C ' ' H ' ' A' ' 29' ' ' ILE . 71.3 mttt -86.52 118.01 69.57 Favored Pre-proline 0 N--CA 1.44 -0.965 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.615 ' O ' ' O ' ' A' ' 29' ' ' ILE . 44.2 Cg_exo -53.83 9.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.498 1.762 0 C-N-CA 122.189 1.926 . . . . 0.0 113.383 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.636 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.9 pp -38.01 176.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 123.703 0.627 . . . . 0.0 110.843 -178.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.453 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 4.0 m80 -122.48 166.73 14.31 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 121.837 -0.539 . . . . 0.0 110.795 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.8 m -148.57 171.17 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.27 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.01 135.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.59 166.87 11.1 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.571 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.48 142.4 43.55 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.091 0.472 . . . . 0.0 110.25 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.76 178.67 4.2 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -66.8 -15.53 63.65 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.192 -0.318 . . . . 0.0 110.906 179.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -75.94 -22.0 56.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.685 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.9 -7.01 67.33 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.7 p -77.2 145.12 37.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.187 0.517 . . . . 0.0 111.291 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 64.9 mt -100.4 132.89 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.857 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -141.37 138.96 33.4 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.795 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.06 143.03 52.6 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.673 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NH1' ' OE1' ' A' ' 125' ' ' GLU . 0.9 OUTLIER -142.72 138.34 16.02 Favored Pre-proline 0 CA--C 1.54 0.584 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.187 -179.594 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.67 158.58 31.92 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.916 2.411 . . . . 0.0 112.729 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.4 t -100.73 136.07 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.359 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.95 2.06 3.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.589 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 t -146.33 137.07 24.19 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 118.922 0.783 . . . . 0.0 109.149 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -139.32 124.17 18.64 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -138.23 146.84 43.07 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -179.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.44 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 52.7 p-10 -113.14 140.62 47.75 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 122.027 0.918 . . . . 0.0 108.593 176.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 -105.5 0.35 Allowed 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.602 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -165.58 -156.43 9.24 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.332 -1.304 . . . . 0.0 112.918 -176.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -88.51 127.89 35.54 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.983 0.421 . . . . 0.0 111.482 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -145.8 158.65 43.84 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -76.17 140.88 41.93 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.253 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.1 143.72 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.121 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.56 HD11 ' CB ' ' A' ' 84' ' ' ALA . 18.9 pt -96.13 152.36 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.408 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.94 132.66 11.15 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.0 mt -110.76 112.26 24.01 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.493 ' C ' HD12 ' A' ' 61' ' ' ILE . 60.0 ttm-85 -85.81 113.24 21.81 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.972 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.694 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -104.46 149.83 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.806 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.78 139.8 16.05 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.734 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.78 -3.31 60.72 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 96.41 -17.93 58.39 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.16 125.75 20.27 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.347 0.594 . . . . 0.0 109.589 -178.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -130.76 155.96 42.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.671 -179.174 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.4 tp -142.79 124.0 14.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.851 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -104.52 125.19 50.46 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.9 171.11 18.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.144 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -78.7 155.52 78.26 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-O 120.71 0.291 . . . . 0.0 111.035 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.48 -20.51 70.76 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.675 2.25 . . . . 0.0 112.085 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -89.36 -7.97 54.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.008 0.432 . . . . 0.0 110.178 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.598 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 11.5 t60 -72.66 131.17 42.06 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -87.93 132.04 34.37 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 121.153 0.501 . . . . 0.0 111.142 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.87 140.38 22.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.728 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 53.1 tp -80.99 94.7 6.6 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.776 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.8 p -99.2 178.0 5.04 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -178.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -67.03 -17.88 65.11 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.498 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.474 ' CD2' ' O ' ' A' ' 79' ' ' TYR . 33.3 t80 -106.25 24.31 12.7 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 120.655 0.264 . . . . 0.0 111.35 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.33 -142.63 15.96 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -92.78 128.85 38.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.85 0.357 . . . . 0.0 110.85 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 82.8 mtp180 -140.91 130.85 24.5 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.903 179.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.73 142.7 22.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.111 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.56 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -61.82 -38.28 87.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.065 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.51 -1.23 4.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.195 -1.002 . . . . 0.0 111.902 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.7 tt0 -107.72 -4.04 18.56 Favored 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 121.446 0.641 . . . . 0.0 110.003 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.2 mt -77.4 128.78 34.84 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.535 0.683 . . . . 0.0 111.259 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.523 ' O ' ' N ' ' A' ' 90' ' ' GLY . 2.3 mmm180 -129.14 147.1 50.96 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.955 -1.02 . . . . 0.0 111.1 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -43.55 91.46 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 121.08 0.467 . . . . 0.0 110.527 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.71 -13.4 0.67 Allowed Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -86.46 130.38 34.52 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.858 0.361 . . . . 0.0 110.32 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.43 ' HE ' HG22 ' A' ' 107' ' ' VAL . 99.5 mtt180 -92.7 134.91 34.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.65 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.2 m -120.53 153.54 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.835 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -69.57 125.64 27.31 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.986 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 104' ' ' ARG . 17.3 m -124.1 160.43 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.76 178.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -105.2 128.88 53.62 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.784 0.325 . . . . 0.0 110.543 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 104' ' ' ARG . 43.0 t0 -100.11 123.3 44.19 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 178.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.3 p -75.16 -15.41 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 118.47 0.577 . . . . 0.0 111.223 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.7 mm-40 -69.43 -59.13 3.19 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 120.616 -0.434 . . . . 0.0 109.956 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.419 ' C ' ' H ' ' A' ' 102' ' ' GLU . 44.1 p -97.09 -11.54 24.26 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.83 -12.51 8.5 Favored Glycine 0 C--N 1.332 0.355 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.419 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -84.45 159.69 20.72 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.947 0.403 . . . . 0.0 110.892 -177.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.569 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.31 140.29 36.22 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.865 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.481 ' CZ ' ' OD2' ' A' ' 97' ' ' ASP . 32.5 mtm180 -137.83 168.79 18.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.962 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -109.32 141.17 42.03 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.633 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.402 ' OG ' HG21 ' A' ' 95' ' ' VAL . 11.4 m -138.03 158.69 43.81 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' HE ' ' A' ' 92' ' ' ARG . 65.1 t -92.1 154.3 3.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.554 0.216 . . . . 0.0 110.49 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.403 ' N ' HG12 ' A' ' 107' ' ' VAL . 79.1 mt -74.15 155.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.03 0.443 . . . . 0.0 110.437 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.4 ' N ' HG22 ' A' ' 108' ' ' ILE . 14.2 mmt180 -101.68 -45.64 5.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.038 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -167.44 149.88 5.95 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.427 ' C ' HD22 ' A' ' 112' ' ' LEU . 80.6 t -94.1 133.41 35.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.466 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -100.15 148.33 34.73 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.239 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.14 156.12 66.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 122.51 2.14 . . . . 0.0 111.095 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.461 HG23 ' H ' ' A' ' 114' ' ' THR . 1.1 p -63.63 154.74 31.9 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -148.41 144.66 27.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 82.0 mtm-85 -77.38 132.02 38.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.184 0.516 . . . . 0.0 110.612 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -165.34 164.12 19.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.066 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 1.1 tpp85 -74.36 145.21 44.0 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.845 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 22.3 p -129.41 143.78 50.98 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -116.88 175.87 5.38 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.085 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -144.29 129.14 18.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.817 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.459 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.7 mt -122.24 171.09 9.28 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.619 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -137.94 107.17 6.07 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.623 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.521 ' O ' ' C ' ' A' ' 125' ' ' GLU . 23.7 t -88.03 115.55 28.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.068 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.533 ' OE1' ' NH1' ' A' ' 43' ' ' ARG . 28.1 tt0 15.54 -118.3 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 O-C-N 124.011 0.82 . . . . 0.0 111.212 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -98.64 -27.2 14.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.027 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 81.2 mt -84.99 87.25 7.35 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.594 ' C ' HG22 ' A' ' 129' ' ' THR . 2.9 m-70 -60.44 98.05 0.06 Allowed 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.594 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.44 152.71 0.03 OUTLIER 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.566 ' N ' HD23 ' A' ' 130' ' ' LEU . 1.4 pt? -156.04 157.85 36.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.542 0.686 . . . . 0.0 112.095 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.471 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.9 p -89.08 125.47 42.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.568 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.03 123.31 24.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.665 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.472 ' C ' ' H ' ' A' ' 135' ' ' VAL . 77.6 mm-40 56.94 45.3 21.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.2 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.6 -19.67 0.88 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.386 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.472 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.4 t -90.08 152.43 3.34 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.33 0 CA-C-N 117.212 0.506 . . . . 0.0 110.773 -179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.5 t -112.93 117.75 56.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 138' ' ' HIS . 19.1 m -147.28 139.49 18.83 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.601 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.598 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 59.8 t-80 -36.17 157.5 0.01 OUTLIER 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 118.043 0.383 . . . . 0.0 111.93 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.484 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 25.5 p30 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.447 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.402 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 22.2 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 62.3 mt -110.59 134.82 52.06 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.459 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.14 161.57 25.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.833 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.42 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 49.3 tt0 -63.41 144.54 56.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.125 178.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.53 -16.45 31.63 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.615 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 24.7 m -68.44 122.54 18.63 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -95.99 115.67 27.78 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-O 120.858 0.361 . . . . 0.0 110.35 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.4 mt -100.53 113.31 35.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -76.47 136.8 39.39 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 12.0 t0 -104.08 130.81 22.7 Favored Pre-proline 0 CA--C 1.539 0.522 0 N-CA-C 110.28 -0.267 . . . . 0.0 110.28 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.56 -29.57 13.12 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.018 1.812 . . . . 0.0 112.431 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.513 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.9 t -71.18 -55.17 14.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.042 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.1 p -77.33 -33.58 55.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 120.902 0.382 . . . . 0.0 110.236 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.25 11.4 84.34 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.52 -168.68 1.38 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 117.498 0.649 . . . . 0.0 109.858 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.2 m -112.79 115.87 29.19 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.198 0.523 . . . . 0.0 110.24 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.5 m170 -105.64 145.6 30.82 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.061 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -99.47 129.67 45.67 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.982 -0.287 . . . . 0.0 110.315 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.449 HD11 HD23 ' A' ' 122' ' ' LEU . 1.0 OUTLIER -53.5 -38.64 33.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-O 120.885 0.374 . . . . 0.0 111.121 -178.918 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.8 pt-20 -60.39 -35.13 75.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.883 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -83.74 -40.22 19.1 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.167 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.4 t -67.53 -42.08 86.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.614 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.538 ' CG2' HD21 ' A' ' 122' ' ' LEU . 53.4 t -74.96 -45.38 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.807 -178.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 62.8 t0 -60.87 -35.52 76.81 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 120.775 0.321 . . . . 0.0 111.088 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.47 26.23 24.26 Favored Glycine 0 C--O 1.229 -0.157 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 81.3 mtt85 17.63 60.95 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.121 0 O-C-N 123.907 0.416 . . . . 0.0 109.892 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.5 mttt -86.26 133.6 40.29 Favored Pre-proline 0 N--CA 1.447 -0.619 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.959 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -75.48 86.06 1.51 Allowed 'Trans proline' 0 C--N 1.313 -1.295 0 C-N-CA 121.499 1.466 . . . . 0.0 110.56 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.613 ' C ' HD12 ' A' ' 29' ' ' ILE . 2.4 pp -116.91 -172.81 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 120.778 0.323 . . . . 0.0 110.776 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.407 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 38.2 m80 -128.37 162.57 26.79 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.449 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -146.52 170.5 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.8 t -90.05 134.18 29.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.99 167.43 10.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.71 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.76 142.78 43.01 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.04 0.448 . . . . 0.0 110.521 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.96 176.78 4.89 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.406 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.673 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 73.4 mmtt -71.41 -13.73 61.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.634 0.254 . . . . 0.0 110.531 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.13 -16.1 57.16 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.333 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.43 18.89 56.28 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.8 p -100.44 137.38 38.93 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.759 0.314 . . . . 0.0 111.139 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -93.95 130.43 40.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.683 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -139.05 138.61 37.3 Favored 'General case' 0 C--O 1.223 -0.298 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.743 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.52 142.18 51.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.635 -178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.535 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 11.1 mmp_? -144.06 138.26 14.83 Favored Pre-proline 0 CA--C 1.537 0.458 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.645 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.07 156.5 33.99 Favored 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 122.393 2.062 . . . . 0.0 112.732 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.9 t -98.72 136.26 30.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.502 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 178.06 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 18.6 m -127.62 3.24 3.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.855 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.7 OUTLIER -151.64 145.33 25.01 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.345 179.089 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.583 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.92 124.23 14.65 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.148 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -139.56 145.66 38.89 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.431 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 49.0 p-10 -90.52 137.36 32.41 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.438 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -96.95 -0.97 46.65 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.479 -179.669 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.24 -178.39 53.49 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.416 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.3 m -85.11 121.99 28.66 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.907 0.384 . . . . 0.0 110.214 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 -145.14 165.48 28.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.551 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -76.94 140.79 40.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.073 179.105 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.4 m -146.59 154.49 12.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.65 HD11 ' HB1' ' A' ' 84' ' ' ALA . 47.3 pt -107.62 160.72 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.463 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -115.67 139.71 15.63 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 179.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 67.0 mt -114.23 108.53 17.07 Favored 'General case' 0 C--O 1.219 -0.526 0 CA-C-O 120.801 0.334 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.436 HH11 ' CG2' ' A' ' 66' ' ' ILE . 10.9 tpt180 -78.67 108.28 11.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.449 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.662 ' O ' ' N ' ' A' ' 63' ' ' GLY . 1.9 mp -94.37 132.55 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.518 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.624 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 23.89 33.97 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.818 0.699 . . . . 0.0 112.539 178.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.662 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 66.82 -21.24 0.19 Allowed Glycine 0 CA--C 1.531 1.088 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.202 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.624 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -52.47 -106.41 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.679 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.58 171.69 7.97 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.665 HD13 ' H ' ' A' ' 66' ' ' ILE . 0.0 OUTLIER -129.19 168.75 21.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 120.846 0.355 . . . . 0.0 110.547 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.9 tp -130.79 115.55 16.77 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.621 0.248 . . . . 0.0 110.545 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.2 m95 -101.64 105.36 16.28 Favored 'General case' 0 N--CA 1.463 0.209 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 178.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.44 171.22 14.81 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.144 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -76.99 157.66 81.19 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.571 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 85' ' ' GLY . 33.8 Cg_endo -62.46 -17.07 55.97 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.603 2.202 . . . . 0.0 111.869 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 23.6 p30 -98.07 -5.64 33.41 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.861 0.362 . . . . 0.0 110.527 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.555 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 9.0 t60 -72.56 131.98 43.19 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -86.01 123.2 31.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.273 0.559 . . . . 0.0 111.082 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' LEU . 91.4 t -102.4 91.4 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.366 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' VAL . 35.2 tp -32.22 95.84 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.366 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.478 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -99.75 173.62 6.61 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -177.979 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -63.37 -20.0 65.15 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.042 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.413 ' CD2' ' NH2' ' A' ' 82' ' ' ARG . 63.9 m-85 -104.94 22.79 14.62 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.847 -0.16 . . . . 0.0 111.046 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.69 -144.64 16.16 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.673 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 89.2 m95 -90.75 124.74 35.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.509 0.195 . . . . 0.0 111.157 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.413 ' NH2' ' CD2' ' A' ' 79' ' ' TYR . 88.7 mtt180 -130.23 130.03 44.1 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.563 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.13 141.91 54.52 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.65 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -72.34 2.0 6.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.485 179.588 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -83.67 -14.52 73.0 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -129.37 19.23 5.82 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 122.829 -0.218 . . . . 0.0 111.44 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.476 HD12 ' HA ' ' A' ' 84' ' ' ALA . 28.3 mt -82.41 136.23 34.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.308 0.575 . . . . 0.0 110.797 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 58.0 mmt-85 -132.79 148.84 52.32 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.709 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -45.41 103.0 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.593 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.41 -15.59 1.11 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -82.31 130.28 35.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.791 0.329 . . . . 0.0 110.913 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HE ' ' CG1' ' A' ' 107' ' ' VAL . 99.5 mtt180 -91.32 129.17 37.35 Favored 'General case' 0 C--O 1.224 -0.264 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.686 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.4 m -109.52 143.37 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.986 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -63.63 125.79 25.44 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.579 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 104' ' ' ARG . 30.3 m -122.02 155.47 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.72 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.2 ttt85 -102.54 130.27 49.33 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.607 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -100.34 123.03 44.06 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.17 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.76 -16.65 16.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 118.056 0.389 . . . . 0.0 110.906 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -70.46 -58.87 3.24 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.09 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.431 ' C ' ' H ' ' A' ' 102' ' ' GLU . 30.0 p -96.48 -13.62 22.94 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.539 0.209 . . . . 0.0 110.62 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.33 -14.43 8.7 Favored Glycine 0 C--N 1.331 0.303 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.431 ' H ' ' C ' ' A' ' 100' ' ' THR . 76.7 mt-10 -79.44 153.09 29.91 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.906 0.384 . . . . 0.0 111.185 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.595 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -81.08 139.33 35.74 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.764 179.497 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.434 ' O ' HG22 ' A' ' 95' ' ' VAL . 75.2 mtp180 -138.51 174.27 10.72 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.968 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.478 ' OH ' ' C ' ' A' ' 77' ' ' THR . 2.4 m-85 -113.01 149.67 33.0 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.182 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.6 m -143.25 164.55 29.89 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.4 ' CG1' ' HE ' ' A' ' 92' ' ' ARG . 18.0 m -97.08 155.06 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.695 0.225 . . . . 0.0 110.8 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 95.7 mt -86.99 121.75 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.211 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 67.2 mtp180 -68.55 -33.9 74.9 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -168.24 150.45 5.32 Favored 'General case' 0 N--CA 1.456 -0.163 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.8 t -97.15 136.38 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.474 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.2 mm? -96.22 122.38 58.06 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.082 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.64 166.0 0.16 Allowed 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.266 1.977 . . . . 0.0 111.607 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.408 ' H ' HG23 ' A' ' 114' ' ' THR . 4.5 p -66.93 151.32 47.83 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.166 0.508 . . . . 0.0 110.949 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.5 mtp85 -134.89 -143.28 0.2 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.81 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 36.4 mtm-85 -154.01 131.1 11.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.848 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.58 171.98 3.18 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.26 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 81.3 mtp180 -74.42 145.09 43.98 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.954 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.1 p -123.14 142.47 50.86 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.659 -0.496 . . . . 0.0 109.659 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -113.62 171.98 7.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.66 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.577 ' C ' HD22 ' A' ' 122' ' ' LEU . 49.6 t0 -151.85 125.8 9.13 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.896 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.6 170.16 8.52 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.207 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.4 tp10 -137.61 105.28 5.57 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.33 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.61 118.62 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -61.85 146.04 50.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.523 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 69.24 -69.9 0.15 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.288 178.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 90.5 mt -100.44 95.8 6.98 Favored 'General case' 0 CA--C 1.514 -0.424 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.524 ' O ' HG23 ' A' ' 129' ' ' THR . 9.2 p-80 -65.83 99.73 0.5 Allowed 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.6 145.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.578 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.661 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.5 pp -145.62 154.05 41.7 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.437 0.637 . . . . 0.0 111.619 -179.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 130' ' ' LEU . 68.7 t -89.92 125.69 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.738 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.615 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.73 135.35 43.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.249 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.621 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.2 mm-40 49.73 45.59 24.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.123 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.14 22.51 55.72 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.916 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.6 t -128.99 152.07 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.8 t -105.25 110.84 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 O-C-N 122.065 -0.397 . . . . 0.0 110.536 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 138' ' ' HIS . 13.4 m -146.99 138.52 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.555 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 56.2 t-80 -33.93 153.73 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.752 0.311 . . . . 0.0 111.793 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.287 -179.571 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.471 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 30.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 89.0 mt -107.11 134.55 50.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.912 0.387 . . . . 0.0 110.406 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.32 163.61 23.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.089 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -64.14 139.69 58.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.615 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.17 -18.66 25.67 Favored Glycine 0 C--N 1.334 0.454 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.459 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.6 m -69.78 123.93 22.69 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.505 ' NE ' HG21 ' A' ' 16' ' ' THR . 77.5 mtp85 -97.85 116.64 30.46 Favored 'General case' 0 C--O 1.231 0.088 0 CA-C-O 120.982 0.42 . . . . 0.0 110.7 -179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.462 HD11 HD13 ' A' ' 19' ' ' ILE . 18.0 mt -101.53 115.23 42.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.756 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -76.57 135.9 39.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 5.0 t70 -104.15 132.42 21.01 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 110.571 -0.159 . . . . 0.0 110.571 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.23 -31.84 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 121.838 1.692 . . . . 0.0 112.462 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 74.9 t -69.89 -55.25 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.047 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.6 p -77.54 -35.6 53.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.973 0.415 . . . . 0.0 110.182 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 10.45 85.46 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.458 HG22 ' N ' ' A' ' 16' ' ' THR . 88.2 m -114.09 157.51 22.47 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 117.276 0.538 . . . . 0.0 110.09 -179.659 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.505 HG21 ' NE ' ' A' ' 7' ' ' ARG . 28.2 m -78.97 116.13 19.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.555 0.693 . . . . 0.0 110.897 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' HIS . . . . . 0.459 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 61.8 m-70 -104.89 144.87 31.19 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.848 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -98.75 128.32 44.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.304 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.523 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -52.8 -38.83 29.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 CA-C-O 120.704 0.287 . . . . 0.0 111.012 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.497 ' N ' HG23 ' A' ' 19' ' ' ILE . 9.1 pt-20 -57.03 -32.62 66.36 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.295 0.569 . . . . 0.0 110.806 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -83.57 -37.87 22.41 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.033 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.75 -42.4 86.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.719 HG22 HD21 ' A' ' 122' ' ' LEU . 87.5 t -73.08 -46.9 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 65.2 t0 -57.67 -36.0 71.32 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.836 0.351 . . . . 0.0 110.831 -178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -108.31 29.12 10.46 Favored Glycine 0 C--O 1.228 -0.254 0 CA-C-O 118.829 -0.984 . . . . 0.0 111.147 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.1 ptm180 13.08 67.91 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.488 0.644 . . . . 0.0 110.836 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.436 ' C ' ' H ' ' A' ' 29' ' ' ILE . 82.7 mttt -87.56 144.62 35.74 Favored Pre-proline 0 N--CA 1.45 -0.431 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.31 -177.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.587 ' O ' ' O ' ' A' ' 29' ' ' ILE . 57.4 Cg_endo -70.87 8.22 1.08 Allowed 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 122.057 1.838 . . . . 0.0 111.744 179.292 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.587 ' O ' ' O ' ' A' ' 28' ' ' PRO . 15.1 tt -37.1 172.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.847 -178.179 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.527 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 9.5 m80 -124.83 162.97 23.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.7 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 34.7 m -146.2 169.87 5.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.2 t -87.3 134.13 28.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.455 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.36 166.17 10.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.704 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.87 141.6 40.71 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.184 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.36 178.19 4.37 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -72.82 -12.78 61.12 Favored 'General case' 0 C--O 1.233 0.186 0 O-C-N 122.248 -0.283 . . . . 0.0 110.676 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -78.59 -17.71 55.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.366 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.92 18.59 55.85 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.1 p -100.01 137.29 38.66 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.983 0.42 . . . . 0.0 111.001 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.7 mt -94.34 131.05 40.37 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.714 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 23.9 t60 -139.55 138.99 36.74 Favored 'General case' 0 C--O 1.221 -0.425 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.791 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.56 142.59 51.76 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -145.64 137.46 13.11 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.869 -179.4 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_endo -75.79 157.65 39.36 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.644 2.229 . . . . 0.0 112.401 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.6 t -90.91 127.44 43.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.8 -4.8 11.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.782 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.0 p -151.79 143.08 23.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 O-C-N 121.756 -0.59 . . . . 0.0 109.445 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -137.6 117.28 13.06 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.189 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -144.8 146.29 32.05 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 45.7 p-10 -90.61 138.41 31.59 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.746 ' OE1' ' O ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -103.74 7.04 37.21 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.771 -179.826 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.746 ' O ' ' OE1' ' A' ' 51' ' ' GLN . . . 92.02 -175.65 38.43 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-O 121.552 0.529 . . . . 0.0 112.802 177.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.581 HG23 ' C ' ' A' ' 117' ' ' ALA . 61.3 m -100.84 131.73 46.58 Favored 'General case' 0 N--CA 1.468 0.457 0 O-C-N 121.296 -1.12 . . . . 0.0 108.981 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 80.5 mtp180 -148.32 172.94 13.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.32 0.581 . . . . 0.0 110.382 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -75.54 140.34 42.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.622 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.6 m -140.92 158.13 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.542 HD11 ' CB ' ' A' ' 84' ' ' ALA . 46.6 pt -112.7 151.56 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 CA-C-O 120.848 0.356 . . . . 0.0 110.809 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.86 132.17 10.99 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.7 mt -111.84 106.27 14.96 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.259 0.552 . . . . 0.0 109.781 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -86.16 117.37 24.94 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.278 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.403 HG22 ' N ' ' A' ' 62' ' ' ALA . 25.4 mm -110.05 156.7 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.461 -179.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.403 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -47.49 138.65 7.55 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.712 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.47 -1.49 58.66 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 90.52 -9.99 75.91 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.2 129.13 33.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.14 -0.624 . . . . 0.0 109.371 -177.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 8.9 tp -123.36 144.03 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.892 -178.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 36.5 tp -136.74 118.97 15.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.862 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.05 127.66 50.23 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.36 170.27 20.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.886 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.87 155.9 82.76 Favored Pre-proline 0 CA--C 1.536 0.439 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.767 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 -18.92 64.18 Favored 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.68 2.254 . . . . 0.0 111.989 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -95.46 -5.0 44.0 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.025 0.441 . . . . 0.0 110.022 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.561 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -69.8 130.13 41.45 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.215 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -86.31 128.66 34.95 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.459 0.647 . . . . 0.0 111.446 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.56 144.44 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.185 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.469 HD13 ' C ' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -82.55 94.47 7.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.512 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 17.0 p -100.82 175.89 5.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.83 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.654 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 0.7 OUTLIER -60.41 -21.06 61.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.524 -179.32 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.98 24.25 13.1 Favored 'General case' 0 CA--C 1.516 -0.33 0 C-N-CA 121.303 -0.159 . . . . 0.0 111.095 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.62 -169.39 34.08 Favored Glycine 0 CA--C 1.523 0.583 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.509 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -60.84 123.78 18.55 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.925 -0.638 . . . . 0.0 110.775 -178.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -140.01 134.15 31.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.028 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.81 139.24 40.42 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.04 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.542 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.21 -37.29 86.66 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.28 1.87 1.85 Allowed Glycine 0 C--N 1.336 0.573 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.015 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.421 ' H ' ' C ' ' A' ' 84' ' ' ALA . 75.8 mt-10 -110.01 3.4 20.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.272 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.68 133.76 34.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.334 0.588 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.533 ' O ' ' N ' ' A' ' 90' ' ' GLY . 10.2 tpt180 -127.88 148.66 50.48 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.599 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -49.72 86.76 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.232 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 159.27 -18.37 0.26 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -77.94 134.75 37.81 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 88.8 mtm180 -92.36 139.59 30.45 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.927 -178.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.52 154.2 39.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.285 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -83.52 133.87 34.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.904 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.514 HG12 HG22 ' A' ' 135' ' ' VAL . 30.9 m -129.0 165.46 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.224 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.54 128.62 44.43 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.816 0.341 . . . . 0.0 111.0 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -99.64 122.64 42.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.982 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.6 p -75.33 -16.43 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 CA-C-N 118.425 0.557 . . . . 0.0 110.69 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -69.15 -58.59 3.86 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 120.524 -0.471 . . . . 0.0 109.877 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.469 ' C ' ' H ' ' A' ' 102' ' ' GLU . 72.5 p -95.99 -10.78 27.75 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.98 -12.34 6.61 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.469 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.0 mt-10 -89.13 161.23 16.61 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.269 0.557 . . . . 0.0 111.605 -177.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.552 ' CD2' ' H ' ' A' ' 103' ' ' LEU . 1.9 pt? -74.56 139.26 43.61 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.052 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 37.6 ptt180 -130.98 158.05 41.31 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.654 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -104.15 135.98 44.62 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 42.8 m -144.07 166.19 25.68 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 108' ' ' ILE . 94.1 t -94.84 154.44 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 110.417 -0.216 . . . . 0.0 110.417 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.471 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.9 mt -67.42 160.2 4.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.087 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.471 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 74.3 ttt180 -105.64 -48.91 3.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.648 179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -164.82 142.36 6.3 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.3 t -94.37 134.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.8 mm? -101.8 147.16 33.48 Favored Pre-proline 0 CA--C 1.538 0.501 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.855 -179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.17 165.27 30.87 Favored 'Trans proline' 0 N--CA 1.499 1.805 0 C-N-CA 122.967 2.445 . . . . 0.0 110.938 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -69.38 157.1 37.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.794 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttp180 -141.92 -141.75 0.13 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.377 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.405 ' H ' ' HG2' ' A' ' 115' ' ' ARG . 78.3 mtm-85 -151.89 135.23 15.99 Favored 'General case' 0 C--N 1.33 -0.243 0 O-C-N 123.471 0.482 . . . . 0.0 110.272 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ALA . . . . . 0.581 ' C ' HG23 ' A' ' 53' ' ' THR . . . -173.17 169.45 4.56 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.141 0.496 . . . . 0.0 110.952 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 18.5 tpp180 -74.59 146.46 42.5 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.592 ' OG1' ' NE2' ' A' ' 51' ' ' GLN . 0.6 OUTLIER -136.47 154.14 50.84 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -131.53 -178.53 4.9 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.677 -175.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -153.74 121.56 5.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.192 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.719 HD21 HG22 ' A' ' 23' ' ' VAL . 85.4 mt -117.13 127.9 54.59 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.783 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -88.52 108.18 19.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.815 0.341 . . . . 0.0 110.36 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' A' ' 126' ' ' GLU . 18.1 t -80.6 111.84 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.993 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 124' ' ' VAL . 2.8 tm-20 25.1 -87.63 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.498 ' N ' ' O ' ' A' ' 124' ' ' VAL . 44.2 tp10 -139.25 -27.86 0.79 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.545 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.499 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.1 mt -80.58 66.0 5.93 Favored 'General case' 0 CA--C 1.506 -0.732 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 127' ' ' LEU . 48.3 m170 -38.9 94.96 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.423 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 172.07 141.05 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.612 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.668 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.8 pp -147.56 154.79 41.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.46 0.648 . . . . 0.0 111.858 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 8' ' ' ILE . 72.7 t -91.01 126.38 43.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.77 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.459 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.91 134.09 42.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.0 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.573 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 50.68 45.06 27.41 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.933 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.36 24.72 59.49 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.162 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.7 t -129.69 152.47 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -106.49 111.31 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 118.203 0.456 . . . . 0.0 110.75 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' A' ' 138' ' ' HIS . 5.9 m -146.54 140.52 20.54 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.561 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 11.1 t60 -31.35 152.86 0.0 OUTLIER 'General case' 0 C--O 1.226 -0.149 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 17.9 p30 . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.429 -179.406 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.4 mt -117.04 132.13 56.77 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.887 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.93 161.95 26.34 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -63.8 147.1 52.63 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.968 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.31 -15.18 39.3 Favored Glycine 0 C--N 1.336 0.581 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.559 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.5 m -67.13 121.59 15.96 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 80.9 mtm-85 -97.39 116.66 30.02 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 120.764 0.316 . . . . 0.0 110.272 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.422 HD11 ' HB ' ' A' ' 19' ' ' ILE . 9.0 mt -103.68 116.03 46.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.761 -179.228 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -76.13 136.04 39.82 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 11.9 t0 -103.19 130.41 23.68 Favored Pre-proline 0 CA--C 1.54 0.56 0 C-N-CA 121.187 -0.205 . . . . 0.0 110.52 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.05 -30.54 10.68 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.356 2.037 . . . . 0.0 112.196 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.544 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 57.8 t -72.05 -55.1 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.767 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 m -77.4 -39.98 45.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.175 0.512 . . . . 0.0 110.36 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 10.61 80.83 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.299 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.1 m -112.91 154.87 25.68 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-N 117.612 0.706 . . . . 0.0 109.636 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.8 m -79.05 117.15 19.83 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.265 0.555 . . . . 0.0 110.827 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -106.93 148.55 28.48 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.43 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -100.37 127.54 46.66 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.657 178.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.49 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.5 tt -54.09 -38.01 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 CA-C-O 120.923 0.392 . . . . 0.0 111.523 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.421 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.8 pt-20 -60.03 -33.12 71.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.078 0.466 . . . . 0.0 110.984 -179.378 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -83.79 -38.2 21.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.713 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.7 -41.26 85.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.245 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.697 HG22 HD21 ' A' ' 122' ' ' LEU . 60.7 t -72.99 -45.62 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -58.1 -34.85 70.64 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 120.696 0.284 . . . . 0.0 110.619 -178.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.76 27.34 11.26 Favored Glycine 0 C--O 1.226 -0.363 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.9 ptt-85 15.01 68.06 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.129 0.49 . . . . 0.0 109.82 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -89.8 135.27 30.69 Favored Pre-proline 0 N--CA 1.446 -0.655 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.984 -176.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.9 85.14 1.54 Allowed 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.848 1.699 . . . . 0.0 110.427 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 16.4 pt -111.92 -171.44 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 110.963 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.45 ' CG ' HG21 ' A' ' 12' ' ' VAL . 65.7 m80 -130.44 159.62 36.49 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.454 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.55 170.49 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.5 t -86.61 131.52 34.56 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.6 146.66 37.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.396 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.02 143.45 45.73 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.938 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.79 176.71 4.94 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.506 ' HD3' ' H ' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -69.87 -14.43 62.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.772 0.32 . . . . 0.0 110.749 179.523 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 56.0 t0 -80.44 -18.34 49.08 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.177 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.8 21.23 43.86 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 22.3 p -101.62 137.38 40.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.116 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.58 HD11 ' CD1' ' A' ' 103' ' ' LEU . 62.6 mt -91.35 126.68 36.51 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.745 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 76.1 m-70 -136.76 136.71 39.14 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.579 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.548 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.51 142.02 51.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.487 -178.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.572 HH11 ' CD ' ' A' ' 125' ' ' GLU . 4.2 mmp_? -143.87 137.11 13.98 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.672 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.89 156.47 34.72 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 122.769 2.313 . . . . 0.0 112.962 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -96.64 134.93 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.37 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.34 -0.46 4.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.768 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.7 t -146.65 136.32 23.1 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 118.535 0.607 . . . . 0.0 109.513 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.56 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.62 118.42 15.12 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.291 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -140.74 147.13 38.67 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -96.93 134.04 40.79 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 176.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.408 ' OE1' ' O ' ' A' ' 120' ' ' PHE . 9.1 mt-30 -96.64 3.77 52.32 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.315 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.29 -178.0 49.1 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.724 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -87.67 124.97 34.1 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-O 120.836 0.351 . . . . 0.0 110.17 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 48.2 mmt-85 -143.35 165.04 28.61 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.727 -179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -76.05 142.45 41.79 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.784 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.57 149.8 16.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.61 HD11 ' HB1' ' A' ' 84' ' ' ALA . 46.7 pt -98.87 149.44 5.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.577 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.32 125.8 8.41 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 78.0 mt -108.58 113.37 26.32 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.201 0.524 . . . . 0.0 110.199 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.435 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 53.4 ttp180 -87.46 115.45 24.89 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.481 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.6 mm -106.09 152.47 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.441 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.05 -10.1 0.75 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.715 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.87 -12.21 34.45 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 89.32 -20.72 32.3 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.17 172.47 8.2 Favored 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.441 HD11 ' CZ2' ' A' ' 68' ' ' TRP . 20.9 tt -118.91 143.65 29.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.11 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.7 tt -118.49 115.38 24.49 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.363 -179.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.441 ' CZ2' HD11 ' A' ' 66' ' ' ILE . 98.0 m95 -102.68 125.51 49.44 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.78 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.02 170.97 19.12 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.879 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.53 157.06 65.1 Favored Pre-proline 0 CA--C 1.535 0.372 0 C-N-CA 120.739 -0.385 . . . . 0.0 110.551 179.695 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 85' ' ' GLY . 38.3 Cg_endo -66.24 -18.7 56.17 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.549 2.166 . . . . 0.0 111.985 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -95.39 -6.29 41.32 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.368 . . . . 0.0 110.395 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.543 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 41.4 t60 -72.01 132.2 43.96 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -85.12 123.76 31.0 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.381 0.61 . . . . 0.0 111.629 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.83 140.92 16.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.061 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 47.9 tp -81.4 92.33 6.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.076 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.471 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 39.3 p -98.86 173.15 7.0 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 92' ' ' ARG . 17.3 pt-20 -64.49 -17.05 63.5 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.291 -179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -105.95 24.85 11.7 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.691 0.281 . . . . 0.0 110.787 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.03 -143.5 16.64 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 79.5 m95 -89.1 123.29 33.24 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.729 0.3 . . . . 0.0 111.14 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -122.88 126.06 46.57 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.026 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.45 132.0 46.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.784 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.61 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -69.36 -1.07 7.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.029 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -76.37 -12.93 83.85 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -134.76 27.76 3.61 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.451 HD12 ' HA ' ' A' ' 84' ' ' ALA . 13.3 mt -83.03 133.25 35.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.373 0.606 . . . . 0.0 111.02 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -133.38 148.02 51.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.615 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -47.59 106.59 0.09 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.551 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 147.12 -17.89 1.55 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -82.7 132.94 35.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.643 0.258 . . . . 0.0 110.695 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 85.2 mtm180 -90.04 130.21 36.25 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.364 -0.535 . . . . 0.0 110.302 -179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.9 m -113.49 144.77 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.66 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.15 124.72 26.88 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.708 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.6 m -121.66 165.02 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.146 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.1 tpt180 -101.64 128.91 47.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.61 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.433 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 34.8 t0 -101.13 124.03 46.21 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.534 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG12 ' A' ' 98' ' ' VAL . 97.1 t -74.37 -16.2 16.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 118.29 0.495 . . . . 0.0 111.065 178.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -70.3 -59.29 2.96 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.405 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.426 ' C ' ' H ' ' A' ' 102' ' ' GLU . 19.5 p -98.84 -13.93 19.88 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.627 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.38 -14.26 6.92 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 100' ' ' THR . 46.0 mt-10 -82.09 157.46 24.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 111.175 -177.22 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.58 ' CD1' HD11 ' A' ' 40' ' ' LEU . 7.8 mp -77.22 134.86 38.5 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-O 121.228 0.537 . . . . 0.0 110.153 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.433 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 38.9 ptt180 -132.62 165.4 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.592 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.471 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.1 m-85 -112.04 148.55 33.61 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.048 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 65.1 m -145.15 165.84 27.14 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 57.7 t -91.81 152.31 3.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.62 0.248 . . . . 0.0 110.69 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.516 HG22 ' N ' ' A' ' 109' ' ' ARG . 71.9 mt -70.49 162.26 4.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.304 178.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.516 ' N ' HG22 ' A' ' 108' ' ' ILE . 37.4 mtp85 -106.04 -48.47 3.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.817 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.435 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 85.3 tt0 -167.53 149.14 5.62 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.963 -0.461 . . . . 0.0 109.853 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 112' ' ' LEU . 72.0 t -96.16 134.35 34.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -102.59 151.22 38.22 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.168 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.22 159.85 50.26 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.664 2.243 . . . . 0.0 111.301 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 57' ' ' ILE . 81.7 p -65.75 154.19 39.69 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 120.886 -0.326 . . . . 0.0 110.431 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -149.8 153.36 36.67 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.804 0.811 . . . . 0.0 110.307 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.0 mmm180 -82.55 132.42 35.2 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.634 -179.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.81 167.63 12.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.973 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.1 ttm180 -80.53 145.12 31.98 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.708 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.9 p -125.95 145.01 50.46 Favored 'General case' 0 CA--C 1.521 -0.142 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.427 ' HB3' HG21 ' A' ' 23' ' ' VAL . 59.6 m-85 -120.5 175.09 6.16 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.42 -178.438 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -151.77 123.84 8.14 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.697 HD21 HG22 ' A' ' 23' ' ' VAL . 89.8 mt -122.46 124.59 43.95 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.629 0.252 . . . . 0.0 110.508 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tp10 -89.25 109.56 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.989 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.504 ' O ' ' C ' ' A' ' 125' ' ' GLU . 18.6 t -83.6 115.78 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.918 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.572 ' CD ' HH11 ' A' ' 43' ' ' ARG . 43.7 tt0 20.7 -92.01 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.519 0 O-C-N 123.733 0.645 . . . . 0.0 111.749 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.4 ' N ' ' O ' ' A' ' 124' ' ' VAL . 40.8 tp10 -133.22 -32.46 1.19 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.882 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.508 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.8 mt -74.03 63.04 0.92 Allowed 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.315 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.528 ' O ' HG23 ' A' ' 129' ' ' THR . 30.8 m170 -38.48 95.04 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.528 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.33 140.84 0.02 OUTLIER 'General case' 0 C--O 1.233 0.191 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.1 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.6 pp -149.29 156.89 42.81 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.321 0.582 . . . . 0.0 111.796 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.9 121.44 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.607 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.5 145.77 50.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.558 -178.429 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 135' ' ' VAL . 40.0 mt-10 40.8 46.5 2.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.155 179.063 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.32 -22.24 0.29 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.658 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.4 t -90.91 152.01 3.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 C-N-CA 122.596 0.358 . . . . 0.0 110.701 179.706 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.3 t -108.8 115.84 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 120.757 0.313 . . . . 0.0 110.416 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 33.5 m -149.94 144.18 17.62 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.057 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.543 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 52.2 t-80 -30.01 149.95 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 179.428 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.429 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 22.2 p30 . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.415 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.0 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.415 HD11 HD11 ' A' ' 130' ' ' LEU . 68.9 mt -108.25 135.31 49.79 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.599 -179.489 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.85 163.22 23.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.732 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 65.2 tt0 -63.19 141.5 58.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.053 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.19 -19.73 31.74 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.3 m -67.68 124.55 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.261 0.077 . . . . 0.0 111.169 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -85.32 150.1 25.0 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.992 0.425 . . . . 0.0 109.989 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 12.9 mt -134.47 108.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.191 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -76.01 125.83 29.86 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 178.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.9 129.85 25.66 Favored Pre-proline 0 CA--C 1.536 0.429 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.12 -30.12 16.62 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.703 1.602 . . . . 0.0 112.433 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 72.2 t -73.73 -55.18 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 32.4 m -74.7 -40.34 61.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.472 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.32 6.64 83.85 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 85.3 m -116.92 162.0 18.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.512 0.656 . . . . 0.0 109.794 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 1.9 p -81.02 116.15 20.83 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.609 0.719 . . . . 0.0 111.301 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 13.4 m80 -97.32 138.6 34.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.22 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -95.64 126.67 41.07 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.695 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.9 tp -53.07 -40.44 37.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 111.388 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.0 pt-20 -57.12 -36.59 70.86 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.371 0.605 . . . . 0.0 110.968 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.2 t0 -81.85 -36.89 27.77 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.63 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.2 t -67.38 -42.24 87.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.252 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 91.5 t -72.2 -46.52 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -55.04 -37.9 67.28 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 120.96 0.41 . . . . 0.0 110.472 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.579 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -111.99 33.32 5.8 Favored Glycine 0 CA--C 1.52 0.374 0 CA-C-O 118.688 -1.062 . . . . 0.0 110.873 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.579 ' C ' ' O ' ' A' ' 25' ' ' GLY . 26.2 ptt180 8.97 74.63 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 117.576 0.688 . . . . 0.0 110.588 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.453 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.4 mttt -89.04 142.03 29.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.944 -177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.514 ' O ' ' O ' ' A' ' 29' ' ' ILE . 58.4 Cg_endo -70.87 11.22 0.53 Allowed 'Trans proline' 0 N--CA 1.491 1.338 0 C-N-CA 121.832 1.688 . . . . 0.0 111.534 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.514 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.3 pp -39.78 171.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.237 -177.411 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.427 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 4.2 m80 -120.99 166.08 14.35 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.425 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.9 m -148.12 170.01 3.23 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 99.5 t -85.75 137.64 20.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.59 165.47 11.51 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.46 138.66 41.67 Favored 'General case' 0 N--CA 1.462 0.161 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.21 178.0 4.43 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.13 -14.9 61.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.883 0.373 . . . . 0.0 110.885 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -77.93 -18.32 56.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.331 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.38 24.97 34.76 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.7 p -102.87 136.4 42.77 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.649 0.262 . . . . 0.0 110.808 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.97 130.84 44.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.954 0.407 . . . . 0.0 110.532 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 6.9 t60 -141.64 140.05 33.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.734 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -68.9 142.97 54.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.4 mmp_? -146.24 137.57 12.9 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.428 -179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -74.6 158.32 43.78 Favored 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.611 2.208 . . . . 0.0 112.695 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.2 t -100.03 136.53 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 177.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.1 m -127.83 2.59 3.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 119.032 -0.508 . . . . 0.0 112.159 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.8 t -145.85 134.79 22.55 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 119.349 0.977 . . . . 0.0 108.915 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -132.89 117.6 17.91 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 177.86 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.504 ' O ' ' OE1' ' A' ' 51' ' ' GLN . 68.4 m-85 -142.81 148.73 37.61 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.421 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 48.6 p-10 -97.61 135.8 38.92 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.504 ' OE1' ' O ' ' A' ' 49' ' ' PHE . 0.6 OUTLIER -97.27 8.27 44.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.41 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.47 177.92 50.52 Favored Glycine 0 CA--C 1.527 0.825 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.488 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.549 ' OG1' ' NH1' ' A' ' 118' ' ' ARG . 4.3 m -87.51 127.68 35.24 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.337 -0.432 . . . . 0.0 109.87 179.007 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.2 mmm180 -148.51 167.49 25.24 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.049 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -73.95 141.79 45.92 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.509 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.7 m -128.88 141.22 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 110.491 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.788 ' H ' HD13 ' A' ' 57' ' ' ILE . 0.1 OUTLIER -100.9 139.78 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.87 179.794 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.48 140.95 15.31 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.103 -0.57 . . . . 0.0 111.846 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 27.6 mt -129.0 115.86 18.43 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-O 121.197 0.522 . . . . 0.0 109.972 -179.036 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.611 ' NH2' ' NH1' ' A' ' 109' ' ' ARG . 62.9 ttt180 -97.02 114.55 26.18 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.729 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.542 ' O ' ' N ' ' A' ' 63' ' ' GLY . 16.4 mm -100.76 123.9 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.287 -178.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.471 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 39.92 20.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.001 -178.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 75.82 -29.91 1.3 Allowed Glycine 0 CA--C 1.52 0.354 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 63' ' ' GLY . . . -45.77 -108.77 0.01 OUTLIER Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -177.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -81.78 167.89 18.6 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.215 0.531 . . . . 0.0 111.174 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.425 HG21 ' CZ2' ' A' ' 68' ' ' TRP . 0.1 OUTLIER -132.07 156.81 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.579 -178.729 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.9 tp -146.21 123.75 11.76 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.427 -0.352 . . . . 0.0 111.723 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.425 ' CZ2' HG21 ' A' ' 66' ' ' ILE . 2.1 m95 -99.42 107.85 20.19 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 175.961 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.451 ' O ' HD13 ' A' ' 57' ' ' ILE . . . -127.51 177.14 6.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.158 -177.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.9 155.27 52.87 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.225 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -60.44 -27.38 84.74 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.909 2.406 . . . . 0.0 112.08 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' A' ' 74' ' ' LYS . 38.7 t70 -85.9 -6.93 58.99 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.476 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 6.8 t60 -70.53 126.37 29.45 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' A' ' 72' ' ' ASP . 14.3 mptt -89.55 137.4 32.36 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.352 0.596 . . . . 0.0 110.517 -179.202 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.5 t -105.09 135.85 41.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.151 -0.932 . . . . 0.0 109.586 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.5 tp -76.54 100.37 5.27 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.671 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.492 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 81.8 p -98.81 174.78 6.22 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -178.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.431 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 10.0 pt-20 -67.11 -12.75 60.84 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.674 -0.411 . . . . 0.0 111.438 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.431 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 60.2 m-85 -112.89 22.13 14.76 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.473 0.175 . . . . 0.0 111.473 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.88 -138.01 14.67 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -107.12 138.32 43.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.716 0.293 . . . . 0.0 110.387 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 tpt180 -137.82 130.33 29.51 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.66 141.9 36.07 Favored 'General case' 0 CA--C 1.516 -0.33 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.03 -40.06 88.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.92 -179.064 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.29 -3.74 20.05 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 119.808 -1.187 . . . . 0.0 111.893 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.83 -6.14 20.51 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 117.139 0.469 . . . . 0.0 110.382 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.25 128.74 35.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.622 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.4 mmt85 -134.02 148.44 51.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.383 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.8 ttmt -43.42 92.71 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.002 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.1 -17.58 0.53 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -89.67 128.95 36.16 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.895 0.378 . . . . 0.0 111.059 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -89.63 133.31 34.7 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -178.101 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.4 m -114.32 144.58 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.791 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.59 130.55 43.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.072 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.5 m -128.92 161.04 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.416 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -107.51 130.59 54.84 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -100.27 123.17 44.17 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.359 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.0 m -75.19 -14.68 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-N 118.534 0.606 . . . . 0.0 110.638 177.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -70.07 -58.38 3.88 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.604 -0.438 . . . . 0.0 109.952 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.7 p -98.12 -10.68 23.82 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.93 -12.61 6.23 Favored Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 93.3 mt-10 -82.32 155.62 24.69 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 120.926 0.393 . . . . 0.0 111.578 -176.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.609 ' H ' HD23 ' A' ' 103' ' ' LEU . 2.0 pt? -81.56 139.83 34.85 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.513 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -140.01 178.39 7.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.17 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.492 ' OH ' ' C ' ' A' ' 77' ' ' THR . 3.6 m-85 -117.36 147.9 42.21 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.028 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.7 m -138.28 161.35 37.13 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.413 HG22 ' N ' ' A' ' 108' ' ' ILE . 10.4 p -91.93 154.57 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.413 ' N ' HG22 ' A' ' 107' ' ' VAL . 50.1 mt -75.89 151.59 6.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 178.684 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.611 ' NH1' ' NH2' ' A' ' 60' ' ' ARG . 68.7 ttt180 -104.11 -42.39 5.55 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.579 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.46 147.85 5.34 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.404 ' C ' HD12 ' A' ' 112' ' ' LEU . 73.4 t -94.92 133.37 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.0 mp -100.91 151.24 37.57 Favored Pre-proline 0 CA--C 1.537 0.475 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.1 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.47 158.42 56.07 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.804 2.336 . . . . 0.0 111.57 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.6 p -67.57 156.9 35.66 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.101 0.477 . . . . 0.0 110.478 -179.035 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -133.77 -141.28 0.19 Allowed 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.431 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.1 mtt85 -157.59 130.1 7.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.041 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.7 170.54 4.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.274 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.549 ' NH1' ' OG1' ' A' ' 53' ' ' THR . 64.7 mmt-85 -74.15 151.38 40.07 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.372 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.3 p -131.2 146.52 52.36 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.172 0.511 . . . . 0.0 109.861 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.46 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 68.6 m-85 -123.3 174.07 7.55 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.275 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 120' ' ' PHE . 78.5 m-20 -153.62 123.26 6.73 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.71 177.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 65.5 mt -118.52 126.13 51.34 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -86.59 112.02 21.19 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 120.951 0.405 . . . . 0.0 110.399 -178.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.471 ' O ' ' C ' ' A' ' 125' ' ' GLU . 62.7 t -86.52 114.14 25.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.895 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.471 ' C ' ' O ' ' A' ' 124' ' ' VAL . 40.4 tp10 22.14 -115.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 O-C-N 123.811 0.694 . . . . 0.0 111.936 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.9 tp10 -109.8 -25.64 10.24 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.316 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 129' ' ' THR . 86.3 mt -82.83 66.68 8.56 Favored 'General case' 0 CA--C 1.505 -0.781 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.444 ' O ' HG23 ' A' ' 129' ' ' THR . 2.5 p-80 -41.21 98.42 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.122 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.77 142.98 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.688 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.663 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.9 pp -149.02 152.78 36.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.396 0.617 . . . . 0.0 111.961 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.411 ' N ' HD12 ' A' ' 130' ' ' LEU . 97.7 t -90.96 126.58 43.67 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.04 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.441 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.39 132.91 41.74 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.067 -179.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.557 ' O ' HG23 ' A' ' 135' ' ' VAL . 14.2 mm-40 52.01 43.71 30.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.542 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.62 28.13 62.23 Favored Glycine 0 CA--C 1.524 0.648 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.175 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.8 t -129.6 151.91 36.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -104.38 109.6 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.551 0.614 . . . . 0.0 110.722 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.431 ' O ' ' C ' ' A' ' 138' ' ' HIS . 28.8 m -147.28 139.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 62.7 t-80 -33.54 149.65 0.01 OUTLIER 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.751 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.3 p30 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.349 -179.419 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.445 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 4.8 m . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 85.4 mt -115.57 134.05 55.43 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.76 162.04 23.07 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.605 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.47 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 25.8 tt0 -62.62 144.42 56.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.939 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.13 -14.6 36.88 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.518 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.2 m -69.22 121.46 16.85 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 121.104 -0.239 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 86.8 mtm180 -84.55 149.89 25.6 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.284 179.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' A' ' 19' ' ' ILE . 73.5 mt -133.49 107.21 10.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.301 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -78.42 131.84 37.08 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -108.83 124.72 33.45 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' HD1' ' A' ' 30' ' ' HIS . 42.4 Cg_endo -68.97 -25.53 32.23 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.248 1.966 . . . . 0.0 111.841 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.1 t -69.95 -56.23 12.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 p -83.55 -38.2 22.01 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.056 0.455 . . . . 0.0 109.887 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.47 12.1 70.46 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.9 m -114.75 155.37 26.82 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 117.963 0.882 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.8 m -80.59 120.65 24.81 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.311 0.577 . . . . 0.0 110.971 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -105.36 145.85 30.21 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.34 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.414 ' O ' HG23 ' A' ' 22' ' ' VAL . 6.6 ttm180 -97.31 123.05 41.0 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.603 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.1 tt -53.99 -40.07 43.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.619 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.7 pt-20 -60.42 -32.71 71.6 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.945 0.402 . . . . 0.0 111.202 -179.356 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -83.7 -39.07 20.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.672 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.488 HG11 ' CD1' ' A' ' 29' ' ' ILE . 92.8 t -67.53 -40.67 84.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.11 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.639 HG22 HD21 ' A' ' 122' ' ' LEU . 61.8 t -72.43 -46.72 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.619 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.11 -34.76 70.55 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-O 120.65 0.262 . . . . 0.0 110.866 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.556 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.81 26.7 18.66 Favored Glycine 0 CA--C 1.518 0.224 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.556 ' C ' ' O ' ' A' ' 25' ' ' GLY . 94.1 mtt-85 17.47 64.55 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.419 ' O ' HG23 ' A' ' 29' ' ' ILE . 78.8 mttt -90.14 114.22 60.12 Favored Pre-proline 0 N--CA 1.448 -0.568 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.058 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -55.88 86.5 0.04 OUTLIER 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.836 1.69 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.488 ' CD1' HG11 ' A' ' 22' ' ' VAL . 12.5 pt -109.24 -172.68 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-O 120.752 0.31 . . . . 0.0 110.707 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.873 ' NE2' ' HB1' ' A' ' 42' ' ' ALA . 6.3 t-80 -127.02 156.86 40.96 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.712 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.64 ' O ' ' CE1' ' A' ' 30' ' ' HIS . 29.2 m -148.46 169.7 3.05 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.87 134.91 27.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 O-C-N 122.115 -0.365 . . . . 0.0 110.36 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.1 167.18 10.19 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.799 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.44 145.3 40.75 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.261 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.12 178.22 4.37 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.577 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.74 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 69.7 mmtt -71.4 -11.6 60.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.024 0.44 . . . . 0.0 110.458 179.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.0 p30 -80.22 -13.41 59.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.29 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.3 19.74 61.87 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 47.4 p -102.18 138.83 38.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 111.594 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.3 mt -92.29 131.0 37.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.181 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -137.3 138.24 39.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.873 ' HB1' ' NE2' ' A' ' 30' ' ' HIS . . . -69.26 136.12 51.48 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.297 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.662 ' N ' ' NE2' ' A' ' 30' ' ' HIS . 4.6 mmp_? -146.13 136.53 12.16 Favored Pre-proline 0 CA--C 1.537 0.454 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.178 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.88 159.85 30.87 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.865 2.377 . . . . 0.0 113.118 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.9 t -101.42 139.02 23.66 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 177.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.6 m -130.68 4.56 2.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.06 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 p -149.34 145.2 26.89 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.175 0.898 . . . . 0.0 109.025 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.612 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.26 123.76 13.98 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.51 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -136.41 145.12 44.94 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -91.88 140.32 29.79 Favored 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.445 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 3.9 mm100 -89.84 -4.19 57.72 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.338 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 77.46 21.62 72.18 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.657 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ARG . 0.4 OUTLIER 64.53 135.3 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.836 0.35 . . . . 0.0 110.087 -179.945 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . 0.419 ' CG ' ' O ' ' A' ' 53' ' ' THR . 72.0 mtp180 -157.27 174.92 14.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.404 178.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASP . . . . . 0.443 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 50.3 t0 -73.93 139.67 45.07 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -142.13 152.73 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.09 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.726 HD11 ' HB1' ' A' ' 84' ' ' ALA . 44.6 pt -104.86 152.05 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.177 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.79 138.1 14.26 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.6 mt -121.32 114.57 21.53 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 121.111 0.481 . . . . 0.0 110.365 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -87.0 113.78 23.05 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.888 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.662 ' O ' ' N ' ' A' ' 63' ' ' GLY . 15.7 mm -98.54 134.09 38.51 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.523 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.664 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 24.13 34.25 0.0 OUTLIER 'General case' 0 C--N 1.35 0.607 0 O-C-N 123.848 0.718 . . . . 0.0 112.038 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.662 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 62.72 -18.3 0.07 OUTLIER Glycine 0 CA--C 1.535 1.281 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.295 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.664 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -52.9 -107.84 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 110.079 -1.208 . . . . 0.0 110.079 -178.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.23 168.91 11.01 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 120.887 0.375 . . . . 0.0 110.441 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.47 150.77 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.212 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 57.9 tp -123.99 113.55 18.58 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.823 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.556 ' CG ' ' NH2' ' A' ' 115' ' ' ARG . 95.3 m95 -104.5 121.28 43.14 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.95 171.94 15.53 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.318 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' THR . . . . . 0.418 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 40.2 p -78.56 154.41 78.79 Favored Pre-proline 0 C--N 1.329 -0.294 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.109 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.66 -22.15 59.23 Favored 'Trans proline' 0 N--CA 1.495 1.578 0 C-N-CA 122.027 1.818 . . . . 0.0 112.113 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -93.15 -7.71 44.6 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.79 0.328 . . . . 0.0 110.364 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.8 t60 -66.81 126.83 30.29 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mptt -82.72 123.42 29.28 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.219 0.533 . . . . 0.0 111.395 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.5 t -99.73 139.68 20.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.732 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.66 95.02 5.16 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.867 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 13.9 p -98.7 174.67 6.3 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -66.78 -14.9 63.15 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.29 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 68.4 m-85 -108.05 25.22 11.86 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.483 0.183 . . . . 0.0 110.744 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.59 -141.15 15.35 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.74 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 92.5 m95 -94.47 129.31 41.29 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.966 0.412 . . . . 0.0 111.172 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.9 tpt180 -138.7 131.42 29.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.441 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.62 144.49 26.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.012 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.726 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.07 -37.94 84.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 120.936 -0.306 . . . . 0.0 111.613 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.77 -5.33 24.16 Favored Glycine 0 CA--C 1.528 0.9 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.795 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -103.38 4.9 36.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.962 0.411 . . . . 0.0 110.432 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.5 mt -90.67 131.05 36.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.404 0.621 . . . . 0.0 111.122 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.517 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.4 mmt180 -129.2 148.96 51.18 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.705 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -45.27 90.83 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 153.72 -12.33 0.55 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -84.09 130.77 34.84 Favored 'General case' 0 C--O 1.228 -0.079 0 CA-C-O 120.936 0.398 . . . . 0.0 110.672 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.411 ' HE ' HG12 ' A' ' 107' ' ' VAL . 93.9 mtt180 -92.48 141.55 28.39 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.724 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.51 158.98 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.282 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.6 130.35 43.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.105 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.452 HG21 ' OG ' ' A' ' 106' ' ' SER . 1.4 t -130.87 132.79 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.434 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -84.29 125.61 32.42 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.742 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 37.5 t0 -99.81 122.62 43.04 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.999 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 -17.8 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 118.35 0.523 . . . . 0.0 111.303 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 -69.64 -59.74 2.77 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 120.517 -0.473 . . . . 0.0 109.898 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.438 ' C ' ' H ' ' A' ' 102' ' ' GLU . 33.8 p -93.1 -12.85 29.46 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.12 -14.27 6.52 Favored Glycine 0 C--N 1.331 0.278 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.438 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.5 mt-10 -83.38 157.95 22.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.841 0.353 . . . . 0.0 110.824 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.604 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -82.39 133.71 35.23 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.22 0.533 . . . . 0.0 109.852 179.755 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.4 ptt85 -138.18 137.14 37.32 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.408 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -78.55 147.32 33.83 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -177.538 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.452 ' OG ' HG21 ' A' ' 95' ' ' VAL . 3.2 m -134.98 160.44 38.31 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.575 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.431 HG22 ' H ' ' A' ' 107' ' ' VAL . 17.0 m -91.73 153.67 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.5 mm -70.23 156.33 7.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.084 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.443 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt85 -107.61 -46.63 3.79 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.989 178.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -166.3 145.95 6.0 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.436 ' C ' HD22 ' A' ' 112' ' ' LEU . 19.3 t -93.33 131.84 39.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -99.57 148.48 34.79 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.047 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.88 160.34 50.16 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.408 2.072 . . . . 0.0 111.126 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.425 HG23 ' H ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -69.26 156.67 38.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 120.999 0.428 . . . . 0.0 110.585 -179.387 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.556 ' NH2' ' CG ' ' A' ' 68' ' ' TRP . 39.3 ptt180 -139.87 -144.41 0.17 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.964 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -154.03 134.75 13.66 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.69 172.12 3.64 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.983 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.47 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 91.4 mtm-85 -71.45 140.54 50.07 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.519 178.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 143.01 51.28 Favored 'General case' 0 C--O 1.231 0.126 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.455 ' HB3' HG21 ' A' ' 23' ' ' VAL . 52.2 m-85 -120.61 178.02 4.84 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.719 -177.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -153.49 120.75 5.81 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.269 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.639 HD21 HG22 ' A' ' 23' ' ' VAL . 84.8 mt -119.57 123.53 44.15 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.744 0.307 . . . . 0.0 110.443 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -88.51 111.51 21.91 Favored 'General case' 0 CA--C 1.514 -0.441 0 C-N-CA 120.612 -0.435 . . . . 0.0 109.899 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 59.8 t -86.49 119.74 35.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.464 -0.495 . . . . 0.0 109.849 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 33.2 tp10 21.71 -121.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.961 0.788 . . . . 0.0 111.148 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -104.17 -26.81 12.39 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.916 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.431 ' O ' ' N ' ' A' ' 129' ' ' THR . 66.9 mt -81.86 70.54 8.78 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.527 ' O ' HG23 ' A' ' 129' ' ' THR . 1.7 m-70 -41.57 98.83 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 179.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.46 141.49 0.02 OUTLIER 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.997 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.3 pp -146.65 155.85 42.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.377 0.608 . . . . 0.0 111.614 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 131' ' ' VAL . 8.4 p -89.8 125.48 42.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.875 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.518 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -132.62 132.36 42.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.784 -179.222 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.618 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 49.7 46.49 23.8 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.22 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.39 -13.35 0.58 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.431 -0.667 . . . . 0.0 111.431 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.2 t -95.18 150.64 4.08 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.27 0 CA-C-N 117.061 0.43 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.6 t -107.97 113.52 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.65 0.262 . . . . 0.0 110.531 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' HIS . 22.9 m -148.28 141.05 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.109 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.546 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 57.2 t-80 -30.25 151.5 0.0 OUTLIER 'General case' 0 C--O 1.224 -0.254 0 CA-C-O 120.989 0.424 . . . . 0.0 112.05 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 p30 . . . . . 0 C--N 1.32 -0.683 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.674 -179.342 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 39.4 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 0.464 HD11 HD11 ' A' ' 130' ' ' LEU . 76.5 mt -109.34 136.42 48.8 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.906 0.384 . . . . 0.0 110.338 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.32 162.75 21.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.519 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.74 141.1 58.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.115 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.87 -17.67 22.5 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 14.4 m -68.91 120.43 14.8 Favored 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.534 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.424 ' HG2' ' HE ' ' A' ' 18' ' ' ARG . 85.9 mtm180 -94.6 114.59 26.57 Favored 'General case' 0 N--CA 1.456 -0.141 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.6 mp -102.37 114.87 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 4.6 t80 -77.16 135.41 38.53 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 9.7 t0 -102.79 132.62 21.05 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.647 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.22 -30.95 9.94 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.672 2.248 . . . . 0.0 112.37 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.512 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 47.1 t -71.31 -55.02 15.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.737 -179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.0 p -78.19 -37.0 46.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.043 0.449 . . . . 0.0 110.271 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.29 82.68 Favored Glycine 0 CA--C 1.52 0.389 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.23 -168.73 1.43 Allowed 'General case' 0 C--N 1.34 0.171 0 CA-C-N 117.621 0.71 . . . . 0.0 109.501 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 63.7 m -113.6 117.34 31.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.259 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 58.9 m170 -103.46 143.59 32.51 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.341 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.424 ' HE ' ' HG2' ' A' ' 7' ' ' ARG . 23.2 mmt85 -96.59 126.08 41.52 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.64 179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.457 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -51.4 -42.54 28.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.213 0.53 . . . . 0.0 111.19 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 4.5 pt-20 -58.72 -32.08 68.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.823 -177.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.5 t0 -83.81 -38.49 21.19 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.29 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 86.6 t -64.65 -40.8 90.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.337 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 50.3 t -73.51 -44.58 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -57.52 -37.94 73.86 Favored 'General case' 0 CA--C 1.513 -0.472 0 C-N-CA 120.823 -0.351 . . . . 0.0 111.227 -177.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.568 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.2 29.37 9.27 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.568 ' C ' ' O ' ' A' ' 25' ' ' GLY . 89.1 mtt-85 16.12 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -87.31 113.99 56.5 Favored Pre-proline 0 N--CA 1.449 -0.491 0 O-C-N 123.434 0.459 . . . . 0.0 111.177 -176.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.6 89.43 0.06 OUTLIER 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.159 1.906 . . . . 0.0 110.414 178.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.51 -172.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 120.867 0.365 . . . . 0.0 110.497 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.425 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 52.4 m80 -127.94 160.63 31.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.598 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -149.41 172.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.2 t -90.93 136.05 25.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.406 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.7 167.77 10.34 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.763 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.0 143.24 44.69 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.325 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.01 177.7 4.55 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.653 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -70.0 -13.63 62.32 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 110.658 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -80.13 -18.21 50.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.453 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.89 24.16 39.14 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.6 p -103.06 136.83 42.15 Favored 'General case' 0 N--CA 1.463 0.207 0 O-C-N 122.724 -0.28 . . . . 0.0 111.281 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.3 mt -94.22 130.67 40.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.819 0.343 . . . . 0.0 110.648 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 7.1 t-160 -142.36 139.24 31.69 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.838 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.91 139.95 53.04 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.555 -178.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.487 ' CZ ' ' OE1' ' A' ' 126' ' ' GLU . 14.5 mmt180 -142.92 140.35 17.99 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.376 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -78.37 157.03 29.28 Favored 'Trans proline' 0 N--CA 1.491 1.324 0 C-N-CA 122.757 2.305 . . . . 0.0 113.019 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.57 134.87 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.067 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.8 m -125.6 0.23 4.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.645 -179.06 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.1 141.99 25.8 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 119.144 0.884 . . . . 0.0 108.912 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.592 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -139.39 120.74 14.93 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 178.398 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -139.22 145.86 39.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.318 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -89.95 133.52 34.74 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.446 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -92.75 -1.98 56.36 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.653 -0.249 . . . . 0.0 111.298 179.934 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 119' ' ' THR . . . 87.66 175.76 48.35 Favored Glycine 0 C--N 1.339 0.698 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.376 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.0 m -90.44 118.67 30.1 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -141.95 172.6 12.46 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.939 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 99.5 m-20 -75.32 141.57 43.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.889 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.1 m -141.85 157.67 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.494 ' CG2' HG22 ' A' ' 114' ' ' THR . 45.5 pt -112.79 153.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.206 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.32 139.26 14.5 Favored Glycine 0 N--CA 1.465 0.577 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.2 mt -120.41 112.35 18.88 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.143 0.497 . . . . 0.0 110.464 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -89.39 111.43 22.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.555 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 63' ' ' GLY . 16.8 mm -99.95 126.3 53.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.737 -179.066 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.53 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 35.98 25.6 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.879 0.737 . . . . 0.0 110.782 -178.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 70.86 -23.83 0.53 Allowed Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.084 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.24 -106.71 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.37 170.49 10.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 120.948 0.404 . . . . 0.0 110.311 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.453 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.6 mt -124.89 155.01 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.462 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.453 ' N ' HG22 ' A' ' 66' ' ' ILE . 47.1 tp -132.08 116.5 17.13 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.118 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -104.63 115.54 30.52 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.18 172.49 12.62 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.62 156.87 80.41 Favored Pre-proline 0 C--N 1.327 -0.401 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -61.68 -21.65 72.59 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.649 2.233 . . . . 0.0 111.826 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 24.5 p30 -93.09 -4.83 51.66 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.248 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.533 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.5 t60 -72.27 129.56 38.72 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -86.19 127.47 34.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-O 121.277 0.56 . . . . 0.0 110.251 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.827 ' O ' HG23 ' A' ' 77' ' ' THR . 91.2 t -108.26 92.39 2.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.117 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 75' ' ' VAL . 9.6 tp -31.01 93.59 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.644 0.59 . . . . 0.0 111.442 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.827 HG23 ' O ' ' A' ' 75' ' ' VAL . 29.9 p -98.34 177.19 5.44 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.747 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.524 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 6.0 pt-20 -65.05 -21.36 66.82 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.232 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.524 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 57.8 m-85 -104.47 25.09 10.64 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 120.459 0.171 . . . . 0.0 110.905 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.445 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.22 -176.07 41.73 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -58.62 129.68 43.24 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.696 -177.142 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 73.4 mtm180 -145.9 134.55 22.21 Favored 'General case' 0 C--N 1.339 0.118 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.063 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.27 141.11 24.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.04 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.5 -36.98 84.27 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.143 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.73 -1.44 2.7 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.672 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.7 mt-10 -108.16 6.58 26.92 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 88.9 mt -85.1 125.95 33.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.262 0.553 . . . . 0.0 110.975 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.553 ' O ' ' N ' ' A' ' 90' ' ' GLY . 25.2 mmt85 -130.5 147.53 52.2 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.584 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -45.89 88.22 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 120.897 0.38 . . . . 0.0 110.632 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.0 -16.82 0.37 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -86.23 130.88 34.37 Favored 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.885 0.374 . . . . 0.0 110.419 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.67 135.25 34.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.0 m -120.43 152.02 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.52 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -64.3 139.64 58.79 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.164 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.73 HG21 ' OG ' ' A' ' 106' ' ' SER . 26.9 m -138.55 156.7 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.391 178.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -106.09 130.65 53.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.679 0.276 . . . . 0.0 110.317 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -101.63 125.86 48.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.581 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 98' ' ' VAL . 7.4 p -73.94 -14.74 16.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 118.203 0.456 . . . . 0.0 111.279 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -67.85 -60.38 2.56 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.822 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.571 ' HB ' ' OE1' ' A' ' 102' ' ' GLU . 53.3 m -103.39 -12.9 16.89 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.251 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 80.39 -11.19 39.35 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.995 177.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.703 ' N ' ' OE1' ' A' ' 102' ' ' GLU . 0.0 OUTLIER -77.18 158.8 30.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-O 121.558 0.694 . . . . 0.0 112.161 -179.149 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.52 HD21 ' HB1' ' A' ' 94' ' ' ALA . 5.9 tp -83.07 133.08 35.09 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.824 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.514 ' O ' HG22 ' A' ' 95' ' ' VAL . 85.0 mtp180 -133.9 172.87 12.2 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.3 m-30 -109.46 142.25 40.74 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.389 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.73 ' OG ' HG21 ' A' ' 95' ' ' VAL . 6.7 m -134.43 154.39 51.41 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.37 155.15 3.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 110.864 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 63.1 mt -73.44 153.05 7.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.836 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.8 mmm180 -108.29 -43.24 4.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.021 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -164.69 141.82 6.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.472 ' C ' HD22 ' A' ' 112' ' ' LEU . 16.5 t -95.13 134.09 33.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.034 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.472 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.3 mm? -101.97 125.46 36.78 Favored Pre-proline 0 CA--C 1.538 0.509 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.88 163.72 0.2 Allowed 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.217 1.945 . . . . 0.0 111.831 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.494 HG22 ' CG2' ' A' ' 57' ' ' ILE . 61.4 p -68.04 156.78 36.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.089 0.471 . . . . 0.0 110.812 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' O ' ' OD1' ' A' ' 55' ' ' ASP . 42.4 ttm-85 -139.64 -136.94 0.12 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.974 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -158.97 131.16 6.66 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.411 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.33 172.8 3.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.071 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -76.18 145.75 39.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.871 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 52' ' ' GLY . 3.9 p -122.63 141.49 51.67 Favored 'General case' 0 N--CA 1.463 0.175 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CB ' HD12 ' A' ' 19' ' ' ILE . 83.5 m-85 -119.66 174.04 6.65 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.215 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -156.18 125.72 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.389 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 76.5 mt -119.54 121.7 39.98 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -86.73 115.28 24.06 Favored 'General case' 0 CA--C 1.512 -0.491 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.127 -177.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.53 117.89 33.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.542 ' O ' ' N ' ' A' ' 127' ' ' LEU . 40.0 tt0 -58.26 156.05 10.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.505 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.487 ' OE1' ' CZ ' ' A' ' 43' ' ' ARG . 91.0 mt-10 56.24 -69.16 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.395 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.542 ' N ' ' O ' ' A' ' 125' ' ' GLU . 95.9 mt -98.27 101.23 12.62 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.532 ' O ' HG23 ' A' ' 129' ' ' THR . 39.6 m80 -72.3 99.61 2.44 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.04 143.86 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.969 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.641 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.2 pp -144.38 152.86 41.3 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 121.182 0.515 . . . . 0.0 111.293 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.444 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.0 p -87.67 128.15 40.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.545 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.32 128.28 35.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.935 -179.308 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 72.9 mm-40 52.46 47.23 25.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.204 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.87 -18.43 0.47 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.7 t -90.59 151.02 3.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 CA-C-N 117.169 0.485 . . . . 0.0 110.287 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 62.1 t -106.41 112.98 41.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 138' ' ' HIS . 17.4 m -147.77 138.23 17.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.366 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.424 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.533 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 7.7 t60 -35.46 155.67 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.152 0 CA-C-O 120.747 0.308 . . . . 0.0 111.62 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 14.1 p30 . . . . . 0 C--N 1.322 -0.629 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.659 -179.415 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.625 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 11.9 m . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.72 131.85 53.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.837 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.78 162.72 18.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.525 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -62.18 141.46 58.18 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.442 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.94 -15.45 21.23 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.495 HG23 ' HG2' ' A' ' 133' ' ' GLU . 22.6 m -71.24 120.02 16.21 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.632 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -93.27 115.96 28.54 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 120.908 0.385 . . . . 0.0 110.322 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 57.5 mt -99.9 112.49 32.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.77 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 3.5 t80 -77.76 135.77 38.05 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.269 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.555 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.7 t0 -102.32 131.71 22.24 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.046 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.43 -32.5 7.94 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.577 2.184 . . . . 0.0 112.136 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.555 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.0 t -69.7 -52.88 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.222 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 m -79.02 -40.01 32.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.003 0.43 . . . . 0.0 110.385 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.77 82.17 Favored Glycine 0 N--CA 1.453 -0.205 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.896 HG22 ' H ' ' A' ' 16' ' ' THR . 12.7 m -104.19 -174.5 2.56 Favored 'General case' 0 C--N 1.338 0.086 0 CA-C-N 117.68 0.74 . . . . 0.0 109.613 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.896 ' H ' HG22 ' A' ' 15' ' ' THR . 88.1 m -112.23 118.97 36.76 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.068 179.142 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -113.43 151.8 30.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.477 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 66.3 mtt85 -100.27 128.77 46.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.607 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.423 HG23 ' N ' ' A' ' 20' ' ' GLU . 4.0 tt -52.28 -38.96 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 120.924 0.392 . . . . 0.0 111.2 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.2 pt-20 -60.78 -34.14 74.04 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.167 0.508 . . . . 0.0 110.771 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.575 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 7.1 t70 -85.31 -38.29 18.99 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.352 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.0 t -69.71 -42.71 80.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.9 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.512 ' CG2' HD21 ' A' ' 122' ' ' LEU . 34.1 t -76.14 -47.83 30.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.578 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 33.1 p-10 -56.53 -30.77 63.45 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 120.987 0.423 . . . . 0.0 110.603 -177.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' N ' ' OD1' ' A' ' 24' ' ' ASP . . . -109.64 21.49 25.71 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.52 ' C ' ' O ' ' A' ' 25' ' ' GLY . 43.1 ptt85 21.79 61.65 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.202 0 O-C-N 124.309 0.652 . . . . 0.0 109.324 179.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -79.02 134.65 59.52 Favored Pre-proline 0 N--CA 1.446 -0.658 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.049 -177.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -76.04 81.35 2.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.305 2.003 . . . . 0.0 111.247 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.6 pt -118.33 -169.72 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.499 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.444 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 54.3 m80 -128.35 164.53 22.44 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.826 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.6 m -148.47 171.79 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.401 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 74.6 t -90.81 131.6 37.55 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.11 167.83 9.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.205 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.62 141.81 39.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.912 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.76 177.73 4.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.909 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -70.43 -12.62 61.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 120.93 0.395 . . . . 0.0 110.609 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.446 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 64.6 t0 -81.32 -18.77 44.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.88 23.07 43.24 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.2 p -102.59 136.5 42.3 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.81 0.338 . . . . 0.0 111.012 178.526 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 77.9 mt -91.24 128.64 37.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.835 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -138.98 137.84 36.73 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.596 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.486 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -70.16 140.56 52.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.777 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.486 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.4 mmp_? -144.04 138.8 15.31 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.665 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -77.56 158.21 32.31 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 123.001 2.468 . . . . 0.0 113.142 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.3 t -101.34 136.46 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.4 m -127.89 3.01 3.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.554 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.464 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -152.5 149.54 28.64 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 119.426 1.012 . . . . 0.0 108.585 179.732 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.503 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -149.31 127.04 11.72 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.355 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 -140.02 148.43 41.83 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.708 0.632 . . . . 0.0 112.708 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.446 ' OD2' ' N ' ' A' ' 52' ' ' GLY . 15.1 t70 -105.84 138.58 41.8 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.685 ' NE2' ' C ' ' A' ' 120' ' ' PHE . 4.0 mt-30 -101.77 2.97 39.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.489 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.446 ' N ' ' OD2' ' A' ' 50' ' ' ASP . . . 85.15 -165.05 39.13 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.415 178.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.439 HG22 ' NH2' ' A' ' 116' ' ' ARG . 20.9 m -87.16 127.72 35.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -148.82 160.79 42.9 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.821 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.79 139.73 41.95 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.05 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.77 156.07 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.4 pt -107.8 149.37 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.359 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.38 142.68 15.67 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 75.8 mt -127.9 114.73 17.56 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.2 0.524 . . . . 0.0 110.654 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 56.6 ttp180 -96.66 122.45 39.6 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.526 HG22 ' N ' ' A' ' 62' ' ' ALA . 55.1 mt -117.91 160.97 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.526 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -53.14 -27.04 19.0 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.777 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.49 -15.43 0.46 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.449 ' N ' ' C ' ' A' ' 62' ' ' ALA . . . 87.28 -18.39 37.32 Favored Glycine 0 C--N 1.335 0.48 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.89 170.48 9.65 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 110.117 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.1 mt -122.65 151.06 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.236 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -126.56 115.69 19.91 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.931 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -105.41 116.34 31.77 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -143.04 171.78 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.397 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -79.41 156.2 76.1 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.616 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -62.26 -17.48 57.27 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.597 2.198 . . . . 0.0 111.882 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -95.9 -6.71 38.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.742 0.306 . . . . 0.0 110.38 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.4 t60 -69.03 127.46 33.23 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.7 mmtp -85.97 128.19 34.79 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.902 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.6 t -103.31 141.29 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.341 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 56.3 tp -78.0 93.29 4.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.886 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.494 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 76.1 p -98.33 173.66 6.87 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -178.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -63.7 -16.24 60.54 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.367 -179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -108.06 25.65 11.34 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.82 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.58 -176.1 46.1 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -58.64 133.12 55.61 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.206 0.527 . . . . 0.0 110.478 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -146.11 134.73 22.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.666 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.99 137.98 31.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.08 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.402 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.3 -37.9 87.32 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.222 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.32 -2.42 3.02 Favored Glycine 0 C--N 1.335 0.503 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.734 -179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.402 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.8 mm-40 -108.17 11.51 27.41 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.918 0.389 . . . . 0.0 110.321 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.0 mt -92.93 128.15 38.7 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.465 0.65 . . . . 0.0 111.072 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.572 ' O ' ' N ' ' A' ' 90' ' ' GLY . 14.8 tpt180 -130.51 149.52 52.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.976 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -45.76 86.57 0.0 OUTLIER 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.557 179.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.77 -14.83 0.29 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -85.02 131.78 34.42 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.707 -0.29 . . . . 0.0 110.29 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -89.21 130.74 35.58 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.434 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.0 m -116.64 146.35 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.584 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.452 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -71.64 137.55 47.98 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.704 0.288 . . . . 0.0 111.073 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.17 161.92 38.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.004 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -103.5 130.98 50.99 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.508 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.543 ' OD2' ' NH2' ' A' ' 104' ' ' ARG . 42.5 t0 -100.62 123.96 45.54 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.33 -16.65 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 CA-C-N 118.297 0.499 . . . . 0.0 111.261 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -71.26 -58.27 3.7 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.139 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.8 p -95.18 -15.02 23.61 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.651 -0.25 . . . . 0.0 110.34 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.99 -13.98 5.07 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 98.2 mt-10 -81.49 159.87 24.09 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-O 120.755 0.312 . . . . 0.0 110.758 -177.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.452 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.7 tp -85.32 128.79 34.83 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.163 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.543 ' NH2' ' OD2' ' A' ' 97' ' ' ASP . 16.5 ptp180 -127.24 175.81 7.88 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.33 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.494 ' OH ' ' C ' ' A' ' 77' ' ' THR . 0.8 OUTLIER -114.68 147.26 39.88 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.835 179.877 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -144.23 163.06 34.76 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.413 ' H ' HG22 ' A' ' 107' ' ' VAL . 9.4 m -94.79 155.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-O 120.674 0.273 . . . . 0.0 110.483 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.468 HG22 ' N ' ' A' ' 109' ' ' ARG . 68.1 mt -73.08 159.43 5.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 120.97 0.414 . . . . 0.0 110.303 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.468 ' N ' HG22 ' A' ' 108' ' ' ILE . 24.9 mmt180 -105.26 -44.97 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.192 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -165.23 143.55 6.27 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.497 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.9 p -96.19 134.86 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.497 HD22 ' C ' ' A' ' 111' ' ' VAL . 2.6 mm? -104.06 147.69 34.71 Favored Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.34 166.66 27.57 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 122.533 2.155 . . . . 0.0 111.357 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 21.8 p -66.12 151.56 46.65 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.21 0.528 . . . . 0.0 110.689 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -133.86 -148.48 0.33 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.092 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.439 ' NH2' HG22 ' A' ' 53' ' ' THR . 25.7 mmm180 -148.88 127.62 12.52 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.147 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.61 175.52 2.48 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.756 -178.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -79.48 147.03 32.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.928 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.2 p -121.12 140.81 51.48 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.1 0.476 . . . . 0.0 109.747 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.685 ' C ' ' NE2' ' A' ' 51' ' ' GLN . 58.3 m-85 -114.9 168.02 10.28 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.921 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.599 ' C ' HD22 ' A' ' 122' ' ' LEU . 66.4 t0 -147.47 131.16 16.91 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.219 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.599 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.62 163.88 14.81 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.486 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -135.1 104.84 6.08 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.017 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 17.4 t -91.93 120.7 41.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.418 ' O ' ' N ' ' A' ' 127' ' ' LEU . 75.7 tt0 -62.69 152.9 34.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.5 tt0 62.17 -70.57 0.05 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.81 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.418 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -99.96 104.45 16.07 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.548 ' O ' HG23 ' A' ' 129' ' ' THR . 62.3 m80 -73.99 100.2 3.49 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.675 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 165.89 144.67 0.02 OUTLIER 'General case' 0 C--N 1.344 0.35 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.634 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.43 155.5 43.77 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-O 121.759 0.79 . . . . 0.0 111.566 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.88 125.14 40.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.473 ' HB1' HG21 ' A' ' 6' ' ' THR . . . -131.88 125.73 32.45 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.052 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.525 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 50.36 46.47 25.11 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.939 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.17 -17.24 0.43 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.525 ' H ' ' C ' ' A' ' 133' ' ' GLU . 12.1 t -92.34 150.94 3.68 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 O-C-N 122.285 -0.538 . . . . 0.0 110.727 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.19 114.35 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.438 HG23 ' O ' ' A' ' 137' ' ' VAL . 18.0 m -146.74 132.14 12.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.315 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.517 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 50.2 t-80 -37.21 159.86 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.74 0.305 . . . . 0.0 111.74 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.485 ' N ' ' CG ' ' A' ' 138' ' ' HIS . 21.1 p30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.388 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 73.0 mt -106.9 138.44 43.07 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.415 -179.289 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.87 164.13 20.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.85 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -64.02 145.41 55.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.233 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.03 -17.6 44.43 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.6 m -67.67 123.93 21.86 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.437 ' HE ' HG21 ' A' ' 16' ' ' THR . 61.0 mtp180 -81.62 147.78 29.4 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.829 0.347 . . . . 0.0 110.263 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 19' ' ' ILE . 90.3 mt -134.46 106.4 7.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.857 179.182 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.4 t80 -77.52 133.5 38.52 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.238 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 17.1 t0 -106.49 129.62 24.2 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.44 -26.4 24.42 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.119 1.88 . . . . 0.0 112.512 -179.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.509 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 38.9 t -78.34 -53.1 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.016 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.8 p -79.97 -34.63 38.5 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 120.975 0.417 . . . . 0.0 110.134 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.94 9.5 86.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.595 HG22 ' N ' ' A' ' 16' ' ' THR . 87.8 m -113.17 166.73 11.16 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 117.873 0.836 . . . . 0.0 109.65 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.595 ' N ' HG22 ' A' ' 15' ' ' THR . 38.5 m -90.26 116.09 27.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.316 0.579 . . . . 0.0 111.321 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -102.12 144.47 30.65 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.153 -0.931 . . . . 0.0 110.147 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 92.2 mtt-85 -98.77 129.84 45.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.606 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.492 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.6 tp -52.79 -40.03 33.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.721 0.296 . . . . 0.0 111.154 -179.104 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.492 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -60.56 -34.98 74.95 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.263 0.554 . . . . 0.0 110.11 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.76 -40.45 22.64 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.741 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 83.4 t -68.47 -42.58 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.4 t -72.21 -46.19 58.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.014 0.375 . . . . 0.0 112.014 -178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 66.8 t0 -58.56 -35.17 71.94 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.157 0.503 . . . . 0.0 110.549 -177.938 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.3 25.45 12.45 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-O 118.853 -0.971 . . . . 0.0 111.049 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.566 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.2 ptt180 14.03 72.74 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 CA-C-N 117.427 0.614 . . . . 0.0 109.523 179.219 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -87.45 137.61 32.33 Favored Pre-proline 0 N--CA 1.445 -0.705 0 O-C-N 121.673 -0.642 . . . . 0.0 110.925 -175.623 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -74.52 83.33 1.74 Allowed 'Trans proline' 0 C--N 1.31 -1.465 0 C-N-CA 121.311 1.341 . . . . 0.0 110.618 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.7 pt -119.51 -170.53 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.811 0.339 . . . . 0.0 110.097 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.426 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 26.3 m80 -131.35 163.55 27.61 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.621 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.42 170.96 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 85.9 t -87.16 130.88 36.31 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.563 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.23 166.54 10.34 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.599 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.12 141.99 40.18 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.848 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.72 179.31 3.99 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -72.03 -13.63 61.65 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.91 0.386 . . . . 0.0 110.814 179.365 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -79.51 -21.55 45.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.402 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 91.46 19.55 41.12 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.4 p -99.22 135.61 40.38 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 121.098 0.475 . . . . 0.0 111.01 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.5 mt -91.65 127.72 37.21 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.269 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -137.95 138.94 39.46 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.73 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.06 142.42 50.86 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.384 -0.526 . . . . 0.0 109.85 -178.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.597 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.6 mmt180 -144.06 137.47 14.15 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.046 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.35 157.18 33.09 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 122.631 2.221 . . . . 0.0 112.73 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.0 135.7 31.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.57 2.88 3.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.647 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -150.69 144.84 25.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 119.173 0.897 . . . . 0.0 108.844 178.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -144.95 128.97 17.53 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -136.41 145.03 44.83 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.242 0.544 . . . . 0.0 112.255 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 53.2 p-10 -114.43 141.22 47.95 Favored 'General case' 0 CA--C 1.5 -0.959 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -110.27 -101.15 0.39 Allowed 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.002 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -173.82 -153.13 9.47 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 114.408 -1.269 . . . . 0.0 112.951 -177.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.1 m -86.32 129.3 34.9 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.1 0.476 . . . . 0.0 111.549 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -150.48 162.25 40.95 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.498 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -78.53 138.61 38.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.21 141.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 120.828 0.347 . . . . 0.0 110.281 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.657 HD11 ' HB1' ' A' ' 84' ' ' ALA . 41.1 pt -90.41 145.64 7.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.795 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.97 140.53 14.91 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 15.1 mt -125.12 114.09 18.57 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.102 0.477 . . . . 0.0 110.559 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.522 ' C ' HD12 ' A' ' 61' ' ' ILE . 36.0 ttm180 -91.53 112.85 24.94 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.275 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.726 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -105.36 154.06 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.412 -179.487 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.416 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -54.89 -4.22 0.06 Allowed 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.826 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.513 ' H ' HG22 ' A' ' 61' ' ' ILE . . . -70.87 -12.75 71.44 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 86.87 -19.43 29.74 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.93 171.62 9.16 Favored 'General case' 0 CA--C 1.523 -0.093 0 CA-C-O 120.889 0.376 . . . . 0.0 110.25 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.7 mt -119.13 142.0 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.24 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.566 HD23 ' C ' ' A' ' 67' ' ' LEU . 4.2 tt -120.41 113.08 19.8 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.197 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.555 ' N ' HD23 ' A' ' 67' ' ' LEU . 99.5 m95 -103.02 127.6 50.19 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.472 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.27 172.22 14.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.317 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.19 155.34 60.43 Favored Pre-proline 0 CA--C 1.535 0.38 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.353 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -63.62 -22.21 70.3 Favored 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.566 2.177 . . . . 0.0 112.012 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -91.24 -8.1 49.36 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 120.977 0.418 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.584 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.7 t60 -70.52 127.52 33.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.559 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.7 mtmm -86.11 132.62 33.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.135 0.493 . . . . 0.0 111.159 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.94 148.82 17.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.22 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 25.9 tp -85.37 92.07 8.37 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.794 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 79' ' ' TYR . 0.1 OUTLIER -107.73 139.92 41.56 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.16 0.505 . . . . 0.0 110.434 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.54 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 67.5 mm-40 60.02 -64.66 0.05 Allowed 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.134 -1.394 . . . . 0.0 111.262 178.433 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.582 ' N ' ' O ' ' A' ' 77' ' ' THR . 0.3 OUTLIER 179.15 55.71 0.01 OUTLIER 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 174.32 175.81 42.21 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 119.56 -1.305 . . . . 0.0 111.976 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -91.71 129.31 37.71 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.874 0.368 . . . . 0.0 110.815 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 -145.46 138.53 26.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.365 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.89 142.74 23.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.144 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.657 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -65.24 -37.82 88.45 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 120.885 -0.326 . . . . 0.0 111.724 -179.573 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.41 5.22 0.17 Allowed Glycine 0 CA--C 1.527 0.839 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.863 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.9 mt-10 -110.57 1.96 18.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.888 0.344 . . . . 0.0 110.259 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 61.3 mt -80.49 130.6 35.25 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.484 0.659 . . . . 0.0 111.127 -179.274 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.506 ' O ' ' N ' ' A' ' 90' ' ' GLY . 32.5 mmt180 -129.46 151.2 50.35 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.944 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -51.91 87.19 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.27 -21.32 0.49 Allowed Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -73.5 135.93 44.08 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.491 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -90.2 132.21 35.61 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 120.96 0.41 . . . . 0.0 110.248 -178.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.1 143.74 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.502 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.584 ' HB1' HD11 ' A' ' 103' ' ' LEU . . . -65.55 138.07 57.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.734 0.302 . . . . 0.0 110.52 -179.393 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.2 m -135.18 158.14 40.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.622 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -101.93 129.0 48.09 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.581 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -99.84 120.22 39.41 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.18 179.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 42.4 t -74.62 -15.1 16.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.387 0.539 . . . . 0.0 110.821 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.37 -60.09 2.56 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 120.447 -0.501 . . . . 0.0 109.923 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 74.5 p -96.2 -10.47 28.02 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.78 -12.66 5.99 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -83.21 158.13 22.43 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 120.792 0.33 . . . . 0.0 110.748 -177.622 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.584 HD11 ' HB1' ' A' ' 94' ' ' ALA . 5.2 tt -86.79 130.5 34.45 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.3 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.7 ptt85 -127.81 173.16 10.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.729 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.54 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.41 143.5 37.25 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.164 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.2 m -141.22 164.15 31.04 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.419 HG12 ' N ' ' A' ' 108' ' ' ILE . 98.2 t -98.1 154.91 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.423 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -70.78 157.1 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.875 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.423 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 59.8 ttt85 -101.43 -47.34 4.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.749 179.274 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -164.62 144.43 7.42 Favored 'General case' 0 C--N 1.341 0.197 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.425 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.7 p -93.0 132.34 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.425 HD22 ' C ' ' A' ' 111' ' ' VAL . 2.6 mm? -102.85 148.03 34.96 Favored Pre-proline 0 N--CA 1.469 0.491 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.426 -178.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.71 160.2 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.606 2.204 . . . . 0.0 110.992 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 114' ' ' THR . 1.4 p -65.96 155.01 37.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.061 0.458 . . . . 0.0 110.318 -178.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -147.99 143.69 27.44 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.002 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -71.92 131.01 42.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.964 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.69 168.21 14.58 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.723 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -81.46 149.72 28.63 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.669 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 50.6 p -133.12 144.38 49.89 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.375 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 2.8 m-85 -121.5 177.95 5.01 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.475 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -144.22 149.21 36.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.947 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.408 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.3 mt -138.97 170.14 16.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.616 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -137.29 106.66 6.09 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.926 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.48 ' O ' ' C ' ' A' ' 125' ' ' GLU . 48.9 t -85.72 113.55 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 124' ' ' VAL . 0.3 OUTLIER 21.4 -91.11 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 123.816 0.698 . . . . 0.0 111.771 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 124' ' ' VAL . 9.0 tp10 -135.23 -27.97 1.18 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.658 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.597 HD12 ' HE ' ' A' ' 43' ' ' ARG . 83.0 mt -82.13 67.59 8.21 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.416 ' C ' ' O ' ' A' ' 127' ' ' LEU . 20.6 m170 -39.61 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 170.89 140.89 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.117 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.533 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.1 pt? -151.15 160.88 43.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.69 0.757 . . . . 0.0 112.386 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 25.2 t -90.27 124.65 43.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -135.28 124.72 24.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.941 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.5 mm-40 53.12 42.53 32.19 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.04 28.07 68.24 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.652 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -131.58 152.12 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 97.6 t -106.67 111.06 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 O-C-N 122.11 -0.369 . . . . 0.0 110.308 179.146 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 138' ' ' HIS . 6.5 m -146.14 137.1 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.638 -0.256 . . . . 0.0 110.48 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.584 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 50.4 t-80 -33.57 156.72 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.565 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.436 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 7.7 p-10 . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.363 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.443 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 53.9 m . . . . . 0 N--CA 1.487 1.405 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.2 mt -118.38 134.68 54.85 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.728 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.4 ' HB2' ' CD1' ' A' ' 68' ' ' TRP . . . -80.59 161.7 24.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.503 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.45 145.98 54.53 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.55 -14.38 50.4 Favored Glycine 0 C--N 1.338 0.686 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.442 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.7 m -68.96 123.75 21.87 Favored 'General case' 0 C--O 1.234 0.278 0 O-C-N 122.652 -0.322 . . . . 0.0 110.587 -179.562 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 18' ' ' ARG . 10.6 mpt_? -83.67 150.62 25.75 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.238 0.542 . . . . 0.0 109.857 178.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 99.1 mt -133.89 107.74 10.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.691 179.252 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -77.25 126.57 31.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.1 t0 -104.91 129.76 24.3 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.982 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.79 -31.03 13.54 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.51 2.14 . . . . 0.0 111.989 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 71.1 t -69.13 -55.95 13.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.31 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 p -78.85 -37.58 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 110.059 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.27 7.99 85.92 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.461 HG22 ' N ' ' A' ' 16' ' ' THR . 91.6 m -115.61 157.63 23.88 Favored 'General case' 0 C--N 1.341 0.196 0 O-C-N 121.937 -0.743 . . . . 0.0 109.756 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.461 ' N ' HG22 ' A' ' 15' ' ' THR . 15.2 m -78.91 116.95 19.56 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.05 0.452 . . . . 0.0 110.982 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -102.24 144.16 31.11 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.371 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 7' ' ' ARG . 39.1 ttm180 -96.53 124.07 40.41 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.324 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -52.67 -40.37 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 O-C-N 121.992 -0.443 . . . . 0.0 111.426 -178.433 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 4.0 pt-20 -56.82 -35.23 68.54 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.984 0.421 . . . . 0.0 110.666 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -83.22 -39.44 20.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.125 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.8 t -66.93 -41.73 87.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.563 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.75 HG22 HD21 ' A' ' 122' ' ' LEU . 71.9 t -72.1 -46.29 59.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.513 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -57.87 -36.34 72.21 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 120.948 -0.301 . . . . 0.0 110.866 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.537 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.85 30.13 10.84 Favored Glycine 0 N--CA 1.452 -0.292 0 N-CA-C 110.536 -1.026 . . . . 0.0 110.536 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.537 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtt85 15.79 64.33 0.01 OUTLIER 'General case' 0 C--N 1.364 1.207 0 CA-C-N 117.418 0.609 . . . . 0.0 110.254 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.429 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.0 mttt -89.78 144.2 31.36 Favored Pre-proline 0 N--CA 1.444 -0.732 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.294 -178.074 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.541 ' O ' ' O ' ' A' ' 29' ' ' ILE . 45.7 Cg_endo -70.21 10.11 0.59 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.236 1.957 . . . . 0.0 112.33 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.616 HG22 ' N ' ' A' ' 30' ' ' HIS . 3.7 mm -37.37 168.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 O-C-N 123.718 0.636 . . . . 0.0 110.124 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.616 ' N ' HG22 ' A' ' 29' ' ' ILE . 3.7 m80 -122.68 167.27 13.65 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.953 0.406 . . . . 0.0 110.707 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.9 m -148.63 170.73 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -89.52 134.65 28.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.246 0 O-C-N 121.675 -0.64 . . . . 0.0 109.624 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.48 166.91 10.61 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.785 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.27 144.99 42.99 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.068 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.12 179.0 4.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.642 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.431 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 68.5 mmtt -68.03 -12.57 61.05 Favored 'General case' 0 C--O 1.235 0.322 0 O-C-N 121.821 -0.549 . . . . 0.0 110.767 179.289 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -76.81 -19.41 57.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.346 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.04 -7.57 76.34 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.9 p -80.08 150.21 30.37 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.262 0.553 . . . . 0.0 111.203 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.9 mt -103.77 135.66 44.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.934 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -141.11 139.72 34.03 Favored 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.701 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.36 140.74 52.22 Favored 'General case' 0 CA--C 1.506 -0.736 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.657 -178.175 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.452 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.0 OUTLIER -143.51 137.66 14.73 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.231 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 43' ' ' ARG . 2.9 Cg_exo -74.78 158.27 43.13 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 123.105 2.537 . . . . 0.0 112.711 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 70.3 t -98.29 133.59 39.96 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 177.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.6 m -125.73 0.14 4.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.215 -179.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.416 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -150.16 145.04 26.05 Favored 'General case' 0 N--CA 1.448 -0.563 0 O-C-N 121.026 -1.046 . . . . 0.0 108.676 179.411 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.584 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.06 123.2 13.68 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 178.095 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -140.94 146.73 37.76 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -87.58 133.24 33.83 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.415 ' HB3' HE21 ' A' ' 51' ' ' GLN . 1.8 mm100 -89.79 -0.49 57.58 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.86 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.73 174.28 50.06 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 97.4 m -91.67 127.43 37.12 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.031 0.443 . . . . 0.0 110.354 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -154.92 176.2 12.82 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.715 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 55' ' ' ASP . 0.6 OUTLIER -74.19 136.57 42.81 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.163 -179.539 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.959 ' CG2' ' HE1' ' A' ' 68' ' ' TRP . 1.5 m -145.4 156.59 13.3 Favored 'Isoleucine or valine' 0 C--N 1.34 0.153 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.536 HD13 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -109.14 155.79 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.845 -178.782 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.77 121.07 5.45 Favored Glycine 0 CA--C 1.521 0.455 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 20.7 mt -102.55 116.77 33.28 Favored 'General case' 0 C--O 1.225 -0.219 0 O-C-N 122.381 -0.482 . . . . 0.0 110.133 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.525 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 55.7 ttp180 -101.09 128.58 47.09 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.161 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.613 HG22 ' N ' ' A' ' 62' ' ' ALA . 91.6 mt -117.63 164.22 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.613 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -60.34 139.82 57.44 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.759 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.527 ' H ' ' NH2' ' A' ' 109' ' ' ARG . . . 99.99 -9.29 59.81 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 102.49 -19.3 48.43 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.65 119.95 6.03 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.087 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.1 tt -121.12 138.79 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.82 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 42.6 tp -126.4 112.5 15.71 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.099 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.959 ' HE1' ' CG2' ' A' ' 56' ' ' VAL . 4.3 t-105 -107.71 125.79 51.81 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HB1' ' O ' ' A' ' 1' ' ' CYS . . . -154.85 175.44 13.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.233 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' THR . . . . . 0.736 ' HA ' HG12 ' A' ' 56' ' ' VAL . 71.3 p -77.06 154.0 82.64 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.16 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.12 -22.21 73.97 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.649 2.233 . . . . 0.0 111.889 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -91.07 -6.0 54.41 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.1 t60 -70.96 128.7 36.87 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -85.34 128.42 34.7 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.01 0.433 . . . . 0.0 111.304 -179.125 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -102.8 139.79 22.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.59 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.9 tp -79.37 93.41 5.33 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.955 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.46 HG21 ' HE ' ' A' ' 82' ' ' ARG . 44.7 p -99.22 175.89 5.73 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.278 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.763 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.0 pt-20 -64.94 -17.53 64.46 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.284 -0.567 . . . . 0.0 111.268 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -105.77 25.97 10.18 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 121.125 -0.23 . . . . 0.0 110.811 -178.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.72 -141.13 15.43 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.431 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 87.7 m95 -93.64 129.99 39.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.452 -0.374 . . . . 0.0 111.142 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.46 ' HE ' HG21 ' A' ' 77' ' ' THR . 77.4 mtm180 -142.01 131.78 24.22 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.274 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.76 17.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.024 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.84 -37.67 87.76 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.124 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.1 -2.72 2.97 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.619 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.64 10.87 28.95 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.93 0.395 . . . . 0.0 110.378 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.1 mt -93.51 126.94 38.94 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.378 0.608 . . . . 0.0 111.638 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.589 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.6 mmt180 -132.14 151.63 51.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.469 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -47.88 85.52 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.242 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 160.28 -15.97 0.2 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -84.91 130.32 34.66 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 116.748 0.274 . . . . 0.0 110.304 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -93.37 143.21 26.5 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.275 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.4 m -135.08 158.97 41.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.593 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -75.2 131.62 40.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.635 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 m -129.21 132.88 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -74.13 125.62 28.75 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.927 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -99.7 123.84 44.36 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.182 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 16.1 t -75.39 -16.84 15.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 121.653 -0.654 . . . . 0.0 111.43 178.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -68.97 -59.03 3.33 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 23.1 p -95.43 -11.97 26.72 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.56 -13.2 6.73 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.8 mt-10 -87.15 162.81 17.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.942 0.401 . . . . 0.0 110.639 -177.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.623 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.8 pt? -76.35 140.08 41.28 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -133.18 164.32 27.32 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.763 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.38 137.36 46.48 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.114 -178.373 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -144.04 163.03 34.7 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 107' ' ' VAL . 16.9 m -90.93 154.03 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.605 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -67.94 160.31 4.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.913 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.527 ' NH2' ' H ' ' A' ' 63' ' ' GLY . 37.9 ttm180 -106.87 -51.71 2.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.973 179.304 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.525 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 83.1 tt0 -166.93 147.3 5.67 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.796 -0.565 . . . . 0.0 109.739 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.471 ' C ' HD22 ' A' ' 112' ' ' LEU . 91.8 t -96.77 134.46 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.471 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.1 mm? -101.64 131.27 23.13 Favored Pre-proline 0 CA--C 1.538 0.504 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.555 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.76 158.53 0.74 Allowed 'Trans proline' 0 N--CA 1.489 1.22 0 C-N-CA 121.956 1.771 . . . . 0.0 111.587 178.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.467 ' H ' HG23 ' A' ' 114' ' ' THR . 1.7 p -69.67 157.38 37.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.462 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.6 mtp85 -154.71 161.62 41.46 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.789 0.804 . . . . 0.0 111.11 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 83.7 mtt180 -85.01 130.21 34.66 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.354 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.54 167.38 13.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.164 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 87.0 mtm180 -81.17 149.92 28.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.143 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 1.4 p -127.61 143.32 51.18 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.288 0.566 . . . . 0.0 109.931 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -114.64 171.32 7.71 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.846 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.5 t0 -156.24 128.06 7.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.977 179.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.75 HD21 HG22 ' A' ' 23' ' ' VAL . 94.4 mt -126.0 125.75 43.18 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.751 0.31 . . . . 0.0 110.375 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 tp10 -86.67 112.62 21.81 Favored 'General case' 0 CA--C 1.513 -0.468 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.957 -178.703 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.4 t -85.24 112.41 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.55 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 124' ' ' VAL . 52.8 tt0 24.55 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.47 0 O-C-N 123.7 0.625 . . . . 0.0 111.578 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -130.77 -27.97 2.05 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.161 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 129' ' ' THR . 88.2 mt -77.01 66.9 2.92 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.448 ' O ' HG23 ' A' ' 129' ' ' THR . 47.7 m170 -38.27 95.84 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.62 139.32 0.02 OUTLIER 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.464 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.678 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.3 pp -147.29 155.61 42.19 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.659 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.2 p -88.66 123.19 40.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.016 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -131.58 128.78 39.93 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.75 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.537 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.7 mm-40 53.87 45.79 27.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.037 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.81 -17.68 0.5 Allowed Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.22 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.0 t -90.55 150.41 3.75 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.293 0 O-C-N 122.267 -0.549 . . . . 0.0 110.346 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 66.6 t -109.35 113.63 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.671 0.272 . . . . 0.0 110.423 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 138' ' ' HIS . 34.0 m -149.1 143.85 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.998 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.577 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 47.7 t-80 -27.53 148.86 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.087 0.403 . . . . 0.0 112.087 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.319 -0.751 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.721 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -112.25 136.32 51.82 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.392 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.49 161.03 22.52 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.688 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 -62.82 146.22 53.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.832 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.66 -15.82 37.67 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 m -69.07 121.95 17.74 Favored 'General case' 0 C--O 1.233 0.237 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.653 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -83.87 149.86 26.1 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.851 0.358 . . . . 0.0 110.108 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 94.4 mt -134.7 107.4 8.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.34 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -77.41 129.95 36.45 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.247 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.634 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -103.49 133.2 20.43 Favored Pre-proline 0 CA--C 1.541 0.626 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.594 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.32 -32.64 7.97 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.7 2.267 . . . . 0.0 112.236 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.634 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 68.9 t -69.22 -52.61 31.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.538 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 p -80.88 -37.74 29.26 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.03 9.74 83.85 Favored Glycine 0 C--N 1.331 0.293 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.22 -168.17 1.33 Allowed 'General case' 0 C--N 1.341 0.229 0 CA-C-N 117.725 0.763 . . . . 0.0 109.653 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.9 m -113.98 116.12 28.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.151 0.501 . . . . 0.0 110.283 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -105.27 147.41 28.11 Favored 'General case' 0 C--O 1.223 -0.335 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.413 -179.585 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.2 mmt85 -99.1 127.26 45.02 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.443 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.471 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.4 tt -53.02 -40.61 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.471 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -59.39 -33.83 71.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.672 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.6 t0 -84.35 -39.81 18.65 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.968 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 71.0 t -67.9 -43.01 86.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 65.2 t -73.57 -46.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.908 -0.317 . . . . 0.0 111.647 -178.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -60.43 -35.78 76.62 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.929 0.395 . . . . 0.0 111.013 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -100.25 25.17 29.3 Favored Glycine 0 C--N 1.322 -0.22 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.547 ' C ' ' O ' ' A' ' 25' ' ' GLY . 66.0 mtp180 17.14 59.73 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 25' ' ' GLY . 80.2 mttt -86.94 135.06 35.74 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.754 -177.058 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -75.36 84.89 1.64 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.222 1.948 . . . . 0.0 110.234 178.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.655 ' CG1' ' H ' ' A' ' 30' ' ' HIS . 5.2 tt -115.4 -174.5 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.994 0.426 . . . . 0.0 110.243 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.655 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 46.7 m80 -126.43 161.82 27.02 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.08 171.21 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.435 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.2 t -89.58 133.0 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.12 166.51 11.01 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.695 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.45 145.0 42.58 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.228 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.9 177.94 4.46 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -70.8 -14.0 62.25 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 120.848 0.356 . . . . 0.0 110.637 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' O ' ' OD1' ' A' ' 37' ' ' ASP . 54.5 t0 -80.03 -18.97 48.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.28 179.721 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.56 23.34 34.01 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.8 p -102.31 136.11 42.72 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.854 0.359 . . . . 0.0 111.168 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 81.2 mt -92.5 128.59 38.41 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.017 0.437 . . . . 0.0 110.607 179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 34.5 m-70 -140.01 138.49 35.49 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.772 -179.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.07 142.19 52.7 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.779 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -143.07 138.56 15.86 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.148 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.87 157.28 34.97 Favored 'Trans proline' 0 N--CA 1.489 1.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.822 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -98.99 133.7 40.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 20.0 m -124.98 -0.27 5.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.37 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -151.22 146.75 26.3 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.174 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.575 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.45 127.51 17.47 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 178.254 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -131.22 144.6 51.45 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.97 0.414 . . . . 0.0 111.643 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -116.08 139.62 50.11 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 178.713 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.449 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.3 mm-40 -109.2 -110.82 0.32 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.704 -1.134 . . . . 0.0 109.889 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -162.09 -156.81 8.59 Favored Glycine 0 C--N 1.303 -1.277 0 CA-C-N 114.233 -1.348 . . . . 0.0 112.482 -177.307 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 53' ' ' THR . 4.5 t -98.1 126.75 43.68 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.868 0.366 . . . . 0.0 111.178 -179.104 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -145.74 172.04 13.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.614 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -76.3 136.38 39.6 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.126 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.9 m -140.23 135.88 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.942 0.401 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.676 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.3 pt -87.86 148.79 4.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.717 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.47 126.8 8.35 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.0 mt -108.58 115.84 30.85 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.219 0.533 . . . . 0.0 110.938 -179.275 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -83.03 104.74 13.46 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.881 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 63' ' ' GLY . 6.0 mm -89.93 116.31 31.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.242 -178.263 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.521 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 36.36 28.59 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.726 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 72.36 -27.71 0.7 Allowed Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.74 -106.51 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -178.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.64 170.71 9.93 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.883 0.373 . . . . 0.0 110.382 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.87 155.64 37.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.332 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.0 tp -133.39 118.24 18.2 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.153 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.8 m95 -104.34 114.16 28.21 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -139.45 171.2 14.6 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.484 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.65 157.02 72.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.361 -179.645 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -63.42 -18.13 63.17 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.645 2.23 . . . . 0.0 111.9 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -94.46 -9.99 33.78 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.876 0.37 . . . . 0.0 110.309 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.545 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.8 t60 -71.01 130.77 42.42 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -87.03 130.61 34.39 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.148 0.499 . . . . 0.0 111.144 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.36 142.29 18.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.875 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 52.9 tp -79.91 93.17 5.63 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.691 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 12.1 p -99.02 177.67 5.17 Favored 'General case' 0 CA--C 1.52 -0.19 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -178.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -68.09 -19.15 64.83 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.236 -179.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -104.63 24.1 12.28 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-O 120.733 0.302 . . . . 0.0 110.632 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.69 -176.03 42.56 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 81.2 m95 -57.91 127.76 33.68 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.014 0.435 . . . . 0.0 110.12 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 -142.36 133.54 26.11 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.888 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.44 140.01 29.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.675 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.676 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.15 -37.87 86.83 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.243 -179.287 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.01 -2.42 4.92 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.526 -179.618 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -106.0 -0.65 24.77 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.02 0.438 . . . . 0.0 110.418 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -81.55 127.79 33.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.151 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.548 ' O ' ' N ' ' A' ' 90' ' ' GLY . 8.9 tpp180 -131.01 149.75 52.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.179 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -45.5 89.04 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.644 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.05 -15.72 0.43 Allowed Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -86.39 130.15 34.61 Favored 'General case' 0 CA--C 1.523 -0.085 0 CA-C-O 121.023 0.44 . . . . 0.0 110.381 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -90.73 131.3 36.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.37 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 26.8 m -116.93 150.35 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.227 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.39 136.09 47.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.004 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.559 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.1 m -133.85 161.77 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.33 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 67.9 ttt-85 -104.67 128.37 52.7 Favored 'General case' 0 N--CA 1.462 0.14 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -100.92 123.49 45.2 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.082 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.401 ' H ' HG22 ' A' ' 98' ' ' VAL . 28.1 m -75.9 -15.4 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 118.179 0.445 . . . . 0.0 110.906 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -69.59 -58.45 3.93 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.06 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.437 HG23 ' H ' ' A' ' 102' ' ' GLU . 1.5 t -97.87 -12.4 22.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.269 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.35 -12.84 8.85 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.437 ' H ' HG23 ' A' ' 100' ' ' THR . 43.2 mt-10 -83.25 159.44 21.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.79 0.329 . . . . 0.0 110.749 -178.062 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.589 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -84.02 140.06 32.11 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.231 0.538 . . . . 0.0 109.934 179.642 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 59.4 mtp180 -137.07 171.91 13.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.218 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.8 m-30 -105.56 139.14 40.63 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.954 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.559 ' OG ' HG21 ' A' ' 95' ' ' VAL . 7.9 m -135.96 155.31 50.45 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.125 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 108' ' ' ILE . 9.7 p -95.2 157.21 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 122.573 0.349 . . . . 0.0 111.116 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.406 ' N ' HG22 ' A' ' 107' ' ' VAL . 42.7 mm -82.18 136.68 22.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.003 178.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.1 mmt85 -84.88 -38.44 19.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.694 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -169.45 151.85 4.61 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.459 ' C ' HD22 ' A' ' 112' ' ' LEU . 84.6 t -95.31 132.08 40.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.113 0.483 . . . . 0.0 110.176 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.459 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.0 mm? -100.37 131.48 23.91 Favored Pre-proline 0 N--CA 1.467 0.394 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.61 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.37 154.63 2.5 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.129 1.886 . . . . 0.0 111.662 178.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 57' ' ' ILE . 1.3 p -68.39 158.88 32.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.022 0.439 . . . . 0.0 110.518 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -151.46 149.12 28.89 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.047 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 57.0 mtm180 -78.33 132.58 37.49 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.197 0.522 . . . . 0.0 110.354 179.466 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.75 158.13 12.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.43 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -67.16 142.59 56.98 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 71.4 p -124.25 141.34 52.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.206 0.527 . . . . 0.0 109.899 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -116.67 174.84 5.86 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.82 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -152.63 128.96 10.56 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 82.2 mt -116.1 170.79 8.24 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.667 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -137.88 107.74 6.3 Favored 'General case' 0 CA--C 1.516 -0.346 0 C-N-CA 120.604 -0.439 . . . . 0.0 110.576 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.43 116.81 31.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 127' ' ' LEU . 38.8 tt0 -58.39 149.88 23.69 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.757 -179.207 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 61.64 -69.13 0.05 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.254 -0.885 . . . . 0.0 112.159 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -98.0 95.06 7.21 Favored 'General case' 0 CA--C 1.519 -0.23 0 O-C-N 122.285 -0.259 . . . . 0.0 110.413 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.614 ' O ' HG23 ' A' ' 129' ' ' THR . 75.5 m80 -67.04 99.84 0.69 Allowed 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.614 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.55 144.62 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.937 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.573 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.68 154.45 42.79 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 121.635 0.731 . . . . 0.0 111.788 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.76 127.25 41.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 179.253 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.93 129.74 36.74 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.401 -179.076 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 51.73 46.78 26.0 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.033 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.14 -21.01 0.39 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 8.1 t -90.4 152.42 3.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.172 0 O-C-N 122.27 -0.547 . . . . 0.0 110.588 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -106.53 114.64 46.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.358 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 10.1 m -147.15 136.16 15.99 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.467 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 21.7 t-80 -38.54 162.91 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.833 0.349 . . . . 0.0 111.621 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 12.6 p30 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.271 -179.838 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.572 ' HB3' HE22 ' A' ' 51' ' ' GLN . 5.5 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -118.02 134.56 54.86 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 120.89 0.376 . . . . 0.0 110.391 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -86.38 163.61 17.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.396 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.409 ' OE2' ' CD ' ' A' ' 20' ' ' GLU . 57.7 tt0 -63.02 142.16 58.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.506 178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.85 -21.09 30.43 Favored Glycine 0 C--N 1.334 0.458 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.8 m -66.04 123.48 19.96 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.01 148.88 28.41 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.838 0.352 . . . . 0.0 110.068 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.52 107.31 8.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -77.4 125.19 28.94 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.625 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 4.7 t70 -101.99 132.79 21.19 Favored Pre-proline 0 CA--C 1.538 0.501 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.846 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.95 -31.61 7.94 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.619 2.213 . . . . 0.0 112.166 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.625 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 66.2 t -71.47 -54.47 17.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.694 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.9 p -77.32 -38.94 49.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.961 0.41 . . . . 0.0 110.171 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.31 4.62 87.91 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.474 HG22 ' N ' ' A' ' 16' ' ' THR . 55.5 m -114.18 157.63 22.39 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 117.435 0.617 . . . . 0.0 109.85 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.474 ' N ' HG22 ' A' ' 15' ' ' THR . 40.2 m -78.47 116.65 19.01 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.28 0.562 . . . . 0.0 110.794 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' HIS . . . . . 0.541 ' CD2' HD11 ' A' ' 29' ' ' ILE . 87.0 m-70 -103.1 146.7 27.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.452 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -98.52 128.12 44.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.971 179.197 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.6 tp -52.2 -40.87 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.613 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.535 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.4 tt0 -57.56 -36.16 71.31 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.976 0.417 . . . . 0.0 110.852 -179.486 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.519 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 49.4 t0 -81.73 -35.7 29.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.47 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -67.32 -42.17 87.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.642 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.567 HG21 ' HB3' ' A' ' 120' ' ' PHE . 48.5 t -74.11 -46.79 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -177.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 0.6 OUTLIER -56.05 -37.57 69.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.824 -177.869 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.07 32.17 7.63 Favored Glycine 0 C--O 1.227 -0.287 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.6 ptm180 12.45 65.72 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.005 0 CA-C-O 121.189 0.518 . . . . 0.0 110.307 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.402 ' N ' ' O ' ' A' ' 25' ' ' GLY . 78.2 mttt -85.88 141.55 35.84 Favored Pre-proline 0 N--CA 1.447 -0.579 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.811 -177.724 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.548 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.4 Cg_endo -71.3 7.62 1.4 Allowed 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.23 1.953 . . . . 0.0 112.224 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' PRO . 12.8 tt -38.05 169.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 O-C-N 123.505 0.503 . . . . 0.0 110.597 -178.308 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.521 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 2.2 m80 -120.16 170.61 9.16 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.341 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.08 172.76 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.9 t -88.16 135.03 26.5 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.53 167.53 10.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.845 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.6 140.41 40.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.855 0.359 . . . . 0.0 110.373 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.23 179.06 4.06 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.564 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -68.44 -16.06 63.77 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-O 120.754 0.312 . . . . 0.0 110.764 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -74.8 -19.56 60.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.618 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.22 -11.89 69.84 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.0 p -74.8 148.74 40.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.141 0.496 . . . . 0.0 110.961 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 56.6 mt -104.78 135.09 46.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.802 -179.381 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -141.13 138.63 33.62 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.625 -179.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -68.7 143.0 54.86 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.759 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.467 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.3 mmp_? -143.83 138.26 15.01 Favored Pre-proline 0 CA--C 1.538 0.483 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.829 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 160.06 37.42 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 123.058 2.505 . . . . 0.0 112.754 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.88 136.92 34.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.045 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.2 m -128.26 3.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.877 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 m -148.43 142.5 25.96 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.889 0.768 . . . . 0.0 109.239 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -144.09 123.26 12.93 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 178.554 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -143.91 149.13 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.822 0.675 . . . . 0.0 112.822 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -96.51 131.85 42.7 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.355 -0.979 . . . . 0.0 108.355 176.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.657 HE21 ' C ' ' A' ' 119' ' ' THR . 1.9 mt-30 -95.41 4.29 53.48 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.655 -0.248 . . . . 0.0 111.075 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.11 -172.09 47.11 Favored Glycine 0 C--N 1.336 0.576 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.821 179.15 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.463 ' OG1' ' CZ ' ' A' ' 118' ' ' ARG . 67.8 m -86.82 127.44 35.01 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 120.76 0.314 . . . . 0.0 110.308 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -148.18 159.6 43.78 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.605 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.0 143.24 43.67 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.873 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.01 147.11 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.117 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.513 HD13 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -100.86 148.13 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.944 -179.693 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.98 135.5 12.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -119.24 114.96 23.22 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.254 0.549 . . . . 0.0 110.346 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.2 tpt180 -95.95 116.81 29.5 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.776 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.9 mp -104.18 129.83 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-O 120.987 0.422 . . . . 0.0 111.009 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 39.93 23.25 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.561 -178.862 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 71.02 -23.81 0.55 Allowed Glycine 0 CA--C 1.53 1.002 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -46.85 -103.73 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 -178.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.63 173.93 7.53 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.084 0.469 . . . . 0.0 110.516 -179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.5 tt -126.18 158.21 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.681 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.1 tp -138.61 121.73 16.85 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.429 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.1 m95 -106.06 128.96 54.21 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.96 172.39 16.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.411 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' THR . . . . . 0.434 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -82.65 155.98 68.21 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.793 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.31 -24.0 75.61 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.706 2.271 . . . . 0.0 111.918 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -87.6 -7.38 57.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.181 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -73.81 128.65 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -87.88 133.99 33.79 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.134 0.492 . . . . 0.0 111.034 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -105.44 140.44 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.061 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.614 HD23 ' CZ2' ' A' ' 81' ' ' TRP . 0.6 OUTLIER -83.39 95.29 8.18 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.176 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.454 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 50.1 p -98.72 179.37 4.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.493 -179.112 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.447 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 17.6 pt-20 -65.26 -17.61 64.64 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.303 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' TYR . . . . . 0.447 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 50.2 m-85 -107.32 25.48 11.37 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.193 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.47 -139.2 14.32 Favored Glycine 0 C--N 1.335 0.482 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.716 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.614 ' CZ2' HD23 ' A' ' 76' ' ' LEU . 97.5 m95 -94.47 130.13 40.96 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.329 -0.436 . . . . 0.0 111.784 -179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -138.13 125.92 22.41 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ALA . . . . . 0.64 ' HB3' ' OE1' ' A' ' 86' ' ' GLU . . . -53.95 140.81 29.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.95 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.447 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -59.97 -40.7 89.99 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 121.023 -0.271 . . . . 0.0 111.616 -178.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.21 -1.72 0.78 Allowed Glycine 0 CA--C 1.524 0.626 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.075 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.64 ' OE1' ' HB3' ' A' ' 83' ' ' ALA . 57.4 mp0 -118.94 36.75 4.33 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.026 0.441 . . . . 0.0 110.612 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.4 mt -110.73 124.95 52.95 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.955 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.7 mmt180 -131.87 145.65 51.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.567 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -40.94 90.63 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 121.01 0.433 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.12 -13.71 0.38 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -89.99 127.75 36.11 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 120.974 0.416 . . . . 0.0 110.358 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -92.21 133.6 35.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.599 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.4 m -114.57 149.24 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.63 128.46 36.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.918 0.39 . . . . 0.0 110.997 -179.297 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.7 m -130.8 161.74 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.348 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.512 ' NH2' HG11 ' A' ' 131' ' ' VAL . 25.8 ttm180 -110.29 132.9 53.77 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.57 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -100.98 126.11 47.61 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.251 178.673 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 85.3 t -74.96 -15.44 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 O-C-N 121.891 -0.506 . . . . 0.0 111.367 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -70.01 -57.41 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.145 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.1 m -100.51 -14.4 18.26 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.501 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.16 -11.93 14.5 Favored Glycine 0 C--N 1.331 0.261 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.528 ' OE1' ' NH2' ' A' ' 104' ' ' ARG . 95.4 mt-10 -79.14 156.05 28.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 0.0 110.897 -178.144 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.17 132.52 35.36 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 121.605 0.716 . . . . 0.0 110.038 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.528 ' NH2' ' OE1' ' A' ' 102' ' ' GLU . 35.9 mmt180 -132.28 -179.54 5.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.342 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.454 ' OH ' ' C ' ' A' ' 77' ' ' THR . 4.1 m-85 -118.63 147.28 43.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.681 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 28.6 m -138.57 159.0 43.19 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.6 p -89.55 153.09 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.726 0.298 . . . . 0.0 110.72 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.431 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.8 mm -72.64 156.78 6.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.179 0.514 . . . . 0.0 109.963 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.431 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 2.5 tpm_? -106.69 -47.37 3.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.106 179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -166.56 145.56 5.57 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.562 ' C ' HD22 ' A' ' 112' ' ' LEU . 21.3 t -95.63 133.77 35.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.929 0.395 . . . . 0.0 110.072 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.755 ' N ' HD22 ' A' ' 112' ' ' LEU . 2.7 mm? -102.06 148.21 35.04 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.357 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.99 158.52 57.01 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 122.496 2.131 . . . . 0.0 111.549 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.449 ' H ' HG23 ' A' ' 114' ' ' THR . 2.0 p -68.49 158.2 34.3 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.009 0.433 . . . . 0.0 110.66 -179.36 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.402 ' CG ' ' N ' ' A' ' 116' ' ' ARG . 45.2 ttp180 -153.55 153.86 33.18 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.507 179.501 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.402 ' N ' ' CG ' ' A' ' 115' ' ' ARG . 18.5 mmm180 -77.31 125.71 29.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.506 179.768 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -162.89 159.18 23.45 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.701 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.463 ' CZ ' ' OG1' ' A' ' 53' ' ' THR . 11.0 mpt_? -76.26 149.11 37.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.815 179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.657 ' C ' HE21 ' A' ' 51' ' ' GLN . 62.1 p -132.03 145.77 51.65 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.588 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 63.8 m-85 -114.74 173.06 6.66 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.627 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -143.37 130.7 20.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.459 HD21 HG22 ' A' ' 23' ' ' VAL . 87.9 mt -123.69 170.91 10.01 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.417 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -135.32 106.49 6.72 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.085 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 17.4 t -85.42 109.55 18.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.28 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 41.4 tp10 21.86 -108.13 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.9 0.75 . . . . 0.0 111.359 179.556 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -114.41 -26.68 7.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.039 179.526 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 129' ' ' THR . 91.4 mt -84.52 68.53 10.34 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' OG1' ' A' ' 129' ' ' THR . 5.1 m-70 -41.94 99.94 0.02 OUTLIER 'General case' 0 CA--C 1.507 -0.683 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.486 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.435 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.32 137.26 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.248 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.637 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.2 pp -145.34 150.6 36.9 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.157 0.504 . . . . 0.0 111.237 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.512 HG11 ' NH2' ' A' ' 96' ' ' ARG . 5.4 p -87.55 127.9 40.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.351 -0.841 . . . . 0.0 108.935 -179.127 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.4 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.9 124.86 27.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.734 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.502 ' O ' HG23 ' A' ' 135' ' ' VAL . 76.2 mm-40 59.21 44.63 15.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.287 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.0 -19.49 0.75 Allowed Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.6 t -88.76 150.78 3.61 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 117.033 0.416 . . . . 0.0 110.622 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 48.6 t -106.43 113.56 43.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.31 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 138' ' ' HIS . 15.0 m -148.37 140.87 18.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.548 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 60.6 t-80 -32.37 155.6 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.429 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 23.2 p30 . . . . . 0 C--N 1.324 -0.523 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.45 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.469 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 28.2 m . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -111.46 139.12 47.15 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.832 0.349 . . . . 0.0 110.193 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.91 162.45 16.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -60.5 143.11 54.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.489 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.14 -16.12 32.82 Favored Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.579 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.3 m -71.8 122.58 20.94 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.707 -0.29 . . . . 0.0 111.014 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.6 mtt85 -82.04 148.49 28.58 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 120.781 0.324 . . . . 0.0 110.247 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -135.62 108.21 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.289 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -79.72 129.66 34.67 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.413 ' O ' ' N ' ' A' ' 14' ' ' GLY . 55.3 t0 -109.94 113.41 57.23 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.813 -0.176 . . . . 0.0 110.755 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.11 -36.93 78.68 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.625 2.217 . . . . 0.0 112.082 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.4 HG21 ' CG ' ' A' ' 30' ' ' HIS . 49.1 t -61.8 -57.8 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.613 -178.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 p -78.27 -37.96 43.76 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.179 0.514 . . . . 0.0 110.126 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 85.16 5.71 85.35 Favored Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 16' ' ' THR . 96.5 m -114.33 157.29 23.0 Favored 'General case' 0 C--N 1.346 0.449 0 CA-C-N 117.658 0.729 . . . . 0.0 109.837 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 15' ' ' THR . 26.0 m -79.67 119.66 22.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.35 0.595 . . . . 0.0 110.61 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 19.9 m-70 -103.31 145.34 30.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.385 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 29.0 ttm-85 -96.92 124.37 40.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.03 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.6 tp -51.75 -44.14 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.724 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.617 ' N ' HG23 ' A' ' 19' ' ' ILE . 10.8 pt-20 -57.98 -34.9 70.47 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.131 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -82.25 -37.56 25.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.326 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 67.7 t -66.92 -43.24 89.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.517 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.3 t -72.5 -47.23 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -57.18 -38.11 73.15 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.146 -178.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.08 29.52 12.34 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.548 ' C ' ' O ' ' A' ' 25' ' ' GLY . 90.7 mtm180 15.78 62.5 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 O-C-N 124.037 0.492 . . . . 0.0 110.045 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.2 mttt -87.64 126.13 62.85 Favored Pre-proline 0 N--CA 1.44 -0.97 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.944 -177.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -75.23 93.43 0.97 Allowed 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.469 2.113 . . . . 0.0 110.316 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.3 pt -121.21 -170.16 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.87 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.4 ' CG ' HG21 ' A' ' 12' ' ' VAL . 38.0 m80 -125.97 164.49 20.7 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.1 m -150.65 173.68 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.447 HG11 HH21 ' A' ' 96' ' ' ARG . 5.2 t -86.55 125.28 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.17 150.85 25.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.626 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.22 144.12 49.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.411 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.26 178.26 4.39 Favored 'General case' 0 N--CA 1.472 0.664 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.8 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp -68.45 -15.25 63.48 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.693 0.283 . . . . 0.0 110.396 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -78.43 -20.3 51.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.083 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.45 -9.67 71.56 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.5 p -73.1 139.01 46.17 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.363 0.601 . . . . 0.0 111.297 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.616 HD13 ' NH2' ' A' ' 96' ' ' ARG . 50.6 mt -95.7 135.33 37.54 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.558 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -145.98 141.48 27.75 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.39 147.54 44.2 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.663 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.512 ' HD2' HD12 ' A' ' 127' ' ' LEU . 6.5 mtp180 -152.81 148.98 21.15 Favored Pre-proline 0 N--CA 1.457 -0.124 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.231 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.6 149.55 61.71 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.557 2.172 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.7 t -112.87 146.53 17.44 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.847 0 CA-C-O 121.502 0.668 . . . . 0.0 109.312 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.705 ' O ' ' CE2' ' A' ' 48' ' ' TRP . 2.1 m -139.49 -100.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.61 ' H ' HG23 ' A' ' 46' ' ' VAL . 9.3 t -19.0 113.84 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 114.164 -1.38 . . . . 0.0 111.542 -175.525 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.705 ' CE2' ' O ' ' A' ' 46' ' ' VAL . 1.5 m-90 -120.3 110.89 17.1 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.7 m-85 -138.43 147.02 42.86 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.304 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' A' ' 50' ' ' ASP . 46.4 p-10 -91.65 134.98 34.22 Favored 'General case' 0 C--N 1.334 -0.069 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.465 ' CD ' ' SG ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -92.67 -4.83 52.6 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.715 -0.22 . . . . 0.0 111.219 179.638 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 -179.11 48.68 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 79.9 m -94.24 122.66 37.01 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.8 mtp85 -146.54 171.38 15.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.435 0.636 . . . . 0.0 110.656 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -74.42 139.63 44.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.219 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -139.36 153.3 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.651 HD11 ' HB1' ' A' ' 84' ' ' ALA . 14.4 pt -108.88 155.83 9.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.183 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.03 128.73 8.71 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 28.4 mt -108.94 115.3 29.82 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.205 0.526 . . . . 0.0 110.413 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.6 tpp180 -85.81 109.29 18.57 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.055 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' A' ' 63' ' ' GLY . 12.8 mm -97.47 125.76 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.615 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 33.73 29.16 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.815 0.697 . . . . 0.0 110.852 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 65.03 -22.62 0.11 Allowed Glycine 0 CA--C 1.532 1.139 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.615 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.76 -104.22 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.46 171.39 9.07 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.949 0.404 . . . . 0.0 110.462 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.4 tt -124.94 153.47 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.357 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 43.9 tp -132.75 118.72 19.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.337 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -105.8 118.21 36.01 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.96 170.97 15.12 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.534 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 37.6 p -79.5 153.56 76.24 Favored Pre-proline 0 N--CA 1.45 -0.432 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.128 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.78 -30.25 88.6 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 122.534 2.156 . . . . 0.0 112.146 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -80.97 -9.46 59.84 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.428 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.7 t60 -70.46 129.04 38.2 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -86.75 131.61 34.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.399 0.619 . . . . 0.0 111.154 -179.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -103.62 139.21 25.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.783 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 58.7 tp -78.35 91.95 4.51 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.856 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.9 p -97.38 -179.34 4.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -178.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -69.87 -16.41 63.24 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.196 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -106.27 26.31 9.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.933 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.88 -138.54 13.97 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -95.67 130.61 42.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.537 -0.331 . . . . 0.0 111.138 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ARG . . . . . 0.511 ' NH1' ' OD1' ' A' ' 91' ' ' ASP . 84.0 mtp180 -140.56 129.89 23.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.246 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.38 145.29 18.42 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.011 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.651 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.48 -40.14 95.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 121.249 -0.18 . . . . 0.0 111.473 -179.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.3 -3.46 3.89 Favored Glycine 0 C--N 1.337 0.614 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.757 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -113.24 32.73 5.54 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.732 0.301 . . . . 0.0 110.56 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.9 mt -112.7 126.81 55.8 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 121.38 0.61 . . . . 0.0 111.226 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 37.5 mmt180 -130.89 147.19 52.51 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.884 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -42.66 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.876 0.369 . . . . 0.0 110.741 -179.516 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.25 -12.68 0.43 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.511 ' OD1' ' NH1' ' A' ' 82' ' ' ARG . 17.8 t70 -87.85 128.57 35.35 Favored 'General case' 0 C--O 1.227 -0.102 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -89.84 131.74 35.62 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.393 -179.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -118.32 150.91 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.121 -0.49 . . . . 0.0 109.797 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -66.76 134.98 53.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.955 0.407 . . . . 0.0 111.015 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 104' ' ' ARG . 21.4 m -134.22 159.68 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.013 179.077 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.616 ' NH2' HD13 ' A' ' 40' ' ' LEU . 52.6 ttm-85 -107.02 130.24 54.68 Favored 'General case' 0 C--N 1.334 -0.098 0 CA-C-O 120.677 0.275 . . . . 0.0 110.333 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.36 122.9 43.86 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.365 178.7 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 62.3 t -76.28 -16.19 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 118.133 0.424 . . . . 0.0 110.749 179.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 99' ' ' GLU . 0.5 OUTLIER -72.02 -57.26 4.44 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.849 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.449 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.3 p -94.45 -13.81 25.83 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.13 -14.76 3.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.449 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.5 mt-10 -83.56 163.53 20.34 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 120.981 0.42 . . . . 0.0 110.764 -177.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.47 HD21 ' HB1' ' A' ' 94' ' ' ALA . 4.6 tt -80.51 136.88 36.38 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.431 ' O ' HG22 ' A' ' 95' ' ' VAL . 45.9 mtp85 -134.42 168.81 18.25 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.099 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -110.87 140.6 45.2 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.672 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.416 ' OG ' HG21 ' A' ' 95' ' ' VAL . 23.3 m -136.49 155.39 50.05 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.409 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 108' ' ' ILE . 58.1 t -91.33 156.68 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.008 0.432 . . . . 0.0 110.555 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.485 ' N ' HG12 ' A' ' 107' ' ' VAL . 3.5 mm -72.66 153.13 7.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.237 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -106.0 -45.93 4.23 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.454 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -166.05 145.36 6.08 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.457 ' C ' HD22 ' A' ' 112' ' ' LEU . 83.5 t -96.46 132.88 39.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.137 0.494 . . . . 0.0 110.163 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.484 ' N ' HD22 ' A' ' 112' ' ' LEU . 4.1 mm? -98.57 128.73 32.0 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.288 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.63 157.99 2.11 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 122.384 2.056 . . . . 0.0 111.743 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.436 HG23 ' H ' ' A' ' 114' ' ' THR . 1.2 p -66.94 156.93 34.56 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.49 0.662 . . . . 0.0 110.685 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -139.04 -140.1 0.14 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.915 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 80.7 mtm180 -153.66 132.6 12.46 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.902 0.382 . . . . 0.0 110.115 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.7 173.67 3.86 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.651 -179.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 -83.51 154.27 23.96 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.144 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -132.64 143.47 49.69 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.95 174.83 5.7 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.483 -0.78 . . . . 0.0 111.5 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -148.03 128.79 14.26 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.164 -179.572 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.2 mt -132.15 123.39 27.0 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.852 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -87.51 115.67 25.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.144 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 125' ' ' GLU . 98.5 t -85.48 114.09 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 127' ' ' LEU . 39.7 tp10 -28.2 111.92 0.06 Allowed 'General case' 0 N--CA 1.466 0.367 0 O-C-N 123.574 0.546 . . . . 0.0 111.762 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 60.49 -65.87 0.05 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 178.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.512 HD12 ' HD2' ' A' ' 43' ' ' ARG . 86.0 mt -72.76 75.17 1.13 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.041 0.448 . . . . 0.0 111.005 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.629 ' O ' HG23 ' A' ' 129' ' ' THR . 31.5 m170 -56.01 98.96 0.03 OUTLIER 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.629 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.45 143.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 O-C-N 123.712 0.632 . . . . 0.0 109.439 178.936 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.723 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.8 pp -149.23 154.1 38.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.542 0.687 . . . . 0.0 111.446 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.513 ' N ' HD12 ' A' ' 130' ' ' LEU . 85.6 t -90.01 123.69 42.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.033 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.649 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.08 129.16 37.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -178.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.551 ' O ' HG23 ' A' ' 135' ' ' VAL . 70.2 mm-40 58.77 43.23 18.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.897 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.76 -20.89 0.48 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.9 t -89.18 151.13 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-O 120.943 0.402 . . . . 0.0 110.821 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.403 HG21 HD11 ' A' ' 103' ' ' LEU . 2.5 t -104.69 112.78 39.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.548 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 11.5 m -148.3 138.65 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 CA-C-O 118.988 -0.529 . . . . 0.0 110.29 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.537 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 14.4 t-80 -28.41 147.63 0.0 OUTLIER 'General case' 0 C--N 1.342 0.259 0 O-C-N 123.571 0.544 . . . . 0.0 111.956 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.428 ' OD1' ' NE2' ' A' ' 138' ' ' HIS . 26.8 p30 . . . . . 0 C--N 1.321 -0.673 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.895 -179.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -91.45 139.01 31.13 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.839 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.52 161.7 28.95 Favored 'General case' 0 CA--C 1.529 0.135 0 CA-C-O 120.978 0.418 . . . . 0.0 111.262 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 77.5 tt0 -66.62 143.27 57.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.826 178.93 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.97 -18.85 33.58 Favored Glycine 0 C--N 1.336 0.561 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.512 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 26.9 m -66.05 124.97 24.01 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.48 ' HE ' ' CD ' ' A' ' 18' ' ' ARG . 1.6 mpt_? -97.25 116.39 29.36 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 121.014 0.435 . . . . 0.0 110.214 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.47 HD11 HD13 ' A' ' 19' ' ' ILE . 15.4 mt -100.41 113.06 34.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.209 179.844 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -75.47 133.93 40.96 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.379 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.07 129.97 26.02 Favored Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 121.145 -0.222 . . . . 0.0 110.678 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.72 -27.47 18.2 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.91 1.74 . . . . 0.0 112.277 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 42.7 t -76.42 -53.81 14.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.19 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.9 p -76.94 -35.88 56.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.983 0.42 . . . . 0.0 110.251 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.64 10.5 85.13 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 54.8 m -115.56 160.42 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 117.564 0.682 . . . . 0.0 109.694 -179.689 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 12.5 m -79.54 115.0 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.194 0.521 . . . . 0.0 110.911 -179.229 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -101.3 143.46 31.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.866 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.48 ' CD ' ' HE ' ' A' ' 7' ' ' ARG . 69.3 mtm180 -99.65 128.38 45.75 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.753 -0.203 . . . . 0.0 110.574 178.247 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.1 tp -53.1 -38.42 29.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.561 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.509 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.3 pt-20 -58.17 -35.34 71.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.318 0.58 . . . . 0.0 110.969 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -85.18 -38.38 19.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.63 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 94.2 t -69.04 -42.39 81.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.838 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.56 HG22 HD21 ' A' ' 122' ' ' LEU . 75.2 t -75.36 -45.89 39.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.833 -178.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -57.67 -34.5 69.45 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.681 -178.332 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.577 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.25 29.31 9.3 Favored Glycine 0 CA--C 1.519 0.298 0 CA-C-O 119.108 -0.829 . . . . 0.0 111.033 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.577 ' C ' ' O ' ' A' ' 25' ' ' GLY . 44.6 ptt85 13.62 64.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.45 0.643 . . . . 0.0 110.054 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 25' ' ' GLY . 81.6 mttt -84.86 139.49 37.36 Favored Pre-proline 0 N--CA 1.449 -0.503 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.369 -176.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.9 83.27 2.14 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.352 1.368 . . . . 0.0 110.164 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.563 ' C ' HD12 ' A' ' 29' ' ' ILE . 1.9 pp -116.27 -174.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.811 0.338 . . . . 0.0 110.486 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.422 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 34.7 m80 -128.65 161.95 28.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.511 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.9 m -146.96 170.47 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.97 134.98 26.56 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.358 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -107.78 166.55 10.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.534 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.2 137.59 39.29 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.914 0.387 . . . . 0.0 110.23 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -112.28 175.42 5.44 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -73.02 -13.34 61.2 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.865 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -78.32 -11.44 59.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.429 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.46 17.37 64.38 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.2 p -100.81 139.34 36.64 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.024 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.9 mt -98.54 131.61 44.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.655 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -139.52 138.3 36.21 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.965 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.87 142.7 52.99 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.465 -0.494 . . . . 0.0 109.959 -178.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.526 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.7 mmt180 -145.04 138.6 14.36 Favored Pre-proline 0 N--CA 1.468 0.461 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.297 -179.156 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.12 157.2 33.96 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 122.555 2.17 . . . . 0.0 112.424 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -98.84 138.17 24.14 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 177.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.99 2.66 3.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.183 -178.471 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 m -146.97 133.99 20.33 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 120.038 -0.665 . . . . 0.0 110.006 179.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.508 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.77 121.71 18.85 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.003 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -138.14 143.59 40.39 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.644 ' O ' ' HG2' ' A' ' 51' ' ' GLN . 29.3 t70 -88.42 125.77 34.89 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.644 ' HG2' ' O ' ' A' ' 50' ' ' ASP . 8.2 mt-30 -160.86 60.08 0.31 Allowed 'General case' 0 CA--C 1.498 -1.042 0 O-C-N 124.158 0.911 . . . . 0.0 108.55 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.818 ' CA ' ' H ' ' A' ' 119' ' ' THR . . . -118.62 167.06 12.98 Favored Glycine 0 C--N 1.314 -0.684 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.398 -178.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.562 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 33.3 m 113.99 63.53 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 O-C-N 125.436 1.315 . . . . 0.0 111.261 177.788 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.6 mtt-85 -148.78 175.72 10.99 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.634 0.254 . . . . 0.0 110.794 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -77.47 139.56 39.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.481 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.61 151.81 19.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.525 HD13 ' N ' ' A' ' 57' ' ' ILE . 0.0 OUTLIER -103.41 144.77 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 109.963 179.934 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.93 134.7 12.15 Favored Glycine 0 N--CA 1.462 0.39 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 71.6 mt -116.78 116.34 27.3 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-O 121.064 0.459 . . . . 0.0 110.313 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.449 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.1 tpt180 -84.75 107.73 17.09 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.103 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.754 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.6 mp -93.86 133.49 34.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 179.007 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.622 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 24.11 31.43 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.743 0.652 . . . . 0.0 112.756 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.696 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 65.81 -23.92 0.14 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.622 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.4 -107.47 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -178.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.71 170.24 10.3 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.811 0.338 . . . . 0.0 110.503 -179.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.412 HG22 ' N ' ' A' ' 67' ' ' LEU . 95.0 mt -124.7 154.72 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.123 179.689 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.412 ' N ' HG22 ' A' ' 66' ' ' ILE . 61.9 tp -128.79 114.73 16.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.814 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -103.83 109.96 21.9 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -134.2 172.32 13.02 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.198 -179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.14 156.8 69.13 Favored Pre-proline 0 CA--C 1.535 0.401 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.435 179.487 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -63.15 -17.72 61.5 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.734 2.29 . . . . 0.0 112.169 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 49.3 p-10 -97.62 -6.67 32.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.992 0.425 . . . . 0.0 110.185 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.4 t60 -71.85 129.68 39.21 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -83.57 124.07 30.4 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.375 0.607 . . . . 0.0 111.631 -179.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 73.5 t -98.14 138.35 23.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.058 -0.973 . . . . 0.0 109.889 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 37.9 tp -81.67 95.64 7.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.036 -179.524 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 p -100.28 175.87 5.57 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -67.67 -18.14 64.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.459 -178.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -105.97 21.07 17.93 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.647 0.26 . . . . 0.0 110.642 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.89 -144.63 15.88 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -91.95 126.54 37.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.527 0.204 . . . . 0.0 110.97 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -127.83 126.75 42.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.79 136.9 54.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.949 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.591 ' HA ' HD12 ' A' ' 87' ' ' LEU . . . -69.78 -0.88 7.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.683 179.666 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.71 -13.78 77.22 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.618 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -132.22 15.44 4.61 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.758 0.313 . . . . 0.0 111.46 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 84' ' ' ALA . 20.5 mt -80.32 141.41 35.47 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.233 0.54 . . . . 0.0 110.877 179.374 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.0 tpp85 -142.08 155.21 45.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.014 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -48.51 113.86 0.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.334 179.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 141.77 -22.33 2.5 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -83.09 130.56 35.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.706 0.289 . . . . 0.0 110.766 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -88.84 136.62 32.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.128 0.49 . . . . 0.0 110.795 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.0 m -122.02 144.05 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.5 -179.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.52 131.53 42.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.912 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.4 m -127.06 163.11 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.98 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -100.5 128.14 46.65 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.671 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -100.54 124.28 45.88 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 98' ' ' VAL . 89.8 t -75.63 -15.81 15.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 118.24 0.473 . . . . 0.0 110.909 178.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 37.7 tp10 -69.35 -58.66 3.72 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.097 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 70.3 p -99.73 -12.18 20.2 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.772 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.32 -13.87 9.78 Favored Glycine 0 C--N 1.332 0.312 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.6 mt-10 -82.05 153.84 25.93 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.953 0.406 . . . . 0.0 111.622 -177.423 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.586 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.16 139.92 36.59 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 179.479 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.419 ' O ' HG22 ' A' ' 95' ' ' VAL . 53.0 ptt85 -142.64 138.47 30.7 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.702 -179.292 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.9 m-30 -78.28 147.8 34.16 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.38 -0.528 . . . . 0.0 109.998 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -139.34 162.68 34.43 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.7 t -95.32 154.29 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 61.6 mt -73.54 154.61 6.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.0 ttm180 -104.75 -42.72 5.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.16 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -167.23 147.82 5.53 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 112' ' ' LEU . 23.1 t -92.81 130.85 41.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.6 mp -98.99 124.93 43.69 Favored Pre-proline 0 CA--C 1.543 0.709 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.973 -179.519 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -48.45 162.73 0.31 Allowed 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.228 1.952 . . . . 0.0 111.998 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.1 p -73.02 160.44 32.07 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.28 0.562 . . . . 0.0 110.823 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.434 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 10.0 tpt180 -144.89 -132.47 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.195 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.434 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 1.5 tmm_? -155.39 134.83 12.47 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.983 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 170.77 4.27 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.072 -178.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 84.2 mtm-85 -83.87 140.36 32.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.843 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' THR . . . . . 0.818 ' H ' ' CA ' ' A' ' 52' ' ' GLY . 4.2 p -128.39 148.78 50.72 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.559 177.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -122.75 179.76 4.51 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.971 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -147.64 124.83 11.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.368 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.56 HD21 HG22 ' A' ' 23' ' ' VAL . 95.6 mt -115.84 173.08 6.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.444 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -136.38 105.36 5.92 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.241 178.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 125' ' ' GLU . 16.4 t -83.56 108.64 16.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.0 tt0 20.37 -89.14 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.639 0.587 . . . . 0.0 112.322 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 124' ' ' VAL . 81.6 mt-10 -129.27 -39.94 1.49 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.392 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.526 HD12 ' HE ' ' A' ' 43' ' ' ARG . 84.3 mt -71.04 64.86 0.35 Allowed 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.183 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.438 ' O ' HG23 ' A' ' 129' ' ' THR . 39.3 m80 -41.78 94.82 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 179.351 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.515 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 171.63 141.28 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.189 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.681 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.0 pp -147.79 155.96 42.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.425 0.631 . . . . 0.0 111.885 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -89.12 126.78 42.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.18 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.582 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.512 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.23 132.62 39.9 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.219 -179.099 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.583 ' O ' HG23 ' A' ' 135' ' ' VAL . 68.8 mm-40 50.64 46.23 25.95 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.156 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.99 23.26 56.82 Favored Glycine 0 CA--C 1.522 0.523 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.802 178.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -129.75 153.69 39.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.436 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -105.32 111.9 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 O-C-N 121.944 -0.473 . . . . 0.0 110.611 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 26.8 m -147.38 139.33 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 55.6 t-80 -31.25 151.53 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.201 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.264 -179.635 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.647 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 6.2 m . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 80.5 mt -123.22 132.69 54.13 Favored 'General case' 0 C--N 1.34 0.189 0 CA-C-O 121.182 0.515 . . . . 0.0 110.72 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.09 162.26 24.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.39 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.76 146.52 52.25 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.45 -17.34 40.13 Favored Glycine 0 C--N 1.34 0.754 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.477 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.7 m -67.03 124.76 23.95 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.08 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.543 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.1 mtp180 -83.98 149.35 26.35 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.238 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 75.2 mt -134.6 107.42 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.81 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -77.0 127.22 32.3 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 14' ' ' GLY . 61.6 t0 -107.32 111.44 63.17 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.07 -37.3 68.24 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 122.508 2.139 . . . . 0.0 111.969 178.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -61.21 -58.41 7.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.518 -179.098 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 30.5 p -74.88 -33.07 62.01 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.181 0.515 . . . . 0.0 109.788 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 80.47 7.74 88.24 Favored Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.479 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -110.87 -163.82 0.88 Allowed 'General case' 0 C--N 1.347 0.471 0 CA-C-N 117.727 0.764 . . . . 0.0 109.507 -179.248 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.543 HG21 ' HE ' ' A' ' 7' ' ' ARG . 87.4 m -114.71 115.7 27.49 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.516 0.674 . . . . 0.0 110.511 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -100.18 141.72 32.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.206 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -97.65 125.99 42.72 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.969 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -52.92 -41.01 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.217 -179.333 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.562 ' N ' HG23 ' A' ' 19' ' ' ILE . 2.8 pt-20 -55.31 -35.23 64.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.355 0.598 . . . . 0.0 110.646 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 50.9 t0 -83.1 -36.18 25.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.972 . . . . 0.0 111.62 -178.33 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 54.1 t -66.65 -43.83 90.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.408 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 72.2 t -69.52 -46.11 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.721 -179.279 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -56.04 -36.9 68.53 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 120.946 -0.302 . . . . 0.0 110.596 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.558 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.71 32.64 6.09 Favored Glycine 0 C--O 1.228 -0.257 0 CA-C-O 118.222 -1.321 . . . . 0.0 110.563 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.558 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.0 ptt-85 10.37 72.55 0.01 OUTLIER 'General case' 0 C--N 1.367 1.341 0 O-C-N 124.437 0.728 . . . . 0.0 110.004 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.406 ' C ' ' H ' ' A' ' 29' ' ' ILE . 74.1 mttt -90.06 144.71 31.7 Favored Pre-proline 0 N--CA 1.443 -0.791 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.716 -177.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.561 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.2 Cg_endo -71.77 9.83 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.581 2.187 . . . . 0.0 112.464 179.517 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.561 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.1 pp -38.19 171.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 124.087 0.867 . . . . 0.0 110.374 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.557 ' N ' ' ND1' ' A' ' 30' ' ' HIS . 1.2 m80 -123.05 166.74 14.62 Favored 'General case' 0 CA--C 1.509 -0.622 0 O-C-N 122.103 -0.373 . . . . 0.0 111.057 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -150.42 173.96 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.385 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 3.8 t -87.3 132.51 32.46 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.152 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -102.38 166.93 10.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.79 137.08 36.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.074 0.464 . . . . 0.0 110.315 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.5 177.46 4.64 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -72.76 -14.73 61.6 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.615 0.245 . . . . 0.0 110.677 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -78.98 -14.66 59.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.7 20.46 56.1 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.6 p -100.82 135.29 42.49 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 120.76 0.314 . . . . 0.0 110.691 178.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 53.2 mt -99.78 137.63 37.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.561 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -147.72 143.56 27.67 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.795 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.86 145.01 48.86 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.641 ' HE ' HD12 ' A' ' 127' ' ' LEU . 86.6 mtt-85 -153.25 142.44 14.67 Favored Pre-proline 0 CA--C 1.54 0.587 0 O-C-N 123.813 0.696 . . . . 0.0 111.097 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.36 160.0 39.46 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 123.094 2.529 . . . . 0.0 113.267 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -97.89 135.76 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 177.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.3 m -122.24 -1.33 7.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 118.803 -0.618 . . . . 0.0 111.167 -178.705 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.8 p -148.79 141.33 24.35 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 119.203 0.91 . . . . 0.0 108.717 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.509 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.23 121.32 12.93 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.047 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -142.1 148.23 38.03 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -99.74 135.06 41.73 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.026 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.815 HE22 ' C ' ' A' ' 120' ' ' PHE . 4.8 mt-30 -97.75 4.56 49.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 119.412 -0.327 . . . . 0.0 111.53 178.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.05 -169.73 42.49 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 98.0 m -88.26 128.33 35.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.397 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.5 mtt-85 -147.17 161.59 40.6 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.544 -179.575 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -77.18 142.8 39.46 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.489 179.368 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.8 m -141.12 160.27 22.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.528 HD11 ' CB ' ' A' ' 84' ' ' ALA . 43.8 pt -111.89 147.29 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.257 179.491 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.59 137.53 13.32 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.409 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 43.6 mt -120.63 111.99 18.34 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.403 0.62 . . . . 0.0 110.276 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.524 ' C ' HD12 ' A' ' 61' ' ' ILE . 14.4 tpt180 -87.21 109.24 19.34 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.189 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -98.99 132.61 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.079 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.636 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 32.19 28.42 0.0 OUTLIER 'General case' 0 C--N 1.343 0.303 0 O-C-N 124.052 0.845 . . . . 0.0 111.0 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 64.43 -25.88 0.1 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 -178.393 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.636 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -47.53 -104.91 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 -178.293 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.22 171.93 9.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 120.747 0.308 . . . . 0.0 110.376 -179.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.2 tt -125.21 154.75 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.346 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 54.1 tp -130.97 116.82 18.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -104.4 115.17 29.9 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.73 172.69 12.35 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.261 -179.227 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.34 156.28 78.79 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.689 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.29 -21.44 72.63 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 122.794 2.33 . . . . 0.0 111.931 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -92.95 -4.69 52.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.28 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.647 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.7 t60 -72.02 129.98 39.86 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 48.9 mttp -86.86 127.58 35.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 121.51 0.672 . . . . 0.0 110.493 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 93.8 t -105.16 91.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.602 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 15.3 tp -31.01 95.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 O-C-N 123.924 0.765 . . . . 0.0 111.123 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.446 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -98.92 176.93 5.42 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 -177.973 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.478 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 12.8 pt-20 -63.85 -18.35 64.06 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.291 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.73 24.3 13.13 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.432 0.158 . . . . 0.0 110.965 -179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.81 -141.37 15.26 Favored Glycine 0 C--N 1.321 -0.253 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.519 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -94.05 127.24 39.74 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.633 -0.283 . . . . 0.0 111.264 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -137.61 129.04 28.08 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.25 141.39 29.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.807 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.528 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -60.11 -38.58 83.41 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.164 -179.206 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.27 -3.2 4.86 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.678 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -105.49 0.46 26.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.923 0.392 . . . . 0.0 110.179 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 93.3 mt -80.95 127.63 32.78 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.554 0.693 . . . . 0.0 111.245 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.583 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.6 mmt85 -131.64 149.26 52.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.788 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -44.57 86.33 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 123.465 0.478 . . . . 0.0 110.845 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 158.08 -15.85 0.29 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -85.39 130.1 34.67 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 117.209 0.505 . . . . 0.0 110.394 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.478 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 90.1 mtm180 -88.94 131.17 35.26 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.408 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.7 m -114.42 142.69 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.459 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -67.1 131.52 45.98 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.72 -179.141 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.36 160.72 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.408 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.534 ' NH1' ' O ' ' A' ' 101' ' ' GLY . 9.0 tpt180 -104.6 129.63 52.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.59 -179.592 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 42.1 t0 -101.33 123.67 45.78 Favored 'General case' 0 C--O 1.22 -0.49 0 CA-C-O 118.996 -0.526 . . . . 0.0 110.468 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 61.4 t -77.21 -16.72 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 118.474 0.579 . . . . 0.0 111.12 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -69.65 -58.43 3.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.45 ' C ' ' H ' ' A' ' 102' ' ' GLU . 80.8 p -95.86 -12.65 24.88 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.303 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.534 ' O ' ' NH1' ' A' ' 96' ' ' ARG . . . 76.13 -16.05 4.88 Favored Glycine 0 C--O 1.223 -0.583 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.555 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.45 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.2 mt-10 -80.78 158.05 25.59 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.614 0.245 . . . . 0.0 110.606 -177.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.572 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -86.68 141.12 29.16 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.359 0.6 . . . . 0.0 110.059 179.77 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.45 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 37.6 ptt180 -139.81 178.65 7.09 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.214 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.446 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.8 m-85 -113.31 147.74 37.03 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.801 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -139.63 160.17 40.48 Favored 'General case' 0 C--O 1.222 -0.366 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.004 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.6 m -90.63 153.02 3.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-O 121.015 0.436 . . . . 0.0 110.842 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.41 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.6 mm -70.31 155.39 7.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.094 179.297 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.41 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt180 -106.01 -48.31 3.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.704 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -166.07 145.74 6.19 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.78 134.38 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 mt -102.68 145.22 30.15 Favored Pre-proline 0 N--CA 1.466 0.358 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.367 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -67.16 164.06 31.75 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.408 2.072 . . . . 0.0 111.534 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.467 HG22 HG22 ' A' ' 57' ' ' ILE . 81.3 p -67.03 156.42 36.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 121.388 0.613 . . . . 0.0 110.873 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 79.3 mtp180 -139.98 -137.35 0.12 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.757 -179.689 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -158.04 131.31 7.58 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.079 0.466 . . . . 0.0 110.254 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.79 173.26 3.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.13 -179.07 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.3 mtp85 -78.39 145.48 35.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 2.9 p -119.5 141.08 49.51 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.155 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.815 ' C ' HE22 ' A' ' 51' ' ' GLN . 57.2 m-85 -118.5 168.55 10.56 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.199 -179.372 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -157.79 120.33 3.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.989 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 67.1 mt -118.04 129.52 55.62 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -87.5 109.63 19.75 Favored 'General case' 0 CA--C 1.516 -0.338 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.463 HG21 ' O ' ' A' ' 129' ' ' THR . 21.6 t -83.0 113.09 21.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.97 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.7 tt0 29.96 -98.38 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 O-C-N 123.775 0.672 . . . . 0.0 111.1 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -123.62 -25.92 4.26 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.271 179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.641 HD12 ' HE ' ' A' ' 43' ' ' ARG . 96.4 mt -84.85 94.55 8.76 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.62 ' C ' HG22 ' A' ' 129' ' ' THR . 29.7 m170 -60.6 98.24 0.06 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.62 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.1 154.77 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.941 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.608 ' N ' HD23 ' A' ' 130' ' ' LEU . 1.2 pt? -162.83 161.49 26.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.796 0.808 . . . . 0.0 112.369 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 136' ' ' VAL . 9.3 t -86.2 126.15 40.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.42 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.477 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.88 123.78 25.32 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.757 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.602 ' O ' HG23 ' A' ' 135' ' ' VAL . 77.8 mm-40 54.29 44.66 28.68 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.682 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.0 28.1 69.88 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.2 t -132.67 151.3 34.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 CA-C-N 118.155 0.977 . . . . 0.0 108.681 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 131' ' ' VAL . 89.9 t -108.9 112.34 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 118.232 0.469 . . . . 0.0 110.239 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 138' ' ' HIS . 29.4 m -146.63 136.72 17.51 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-O 119.086 -0.483 . . . . 0.0 110.021 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 37.4 t-80 -31.54 152.08 0.0 OUTLIER 'General case' 0 C--O 1.223 -0.295 0 O-C-N 123.577 0.548 . . . . 0.0 111.36 179.597 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.521 ' OD1' ' CE1' ' A' ' 138' ' ' HIS . 49.2 p30 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.74 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -101.16 143.72 30.91 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.365 -179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -88.18 162.41 16.71 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.637 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.431 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 59.8 tt0 -60.37 142.69 54.54 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 120.786 0.327 . . . . 0.0 110.466 178.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 115.98 -21.66 12.08 Favored Glycine 0 C--N 1.333 0.376 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.577 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 23.0 m -69.01 120.03 14.24 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.11 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.508 ' NE ' HG21 ' A' ' 16' ' ' THR . 74.7 mtp85 -95.15 112.63 24.31 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.91 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.6 mt -99.17 113.29 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.621 -179.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -76.48 137.79 39.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 10.2 t0 -106.31 132.64 20.73 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 121.25 -0.18 . . . . 0.0 110.622 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.03 -30.88 10.36 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.187 1.925 . . . . 0.0 112.433 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.533 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 24.9 t -72.98 -53.89 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.868 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.8 p -77.64 -36.79 51.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.136 0.493 . . . . 0.0 110.159 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 6.9 89.01 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.447 HG22 ' N ' ' A' ' 16' ' ' THR . 48.1 m -111.55 156.53 21.6 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.769 0.785 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.508 HG21 ' NE ' ' A' ' 7' ' ' ARG . 27.0 m -80.49 116.77 20.71 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.146 0.498 . . . . 0.0 110.976 -179.154 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -107.32 150.29 26.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.302 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -101.43 132.74 46.86 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.914 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.8 tp -52.69 -40.21 33.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.764 0.316 . . . . 0.0 111.077 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.548 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.9 tt0 -58.51 -36.25 73.51 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.191 0.519 . . . . 0.0 110.483 -179.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -82.18 -38.36 24.76 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.615 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -69.51 -43.76 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.589 HG22 HD21 ' A' ' 122' ' ' LEU . 72.5 t -73.82 -46.73 46.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.9 t0 -60.85 -36.4 79.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.019 0.437 . . . . 0.0 110.813 -178.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.36 24.55 31.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtm180 17.22 62.73 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 79.2 mttt -86.57 131.96 44.11 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.869 -176.438 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -75.07 87.21 1.35 Allowed 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.491 1.461 . . . . 0.0 110.41 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 29' ' ' ILE . 30.1 pt -120.67 -172.01 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.917 0.389 . . . . 0.0 110.491 -179.234 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.43 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 16.5 m80 -127.21 162.88 25.13 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.747 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.46 171.24 2.44 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.237 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.01 136.33 23.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -115.27 164.33 14.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.67 -0.241 . . . . 0.0 110.414 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.97 50.42 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.36 177.66 4.55 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -72.74 -16.33 61.66 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 122.101 -0.375 . . . . 0.0 111.105 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -78.71 -16.46 57.22 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.336 179.288 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 22.85 40.45 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.49 ' C ' HD22 ' A' ' 40' ' ' LEU . 33.1 p -102.11 133.84 46.31 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.676 0.274 . . . . 0.0 111.052 178.13 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.776 ' N ' HD22 ' A' ' 40' ' ' LEU . 2.2 mm? -94.57 133.05 38.63 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 121.069 0.461 . . . . 0.0 111.128 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -143.66 139.87 29.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.569 -179.173 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.2 144.86 49.99 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.969 -178.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HE ' ' HB3' ' A' ' 125' ' ' GLU . 15.7 mtp85 -147.81 138.91 13.36 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.181 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -74.94 158.1 42.64 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.7 2.267 . . . . 0.0 112.831 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.9 t -93.82 131.85 39.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.0 t -119.24 -3.1 9.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.387 -177.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' SER . . . . . 0.442 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.3 OUTLIER -155.06 149.01 25.7 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.612 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.571 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -144.84 131.02 19.48 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.701 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -134.64 144.56 47.92 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.379 0.609 . . . . 0.0 111.899 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.414 ' OD1' ' N ' ' A' ' 51' ' ' GLN . 58.1 t0 -112.76 139.21 48.57 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.224 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.448 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.8 mm-40 -105.15 -106.46 0.3 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.328 -1.305 . . . . 0.0 108.854 -178.473 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.448 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -167.24 -156.1 9.59 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 114.457 -1.247 . . . . 0.0 112.354 -177.26 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.457 HG22 ' HG3' ' A' ' 116' ' ' ARG . 0.5 OUTLIER -94.58 119.56 33.45 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.077 0.465 . . . . 0.0 111.2 -179.264 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -138.31 164.66 28.7 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.51 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -76.98 140.9 40.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.12 159.61 26.1 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.164 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.596 HD11 ' HB1' ' A' ' 84' ' ' ALA . 32.7 pt -112.58 151.26 14.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.966 0.412 . . . . 0.0 109.991 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.16 131.68 10.76 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 32.2 mt -113.16 113.19 25.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 0.0 110.044 -179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.467 ' C ' HD12 ' A' ' 61' ' ' ILE . 12.6 tpt180 -87.75 107.06 18.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.355 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.742 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -96.69 127.79 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.929 -179.475 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.578 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 35.02 27.2 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.072 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.546 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 68.22 -26.31 0.26 Allowed Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.578 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -47.51 -104.78 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -178.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.95 171.82 9.02 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.105 0.479 . . . . 0.0 110.726 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.448 HD13 ' HE1' ' A' ' 68' ' ' TRP . 19.1 tt -125.38 152.06 31.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.34 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 68' ' ' TRP . 2.2 tt -127.63 114.91 17.98 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.496 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.57 ' N ' HD23 ' A' ' 67' ' ' LEU . 81.3 m95 -102.93 120.04 39.92 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.85 171.09 18.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.158 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 20.4 p -76.91 154.71 83.04 Favored Pre-proline 0 CA--C 1.531 0.232 0 C-N-CA 120.584 -0.447 . . . . 0.0 111.227 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 -24.09 70.8 Favored 'Trans proline' 0 N--CA 1.499 1.849 0 C-N-CA 122.096 1.864 . . . . 0.0 112.211 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -84.75 -8.64 58.76 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.853 0.359 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.573 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.2 t60 -72.8 132.66 43.86 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -90.44 131.73 36.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.183 0.516 . . . . 0.0 110.348 -178.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.726 ' O ' HG23 ' A' ' 77' ' ' THR . 92.5 t -107.37 89.59 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.117 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 55.7 tp -29.12 97.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.508 0.505 . . . . 0.0 111.717 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.726 HG23 ' O ' ' A' ' 75' ' ' VAL . 38.5 p -98.68 177.21 5.37 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.531 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.548 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.8 pt-20 -66.45 -17.56 64.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.341 -179.75 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.07 22.22 16.25 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.745 0.307 . . . . 0.0 111.117 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.76 -141.09 15.34 Favored Glycine 0 N--CA 1.462 0.431 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.0 m95 -97.38 130.91 44.47 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.724 -0.238 . . . . 0.0 110.924 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.8 mtp85 -139.7 131.12 26.9 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.43 144.73 20.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.084 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.596 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -63.11 -38.88 92.93 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.576 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.7 -1.75 2.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.622 -0.799 . . . . 0.0 111.428 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.408 ' H ' ' C ' ' A' ' 84' ' ' ALA . 72.3 mm-40 -107.49 -2.99 19.9 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.941 0.4 . . . . 0.0 110.184 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 85.7 mt -76.88 125.59 29.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.917 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.558 ' O ' ' N ' ' A' ' 90' ' ' GLY . 7.1 tpt180 -132.1 148.42 52.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.501 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -43.34 88.83 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.932 0.396 . . . . 0.0 110.693 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.97 -16.57 0.45 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -87.21 129.79 34.82 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.728 0.299 . . . . 0.0 110.771 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 87.1 mtm180 -90.19 131.06 36.23 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 121.083 0.468 . . . . 0.0 110.586 -178.617 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.15 143.32 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.391 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.13 131.78 49.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 104' ' ' ARG . 25.8 m -129.57 157.81 42.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.368 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 71.7 ttt180 -106.98 130.28 54.65 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.458 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.53 121.9 42.34 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.373 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 57.6 t -75.01 -15.44 15.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 O-C-N 122.081 -0.387 . . . . 0.0 110.648 178.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -70.75 -58.03 4.06 Favored 'General case' 0 C--O 1.232 0.154 0 C-N-CA 120.485 -0.486 . . . . 0.0 109.927 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.442 ' C ' ' H ' ' A' ' 102' ' ' GLU . 45.9 p -96.79 -12.56 23.48 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 116.751 -0.204 . . . . 0.0 110.562 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.53 -13.72 6.17 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.4 mt-10 -81.74 157.1 24.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.972 0.415 . . . . 0.0 111.078 -177.794 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.629 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -78.48 140.4 38.61 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 179.393 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.451 ' O ' HG22 ' A' ' 95' ' ' VAL . 52.5 mtm180 -139.55 174.51 10.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.809 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.47 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.9 m-85 -115.3 146.09 41.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.222 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.44 ' OG ' HG21 ' A' ' 95' ' ' VAL . 14.8 m -139.78 161.44 37.54 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.033 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.3 t -94.35 154.75 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.667 0.27 . . . . 0.0 110.467 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 97.0 mt -76.38 149.96 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 178.735 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 74.1 ttt-85 -99.16 -41.77 7.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.613 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -165.74 146.81 6.97 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.444 ' C ' HD12 ' A' ' 112' ' ' LEU . 71.9 t -97.63 134.43 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -98.67 148.78 35.02 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.074 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.79 162.03 44.03 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.796 2.331 . . . . 0.0 111.436 179.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 114' ' ' THR . 2.9 p -62.49 149.38 43.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.981 0.419 . . . . 0.0 110.742 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttt85 -132.3 -141.24 0.21 Allowed 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.663 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ARG . . . . . 0.457 ' HG3' HG22 ' A' ' 53' ' ' THR . 12.8 tpt180 -157.06 129.98 7.71 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.322 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.19 170.5 5.16 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.087 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -75.57 149.29 38.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.868 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 59.2 p -128.78 142.7 50.9 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.069 0.461 . . . . 0.0 109.764 179.287 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 9.2 m-85 -120.85 176.4 5.56 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.897 -178.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -148.76 153.54 38.31 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.855 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.589 HD21 HG22 ' A' ' 23' ' ' VAL . 90.8 mt -140.18 171.14 14.59 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.681 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -135.17 106.11 6.61 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' C ' ' A' ' 125' ' ' GLU . 7.9 t -86.89 111.74 22.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.498 ' C ' ' O ' ' A' ' 124' ' ' VAL . 5.2 tp10 20.79 -116.57 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 O-C-N 123.657 0.598 . . . . 0.0 111.685 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -106.74 -26.14 11.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.277 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.9 mt -89.21 69.84 8.26 Favored 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.498 ' O ' HG23 ' A' ' 129' ' ' THR . 28.9 m170 -42.92 104.88 0.04 OUTLIER 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.498 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.4 139.59 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.675 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.569 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.3 pt? -147.14 156.73 43.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 121.509 0.671 . . . . 0.0 112.122 179.542 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 131' ' ' VAL . 9.0 p -89.02 125.35 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.577 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.8 126.59 30.9 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.947 -179.011 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.503 ' C ' ' H ' ' A' ' 135' ' ' VAL . 15.4 mm-40 53.81 46.78 25.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.982 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.33 -22.06 0.51 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.503 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.1 t -89.01 152.56 3.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 117.121 0.461 . . . . 0.0 110.66 -179.411 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -110.44 115.55 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.416 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 138' ' ' HIS . 12.3 m -147.31 137.69 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.528 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.573 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 53.1 t-80 -36.52 156.79 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.529 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 16.1 p30 . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.468 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.5 mt -105.12 141.49 36.58 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-O 120.938 0.399 . . . . 0.0 110.543 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -84.35 161.42 20.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.463 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 63.8 tt0 -61.68 146.03 50.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.381 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.57 -16.4 40.81 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.633 HG23 ' HG3' ' A' ' 133' ' ' GLU . 26.3 m -68.47 124.16 22.81 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.789 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.472 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.0 mtp180 -85.03 149.82 25.31 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.162 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 56.2 mt -134.13 108.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.271 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.413 ' HB3' HH22 ' A' ' 96' ' ' ARG . 43.9 t80 -76.94 126.7 31.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 178.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -96.06 131.2 29.37 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.094 -179.335 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.05 -33.17 4.73 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.33 2.02 . . . . 0.0 111.8 179.02 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 73.6 t -73.31 -54.27 16.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.64 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.5 m -75.17 -38.09 61.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.163 0.506 . . . . 0.0 110.065 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.23 7.36 85.18 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.059 -0.816 . . . . 0.0 111.059 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 16' ' ' THR . 3.0 t -106.9 -167.22 1.25 Allowed 'General case' 0 C--N 1.338 0.09 0 CA-C-N 117.652 0.726 . . . . 0.0 109.895 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.472 HG21 ' HE ' ' A' ' 7' ' ' ARG . 93.3 m -115.0 115.28 26.6 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.547 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -100.68 140.75 34.51 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.744 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.7 tpp85 -97.27 127.2 43.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.538 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.671 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -51.57 -40.3 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.771 -178.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.541 ' N ' HG23 ' A' ' 19' ' ' ILE . 14.3 tt0 -53.74 -35.29 61.06 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.961 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.72 -34.13 40.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.695 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.662 ' O ' ' O ' ' A' ' 26' ' ' ARG . 85.1 t -64.83 -45.61 94.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.807 0.337 . . . . 0.0 111.122 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 120' ' ' PHE . 87.9 t -66.54 -45.16 89.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 O-C-N 121.186 -0.946 . . . . 0.0 111.951 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -55.41 -42.41 74.04 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.741 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.75 33.49 3.72 Favored Glycine 0 CA--C 1.529 0.95 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.662 ' O ' ' O ' ' A' ' 22' ' ' VAL . 82.4 mtp180 58.14 -100.58 0.11 Allowed 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.216 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.638 ' C ' ' H ' ' A' ' 29' ' ' ILE . 40.7 mttt 79.94 82.65 0.09 OUTLIER Pre-proline 0 C--N 1.299 -1.604 0 C-N-CA 122.898 0.479 . . . . 0.0 110.388 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.7 ' O ' ' O ' ' A' ' 29' ' ' ILE . 34.1 Cg_exo -59.52 19.76 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.745 2.297 . . . . 0.0 112.577 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.7 ' O ' ' O ' ' A' ' 28' ' ' PRO . 20.3 pt -35.41 -178.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 O-C-N 124.041 0.838 . . . . 0.0 111.189 -178.258 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.426 ' CG ' HG21 ' A' ' 12' ' ' VAL . 56.6 m80 -119.78 163.33 17.63 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 121.43 -0.794 . . . . 0.0 110.891 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.1 171.33 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.9 t -91.03 135.13 27.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.47 168.09 9.81 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.82 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.06 142.67 46.39 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.216 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.39 177.93 4.48 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.785 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -70.54 -13.9 62.29 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.92 0.39 . . . . 0.0 110.656 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -81.34 -18.53 45.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.279 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.9 24.91 36.28 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.6 p -103.11 135.18 45.25 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.7 0.286 . . . . 0.0 111.203 178.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 65.4 mt -92.59 131.24 37.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.654 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 8.2 t-160 -142.82 139.82 31.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.483 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.55 141.95 51.82 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.794 -178.51 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.1 mmp_? -143.85 138.21 14.95 Favored Pre-proline 0 CA--C 1.535 0.398 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.8 158.81 31.46 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.86 2.373 . . . . 0.0 112.727 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.32 135.42 36.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.243 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.9 m -124.9 1.05 5.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.543 -178.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.9 t -144.34 133.68 23.16 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.548 0.613 . . . . 0.0 109.792 179.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.531 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -132.68 117.26 17.65 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 178.106 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -141.24 146.55 37.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -89.2 132.83 34.67 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 176.642 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.434 HE21 ' HA ' ' A' ' 51' ' ' GLN . 0.0 OUTLIER -92.17 -0.64 57.42 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.186 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.36 -179.6 51.66 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.31 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.8 m -91.74 126.6 36.89 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 120.945 0.402 . . . . 0.0 110.39 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 78.1 mtp85 -150.25 170.48 18.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.798 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -75.45 141.83 43.07 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.041 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -142.44 156.46 18.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.466 ' CG2' HG22 ' A' ' 114' ' ' THR . 37.7 pt -110.75 154.4 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.978 0.418 . . . . 0.0 110.258 179.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.84 132.73 11.26 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 21.0 mt -115.26 114.29 25.0 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.104 0.478 . . . . 0.0 110.222 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -99.19 122.75 42.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.968 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 63' ' ' GLY . 94.4 mt -111.37 143.56 20.98 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.633 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 29.04 30.62 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 O-C-N 123.831 0.707 . . . . 0.0 111.517 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.629 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 64.1 -20.26 0.09 OUTLIER Glycine 0 CA--C 1.533 1.184 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.672 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.633 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.38 -109.13 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -178.094 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.28 172.89 8.11 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.994 0.426 . . . . 0.0 110.553 -178.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ILE . . . . . 0.508 HG22 ' N ' ' A' ' 67' ' ' LEU . 97.1 mt -125.89 158.64 34.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.524 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.508 ' N ' HG22 ' A' ' 66' ' ' ILE . 42.5 tp -132.68 117.43 17.85 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.582 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -102.79 115.74 31.19 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.13 171.74 14.86 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.368 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 75.9 p -77.09 152.52 82.19 Favored Pre-proline 0 C--N 1.327 -0.394 0 C-N-CA 120.457 -0.497 . . . . 0.0 111.35 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.19 -28.8 81.01 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 122.214 1.943 . . . . 0.0 112.336 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -83.21 -5.66 59.2 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.899 0.38 . . . . 0.0 110.563 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.9 t60 -71.64 130.02 40.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.43 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.422 ' H ' ' HD2' ' A' ' 74' ' ' LYS . 0.0 OUTLIER -85.64 127.26 34.43 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.236 0.541 . . . . 0.0 110.737 -179.464 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.5 t -109.6 93.75 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.619 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.117 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.448 HD13 ' CH2' ' A' ' 81' ' ' TRP . 6.4 tp -31.42 93.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.677 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 75' ' ' VAL . 0.9 OUTLIER -97.25 177.86 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -178.236 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.2 pt-20 -64.68 -22.84 67.07 Favored 'General case' 0 N--CA 1.448 -0.573 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.262 -179.012 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -104.59 26.39 9.11 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 121.235 -0.186 . . . . 0.0 110.99 -179.388 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.18 -177.88 43.01 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.448 ' CH2' HD13 ' A' ' 76' ' ' LEU . 83.1 m95 -57.01 130.74 47.38 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.977 0.418 . . . . 0.0 110.335 -177.284 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -146.38 135.26 22.42 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.78 144.5 14.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.917 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.462 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -64.25 -38.76 92.21 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.488 -179.014 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.51 1.02 0.52 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.449 -0.881 . . . . 0.0 111.76 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.462 ' H ' ' C ' ' A' ' 84' ' ' ALA . 19.9 tp10 -107.66 5.43 26.83 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.159 0.504 . . . . 0.0 110.049 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.29 123.19 29.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.226 0.536 . . . . 0.0 111.018 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 90' ' ' GLY . 33.1 mmt180 -132.47 149.76 52.28 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.803 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -48.02 87.89 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.977 0.418 . . . . 0.0 110.657 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -20.0 0.44 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.911 -0.875 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -84.18 129.48 34.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.83 0.348 . . . . 0.0 110.582 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.411 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 88.2 mtm180 -90.68 132.38 35.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.142 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 m -119.93 152.14 22.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.823 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -68.69 137.36 54.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.491 -179.422 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.436 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.0 m -137.19 162.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.465 178.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.709 HH21 HG11 ' A' ' 131' ' ' VAL . 12.2 ttm180 -106.58 129.45 54.51 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.535 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 101' ' ' GLY . 45.9 t0 -100.97 123.77 45.67 Favored 'General case' 0 C--O 1.224 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.426 178.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -74.24 -15.73 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 118.184 0.447 . . . . 0.0 111.12 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -72.45 -55.18 7.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.01 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.2 m -99.44 -16.27 18.43 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.735 -0.211 . . . . 0.0 110.632 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 97' ' ' ASP . . . 73.84 -14.32 3.67 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.3 mt-10 -80.71 160.4 24.97 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-O 120.781 0.324 . . . . 0.0 110.64 -177.651 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.442 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.5 tp -79.03 126.59 30.9 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.027 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.408 ' O ' HG22 ' A' ' 95' ' ' VAL . 65.8 mtp85 -126.81 168.17 14.8 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.956 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -110.32 142.72 41.58 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.5 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' SER . . . . . 0.436 ' OG ' HG21 ' A' ' 95' ' ' VAL . 12.7 m -137.94 158.44 44.33 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.85 152.82 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.737 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.43 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.9 mm -67.46 156.7 6.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.844 179.502 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.43 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 17.2 tpt180 -108.39 -52.33 2.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.01 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -165.56 144.47 6.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 70.0 t -95.09 133.29 36.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.087 0.47 . . . . 0.0 110.037 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.62 127.02 32.39 Favored Pre-proline 0 CA--C 1.536 0.432 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.518 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -47.88 161.64 0.33 Allowed 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 122.206 1.937 . . . . 0.0 112.021 179.274 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.466 HG22 ' CG2' ' A' ' 57' ' ' ILE . 80.6 p -64.99 153.82 39.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.0 0.429 . . . . 0.0 110.699 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.8 ttp180 -134.98 -140.8 0.17 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.586 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.8 mtm-85 -156.79 130.44 8.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.11 172.82 3.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.979 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 22.6 mmt85 -77.51 147.03 36.03 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.971 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 18.5 p -125.13 142.9 51.21 Favored 'General case' 0 CA--C 1.52 -0.181 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' PHE . . . . . 0.925 ' CD1' HG21 ' A' ' 23' ' ' VAL . 75.6 m-85 -118.93 175.54 5.71 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.821 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -153.47 120.51 5.74 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.553 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.671 HD11 HD12 ' A' ' 19' ' ' ILE . 75.1 mt -120.03 123.95 44.7 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -87.58 118.41 27.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.209 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 50.5 t -90.42 115.23 29.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -58.1 149.28 24.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.715 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.9 tt0 63.85 -69.73 0.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.295 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.82 100.79 11.78 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 110.43 -0.211 . . . . 0.0 110.43 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.55 ' O ' HG23 ' A' ' 129' ' ' THR . 72.4 m-70 -69.73 100.28 1.47 Allowed 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.161 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.55 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 164.15 144.37 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.962 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.558 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.5 pt? -145.33 157.02 44.13 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.636 0.732 . . . . 0.0 112.011 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.709 HG11 HH21 ' A' ' 96' ' ' ARG . 8.9 p -92.35 120.56 41.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.832 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.604 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.89 126.45 30.46 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.891 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.633 ' HG3' HG23 ' A' ' 6' ' ' THR . 8.9 mt-10 59.86 45.33 12.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.222 0.534 . . . . 0.0 110.029 -179.475 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.41 -24.7 0.35 Allowed Glycine 0 CA--C 1.522 0.524 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.28 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.533 ' H ' ' C ' ' A' ' 133' ' ' GLU . 10.3 t -90.25 151.21 3.53 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 O-C-N 122.485 -0.42 . . . . 0.0 110.68 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.89 115.84 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.68 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 138' ' ' HIS . 20.9 m -147.28 136.67 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.434 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 17.9 t-80 -34.99 154.36 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.089 0.403 . . . . 0.0 112.089 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.277 -179.861 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.6 mt -108.97 137.53 46.74 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.341 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 161.46 23.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.687 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -62.36 145.91 52.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.092 179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.56 -17.65 33.3 Favored Glycine 0 C--N 1.337 0.63 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.8 m -66.89 122.4 17.63 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.224 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -98.35 115.72 29.06 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.143 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 131' ' ' VAL . 3.6 mt -102.59 117.33 47.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.734 -179.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -75.84 133.23 40.66 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASP . . . . . 0.823 ' OD1' HG22 ' A' ' 13' ' ' THR . 4.1 t70 -104.0 134.93 19.45 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.526 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.52 -32.51 3.71 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.512 2.142 . . . . 0.0 112.321 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.07 -59.6 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.417 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.823 HG22 ' OD1' ' A' ' 10' ' ' ASP . 1.9 t -76.9 -34.21 57.74 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.97 12.84 76.11 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.648 ' H ' HG23 ' A' ' 13' ' ' THR . 75.5 m -116.94 161.6 19.1 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 117.977 0.888 . . . . 0.0 109.753 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' THR . . . . . 0.523 ' N ' HG22 ' A' ' 15' ' ' THR . 43.0 m -79.71 115.83 19.54 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.278 0.561 . . . . 0.0 110.713 -179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' HIS . . . . . 0.669 ' NE2' HG21 ' A' ' 13' ' ' THR . 24.8 m-70 -101.84 147.07 26.94 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.206 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -101.23 125.53 47.87 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.004 178.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -53.46 -39.32 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.265 -179.234 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.2 pt-20 -58.55 -33.72 70.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 68.4 t0 -83.97 -37.22 22.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.596 179.611 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 78.4 t -66.39 -42.74 91.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.27 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.447 HG22 HD21 ' A' ' 122' ' ' LEU . 75.9 t -69.51 -44.81 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 121.093 -0.243 . . . . 0.0 111.428 -179.697 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -54.15 -36.32 63.19 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 121.036 -0.266 . . . . 0.0 110.761 -178.222 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -117.25 33.31 5.07 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER 12.42 74.95 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 124.056 0.504 . . . . 0.0 109.9 179.859 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LYS . . . . . 0.652 ' C ' ' H ' ' A' ' 29' ' ' ILE . 64.0 mttt -91.29 117.74 68.04 Favored Pre-proline 0 N--CA 1.442 -0.862 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -178.201 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.68 ' O ' ' O ' ' A' ' 29' ' ' ILE . 52.5 Cg_exo -52.67 7.54 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.964 2.442 . . . . 0.0 113.005 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.68 ' O ' ' O ' ' A' ' 28' ' ' PRO . 1.3 pp -37.05 -178.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 O-C-N 123.949 0.781 . . . . 0.0 110.722 -178.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' HIS . . . . . 0.506 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 2.4 m80 -126.49 168.14 14.65 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 121.404 -0.81 . . . . 0.0 111.247 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.1 m -148.12 171.78 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.264 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 62.9 t -88.11 131.11 36.53 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.641 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -109.07 149.72 28.86 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.055 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.69 140.79 50.1 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.933 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB3' ' OD1' ' A' ' 37' ' ' ASP . . . -113.69 174.31 5.99 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.771 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -68.42 -14.62 63.13 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.651 0.263 . . . . 0.0 110.648 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.485 ' OD1' ' HB3' ' A' ' 35' ' ' ALA . 38.4 p30 -81.79 -15.71 53.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.488 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 87.04 22.64 44.45 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.42 ' OG1' ' OD1' ' A' ' 37' ' ' ASP . 22.0 p -102.87 137.29 41.27 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.622 0.249 . . . . 0.0 111.108 178.783 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.7 mt -94.79 130.18 41.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.884 0.374 . . . . 0.0 110.47 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.48 138.7 33.01 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.404 -179.073 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.74 139.9 53.4 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.609 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.7 mmt-85 -143.38 137.97 15.1 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.897 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.73 156.34 35.37 Favored 'Trans proline' 0 C--N 1.316 -1.177 0 C-N-CA 122.783 2.322 . . . . 0.0 112.969 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.9 t -93.86 130.75 42.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -118.11 -5.02 11.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.527 -178.623 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.1 t -145.97 134.73 22.35 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.203 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' TRP . . . . . 0.557 ' CD2' ' N ' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -134.02 116.28 15.32 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.359 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 0.514 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 47.5 m-85 -140.94 150.71 43.48 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.063 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -93.54 133.16 37.13 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 176.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -92.17 -0.35 57.43 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.202 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.5 179.73 51.48 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 32.0 m -91.41 123.07 34.55 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -143.79 169.97 16.76 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.915 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -76.99 142.71 39.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.971 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.7 m -147.15 157.59 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.113 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.629 HD11 ' HB1' ' A' ' 84' ' ' ALA . 45.9 pt -108.12 159.05 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.238 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.83 139.55 15.75 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.7 mt -118.53 112.04 19.39 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.148 0.499 . . . . 0.0 109.689 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.735 ' NE ' ' HE ' ' A' ' 109' ' ' ARG . 56.8 ttp180 -98.94 126.17 44.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.001 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.733 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -106.28 160.79 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.448 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.546 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -34.84 92.85 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.303 0.377 . . . . 0.0 111.256 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 40.46 20.84 0.03 OUTLIER Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.774 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 62' ' ' ALA . . . -89.61 -149.1 20.59 Favored Glycine 0 N--CA 1.439 -1.15 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 -179.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.17 169.21 16.05 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.069 -0.565 . . . . 0.0 110.556 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 93.5 mt -120.89 135.55 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.222 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.7 tp -112.53 111.0 21.51 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.798 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' TRP . . . . . 0.515 ' CE3' ' NH2' ' A' ' 115' ' ' ARG . 97.9 m95 -103.73 105.71 16.0 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.25 172.47 12.87 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.549 -179.059 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -72.76 156.24 90.11 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.759 -179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 85' ' ' GLY . 31.4 Cg_endo -64.3 -19.36 65.59 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.644 2.229 . . . . 0.0 111.866 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 39.6 p-10 -90.99 -4.98 56.0 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' HIS . . . . . 0.534 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.6 t60 -71.88 132.09 43.91 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.19 124.65 32.09 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.442 0.639 . . . . 0.0 111.386 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.8 t -99.03 143.01 13.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.159 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.4 tp -82.83 89.87 6.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.699 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.473 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 30.0 p -97.86 176.25 5.86 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -67.39 -20.03 65.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.117 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -101.73 24.35 9.98 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-O 120.656 0.265 . . . . 0.0 110.825 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.09 -144.71 17.5 Favored Glycine 0 C--N 1.332 0.306 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -86.88 121.88 29.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.732 0.301 . . . . 0.0 111.289 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.7 mmt85 -122.56 125.8 46.45 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.089 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -68.54 129.84 41.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.507 -179.72 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.629 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -66.83 -0.03 2.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.799 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -75.55 -13.13 83.22 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -136.97 30.84 2.74 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.914 0.387 . . . . 0.0 111.378 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LEU . . . . . 0.455 HD12 ' HA ' ' A' ' 84' ' ' ALA . 10.9 mt -82.88 131.81 35.18 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.403 0.62 . . . . 0.0 111.007 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 83.2 mmt-85 -133.62 148.38 51.55 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.082 -0.963 . . . . 0.0 111.346 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -46.37 97.92 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.547 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 158.48 -16.52 0.28 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -88.29 129.91 35.25 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -88.57 129.74 35.41 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.36 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.9 m -108.9 141.86 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.046 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ALA . . . . . 0.465 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -72.08 120.71 18.06 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.722 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' VAL . . . . . 0.406 ' O ' HG23 ' A' ' 95' ' ' VAL . 33.2 m -121.85 131.28 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.945 0.402 . . . . 0.0 110.07 179.09 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -67.73 132.05 46.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.848 -179.413 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 48.7 t0 -101.77 122.9 44.81 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 119.297 -0.382 . . . . 0.0 110.443 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.5 p -75.22 -16.87 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 CA-C-N 118.427 0.558 . . . . 0.0 111.323 179.101 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.75 -58.49 3.59 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.436 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' THR . . . . . 0.439 ' C ' ' H ' ' A' ' 102' ' ' GLU . 48.8 p -98.58 -14.89 19.72 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.456 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.37 -17.22 4.26 Favored Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.439 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.4 mt-10 -78.38 157.75 28.97 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -177.769 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.494 HD11 HG21 ' A' ' 136' ' ' VAL . 2.1 tp -75.06 135.18 41.24 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.314 -179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 32.5 ptt180 -135.04 167.46 20.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.216 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.473 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.0 m-85 -117.12 152.83 33.9 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.029 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.1 m -146.2 165.21 29.85 Favored 'General case' 0 CA--C 1.516 -0.348 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.8 t -89.2 150.37 3.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 120.775 0.321 . . . . 0.0 110.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ILE . . . . . 0.491 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.2 mm -69.83 160.75 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.211 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.735 ' HE ' ' NE ' ' A' ' 60' ' ' ARG . 12.6 ttp85 -107.67 -49.32 3.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.533 179.252 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLU . . . . . 0.527 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 74.8 tt0 -166.78 146.66 5.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.473 ' C ' HD22 ' A' ' 112' ' ' LEU . 1.0 OUTLIER -94.09 134.58 31.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.238 0.542 . . . . 0.0 110.019 179.688 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 3.0 mm? -97.86 145.48 29.82 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.157 -179.208 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.47 160.18 50.78 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 122.568 2.179 . . . . 0.0 111.468 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -64.88 154.12 38.22 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.146 0.498 . . . . 0.0 110.655 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.515 ' NH2' ' CE3' ' A' ' 68' ' ' TRP . 74.4 mtm180 -140.95 -138.82 0.12 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.657 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -155.58 132.01 10.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.236 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -171.13 173.03 5.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.764 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -77.77 140.24 39.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.779 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 3.1 p -114.98 140.46 49.01 Favored 'General case' 0 CA--C 1.522 -0.117 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -119.59 171.59 8.26 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.24 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.514 ' OD1' ' O ' ' A' ' 49' ' ' PHE . 43.6 p-10 -160.72 120.31 2.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.089 179.346 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 23' ' ' VAL . 69.9 mt -117.38 131.67 56.73 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 120.72 0.295 . . . . 0.0 110.63 179.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -87.71 110.18 20.25 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.568 ' O ' ' N ' ' A' ' 126' ' ' GLU . 21.6 t -81.04 109.49 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.467 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.074 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.488 ' C ' ' O ' ' A' ' 124' ' ' VAL . 1.6 tm-20 24.14 -85.53 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.815 0.697 . . . . 0.0 111.435 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.568 ' N ' ' O ' ' A' ' 124' ' ' VAL . 79.8 tt0 -136.87 -36.44 0.68 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.157 -0.928 . . . . 0.0 111.141 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.481 ' O ' ' N ' ' A' ' 129' ' ' THR . 74.0 mt -72.4 67.69 0.74 Allowed 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.019 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' HIS . . . . . 0.602 ' HA ' HD22 ' A' ' 139' ' ' ASN . 35.4 m80 -40.82 95.92 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.58 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.5 136.36 0.01 OUTLIER 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.685 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.5 pp -144.99 154.37 42.47 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.449 0.642 . . . . 0.0 111.679 -178.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 8' ' ' ILE . 97.2 t -87.81 123.99 40.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ALA . . . . . 0.603 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.51 142.22 48.13 Favored 'General case' 0 C--O 1.227 -0.106 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.444 -178.511 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.581 ' O ' HG23 ' A' ' 135' ' ' VAL . 71.1 mm-40 40.23 49.79 2.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.196 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.45 -25.32 0.27 Allowed Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.446 -0.662 . . . . 0.0 111.446 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 133' ' ' GLU . 2.7 t -89.12 152.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.394 0 O-C-N 122.48 -0.423 . . . . 0.0 110.689 -179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' VAL . . . . . 0.494 HG21 HD11 ' A' ' 103' ' ' LEU . 2.7 t -109.87 117.64 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.437 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 138' ' ' HIS . 20.5 m -149.87 141.01 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.531 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.492 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 54.3 t-80 -31.42 150.31 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.173 0 O-C-N 123.209 0.318 . . . . 0.0 111.741 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.602 HD22 ' HA ' ' A' ' 128' ' ' HIS . 3.0 m-20 . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 118.056 -0.973 . . . . 0.0 110.628 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.543 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.1 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.3 mt -99.47 141.8 31.79 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.356 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.66 162.46 17.1 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.758 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 20' ' ' GLU . 41.3 tt0 -64.51 140.77 58.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.443 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.91 -17.72 29.64 Favored Glycine 0 C--N 1.338 0.693 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.5 m -70.63 122.81 20.48 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.607 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.6 mtp180 -82.65 147.99 28.21 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.043 0.449 . . . . 0.0 110.429 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 84.7 mt -133.94 107.67 10.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.26 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -77.97 129.69 35.61 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -101.49 132.02 22.3 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.45 -31.2 9.25 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.857 1.705 . . . . 0.0 112.449 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.2 t -69.99 -53.61 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.049 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -80.19 -39.76 28.59 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.858 0.361 . . . . 0.0 110.24 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.61 74.61 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.416 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -105.8 -168.32 1.43 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 117.363 0.582 . . . . 0.0 109.855 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.607 HG21 ' HE ' ' A' ' 7' ' ' ARG . 72.8 m -117.34 119.79 36.2 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.346 0.593 . . . . 0.0 110.397 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 63.9 m170 -109.75 148.07 32.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.089 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -98.87 130.24 45.27 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.502 HG23 ' N ' ' A' ' 20' ' ' GLU . 5.6 tp -51.93 -40.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.632 0.253 . . . . 0.0 111.109 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.502 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.6 pt-20 -58.87 -34.57 71.77 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.113 0.482 . . . . 0.0 110.901 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -84.51 -37.49 21.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.432 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 75.4 t -68.09 -41.54 84.39 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.937 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.67 HG22 HD21 ' A' ' 122' ' ' LEU . 53.5 t -77.42 -46.33 28.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.2 t0 -55.65 -35.48 65.99 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 120.764 0.316 . . . . 0.0 110.829 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.564 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.77 26.49 14.13 Favored Glycine 0 N--CA 1.46 0.238 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.564 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.2 OUTLIER 15.37 68.77 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.225 0 O-C-N 124.042 0.496 . . . . 0.0 109.71 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 29' ' ' ILE . 83.4 mttt -83.8 114.46 54.05 Favored Pre-proline 0 N--CA 1.45 -0.449 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.87 -175.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -57.16 83.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 CA-C-N 119.78 0.957 . . . . 0.0 111.294 178.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.47 ' N ' ' O ' ' A' ' 27' ' ' LYS . 49.1 pt -119.11 -170.12 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 CA-C-O 121.063 0.459 . . . . 0.0 110.973 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.449 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 67.6 m80 -126.37 161.66 27.34 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.432 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.05 170.56 3.9 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.357 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 97.3 t -88.86 133.68 30.44 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.36 155.64 24.84 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.549 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -127.22 145.71 50.67 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.395 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.73 -176.55 2.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.428 ' HD2' ' H ' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -71.63 -12.75 61.5 Favored 'General case' 0 CA--C 1.523 -0.092 0 CA-C-O 120.868 0.366 . . . . 0.0 110.686 179.561 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.491 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 32.3 p30 -76.28 -20.2 57.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.565 179.513 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.491 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 93.95 -8.25 73.34 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.457 ' HG1' ' CE1' ' A' ' 41' ' ' HIS . 33.6 p -82.31 151.09 26.88 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 121.946 0.879 . . . . 0.0 111.783 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.0 mt -100.94 132.21 46.45 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.258 -1.337 . . . . 0.0 111.877 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . 0.457 ' CE1' ' HG1' ' A' ' 39' ' ' THR . 5.7 m80 -137.88 137.39 38.02 Favored 'General case' 0 C--O 1.221 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.375 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.62 143.69 49.7 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.454 -178.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.537 HH21 ' CD ' ' A' ' 125' ' ' GLU . 8.9 mtp85 -149.21 138.61 12.7 Favored Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.991 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -74.85 157.17 43.55 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.239 1.959 . . . . 0.0 112.677 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 99.1 t -96.24 136.67 26.38 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.9 m -123.7 1.39 5.69 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.618 0 CA-C-O 119.202 -0.428 . . . . 0.0 111.856 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.5 p -151.04 144.87 25.13 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 118.987 0.812 . . . . 0.0 109.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.478 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.1 OUTLIER -142.12 123.07 14.47 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.373 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -141.57 145.32 34.93 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -86.88 136.55 32.92 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.437 ' HA ' HE21 ' A' ' 51' ' ' GLN . 0.0 OUTLIER -99.14 1.84 45.4 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.806 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.6 -175.44 53.41 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.375 -0.917 . . . . 0.0 111.613 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 70.0 m -95.14 126.66 40.62 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -148.21 168.3 22.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.433 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -73.1 138.36 45.78 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.607 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -139.22 155.11 25.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-O 120.752 0.31 . . . . 0.0 110.181 -179.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.791 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.0 pt -110.45 153.17 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 110.179 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.28 125.47 7.7 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.5 mt -106.93 112.46 25.44 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 56.8 ttp180 -96.17 123.36 39.77 Favored 'General case' 0 C--O 1.219 -0.521 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.416 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 24.1 mm . . . . . 0 N--CA 1.468 0.427 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 -179.556 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.315 0 CA-C-O 121.543 0.687 . . . . 0.0 109.213 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -132.01 154.67 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.408 -178.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.2 tp -143.69 125.84 15.5 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -105.87 123.52 48.1 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.85 170.77 17.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 6.5 p -78.49 156.7 78.16 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.982 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -59.25 -22.92 67.32 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 121.872 1.715 . . . . 0.0 111.995 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -87.09 -8.9 56.59 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.743 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 8.2 t60 -68.7 126.76 30.71 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.751 ' H ' ' CE1' ' A' ' 138' ' ' HIS . 69.0 mttm -86.22 130.88 34.37 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 121.509 0.671 . . . . 0.0 111.418 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -104.66 139.27 26.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.83 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 59.6 tp -77.81 95.96 4.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.955 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.2 p -99.32 178.04 5.01 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.698 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.7 pm0 -64.91 -16.93 63.87 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.556 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.456 ' HB2' ' HE ' ' A' ' 82' ' ' ARG . 77.3 m-85 -109.73 26.24 10.88 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.08 -138.38 13.87 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -98.72 132.44 44.09 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.451 -0.374 . . . . 0.0 110.746 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.456 ' HE ' ' HB2' ' A' ' 79' ' ' TYR . 90.8 mtt-85 -140.3 132.41 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.266 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.36 144.81 23.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.902 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.791 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.45 -38.24 86.47 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.569 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.07 -2.12 6.29 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 120.537 -0.84 . . . . 0.0 111.713 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.67 25.69 11.5 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.95 0.405 . . . . 0.0 110.433 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 77.5 mt -110.18 130.34 55.56 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.608 0.718 . . . . 0.0 111.126 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.522 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.1 mmt180 -130.4 147.53 52.11 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.744 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -45.01 90.35 0.0 OUTLIER 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.888 0.375 . . . . 0.0 110.454 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -13.78 0.33 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -84.48 130.16 34.78 Favored 'General case' 0 C--O 1.225 -0.223 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.43 ' O ' ' OE1' ' A' ' 78' ' ' GLU . 89.1 mtm180 -90.26 136.72 32.88 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 -178.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.2 m -125.24 151.52 31.11 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.209 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.494 ' HB1' ' CD1' ' A' ' 103' ' ' LEU . . . -84.92 128.59 34.69 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.457 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.3 135.14 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.898 0.38 . . . . 0.0 110.441 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -66.74 133.66 50.62 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.055 0.455 . . . . 0.0 111.344 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -98.54 122.67 42.03 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-N 115.872 -0.603 . . . . 0.0 109.562 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.0 t -75.02 -17.23 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 118.401 0.546 . . . . 0.0 110.649 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.77 -59.25 3.06 Favored 'General case' 0 CA--C 1.522 -0.096 0 C-N-CA 120.197 -0.601 . . . . 0.0 109.964 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.494 ' C ' ' H ' ' A' ' 102' ' ' GLU . 73.6 p -93.88 -11.34 31.31 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 110.435 -0.209 . . . . 0.0 110.435 179.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 72.89 -12.04 4.12 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.494 ' H ' ' C ' ' A' ' 100' ' ' THR . 41.8 mt-10 -88.49 164.57 15.39 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 121.036 0.446 . . . . 0.0 111.24 -177.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.513 HD13 ' H ' ' A' ' 104' ' ' ARG . 0.2 OUTLIER -71.12 142.06 50.77 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.589 -179.459 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.513 ' H ' HD13 ' A' ' 103' ' ' LEU . 6.0 ptt85 -136.89 158.76 43.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.611 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.698 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -112.32 135.8 52.56 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.926 -179.746 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.481 ' OG ' ' NH2' ' A' ' 104' ' ' ARG . 6.7 m -142.55 161.84 37.01 Favored 'General case' 0 C--N 1.344 0.329 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.1 p -94.43 156.48 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 111.33 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.459 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.3 mt -71.1 159.35 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.459 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 43.2 ttm180 -106.57 -46.36 4.02 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.759 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 81.4 tt0 -165.01 143.72 6.55 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.424 ' C ' HD22 ' A' ' 112' ' ' LEU . 10.7 p -93.95 133.14 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.433 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.3 mm? -101.11 125.4 38.24 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-O 119.674 -0.203 . . . . 0.0 110.977 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.39 165.93 0.1 Allowed 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.225 1.95 . . . . 0.0 112.0 179.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 19.9 p -66.69 151.47 47.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 121.276 0.56 . . . . 0.0 110.776 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -133.06 -142.05 0.21 Allowed 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.678 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.5 mtt85 -156.79 130.93 8.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.285 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.53 169.83 5.03 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.943 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -72.89 148.25 44.56 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.241 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 42.0 p -131.1 143.36 50.6 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.49 ' HB3' HG21 ' A' ' 23' ' ' VAL . 68.3 m-85 -115.65 174.55 5.96 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.753 -179.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -145.28 137.48 25.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.109 -0.95 . . . . 0.0 111.074 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.67 HD21 HG22 ' A' ' 23' ' ' VAL . 97.2 mt -130.23 170.8 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.449 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -138.01 106.99 5.98 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.926 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 125' ' ' GLU . 8.5 t -86.04 115.14 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.863 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.537 ' CD ' HH21 ' A' ' 43' ' ' ARG . 81.4 tt0 18.52 -95.65 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.729 0 O-C-N 123.762 0.664 . . . . 0.0 112.327 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -128.03 -33.11 2.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.154 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.439 ' O ' ' N ' ' A' ' 129' ' ' THR . 54.3 mt -78.02 67.93 3.96 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -42.7 97.81 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.229 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 175.14 143.48 0.06 Allowed 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.634 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.9 pp -151.47 154.5 36.68 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.415 0.626 . . . . 0.0 111.676 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.7 t -89.76 123.54 42.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.872 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.86 122.87 22.62 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.137 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.8 mm-40 55.83 43.54 27.48 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.021 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.51 -15.81 0.8 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.176 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.7 t -90.53 146.87 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 117.268 0.534 . . . . 0.0 110.456 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.19 115.12 47.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.792 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.416 ' O ' ' C ' ' A' ' 138' ' ' HIS . 21.6 m -147.65 142.19 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.226 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.751 ' CE1' ' H ' ' A' ' 74' ' ' LYS . 0.3 OUTLIER -37.37 153.48 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.206 0.457 . . . . 0.0 111.681 -179.816 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.9 p30 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.382 179.745 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.431 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 24.5 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -109.34 136.51 48.67 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.845 0.355 . . . . 0.0 110.527 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.04 162.66 21.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.518 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 44.6 tt0 -63.27 143.18 58.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.961 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.83 -20.83 23.96 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.619 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.3 m -67.48 123.56 20.74 Favored 'General case' 0 C--N 1.331 -0.218 0 O-C-N 122.768 -0.254 . . . . 0.0 111.244 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.817 ' HE ' HG21 ' A' ' 16' ' ' THR . 72.6 mtp180 -82.72 147.63 28.35 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.781 0.324 . . . . 0.0 110.162 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -134.79 107.3 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.497 179.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -76.95 129.8 36.64 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' A' ' 10' ' ' ASP . 50.8 t0 -109.91 110.24 59.06 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-O 119.53 -0.272 . . . . 0.0 110.377 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_exo -51.96 -36.8 65.84 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 121.765 1.643 . . . . 0.0 112.561 178.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.2 t -62.11 -58.25 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.037 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 24.8 p -77.49 -33.93 54.35 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.365 0.602 . . . . 0.0 109.834 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.31 6.47 89.27 Favored Glycine 0 N--CA 1.449 -0.465 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.175 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.494 HG22 ' N ' ' A' ' 16' ' ' THR . 50.6 m -113.83 159.91 19.3 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 117.719 0.759 . . . . 0.0 109.926 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.817 HG21 ' HE ' ' A' ' 7' ' ' ARG . 13.9 m -80.4 117.05 20.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.17 0.51 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -98.94 139.92 33.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.041 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -95.66 127.47 41.71 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.791 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.561 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.2 tp -53.98 -40.8 46.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.861 0.362 . . . . 0.0 111.429 -178.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.561 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.7 tt0 -58.88 -36.64 74.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.135 0.493 . . . . 0.0 110.729 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -81.5 -36.64 29.0 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.567 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.6 t -66.96 -41.71 87.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.22 -43.56 57.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -58.85 -37.87 77.46 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 121.084 -0.247 . . . . 0.0 111.3 -177.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.87 29.54 10.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.512 ' C ' ' O ' ' A' ' 25' ' ' GLY . 96.3 mtt-85 22.61 56.49 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.088 0 CA-C-O 121.27 0.557 . . . . 0.0 110.266 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.626 ' C ' ' H ' ' A' ' 29' ' ' ILE . 31.1 mmtt -75.41 115.68 47.67 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.917 -177.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.558 ' O ' ' O ' ' A' ' 29' ' ' ILE . 32.6 Cg_exo -58.1 12.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.505 2.191 0 C-N-CA 122.001 1.801 . . . . 0.0 112.843 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.626 ' H ' ' C ' ' A' ' 27' ' ' LYS . 2.1 pp -40.23 175.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.713 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.478 ' ND1' ' N ' ' A' ' 30' ' ' HIS . 2.8 m80 -121.71 167.51 12.86 Favored 'General case' 0 N--CA 1.467 0.401 0 O-C-N 122.22 -0.3 . . . . 0.0 110.611 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -148.28 170.08 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.1 t -87.59 137.2 21.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 121.896 -0.502 . . . . 0.0 109.772 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.78 168.03 9.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.138 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.22 140.23 37.69 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.29 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.57 176.02 5.21 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -70.71 -14.07 62.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.803 0.335 . . . . 0.0 110.837 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -79.37 -17.64 54.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.38 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.81 22.1 40.54 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.2 p -101.6 136.64 41.1 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.076 178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.94 134.1 42.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.848 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -144.4 141.66 29.81 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.781 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.17 141.82 52.57 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.533 -178.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -142.39 140.67 19.31 Favored Pre-proline 0 CA--C 1.542 0.653 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.272 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 157.57 30.53 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.771 2.314 . . . . 0.0 112.52 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -102.96 138.25 27.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.7 m -128.3 4.67 3.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.046 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.431 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 1.2 t -151.91 145.11 24.64 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 119.05 0.841 . . . . 0.0 109.19 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.86 124.66 15.06 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 178.703 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -141.62 146.27 36.02 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -88.68 133.08 34.32 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 176.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.431 ' OE1' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -92.8 -0.23 57.3 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.6 177.44 51.16 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.307 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 39.2 m -89.43 123.85 33.94 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.025 0.44 . . . . 0.0 109.974 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -148.63 173.7 12.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.257 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -77.1 140.86 40.37 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.259 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 m -139.35 154.87 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.558 HD11 ' CB ' ' A' ' 84' ' ' ALA . 30.8 pt -112.05 151.34 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.024 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.88 144.82 15.9 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 27.4 mt -123.33 112.93 18.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.322 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.426 ' C ' HD12 ' A' ' 61' ' ' ILE . 67.1 ttt180 -86.98 107.49 18.42 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.36 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.755 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.8 mp . . . . . 0 N--CA 1.467 0.387 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.936 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.129 0 CA-C-O 120.832 0.349 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.0 mt -125.48 157.29 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.392 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.501 ' N ' HG22 ' A' ' 66' ' ' ILE . 49.8 tp -132.74 116.62 16.81 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.064 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.3 m95 -102.8 125.42 49.54 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.76 171.52 17.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.214 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.21 156.9 73.8 Favored Pre-proline 0 CA--C 1.533 0.323 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.586 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.74 -19.98 69.8 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.562 2.175 . . . . 0.0 112.066 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -93.26 -7.04 46.18 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.031 0.444 . . . . 0.0 110.189 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 9.6 t60 -73.42 131.36 41.74 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -88.04 130.63 34.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 110.271 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' THR . 95.2 t -108.95 90.63 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.847 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' VAL . 49.0 tp -31.21 99.12 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 O-C-N 123.244 0.34 . . . . 0.0 111.707 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 75' ' ' VAL . 61.4 p -98.22 176.08 5.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -63.37 -19.04 64.31 Favored 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.166 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 -106.86 23.77 13.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.428 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 77' ' ' THR . . . 105.55 -141.47 15.38 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 96.8 m95 -96.11 130.31 43.18 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.732 -0.234 . . . . 0.0 110.766 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -142.35 132.32 24.44 Favored 'General case' 0 C--O 1.232 0.157 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.65 143.8 19.37 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.398 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.558 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.52 -37.91 89.13 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.488 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.5 0.09 3.19 Favored Glycine 0 CA--C 1.529 0.965 0 C-N-CA 120.44 -0.886 . . . . 0.0 111.833 -179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -109.19 -2.28 18.11 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.989 0.423 . . . . 0.0 110.426 179.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 83.7 mt -74.67 129.52 37.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.472 ' O ' ' N ' ' A' ' 90' ' ' GLY . 36.2 mmt180 -133.12 147.99 52.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.435 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -46.37 92.59 0.01 OUTLIER 'General case' 0 C--O 1.233 0.192 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.474 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.85 -20.38 0.78 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -83.63 130.12 34.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.805 0.336 . . . . 0.0 110.694 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.406 ' NH2' ' O ' ' A' ' 105' ' ' TYR . 79.1 mtp85 -91.18 138.66 31.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.518 -179.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 33.2 m -126.36 151.46 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.285 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.14 134.98 52.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.443 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.632 HG21 ' OG ' ' A' ' 106' ' ' SER . 27.3 m -133.77 158.45 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.555 179.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -104.64 127.95 52.53 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.149 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -100.06 124.51 45.52 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.247 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 12.5 p -75.2 -15.46 15.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.352 0.524 . . . . 0.0 111.087 178.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -69.55 -58.3 4.13 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.224 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.429 ' C ' ' H ' ' A' ' 102' ' ' GLU . 15.6 p -99.18 -12.06 20.79 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.739 -0.21 . . . . 0.0 110.473 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.77 -13.26 8.85 Favored Glycine 0 C--N 1.329 0.187 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.429 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.4 mt-10 -82.05 155.32 25.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.975 0.417 . . . . 0.0 111.222 -177.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.576 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -75.74 139.94 42.13 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.195 179.41 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.62 ' O ' HG22 ' A' ' 95' ' ' VAL . 98.8 mtt180 -139.17 169.61 17.46 Favored 'General case' 0 CA--C 1.51 -0.589 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.406 ' O ' ' NH2' ' A' ' 92' ' ' ARG . 8.2 m-30 -108.1 141.88 39.13 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.197 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.632 ' OG ' HG21 ' A' ' 95' ' ' VAL . 4.1 m -136.99 159.59 41.42 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.196 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 108' ' ' ILE . 85.0 t -98.32 156.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 107' ' ' VAL . 29.4 mm -84.66 131.33 34.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.184 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.3 mmm180 -82.44 -34.13 28.29 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.765 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -166.21 145.41 5.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.408 HG22 ' H ' ' A' ' 111' ' ' VAL . 0.8 OUTLIER -95.38 135.42 29.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.441 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.444 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.4 mm? -98.35 123.92 48.73 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 120.626 -0.429 . . . . 0.0 111.149 -179.471 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.5 162.91 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.039 1.826 . . . . 0.0 111.711 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 57' ' ' ILE . 74.7 p -65.35 152.95 42.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 ttt180 -135.18 -139.15 0.17 Allowed 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.691 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 13.0 tpt180 -157.99 129.77 6.86 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.402 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.39 171.09 4.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.179 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.518 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 88.1 mtm180 -74.68 146.97 41.9 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.62 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 6.6 p -126.22 143.3 51.19 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -115.6 173.1 6.71 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.819 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -152.33 127.02 9.48 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.528 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.415 HD11 HD12 ' A' ' 19' ' ' ILE . 87.3 mt -116.24 171.9 7.53 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.233 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -134.95 107.2 7.21 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.352 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 129' ' ' THR . 20.9 t -91.94 119.86 40.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -60.87 144.42 52.86 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.76 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 69.21 -67.78 0.21 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.662 179.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.36 89.7 4.54 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 116.695 -0.23 . . . . 0.0 110.838 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.624 ' C ' HG22 ' A' ' 129' ' ' THR . 97.6 m-70 -62.08 96.83 0.08 Allowed 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.624 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 165.4 155.06 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 178.584 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.9 pp -150.94 151.84 32.73 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.307 -0.557 . . . . 0.0 111.544 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 135' ' ' VAL . 40.0 t -93.14 127.69 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.151 -179.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.49 133.54 42.35 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.006 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.535 ' O ' HG23 ' A' ' 135' ' ' VAL . 81.1 mm-40 55.29 42.31 30.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.531 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.0 27.47 67.19 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.623 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 133' ' ' GLU . 23.3 t -130.17 150.75 34.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 118.135 0.968 . . . . 0.0 108.391 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 3.5 t -105.12 111.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-N 118.329 0.513 . . . . 0.0 111.038 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' ' C ' ' A' ' 138' ' ' HIS . 16.9 m -145.88 134.67 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.627 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 51.8 t-80 -34.42 148.06 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.676 0.274 . . . . 0.0 111.649 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.763 HD22 ' N ' ' A' ' 139' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.369 -179.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 75.0 mt -96.5 143.63 27.33 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.316 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.3 163.91 16.57 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.701 0.286 . . . . 0.0 110.841 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.433 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 48.3 tt0 -64.78 142.12 58.54 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.523 178.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.66 -22.06 17.67 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.568 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.5 m -66.68 121.67 15.92 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.59 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.4 mtt85 -80.57 147.17 30.9 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 6.4 mm -134.77 106.3 7.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.014 0.435 . . . . 0.0 111.212 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -77.82 130.46 36.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -111.68 110.46 54.97 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.713 -0.221 . . . . 0.0 110.547 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.08 -35.58 62.42 Favored 'Trans proline' 0 N--CA 1.497 1.686 0 C-N-CA 122.171 1.914 . . . . 0.0 112.409 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 56.5 t -61.88 -57.8 10.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.767 -178.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 43.5 p -79.53 -36.63 38.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.305 0.574 . . . . 0.0 109.905 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.78 6.9 84.87 Favored Glycine 0 N--CA 1.451 -0.362 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.472 HG22 ' N ' ' A' ' 16' ' ' THR . 52.4 m -113.78 157.97 21.58 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 117.769 0.784 . . . . 0.0 109.918 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.472 ' N ' HG22 ' A' ' 15' ' ' THR . 30.6 m -80.47 117.71 21.44 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.121 0.486 . . . . 0.0 110.87 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 18.4 m80 -100.52 143.51 30.62 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.011 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -97.34 128.22 43.97 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.222 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.536 HG23 ' N ' ' A' ' 20' ' ' GLU . 8.3 tp -52.9 -40.8 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.252 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.3 tt0 -58.48 -35.96 73.0 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -81.91 -38.05 25.87 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.605 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.8 t -67.45 -42.33 87.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.04 -45.24 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.63 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -57.38 -37.19 72.28 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 120.728 0.299 . . . . 0.0 110.971 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.57 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.38 29.66 9.33 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-O 118.944 -0.92 . . . . 0.0 110.848 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.57 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.7 ptt180 15.15 67.68 0.01 OUTLIER 'General case' 0 C--N 1.363 1.16 0 CA-C-N 117.313 0.557 . . . . 0.0 110.123 179.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.636 ' C ' ' H ' ' A' ' 29' ' ' ILE . 71.3 mttt -86.52 118.01 69.57 Favored Pre-proline 0 N--CA 1.44 -0.965 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.615 ' O ' ' O ' ' A' ' 29' ' ' ILE . 44.2 Cg_exo -53.83 9.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.498 1.762 0 C-N-CA 122.189 1.926 . . . . 0.0 113.383 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.636 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.9 pp -38.01 176.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 123.703 0.627 . . . . 0.0 110.843 -178.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.453 ' ND1' ' N ' ' A' ' 30' ' ' HIS . 4.0 m80 -122.48 166.73 14.31 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 121.837 -0.539 . . . . 0.0 110.795 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.8 m -148.57 171.17 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.27 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.01 135.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.59 166.87 11.1 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.571 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.48 142.4 43.55 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.091 0.472 . . . . 0.0 110.25 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.76 178.67 4.2 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -66.8 -15.53 63.65 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.192 -0.318 . . . . 0.0 110.906 179.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -75.94 -22.0 56.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.685 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.9 -7.01 67.33 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.7 p -77.2 145.12 37.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.187 0.517 . . . . 0.0 111.291 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 64.9 mt -100.4 132.89 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.857 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -141.37 138.96 33.4 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.795 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.06 143.03 52.6 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.673 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NH1' ' OE1' ' A' ' 125' ' ' GLU . 0.9 OUTLIER -142.72 138.34 16.02 Favored Pre-proline 0 CA--C 1.54 0.584 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.187 -179.594 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.67 158.58 31.92 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.916 2.411 . . . . 0.0 112.729 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.4 t -100.73 136.07 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.359 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.95 2.06 3.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.589 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 t -146.33 137.07 24.19 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 118.922 0.783 . . . . 0.0 109.149 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -139.32 124.17 18.64 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -138.23 146.84 43.07 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -179.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 52.7 p-10 -113.14 140.62 47.75 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 122.027 0.918 . . . . 0.0 108.593 176.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 -105.5 0.35 Allowed 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.602 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -165.58 -156.43 9.24 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.332 -1.304 . . . . 0.0 112.918 -176.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -88.51 127.89 35.54 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.983 0.421 . . . . 0.0 111.482 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -145.8 158.65 43.84 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -76.17 140.88 41.93 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.253 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.1 143.72 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.121 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.56 HD11 ' CB ' ' A' ' 84' ' ' ALA . 18.9 pt -96.13 152.36 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.408 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.94 132.66 11.15 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.0 mt -110.76 112.26 24.01 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.493 ' C ' HD12 ' A' ' 61' ' ' ILE . 60.0 ttm-85 -85.81 113.24 21.81 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.972 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.694 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.467 0.418 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.806 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.265 0 CA-C-O 121.347 0.594 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -130.76 155.96 42.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.671 -179.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.4 tp -142.79 124.0 14.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.851 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -104.52 125.19 50.46 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.9 171.11 18.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.144 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -78.7 155.52 78.26 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-O 120.71 0.291 . . . . 0.0 111.035 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.48 -20.51 70.76 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.675 2.25 . . . . 0.0 112.085 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -89.36 -7.97 54.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.008 0.432 . . . . 0.0 110.178 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.598 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 11.5 t60 -72.66 131.17 42.06 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -87.93 132.04 34.37 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 121.153 0.501 . . . . 0.0 111.142 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.87 140.38 22.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.728 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 53.1 tp -80.99 94.7 6.6 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.776 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.8 p -99.2 178.0 5.04 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -178.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -67.03 -17.88 65.11 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.498 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.474 ' O ' ' CD2' ' A' ' 79' ' ' TYR . 33.3 t80 -106.25 24.31 12.7 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 120.655 0.264 . . . . 0.0 111.35 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.33 -142.63 15.96 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -92.78 128.85 38.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.85 0.357 . . . . 0.0 110.85 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 82.8 mtp180 -140.91 130.85 24.5 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.903 179.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.73 142.7 22.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.111 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.56 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -61.82 -38.28 87.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.065 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.51 -1.23 4.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.195 -1.002 . . . . 0.0 111.902 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.7 tt0 -107.72 -4.04 18.56 Favored 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 121.446 0.641 . . . . 0.0 110.003 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.2 mt -77.4 128.78 34.84 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.535 0.683 . . . . 0.0 111.259 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.523 ' O ' ' N ' ' A' ' 90' ' ' GLY . 2.3 mmm180 -129.14 147.1 50.96 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.955 -1.02 . . . . 0.0 111.1 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -43.55 91.46 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 121.08 0.467 . . . . 0.0 110.527 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.71 -13.4 0.67 Allowed Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -86.46 130.38 34.52 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.858 0.361 . . . . 0.0 110.32 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.43 ' HE ' HG22 ' A' ' 107' ' ' VAL . 99.5 mtt180 -92.7 134.91 34.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.65 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.2 m -120.53 153.54 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.835 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -69.57 125.64 27.31 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.986 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 104' ' ' ARG . 17.3 m -124.1 160.43 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.76 178.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -105.2 128.88 53.62 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.784 0.325 . . . . 0.0 110.543 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 104' ' ' ARG . 43.0 t0 -100.11 123.3 44.19 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 178.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.3 p -75.16 -15.41 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 118.47 0.577 . . . . 0.0 111.223 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.7 mm-40 -69.43 -59.13 3.19 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 120.616 -0.434 . . . . 0.0 109.956 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.419 ' C ' ' H ' ' A' ' 102' ' ' GLU . 44.1 p -97.09 -11.54 24.26 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.83 -12.51 8.5 Favored Glycine 0 C--N 1.332 0.355 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.419 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -84.45 159.69 20.72 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.947 0.403 . . . . 0.0 110.892 -177.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.569 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.31 140.29 36.22 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.865 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.481 ' CZ ' ' OD2' ' A' ' 97' ' ' ASP . 32.5 mtm180 -137.83 168.79 18.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.962 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -109.32 141.17 42.03 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.633 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.402 ' OG ' HG21 ' A' ' 95' ' ' VAL . 11.4 m -138.03 158.69 43.81 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' HE ' ' A' ' 92' ' ' ARG . 65.1 t -92.1 154.3 3.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.554 0.216 . . . . 0.0 110.49 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.403 ' N ' HG12 ' A' ' 107' ' ' VAL . 79.1 mt -74.15 155.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.03 0.443 . . . . 0.0 110.437 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.4 ' N ' HG22 ' A' ' 108' ' ' ILE . 14.2 mmt180 -101.68 -45.64 5.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.038 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -167.44 149.88 5.95 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.427 ' C ' HD22 ' A' ' 112' ' ' LEU . 80.6 t -94.1 133.41 35.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.466 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -100.15 148.33 34.73 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.239 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.14 156.12 66.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 122.51 2.14 . . . . 0.0 111.095 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.461 HG23 ' H ' ' A' ' 114' ' ' THR . 1.1 p -63.63 154.74 31.9 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -148.41 144.66 27.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 82.0 mtm-85 -77.38 132.02 38.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.184 0.516 . . . . 0.0 110.612 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -165.34 164.12 19.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.066 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 1.1 tpp85 -74.36 145.21 44.0 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.845 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 22.3 p -129.41 143.78 50.98 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -116.88 175.87 5.38 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.085 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -144.29 129.14 18.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.817 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.459 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.7 mt -122.24 171.09 9.28 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.619 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -137.94 107.17 6.07 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.623 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.521 ' O ' ' C ' ' A' ' 125' ' ' GLU . 23.7 t -88.03 115.55 28.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.068 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.533 ' OE1' ' NH1' ' A' ' 43' ' ' ARG . 28.1 tt0 15.54 -118.3 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 O-C-N 124.011 0.82 . . . . 0.0 111.212 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -98.64 -27.2 14.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.027 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 81.2 mt -84.99 87.25 7.35 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.594 ' C ' HG22 ' A' ' 129' ' ' THR . 6.5 m170 -60.44 98.05 0.06 Allowed 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.594 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.44 152.71 0.03 OUTLIER 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.566 HD23 ' N ' ' A' ' 130' ' ' LEU . 1.4 pt? -156.04 157.85 36.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.542 0.686 . . . . 0.0 112.095 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.9 p -89.08 125.47 42.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.568 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.03 123.31 24.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.665 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.472 ' C ' ' H ' ' A' ' 135' ' ' VAL . 77.6 mm-40 56.94 45.3 21.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.2 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.6 -19.67 0.88 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.386 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.472 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.4 t -90.08 152.43 3.34 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.33 0 CA-C-N 117.212 0.506 . . . . 0.0 110.773 -179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.5 t -112.93 117.75 56.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 138' ' ' HIS . 19.1 m -147.28 139.49 18.83 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.601 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.598 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 59.8 t-80 -36.17 157.5 0.01 OUTLIER 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 118.043 0.383 . . . . 0.0 111.93 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.484 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 25.5 p30 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.447 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.402 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 22.2 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 62.3 mt -110.59 134.82 52.06 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.459 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.14 161.57 25.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.833 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.42 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 49.3 tt0 -63.41 144.54 56.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.125 178.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.53 -16.45 31.63 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.615 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 24.7 m -68.44 122.54 18.63 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -95.99 115.67 27.78 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-O 120.858 0.361 . . . . 0.0 110.35 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.4 mt -100.53 113.31 35.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -76.47 136.8 39.39 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 12.0 t0 -104.08 130.81 22.7 Favored Pre-proline 0 CA--C 1.539 0.522 0 N-CA-C 110.28 -0.267 . . . . 0.0 110.28 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.56 -29.57 13.12 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.018 1.812 . . . . 0.0 112.431 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.513 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.9 t -71.18 -55.17 14.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.042 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.1 p -77.33 -33.58 55.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 120.902 0.382 . . . . 0.0 110.236 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.25 11.4 84.34 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.52 -168.68 1.38 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 117.498 0.649 . . . . 0.0 109.858 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.2 m -112.79 115.87 29.19 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.198 0.523 . . . . 0.0 110.24 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.5 m170 -105.64 145.6 30.82 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.061 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -99.47 129.67 45.67 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.982 -0.287 . . . . 0.0 110.315 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.449 HD11 HD23 ' A' ' 122' ' ' LEU . 1.0 OUTLIER -53.5 -38.64 33.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-O 120.885 0.374 . . . . 0.0 111.121 -178.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.8 pt-20 -60.39 -35.13 75.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.883 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -83.74 -40.22 19.1 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.167 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.4 t -67.53 -42.08 86.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.614 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.538 ' CG2' HD21 ' A' ' 122' ' ' LEU . 53.4 t -74.96 -45.38 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.807 -178.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 62.8 t0 -60.87 -35.52 76.81 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 120.775 0.321 . . . . 0.0 111.088 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.47 26.23 24.26 Favored Glycine 0 C--O 1.229 -0.157 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 81.3 mtt85 17.63 60.95 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.121 0 O-C-N 123.907 0.416 . . . . 0.0 109.892 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.5 mttt -86.26 133.6 40.29 Favored Pre-proline 0 N--CA 1.447 -0.619 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.959 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -75.48 86.06 1.51 Allowed 'Trans proline' 0 C--N 1.313 -1.295 0 C-N-CA 121.499 1.466 . . . . 0.0 110.56 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.613 ' C ' HD12 ' A' ' 29' ' ' ILE . 2.4 pp -116.91 -172.81 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 120.778 0.323 . . . . 0.0 110.776 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.407 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 38.2 m80 -128.37 162.57 26.79 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.449 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -146.52 170.5 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.8 t -90.05 134.18 29.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.99 167.43 10.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.71 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.76 142.78 43.01 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.04 0.448 . . . . 0.0 110.521 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.96 176.78 4.89 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.406 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.673 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 73.4 mmtt -71.41 -13.73 61.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.634 0.254 . . . . 0.0 110.531 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.13 -16.1 57.16 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.333 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.43 18.89 56.28 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.8 p -100.44 137.38 38.93 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.759 0.314 . . . . 0.0 111.139 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -93.95 130.43 40.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.683 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -139.05 138.61 37.3 Favored 'General case' 0 C--O 1.223 -0.298 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.743 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.52 142.18 51.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.635 -178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.535 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 11.1 mmp_? -144.06 138.26 14.83 Favored Pre-proline 0 CA--C 1.537 0.458 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.645 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.07 156.5 33.99 Favored 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 122.393 2.062 . . . . 0.0 112.732 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.9 t -98.72 136.26 30.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.502 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 178.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 18.6 m -127.62 3.24 3.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.855 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.7 OUTLIER -151.64 145.33 25.01 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.345 179.089 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.583 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.92 124.23 14.65 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.148 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -139.56 145.66 38.89 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 49.0 p-10 -90.52 137.36 32.41 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.438 ' HA ' HE21 ' A' ' 51' ' ' GLN . 0.0 OUTLIER -96.95 -0.97 46.65 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.479 -179.669 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.24 -178.39 53.49 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.416 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.3 m -85.11 121.99 28.66 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.907 0.384 . . . . 0.0 110.214 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 -145.14 165.48 28.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.551 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -76.94 140.79 40.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.073 179.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.4 m -146.59 154.49 12.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.65 HD11 ' HB1' ' A' ' 84' ' ' ALA . 47.3 pt -107.62 160.72 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.463 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -115.67 139.71 15.63 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 179.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 67.0 mt -114.23 108.53 17.07 Favored 'General case' 0 C--O 1.219 -0.526 0 CA-C-O 120.801 0.334 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.436 HH11 ' CG2' ' A' ' 66' ' ' ILE . 10.9 tpt180 -78.67 108.28 11.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.449 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.627 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.9 mp . . . . . 0 CA--C 1.512 -0.518 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.248 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.665 HD13 ' H ' ' A' ' 66' ' ' ILE . 0.0 OUTLIER -129.19 168.75 21.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 120.846 0.355 . . . . 0.0 110.547 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.9 tp -130.79 115.55 16.77 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.621 0.248 . . . . 0.0 110.545 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.2 m95 -101.64 105.36 16.28 Favored 'General case' 0 N--CA 1.463 0.209 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 178.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.44 171.22 14.81 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.144 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -76.99 157.66 81.19 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.571 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 85' ' ' GLY . 33.8 Cg_endo -62.46 -17.07 55.97 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.603 2.202 . . . . 0.0 111.869 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 23.6 p30 -98.07 -5.64 33.41 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.861 0.362 . . . . 0.0 110.527 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.555 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 9.0 t60 -72.56 131.98 43.19 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -86.01 123.2 31.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.273 0.559 . . . . 0.0 111.082 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' LEU . 91.4 t -102.4 91.4 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.366 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' VAL . 35.2 tp -32.22 95.84 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.366 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.478 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -99.75 173.62 6.61 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -177.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -63.37 -20.0 65.15 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.042 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.413 ' CD2' ' NH2' ' A' ' 82' ' ' ARG . 63.9 m-85 -104.94 22.79 14.62 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.847 -0.16 . . . . 0.0 111.046 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.69 -144.64 16.16 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.673 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 89.2 m95 -90.75 124.74 35.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.509 0.195 . . . . 0.0 111.157 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.413 ' NH2' ' CD2' ' A' ' 79' ' ' TYR . 88.7 mtt180 -130.23 130.03 44.1 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.13 141.91 54.52 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.65 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -72.34 2.0 6.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.485 179.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -83.67 -14.52 73.0 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -129.37 19.23 5.82 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 122.829 -0.218 . . . . 0.0 111.44 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.476 HD12 ' HA ' ' A' ' 84' ' ' ALA . 28.3 mt -82.41 136.23 34.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.308 0.575 . . . . 0.0 110.797 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 58.0 mmt-85 -132.79 148.84 52.32 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.709 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -45.41 103.0 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.593 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.41 -15.59 1.11 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -82.31 130.28 35.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.791 0.329 . . . . 0.0 110.913 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HE ' ' CG1' ' A' ' 107' ' ' VAL . 99.5 mtt180 -91.32 129.17 37.35 Favored 'General case' 0 C--O 1.224 -0.264 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.686 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.4 m -109.52 143.37 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.986 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -63.63 125.79 25.44 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.579 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 104' ' ' ARG . 30.3 m -122.02 155.47 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.72 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.2 ttt85 -102.54 130.27 49.33 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.607 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -100.34 123.03 44.06 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.17 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.76 -16.65 16.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 118.056 0.389 . . . . 0.0 110.906 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -70.46 -58.87 3.24 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.09 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.431 ' C ' ' H ' ' A' ' 102' ' ' GLU . 30.0 p -96.48 -13.62 22.94 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.539 0.209 . . . . 0.0 110.62 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.33 -14.43 8.7 Favored Glycine 0 C--N 1.331 0.303 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.431 ' H ' ' C ' ' A' ' 100' ' ' THR . 76.7 mt-10 -79.44 153.09 29.91 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.906 0.384 . . . . 0.0 111.185 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.595 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -81.08 139.33 35.74 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.764 179.497 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.434 ' O ' HG22 ' A' ' 95' ' ' VAL . 75.2 mtp180 -138.51 174.27 10.72 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.968 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.478 ' OH ' ' C ' ' A' ' 77' ' ' THR . 2.4 m-85 -113.01 149.67 33.0 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.182 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.6 m -143.25 164.55 29.89 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.4 ' CG1' ' HE ' ' A' ' 92' ' ' ARG . 18.0 m -97.08 155.06 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.695 0.225 . . . . 0.0 110.8 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 95.7 mt -86.99 121.75 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.211 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 67.2 mtp180 -68.55 -33.9 74.9 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -168.24 150.45 5.32 Favored 'General case' 0 N--CA 1.456 -0.163 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.8 t -97.15 136.38 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.474 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.2 mm? -96.22 122.38 58.06 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.082 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.64 166.0 0.16 Allowed 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.266 1.977 . . . . 0.0 111.607 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.408 ' H ' HG23 ' A' ' 114' ' ' THR . 4.5 p -66.93 151.32 47.83 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.166 0.508 . . . . 0.0 110.949 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.5 mtp85 -134.89 -143.28 0.2 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.81 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 36.4 mtm-85 -154.01 131.1 11.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.848 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.58 171.98 3.18 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.26 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 81.3 mtp180 -74.42 145.09 43.98 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.954 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.1 p -123.14 142.47 50.86 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.659 -0.496 . . . . 0.0 109.659 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -113.62 171.98 7.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.66 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.577 ' C ' HD22 ' A' ' 122' ' ' LEU . 49.6 t0 -151.85 125.8 9.13 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.896 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.6 170.16 8.52 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.207 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.4 tp10 -137.61 105.28 5.57 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.33 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.61 118.62 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -61.85 146.04 50.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.523 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 69.24 -69.9 0.15 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.288 178.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 90.5 mt -100.44 95.8 6.98 Favored 'General case' 0 CA--C 1.514 -0.424 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.591 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 4.8 p80 -65.83 99.73 0.5 Allowed 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.6 145.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.578 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.661 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.5 pp -145.62 154.05 41.7 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.437 0.637 . . . . 0.0 111.619 -179.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 130' ' ' LEU . 68.7 t -89.92 125.69 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.738 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.615 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.73 135.35 43.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.249 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.621 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.2 mm-40 49.73 45.59 24.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.123 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.14 22.51 55.72 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.916 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.6 t -128.99 152.07 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.8 t -105.25 110.84 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 O-C-N 122.065 -0.397 . . . . 0.0 110.536 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 138' ' ' HIS . 13.4 m -146.99 138.52 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.555 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 56.2 t-80 -33.93 153.73 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.752 0.311 . . . . 0.0 111.793 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.287 -179.571 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.471 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 30.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 89.0 mt -107.11 134.55 50.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.912 0.387 . . . . 0.0 110.406 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.32 163.61 23.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.089 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -64.14 139.69 58.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.615 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.17 -18.66 25.67 Favored Glycine 0 C--N 1.334 0.454 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.459 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.6 m -69.78 123.93 22.69 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.505 ' NE ' HG21 ' A' ' 16' ' ' THR . 77.5 mtp85 -97.85 116.64 30.46 Favored 'General case' 0 C--O 1.231 0.088 0 CA-C-O 120.982 0.42 . . . . 0.0 110.7 -179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.462 HD11 HD13 ' A' ' 19' ' ' ILE . 18.0 mt -101.53 115.23 42.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.756 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -76.57 135.9 39.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 5.0 t70 -104.15 132.42 21.01 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 110.571 -0.159 . . . . 0.0 110.571 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.23 -31.84 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 121.838 1.692 . . . . 0.0 112.462 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 74.9 t -69.89 -55.25 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.047 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.6 p -77.54 -35.6 53.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.973 0.415 . . . . 0.0 110.182 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 10.45 85.46 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.458 HG22 ' N ' ' A' ' 16' ' ' THR . 88.2 m -114.09 157.51 22.47 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 117.276 0.538 . . . . 0.0 110.09 -179.659 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.505 HG21 ' NE ' ' A' ' 7' ' ' ARG . 28.2 m -78.97 116.13 19.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.555 0.693 . . . . 0.0 110.897 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . 0.459 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 61.8 m-70 -104.89 144.87 31.19 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.848 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -98.75 128.32 44.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.304 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.523 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -52.8 -38.83 29.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 CA-C-O 120.704 0.287 . . . . 0.0 111.012 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.497 ' N ' HG23 ' A' ' 19' ' ' ILE . 9.1 pt-20 -57.03 -32.62 66.36 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.295 0.569 . . . . 0.0 110.806 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -83.57 -37.87 22.41 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.033 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.75 -42.4 86.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.719 HG22 HD21 ' A' ' 122' ' ' LEU . 87.5 t -73.08 -46.9 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 65.2 t0 -57.67 -36.0 71.32 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.836 0.351 . . . . 0.0 110.831 -178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -108.31 29.12 10.46 Favored Glycine 0 C--O 1.228 -0.254 0 CA-C-O 118.829 -0.984 . . . . 0.0 111.147 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.1 ptm180 13.08 67.91 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.488 0.644 . . . . 0.0 110.836 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.436 ' C ' ' H ' ' A' ' 29' ' ' ILE . 82.7 mttt -87.56 144.62 35.74 Favored Pre-proline 0 N--CA 1.45 -0.431 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.31 -177.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.587 ' O ' ' O ' ' A' ' 29' ' ' ILE . 57.4 Cg_endo -70.87 8.22 1.08 Allowed 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 122.057 1.838 . . . . 0.0 111.744 179.292 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.587 ' O ' ' O ' ' A' ' 28' ' ' PRO . 15.1 tt -37.1 172.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.847 -178.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.527 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 9.5 m80 -124.83 162.97 23.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.7 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 34.7 m -146.2 169.87 5.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.2 t -87.3 134.13 28.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.455 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.36 166.17 10.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.704 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.87 141.6 40.71 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.184 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.36 178.19 4.37 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -72.82 -12.78 61.12 Favored 'General case' 0 C--O 1.233 0.186 0 O-C-N 122.248 -0.283 . . . . 0.0 110.676 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -78.59 -17.71 55.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.366 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.92 18.59 55.85 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.1 p -100.01 137.29 38.66 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.983 0.42 . . . . 0.0 111.001 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.7 mt -94.34 131.05 40.37 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.714 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 4.9 t-80 -139.55 138.99 36.74 Favored 'General case' 0 C--O 1.221 -0.425 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.791 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.56 142.59 51.76 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -145.64 137.46 13.11 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.869 -179.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_endo -75.79 157.65 39.36 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.644 2.229 . . . . 0.0 112.401 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.6 t -90.91 127.44 43.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.8 -4.8 11.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.782 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.0 p -151.79 143.08 23.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 O-C-N 121.756 -0.59 . . . . 0.0 109.445 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -137.6 117.28 13.06 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.189 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -144.8 146.29 32.05 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 45.7 p-10 -90.61 138.41 31.59 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.746 ' OE1' ' O ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -103.74 7.04 37.21 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.771 -179.826 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.746 ' O ' ' OE1' ' A' ' 51' ' ' GLN . . . 92.02 -175.65 38.43 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-O 121.552 0.529 . . . . 0.0 112.802 177.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.581 HG23 ' C ' ' A' ' 117' ' ' ALA . 61.3 m -100.84 131.73 46.58 Favored 'General case' 0 N--CA 1.468 0.457 0 O-C-N 121.296 -1.12 . . . . 0.0 108.981 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 80.5 mtp180 -148.32 172.94 13.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.32 0.581 . . . . 0.0 110.382 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -75.54 140.34 42.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.622 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.6 m -140.92 158.13 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.542 HD11 ' CB ' ' A' ' 84' ' ' ALA . 46.6 pt -112.7 151.56 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 CA-C-O 120.848 0.356 . . . . 0.0 110.809 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.86 132.17 10.99 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.7 mt -111.84 106.27 14.96 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.259 0.552 . . . . 0.0 109.781 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -86.16 117.37 24.94 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.278 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 25.4 mm . . . . . 0 N--CA 1.47 0.556 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.461 -179.549 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.377 0 CA-C-O 121.396 0.617 . . . . 0.0 109.371 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 8.9 tp -123.36 144.03 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.892 -178.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 36.5 tp -136.74 118.97 15.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.862 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.05 127.66 50.23 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.36 170.27 20.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.886 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.87 155.9 82.76 Favored Pre-proline 0 CA--C 1.536 0.439 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.767 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 -18.92 64.18 Favored 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.68 2.254 . . . . 0.0 111.989 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -95.46 -5.0 44.0 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.025 0.441 . . . . 0.0 110.022 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.561 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -69.8 130.13 41.45 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.215 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -86.31 128.66 34.95 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.459 0.647 . . . . 0.0 111.446 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.56 144.44 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.185 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.469 HD13 ' C ' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -82.55 94.47 7.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.512 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 17.0 p -100.82 175.89 5.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.83 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.654 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 0.7 OUTLIER -60.41 -21.06 61.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.524 -179.32 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.98 24.25 13.1 Favored 'General case' 0 CA--C 1.516 -0.33 0 C-N-CA 121.303 -0.159 . . . . 0.0 111.095 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.62 -169.39 34.08 Favored Glycine 0 CA--C 1.523 0.583 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.509 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -60.84 123.78 18.55 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.925 -0.638 . . . . 0.0 110.775 -178.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -140.01 134.15 31.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.028 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.81 139.24 40.42 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.04 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.542 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.21 -37.29 86.66 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.28 1.87 1.85 Allowed Glycine 0 C--N 1.336 0.573 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.015 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.421 ' H ' ' C ' ' A' ' 84' ' ' ALA . 75.8 mt-10 -110.01 3.4 20.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.272 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.68 133.76 34.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.334 0.588 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.533 ' O ' ' N ' ' A' ' 90' ' ' GLY . 10.2 tpt180 -127.88 148.66 50.48 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.599 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -49.72 86.76 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.232 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 159.27 -18.37 0.26 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -77.94 134.75 37.81 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 88.8 mtm180 -92.36 139.59 30.45 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.927 -178.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.52 154.2 39.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.285 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -83.52 133.87 34.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.904 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.514 HG12 HG22 ' A' ' 135' ' ' VAL . 30.9 m -129.0 165.46 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.224 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.54 128.62 44.43 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.816 0.341 . . . . 0.0 111.0 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -99.64 122.64 42.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.982 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.6 p -75.33 -16.43 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 CA-C-N 118.425 0.557 . . . . 0.0 110.69 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -69.15 -58.59 3.86 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 120.524 -0.471 . . . . 0.0 109.877 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.469 ' C ' ' H ' ' A' ' 102' ' ' GLU . 72.5 p -95.99 -10.78 27.75 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.98 -12.34 6.61 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.469 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.0 mt-10 -89.13 161.23 16.61 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.269 0.557 . . . . 0.0 111.605 -177.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.552 ' H ' ' CD2' ' A' ' 103' ' ' LEU . 1.9 pt? -74.56 139.26 43.61 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.052 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 37.6 ptt180 -130.98 158.05 41.31 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.654 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -104.15 135.98 44.62 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 42.8 m -144.07 166.19 25.68 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 108' ' ' ILE . 94.1 t -94.84 154.44 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 110.417 -0.216 . . . . 0.0 110.417 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.471 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.9 mt -67.42 160.2 4.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.471 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 74.3 ttt180 -105.64 -48.91 3.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.648 179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -164.82 142.36 6.3 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.3 t -94.37 134.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.8 mm? -101.8 147.16 33.48 Favored Pre-proline 0 CA--C 1.538 0.501 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.855 -179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.17 165.27 30.87 Favored 'Trans proline' 0 N--CA 1.499 1.805 0 C-N-CA 122.967 2.445 . . . . 0.0 110.938 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -69.38 157.1 37.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.794 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttp180 -141.92 -141.75 0.13 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.377 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.405 ' H ' ' HG2' ' A' ' 115' ' ' ARG . 78.3 mtm-85 -151.89 135.23 15.99 Favored 'General case' 0 C--N 1.33 -0.243 0 O-C-N 123.471 0.482 . . . . 0.0 110.272 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . 0.581 ' C ' HG23 ' A' ' 53' ' ' THR . . . -173.17 169.45 4.56 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.141 0.496 . . . . 0.0 110.952 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 18.5 tpp180 -74.59 146.46 42.5 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.592 ' OG1' ' NE2' ' A' ' 51' ' ' GLN . 0.6 OUTLIER -136.47 154.14 50.84 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -131.53 -178.53 4.9 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.677 -175.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -153.74 121.56 5.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.192 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.719 HD21 HG22 ' A' ' 23' ' ' VAL . 85.4 mt -117.13 127.9 54.59 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.783 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -88.52 108.18 19.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.815 0.341 . . . . 0.0 110.36 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' A' ' 126' ' ' GLU . 18.1 t -80.6 111.84 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.993 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 124' ' ' VAL . 2.8 tm-20 25.1 -87.63 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.498 ' N ' ' O ' ' A' ' 124' ' ' VAL . 44.2 tp10 -139.25 -27.86 0.79 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.545 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.499 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.1 mt -80.58 66.0 5.93 Favored 'General case' 0 CA--C 1.506 -0.732 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 127' ' ' LEU . 48.3 m170 -38.9 94.96 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.423 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 172.07 141.05 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.612 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.668 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.8 pp -147.56 154.79 41.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.46 0.648 . . . . 0.0 111.858 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 8' ' ' ILE . 72.7 t -91.01 126.38 43.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.77 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.459 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.91 134.09 42.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.0 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.573 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 50.68 45.06 27.41 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.933 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.36 24.72 59.49 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.162 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.7 t -129.69 152.47 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -106.49 111.31 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 118.203 0.456 . . . . 0.0 110.75 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' A' ' 138' ' ' HIS . 5.9 m -146.54 140.52 20.54 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.561 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 11.1 t60 -31.35 152.86 0.0 OUTLIER 'General case' 0 C--O 1.226 -0.149 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 17.9 p30 . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.429 -179.406 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.4 mt -117.04 132.13 56.77 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.887 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.93 161.95 26.34 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -63.8 147.1 52.63 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.968 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.31 -15.18 39.3 Favored Glycine 0 C--N 1.336 0.581 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.559 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.5 m -67.13 121.59 15.96 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 80.9 mtm-85 -97.39 116.66 30.02 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 120.764 0.316 . . . . 0.0 110.272 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.422 HD11 ' HB ' ' A' ' 19' ' ' ILE . 9.0 mt -103.68 116.03 46.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.761 -179.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -76.13 136.04 39.82 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 11.9 t0 -103.19 130.41 23.68 Favored Pre-proline 0 CA--C 1.54 0.56 0 C-N-CA 121.187 -0.205 . . . . 0.0 110.52 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.05 -30.54 10.68 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.356 2.037 . . . . 0.0 112.196 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.544 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 57.8 t -72.05 -55.1 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.767 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 m -77.4 -39.98 45.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.175 0.512 . . . . 0.0 110.36 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 10.61 80.83 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.299 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.1 m -112.91 154.87 25.68 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-N 117.612 0.706 . . . . 0.0 109.636 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.8 m -79.05 117.15 19.83 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.265 0.555 . . . . 0.0 110.827 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -106.93 148.55 28.48 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.43 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -100.37 127.54 46.66 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.657 178.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.49 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.5 tt -54.09 -38.01 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 CA-C-O 120.923 0.392 . . . . 0.0 111.523 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.421 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.8 pt-20 -60.03 -33.12 71.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.078 0.466 . . . . 0.0 110.984 -179.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -83.79 -38.2 21.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.713 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.7 -41.26 85.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.245 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.697 HG22 HD21 ' A' ' 122' ' ' LEU . 60.7 t -72.99 -45.62 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -58.1 -34.85 70.64 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 120.696 0.284 . . . . 0.0 110.619 -178.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.76 27.34 11.26 Favored Glycine 0 C--O 1.226 -0.363 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.9 ptt-85 15.01 68.06 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.129 0.49 . . . . 0.0 109.82 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -89.8 135.27 30.69 Favored Pre-proline 0 N--CA 1.446 -0.655 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.984 -176.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.9 85.14 1.54 Allowed 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.848 1.699 . . . . 0.0 110.427 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 16.4 pt -111.92 -171.44 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 110.963 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.45 ' CG ' HG21 ' A' ' 12' ' ' VAL . 65.7 m80 -130.44 159.62 36.49 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.454 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.55 170.49 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.5 t -86.61 131.52 34.56 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.6 146.66 37.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.396 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.02 143.45 45.73 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.938 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.79 176.71 4.94 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.506 ' H ' ' HD3' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -69.87 -14.43 62.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.772 0.32 . . . . 0.0 110.749 179.523 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 37' ' ' ASP . 56.0 t0 -80.44 -18.34 49.08 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.177 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.8 21.23 43.86 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 22.3 p -101.62 137.38 40.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.116 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.58 HD11 ' CD1' ' A' ' 103' ' ' LEU . 62.6 mt -91.35 126.68 36.51 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.745 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -136.76 136.71 39.14 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.579 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.548 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.51 142.02 51.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.487 -178.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.572 HH11 ' CD ' ' A' ' 125' ' ' GLU . 4.2 mmp_? -143.87 137.11 13.98 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.672 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.89 156.47 34.72 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 122.769 2.313 . . . . 0.0 112.962 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -96.64 134.93 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.37 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.34 -0.46 4.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.768 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.7 t -146.65 136.32 23.1 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 118.535 0.607 . . . . 0.0 109.513 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.56 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.62 118.42 15.12 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.291 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -140.74 147.13 38.67 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -96.93 134.04 40.79 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 176.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.604 HE21 ' C ' ' A' ' 119' ' ' THR . 2.2 mt-30 -96.64 3.77 52.32 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.315 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.29 -178.0 49.1 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.724 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -87.67 124.97 34.1 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-O 120.836 0.351 . . . . 0.0 110.17 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 48.2 mmt-85 -143.35 165.04 28.61 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.727 -179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -76.05 142.45 41.79 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.784 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.57 149.8 16.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.61 HD11 ' HB1' ' A' ' 84' ' ' ALA . 46.7 pt -98.87 149.44 5.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.577 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.32 125.8 8.41 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 78.0 mt -108.58 113.37 26.32 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.201 0.524 . . . . 0.0 110.199 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.435 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 53.4 ttp180 -87.46 115.45 24.89 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.481 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.6 mm . . . . . 0 N--CA 1.467 0.411 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.441 -179.66 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.52 -0.204 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.441 HD11 ' CZ2' ' A' ' 68' ' ' TRP . 20.9 tt -118.91 143.65 29.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.11 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.7 tt -118.49 115.38 24.49 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.363 -179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.441 ' CZ2' HD11 ' A' ' 66' ' ' ILE . 98.0 m95 -102.68 125.51 49.44 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.78 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.02 170.97 19.12 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.879 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.53 157.06 65.1 Favored Pre-proline 0 CA--C 1.535 0.372 0 C-N-CA 120.739 -0.385 . . . . 0.0 110.551 179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 85' ' ' GLY . 38.3 Cg_endo -66.24 -18.7 56.17 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.549 2.166 . . . . 0.0 111.985 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -95.39 -6.29 41.32 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.368 . . . . 0.0 110.395 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.543 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 41.4 t60 -72.01 132.2 43.96 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -85.12 123.76 31.0 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.381 0.61 . . . . 0.0 111.629 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.83 140.92 16.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.061 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 47.9 tp -81.4 92.33 6.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.076 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.471 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 39.3 p -98.86 173.15 7.0 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 92' ' ' ARG . 17.3 pt-20 -64.49 -17.05 63.5 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.291 -179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -105.95 24.85 11.7 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.691 0.281 . . . . 0.0 110.787 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.03 -143.5 16.64 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 79.5 m95 -89.1 123.29 33.24 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.729 0.3 . . . . 0.0 111.14 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -122.88 126.06 46.57 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.026 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.45 132.0 46.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.784 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.61 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -69.36 -1.07 7.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.029 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -76.37 -12.93 83.85 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -134.76 27.76 3.61 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.451 HD12 ' HA ' ' A' ' 84' ' ' ALA . 13.3 mt -83.03 133.25 35.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.373 0.606 . . . . 0.0 111.02 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -133.38 148.02 51.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.615 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -47.59 106.59 0.09 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.551 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 147.12 -17.89 1.55 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -82.7 132.94 35.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.643 0.258 . . . . 0.0 110.695 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 85.2 mtm180 -90.04 130.21 36.25 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.364 -0.535 . . . . 0.0 110.302 -179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.9 m -113.49 144.77 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.66 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.15 124.72 26.88 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.708 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.6 m -121.66 165.02 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.146 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.1 tpt180 -101.64 128.91 47.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.61 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.433 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 34.8 t0 -101.13 124.03 46.21 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.534 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG12 ' A' ' 98' ' ' VAL . 97.1 t -74.37 -16.2 16.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 118.29 0.495 . . . . 0.0 111.065 178.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -70.3 -59.29 2.96 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.405 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.426 ' C ' ' H ' ' A' ' 102' ' ' GLU . 19.5 p -98.84 -13.93 19.88 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.627 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.38 -14.26 6.92 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 100' ' ' THR . 46.0 mt-10 -82.09 157.46 24.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 111.175 -177.22 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.58 ' CD1' HD11 ' A' ' 40' ' ' LEU . 7.8 mp -77.22 134.86 38.5 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-O 121.228 0.537 . . . . 0.0 110.153 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.433 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 38.9 ptt180 -132.62 165.4 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.592 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.471 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.1 m-85 -112.04 148.55 33.61 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.048 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 65.1 m -145.15 165.84 27.14 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 57.7 t -91.81 152.31 3.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.62 0.248 . . . . 0.0 110.69 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.516 HG22 ' N ' ' A' ' 109' ' ' ARG . 71.9 mt -70.49 162.26 4.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.304 178.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.516 ' N ' HG22 ' A' ' 108' ' ' ILE . 37.4 mtp85 -106.04 -48.47 3.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.817 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.435 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 85.3 tt0 -167.53 149.14 5.62 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.963 -0.461 . . . . 0.0 109.853 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 112' ' ' LEU . 72.0 t -96.16 134.35 34.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -102.59 151.22 38.22 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.168 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.22 159.85 50.26 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.664 2.243 . . . . 0.0 111.301 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 57' ' ' ILE . 81.7 p -65.75 154.19 39.69 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 120.886 -0.326 . . . . 0.0 110.431 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -149.8 153.36 36.67 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.804 0.811 . . . . 0.0 110.307 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.0 mmm180 -82.55 132.42 35.2 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.634 -179.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.81 167.63 12.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.973 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.1 ttm180 -80.53 145.12 31.98 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.708 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.604 ' C ' HE21 ' A' ' 51' ' ' GLN . 41.9 p -125.95 145.01 50.46 Favored 'General case' 0 CA--C 1.521 -0.142 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.558 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 59.6 m-85 -120.5 175.09 6.16 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.42 -178.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -151.77 123.84 8.14 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.697 HD21 HG22 ' A' ' 23' ' ' VAL . 89.8 mt -122.46 124.59 43.95 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.629 0.252 . . . . 0.0 110.508 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tp10 -89.25 109.56 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.989 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.504 ' O ' ' C ' ' A' ' 125' ' ' GLU . 18.6 t -83.6 115.78 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.918 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.572 ' CD ' HH11 ' A' ' 43' ' ' ARG . 43.7 tt0 20.7 -92.01 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.519 0 O-C-N 123.733 0.645 . . . . 0.0 111.749 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.4 ' N ' ' O ' ' A' ' 124' ' ' VAL . 40.8 tp10 -133.22 -32.46 1.19 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.882 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.508 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.8 mt -74.03 63.04 0.92 Allowed 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.528 ' O ' HG23 ' A' ' 129' ' ' THR . 30.8 m170 -38.48 95.04 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.528 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.33 140.84 0.02 OUTLIER 'General case' 0 C--O 1.233 0.191 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.1 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.6 pp -149.29 156.89 42.81 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.321 0.582 . . . . 0.0 111.796 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.9 121.44 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.607 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.5 145.77 50.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.558 -178.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 135' ' ' VAL . 40.0 mt-10 40.8 46.5 2.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.155 179.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.32 -22.24 0.29 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.658 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.4 t -90.91 152.01 3.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 C-N-CA 122.596 0.358 . . . . 0.0 110.701 179.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.3 t -108.8 115.84 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 120.757 0.313 . . . . 0.0 110.416 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 33.5 m -149.94 144.18 17.62 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.057 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.543 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 52.2 t-80 -30.01 149.95 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 179.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.429 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 22.2 p30 . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.415 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.0 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.415 HD11 HD11 ' A' ' 130' ' ' LEU . 68.9 mt -108.25 135.31 49.79 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.599 -179.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.85 163.22 23.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.732 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 65.2 tt0 -63.19 141.5 58.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.053 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.19 -19.73 31.74 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.3 m -67.68 124.55 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.261 0.077 . . . . 0.0 111.169 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -85.32 150.1 25.0 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.992 0.425 . . . . 0.0 109.989 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 12.9 mt -134.47 108.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.191 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -76.01 125.83 29.86 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 178.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.9 129.85 25.66 Favored Pre-proline 0 CA--C 1.536 0.429 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.12 -30.12 16.62 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.703 1.602 . . . . 0.0 112.433 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 72.2 t -73.73 -55.18 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 32.4 m -74.7 -40.34 61.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.472 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.32 6.64 83.85 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 85.3 m -116.92 162.0 18.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.512 0.656 . . . . 0.0 109.794 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 1.9 p -81.02 116.15 20.83 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.609 0.719 . . . . 0.0 111.301 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 13.4 m80 -97.32 138.6 34.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.22 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -95.64 126.67 41.07 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.695 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.9 tp -53.07 -40.44 37.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 111.388 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.0 pt-20 -57.12 -36.59 70.86 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.371 0.605 . . . . 0.0 110.968 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.2 t0 -81.85 -36.89 27.77 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.63 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.2 t -67.38 -42.24 87.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.252 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 91.5 t -72.2 -46.52 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -55.04 -37.9 67.28 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 120.96 0.41 . . . . 0.0 110.472 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.579 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -111.99 33.32 5.8 Favored Glycine 0 CA--C 1.52 0.374 0 CA-C-O 118.688 -1.062 . . . . 0.0 110.873 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.579 ' C ' ' O ' ' A' ' 25' ' ' GLY . 26.2 ptt180 8.97 74.63 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 117.576 0.688 . . . . 0.0 110.588 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.453 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.4 mttt -89.04 142.03 29.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.944 -177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.514 ' O ' ' O ' ' A' ' 29' ' ' ILE . 58.4 Cg_endo -70.87 11.22 0.53 Allowed 'Trans proline' 0 N--CA 1.491 1.338 0 C-N-CA 121.832 1.688 . . . . 0.0 111.534 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.514 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.3 pp -39.78 171.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.237 -177.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.427 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 4.2 m80 -120.99 166.08 14.35 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.425 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.9 m -148.12 170.01 3.23 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 99.5 t -85.75 137.64 20.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.59 165.47 11.51 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.46 138.66 41.67 Favored 'General case' 0 N--CA 1.462 0.161 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.21 178.0 4.43 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.13 -14.9 61.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.883 0.373 . . . . 0.0 110.885 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -77.93 -18.32 56.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.331 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.38 24.97 34.76 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.7 p -102.87 136.4 42.77 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.649 0.262 . . . . 0.0 110.808 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.97 130.84 44.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.954 0.407 . . . . 0.0 110.532 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -141.64 140.05 33.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.734 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -68.9 142.97 54.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.4 mmp_? -146.24 137.57 12.9 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.428 -179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -74.6 158.32 43.78 Favored 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.611 2.208 . . . . 0.0 112.695 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.2 t -100.03 136.53 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 177.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.1 m -127.83 2.59 3.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 119.032 -0.508 . . . . 0.0 112.159 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.8 t -145.85 134.79 22.55 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 119.349 0.977 . . . . 0.0 108.915 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -132.89 117.6 17.91 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 177.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.504 ' O ' ' OE1' ' A' ' 51' ' ' GLN . 68.4 m-85 -142.81 148.73 37.61 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 48.6 p-10 -97.61 135.8 38.92 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.504 ' OE1' ' O ' ' A' ' 49' ' ' PHE . 0.6 OUTLIER -97.27 8.27 44.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.41 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.47 177.92 50.52 Favored Glycine 0 CA--C 1.527 0.825 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.488 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.549 ' OG1' ' NH1' ' A' ' 118' ' ' ARG . 4.3 m -87.51 127.68 35.24 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.337 -0.432 . . . . 0.0 109.87 179.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.2 mmm180 -148.51 167.49 25.24 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.049 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -73.95 141.79 45.92 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.509 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.7 m -128.88 141.22 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 110.491 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.788 HD13 ' H ' ' A' ' 57' ' ' ILE . 0.1 OUTLIER -100.9 139.78 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.87 179.794 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.48 140.95 15.31 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.103 -0.57 . . . . 0.0 111.846 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 27.6 mt -129.0 115.86 18.43 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-O 121.197 0.522 . . . . 0.0 109.972 -179.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.611 ' NH2' ' NH1' ' A' ' 109' ' ' ARG . 62.9 ttt180 -97.02 114.55 26.18 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.729 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.4 mm . . . . . 0 N--CA 1.465 0.31 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.287 -178.52 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.23 0.067 0 CA-C-O 121.215 0.531 . . . . 0.0 111.174 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.425 HG21 ' CZ2' ' A' ' 68' ' ' TRP . 0.1 OUTLIER -132.07 156.81 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.579 -178.729 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.9 tp -146.21 123.75 11.76 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.427 -0.352 . . . . 0.0 111.723 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.425 ' CZ2' HG21 ' A' ' 66' ' ' ILE . 2.1 m95 -99.42 107.85 20.19 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 175.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.451 ' O ' HD13 ' A' ' 57' ' ' ILE . . . -127.51 177.14 6.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.158 -177.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.9 155.27 52.87 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.225 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -60.44 -27.38 84.74 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.909 2.406 . . . . 0.0 112.08 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' A' ' 74' ' ' LYS . 38.7 t70 -85.9 -6.93 58.99 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.476 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 6.8 t60 -70.53 126.37 29.45 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' A' ' 72' ' ' ASP . 14.3 mptt -89.55 137.4 32.36 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.352 0.596 . . . . 0.0 110.517 -179.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.5 t -105.09 135.85 41.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.151 -0.932 . . . . 0.0 109.586 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.5 tp -76.54 100.37 5.27 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.671 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.492 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 81.8 p -98.81 174.78 6.22 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -178.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.431 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 10.0 pt-20 -67.11 -12.75 60.84 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.674 -0.411 . . . . 0.0 111.438 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.431 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 60.2 m-85 -112.89 22.13 14.76 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.473 0.175 . . . . 0.0 111.473 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.88 -138.01 14.67 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -107.12 138.32 43.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.716 0.293 . . . . 0.0 110.387 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 tpt180 -137.82 130.33 29.51 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.66 141.9 36.07 Favored 'General case' 0 CA--C 1.516 -0.33 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.03 -40.06 88.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.92 -179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.29 -3.74 20.05 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 119.808 -1.187 . . . . 0.0 111.893 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.83 -6.14 20.51 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 117.139 0.469 . . . . 0.0 110.382 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.25 128.74 35.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.622 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.4 mmt85 -134.02 148.44 51.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.383 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.8 ttmt -43.42 92.71 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.002 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.1 -17.58 0.53 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -89.67 128.95 36.16 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.895 0.378 . . . . 0.0 111.059 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -89.63 133.31 34.7 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -178.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.4 m -114.32 144.58 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.791 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.59 130.55 43.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.072 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.5 m -128.92 161.04 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.416 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -107.51 130.59 54.84 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -100.27 123.17 44.17 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.359 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.0 m -75.19 -14.68 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-N 118.534 0.606 . . . . 0.0 110.638 177.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -70.07 -58.38 3.88 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.604 -0.438 . . . . 0.0 109.952 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.7 p -98.12 -10.68 23.82 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.93 -12.61 6.23 Favored Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 93.3 mt-10 -82.32 155.62 24.69 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 120.926 0.393 . . . . 0.0 111.578 -176.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.609 ' H ' HD23 ' A' ' 103' ' ' LEU . 2.0 pt? -81.56 139.83 34.85 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.513 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -140.01 178.39 7.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.17 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.492 ' OH ' ' C ' ' A' ' 77' ' ' THR . 3.6 m-85 -117.36 147.9 42.21 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.028 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.7 m -138.28 161.35 37.13 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.413 HG22 ' N ' ' A' ' 108' ' ' ILE . 10.4 p -91.93 154.57 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.413 ' N ' HG22 ' A' ' 107' ' ' VAL . 50.1 mt -75.89 151.59 6.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 178.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.611 ' NH1' ' NH2' ' A' ' 60' ' ' ARG . 68.7 ttt180 -104.11 -42.39 5.55 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.579 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.46 147.85 5.34 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.404 ' C ' HD12 ' A' ' 112' ' ' LEU . 73.4 t -94.92 133.37 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.0 mp -100.91 151.24 37.57 Favored Pre-proline 0 CA--C 1.537 0.475 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.1 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.47 158.42 56.07 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.804 2.336 . . . . 0.0 111.57 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.6 p -67.57 156.9 35.66 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.101 0.477 . . . . 0.0 110.478 -179.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -133.77 -141.28 0.19 Allowed 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.431 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.1 mtt85 -157.59 130.1 7.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.041 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.7 170.54 4.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.274 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.549 ' NH1' ' OG1' ' A' ' 53' ' ' THR . 64.7 mmt-85 -74.15 151.38 40.07 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.372 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.3 p -131.2 146.52 52.36 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.172 0.511 . . . . 0.0 109.861 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.46 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 68.6 m-85 -123.3 174.07 7.55 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.275 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 120' ' ' PHE . 78.5 m-20 -153.62 123.26 6.73 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.71 177.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 65.5 mt -118.52 126.13 51.34 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -86.59 112.02 21.19 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 120.951 0.405 . . . . 0.0 110.399 -178.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.471 ' O ' ' C ' ' A' ' 125' ' ' GLU . 62.7 t -86.52 114.14 25.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.895 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.471 ' C ' ' O ' ' A' ' 124' ' ' VAL . 40.4 tp10 22.14 -115.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 O-C-N 123.811 0.694 . . . . 0.0 111.936 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.9 tp10 -109.8 -25.64 10.24 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.316 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 129' ' ' THR . 86.3 mt -82.83 66.68 8.56 Favored 'General case' 0 CA--C 1.505 -0.781 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.486 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 2.0 p80 -41.21 98.42 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.77 142.98 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.688 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.663 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.9 pp -149.02 152.78 36.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.396 0.617 . . . . 0.0 111.961 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.411 ' N ' HD12 ' A' ' 130' ' ' LEU . 97.7 t -90.96 126.58 43.67 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.04 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.441 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.39 132.91 41.74 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.067 -179.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.557 ' O ' HG23 ' A' ' 135' ' ' VAL . 14.2 mm-40 52.01 43.71 30.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.542 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.62 28.13 62.23 Favored Glycine 0 CA--C 1.524 0.648 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.175 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.8 t -129.6 151.91 36.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -104.38 109.6 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.551 0.614 . . . . 0.0 110.722 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.431 ' O ' ' C ' ' A' ' 138' ' ' HIS . 28.8 m -147.28 139.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 62.7 t-80 -33.54 149.65 0.01 OUTLIER 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.751 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.349 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.445 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 4.8 m . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 85.4 mt -115.57 134.05 55.43 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.76 162.04 23.07 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.605 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.47 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 25.8 tt0 -62.62 144.42 56.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.939 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.13 -14.6 36.88 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.518 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.2 m -69.22 121.46 16.85 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 121.104 -0.239 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 86.8 mtm180 -84.55 149.89 25.6 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.284 179.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' A' ' 19' ' ' ILE . 73.5 mt -133.49 107.21 10.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.301 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -78.42 131.84 37.08 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -108.83 124.72 33.45 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' HD1' ' A' ' 30' ' ' HIS . 42.4 Cg_endo -68.97 -25.53 32.23 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.248 1.966 . . . . 0.0 111.841 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.1 t -69.95 -56.23 12.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 p -83.55 -38.2 22.01 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.056 0.455 . . . . 0.0 109.887 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.47 12.1 70.46 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.9 m -114.75 155.37 26.82 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 117.963 0.882 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.8 m -80.59 120.65 24.81 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.311 0.577 . . . . 0.0 110.971 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -105.36 145.85 30.21 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.34 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.414 ' O ' HG23 ' A' ' 22' ' ' VAL . 6.6 ttm180 -97.31 123.05 41.0 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.603 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.1 tt -53.99 -40.07 43.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.619 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.7 pt-20 -60.42 -32.71 71.6 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.945 0.402 . . . . 0.0 111.202 -179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -83.7 -39.07 20.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.672 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.488 HG11 ' CD1' ' A' ' 29' ' ' ILE . 92.8 t -67.53 -40.67 84.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.11 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.639 HG22 HD21 ' A' ' 122' ' ' LEU . 61.8 t -72.43 -46.72 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.619 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.11 -34.76 70.55 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-O 120.65 0.262 . . . . 0.0 110.866 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.556 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.81 26.7 18.66 Favored Glycine 0 CA--C 1.518 0.224 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.556 ' C ' ' O ' ' A' ' 25' ' ' GLY . 94.1 mtt-85 17.47 64.55 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.419 ' O ' HG23 ' A' ' 29' ' ' ILE . 78.8 mttt -90.14 114.22 60.12 Favored Pre-proline 0 N--CA 1.448 -0.568 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.058 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -55.88 86.5 0.04 OUTLIER 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.836 1.69 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.488 ' CD1' HG11 ' A' ' 22' ' ' VAL . 12.5 pt -109.24 -172.68 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-O 120.752 0.31 . . . . 0.0 110.707 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.873 ' NE2' ' HB1' ' A' ' 42' ' ' ALA . 6.3 t-80 -127.02 156.86 40.96 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.712 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.64 ' O ' ' CE1' ' A' ' 30' ' ' HIS . 29.2 m -148.46 169.7 3.05 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.87 134.91 27.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 O-C-N 122.115 -0.365 . . . . 0.0 110.36 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.1 167.18 10.19 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.799 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.44 145.3 40.75 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.261 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.12 178.22 4.37 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.577 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.74 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 69.7 mmtt -71.4 -11.6 60.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.024 0.44 . . . . 0.0 110.458 179.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.0 p30 -80.22 -13.41 59.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.29 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.3 19.74 61.87 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 47.4 p -102.18 138.83 38.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 111.594 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.3 mt -92.29 131.0 37.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.181 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -137.3 138.24 39.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.873 ' HB1' ' NE2' ' A' ' 30' ' ' HIS . . . -69.26 136.12 51.48 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.662 ' N ' ' NE2' ' A' ' 30' ' ' HIS . 4.6 mmp_? -146.13 136.53 12.16 Favored Pre-proline 0 CA--C 1.537 0.454 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.178 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.88 159.85 30.87 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.865 2.377 . . . . 0.0 113.118 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.9 t -101.42 139.02 23.66 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 177.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.6 m -130.68 4.56 2.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.06 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 p -149.34 145.2 26.89 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.175 0.898 . . . . 0.0 109.025 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.612 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.26 123.76 13.98 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.51 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -136.41 145.12 44.94 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -91.88 140.32 29.79 Favored 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.496 HE21 ' HB2' ' A' ' 121' ' ' ASP . 46.8 mm-40 -89.84 -4.19 57.72 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.338 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 77.46 21.62 72.18 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.657 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ARG . 0.4 OUTLIER 64.53 135.3 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.836 0.35 . . . . 0.0 110.087 -179.945 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . 0.419 ' CG ' ' O ' ' A' ' 53' ' ' THR . 72.0 mtp180 -157.27 174.92 14.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.404 178.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . 0.443 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 50.3 t0 -73.93 139.67 45.07 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -142.13 152.73 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.09 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.726 HD11 ' HB1' ' A' ' 84' ' ' ALA . 44.6 pt -104.86 152.05 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.177 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.79 138.1 14.26 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.6 mt -121.32 114.57 21.53 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 121.111 0.481 . . . . 0.0 110.365 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -87.0 113.78 23.05 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.888 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 15.7 mm . . . . . 0 CA--C 1.511 -0.523 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 120.887 0.375 . . . . 0.0 110.441 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.47 150.77 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.212 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 57.9 tp -123.99 113.55 18.58 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.823 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.556 ' CG ' ' NH2' ' A' ' 115' ' ' ARG . 95.3 m95 -104.5 121.28 43.14 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.95 171.94 15.53 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.318 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . 0.418 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 40.2 p -78.56 154.41 78.79 Favored Pre-proline 0 C--N 1.329 -0.294 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.109 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.66 -22.15 59.23 Favored 'Trans proline' 0 N--CA 1.495 1.578 0 C-N-CA 122.027 1.818 . . . . 0.0 112.113 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -93.15 -7.71 44.6 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.79 0.328 . . . . 0.0 110.364 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.8 t60 -66.81 126.83 30.29 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mptt -82.72 123.42 29.28 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.219 0.533 . . . . 0.0 111.395 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.5 t -99.73 139.68 20.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.732 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.66 95.02 5.16 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.867 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 13.9 p -98.7 174.67 6.3 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -66.78 -14.9 63.15 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.29 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 68.4 m-85 -108.05 25.22 11.86 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.483 0.183 . . . . 0.0 110.744 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.59 -141.15 15.35 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.74 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 92.5 m95 -94.47 129.31 41.29 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.966 0.412 . . . . 0.0 111.172 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.9 tpt180 -138.7 131.42 29.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.441 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.62 144.49 26.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.012 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.726 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.07 -37.94 84.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 120.936 -0.306 . . . . 0.0 111.613 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.77 -5.33 24.16 Favored Glycine 0 CA--C 1.528 0.9 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.795 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -103.38 4.9 36.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.962 0.411 . . . . 0.0 110.432 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.5 mt -90.67 131.05 36.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.404 0.621 . . . . 0.0 111.122 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.517 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.4 mmt180 -129.2 148.96 51.18 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.705 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -45.27 90.83 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 153.72 -12.33 0.55 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -84.09 130.77 34.84 Favored 'General case' 0 C--O 1.228 -0.079 0 CA-C-O 120.936 0.398 . . . . 0.0 110.672 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.411 ' HE ' HG12 ' A' ' 107' ' ' VAL . 93.9 mtt180 -92.48 141.55 28.39 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.724 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.51 158.98 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.282 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.6 130.35 43.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.105 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.452 HG21 ' OG ' ' A' ' 106' ' ' SER . 1.4 t -130.87 132.79 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.434 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -84.29 125.61 32.42 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.742 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 37.5 t0 -99.81 122.62 43.04 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.999 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 -17.8 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 118.35 0.523 . . . . 0.0 111.303 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 -69.64 -59.74 2.77 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 120.517 -0.473 . . . . 0.0 109.898 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.438 ' C ' ' H ' ' A' ' 102' ' ' GLU . 33.8 p -93.1 -12.85 29.46 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.12 -14.27 6.52 Favored Glycine 0 C--N 1.331 0.278 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.438 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.5 mt-10 -83.38 157.95 22.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.841 0.353 . . . . 0.0 110.824 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.604 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -82.39 133.71 35.23 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.22 0.533 . . . . 0.0 109.852 179.755 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.4 ptt85 -138.18 137.14 37.32 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.408 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -78.55 147.32 33.83 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -177.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.452 ' OG ' HG21 ' A' ' 95' ' ' VAL . 3.2 m -134.98 160.44 38.31 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.575 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.431 HG22 ' H ' ' A' ' 107' ' ' VAL . 17.0 m -91.73 153.67 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.5 mm -70.23 156.33 7.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.084 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.443 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt85 -107.61 -46.63 3.79 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.989 178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -166.3 145.95 6.0 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.436 ' C ' HD22 ' A' ' 112' ' ' LEU . 19.3 t -93.33 131.84 39.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -99.57 148.48 34.79 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.047 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.88 160.34 50.16 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.408 2.072 . . . . 0.0 111.126 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.425 HG23 ' H ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -69.26 156.67 38.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 120.999 0.428 . . . . 0.0 110.585 -179.387 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.556 ' NH2' ' CG ' ' A' ' 68' ' ' TRP . 39.3 ptt180 -139.87 -144.41 0.17 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.964 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -154.03 134.75 13.66 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.69 172.12 3.64 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.983 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.47 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 91.4 mtm-85 -71.45 140.54 50.07 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.519 178.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 143.01 51.28 Favored 'General case' 0 C--O 1.231 0.126 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.455 ' HB3' HG21 ' A' ' 23' ' ' VAL . 52.2 m-85 -120.61 178.02 4.84 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.719 -177.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.496 ' HB2' HE21 ' A' ' 51' ' ' GLN . 51.0 t0 -153.49 120.75 5.81 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.269 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.639 HD21 HG22 ' A' ' 23' ' ' VAL . 84.8 mt -119.57 123.53 44.15 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.744 0.307 . . . . 0.0 110.443 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -88.51 111.51 21.91 Favored 'General case' 0 CA--C 1.514 -0.441 0 C-N-CA 120.612 -0.435 . . . . 0.0 109.899 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 59.8 t -86.49 119.74 35.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.464 -0.495 . . . . 0.0 109.849 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 33.2 tp10 21.71 -121.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.961 0.788 . . . . 0.0 111.148 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -104.17 -26.81 12.39 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.916 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.431 ' O ' ' N ' ' A' ' 129' ' ' THR . 66.9 mt -81.86 70.54 8.78 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.527 ' O ' HG23 ' A' ' 129' ' ' THR . 31.2 m170 -41.57 98.83 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 179.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.46 141.49 0.02 OUTLIER 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.997 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.3 pp -146.65 155.85 42.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.377 0.608 . . . . 0.0 111.614 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 131' ' ' VAL . 8.4 p -89.8 125.48 42.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.875 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.518 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -132.62 132.36 42.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.784 -179.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.618 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 49.7 46.49 23.8 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.22 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.39 -13.35 0.58 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.431 -0.667 . . . . 0.0 111.431 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.2 t -95.18 150.64 4.08 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.27 0 CA-C-N 117.061 0.43 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.6 t -107.97 113.52 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.65 0.262 . . . . 0.0 110.531 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' HIS . 22.9 m -148.28 141.05 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.109 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.546 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 15.8 t60 -30.25 151.5 0.0 OUTLIER 'General case' 0 C--O 1.224 -0.254 0 CA-C-O 120.989 0.424 . . . . 0.0 112.05 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 p30 . . . . . 0 C--N 1.32 -0.683 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.674 -179.342 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 39.4 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . 0.464 HD11 HD11 ' A' ' 130' ' ' LEU . 76.5 mt -109.34 136.42 48.8 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.906 0.384 . . . . 0.0 110.338 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.32 162.75 21.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.519 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.74 141.1 58.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.115 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.87 -17.67 22.5 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 14.4 m -68.91 120.43 14.8 Favored 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.534 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.424 ' HG2' ' HE ' ' A' ' 18' ' ' ARG . 85.9 mtm180 -94.6 114.59 26.57 Favored 'General case' 0 N--CA 1.456 -0.141 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.6 mp -102.37 114.87 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 4.6 t80 -77.16 135.41 38.53 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 9.7 t0 -102.79 132.62 21.05 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.647 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.22 -30.95 9.94 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.672 2.248 . . . . 0.0 112.37 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.512 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 47.1 t -71.31 -55.02 15.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.737 -179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.0 p -78.19 -37.0 46.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.043 0.449 . . . . 0.0 110.271 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.29 82.68 Favored Glycine 0 CA--C 1.52 0.389 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.23 -168.73 1.43 Allowed 'General case' 0 C--N 1.34 0.171 0 CA-C-N 117.621 0.71 . . . . 0.0 109.501 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 63.7 m -113.6 117.34 31.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.259 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 58.9 m170 -103.46 143.59 32.51 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.341 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.424 ' HE ' ' HG2' ' A' ' 7' ' ' ARG . 23.2 mmt85 -96.59 126.08 41.52 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.64 179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.457 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -51.4 -42.54 28.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.213 0.53 . . . . 0.0 111.19 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 4.5 pt-20 -58.72 -32.08 68.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.823 -177.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.5 t0 -83.81 -38.49 21.19 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.29 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 86.6 t -64.65 -40.8 90.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.337 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 50.3 t -73.51 -44.58 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -57.52 -37.94 73.86 Favored 'General case' 0 CA--C 1.513 -0.472 0 C-N-CA 120.823 -0.351 . . . . 0.0 111.227 -177.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.568 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.2 29.37 9.27 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.568 ' C ' ' O ' ' A' ' 25' ' ' GLY . 89.1 mtt-85 16.12 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -87.31 113.99 56.5 Favored Pre-proline 0 N--CA 1.449 -0.491 0 O-C-N 123.434 0.459 . . . . 0.0 111.177 -176.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.6 89.43 0.06 OUTLIER 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.159 1.906 . . . . 0.0 110.414 178.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.51 -172.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 120.867 0.365 . . . . 0.0 110.497 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.425 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 52.4 m80 -127.94 160.63 31.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.598 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -149.41 172.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.2 t -90.93 136.05 25.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.406 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.7 167.77 10.34 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.763 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.0 143.24 44.69 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.325 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.01 177.7 4.55 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.653 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -70.0 -13.63 62.32 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 110.658 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -80.13 -18.21 50.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.453 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.89 24.16 39.14 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.6 p -103.06 136.83 42.15 Favored 'General case' 0 N--CA 1.463 0.207 0 O-C-N 122.724 -0.28 . . . . 0.0 111.281 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.3 mt -94.22 130.67 40.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.819 0.343 . . . . 0.0 110.648 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 7.1 t-160 -142.36 139.24 31.69 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.838 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.91 139.95 53.04 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.555 -178.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.487 ' CZ ' ' OE1' ' A' ' 126' ' ' GLU . 14.5 mmt180 -142.92 140.35 17.99 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.376 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -78.37 157.03 29.28 Favored 'Trans proline' 0 N--CA 1.491 1.324 0 C-N-CA 122.757 2.305 . . . . 0.0 113.019 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.57 134.87 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.8 m -125.6 0.23 4.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.645 -179.06 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.1 141.99 25.8 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 119.144 0.884 . . . . 0.0 108.912 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.592 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -139.39 120.74 14.93 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 178.398 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -139.22 145.86 39.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.318 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -89.95 133.52 34.74 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.545 HE21 ' HB2' ' A' ' 121' ' ' ASP . 27.3 mm-40 -92.75 -1.98 56.36 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.653 -0.249 . . . . 0.0 111.298 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 119' ' ' THR . . . 87.66 175.76 48.35 Favored Glycine 0 C--N 1.339 0.698 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.0 m -90.44 118.67 30.1 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -141.95 172.6 12.46 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.939 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 99.5 m-20 -75.32 141.57 43.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.889 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.1 m -141.85 157.67 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.494 ' CG2' HG22 ' A' ' 114' ' ' THR . 45.5 pt -112.79 153.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.206 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.32 139.26 14.5 Favored Glycine 0 N--CA 1.465 0.577 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.2 mt -120.41 112.35 18.88 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.143 0.497 . . . . 0.0 110.464 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -89.39 111.43 22.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.555 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 16.8 mm . . . . . 0 N--CA 1.468 0.433 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.737 -179.066 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.234 0 CA-C-O 120.948 0.404 . . . . 0.0 110.311 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.453 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.6 mt -124.89 155.01 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.462 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.453 ' N ' HG22 ' A' ' 66' ' ' ILE . 47.1 tp -132.08 116.5 17.13 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.118 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -104.63 115.54 30.52 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.18 172.49 12.62 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.62 156.87 80.41 Favored Pre-proline 0 C--N 1.327 -0.401 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -61.68 -21.65 72.59 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.649 2.233 . . . . 0.0 111.826 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 24.5 p30 -93.09 -4.83 51.66 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.248 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.533 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.5 t60 -72.27 129.56 38.72 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -86.19 127.47 34.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-O 121.277 0.56 . . . . 0.0 110.251 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.827 ' O ' HG23 ' A' ' 77' ' ' THR . 91.2 t -108.26 92.39 2.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.117 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 75' ' ' VAL . 9.6 tp -31.01 93.59 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.644 0.59 . . . . 0.0 111.442 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.827 HG23 ' O ' ' A' ' 75' ' ' VAL . 29.9 p -98.34 177.19 5.44 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.747 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.524 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 6.0 pt-20 -65.05 -21.36 66.82 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.232 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.524 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 57.8 m-85 -104.47 25.09 10.64 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 120.459 0.171 . . . . 0.0 110.905 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.445 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.22 -176.07 41.73 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -58.62 129.68 43.24 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.696 -177.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 73.4 mtm180 -145.9 134.55 22.21 Favored 'General case' 0 C--N 1.339 0.118 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.063 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.27 141.11 24.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.04 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.5 -36.98 84.27 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.143 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.73 -1.44 2.7 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.672 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.7 mt-10 -108.16 6.58 26.92 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 88.9 mt -85.1 125.95 33.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.262 0.553 . . . . 0.0 110.975 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.553 ' O ' ' N ' ' A' ' 90' ' ' GLY . 25.2 mmt85 -130.5 147.53 52.2 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.584 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -45.89 88.22 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 120.897 0.38 . . . . 0.0 110.632 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.0 -16.82 0.37 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -86.23 130.88 34.37 Favored 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.885 0.374 . . . . 0.0 110.419 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.67 135.25 34.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.0 m -120.43 152.02 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.52 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -64.3 139.64 58.79 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.164 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.73 HG21 ' OG ' ' A' ' 106' ' ' SER . 26.9 m -138.55 156.7 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.391 178.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -106.09 130.65 53.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.679 0.276 . . . . 0.0 110.317 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -101.63 125.86 48.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.581 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 98' ' ' VAL . 7.4 p -73.94 -14.74 16.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 118.203 0.456 . . . . 0.0 111.279 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -67.85 -60.38 2.56 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.822 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.571 ' HB ' ' OE1' ' A' ' 102' ' ' GLU . 53.3 m -103.39 -12.9 16.89 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.251 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 80.39 -11.19 39.35 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.995 177.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.703 ' OE1' ' N ' ' A' ' 102' ' ' GLU . 0.0 OUTLIER -77.18 158.8 30.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-O 121.558 0.694 . . . . 0.0 112.161 -179.149 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.52 HD21 ' HB1' ' A' ' 94' ' ' ALA . 5.9 tp -83.07 133.08 35.09 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.824 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.514 ' O ' HG22 ' A' ' 95' ' ' VAL . 85.0 mtp180 -133.9 172.87 12.2 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.3 m-30 -109.46 142.25 40.74 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.389 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.73 ' OG ' HG21 ' A' ' 95' ' ' VAL . 6.7 m -134.43 154.39 51.41 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.37 155.15 3.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 110.864 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 63.1 mt -73.44 153.05 7.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.836 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.8 mmm180 -108.29 -43.24 4.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.021 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -164.69 141.82 6.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.472 ' C ' HD22 ' A' ' 112' ' ' LEU . 16.5 t -95.13 134.09 33.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.034 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.472 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.3 mm? -101.97 125.46 36.78 Favored Pre-proline 0 CA--C 1.538 0.509 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.88 163.72 0.2 Allowed 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.217 1.945 . . . . 0.0 111.831 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.494 HG22 ' CG2' ' A' ' 57' ' ' ILE . 61.4 p -68.04 156.78 36.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.089 0.471 . . . . 0.0 110.812 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' O ' ' OD1' ' A' ' 55' ' ' ASP . 42.4 ttm-85 -139.64 -136.94 0.12 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.974 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -158.97 131.16 6.66 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.411 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.33 172.8 3.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.071 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -76.18 145.75 39.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.871 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 52' ' ' GLY . 3.9 p -122.63 141.49 51.67 Favored 'General case' 0 N--CA 1.463 0.175 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CB ' HD12 ' A' ' 19' ' ' ILE . 83.5 m-85 -119.66 174.04 6.65 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.215 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.545 ' HB2' HE21 ' A' ' 51' ' ' GLN . 43.2 t0 -156.18 125.72 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.389 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 76.5 mt -119.54 121.7 39.98 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -86.73 115.28 24.06 Favored 'General case' 0 CA--C 1.512 -0.491 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.127 -177.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.53 117.89 33.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.542 ' O ' ' N ' ' A' ' 127' ' ' LEU . 40.0 tt0 -58.26 156.05 10.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.505 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.487 ' OE1' ' CZ ' ' A' ' 43' ' ' ARG . 91.0 mt-10 56.24 -69.16 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.395 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.542 ' N ' ' O ' ' A' ' 125' ' ' GLU . 95.9 mt -98.27 101.23 12.62 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.532 ' O ' HG23 ' A' ' 129' ' ' THR . 39.6 m80 -72.3 99.61 2.44 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.04 143.86 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.969 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.641 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.2 pp -144.38 152.86 41.3 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 121.182 0.515 . . . . 0.0 111.293 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.0 p -87.67 128.15 40.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.545 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.32 128.28 35.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.935 -179.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 72.9 mm-40 52.46 47.23 25.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.204 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.87 -18.43 0.47 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.7 t -90.59 151.02 3.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 CA-C-N 117.169 0.485 . . . . 0.0 110.287 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 62.1 t -106.41 112.98 41.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 138' ' ' HIS . 17.4 m -147.77 138.23 17.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.366 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.424 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.533 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 7.7 t60 -35.46 155.67 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.152 0 CA-C-O 120.747 0.308 . . . . 0.0 111.62 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 14.1 p30 . . . . . 0 C--N 1.322 -0.629 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.659 -179.415 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.755 ' CB ' HE22 ' A' ' 51' ' ' GLN . 11.9 m . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.72 131.85 53.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.837 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.78 162.72 18.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.525 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -62.18 141.46 58.18 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.442 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.94 -15.45 21.23 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.495 HG23 ' HG2' ' A' ' 133' ' ' GLU . 22.6 m -71.24 120.02 16.21 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.632 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -93.27 115.96 28.54 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 120.908 0.385 . . . . 0.0 110.322 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 57.5 mt -99.9 112.49 32.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.77 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 3.5 t80 -77.76 135.77 38.05 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.555 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.7 t0 -102.32 131.71 22.24 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.046 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.43 -32.5 7.94 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.577 2.184 . . . . 0.0 112.136 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.555 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.0 t -69.7 -52.88 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.222 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 m -79.02 -40.01 32.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.003 0.43 . . . . 0.0 110.385 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.77 82.17 Favored Glycine 0 N--CA 1.453 -0.205 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.896 HG22 ' H ' ' A' ' 16' ' ' THR . 12.7 m -104.19 -174.5 2.56 Favored 'General case' 0 C--N 1.338 0.086 0 CA-C-N 117.68 0.74 . . . . 0.0 109.613 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.896 ' H ' HG22 ' A' ' 15' ' ' THR . 88.1 m -112.23 118.97 36.76 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.068 179.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -113.43 151.8 30.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.477 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 66.3 mtt85 -100.27 128.77 46.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.607 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.423 HG23 ' N ' ' A' ' 20' ' ' GLU . 4.0 tt -52.28 -38.96 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 120.924 0.392 . . . . 0.0 111.2 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.2 pt-20 -60.78 -34.14 74.04 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.167 0.508 . . . . 0.0 110.771 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.575 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 7.1 t70 -85.31 -38.29 18.99 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.352 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.0 t -69.71 -42.71 80.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.9 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.512 ' CG2' HD21 ' A' ' 122' ' ' LEU . 34.1 t -76.14 -47.83 30.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.578 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 33.1 p-10 -56.53 -30.77 63.45 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 120.987 0.423 . . . . 0.0 110.603 -177.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' N ' ' OD1' ' A' ' 24' ' ' ASP . . . -109.64 21.49 25.71 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.52 ' C ' ' O ' ' A' ' 25' ' ' GLY . 43.1 ptt85 21.79 61.65 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.202 0 O-C-N 124.309 0.652 . . . . 0.0 109.324 179.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -79.02 134.65 59.52 Favored Pre-proline 0 N--CA 1.446 -0.658 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.049 -177.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -76.04 81.35 2.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.305 2.003 . . . . 0.0 111.247 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.6 pt -118.33 -169.72 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.499 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.444 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 54.3 m80 -128.35 164.53 22.44 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.826 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.6 m -148.47 171.79 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.401 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 74.6 t -90.81 131.6 37.55 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.11 167.83 9.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.205 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.62 141.81 39.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.912 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.76 177.73 4.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.909 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -70.43 -12.62 61.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 120.93 0.395 . . . . 0.0 110.609 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 37' ' ' ASP . 64.6 t0 -81.32 -18.77 44.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.88 23.07 43.24 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.2 p -102.59 136.5 42.3 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.81 0.338 . . . . 0.0 111.012 178.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 77.9 mt -91.24 128.64 37.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.835 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -138.98 137.84 36.73 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.596 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.486 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -70.16 140.56 52.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.777 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.486 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.4 mmp_? -144.04 138.8 15.31 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.665 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -77.56 158.21 32.31 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 123.001 2.468 . . . . 0.0 113.142 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.3 t -101.34 136.46 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.4 m -127.89 3.01 3.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.554 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.464 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -152.5 149.54 28.64 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 119.426 1.012 . . . . 0.0 108.585 179.732 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.503 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -149.31 127.04 11.72 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.355 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 -140.02 148.43 41.83 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.708 0.632 . . . . 0.0 112.708 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.446 ' OD2' ' N ' ' A' ' 52' ' ' GLY . 15.1 t70 -105.84 138.58 41.8 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.755 HE22 ' CB ' ' A' ' 1' ' ' CYS . 1.4 mt-30 -101.77 2.97 39.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.489 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.446 ' N ' ' OD2' ' A' ' 50' ' ' ASP . . . 85.15 -165.05 39.13 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.415 178.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.439 HG22 ' NH2' ' A' ' 116' ' ' ARG . 20.9 m -87.16 127.72 35.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -148.82 160.79 42.9 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.821 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.79 139.73 41.95 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.05 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.77 156.07 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.4 pt -107.8 149.37 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.359 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.38 142.68 15.67 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 75.8 mt -127.9 114.73 17.56 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.2 0.524 . . . . 0.0 110.654 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 56.6 ttp180 -96.66 122.45 39.6 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 55.1 mt . . . . . 0 N--CA 1.467 0.403 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.232 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.519 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.1 mt -122.65 151.06 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.236 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -126.56 115.69 19.91 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.931 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -105.41 116.34 31.77 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -143.04 171.78 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.397 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -79.41 156.2 76.1 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.616 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -62.26 -17.48 57.27 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.597 2.198 . . . . 0.0 111.882 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -95.9 -6.71 38.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.742 0.306 . . . . 0.0 110.38 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.4 t60 -69.03 127.46 33.23 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.7 mmtp -85.97 128.19 34.79 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.902 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.6 t -103.31 141.29 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.341 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 56.3 tp -78.0 93.29 4.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.886 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.494 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 76.1 p -98.33 173.66 6.87 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -63.7 -16.24 60.54 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.367 -179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -108.06 25.65 11.34 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.82 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.58 -176.1 46.1 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -58.64 133.12 55.61 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.206 0.527 . . . . 0.0 110.478 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -146.11 134.73 22.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.666 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.99 137.98 31.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.08 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.402 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.3 -37.9 87.32 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.222 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.32 -2.42 3.02 Favored Glycine 0 C--N 1.335 0.503 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.734 -179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.402 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.8 mm-40 -108.17 11.51 27.41 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.918 0.389 . . . . 0.0 110.321 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.0 mt -92.93 128.15 38.7 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.465 0.65 . . . . 0.0 111.072 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.572 ' O ' ' N ' ' A' ' 90' ' ' GLY . 14.8 tpt180 -130.51 149.52 52.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.976 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -45.76 86.57 0.0 OUTLIER 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.557 179.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.77 -14.83 0.29 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -85.02 131.78 34.42 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.707 -0.29 . . . . 0.0 110.29 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -89.21 130.74 35.58 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.434 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.0 m -116.64 146.35 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.584 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.452 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -71.64 137.55 47.98 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.704 0.288 . . . . 0.0 111.073 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.17 161.92 38.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.004 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -103.5 130.98 50.99 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.508 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.543 ' OD2' ' NH2' ' A' ' 104' ' ' ARG . 42.5 t0 -100.62 123.96 45.54 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.33 -16.65 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 CA-C-N 118.297 0.499 . . . . 0.0 111.261 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -71.26 -58.27 3.7 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.139 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.8 p -95.18 -15.02 23.61 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.651 -0.25 . . . . 0.0 110.34 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.99 -13.98 5.07 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 98.2 mt-10 -81.49 159.87 24.09 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-O 120.755 0.312 . . . . 0.0 110.758 -177.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.452 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.7 tp -85.32 128.79 34.83 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.163 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.543 ' NH2' ' OD2' ' A' ' 97' ' ' ASP . 16.5 ptp180 -127.24 175.81 7.88 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.33 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.494 ' OH ' ' C ' ' A' ' 77' ' ' THR . 0.8 OUTLIER -114.68 147.26 39.88 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.835 179.877 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -144.23 163.06 34.76 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.413 ' H ' HG22 ' A' ' 107' ' ' VAL . 9.4 m -94.79 155.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-O 120.674 0.273 . . . . 0.0 110.483 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.468 HG22 ' N ' ' A' ' 109' ' ' ARG . 68.1 mt -73.08 159.43 5.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 120.97 0.414 . . . . 0.0 110.303 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.468 ' N ' HG22 ' A' ' 108' ' ' ILE . 24.9 mmt180 -105.26 -44.97 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.192 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -165.23 143.55 6.27 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.497 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.9 p -96.19 134.86 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.497 HD22 ' C ' ' A' ' 111' ' ' VAL . 2.6 mm? -104.06 147.69 34.71 Favored Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.34 166.66 27.57 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 122.533 2.155 . . . . 0.0 111.357 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 21.8 p -66.12 151.56 46.65 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.21 0.528 . . . . 0.0 110.689 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -133.86 -148.48 0.33 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.092 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.439 ' NH2' HG22 ' A' ' 53' ' ' THR . 25.7 mmm180 -148.88 127.62 12.52 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.147 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.61 175.52 2.48 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.756 -178.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -79.48 147.03 32.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.928 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.2 p -121.12 140.81 51.48 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.1 0.476 . . . . 0.0 109.747 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.542 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 58.3 m-85 -114.9 168.02 10.28 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.921 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.599 ' C ' HD22 ' A' ' 122' ' ' LEU . 66.4 t0 -147.47 131.16 16.91 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.219 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.599 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.62 163.88 14.81 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.486 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -135.1 104.84 6.08 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.017 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 17.4 t -91.93 120.7 41.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.418 ' O ' ' N ' ' A' ' 127' ' ' LEU . 75.7 tt0 -62.69 152.9 34.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.5 tt0 62.17 -70.57 0.05 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.81 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.418 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -99.96 104.45 16.07 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.548 ' O ' HG23 ' A' ' 129' ' ' THR . 62.3 m80 -73.99 100.2 3.49 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 165.89 144.67 0.02 OUTLIER 'General case' 0 C--N 1.344 0.35 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.634 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.43 155.5 43.77 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-O 121.759 0.79 . . . . 0.0 111.566 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.88 125.14 40.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.473 ' HB1' HG21 ' A' ' 6' ' ' THR . . . -131.88 125.73 32.45 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.052 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.525 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 50.36 46.47 25.11 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.939 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.17 -17.24 0.43 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.525 ' H ' ' C ' ' A' ' 133' ' ' GLU . 12.1 t -92.34 150.94 3.68 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 O-C-N 122.285 -0.538 . . . . 0.0 110.727 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.19 114.35 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' HG23 ' A' ' 137' ' ' VAL . 18.0 m -146.74 132.14 12.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.315 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.517 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 50.2 t-80 -37.21 159.86 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.74 0.305 . . . . 0.0 111.74 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.485 ' N ' ' CG ' ' A' ' 138' ' ' HIS . 21.1 p30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.388 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 73.0 mt -106.9 138.44 43.07 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.415 -179.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.87 164.13 20.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.85 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -64.02 145.41 55.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.233 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.03 -17.6 44.43 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.6 m -67.67 123.93 21.86 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.437 ' HE ' HG21 ' A' ' 16' ' ' THR . 61.0 mtp180 -81.62 147.78 29.4 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.829 0.347 . . . . 0.0 110.263 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 19' ' ' ILE . 90.3 mt -134.46 106.4 7.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.857 179.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.4 t80 -77.52 133.5 38.52 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.238 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 17.1 t0 -106.49 129.62 24.2 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.44 -26.4 24.42 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.119 1.88 . . . . 0.0 112.512 -179.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.509 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 38.9 t -78.34 -53.1 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.016 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.8 p -79.97 -34.63 38.5 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 120.975 0.417 . . . . 0.0 110.134 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.94 9.5 86.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.595 HG22 ' N ' ' A' ' 16' ' ' THR . 87.8 m -113.17 166.73 11.16 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 117.873 0.836 . . . . 0.0 109.65 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.595 ' N ' HG22 ' A' ' 15' ' ' THR . 38.5 m -90.26 116.09 27.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.316 0.579 . . . . 0.0 111.321 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -102.12 144.47 30.65 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.153 -0.931 . . . . 0.0 110.147 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 92.2 mtt-85 -98.77 129.84 45.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.606 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.492 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.6 tp -52.79 -40.03 33.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.721 0.296 . . . . 0.0 111.154 -179.104 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.492 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -60.56 -34.98 74.95 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.263 0.554 . . . . 0.0 110.11 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.76 -40.45 22.64 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.741 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 83.4 t -68.47 -42.58 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.4 t -72.21 -46.19 58.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.014 0.375 . . . . 0.0 112.014 -178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 66.8 t0 -58.56 -35.17 71.94 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.157 0.503 . . . . 0.0 110.549 -177.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.3 25.45 12.45 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-O 118.853 -0.971 . . . . 0.0 111.049 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.566 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.2 ptt180 14.03 72.74 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 CA-C-N 117.427 0.614 . . . . 0.0 109.523 179.219 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -87.45 137.61 32.33 Favored Pre-proline 0 N--CA 1.445 -0.705 0 O-C-N 121.673 -0.642 . . . . 0.0 110.925 -175.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -74.52 83.33 1.74 Allowed 'Trans proline' 0 C--N 1.31 -1.465 0 C-N-CA 121.311 1.341 . . . . 0.0 110.618 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.7 pt -119.51 -170.53 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.811 0.339 . . . . 0.0 110.097 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.426 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 26.3 m80 -131.35 163.55 27.61 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.621 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.42 170.96 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 85.9 t -87.16 130.88 36.31 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.563 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.23 166.54 10.34 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.599 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.12 141.99 40.18 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.848 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.72 179.31 3.99 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -72.03 -13.63 61.65 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.91 0.386 . . . . 0.0 110.814 179.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -79.51 -21.55 45.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.402 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 91.46 19.55 41.12 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.4 p -99.22 135.61 40.38 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 121.098 0.475 . . . . 0.0 111.01 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.5 mt -91.65 127.72 37.21 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.269 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -137.95 138.94 39.46 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.73 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.06 142.42 50.86 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.384 -0.526 . . . . 0.0 109.85 -178.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.597 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.6 mmt180 -144.06 137.47 14.15 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.046 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.35 157.18 33.09 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 122.631 2.221 . . . . 0.0 112.73 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.0 135.7 31.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.57 2.88 3.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.647 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -150.69 144.84 25.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 119.173 0.897 . . . . 0.0 108.844 178.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -144.95 128.97 17.53 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -136.41 145.03 44.83 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.242 0.544 . . . . 0.0 112.255 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 53.2 p-10 -114.43 141.22 47.95 Favored 'General case' 0 CA--C 1.5 -0.959 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -110.27 -101.15 0.39 Allowed 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.002 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -173.82 -153.13 9.47 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 114.408 -1.269 . . . . 0.0 112.951 -177.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.1 m -86.32 129.3 34.9 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.1 0.476 . . . . 0.0 111.549 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -150.48 162.25 40.95 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.498 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -78.53 138.61 38.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.21 141.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 120.828 0.347 . . . . 0.0 110.281 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.657 HD11 ' HB1' ' A' ' 84' ' ' ALA . 41.1 pt -90.41 145.64 7.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.795 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.97 140.53 14.91 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 15.1 mt -125.12 114.09 18.57 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.102 0.477 . . . . 0.0 110.559 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.522 ' C ' HD12 ' A' ' 61' ' ' ILE . 36.0 ttm180 -91.53 112.85 24.94 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.275 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.726 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.469 0.489 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.412 -179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 -0.093 0 CA-C-O 120.889 0.376 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.7 mt -119.13 142.0 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.24 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.566 HD23 ' C ' ' A' ' 67' ' ' LEU . 4.2 tt -120.41 113.08 19.8 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.197 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.555 ' N ' HD23 ' A' ' 67' ' ' LEU . 99.5 m95 -103.02 127.6 50.19 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.27 172.22 14.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.317 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.19 155.34 60.43 Favored Pre-proline 0 CA--C 1.535 0.38 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.353 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -63.62 -22.21 70.3 Favored 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.566 2.177 . . . . 0.0 112.012 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -91.24 -8.1 49.36 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 120.977 0.418 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.584 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.7 t60 -70.52 127.52 33.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.559 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.7 mtmm -86.11 132.62 33.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.135 0.493 . . . . 0.0 111.159 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.94 148.82 17.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.22 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 25.9 tp -85.37 92.07 8.37 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.794 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 79' ' ' TYR . 0.1 OUTLIER -107.73 139.92 41.56 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.16 0.505 . . . . 0.0 110.434 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.54 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 67.5 mm-40 60.02 -64.66 0.05 Allowed 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.134 -1.394 . . . . 0.0 111.262 178.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.582 ' N ' ' O ' ' A' ' 77' ' ' THR . 0.3 OUTLIER 179.15 55.71 0.01 OUTLIER 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 174.32 175.81 42.21 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 119.56 -1.305 . . . . 0.0 111.976 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -91.71 129.31 37.71 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.874 0.368 . . . . 0.0 110.815 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 -145.46 138.53 26.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.365 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.89 142.74 23.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.144 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.657 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -65.24 -37.82 88.45 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 120.885 -0.326 . . . . 0.0 111.724 -179.573 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.41 5.22 0.17 Allowed Glycine 0 CA--C 1.527 0.839 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.863 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.9 mt-10 -110.57 1.96 18.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.888 0.344 . . . . 0.0 110.259 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 61.3 mt -80.49 130.6 35.25 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.484 0.659 . . . . 0.0 111.127 -179.274 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.506 ' O ' ' N ' ' A' ' 90' ' ' GLY . 32.5 mmt180 -129.46 151.2 50.35 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.944 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -51.91 87.19 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.27 -21.32 0.49 Allowed Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -73.5 135.93 44.08 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.491 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -90.2 132.21 35.61 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 120.96 0.41 . . . . 0.0 110.248 -178.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.1 143.74 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.502 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.584 ' HB1' HD11 ' A' ' 103' ' ' LEU . . . -65.55 138.07 57.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.734 0.302 . . . . 0.0 110.52 -179.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.2 m -135.18 158.14 40.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.622 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -101.93 129.0 48.09 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.581 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -99.84 120.22 39.41 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.18 179.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 42.4 t -74.62 -15.1 16.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.387 0.539 . . . . 0.0 110.821 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.37 -60.09 2.56 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 120.447 -0.501 . . . . 0.0 109.923 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 74.5 p -96.2 -10.47 28.02 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.78 -12.66 5.99 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -83.21 158.13 22.43 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 120.792 0.33 . . . . 0.0 110.748 -177.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.584 HD11 ' HB1' ' A' ' 94' ' ' ALA . 5.2 tt -86.79 130.5 34.45 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.3 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.7 ptt85 -127.81 173.16 10.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.729 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.54 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.41 143.5 37.25 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.164 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.2 m -141.22 164.15 31.04 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.419 HG12 ' N ' ' A' ' 108' ' ' ILE . 98.2 t -98.1 154.91 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.423 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -70.78 157.1 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.875 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.423 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 59.8 ttt85 -101.43 -47.34 4.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.749 179.274 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -164.62 144.43 7.42 Favored 'General case' 0 C--N 1.341 0.197 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.425 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.7 p -93.0 132.34 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.6 mm? -102.85 148.03 34.96 Favored Pre-proline 0 N--CA 1.469 0.491 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.426 -178.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.71 160.2 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.606 2.204 . . . . 0.0 110.992 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 114' ' ' THR . 1.4 p -65.96 155.01 37.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.061 0.458 . . . . 0.0 110.318 -178.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -147.99 143.69 27.44 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.002 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -71.92 131.01 42.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.964 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.69 168.21 14.58 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.723 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -81.46 149.72 28.63 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.669 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 50.6 p -133.12 144.38 49.89 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 2.8 m-85 -121.5 177.95 5.01 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.475 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -144.22 149.21 36.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.947 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.408 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.3 mt -138.97 170.14 16.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.616 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -137.29 106.66 6.09 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.926 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.48 ' O ' ' C ' ' A' ' 125' ' ' GLU . 48.9 t -85.72 113.55 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 124' ' ' VAL . 0.3 OUTLIER 21.4 -91.11 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 123.816 0.698 . . . . 0.0 111.771 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 124' ' ' VAL . 9.0 tp10 -135.23 -27.97 1.18 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.658 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.597 HD12 ' HE ' ' A' ' 43' ' ' ARG . 83.0 mt -82.13 67.59 8.21 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.416 ' C ' ' O ' ' A' ' 127' ' ' LEU . 20.6 m170 -39.61 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 170.89 140.89 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.117 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.533 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.1 pt? -151.15 160.88 43.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.69 0.757 . . . . 0.0 112.386 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 25.2 t -90.27 124.65 43.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -135.28 124.72 24.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.941 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.5 mm-40 53.12 42.53 32.19 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.04 28.07 68.24 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.652 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -131.58 152.12 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 97.6 t -106.67 111.06 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 O-C-N 122.11 -0.369 . . . . 0.0 110.308 179.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 138' ' ' HIS . 6.5 m -146.14 137.1 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.638 -0.256 . . . . 0.0 110.48 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.584 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 50.4 t-80 -33.57 156.72 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.565 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.436 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 7.7 p-10 . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.363 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.443 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 53.9 m . . . . . 0 N--CA 1.487 1.405 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.2 mt -118.38 134.68 54.85 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.728 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.4 ' HB2' ' CD1' ' A' ' 68' ' ' TRP . . . -80.59 161.7 24.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.503 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.45 145.98 54.53 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.55 -14.38 50.4 Favored Glycine 0 C--N 1.338 0.686 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.442 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.7 m -68.96 123.75 21.87 Favored 'General case' 0 C--O 1.234 0.278 0 O-C-N 122.652 -0.322 . . . . 0.0 110.587 -179.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 18' ' ' ARG . 10.6 mpt_? -83.67 150.62 25.75 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.238 0.542 . . . . 0.0 109.857 178.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 99.1 mt -133.89 107.74 10.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.691 179.252 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -77.25 126.57 31.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.1 t0 -104.91 129.76 24.3 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.982 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.79 -31.03 13.54 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.51 2.14 . . . . 0.0 111.989 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 71.1 t -69.13 -55.95 13.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.31 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 p -78.85 -37.58 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 110.059 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.27 7.99 85.92 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.461 HG22 ' N ' ' A' ' 16' ' ' THR . 91.6 m -115.61 157.63 23.88 Favored 'General case' 0 C--N 1.341 0.196 0 O-C-N 121.937 -0.743 . . . . 0.0 109.756 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.461 ' N ' HG22 ' A' ' 15' ' ' THR . 15.2 m -78.91 116.95 19.56 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.05 0.452 . . . . 0.0 110.982 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -102.24 144.16 31.11 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.371 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 7' ' ' ARG . 39.1 ttm180 -96.53 124.07 40.41 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.324 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -52.67 -40.37 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 O-C-N 121.992 -0.443 . . . . 0.0 111.426 -178.433 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 4.0 pt-20 -56.82 -35.23 68.54 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.984 0.421 . . . . 0.0 110.666 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -83.22 -39.44 20.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.125 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.8 t -66.93 -41.73 87.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.563 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.75 HG22 HD21 ' A' ' 122' ' ' LEU . 71.9 t -72.1 -46.29 59.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.513 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -57.87 -36.34 72.21 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 120.948 -0.301 . . . . 0.0 110.866 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.537 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.85 30.13 10.84 Favored Glycine 0 N--CA 1.452 -0.292 0 N-CA-C 110.536 -1.026 . . . . 0.0 110.536 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.537 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtt85 15.79 64.33 0.01 OUTLIER 'General case' 0 C--N 1.364 1.207 0 CA-C-N 117.418 0.609 . . . . 0.0 110.254 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.429 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.0 mttt -89.78 144.2 31.36 Favored Pre-proline 0 N--CA 1.444 -0.732 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.294 -178.074 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.541 ' O ' ' O ' ' A' ' 29' ' ' ILE . 45.7 Cg_endo -70.21 10.11 0.59 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.236 1.957 . . . . 0.0 112.33 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.616 HG22 ' N ' ' A' ' 30' ' ' HIS . 3.7 mm -37.37 168.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 O-C-N 123.718 0.636 . . . . 0.0 110.124 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.616 ' N ' HG22 ' A' ' 29' ' ' ILE . 3.7 m80 -122.68 167.27 13.65 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.953 0.406 . . . . 0.0 110.707 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.9 m -148.63 170.73 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -89.52 134.65 28.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.246 0 O-C-N 121.675 -0.64 . . . . 0.0 109.624 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.48 166.91 10.61 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.785 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.27 144.99 42.99 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.068 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.12 179.0 4.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.642 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.431 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 68.5 mmtt -68.03 -12.57 61.05 Favored 'General case' 0 C--O 1.235 0.322 0 O-C-N 121.821 -0.549 . . . . 0.0 110.767 179.289 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -76.81 -19.41 57.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.346 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.04 -7.57 76.34 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.9 p -80.08 150.21 30.37 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.262 0.553 . . . . 0.0 111.203 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.9 mt -103.77 135.66 44.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.934 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -141.11 139.72 34.03 Favored 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.701 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.36 140.74 52.22 Favored 'General case' 0 CA--C 1.506 -0.736 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.657 -178.175 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.452 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.0 OUTLIER -143.51 137.66 14.73 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.231 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 43' ' ' ARG . 2.9 Cg_exo -74.78 158.27 43.13 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 123.105 2.537 . . . . 0.0 112.711 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 70.3 t -98.29 133.59 39.96 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 177.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.6 m -125.73 0.14 4.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.215 -179.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.416 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -150.16 145.04 26.05 Favored 'General case' 0 N--CA 1.448 -0.563 0 O-C-N 121.026 -1.046 . . . . 0.0 108.676 179.411 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.584 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.06 123.2 13.68 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 178.095 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -140.94 146.73 37.76 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -87.58 133.24 33.83 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.545 HE21 ' HB2' ' A' ' 121' ' ' ASP . 33.6 mm-40 -89.79 -0.49 57.58 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.86 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.73 174.28 50.06 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 97.4 m -91.67 127.43 37.12 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.031 0.443 . . . . 0.0 110.354 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -154.92 176.2 12.82 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.715 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 55' ' ' ASP . 0.6 OUTLIER -74.19 136.57 42.81 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.163 -179.539 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.959 ' CG2' ' HE1' ' A' ' 68' ' ' TRP . 1.5 m -145.4 156.59 13.3 Favored 'Isoleucine or valine' 0 C--N 1.34 0.153 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.536 ' N ' HD13 ' A' ' 57' ' ' ILE . 0.0 OUTLIER -109.14 155.79 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.845 -178.782 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.77 121.07 5.45 Favored Glycine 0 CA--C 1.521 0.455 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 20.7 mt -102.55 116.77 33.28 Favored 'General case' 0 C--O 1.225 -0.219 0 O-C-N 122.381 -0.482 . . . . 0.0 110.133 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.525 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 55.7 ttp180 -101.09 128.58 47.09 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.161 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 91.6 mt . . . . . 0 N--CA 1.465 0.297 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.575 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.454 -0.266 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.1 tt -121.12 138.79 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.82 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 42.6 tp -126.4 112.5 15.71 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.099 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.959 ' HE1' ' CG2' ' A' ' 56' ' ' VAL . 4.3 t-105 -107.71 125.79 51.81 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HB1' ' O ' ' A' ' 1' ' ' CYS . . . -154.85 175.44 13.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.233 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . 0.736 ' HA ' HG12 ' A' ' 56' ' ' VAL . 71.3 p -77.06 154.0 82.64 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.16 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.12 -22.21 73.97 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.649 2.233 . . . . 0.0 111.889 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -91.07 -6.0 54.41 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.1 t60 -70.96 128.7 36.87 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -85.34 128.42 34.7 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.01 0.433 . . . . 0.0 111.304 -179.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -102.8 139.79 22.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.59 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.9 tp -79.37 93.41 5.33 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.955 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.46 HG21 ' HE ' ' A' ' 82' ' ' ARG . 44.7 p -99.22 175.89 5.73 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.763 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.0 pt-20 -64.94 -17.53 64.46 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.284 -0.567 . . . . 0.0 111.268 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -105.77 25.97 10.18 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 121.125 -0.23 . . . . 0.0 110.811 -178.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.72 -141.13 15.43 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.431 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 87.7 m95 -93.64 129.99 39.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.452 -0.374 . . . . 0.0 111.142 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.46 ' HE ' HG21 ' A' ' 77' ' ' THR . 77.4 mtm180 -142.01 131.78 24.22 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.274 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.76 17.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.024 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.84 -37.67 87.76 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.124 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.1 -2.72 2.97 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.619 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.64 10.87 28.95 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.93 0.395 . . . . 0.0 110.378 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.1 mt -93.51 126.94 38.94 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.378 0.608 . . . . 0.0 111.638 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.589 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.6 mmt180 -132.14 151.63 51.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.469 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -47.88 85.52 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.242 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 160.28 -15.97 0.2 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -84.91 130.32 34.66 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 116.748 0.274 . . . . 0.0 110.304 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -93.37 143.21 26.5 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.275 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.4 m -135.08 158.97 41.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.593 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -75.2 131.62 40.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.635 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 m -129.21 132.88 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -74.13 125.62 28.75 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.927 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -99.7 123.84 44.36 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.182 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 16.1 t -75.39 -16.84 15.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 121.653 -0.654 . . . . 0.0 111.43 178.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -68.97 -59.03 3.33 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 23.1 p -95.43 -11.97 26.72 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.56 -13.2 6.73 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.8 mt-10 -87.15 162.81 17.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.942 0.401 . . . . 0.0 110.639 -177.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.623 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.8 pt? -76.35 140.08 41.28 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -133.18 164.32 27.32 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.763 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.38 137.36 46.48 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.114 -178.373 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -144.04 163.03 34.7 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 107' ' ' VAL . 16.9 m -90.93 154.03 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.605 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -67.94 160.31 4.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.913 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.479 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 37.9 ttm180 -106.87 -51.71 2.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.973 179.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.525 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 83.1 tt0 -166.93 147.3 5.67 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.796 -0.565 . . . . 0.0 109.739 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.471 ' C ' HD22 ' A' ' 112' ' ' LEU . 91.8 t -96.77 134.46 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.471 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.1 mm? -101.64 131.27 23.13 Favored Pre-proline 0 CA--C 1.538 0.504 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.555 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.76 158.53 0.74 Allowed 'Trans proline' 0 N--CA 1.489 1.22 0 C-N-CA 121.956 1.771 . . . . 0.0 111.587 178.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.467 ' H ' HG23 ' A' ' 114' ' ' THR . 1.7 p -69.67 157.38 37.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.462 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.6 mtp85 -154.71 161.62 41.46 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.789 0.804 . . . . 0.0 111.11 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 83.7 mtt180 -85.01 130.21 34.66 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.354 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.54 167.38 13.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.164 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 87.0 mtm180 -81.17 149.92 28.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.143 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 1.4 p -127.61 143.32 51.18 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.288 0.566 . . . . 0.0 109.931 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -114.64 171.32 7.71 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.846 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.545 ' HB2' HE21 ' A' ' 51' ' ' GLN . 45.5 t0 -156.24 128.06 7.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.977 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.75 HD21 HG22 ' A' ' 23' ' ' VAL . 94.4 mt -126.0 125.75 43.18 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.751 0.31 . . . . 0.0 110.375 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 tp10 -86.67 112.62 21.81 Favored 'General case' 0 CA--C 1.513 -0.468 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.957 -178.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.4 t -85.24 112.41 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.55 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 124' ' ' VAL . 52.8 tt0 24.55 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.47 0 O-C-N 123.7 0.625 . . . . 0.0 111.578 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -130.77 -27.97 2.05 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.161 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 129' ' ' THR . 88.2 mt -77.01 66.9 2.92 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.448 ' O ' HG23 ' A' ' 129' ' ' THR . 47.7 m170 -38.27 95.84 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.62 139.32 0.02 OUTLIER 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.464 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.678 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.3 pp -147.29 155.61 42.19 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.659 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.2 p -88.66 123.19 40.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.016 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -131.58 128.78 39.93 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.75 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.537 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.7 mm-40 53.87 45.79 27.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.037 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.81 -17.68 0.5 Allowed Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.22 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.0 t -90.55 150.41 3.75 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.293 0 O-C-N 122.267 -0.549 . . . . 0.0 110.346 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 66.6 t -109.35 113.63 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.671 0.272 . . . . 0.0 110.423 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 138' ' ' HIS . 34.0 m -149.1 143.85 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.998 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.577 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 47.7 t-80 -27.53 148.86 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.087 0.403 . . . . 0.0 112.087 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.319 -0.751 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.721 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -112.25 136.32 51.82 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.392 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.49 161.03 22.52 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.688 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 -62.82 146.22 53.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.832 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.66 -15.82 37.67 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 m -69.07 121.95 17.74 Favored 'General case' 0 C--O 1.233 0.237 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.653 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -83.87 149.86 26.1 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.851 0.358 . . . . 0.0 110.108 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 94.4 mt -134.7 107.4 8.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.34 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -77.41 129.95 36.45 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.634 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -103.49 133.2 20.43 Favored Pre-proline 0 CA--C 1.541 0.626 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.594 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.32 -32.64 7.97 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.7 2.267 . . . . 0.0 112.236 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.634 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 68.9 t -69.22 -52.61 31.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.538 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 p -80.88 -37.74 29.26 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.03 9.74 83.85 Favored Glycine 0 C--N 1.331 0.293 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.22 -168.17 1.33 Allowed 'General case' 0 C--N 1.341 0.229 0 CA-C-N 117.725 0.763 . . . . 0.0 109.653 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.9 m -113.98 116.12 28.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.151 0.501 . . . . 0.0 110.283 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -105.27 147.41 28.11 Favored 'General case' 0 C--O 1.223 -0.335 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.413 -179.585 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.2 mmt85 -99.1 127.26 45.02 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.443 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.471 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.4 tt -53.02 -40.61 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.471 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -59.39 -33.83 71.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.672 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.6 t0 -84.35 -39.81 18.65 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.968 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 71.0 t -67.9 -43.01 86.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 65.2 t -73.57 -46.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.908 -0.317 . . . . 0.0 111.647 -178.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -60.43 -35.78 76.62 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.929 0.395 . . . . 0.0 111.013 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -100.25 25.17 29.3 Favored Glycine 0 C--N 1.322 -0.22 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.547 ' C ' ' O ' ' A' ' 25' ' ' GLY . 66.0 mtp180 17.14 59.73 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 25' ' ' GLY . 80.2 mttt -86.94 135.06 35.74 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.754 -177.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -75.36 84.89 1.64 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.222 1.948 . . . . 0.0 110.234 178.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.655 ' CG1' ' H ' ' A' ' 30' ' ' HIS . 5.2 tt -115.4 -174.5 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.994 0.426 . . . . 0.0 110.243 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.655 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 46.7 m80 -126.43 161.82 27.02 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.08 171.21 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.435 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.2 t -89.58 133.0 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.12 166.51 11.01 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.695 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.45 145.0 42.58 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.228 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.9 177.94 4.46 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -70.8 -14.0 62.25 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 120.848 0.356 . . . . 0.0 110.637 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.405 ' OD1' ' O ' ' A' ' 37' ' ' ASP . 54.5 t0 -80.03 -18.97 48.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.28 179.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.56 23.34 34.01 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.8 p -102.31 136.11 42.72 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.854 0.359 . . . . 0.0 111.168 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' A' ' 41' ' ' HIS . 81.2 mt -92.5 128.59 38.41 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.017 0.437 . . . . 0.0 110.607 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . 0.447 ' CD2' ' O ' ' A' ' 40' ' ' LEU . 32.7 m170 -140.01 138.49 35.49 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.772 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.07 142.19 52.7 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.779 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -143.07 138.56 15.86 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.148 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.87 157.28 34.97 Favored 'Trans proline' 0 N--CA 1.489 1.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.822 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -98.99 133.7 40.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 20.0 m -124.98 -0.27 5.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.37 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -151.22 146.75 26.3 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.174 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.575 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.45 127.51 17.47 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 178.254 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -131.22 144.6 51.45 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.97 0.414 . . . . 0.0 111.643 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -116.08 139.62 50.11 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 178.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.449 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.3 mm-40 -109.2 -110.82 0.32 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.704 -1.134 . . . . 0.0 109.889 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -162.09 -156.81 8.59 Favored Glycine 0 C--N 1.303 -1.277 0 CA-C-N 114.233 -1.348 . . . . 0.0 112.482 -177.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.462 ' O ' HG23 ' A' ' 53' ' ' THR . 4.5 t -98.1 126.75 43.68 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.868 0.366 . . . . 0.0 111.178 -179.104 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -145.74 172.04 13.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.614 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -76.3 136.38 39.6 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.126 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.9 m -140.23 135.88 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.942 0.401 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.676 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.3 pt -87.86 148.79 4.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.717 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.47 126.8 8.35 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.0 mt -108.58 115.84 30.85 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.219 0.533 . . . . 0.0 110.938 -179.275 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -83.03 104.74 13.46 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.881 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.0 mm . . . . . 0 C--N 1.328 -0.353 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.242 -178.263 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.204 0 CA-C-O 120.883 0.373 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.87 155.64 37.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.332 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.0 tp -133.39 118.24 18.2 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.153 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.8 m95 -104.34 114.16 28.21 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -139.45 171.2 14.6 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.484 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.65 157.02 72.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.361 -179.645 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -63.42 -18.13 63.17 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.645 2.23 . . . . 0.0 111.9 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -94.46 -9.99 33.78 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.876 0.37 . . . . 0.0 110.309 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.545 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.8 t60 -71.01 130.77 42.42 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -87.03 130.61 34.39 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.148 0.499 . . . . 0.0 111.144 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.36 142.29 18.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.875 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 52.9 tp -79.91 93.17 5.63 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.691 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 12.1 p -99.02 177.67 5.17 Favored 'General case' 0 CA--C 1.52 -0.19 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -178.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -68.09 -19.15 64.83 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.236 -179.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -104.63 24.1 12.28 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-O 120.733 0.302 . . . . 0.0 110.632 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.69 -176.03 42.56 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 81.2 m95 -57.91 127.76 33.68 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.014 0.435 . . . . 0.0 110.12 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 -142.36 133.54 26.11 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.888 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.44 140.01 29.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.675 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.676 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.15 -37.87 86.83 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.243 -179.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.01 -2.42 4.92 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.526 -179.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -106.0 -0.65 24.77 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.02 0.438 . . . . 0.0 110.418 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -81.55 127.79 33.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.151 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.548 ' O ' ' N ' ' A' ' 90' ' ' GLY . 8.9 tpp180 -131.01 149.75 52.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.179 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -45.5 89.04 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.644 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.05 -15.72 0.43 Allowed Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -86.39 130.15 34.61 Favored 'General case' 0 CA--C 1.523 -0.085 0 CA-C-O 121.023 0.44 . . . . 0.0 110.381 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -90.73 131.3 36.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.37 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 26.8 m -116.93 150.35 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.227 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.39 136.09 47.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.004 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.559 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.1 m -133.85 161.77 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.33 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 67.9 ttt-85 -104.67 128.37 52.7 Favored 'General case' 0 N--CA 1.462 0.14 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -100.92 123.49 45.2 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.082 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.401 ' H ' HG22 ' A' ' 98' ' ' VAL . 28.1 m -75.9 -15.4 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 118.179 0.445 . . . . 0.0 110.906 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -69.59 -58.45 3.93 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.06 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.437 HG23 ' H ' ' A' ' 102' ' ' GLU . 1.5 t -97.87 -12.4 22.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.269 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.35 -12.84 8.85 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.437 ' H ' HG23 ' A' ' 100' ' ' THR . 43.2 mt-10 -83.25 159.44 21.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.79 0.329 . . . . 0.0 110.749 -178.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.589 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -84.02 140.06 32.11 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.231 0.538 . . . . 0.0 109.934 179.642 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 59.4 mtp180 -137.07 171.91 13.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.218 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.8 m-30 -105.56 139.14 40.63 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.954 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.559 ' OG ' HG21 ' A' ' 95' ' ' VAL . 7.9 m -135.96 155.31 50.45 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.125 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 108' ' ' ILE . 9.7 p -95.2 157.21 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 122.573 0.349 . . . . 0.0 111.116 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.406 ' N ' HG22 ' A' ' 107' ' ' VAL . 42.7 mm -82.18 136.68 22.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.003 178.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.1 mmt85 -84.88 -38.44 19.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.694 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -169.45 151.85 4.61 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.459 ' C ' HD22 ' A' ' 112' ' ' LEU . 84.6 t -95.31 132.08 40.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.113 0.483 . . . . 0.0 110.176 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.459 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.0 mm? -100.37 131.48 23.91 Favored Pre-proline 0 N--CA 1.467 0.394 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.61 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.37 154.63 2.5 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.129 1.886 . . . . 0.0 111.662 178.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 57' ' ' ILE . 1.3 p -68.39 158.88 32.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.022 0.439 . . . . 0.0 110.518 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -151.46 149.12 28.89 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.047 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 57.0 mtm180 -78.33 132.58 37.49 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.197 0.522 . . . . 0.0 110.354 179.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.75 158.13 12.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.43 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -67.16 142.59 56.98 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 71.4 p -124.25 141.34 52.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.206 0.527 . . . . 0.0 109.899 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -116.67 174.84 5.86 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.82 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -152.63 128.96 10.56 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 82.2 mt -116.1 170.79 8.24 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.667 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -137.88 107.74 6.3 Favored 'General case' 0 CA--C 1.516 -0.346 0 C-N-CA 120.604 -0.439 . . . . 0.0 110.576 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.43 116.81 31.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 127' ' ' LEU . 38.8 tt0 -58.39 149.88 23.69 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.757 -179.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 61.64 -69.13 0.05 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.254 -0.885 . . . . 0.0 112.159 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -98.0 95.06 7.21 Favored 'General case' 0 CA--C 1.519 -0.23 0 O-C-N 122.285 -0.259 . . . . 0.0 110.413 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.614 ' O ' HG23 ' A' ' 129' ' ' THR . 75.5 m80 -67.04 99.84 0.69 Allowed 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.614 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.55 144.62 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.573 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.68 154.45 42.79 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 121.635 0.731 . . . . 0.0 111.788 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.76 127.25 41.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 179.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.93 129.74 36.74 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.401 -179.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 51.73 46.78 26.0 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.033 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.14 -21.01 0.39 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 8.1 t -90.4 152.42 3.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.172 0 O-C-N 122.27 -0.547 . . . . 0.0 110.588 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -106.53 114.64 46.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.358 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 10.1 m -147.15 136.16 15.99 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.467 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 3.2 t60 -38.54 162.91 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.833 0.349 . . . . 0.0 111.621 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.436 ' H ' ' CD2' ' A' ' 138' ' ' HIS . 12.6 p30 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.271 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.572 ' HB3' HE22 ' A' ' 51' ' ' GLN . 5.5 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -118.02 134.56 54.86 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 120.89 0.376 . . . . 0.0 110.391 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -86.38 163.61 17.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.396 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.409 ' OE2' ' CD ' ' A' ' 20' ' ' GLU . 57.7 tt0 -63.02 142.16 58.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.506 178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.85 -21.09 30.43 Favored Glycine 0 C--N 1.334 0.458 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.8 m -66.04 123.48 19.96 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.01 148.88 28.41 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.838 0.352 . . . . 0.0 110.068 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.52 107.31 8.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -77.4 125.19 28.94 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.625 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 4.7 t70 -101.99 132.79 21.19 Favored Pre-proline 0 CA--C 1.538 0.501 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.846 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.95 -31.61 7.94 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.619 2.213 . . . . 0.0 112.166 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.625 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 66.2 t -71.47 -54.47 17.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.694 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.9 p -77.32 -38.94 49.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.961 0.41 . . . . 0.0 110.171 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.31 4.62 87.91 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.474 HG22 ' N ' ' A' ' 16' ' ' THR . 55.5 m -114.18 157.63 22.39 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 117.435 0.617 . . . . 0.0 109.85 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.474 ' N ' HG22 ' A' ' 15' ' ' THR . 40.2 m -78.47 116.65 19.01 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.28 0.562 . . . . 0.0 110.794 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . 0.541 ' CD2' HD11 ' A' ' 29' ' ' ILE . 87.0 m-70 -103.1 146.7 27.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.452 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -98.52 128.12 44.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.971 179.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.6 tp -52.2 -40.87 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.613 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.535 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.4 tt0 -57.56 -36.16 71.31 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.976 0.417 . . . . 0.0 110.852 -179.486 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.519 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 49.4 t0 -81.73 -35.7 29.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.47 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -67.32 -42.17 87.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.642 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.567 HG21 ' HB3' ' A' ' 120' ' ' PHE . 48.5 t -74.11 -46.79 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -177.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 0.6 OUTLIER -56.05 -37.57 69.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.824 -177.869 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.07 32.17 7.63 Favored Glycine 0 C--O 1.227 -0.287 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.6 ptm180 12.45 65.72 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.005 0 CA-C-O 121.189 0.518 . . . . 0.0 110.307 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.402 ' N ' ' O ' ' A' ' 25' ' ' GLY . 78.2 mttt -85.88 141.55 35.84 Favored Pre-proline 0 N--CA 1.447 -0.579 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.811 -177.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.548 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.4 Cg_endo -71.3 7.62 1.4 Allowed 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.23 1.953 . . . . 0.0 112.224 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' PRO . 12.8 tt -38.05 169.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 O-C-N 123.505 0.503 . . . . 0.0 110.597 -178.308 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.521 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 2.2 m80 -120.16 170.61 9.16 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.341 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.08 172.76 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.9 t -88.16 135.03 26.5 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.53 167.53 10.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.845 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.6 140.41 40.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.855 0.359 . . . . 0.0 110.373 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.23 179.06 4.06 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.564 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -68.44 -16.06 63.77 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-O 120.754 0.312 . . . . 0.0 110.764 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -74.8 -19.56 60.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.618 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.22 -11.89 69.84 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.0 p -74.8 148.74 40.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.141 0.496 . . . . 0.0 110.961 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 56.6 mt -104.78 135.09 46.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.802 -179.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -141.13 138.63 33.62 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.625 -179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -68.7 143.0 54.86 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.759 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.467 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.3 mmp_? -143.83 138.26 15.01 Favored Pre-proline 0 CA--C 1.538 0.483 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.829 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 160.06 37.42 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 123.058 2.505 . . . . 0.0 112.754 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.88 136.92 34.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.045 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.2 m -128.26 3.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.877 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 m -148.43 142.5 25.96 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.889 0.768 . . . . 0.0 109.239 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -144.09 123.26 12.93 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 178.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -143.91 149.13 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.822 0.675 . . . . 0.0 112.822 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -96.51 131.85 42.7 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.355 -0.979 . . . . 0.0 108.355 176.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.657 HE21 ' C ' ' A' ' 119' ' ' THR . 1.9 mt-30 -95.41 4.29 53.48 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.655 -0.248 . . . . 0.0 111.075 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.11 -172.09 47.11 Favored Glycine 0 C--N 1.336 0.576 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.821 179.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.463 ' OG1' ' CZ ' ' A' ' 118' ' ' ARG . 67.8 m -86.82 127.44 35.01 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 120.76 0.314 . . . . 0.0 110.308 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -148.18 159.6 43.78 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.605 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.0 143.24 43.67 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.873 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.01 147.11 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.117 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.513 ' N ' HD13 ' A' ' 57' ' ' ILE . 0.0 OUTLIER -100.86 148.13 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.944 -179.693 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.98 135.5 12.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -119.24 114.96 23.22 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.254 0.549 . . . . 0.0 110.346 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.2 tpt180 -95.95 116.81 29.5 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.776 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.9 mp . . . . . 0 N--CA 1.466 0.358 0 CA-C-O 120.987 0.422 . . . . 0.0 111.009 -179.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.194 0 CA-C-O 121.084 0.469 . . . . 0.0 110.516 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.5 tt -126.18 158.21 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.681 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.1 tp -138.61 121.73 16.85 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.429 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.1 m95 -106.06 128.96 54.21 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.96 172.39 16.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.411 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . 0.434 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -82.65 155.98 68.21 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.793 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.31 -24.0 75.61 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.706 2.271 . . . . 0.0 111.918 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -87.6 -7.38 57.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.181 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -73.81 128.65 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -87.88 133.99 33.79 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.134 0.492 . . . . 0.0 111.034 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -105.44 140.44 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.061 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.614 HD23 ' CZ2' ' A' ' 81' ' ' TRP . 0.6 OUTLIER -83.39 95.29 8.18 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.176 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.454 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 50.1 p -98.72 179.37 4.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.493 -179.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.447 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 17.6 pt-20 -65.26 -17.61 64.64 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.303 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . 0.447 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 50.2 m-85 -107.32 25.48 11.37 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.193 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.47 -139.2 14.32 Favored Glycine 0 C--N 1.335 0.482 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.716 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.614 ' CZ2' HD23 ' A' ' 76' ' ' LEU . 97.5 m95 -94.47 130.13 40.96 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.329 -0.436 . . . . 0.0 111.784 -179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -138.13 125.92 22.41 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . 0.64 ' HB3' ' OE1' ' A' ' 86' ' ' GLU . . . -53.95 140.81 29.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.95 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.447 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -59.97 -40.7 89.99 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 121.023 -0.271 . . . . 0.0 111.616 -178.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.21 -1.72 0.78 Allowed Glycine 0 CA--C 1.524 0.626 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.075 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.64 ' OE1' ' HB3' ' A' ' 83' ' ' ALA . 57.4 mp0 -118.94 36.75 4.33 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.026 0.441 . . . . 0.0 110.612 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.4 mt -110.73 124.95 52.95 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.955 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.7 mmt180 -131.87 145.65 51.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.567 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -40.94 90.63 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 121.01 0.433 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.12 -13.71 0.38 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -89.99 127.75 36.11 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 120.974 0.416 . . . . 0.0 110.358 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -92.21 133.6 35.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.599 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.4 m -114.57 149.24 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.63 128.46 36.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.918 0.39 . . . . 0.0 110.997 -179.297 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.7 m -130.8 161.74 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.348 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.512 ' NH2' HG11 ' A' ' 131' ' ' VAL . 25.8 ttm180 -110.29 132.9 53.77 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.57 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -100.98 126.11 47.61 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.251 178.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 85.3 t -74.96 -15.44 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 O-C-N 121.891 -0.506 . . . . 0.0 111.367 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -70.01 -57.41 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.145 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.1 m -100.51 -14.4 18.26 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.501 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.16 -11.93 14.5 Favored Glycine 0 C--N 1.331 0.261 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.528 ' OE1' ' NH2' ' A' ' 104' ' ' ARG . 95.4 mt-10 -79.14 156.05 28.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 0.0 110.897 -178.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.17 132.52 35.36 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 121.605 0.716 . . . . 0.0 110.038 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.528 ' NH2' ' OE1' ' A' ' 102' ' ' GLU . 35.9 mmt180 -132.28 -179.54 5.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.342 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.454 ' OH ' ' C ' ' A' ' 77' ' ' THR . 4.1 m-85 -118.63 147.28 43.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.681 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 28.6 m -138.57 159.0 43.19 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.6 p -89.55 153.09 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.726 0.298 . . . . 0.0 110.72 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.431 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.8 mm -72.64 156.78 6.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.179 0.514 . . . . 0.0 109.963 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.431 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 2.5 tpm_? -106.69 -47.37 3.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.106 179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -166.56 145.56 5.57 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.562 ' C ' HD22 ' A' ' 112' ' ' LEU . 21.3 t -95.63 133.77 35.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.929 0.395 . . . . 0.0 110.072 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.755 HD22 ' N ' ' A' ' 112' ' ' LEU . 2.7 mm? -102.06 148.21 35.04 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.357 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.99 158.52 57.01 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 122.496 2.131 . . . . 0.0 111.549 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.449 ' H ' HG23 ' A' ' 114' ' ' THR . 2.0 p -68.49 158.2 34.3 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.009 0.433 . . . . 0.0 110.66 -179.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.402 ' CG ' ' N ' ' A' ' 116' ' ' ARG . 45.2 ttp180 -153.55 153.86 33.18 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.507 179.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.402 ' N ' ' CG ' ' A' ' 115' ' ' ARG . 18.5 mmm180 -77.31 125.71 29.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.506 179.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -162.89 159.18 23.45 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.701 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.463 ' CZ ' ' OG1' ' A' ' 53' ' ' THR . 11.0 mpt_? -76.26 149.11 37.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.815 179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.657 ' C ' HE21 ' A' ' 51' ' ' GLN . 62.1 p -132.03 145.77 51.65 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.588 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 63.8 m-85 -114.74 173.06 6.66 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.627 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -143.37 130.7 20.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.459 HD21 HG22 ' A' ' 23' ' ' VAL . 87.9 mt -123.69 170.91 10.01 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.417 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -135.32 106.49 6.72 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.085 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 17.4 t -85.42 109.55 18.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.28 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 41.4 tp10 21.86 -108.13 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.9 0.75 . . . . 0.0 111.359 179.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -114.41 -26.68 7.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.039 179.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 129' ' ' THR . 91.4 mt -84.52 68.53 10.34 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' OG1' ' A' ' 129' ' ' THR . 9.7 m170 -41.94 99.94 0.02 OUTLIER 'General case' 0 CA--C 1.507 -0.683 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.486 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.435 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.32 137.26 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.248 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.637 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.2 pp -145.34 150.6 36.9 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.157 0.504 . . . . 0.0 111.237 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.512 HG11 ' NH2' ' A' ' 96' ' ' ARG . 5.4 p -87.55 127.9 40.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.351 -0.841 . . . . 0.0 108.935 -179.127 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.4 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.9 124.86 27.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.734 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.502 ' O ' HG23 ' A' ' 135' ' ' VAL . 76.2 mm-40 59.21 44.63 15.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.287 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.0 -19.49 0.75 Allowed Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.6 t -88.76 150.78 3.61 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 117.033 0.416 . . . . 0.0 110.622 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 48.6 t -106.43 113.56 43.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.31 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 138' ' ' HIS . 15.0 m -148.37 140.87 18.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.548 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 60.6 t-80 -32.37 155.6 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.429 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 23.2 p30 . . . . . 0 C--N 1.324 -0.523 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.45 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.469 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 28.2 m . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -111.46 139.12 47.15 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.832 0.349 . . . . 0.0 110.193 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.91 162.45 16.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -60.5 143.11 54.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.489 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.14 -16.12 32.82 Favored Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.579 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.3 m -71.8 122.58 20.94 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.707 -0.29 . . . . 0.0 111.014 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.6 mtt85 -82.04 148.49 28.58 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 120.781 0.324 . . . . 0.0 110.247 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -135.62 108.21 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.289 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -79.72 129.66 34.67 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.413 ' O ' ' N ' ' A' ' 14' ' ' GLY . 55.3 t0 -109.94 113.41 57.23 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.813 -0.176 . . . . 0.0 110.755 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.11 -36.93 78.68 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.625 2.217 . . . . 0.0 112.082 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.4 HG21 ' CG ' ' A' ' 30' ' ' HIS . 49.1 t -61.8 -57.8 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.613 -178.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 p -78.27 -37.96 43.76 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.179 0.514 . . . . 0.0 110.126 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 85.16 5.71 85.35 Favored Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 16' ' ' THR . 96.5 m -114.33 157.29 23.0 Favored 'General case' 0 C--N 1.346 0.449 0 CA-C-N 117.658 0.729 . . . . 0.0 109.837 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 15' ' ' THR . 26.0 m -79.67 119.66 22.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.35 0.595 . . . . 0.0 110.61 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 19.9 m-70 -103.31 145.34 30.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.385 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 29.0 ttm-85 -96.92 124.37 40.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.03 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.6 tp -51.75 -44.14 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.724 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.617 ' N ' HG23 ' A' ' 19' ' ' ILE . 10.8 pt-20 -57.98 -34.9 70.47 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.131 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -82.25 -37.56 25.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.326 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 67.7 t -66.92 -43.24 89.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.517 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.3 t -72.5 -47.23 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -57.18 -38.11 73.15 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.146 -178.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.08 29.52 12.34 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.548 ' C ' ' O ' ' A' ' 25' ' ' GLY . 90.7 mtm180 15.78 62.5 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 O-C-N 124.037 0.492 . . . . 0.0 110.045 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.2 mttt -87.64 126.13 62.85 Favored Pre-proline 0 N--CA 1.44 -0.97 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.944 -177.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -75.23 93.43 0.97 Allowed 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.469 2.113 . . . . 0.0 110.316 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.3 pt -121.21 -170.16 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.87 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.4 ' CG ' HG21 ' A' ' 12' ' ' VAL . 38.0 m80 -125.97 164.49 20.7 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.1 m -150.65 173.68 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.447 HG11 HH21 ' A' ' 96' ' ' ARG . 5.2 t -86.55 125.28 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.17 150.85 25.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.626 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.22 144.12 49.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.411 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.26 178.26 4.39 Favored 'General case' 0 N--CA 1.472 0.664 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.8 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp -68.45 -15.25 63.48 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.693 0.283 . . . . 0.0 110.396 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -78.43 -20.3 51.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.083 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.45 -9.67 71.56 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.5 p -73.1 139.01 46.17 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.363 0.601 . . . . 0.0 111.297 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.616 HD13 ' NH2' ' A' ' 96' ' ' ARG . 50.6 mt -95.7 135.33 37.54 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.558 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -145.98 141.48 27.75 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.39 147.54 44.2 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.663 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.512 ' HD2' HD12 ' A' ' 127' ' ' LEU . 6.5 mtp180 -152.81 148.98 21.15 Favored Pre-proline 0 N--CA 1.457 -0.124 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.231 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.6 149.55 61.71 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.557 2.172 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.7 t -112.87 146.53 17.44 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.847 0 CA-C-O 121.502 0.668 . . . . 0.0 109.312 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.705 ' O ' ' CE2' ' A' ' 48' ' ' TRP . 2.1 m -139.49 -100.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.61 ' H ' HG23 ' A' ' 46' ' ' VAL . 9.3 t -19.0 113.84 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 114.164 -1.38 . . . . 0.0 111.542 -175.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.705 ' CE2' ' O ' ' A' ' 46' ' ' VAL . 1.5 m-90 -120.3 110.89 17.1 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.7 m-85 -138.43 147.02 42.86 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.304 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.441 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 46.4 p-10 -91.65 134.98 34.22 Favored 'General case' 0 C--N 1.334 -0.069 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.561 HE21 ' HB2' ' A' ' 121' ' ' ASP . 29.8 mm-40 -92.67 -4.83 52.6 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.715 -0.22 . . . . 0.0 111.219 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 -179.11 48.68 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 79.9 m -94.24 122.66 37.01 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.8 mtp85 -146.54 171.38 15.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.435 0.636 . . . . 0.0 110.656 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -74.42 139.63 44.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.219 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -139.36 153.3 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.651 HD11 ' HB1' ' A' ' 84' ' ' ALA . 14.4 pt -108.88 155.83 9.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.183 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.03 128.73 8.71 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 28.4 mt -108.94 115.3 29.82 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.205 0.526 . . . . 0.0 110.413 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.6 tpp180 -85.81 109.29 18.57 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.055 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 12.8 mm . . . . . 0 N--CA 1.469 0.478 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.041 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.369 0 CA-C-O 120.949 0.404 . . . . 0.0 110.462 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.4 tt -124.94 153.47 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.357 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 43.9 tp -132.75 118.72 19.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.337 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -105.8 118.21 36.01 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.96 170.97 15.12 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.534 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 37.6 p -79.5 153.56 76.24 Favored Pre-proline 0 N--CA 1.45 -0.432 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.128 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.78 -30.25 88.6 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 122.534 2.156 . . . . 0.0 112.146 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -80.97 -9.46 59.84 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.428 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.7 t60 -70.46 129.04 38.2 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -86.75 131.61 34.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.399 0.619 . . . . 0.0 111.154 -179.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -103.62 139.21 25.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.783 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 58.7 tp -78.35 91.95 4.51 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.856 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.9 p -97.38 -179.34 4.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -178.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -69.87 -16.41 63.24 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.196 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -106.27 26.31 9.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.933 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.88 -138.54 13.97 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -95.67 130.61 42.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.537 -0.331 . . . . 0.0 111.138 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . 0.511 ' NH1' ' OD1' ' A' ' 91' ' ' ASP . 84.0 mtp180 -140.56 129.89 23.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.246 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.38 145.29 18.42 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.011 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.651 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.48 -40.14 95.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 121.249 -0.18 . . . . 0.0 111.473 -179.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.3 -3.46 3.89 Favored Glycine 0 C--N 1.337 0.614 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.757 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -113.24 32.73 5.54 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.732 0.301 . . . . 0.0 110.56 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.9 mt -112.7 126.81 55.8 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 121.38 0.61 . . . . 0.0 111.226 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 37.5 mmt180 -130.89 147.19 52.51 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.884 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -42.66 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.876 0.369 . . . . 0.0 110.741 -179.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.25 -12.68 0.43 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.511 ' OD1' ' NH1' ' A' ' 82' ' ' ARG . 17.8 t70 -87.85 128.57 35.35 Favored 'General case' 0 C--O 1.227 -0.102 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -89.84 131.74 35.62 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.393 -179.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -118.32 150.91 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.121 -0.49 . . . . 0.0 109.797 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -66.76 134.98 53.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.955 0.407 . . . . 0.0 111.015 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 104' ' ' ARG . 21.4 m -134.22 159.68 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.013 179.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.616 ' NH2' HD13 ' A' ' 40' ' ' LEU . 52.6 ttm-85 -107.02 130.24 54.68 Favored 'General case' 0 C--N 1.334 -0.098 0 CA-C-O 120.677 0.275 . . . . 0.0 110.333 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.36 122.9 43.86 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.365 178.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 62.3 t -76.28 -16.19 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 118.133 0.424 . . . . 0.0 110.749 179.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 99' ' ' GLU . 0.5 OUTLIER -72.02 -57.26 4.44 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.849 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.449 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.3 p -94.45 -13.81 25.83 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.13 -14.76 3.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.449 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.5 mt-10 -83.56 163.53 20.34 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 120.981 0.42 . . . . 0.0 110.764 -177.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.47 HD21 ' HB1' ' A' ' 94' ' ' ALA . 4.6 tt -80.51 136.88 36.38 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.431 ' O ' HG22 ' A' ' 95' ' ' VAL . 45.9 mtp85 -134.42 168.81 18.25 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.099 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -110.87 140.6 45.2 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.672 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.416 ' OG ' HG21 ' A' ' 95' ' ' VAL . 23.3 m -136.49 155.39 50.05 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.409 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 108' ' ' ILE . 58.1 t -91.33 156.68 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.008 0.432 . . . . 0.0 110.555 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.485 ' N ' HG12 ' A' ' 107' ' ' VAL . 3.5 mm -72.66 153.13 7.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.237 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -106.0 -45.93 4.23 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -166.05 145.36 6.08 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.457 ' C ' HD22 ' A' ' 112' ' ' LEU . 83.5 t -96.46 132.88 39.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.137 0.494 . . . . 0.0 110.163 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.484 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.1 mm? -98.57 128.73 32.0 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.288 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.63 157.99 2.11 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 122.384 2.056 . . . . 0.0 111.743 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.436 HG23 ' H ' ' A' ' 114' ' ' THR . 1.2 p -66.94 156.93 34.56 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.49 0.662 . . . . 0.0 110.685 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -139.04 -140.1 0.14 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.915 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 80.7 mtm180 -153.66 132.6 12.46 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.902 0.382 . . . . 0.0 110.115 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.7 173.67 3.86 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.651 -179.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 -83.51 154.27 23.96 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.144 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -132.64 143.47 49.69 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.95 174.83 5.7 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.483 -0.78 . . . . 0.0 111.5 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.561 ' HB2' HE21 ' A' ' 51' ' ' GLN . 26.4 t0 -148.03 128.79 14.26 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.164 -179.572 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.2 mt -132.15 123.39 27.0 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.852 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -87.51 115.67 25.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.144 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 125' ' ' GLU . 98.5 t -85.48 114.09 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 127' ' ' LEU . 39.7 tp10 -28.2 111.92 0.06 Allowed 'General case' 0 N--CA 1.466 0.367 0 O-C-N 123.574 0.546 . . . . 0.0 111.762 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 60.49 -65.87 0.05 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 178.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.512 HD12 ' HD2' ' A' ' 43' ' ' ARG . 86.0 mt -72.76 75.17 1.13 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.041 0.448 . . . . 0.0 111.005 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.629 ' O ' HG23 ' A' ' 129' ' ' THR . 31.5 m170 -56.01 98.96 0.03 OUTLIER 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.629 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.45 143.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 O-C-N 123.712 0.632 . . . . 0.0 109.439 178.936 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.723 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.8 pp -149.23 154.1 38.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.542 0.687 . . . . 0.0 111.446 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.513 ' N ' HD12 ' A' ' 130' ' ' LEU . 85.6 t -90.01 123.69 42.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.033 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.649 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.08 129.16 37.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -178.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.551 ' O ' HG23 ' A' ' 135' ' ' VAL . 70.2 mm-40 58.77 43.23 18.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.897 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.76 -20.89 0.48 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.9 t -89.18 151.13 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-O 120.943 0.402 . . . . 0.0 110.821 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.403 HG21 HD11 ' A' ' 103' ' ' LEU . 2.5 t -104.69 112.78 39.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.548 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 11.5 m -148.3 138.65 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 CA-C-O 118.988 -0.529 . . . . 0.0 110.29 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.578 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 14.4 t-80 -28.41 147.63 0.0 OUTLIER 'General case' 0 C--N 1.342 0.259 0 O-C-N 123.571 0.544 . . . . 0.0 111.956 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.649 HD22 ' C ' ' A' ' 139' ' ' ASN . 0.2 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.895 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -91.45 139.01 31.13 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.839 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.52 161.7 28.95 Favored 'General case' 0 CA--C 1.529 0.135 0 CA-C-O 120.978 0.418 . . . . 0.0 111.262 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 77.5 tt0 -66.62 143.27 57.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.826 178.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.97 -18.85 33.58 Favored Glycine 0 C--N 1.336 0.561 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.512 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 26.9 m -66.05 124.97 24.01 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.48 ' HE ' ' CD ' ' A' ' 18' ' ' ARG . 1.6 mpt_? -97.25 116.39 29.36 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 121.014 0.435 . . . . 0.0 110.214 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.47 HD11 HD13 ' A' ' 19' ' ' ILE . 15.4 mt -100.41 113.06 34.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.209 179.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -75.47 133.93 40.96 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.07 129.97 26.02 Favored Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 121.145 -0.222 . . . . 0.0 110.678 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.72 -27.47 18.2 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.91 1.74 . . . . 0.0 112.277 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 42.7 t -76.42 -53.81 14.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.19 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.9 p -76.94 -35.88 56.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.983 0.42 . . . . 0.0 110.251 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.64 10.5 85.13 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 54.8 m -115.56 160.42 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 117.564 0.682 . . . . 0.0 109.694 -179.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 12.5 m -79.54 115.0 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.194 0.521 . . . . 0.0 110.911 -179.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -101.3 143.46 31.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.866 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.48 ' CD ' ' HE ' ' A' ' 7' ' ' ARG . 69.3 mtm180 -99.65 128.38 45.75 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.753 -0.203 . . . . 0.0 110.574 178.247 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.1 tp -53.1 -38.42 29.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.561 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.509 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.3 pt-20 -58.17 -35.34 71.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.318 0.58 . . . . 0.0 110.969 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -85.18 -38.38 19.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.63 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 94.2 t -69.04 -42.39 81.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.838 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.56 HG22 HD21 ' A' ' 122' ' ' LEU . 75.2 t -75.36 -45.89 39.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.833 -178.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -57.67 -34.5 69.45 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.681 -178.332 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.577 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.25 29.31 9.3 Favored Glycine 0 CA--C 1.519 0.298 0 CA-C-O 119.108 -0.829 . . . . 0.0 111.033 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.577 ' C ' ' O ' ' A' ' 25' ' ' GLY . 44.6 ptt85 13.62 64.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.45 0.643 . . . . 0.0 110.054 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 25' ' ' GLY . 81.6 mttt -84.86 139.49 37.36 Favored Pre-proline 0 N--CA 1.449 -0.503 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.369 -176.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.9 83.27 2.14 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.352 1.368 . . . . 0.0 110.164 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.563 ' C ' HD12 ' A' ' 29' ' ' ILE . 1.9 pp -116.27 -174.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.811 0.338 . . . . 0.0 110.486 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.422 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 34.7 m80 -128.65 161.95 28.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.511 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.9 m -146.96 170.47 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.97 134.98 26.56 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.358 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -107.78 166.55 10.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.534 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.2 137.59 39.29 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.914 0.387 . . . . 0.0 110.23 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -112.28 175.42 5.44 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -73.02 -13.34 61.2 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.865 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -78.32 -11.44 59.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.429 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.46 17.37 64.38 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.2 p -100.81 139.34 36.64 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.024 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.9 mt -98.54 131.61 44.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.655 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -139.52 138.3 36.21 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.965 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.87 142.7 52.99 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.465 -0.494 . . . . 0.0 109.959 -178.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.526 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.7 mmt180 -145.04 138.6 14.36 Favored Pre-proline 0 N--CA 1.468 0.461 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.297 -179.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.12 157.2 33.96 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 122.555 2.17 . . . . 0.0 112.424 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -98.84 138.17 24.14 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 177.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.99 2.66 3.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.183 -178.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 m -146.97 133.99 20.33 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 120.038 -0.665 . . . . 0.0 110.006 179.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.508 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.77 121.71 18.85 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.003 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -138.14 143.59 40.39 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.644 ' O ' ' HG2' ' A' ' 51' ' ' GLN . 29.3 t70 -88.42 125.77 34.89 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.644 ' HG2' ' O ' ' A' ' 50' ' ' ASP . 8.2 mt-30 -160.86 60.08 0.31 Allowed 'General case' 0 CA--C 1.498 -1.042 0 O-C-N 124.158 0.911 . . . . 0.0 108.55 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.818 ' CA ' ' H ' ' A' ' 119' ' ' THR . . . -118.62 167.06 12.98 Favored Glycine 0 C--N 1.314 -0.684 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.398 -178.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.562 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 33.3 m 113.99 63.53 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 O-C-N 125.436 1.315 . . . . 0.0 111.261 177.788 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.6 mtt-85 -148.78 175.72 10.99 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.634 0.254 . . . . 0.0 110.794 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -77.47 139.56 39.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.61 151.81 19.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.525 ' N ' HD13 ' A' ' 57' ' ' ILE . 0.0 OUTLIER -103.41 144.77 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 109.963 179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.93 134.7 12.15 Favored Glycine 0 N--CA 1.462 0.39 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 71.6 mt -116.78 116.34 27.3 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-O 121.064 0.459 . . . . 0.0 110.313 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.449 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.1 tpt180 -84.75 107.73 17.09 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.103 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.754 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.6 mp . . . . . 0 C--N 1.325 -0.461 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 179.007 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.163 0 CA-C-O 120.811 0.338 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.412 HG22 ' N ' ' A' ' 67' ' ' LEU . 95.0 mt -124.7 154.72 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.123 179.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.412 ' N ' HG22 ' A' ' 66' ' ' ILE . 61.9 tp -128.79 114.73 16.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.814 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -103.83 109.96 21.9 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -134.2 172.32 13.02 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.198 -179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.14 156.8 69.13 Favored Pre-proline 0 CA--C 1.535 0.401 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.435 179.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -63.15 -17.72 61.5 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.734 2.29 . . . . 0.0 112.169 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 49.3 p-10 -97.62 -6.67 32.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.992 0.425 . . . . 0.0 110.185 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.4 t60 -71.85 129.68 39.21 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -83.57 124.07 30.4 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.375 0.607 . . . . 0.0 111.631 -179.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 73.5 t -98.14 138.35 23.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.058 -0.973 . . . . 0.0 109.889 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 37.9 tp -81.67 95.64 7.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.036 -179.524 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 p -100.28 175.87 5.57 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -67.67 -18.14 64.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.459 -178.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -105.97 21.07 17.93 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.647 0.26 . . . . 0.0 110.642 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.89 -144.63 15.88 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -91.95 126.54 37.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.527 0.204 . . . . 0.0 110.97 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -127.83 126.75 42.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.79 136.9 54.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.949 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.591 ' HA ' HD12 ' A' ' 87' ' ' LEU . . . -69.78 -0.88 7.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.683 179.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.71 -13.78 77.22 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -132.22 15.44 4.61 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.758 0.313 . . . . 0.0 111.46 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 84' ' ' ALA . 20.5 mt -80.32 141.41 35.47 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.233 0.54 . . . . 0.0 110.877 179.374 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.0 tpp85 -142.08 155.21 45.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.014 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -48.51 113.86 0.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.334 179.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 141.77 -22.33 2.5 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -83.09 130.56 35.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.706 0.289 . . . . 0.0 110.766 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -88.84 136.62 32.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.128 0.49 . . . . 0.0 110.795 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.0 m -122.02 144.05 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.5 -179.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.52 131.53 42.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.912 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.4 m -127.06 163.11 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.98 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -100.5 128.14 46.65 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.671 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -100.54 124.28 45.88 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 98' ' ' VAL . 89.8 t -75.63 -15.81 15.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 118.24 0.473 . . . . 0.0 110.909 178.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 37.7 tp10 -69.35 -58.66 3.72 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.097 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 70.3 p -99.73 -12.18 20.2 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.772 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.32 -13.87 9.78 Favored Glycine 0 C--N 1.332 0.312 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.6 mt-10 -82.05 153.84 25.93 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.953 0.406 . . . . 0.0 111.622 -177.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.586 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.16 139.92 36.59 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 179.479 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.419 ' O ' HG22 ' A' ' 95' ' ' VAL . 53.0 ptt85 -142.64 138.47 30.7 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.702 -179.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.9 m-30 -78.28 147.8 34.16 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.38 -0.528 . . . . 0.0 109.998 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -139.34 162.68 34.43 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.7 t -95.32 154.29 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 61.6 mt -73.54 154.61 6.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.0 ttm180 -104.75 -42.72 5.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.16 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -167.23 147.82 5.53 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 112' ' ' LEU . 23.1 t -92.81 130.85 41.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.6 mp -98.99 124.93 43.69 Favored Pre-proline 0 CA--C 1.543 0.709 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.973 -179.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -48.45 162.73 0.31 Allowed 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.228 1.952 . . . . 0.0 111.998 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.1 p -73.02 160.44 32.07 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.28 0.562 . . . . 0.0 110.823 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.434 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 10.0 tpt180 -144.89 -132.47 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.195 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.434 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 1.5 tmm_? -155.39 134.83 12.47 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.983 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 170.77 4.27 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.072 -178.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 84.2 mtm-85 -83.87 140.36 32.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.843 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . 0.818 ' H ' ' CA ' ' A' ' 52' ' ' GLY . 4.2 p -128.39 148.78 50.72 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.559 177.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -122.75 179.76 4.51 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.971 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -147.64 124.83 11.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.368 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.56 HD21 HG22 ' A' ' 23' ' ' VAL . 95.6 mt -115.84 173.08 6.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.444 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -136.38 105.36 5.92 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.241 178.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 125' ' ' GLU . 16.4 t -83.56 108.64 16.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.0 tt0 20.37 -89.14 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.639 0.587 . . . . 0.0 112.322 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 124' ' ' VAL . 81.6 mt-10 -129.27 -39.94 1.49 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.392 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.526 HD12 ' HE ' ' A' ' 43' ' ' ARG . 84.3 mt -71.04 64.86 0.35 Allowed 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.183 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.438 ' O ' HG23 ' A' ' 129' ' ' THR . 39.3 m80 -41.78 94.82 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 179.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.515 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 171.63 141.28 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.189 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.681 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.0 pp -147.79 155.96 42.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.425 0.631 . . . . 0.0 111.885 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -89.12 126.78 42.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.18 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.582 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.512 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.23 132.62 39.9 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.219 -179.099 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.583 ' O ' HG23 ' A' ' 135' ' ' VAL . 68.8 mm-40 50.64 46.23 25.95 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.156 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.99 23.26 56.82 Favored Glycine 0 CA--C 1.522 0.523 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.802 178.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -129.75 153.69 39.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.436 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -105.32 111.9 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 O-C-N 121.944 -0.473 . . . . 0.0 110.611 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 26.8 m -147.38 139.33 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 55.6 t-80 -31.25 151.53 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.201 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.264 -179.635 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.712 ' CB ' HE22 ' A' ' 51' ' ' GLN . 6.2 m . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 80.5 mt -123.22 132.69 54.13 Favored 'General case' 0 C--N 1.34 0.189 0 CA-C-O 121.182 0.515 . . . . 0.0 110.72 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.09 162.26 24.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.39 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.76 146.52 52.25 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.45 -17.34 40.13 Favored Glycine 0 C--N 1.34 0.754 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.477 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.7 m -67.03 124.76 23.95 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.08 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.543 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.1 mtp180 -83.98 149.35 26.35 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 75.2 mt -134.6 107.42 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.81 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -77.0 127.22 32.3 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 14' ' ' GLY . 61.6 t0 -107.32 111.44 63.17 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.07 -37.3 68.24 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 122.508 2.139 . . . . 0.0 111.969 178.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -61.21 -58.41 7.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.518 -179.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 30.5 p -74.88 -33.07 62.01 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.181 0.515 . . . . 0.0 109.788 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 80.47 7.74 88.24 Favored Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.479 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -110.87 -163.82 0.88 Allowed 'General case' 0 C--N 1.347 0.471 0 CA-C-N 117.727 0.764 . . . . 0.0 109.507 -179.248 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.543 HG21 ' HE ' ' A' ' 7' ' ' ARG . 87.4 m -114.71 115.7 27.49 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.516 0.674 . . . . 0.0 110.511 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -100.18 141.72 32.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.206 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -97.65 125.99 42.72 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.969 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -52.92 -41.01 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.217 -179.333 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.562 ' N ' HG23 ' A' ' 19' ' ' ILE . 2.8 pt-20 -55.31 -35.23 64.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.355 0.598 . . . . 0.0 110.646 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 50.9 t0 -83.1 -36.18 25.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.972 . . . . 0.0 111.62 -178.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 54.1 t -66.65 -43.83 90.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.408 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 72.2 t -69.52 -46.11 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.721 -179.279 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -56.04 -36.9 68.53 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 120.946 -0.302 . . . . 0.0 110.596 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.558 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.71 32.64 6.09 Favored Glycine 0 C--O 1.228 -0.257 0 CA-C-O 118.222 -1.321 . . . . 0.0 110.563 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.558 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.0 ptt-85 10.37 72.55 0.01 OUTLIER 'General case' 0 C--N 1.367 1.341 0 O-C-N 124.437 0.728 . . . . 0.0 110.004 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.406 ' C ' ' H ' ' A' ' 29' ' ' ILE . 74.1 mttt -90.06 144.71 31.7 Favored Pre-proline 0 N--CA 1.443 -0.791 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.716 -177.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.561 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.2 Cg_endo -71.77 9.83 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.581 2.187 . . . . 0.0 112.464 179.517 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.561 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.1 pp -38.19 171.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 124.087 0.867 . . . . 0.0 110.374 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.557 ' ND1' ' N ' ' A' ' 30' ' ' HIS . 1.2 m80 -123.05 166.74 14.62 Favored 'General case' 0 CA--C 1.509 -0.622 0 O-C-N 122.103 -0.373 . . . . 0.0 111.057 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -150.42 173.96 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.385 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 3.8 t -87.3 132.51 32.46 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.152 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -102.38 166.93 10.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.79 137.08 36.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.074 0.464 . . . . 0.0 110.315 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.5 177.46 4.64 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -72.76 -14.73 61.6 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.615 0.245 . . . . 0.0 110.677 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -78.98 -14.66 59.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.7 20.46 56.1 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.6 p -100.82 135.29 42.49 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 120.76 0.314 . . . . 0.0 110.691 178.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 53.2 mt -99.78 137.63 37.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.561 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -147.72 143.56 27.67 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.795 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.86 145.01 48.86 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.641 ' HE ' HD12 ' A' ' 127' ' ' LEU . 86.6 mtt-85 -153.25 142.44 14.67 Favored Pre-proline 0 CA--C 1.54 0.587 0 O-C-N 123.813 0.696 . . . . 0.0 111.097 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.36 160.0 39.46 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 123.094 2.529 . . . . 0.0 113.267 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -97.89 135.76 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 177.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.3 m -122.24 -1.33 7.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 118.803 -0.618 . . . . 0.0 111.167 -178.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.8 p -148.79 141.33 24.35 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 119.203 0.91 . . . . 0.0 108.717 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.509 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.23 121.32 12.93 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.047 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -142.1 148.23 38.03 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -99.74 135.06 41.73 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.712 HE22 ' CB ' ' A' ' 1' ' ' CYS . 2.0 mt-30 -97.75 4.56 49.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 119.412 -0.327 . . . . 0.0 111.53 178.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.05 -169.73 42.49 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 98.0 m -88.26 128.33 35.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.397 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.5 mtt-85 -147.17 161.59 40.6 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.544 -179.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -77.18 142.8 39.46 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.489 179.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.8 m -141.12 160.27 22.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.528 HD11 ' CB ' ' A' ' 84' ' ' ALA . 43.8 pt -111.89 147.29 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.257 179.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.59 137.53 13.32 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.409 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 43.6 mt -120.63 111.99 18.34 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.403 0.62 . . . . 0.0 110.276 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.524 ' C ' HD12 ' A' ' 61' ' ' ILE . 14.4 tpt180 -87.21 109.24 19.34 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.189 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp . . . . . 0 N--CA 1.473 0.715 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.079 -179.238 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.747 0.308 . . . . 0.0 110.376 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.2 tt -125.21 154.75 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.346 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 54.1 tp -130.97 116.82 18.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -104.4 115.17 29.9 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.73 172.69 12.35 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.261 -179.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.34 156.28 78.79 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.689 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.29 -21.44 72.63 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 122.794 2.33 . . . . 0.0 111.931 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -92.95 -4.69 52.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.28 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.647 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.7 t60 -72.02 129.98 39.86 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 48.9 mttp -86.86 127.58 35.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 121.51 0.672 . . . . 0.0 110.493 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 93.8 t -105.16 91.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.602 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 15.3 tp -31.01 95.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 O-C-N 123.924 0.765 . . . . 0.0 111.123 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.446 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -98.92 176.93 5.42 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 -177.973 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.478 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 12.8 pt-20 -63.85 -18.35 64.06 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.291 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.73 24.3 13.13 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.432 0.158 . . . . 0.0 110.965 -179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.81 -141.37 15.26 Favored Glycine 0 C--N 1.321 -0.253 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -94.05 127.24 39.74 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.633 -0.283 . . . . 0.0 111.264 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -137.61 129.04 28.08 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.25 141.39 29.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.807 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.528 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -60.11 -38.58 83.41 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.164 -179.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.27 -3.2 4.86 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.678 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -105.49 0.46 26.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.923 0.392 . . . . 0.0 110.179 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 93.3 mt -80.95 127.63 32.78 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.554 0.693 . . . . 0.0 111.245 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.583 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.6 mmt85 -131.64 149.26 52.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.788 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -44.57 86.33 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 123.465 0.478 . . . . 0.0 110.845 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 158.08 -15.85 0.29 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -85.39 130.1 34.67 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 117.209 0.505 . . . . 0.0 110.394 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.478 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 90.1 mtm180 -88.94 131.17 35.26 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.408 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.7 m -114.42 142.69 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.459 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -67.1 131.52 45.98 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.72 -179.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.36 160.72 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.408 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.534 ' NH1' ' O ' ' A' ' 101' ' ' GLY . 9.0 tpt180 -104.6 129.63 52.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.59 -179.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 42.1 t0 -101.33 123.67 45.78 Favored 'General case' 0 C--O 1.22 -0.49 0 CA-C-O 118.996 -0.526 . . . . 0.0 110.468 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 61.4 t -77.21 -16.72 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 118.474 0.579 . . . . 0.0 111.12 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -69.65 -58.43 3.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.45 ' C ' ' H ' ' A' ' 102' ' ' GLU . 80.8 p -95.86 -12.65 24.88 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.534 ' O ' ' NH1' ' A' ' 96' ' ' ARG . . . 76.13 -16.05 4.88 Favored Glycine 0 C--O 1.223 -0.583 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.45 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.2 mt-10 -80.78 158.05 25.59 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.614 0.245 . . . . 0.0 110.606 -177.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.572 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -86.68 141.12 29.16 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.359 0.6 . . . . 0.0 110.059 179.77 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.45 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 37.6 ptt180 -139.81 178.65 7.09 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.214 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.446 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.8 m-85 -113.31 147.74 37.03 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.801 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -139.63 160.17 40.48 Favored 'General case' 0 C--O 1.222 -0.366 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.6 m -90.63 153.02 3.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-O 121.015 0.436 . . . . 0.0 110.842 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.41 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.6 mm -70.31 155.39 7.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.094 179.297 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.41 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt180 -106.01 -48.31 3.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.704 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -166.07 145.74 6.19 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.78 134.38 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 mt -102.68 145.22 30.15 Favored Pre-proline 0 N--CA 1.466 0.358 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.367 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -67.16 164.06 31.75 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.408 2.072 . . . . 0.0 111.534 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.467 HG22 HG22 ' A' ' 57' ' ' ILE . 81.3 p -67.03 156.42 36.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 121.388 0.613 . . . . 0.0 110.873 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 79.3 mtp180 -139.98 -137.35 0.12 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.757 -179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -158.04 131.31 7.58 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.079 0.466 . . . . 0.0 110.254 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.79 173.26 3.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.13 -179.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.3 mtp85 -78.39 145.48 35.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 2.9 p -119.5 141.08 49.51 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.155 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.62 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 57.2 m-85 -118.5 168.55 10.56 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.199 -179.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -157.79 120.33 3.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.989 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 67.1 mt -118.04 129.52 55.62 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -87.5 109.63 19.75 Favored 'General case' 0 CA--C 1.516 -0.338 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.463 HG21 ' O ' ' A' ' 129' ' ' THR . 21.6 t -83.0 113.09 21.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.97 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.7 tt0 29.96 -98.38 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 O-C-N 123.775 0.672 . . . . 0.0 111.1 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -123.62 -25.92 4.26 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.271 179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.641 HD12 ' HE ' ' A' ' 43' ' ' ARG . 96.4 mt -84.85 94.55 8.76 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.62 ' C ' HG22 ' A' ' 129' ' ' THR . 29.7 m170 -60.6 98.24 0.06 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.62 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.1 154.77 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.608 HD23 ' N ' ' A' ' 130' ' ' LEU . 1.2 pt? -162.83 161.49 26.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.796 0.808 . . . . 0.0 112.369 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 136' ' ' VAL . 9.3 t -86.2 126.15 40.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.42 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.477 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.88 123.78 25.32 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.757 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.602 ' O ' HG23 ' A' ' 135' ' ' VAL . 77.8 mm-40 54.29 44.66 28.68 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.682 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.0 28.1 69.88 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.2 t -132.67 151.3 34.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 CA-C-N 118.155 0.977 . . . . 0.0 108.681 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 131' ' ' VAL . 89.9 t -108.9 112.34 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 118.232 0.469 . . . . 0.0 110.239 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 138' ' ' HIS . 29.4 m -146.63 136.72 17.51 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-O 119.086 -0.483 . . . . 0.0 110.021 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 37.4 t-80 -31.54 152.08 0.0 OUTLIER 'General case' 0 C--O 1.223 -0.295 0 O-C-N 123.577 0.548 . . . . 0.0 111.36 179.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.521 ' OD1' ' CE1' ' A' ' 138' ' ' HIS . 49.2 p30 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.74 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -101.16 143.72 30.91 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.365 -179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -88.18 162.41 16.71 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.637 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . 0.431 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 59.8 tt0 -60.37 142.69 54.54 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 120.786 0.327 . . . . 0.0 110.466 178.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 115.98 -21.66 12.08 Favored Glycine 0 C--N 1.333 0.376 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.577 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 23.0 m -69.01 120.03 14.24 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.11 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.508 ' NE ' HG21 ' A' ' 16' ' ' THR . 74.7 mtp85 -95.15 112.63 24.31 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.91 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.6 mt -99.17 113.29 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.621 -179.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -76.48 137.79 39.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 10.2 t0 -106.31 132.64 20.73 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 121.25 -0.18 . . . . 0.0 110.622 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.03 -30.88 10.36 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.187 1.925 . . . . 0.0 112.433 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.533 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 24.9 t -72.98 -53.89 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.868 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.8 p -77.64 -36.79 51.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.136 0.493 . . . . 0.0 110.159 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 6.9 89.01 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.447 HG22 ' N ' ' A' ' 16' ' ' THR . 48.1 m -111.55 156.53 21.6 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.769 0.785 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.508 HG21 ' NE ' ' A' ' 7' ' ' ARG . 27.0 m -80.49 116.77 20.71 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.146 0.498 . . . . 0.0 110.976 -179.154 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -107.32 150.29 26.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.302 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -101.43 132.74 46.86 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.914 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.8 tp -52.69 -40.21 33.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.764 0.316 . . . . 0.0 111.077 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.548 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.9 tt0 -58.51 -36.25 73.51 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.191 0.519 . . . . 0.0 110.483 -179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -82.18 -38.36 24.76 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.615 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -69.51 -43.76 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.589 HG22 HD21 ' A' ' 122' ' ' LEU . 72.5 t -73.82 -46.73 46.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.9 t0 -60.85 -36.4 79.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.019 0.437 . . . . 0.0 110.813 -178.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.36 24.55 31.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtm180 17.22 62.73 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 79.2 mttt -86.57 131.96 44.11 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.869 -176.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -75.07 87.21 1.35 Allowed 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.491 1.461 . . . . 0.0 110.41 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 29' ' ' ILE . 30.1 pt -120.67 -172.01 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.917 0.389 . . . . 0.0 110.491 -179.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.43 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 16.5 m80 -127.21 162.88 25.13 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.747 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.46 171.24 2.44 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.237 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.01 136.33 23.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -115.27 164.33 14.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.67 -0.241 . . . . 0.0 110.414 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.97 50.42 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.36 177.66 4.55 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -72.74 -16.33 61.66 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 122.101 -0.375 . . . . 0.0 111.105 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -78.71 -16.46 57.22 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.336 179.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 22.85 40.45 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.49 ' C ' HD22 ' A' ' 40' ' ' LEU . 33.1 p -102.11 133.84 46.31 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.676 0.274 . . . . 0.0 111.052 178.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.776 HD22 ' N ' ' A' ' 40' ' ' LEU . 2.2 mm? -94.57 133.05 38.63 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 121.069 0.461 . . . . 0.0 111.128 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -143.66 139.87 29.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.569 -179.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.2 144.86 49.99 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.969 -178.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HE ' ' HB3' ' A' ' 125' ' ' GLU . 15.7 mtp85 -147.81 138.91 13.36 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.181 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -74.94 158.1 42.64 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.7 2.267 . . . . 0.0 112.831 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.9 t -93.82 131.85 39.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.0 t -119.24 -3.1 9.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.387 -177.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . 0.442 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.3 OUTLIER -155.06 149.01 25.7 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.612 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.571 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -144.84 131.02 19.48 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.701 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -134.64 144.56 47.92 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.379 0.609 . . . . 0.0 111.899 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.414 ' OD1' ' N ' ' A' ' 51' ' ' GLN . 58.1 t0 -112.76 139.21 48.57 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.224 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.448 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.8 mm-40 -105.15 -106.46 0.3 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.328 -1.305 . . . . 0.0 108.854 -178.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.448 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -167.24 -156.1 9.59 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 114.457 -1.247 . . . . 0.0 112.354 -177.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.457 HG22 ' HG3' ' A' ' 116' ' ' ARG . 0.5 OUTLIER -94.58 119.56 33.45 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.077 0.465 . . . . 0.0 111.2 -179.264 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -138.31 164.66 28.7 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.51 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -76.98 140.9 40.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.12 159.61 26.1 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.164 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.596 HD11 ' HB1' ' A' ' 84' ' ' ALA . 32.7 pt -112.58 151.26 14.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.966 0.412 . . . . 0.0 109.991 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.16 131.68 10.76 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 32.2 mt -113.16 113.19 25.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 0.0 110.044 -179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.467 ' C ' HD12 ' A' ' 61' ' ' ILE . 12.6 tpt180 -87.75 107.06 18.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.355 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.742 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp . . . . . 0 N--CA 1.467 0.417 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.929 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.233 0.189 0 CA-C-O 121.105 0.479 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.448 HD13 ' HE1' ' A' ' 68' ' ' TRP . 19.1 tt -125.38 152.06 31.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.34 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 68' ' ' TRP . 2.2 tt -127.63 114.91 17.98 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.496 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.57 ' N ' HD23 ' A' ' 67' ' ' LEU . 81.3 m95 -102.93 120.04 39.92 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.85 171.09 18.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.158 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 20.4 p -76.91 154.71 83.04 Favored Pre-proline 0 CA--C 1.531 0.232 0 C-N-CA 120.584 -0.447 . . . . 0.0 111.227 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 -24.09 70.8 Favored 'Trans proline' 0 N--CA 1.499 1.849 0 C-N-CA 122.096 1.864 . . . . 0.0 112.211 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -84.75 -8.64 58.76 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.853 0.359 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.573 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.2 t60 -72.8 132.66 43.86 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -90.44 131.73 36.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.183 0.516 . . . . 0.0 110.348 -178.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.726 ' O ' HG23 ' A' ' 77' ' ' THR . 92.5 t -107.37 89.59 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.117 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 55.7 tp -29.12 97.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.508 0.505 . . . . 0.0 111.717 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.726 HG23 ' O ' ' A' ' 75' ' ' VAL . 38.5 p -98.68 177.21 5.37 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.548 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.8 pt-20 -66.45 -17.56 64.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.341 -179.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.07 22.22 16.25 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.745 0.307 . . . . 0.0 111.117 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.76 -141.09 15.34 Favored Glycine 0 N--CA 1.462 0.431 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.0 m95 -97.38 130.91 44.47 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.724 -0.238 . . . . 0.0 110.924 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.8 mtp85 -139.7 131.12 26.9 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.43 144.73 20.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.084 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.596 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -63.11 -38.88 92.93 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.576 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.7 -1.75 2.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.622 -0.799 . . . . 0.0 111.428 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.408 ' H ' ' C ' ' A' ' 84' ' ' ALA . 72.3 mm-40 -107.49 -2.99 19.9 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.941 0.4 . . . . 0.0 110.184 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 85.7 mt -76.88 125.59 29.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.917 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.558 ' O ' ' N ' ' A' ' 90' ' ' GLY . 7.1 tpt180 -132.1 148.42 52.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.501 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -43.34 88.83 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.932 0.396 . . . . 0.0 110.693 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.97 -16.57 0.45 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -87.21 129.79 34.82 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.728 0.299 . . . . 0.0 110.771 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 87.1 mtm180 -90.19 131.06 36.23 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 121.083 0.468 . . . . 0.0 110.586 -178.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.15 143.32 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.391 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.13 131.78 49.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 104' ' ' ARG . 25.8 m -129.57 157.81 42.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.368 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 71.7 ttt180 -106.98 130.28 54.65 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.458 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.53 121.9 42.34 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.373 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 57.6 t -75.01 -15.44 15.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 O-C-N 122.081 -0.387 . . . . 0.0 110.648 178.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -70.75 -58.03 4.06 Favored 'General case' 0 C--O 1.232 0.154 0 C-N-CA 120.485 -0.486 . . . . 0.0 109.927 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.442 ' C ' ' H ' ' A' ' 102' ' ' GLU . 45.9 p -96.79 -12.56 23.48 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 116.751 -0.204 . . . . 0.0 110.562 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.53 -13.72 6.17 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.4 mt-10 -81.74 157.1 24.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.972 0.415 . . . . 0.0 111.078 -177.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.629 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -78.48 140.4 38.61 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 179.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.451 ' O ' HG22 ' A' ' 95' ' ' VAL . 52.5 mtm180 -139.55 174.51 10.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.47 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.9 m-85 -115.3 146.09 41.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.222 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.44 ' OG ' HG21 ' A' ' 95' ' ' VAL . 14.8 m -139.78 161.44 37.54 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.033 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.3 t -94.35 154.75 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.667 0.27 . . . . 0.0 110.467 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 97.0 mt -76.38 149.96 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 178.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 74.1 ttt-85 -99.16 -41.77 7.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.613 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -165.74 146.81 6.97 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.444 ' C ' HD12 ' A' ' 112' ' ' LEU . 71.9 t -97.63 134.43 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -98.67 148.78 35.02 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.074 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.79 162.03 44.03 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.796 2.331 . . . . 0.0 111.436 179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 114' ' ' THR . 2.9 p -62.49 149.38 43.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.981 0.419 . . . . 0.0 110.742 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttt85 -132.3 -141.24 0.21 Allowed 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.663 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . 0.457 ' HG3' HG22 ' A' ' 53' ' ' THR . 12.8 tpt180 -157.06 129.98 7.71 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.322 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.19 170.5 5.16 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.087 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -75.57 149.29 38.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.868 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 59.2 p -128.78 142.7 50.9 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.069 0.461 . . . . 0.0 109.764 179.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 9.2 m-85 -120.85 176.4 5.56 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.897 -178.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -148.76 153.54 38.31 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.855 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.589 HD21 HG22 ' A' ' 23' ' ' VAL . 90.8 mt -140.18 171.14 14.59 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.681 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -135.17 106.11 6.61 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' C ' ' A' ' 125' ' ' GLU . 7.9 t -86.89 111.74 22.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.498 ' C ' ' O ' ' A' ' 124' ' ' VAL . 5.2 tp10 20.79 -116.57 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 O-C-N 123.657 0.598 . . . . 0.0 111.685 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -106.74 -26.14 11.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.277 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.9 mt -89.21 69.84 8.26 Favored 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.498 ' O ' HG23 ' A' ' 129' ' ' THR . 28.9 m170 -42.92 104.88 0.04 OUTLIER 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.498 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.4 139.59 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.675 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.569 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.3 pt? -147.14 156.73 43.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 121.509 0.671 . . . . 0.0 112.122 179.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.0 p -89.02 125.35 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.577 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.8 126.59 30.9 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.947 -179.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.503 ' C ' ' H ' ' A' ' 135' ' ' VAL . 15.4 mm-40 53.81 46.78 25.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.982 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.33 -22.06 0.51 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.503 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.1 t -89.01 152.56 3.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 117.121 0.461 . . . . 0.0 110.66 -179.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -110.44 115.55 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.416 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 138' ' ' HIS . 12.3 m -147.31 137.69 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.528 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.573 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 53.1 t-80 -36.52 156.79 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.529 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 16.1 p30 . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.468 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.5 mt -105.12 141.49 36.58 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-O 120.938 0.399 . . . . 0.0 110.543 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -84.35 161.42 20.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.463 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 63.8 tt0 -61.68 146.03 50.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.381 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.57 -16.4 40.81 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.633 HG23 ' HG3' ' A' ' 133' ' ' GLU . 26.3 m -68.47 124.16 22.81 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.789 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . 0.472 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.0 mtp180 -85.03 149.82 25.31 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.162 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 56.2 mt -134.13 108.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.271 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . 0.413 ' HB3' HH22 ' A' ' 96' ' ' ARG . 43.9 t80 -76.94 126.7 31.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 178.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -96.06 131.2 29.37 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.094 -179.335 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.05 -33.17 4.73 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.33 2.02 . . . . 0.0 111.8 179.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 73.6 t -73.31 -54.27 16.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.64 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.5 m -75.17 -38.09 61.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.163 0.506 . . . . 0.0 110.065 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.23 7.36 85.18 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.059 -0.816 . . . . 0.0 111.059 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 16' ' ' THR . 3.0 t -106.9 -167.22 1.25 Allowed 'General case' 0 C--N 1.338 0.09 0 CA-C-N 117.652 0.726 . . . . 0.0 109.895 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.472 HG21 ' HE ' ' A' ' 7' ' ' ARG . 93.3 m -115.0 115.28 26.6 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.547 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -100.68 140.75 34.51 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.744 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.7 tpp85 -97.27 127.2 43.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.538 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.671 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -51.57 -40.3 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.771 -178.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.541 ' N ' HG23 ' A' ' 19' ' ' ILE . 14.3 tt0 -53.74 -35.29 61.06 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.961 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.72 -34.13 40.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.695 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.662 ' O ' ' O ' ' A' ' 26' ' ' ARG . 85.1 t -64.83 -45.61 94.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.807 0.337 . . . . 0.0 111.122 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 120' ' ' PHE . 87.9 t -66.54 -45.16 89.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 O-C-N 121.186 -0.946 . . . . 0.0 111.951 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -55.41 -42.41 74.04 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.741 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.75 33.49 3.72 Favored Glycine 0 CA--C 1.529 0.95 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.662 ' O ' ' O ' ' A' ' 22' ' ' VAL . 82.4 mtp180 58.14 -100.58 0.11 Allowed 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.638 ' C ' ' H ' ' A' ' 29' ' ' ILE . 40.7 mttt 79.94 82.65 0.09 OUTLIER Pre-proline 0 C--N 1.299 -1.604 0 C-N-CA 122.898 0.479 . . . . 0.0 110.388 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.7 ' O ' ' O ' ' A' ' 29' ' ' ILE . 34.1 Cg_exo -59.52 19.76 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.745 2.297 . . . . 0.0 112.577 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.7 ' O ' ' O ' ' A' ' 28' ' ' PRO . 20.3 pt -35.41 -178.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 O-C-N 124.041 0.838 . . . . 0.0 111.189 -178.258 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.426 ' CG ' HG21 ' A' ' 12' ' ' VAL . 56.6 m80 -119.78 163.33 17.63 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 121.43 -0.794 . . . . 0.0 110.891 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.1 171.33 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.9 t -91.03 135.13 27.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.47 168.09 9.81 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.82 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.06 142.67 46.39 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.216 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.39 177.93 4.48 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.785 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -70.54 -13.9 62.29 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.92 0.39 . . . . 0.0 110.656 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -81.34 -18.53 45.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.279 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.9 24.91 36.28 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.6 p -103.11 135.18 45.25 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.7 0.286 . . . . 0.0 111.203 178.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 65.4 mt -92.59 131.24 37.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.654 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 8.2 t-160 -142.82 139.82 31.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.483 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.55 141.95 51.82 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.794 -178.51 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.1 mmp_? -143.85 138.21 14.95 Favored Pre-proline 0 CA--C 1.535 0.398 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.8 158.81 31.46 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.86 2.373 . . . . 0.0 112.727 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.32 135.42 36.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.9 m -124.9 1.05 5.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.543 -178.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.9 t -144.34 133.68 23.16 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.548 0.613 . . . . 0.0 109.792 179.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.531 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -132.68 117.26 17.65 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 178.106 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -141.24 146.55 37.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -89.2 132.83 34.67 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 176.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.434 ' HA ' HE21 ' A' ' 51' ' ' GLN . 0.0 OUTLIER -92.17 -0.64 57.42 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.186 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.36 -179.6 51.66 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.31 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.8 m -91.74 126.6 36.89 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 120.945 0.402 . . . . 0.0 110.39 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 78.1 mtp85 -150.25 170.48 18.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.798 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -75.45 141.83 43.07 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.041 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -142.44 156.46 18.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.466 ' CG2' HG22 ' A' ' 114' ' ' THR . 37.7 pt -110.75 154.4 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.978 0.418 . . . . 0.0 110.258 179.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.84 132.73 11.26 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 21.0 mt -115.26 114.29 25.0 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.104 0.478 . . . . 0.0 110.222 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -99.19 122.75 42.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.968 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 94.4 mt . . . . . 0 CA--C 1.513 -0.465 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.692 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 -0.152 0 CA-C-O 120.994 0.426 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . 0.508 HG22 ' N ' ' A' ' 67' ' ' LEU . 97.1 mt -125.89 158.64 34.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.524 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.508 ' N ' HG22 ' A' ' 66' ' ' ILE . 42.5 tp -132.68 117.43 17.85 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.582 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -102.79 115.74 31.19 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.13 171.74 14.86 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.368 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 75.9 p -77.09 152.52 82.19 Favored Pre-proline 0 C--N 1.327 -0.394 0 C-N-CA 120.457 -0.497 . . . . 0.0 111.35 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.19 -28.8 81.01 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 122.214 1.943 . . . . 0.0 112.336 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -83.21 -5.66 59.2 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.899 0.38 . . . . 0.0 110.563 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.9 t60 -71.64 130.02 40.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.43 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.422 ' HD2' ' H ' ' A' ' 74' ' ' LYS . 0.0 OUTLIER -85.64 127.26 34.43 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.236 0.541 . . . . 0.0 110.737 -179.464 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.5 t -109.6 93.75 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.619 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.117 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.448 HD13 ' CH2' ' A' ' 81' ' ' TRP . 6.4 tp -31.42 93.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.677 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 75' ' ' VAL . 0.9 OUTLIER -97.25 177.86 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -178.236 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.411 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.2 pt-20 -64.68 -22.84 67.07 Favored 'General case' 0 N--CA 1.448 -0.573 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.262 -179.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -104.59 26.39 9.11 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 121.235 -0.186 . . . . 0.0 110.99 -179.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.18 -177.88 43.01 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.448 ' CH2' HD13 ' A' ' 76' ' ' LEU . 83.1 m95 -57.01 130.74 47.38 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.977 0.418 . . . . 0.0 110.335 -177.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -146.38 135.26 22.42 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.78 144.5 14.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.917 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.462 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -64.25 -38.76 92.21 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.488 -179.014 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.51 1.02 0.52 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.449 -0.881 . . . . 0.0 111.76 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.462 ' H ' ' C ' ' A' ' 84' ' ' ALA . 19.9 tp10 -107.66 5.43 26.83 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.159 0.504 . . . . 0.0 110.049 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.29 123.19 29.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.226 0.536 . . . . 0.0 111.018 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 90' ' ' GLY . 33.1 mmt180 -132.47 149.76 52.28 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.803 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -48.02 87.89 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.977 0.418 . . . . 0.0 110.657 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -20.0 0.44 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.911 -0.875 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -84.18 129.48 34.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.83 0.348 . . . . 0.0 110.582 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.411 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 88.2 mtm180 -90.68 132.38 35.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.142 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 m -119.93 152.14 22.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.823 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -68.69 137.36 54.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.491 -179.422 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.436 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.0 m -137.19 162.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.465 178.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.709 HH21 HG11 ' A' ' 131' ' ' VAL . 12.2 ttm180 -106.58 129.45 54.51 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.535 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 101' ' ' GLY . 45.9 t0 -100.97 123.77 45.67 Favored 'General case' 0 C--O 1.224 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.426 178.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -74.24 -15.73 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 118.184 0.447 . . . . 0.0 111.12 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -72.45 -55.18 7.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.01 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.2 m -99.44 -16.27 18.43 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.735 -0.211 . . . . 0.0 110.632 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 97' ' ' ASP . . . 73.84 -14.32 3.67 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.3 mt-10 -80.71 160.4 24.97 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-O 120.781 0.324 . . . . 0.0 110.64 -177.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.442 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.5 tp -79.03 126.59 30.9 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.027 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.408 ' O ' HG22 ' A' ' 95' ' ' VAL . 65.8 mtp85 -126.81 168.17 14.8 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.956 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -110.32 142.72 41.58 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.5 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . 0.436 ' OG ' HG21 ' A' ' 95' ' ' VAL . 12.7 m -137.94 158.44 44.33 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.85 152.82 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.737 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.43 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.9 mm -67.46 156.7 6.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.844 179.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.43 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 17.2 tpt180 -108.39 -52.33 2.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.01 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -165.56 144.47 6.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 70.0 t -95.09 133.29 36.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.087 0.47 . . . . 0.0 110.037 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.62 127.02 32.39 Favored Pre-proline 0 CA--C 1.536 0.432 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.518 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -47.88 161.64 0.33 Allowed 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 122.206 1.937 . . . . 0.0 112.021 179.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.466 HG22 ' CG2' ' A' ' 57' ' ' ILE . 80.6 p -64.99 153.82 39.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.0 0.429 . . . . 0.0 110.699 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.8 ttp180 -134.98 -140.8 0.17 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.586 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.8 mtm-85 -156.79 130.44 8.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.11 172.82 3.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.979 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 22.6 mmt85 -77.51 147.03 36.03 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.971 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 18.5 p -125.13 142.9 51.21 Favored 'General case' 0 CA--C 1.52 -0.181 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . 0.925 ' CD1' HG21 ' A' ' 23' ' ' VAL . 75.6 m-85 -118.93 175.54 5.71 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.821 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -153.47 120.51 5.74 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.553 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.671 HD11 HD12 ' A' ' 19' ' ' ILE . 75.1 mt -120.03 123.95 44.7 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -87.58 118.41 27.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.209 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 50.5 t -90.42 115.23 29.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -58.1 149.28 24.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.715 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.9 tt0 63.85 -69.73 0.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.295 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.82 100.79 11.78 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 110.43 -0.211 . . . . 0.0 110.43 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.55 ' O ' HG23 ' A' ' 129' ' ' THR . 72.4 m-70 -69.73 100.28 1.47 Allowed 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.161 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.55 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 164.15 144.37 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.558 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.5 pt? -145.33 157.02 44.13 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.636 0.732 . . . . 0.0 112.011 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.709 HG11 HH21 ' A' ' 96' ' ' ARG . 8.9 p -92.35 120.56 41.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.832 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.604 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.89 126.45 30.46 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.891 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.633 ' HG3' HG23 ' A' ' 6' ' ' THR . 8.9 mt-10 59.86 45.33 12.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.222 0.534 . . . . 0.0 110.029 -179.475 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.41 -24.7 0.35 Allowed Glycine 0 CA--C 1.522 0.524 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.28 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.533 ' H ' ' C ' ' A' ' 133' ' ' GLU . 10.3 t -90.25 151.21 3.53 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 O-C-N 122.485 -0.42 . . . . 0.0 110.68 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.89 115.84 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.68 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 138' ' ' HIS . 20.9 m -147.28 136.67 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.434 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 17.9 t-80 -34.99 154.36 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.089 0.403 . . . . 0.0 112.089 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.277 -179.861 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.6 mt -108.97 137.53 46.74 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.341 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 161.46 23.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.687 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -62.36 145.91 52.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.092 179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.56 -17.65 33.3 Favored Glycine 0 C--N 1.337 0.63 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.8 m -66.89 122.4 17.63 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.224 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -98.35 115.72 29.06 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.143 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 131' ' ' VAL . 3.6 mt -102.59 117.33 47.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.734 -179.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -75.84 133.23 40.66 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASP . . . . . 0.823 ' OD1' HG22 ' A' ' 13' ' ' THR . 4.1 t70 -104.0 134.93 19.45 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.526 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.52 -32.51 3.71 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.512 2.142 . . . . 0.0 112.321 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.07 -59.6 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.417 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.823 HG22 ' OD1' ' A' ' 10' ' ' ASP . 1.9 t -76.9 -34.21 57.74 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.97 12.84 76.11 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.648 ' H ' HG23 ' A' ' 13' ' ' THR . 75.5 m -116.94 161.6 19.1 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 117.977 0.888 . . . . 0.0 109.753 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' THR . . . . . 0.523 ' N ' HG22 ' A' ' 15' ' ' THR . 43.0 m -79.71 115.83 19.54 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.278 0.561 . . . . 0.0 110.713 -179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' HIS . . . . . 0.669 ' NE2' HG21 ' A' ' 13' ' ' THR . 24.8 m-70 -101.84 147.07 26.94 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.206 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -101.23 125.53 47.87 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.004 178.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -53.46 -39.32 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.265 -179.234 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.2 pt-20 -58.55 -33.72 70.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 68.4 t0 -83.97 -37.22 22.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.596 179.611 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 78.4 t -66.39 -42.74 91.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.27 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.447 HG22 HD21 ' A' ' 122' ' ' LEU . 75.9 t -69.51 -44.81 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 121.093 -0.243 . . . . 0.0 111.428 -179.697 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -54.15 -36.32 63.19 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 121.036 -0.266 . . . . 0.0 110.761 -178.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -117.25 33.31 5.07 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER 12.42 74.95 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 124.056 0.504 . . . . 0.0 109.9 179.859 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LYS . . . . . 0.652 ' C ' ' H ' ' A' ' 29' ' ' ILE . 64.0 mttt -91.29 117.74 68.04 Favored Pre-proline 0 N--CA 1.442 -0.862 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -178.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.68 ' O ' ' O ' ' A' ' 29' ' ' ILE . 52.5 Cg_exo -52.67 7.54 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.964 2.442 . . . . 0.0 113.005 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.68 ' O ' ' O ' ' A' ' 28' ' ' PRO . 1.3 pp -37.05 -178.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 O-C-N 123.949 0.781 . . . . 0.0 110.722 -178.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' HIS . . . . . 0.506 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 2.4 m80 -126.49 168.14 14.65 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 121.404 -0.81 . . . . 0.0 111.247 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.1 m -148.12 171.78 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.264 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 62.9 t -88.11 131.11 36.53 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.641 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -109.07 149.72 28.86 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.055 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.69 140.79 50.1 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.933 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB3' ' OD1' ' A' ' 37' ' ' ASP . . . -113.69 174.31 5.99 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.771 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -68.42 -14.62 63.13 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.651 0.263 . . . . 0.0 110.648 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.485 ' OD1' ' HB3' ' A' ' 35' ' ' ALA . 38.4 p30 -81.79 -15.71 53.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.488 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 87.04 22.64 44.45 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.42 ' OG1' ' OD1' ' A' ' 37' ' ' ASP . 22.0 p -102.87 137.29 41.27 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.622 0.249 . . . . 0.0 111.108 178.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.7 mt -94.79 130.18 41.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.884 0.374 . . . . 0.0 110.47 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.48 138.7 33.01 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.404 -179.073 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.74 139.9 53.4 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.609 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.7 mmt-85 -143.38 137.97 15.1 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.897 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.73 156.34 35.37 Favored 'Trans proline' 0 C--N 1.316 -1.177 0 C-N-CA 122.783 2.322 . . . . 0.0 112.969 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.9 t -93.86 130.75 42.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -118.11 -5.02 11.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.527 -178.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.1 t -145.97 134.73 22.35 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.203 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' TRP . . . . . 0.557 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -134.02 116.28 15.32 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.359 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PHE . . . . . 0.514 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 47.5 m-85 -140.94 150.71 43.48 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.063 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -93.54 133.16 37.13 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 176.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.694 HE21 ' CB ' ' A' ' 121' ' ' ASP . 26.1 mm-40 -92.17 -0.35 57.43 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.202 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.5 179.73 51.48 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 32.0 m -91.41 123.07 34.55 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -143.79 169.97 16.76 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.915 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -76.99 142.71 39.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.971 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.7 m -147.15 157.59 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.113 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.629 HD11 ' HB1' ' A' ' 84' ' ' ALA . 45.9 pt -108.12 159.05 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.238 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.83 139.55 15.75 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.7 mt -118.53 112.04 19.39 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.148 0.499 . . . . 0.0 109.689 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.735 ' NE ' ' HE ' ' A' ' 109' ' ' ARG . 56.8 ttp180 -98.94 126.17 44.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.001 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.733 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp . . . . . 0 N--CA 1.469 0.52 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.468 0.472 0 CA-C-O 120.797 0.332 . . . . 0.0 110.556 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 93.5 mt -120.89 135.55 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.222 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.7 tp -112.53 111.0 21.51 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.798 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' TRP . . . . . 0.515 ' CE3' ' NH2' ' A' ' 115' ' ' ARG . 97.9 m95 -103.73 105.71 16.0 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.25 172.47 12.87 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.549 -179.059 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -72.76 156.24 90.11 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.759 -179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 85' ' ' GLY . 31.4 Cg_endo -64.3 -19.36 65.59 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.644 2.229 . . . . 0.0 111.866 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 39.6 p-10 -90.99 -4.98 56.0 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' HIS . . . . . 0.534 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.6 t60 -71.88 132.09 43.91 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.19 124.65 32.09 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.442 0.639 . . . . 0.0 111.386 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.8 t -99.03 143.01 13.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.159 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.4 tp -82.83 89.87 6.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.699 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.473 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 30.0 p -97.86 176.25 5.86 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -67.39 -20.03 65.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.117 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -101.73 24.35 9.98 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-O 120.656 0.265 . . . . 0.0 110.825 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.09 -144.71 17.5 Favored Glycine 0 C--N 1.332 0.306 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -86.88 121.88 29.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.732 0.301 . . . . 0.0 111.289 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.7 mmt85 -122.56 125.8 46.45 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.089 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -68.54 129.84 41.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.507 -179.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.629 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -66.83 -0.03 2.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.799 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -75.55 -13.13 83.22 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -136.97 30.84 2.74 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.914 0.387 . . . . 0.0 111.378 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LEU . . . . . 0.455 HD12 ' HA ' ' A' ' 84' ' ' ALA . 10.9 mt -82.88 131.81 35.18 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.403 0.62 . . . . 0.0 111.007 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 83.2 mmt-85 -133.62 148.38 51.55 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.082 -0.963 . . . . 0.0 111.346 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -46.37 97.92 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.547 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 158.48 -16.52 0.28 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -88.29 129.91 35.25 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -88.57 129.74 35.41 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.36 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.9 m -108.9 141.86 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.046 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ALA . . . . . 0.465 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -72.08 120.71 18.06 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.722 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' VAL . . . . . 0.406 ' O ' HG23 ' A' ' 95' ' ' VAL . 33.2 m -121.85 131.28 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.945 0.402 . . . . 0.0 110.07 179.09 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -67.73 132.05 46.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.848 -179.413 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 48.7 t0 -101.77 122.9 44.81 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 119.297 -0.382 . . . . 0.0 110.443 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.5 p -75.22 -16.87 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 CA-C-N 118.427 0.558 . . . . 0.0 111.323 179.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.75 -58.49 3.59 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.436 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . 0.439 ' C ' ' H ' ' A' ' 102' ' ' GLU . 48.8 p -98.58 -14.89 19.72 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.456 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.37 -17.22 4.26 Favored Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.439 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.4 mt-10 -78.38 157.75 28.97 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -177.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.494 HD11 HG21 ' A' ' 136' ' ' VAL . 2.1 tp -75.06 135.18 41.24 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.314 -179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 32.5 ptt180 -135.04 167.46 20.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.216 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.473 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.0 m-85 -117.12 152.83 33.9 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.029 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.1 m -146.2 165.21 29.85 Favored 'General case' 0 CA--C 1.516 -0.348 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.8 t -89.2 150.37 3.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 120.775 0.321 . . . . 0.0 110.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ILE . . . . . 0.491 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.2 mm -69.83 160.75 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.211 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.735 ' HE ' ' NE ' ' A' ' 60' ' ' ARG . 12.6 ttp85 -107.67 -49.32 3.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.533 179.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLU . . . . . 0.527 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 74.8 tt0 -166.78 146.66 5.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.473 ' C ' HD22 ' A' ' 112' ' ' LEU . 1.0 OUTLIER -94.09 134.58 31.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.238 0.542 . . . . 0.0 110.019 179.688 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 3.0 mm? -97.86 145.48 29.82 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.157 -179.208 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.47 160.18 50.78 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 122.568 2.179 . . . . 0.0 111.468 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -64.88 154.12 38.22 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.146 0.498 . . . . 0.0 110.655 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.515 ' NH2' ' CE3' ' A' ' 68' ' ' TRP . 74.4 mtm180 -140.95 -138.82 0.12 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.657 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -155.58 132.01 10.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.236 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -171.13 173.03 5.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.764 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -77.77 140.24 39.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.779 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 3.1 p -114.98 140.46 49.01 Favored 'General case' 0 CA--C 1.522 -0.117 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -119.59 171.59 8.26 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.24 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.694 ' CB ' HE21 ' A' ' 51' ' ' GLN . 43.6 p-10 -160.72 120.31 2.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.089 179.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 23' ' ' VAL . 69.9 mt -117.38 131.67 56.73 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 120.72 0.295 . . . . 0.0 110.63 179.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -87.71 110.18 20.25 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.568 ' O ' ' N ' ' A' ' 126' ' ' GLU . 21.6 t -81.04 109.49 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.467 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.074 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.488 ' C ' ' O ' ' A' ' 124' ' ' VAL . 1.6 tm-20 24.14 -85.53 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.815 0.697 . . . . 0.0 111.435 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . 0.568 ' N ' ' O ' ' A' ' 124' ' ' VAL . 79.8 tt0 -136.87 -36.44 0.68 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.157 -0.928 . . . . 0.0 111.141 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.481 ' O ' ' N ' ' A' ' 129' ' ' THR . 74.0 mt -72.4 67.69 0.74 Allowed 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' HIS . . . . . 0.58 ' O ' HG23 ' A' ' 129' ' ' THR . 35.4 m80 -40.82 95.92 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.631 ' C ' HD21 ' A' ' 139' ' ' ASN . 0.0 OUTLIER 166.5 136.36 0.01 OUTLIER 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.685 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.5 pp -144.99 154.37 42.47 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.449 0.642 . . . . 0.0 111.679 -178.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 8' ' ' ILE . 97.2 t -87.81 123.99 40.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ALA . . . . . 0.603 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.51 142.22 48.13 Favored 'General case' 0 C--O 1.227 -0.106 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.444 -178.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.581 ' O ' HG23 ' A' ' 135' ' ' VAL . 71.1 mm-40 40.23 49.79 2.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.196 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.45 -25.32 0.27 Allowed Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.446 -0.662 . . . . 0.0 111.446 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 133' ' ' GLU . 2.7 t -89.12 152.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.394 0 O-C-N 122.48 -0.423 . . . . 0.0 110.689 -179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' VAL . . . . . 0.494 HG21 HD11 ' A' ' 103' ' ' LEU . 2.7 t -109.87 117.64 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.437 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 138' ' ' HIS . 20.5 m -149.87 141.01 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.531 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.492 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 54.3 t-80 -31.42 150.31 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.173 0 O-C-N 123.209 0.318 . . . . 0.0 111.741 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.631 HD21 ' C ' ' A' ' 129' ' ' THR . 1.5 m120 . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 118.056 -0.973 . . . . 0.0 110.628 -179.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.543 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 5.1 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 64.3 mt -99.47 141.8 31.79 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.356 -179.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.66 162.46 17.1 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.758 179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.428 ' OE2' ' OE2' ' A' ' 20' ' ' GLU . 41.3 tt0 -64.51 140.77 58.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.443 178.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.91 -17.72 29.64 Favored Glycine 0 C--N 1.338 0.693 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.5 m -70.63 122.81 20.48 Favored 'General case' 0 C--N 1.331 -0.201 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.607 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.6 mtp180 -82.65 147.99 28.21 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-O 121.043 0.449 . . . . 0.0 110.429 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 84.7 mt -133.94 107.67 10.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.964 -0.562 . . . . 0.0 111.26 179.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -77.97 129.69 35.61 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 177.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -101.49 132.02 22.3 Favored Pre-proline 0 CA--C 1.539 0.542 0 N-CA-C 110.318 -0.253 . . . . 0.0 110.318 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 62.6 Cg_endo -73.45 -31.2 9.25 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 121.857 1.705 . . . . 0.0 112.449 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.2 t -69.99 -53.61 22.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.049 -179.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.7 p -80.19 -39.76 28.59 Favored 'General case' 0 CA--C 1.518 -0.266 0 CA-C-O 120.858 0.361 . . . . 0.0 110.24 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.68 9.61 74.61 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 111.419 -0.672 . . . . 0.0 111.419 179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.416 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -105.8 -168.32 1.43 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 117.363 0.582 . . . . 0.0 109.855 -179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.607 HG21 ' HE ' ' A' ' 7' ' ' ARG . 72.8 m -117.34 119.79 36.2 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.346 0.593 . . . . 0.0 110.397 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 63.9 m170 -109.75 148.07 32.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.089 -179.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 85.7 mtt180 -98.87 130.24 45.27 Favored 'General case' 0 N--CA 1.466 0.36 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.502 HG23 ' N ' ' A' ' 20' ' ' GLU . 5.6 tp -51.93 -40.83 29.39 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 120.632 0.253 . . . . 0.0 111.109 -179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.502 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.6 pt-20 -58.87 -34.57 71.77 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.113 0.482 . . . . 0.0 110.901 -179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.6 t0 -84.51 -37.49 21.23 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.432 179.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 75.4 t -68.09 -41.54 84.39 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.14 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.937 -178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.67 HG22 HD21 ' A' ' 122' ' ' LEU . 53.5 t -77.42 -46.33 28.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.424 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.2 t0 -55.65 -35.48 65.99 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-O 120.764 0.316 . . . . 0.0 110.829 -177.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.564 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.77 26.49 14.13 Favored Glycine 0 N--CA 1.46 0.238 0 N-CA-C 110.829 -0.909 . . . . 0.0 110.829 179.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.564 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.2 OUTLIER 15.37 68.77 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.225 0 O-C-N 124.042 0.496 . . . . 0.0 109.71 -179.952 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 29' ' ' ILE . 83.4 mttt -83.8 114.46 54.05 Favored Pre-proline 0 N--CA 1.45 -0.449 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.87 -175.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 34.8 Cg_exo -57.16 83.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.49 1.289 0 CA-C-N 119.78 0.957 . . . . 0.0 111.294 178.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.47 ' N ' ' O ' ' A' ' 27' ' ' LYS . 49.1 pt -119.11 -170.12 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 CA-C-O 121.063 0.459 . . . . 0.0 110.973 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.449 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 67.6 m80 -126.37 161.66 27.34 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.432 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.05 170.56 3.9 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.357 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 97.3 t -88.86 133.68 30.44 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.557 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 179.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.36 155.64 24.84 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.549 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -127.22 145.71 50.67 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.079 0.466 . . . . 0.0 110.395 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.73 -176.55 2.99 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.428 ' HD2' ' H ' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -71.63 -12.75 61.5 Favored 'General case' 0 CA--C 1.523 -0.092 0 CA-C-O 120.868 0.366 . . . . 0.0 110.686 179.561 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.491 ' OD1' ' N ' ' A' ' 38' ' ' GLY . 32.3 p30 -76.28 -20.2 57.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.565 179.513 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.491 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 93.95 -8.25 73.34 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.457 ' HG1' ' CE1' ' A' ' 41' ' ' HIS . 33.6 p -82.31 151.09 26.88 Favored 'General case' 0 C--O 1.232 0.136 0 CA-C-O 121.946 0.879 . . . . 0.0 111.783 -179.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.0 mt -100.94 132.21 46.45 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.258 -1.337 . . . . 0.0 111.877 -179.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . 0.457 ' CE1' ' HG1' ' A' ' 39' ' ' THR . 5.7 m80 -137.88 137.39 38.02 Favored 'General case' 0 C--O 1.221 -0.429 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.375 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.62 143.69 49.7 Favored 'General case' 0 C--N 1.323 -0.571 0 C-N-CA 120.902 -0.319 . . . . 0.0 110.454 -178.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.537 HH21 ' CD ' ' A' ' 125' ' ' GLU . 8.9 mtp85 -149.21 138.61 12.7 Favored Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.499 -0.319 . . . . 0.0 110.991 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -74.85 157.17 43.55 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.239 1.959 . . . . 0.0 112.677 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 99.1 t -96.24 136.67 26.38 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.391 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 12.9 m -123.7 1.39 5.69 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.618 0 CA-C-O 119.202 -0.428 . . . . 0.0 111.856 -178.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.5 p -151.04 144.87 25.13 Favored 'General case' 0 N--CA 1.447 -0.595 0 CA-C-N 118.987 0.812 . . . . 0.0 109.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.478 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.1 OUTLIER -142.12 123.07 14.47 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.373 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -141.57 145.32 34.93 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 179.257 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -86.88 136.55 32.92 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.437 ' HA ' HE21 ' A' ' 51' ' ' GLN . 0.0 OUTLIER -99.14 1.84 45.4 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 119.391 -0.337 . . . . 0.0 111.806 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.6 -175.44 53.41 Favored Glycine 0 CA--C 1.526 0.735 0 C-N-CA 120.375 -0.917 . . . . 0.0 111.613 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 70.0 m -95.14 126.66 40.62 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -148.21 168.3 22.85 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.433 -179.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.7 m-20 -73.1 138.36 45.78 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.607 -179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -139.22 155.11 25.99 Favored 'Isoleucine or valine' 0 C--O 1.232 0.154 0 CA-C-O 120.752 0.31 . . . . 0.0 110.181 -179.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.791 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.0 pt -110.45 153.17 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 120.854 0.359 . . . . 0.0 110.179 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.28 125.47 7.7 Favored Glycine 0 N--CA 1.463 0.474 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.5 mt -106.93 112.46 25.44 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 56.8 ttp180 -96.17 123.36 39.77 Favored 'General case' 0 C--O 1.219 -0.521 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.416 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 24.1 mm -111.36 157.83 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -52.12 138.14 26.25 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.697 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.712 ' H ' ' NH2' ' A' ' 109' ' ' ARG . . . 101.69 -3.57 53.19 Favored Glycine 0 CA--C 1.525 0.717 0 CA-C-N 115.938 -0.573 . . . . 0.0 111.915 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 96.52 -19.8 53.09 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -53.25 125.35 17.3 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.543 0.687 . . . . 0.0 109.213 -177.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -132.01 154.67 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.408 -178.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.2 tp -143.69 125.84 15.5 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.7 m95 -105.87 123.52 48.1 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 178.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.85 170.77 17.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 6.5 p -78.49 156.7 78.16 Favored Pre-proline 0 CA--C 1.532 0.268 0 C-N-CA 120.691 -0.404 . . . . 0.0 110.982 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -59.25 -22.92 67.32 Favored 'Trans proline' 0 N--CA 1.494 1.547 0 C-N-CA 121.872 1.715 . . . . 0.0 111.995 179.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -87.09 -8.9 56.59 Favored 'General case' 0 CA--C 1.521 -0.143 0 CA-C-O 120.679 0.276 . . . . 0.0 110.743 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.543 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 8.2 t60 -68.7 126.76 30.71 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.751 ' H ' ' CE1' ' A' ' 138' ' ' HIS . 69.0 mttm -86.22 130.88 34.37 Favored 'General case' 0 N--CA 1.455 -0.179 0 CA-C-O 121.509 0.671 . . . . 0.0 111.418 -179.185 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -104.66 139.27 26.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.656 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.83 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 59.6 tp -77.81 95.96 4.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.955 -179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 62.2 p -99.32 178.04 5.01 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 -178.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.698 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.7 pm0 -64.91 -16.93 63.87 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.525 -0.47 . . . . 0.0 111.556 -178.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.456 ' HB2' ' HE ' ' A' ' 82' ' ' ARG . 77.3 m-85 -109.73 26.24 10.88 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 111.853 0.316 . . . . 0.0 111.853 -178.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.08 -138.38 13.87 Favored Glycine 0 C--N 1.332 0.343 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -98.72 132.44 44.09 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.451 -0.374 . . . . 0.0 110.746 -179.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.456 ' HE ' ' HB2' ' A' ' 79' ' ' TYR . 90.8 mtt-85 -140.3 132.41 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.266 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.36 144.81 23.97 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.902 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.791 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.45 -38.24 86.47 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 120.83 -0.348 . . . . 0.0 111.569 -179.046 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -64.07 -2.12 6.29 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 120.537 -0.84 . . . . 0.0 111.713 -179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -110.67 25.69 11.5 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.95 0.405 . . . . 0.0 110.433 179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 77.5 mt -110.18 130.34 55.56 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.608 0.718 . . . . 0.0 111.126 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.522 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.1 mmt180 -130.4 147.53 52.11 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.744 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.5 ttpt -45.01 90.35 0.0 OUTLIER 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.888 0.375 . . . . 0.0 110.454 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -13.78 0.33 Allowed Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.757 -0.937 . . . . 0.0 110.757 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -84.48 130.16 34.78 Favored 'General case' 0 C--O 1.225 -0.223 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.43 ' O ' ' OE1' ' A' ' 78' ' ' GLU . 89.1 mtm180 -90.26 136.72 32.88 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.704 -178.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 28.2 m -125.24 151.52 31.11 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.259 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.209 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.494 ' HB1' ' CD1' ' A' ' 103' ' ' LEU . . . -84.92 128.59 34.69 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.457 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 32.6 m -130.3 135.14 61.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.898 0.38 . . . . 0.0 110.441 179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 tmm_? -66.74 133.66 50.62 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-O 121.055 0.455 . . . . 0.0 111.344 -179.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 38.4 t0 -98.54 122.67 42.03 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-N 115.872 -0.603 . . . . 0.0 109.562 179.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 94.0 t -75.02 -17.23 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 118.401 0.546 . . . . 0.0 110.649 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -69.77 -59.25 3.06 Favored 'General case' 0 CA--C 1.522 -0.096 0 C-N-CA 120.197 -0.601 . . . . 0.0 109.964 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.494 ' C ' ' H ' ' A' ' 102' ' ' GLU . 73.6 p -93.88 -11.34 31.31 Favored 'General case' 0 C--O 1.233 0.233 0 N-CA-C 110.435 -0.209 . . . . 0.0 110.435 179.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 72.89 -12.04 4.12 Favored Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.494 ' H ' ' C ' ' A' ' 100' ' ' THR . 41.8 mt-10 -88.49 164.57 15.39 Favored 'General case' 0 N--CA 1.45 -0.472 0 CA-C-O 121.036 0.446 . . . . 0.0 111.24 -177.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.513 HD13 ' H ' ' A' ' 104' ' ' ARG . 0.2 OUTLIER -71.12 142.06 50.77 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.589 -179.459 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.513 ' H ' HD13 ' A' ' 103' ' ' LEU . 6.0 ptt85 -136.89 158.76 43.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.611 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.698 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -112.32 135.8 52.56 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.926 -179.746 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.481 ' OG ' ' NH2' ' A' ' 104' ' ' ARG . 6.7 m -142.55 161.84 37.01 Favored 'General case' 0 C--N 1.344 0.329 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.1 p -94.43 156.48 3.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.797 0.332 . . . . 0.0 111.33 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.459 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.3 mt -71.1 159.35 5.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.712 ' NH2' ' H ' ' A' ' 63' ' ' GLY . 43.2 ttm180 -106.57 -46.36 4.02 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.759 179.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 81.4 tt0 -165.01 143.72 6.55 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.291 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.424 ' C ' HD22 ' A' ' 112' ' ' LEU . 10.7 p -93.95 133.14 36.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.433 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.3 mm? -101.11 125.4 38.24 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-O 119.674 -0.203 . . . . 0.0 110.977 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -47.39 165.93 0.1 Allowed 'Trans proline' 0 N--CA 1.498 1.779 0 C-N-CA 122.225 1.95 . . . . 0.0 112.0 179.065 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 19.9 p -66.69 151.47 47.33 Favored 'General case' 0 N--CA 1.452 -0.325 0 CA-C-O 121.276 0.56 . . . . 0.0 110.776 -179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.0 ttm180 -133.06 -142.05 0.21 Allowed 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.678 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.5 mtt85 -156.79 130.93 8.47 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.285 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.53 169.83 5.03 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.943 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -72.89 148.25 44.56 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.241 178.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 42.0 p -131.1 143.36 50.6 Favored 'General case' 0 CA--C 1.52 -0.21 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.49 ' HB3' HG21 ' A' ' 23' ' ' VAL . 68.3 m-85 -115.65 174.55 5.96 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-O 121.439 0.638 . . . . 0.0 111.753 -179.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -145.28 137.48 25.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.109 -0.95 . . . . 0.0 111.074 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.67 HD21 HG22 ' A' ' 23' ' ' VAL . 97.2 mt -130.23 170.8 13.63 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.449 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -138.01 106.99 5.98 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.926 178.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.491 ' O ' ' C ' ' A' ' 125' ' ' GLU . 8.5 t -86.04 115.14 26.84 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.188 0 CA-C-N 116.228 -0.442 . . . . 0.0 109.863 -179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.537 ' CD ' HH21 ' A' ' 43' ' ' ARG . 81.4 tt0 18.52 -95.65 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.729 0 O-C-N 123.762 0.664 . . . . 0.0 112.327 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -128.03 -33.11 2.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.154 179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.439 ' O ' ' N ' ' A' ' 129' ' ' THR . 54.3 mt -78.02 67.93 3.96 Favored 'General case' 0 CA--C 1.504 -0.8 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . . . . . . . . . 57.5 m170 -42.7 97.81 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.449 0 CA-C-N 115.527 -0.761 . . . . 0.0 109.229 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.439 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 175.14 143.48 0.06 Allowed 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 177.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.634 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.9 pp -151.47 154.5 36.68 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 121.415 0.626 . . . . 0.0 111.676 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 95.7 t -89.76 123.54 42.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.09 -0.959 . . . . 0.0 108.872 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -134.86 122.87 22.62 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.137 -178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.498 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.8 mm-40 55.83 43.54 27.48 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.021 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.51 -15.81 0.8 Allowed Glycine 0 CA--C 1.527 0.825 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.176 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.498 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.7 t -90.53 146.87 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 117.268 0.534 . . . . 0.0 110.456 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.19 115.12 47.87 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.792 179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.416 ' O ' ' C ' ' A' ' 138' ' ' HIS . 21.6 m -147.65 142.19 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.226 179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.751 ' CE1' ' H ' ' A' ' 74' ' ' LYS . 0.3 OUTLIER -37.37 153.48 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 118.206 0.457 . . . . 0.0 111.681 -179.816 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 18.9 p30 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.382 179.745 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.431 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 24.5 m . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -109.34 136.51 48.67 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.845 0.355 . . . . 0.0 110.527 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.04 162.66 21.33 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.685 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.518 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 44.6 tt0 -63.27 143.18 58.02 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.961 179.151 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 110.83 -20.83 23.96 Favored Glycine 0 CA--C 1.521 0.43 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -179.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.619 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.3 m -67.48 123.56 20.74 Favored 'General case' 0 C--N 1.331 -0.218 0 O-C-N 122.768 -0.254 . . . . 0.0 111.244 -179.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.817 ' HE ' HG21 ' A' ' 16' ' ' THR . 72.6 mtp180 -82.72 147.63 28.35 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.781 0.324 . . . . 0.0 110.162 179.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 33.4 mt -134.79 107.3 8.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.497 179.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 80.7 t80 -76.95 129.8 36.64 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' A' ' 10' ' ' ASP . 50.8 t0 -109.91 110.24 59.06 Favored Pre-proline 0 CA--C 1.534 0.329 0 CA-C-O 119.53 -0.272 . . . . 0.0 110.377 -179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_exo -51.96 -36.8 65.84 Favored 'Trans proline' 0 N--CA 1.495 1.617 0 C-N-CA 121.765 1.643 . . . . 0.0 112.561 178.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 75.2 t -62.11 -58.25 8.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 CA-C-N 116.399 -0.364 . . . . 0.0 111.037 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 24.8 p -77.49 -33.93 54.35 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.365 0.602 . . . . 0.0 109.834 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.31 6.47 89.27 Favored Glycine 0 N--CA 1.449 -0.465 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.175 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.494 HG22 ' N ' ' A' ' 16' ' ' THR . 50.6 m -113.83 159.91 19.3 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 117.719 0.759 . . . . 0.0 109.926 -179.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.817 HG21 ' HE ' ' A' ' 7' ' ' ARG . 13.9 m -80.4 117.05 20.81 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.17 0.51 . . . . 0.0 110.926 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 8.8 m-70 -98.94 139.92 33.86 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.251 -0.886 . . . . 0.0 110.041 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 57.2 ttp180 -95.66 127.47 41.71 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.791 179.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.561 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.2 tp -53.98 -40.8 46.86 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-O 120.861 0.362 . . . . 0.0 111.429 -178.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.561 ' N ' HG23 ' A' ' 19' ' ' ILE . 8.7 tt0 -58.88 -36.64 74.98 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.135 0.493 . . . . 0.0 110.729 -179.52 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 25.7 t0 -81.5 -36.64 29.0 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.342 -0.844 . . . . 0.0 111.567 179.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 43.6 t -66.96 -41.71 87.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 N-CA-C 112.148 0.425 . . . . 0.0 112.148 -179.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 92.1 t -73.22 -43.56 57.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.65 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -178.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 -58.85 -37.87 77.46 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 121.084 -0.247 . . . . 0.0 111.3 -177.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.512 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.87 29.54 10.66 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.512 ' C ' ' O ' ' A' ' 25' ' ' GLY . 96.3 mtt-85 22.61 56.49 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.088 0 CA-C-O 121.27 0.557 . . . . 0.0 110.266 178.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.626 ' C ' ' H ' ' A' ' 29' ' ' ILE . 31.1 mmtt -75.41 115.68 47.67 Favored Pre-proline 0 C--N 1.322 -0.604 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.917 -177.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.558 ' O ' ' O ' ' A' ' 29' ' ' ILE . 32.6 Cg_exo -58.1 12.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.505 2.191 0 C-N-CA 122.001 1.801 . . . . 0.0 112.843 179.165 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.626 ' H ' ' C ' ' A' ' 27' ' ' LYS . 2.1 pp -40.23 175.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.713 -177.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.478 ' ND1' ' N ' ' A' ' 30' ' ' HIS . 2.8 m80 -121.71 167.51 12.86 Favored 'General case' 0 N--CA 1.467 0.401 0 O-C-N 122.22 -0.3 . . . . 0.0 110.611 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -148.28 170.08 3.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 7.1 t -87.59 137.2 21.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 O-C-N 121.896 -0.502 . . . . 0.0 109.772 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.78 168.03 9.65 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.138 179.8 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -139.22 140.23 37.69 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.29 179.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.57 176.02 5.21 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -70.71 -14.07 62.31 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 120.803 0.335 . . . . 0.0 110.837 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.5 t0 -79.37 -17.64 54.03 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.38 179.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.81 22.1 40.54 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.2 p -101.6 136.64 41.1 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.727 0.299 . . . . 0.0 111.076 178.532 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.1 mt -98.94 134.1 42.27 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.848 179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -144.4 141.66 29.81 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.781 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.17 141.82 52.57 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.533 -178.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -142.39 140.67 19.31 Favored Pre-proline 0 CA--C 1.542 0.653 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.272 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -78.04 157.57 30.53 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.771 2.314 . . . . 0.0 112.52 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -102.96 138.25 27.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 178.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.7 m -128.3 4.67 3.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.046 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.431 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 1.2 t -151.91 145.11 24.64 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 119.05 0.841 . . . . 0.0 109.19 179.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.86 124.66 15.06 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 178.703 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 48.8 m-85 -141.62 146.27 36.02 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 112.669 0.618 . . . . 0.0 112.669 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 49.6 t0 -88.68 133.08 34.32 Favored 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 176.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.431 ' OE1' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -92.8 -0.23 57.3 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.314 179.938 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.6 177.44 51.16 Favored Glycine 0 CA--C 1.526 0.751 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.307 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 39.2 m -89.43 123.85 33.94 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 121.025 0.44 . . . . 0.0 109.974 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -148.63 173.7 12.91 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.257 -179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 63.6 m-20 -77.1 140.86 40.37 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.705 -0.68 . . . . 0.0 110.259 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.8 m -139.35 154.87 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.175 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.474 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.558 HD11 ' CB ' ' A' ' 84' ' ' ALA . 30.8 pt -112.05 151.34 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.024 179.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.88 144.82 15.9 Favored Glycine 0 N--CA 1.468 0.768 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.455 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 27.4 mt -123.33 112.93 18.19 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.942 0.401 . . . . 0.0 110.322 -179.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.437 ' HE ' ' HA2' ' A' ' 63' ' ' GLY . 67.1 ttt180 -86.98 107.49 18.42 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.36 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.755 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.8 mp -96.51 124.8 49.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.936 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.536 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 36.97 24.43 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.723 -179.291 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 71.98 -25.38 0.67 Allowed Glycine 0 CA--C 1.528 0.884 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.536 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.18 -105.82 0.01 OUTLIER Glycine 0 N--CA 1.449 -0.466 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.96 171.2 9.45 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.48 -0.36 . . . . 0.0 110.246 -179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.501 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.0 mt -125.48 157.29 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.392 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.501 ' N ' HG22 ' A' ' 66' ' ' ILE . 49.8 tp -132.74 116.62 16.81 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.064 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.3 m95 -102.8 125.42 49.54 Favored 'General case' 0 N--CA 1.463 0.225 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.76 171.52 17.06 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.214 -179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.21 156.9 73.8 Favored Pre-proline 0 CA--C 1.533 0.323 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.586 179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -62.74 -19.98 69.8 Favored 'Trans proline' 0 N--CA 1.496 1.654 0 C-N-CA 122.562 2.175 . . . . 0.0 112.066 179.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 76.6 m-20 -93.26 -7.04 46.18 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.031 0.444 . . . . 0.0 110.189 179.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.516 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 9.6 t60 -73.42 131.36 41.74 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 49.7 mttp -88.04 130.63 34.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 121.16 0.505 . . . . 0.0 110.271 -179.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.661 ' O ' HG23 ' A' ' 77' ' ' THR . 95.2 t -108.95 90.63 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.847 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 75' ' ' VAL . 49.0 tp -31.21 99.12 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 O-C-N 123.244 0.34 . . . . 0.0 111.707 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.661 HG23 ' O ' ' A' ' 75' ' ' VAL . 61.4 p -98.22 176.08 5.85 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -63.37 -19.04 64.31 Favored 'General case' 0 N--CA 1.445 -0.676 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.166 -179.211 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 -106.86 23.77 13.82 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.742 -0.208 . . . . 0.0 111.428 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.436 ' O ' ' N ' ' A' ' 77' ' ' THR . . . 105.55 -141.47 15.38 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 96.8 m95 -96.11 130.31 43.18 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.732 -0.234 . . . . 0.0 110.766 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 34.2 ttm180 -142.35 132.32 24.44 Favored 'General case' 0 C--O 1.232 0.157 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.65 143.8 19.37 Favored 'General case' 0 C--N 1.325 -0.462 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.398 -179.421 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.558 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.52 -37.91 89.13 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 120.984 -0.286 . . . . 0.0 111.488 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.5 0.09 3.19 Favored Glycine 0 CA--C 1.529 0.965 0 C-N-CA 120.44 -0.886 . . . . 0.0 111.833 -179.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -109.19 -2.28 18.11 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-O 120.989 0.423 . . . . 0.0 110.426 179.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 83.7 mt -74.67 129.52 37.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.774 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.472 ' O ' ' N ' ' A' ' 90' ' ' GLY . 36.2 mmt180 -133.12 147.99 52.12 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.435 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -46.37 92.59 0.01 OUTLIER 'General case' 0 C--O 1.233 0.192 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.474 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.85 -20.38 0.78 Allowed Glycine 0 CA--C 1.522 0.475 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 25.0 t70 -83.63 130.12 34.97 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.805 0.336 . . . . 0.0 110.694 -179.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.406 ' NH2' ' O ' ' A' ' 105' ' ' TYR . 79.1 mtp85 -91.18 138.66 31.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.518 -179.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 33.2 m -126.36 151.46 32.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.285 -179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.14 134.98 52.82 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.443 -179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.632 HG21 ' OG ' ' A' ' 106' ' ' SER . 27.3 m -133.77 158.45 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.183 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.555 179.345 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -104.64 127.95 52.53 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.149 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -100.06 124.51 45.52 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.247 178.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 12.5 p -75.2 -15.46 15.79 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.352 0.524 . . . . 0.0 111.087 178.232 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -69.55 -58.3 4.13 Favored 'General case' 0 C--O 1.232 0.17 0 C-N-CA 120.654 -0.418 . . . . 0.0 110.224 -179.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.429 ' C ' ' H ' ' A' ' 102' ' ' GLU . 15.6 p -99.18 -12.06 20.79 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.739 -0.21 . . . . 0.0 110.473 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.77 -13.26 8.85 Favored Glycine 0 C--N 1.329 0.187 0 N-CA-C 110.191 -1.164 . . . . 0.0 110.191 179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.429 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.4 mt-10 -82.05 155.32 25.18 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 120.975 0.417 . . . . 0.0 111.222 -177.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.576 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -75.74 139.94 42.13 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.195 179.41 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.62 ' O ' HG22 ' A' ' 95' ' ' VAL . 98.8 mtt180 -139.17 169.61 17.46 Favored 'General case' 0 CA--C 1.51 -0.589 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.084 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.406 ' O ' ' NH2' ' A' ' 92' ' ' ARG . 8.2 m-30 -108.1 141.88 39.13 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.197 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.632 ' OG ' HG21 ' A' ' 95' ' ' VAL . 4.1 m -136.99 159.59 41.42 Favored 'General case' 0 N--CA 1.464 0.249 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 179.196 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 108' ' ' ILE . 85.0 t -98.32 156.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 107' ' ' VAL . 29.4 mm -84.66 131.33 34.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.783 0.325 . . . . 0.0 110.184 178.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.3 mmm180 -82.44 -34.13 28.29 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 116.342 -0.39 . . . . 0.0 111.765 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -166.21 145.41 5.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.408 HG22 ' H ' ' A' ' 111' ' ' VAL . 0.8 OUTLIER -95.38 135.42 29.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 179.441 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.444 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.4 mm? -98.35 123.92 48.73 Favored Pre-proline 0 CA--C 1.545 0.765 0 C-N-CA 120.626 -0.429 . . . . 0.0 111.149 -179.471 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.5 162.91 0.49 Allowed 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 122.039 1.826 . . . . 0.0 111.711 178.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.469 HG22 ' CG2' ' A' ' 57' ' ' ILE . 74.7 p -65.35 152.95 42.56 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.888 0.375 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 41.2 ttt180 -135.18 -139.15 0.17 Allowed 'General case' 0 N--CA 1.466 0.332 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.691 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 13.0 tpt180 -157.99 129.77 6.86 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.402 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.39 171.09 4.06 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.919 -0.582 . . . . 0.0 111.179 -179.664 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.518 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 88.1 mtm180 -74.68 146.97 41.9 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.591 -0.731 . . . . 0.0 109.62 179.034 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 6.6 p -126.22 143.3 51.19 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 179.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 65.0 m-85 -115.6 173.1 6.71 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.819 -179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 65.0 t0 -152.33 127.02 9.48 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.528 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.415 HD11 HD12 ' A' ' 19' ' ' ILE . 87.3 mt -116.24 171.9 7.53 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.233 179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 51.5 tp10 -134.95 107.2 7.21 Favored 'General case' 0 CA--C 1.515 -0.391 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.352 179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 129' ' ' THR . 20.9 t -91.94 119.86 40.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -60.87 144.42 52.86 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.76 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 5.0 tp10 69.21 -67.78 0.21 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.23 -0.895 . . . . 0.0 112.662 179.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.36 89.7 4.54 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 116.695 -0.23 . . . . 0.0 110.838 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.624 ' C ' HG22 ' A' ' 129' ' ' THR . 97.6 m-70 -62.08 96.83 0.08 Allowed 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 178.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.624 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 165.4 155.06 0.02 OUTLIER 'General case' 0 CA--C 1.501 -0.916 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 178.584 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.646 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.9 pp -150.94 151.84 32.73 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 120.307 -0.557 . . . . 0.0 111.544 179.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 135' ' ' VAL . 40.0 t -93.14 127.69 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.151 -179.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.619 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.49 133.54 42.35 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.006 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.535 ' O ' HG23 ' A' ' 135' ' ' VAL . 81.1 mm-40 55.29 42.31 30.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.531 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.0 27.47 67.19 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.623 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 133' ' ' GLU . 23.3 t -130.17 150.75 34.93 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.277 0 CA-C-N 118.135 0.968 . . . . 0.0 108.391 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 3.5 t -105.12 111.6 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.6 0 CA-C-N 118.329 0.513 . . . . 0.0 111.038 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' ' C ' ' A' ' 138' ' ' HIS . 16.9 m -145.88 134.67 16.83 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.627 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 51.8 t-80 -34.42 148.06 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 120.676 0.274 . . . . 0.0 111.649 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.763 HD22 ' N ' ' A' ' 139' ' ' ASN . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.868 -1.063 . . . . 0.0 110.369 -179.695 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.2 m . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 75.0 mt -96.5 143.63 27.33 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.316 -179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.3 163.91 16.57 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.701 0.286 . . . . 0.0 110.841 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.433 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 48.3 tt0 -64.78 142.12 58.54 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.523 178.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.66 -22.06 17.67 Favored Glycine 0 C--N 1.333 0.41 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.568 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.5 m -66.68 121.67 15.92 Favored 'General case' 0 C--N 1.331 -0.229 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.59 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.4 mtt85 -80.57 147.17 30.9 Favored 'General case' 0 CA--C 1.518 -0.26 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 6.4 mm -134.77 106.3 7.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-O 121.014 0.435 . . . . 0.0 111.212 179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -77.82 130.46 36.7 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 178.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 62.7 t0 -111.68 110.46 54.97 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.713 -0.221 . . . . 0.0 110.547 -179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.08 -35.58 62.42 Favored 'Trans proline' 0 N--CA 1.497 1.686 0 C-N-CA 122.171 1.914 . . . . 0.0 112.409 178.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 56.5 t -61.88 -57.8 10.43 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.767 -178.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 43.5 p -79.53 -36.63 38.14 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.305 0.574 . . . . 0.0 109.905 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.78 6.9 84.87 Favored Glycine 0 N--CA 1.451 -0.362 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.205 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.472 HG22 ' N ' ' A' ' 16' ' ' THR . 52.4 m -113.78 157.97 21.58 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 117.769 0.784 . . . . 0.0 109.918 -179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.472 ' N ' HG22 ' A' ' 15' ' ' THR . 30.6 m -80.47 117.71 21.44 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.121 0.486 . . . . 0.0 110.87 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 18.4 m80 -100.52 143.51 30.62 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.011 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.2 ttm180 -97.34 128.22 43.97 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.222 179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.536 HG23 ' N ' ' A' ' 20' ' ' GLU . 8.3 tp -52.9 -40.8 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.352 0 C-N-CA 120.863 -0.335 . . . . 0.0 111.252 -179.01 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.3 tt0 -58.48 -35.96 73.0 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.016 0.436 . . . . 0.0 110.367 -179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 52.8 t0 -81.91 -38.05 25.87 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.605 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 79.8 t -67.45 -42.33 87.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.9 t -72.04 -45.24 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.414 0 C-N-CA 120.944 -0.302 . . . . 0.0 111.63 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -57.38 -37.19 72.28 Favored 'General case' 0 CA--C 1.512 -0.506 0 CA-C-O 120.728 0.299 . . . . 0.0 110.971 -178.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.57 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -109.38 29.66 9.33 Favored Glycine 0 CA--C 1.518 0.224 0 CA-C-O 118.944 -0.92 . . . . 0.0 110.848 179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.57 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.7 ptt180 15.15 67.68 0.01 OUTLIER 'General case' 0 C--N 1.363 1.16 0 CA-C-N 117.313 0.557 . . . . 0.0 110.123 179.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.636 ' C ' ' H ' ' A' ' 29' ' ' ILE . 71.3 mttt -86.52 118.01 69.57 Favored Pre-proline 0 N--CA 1.44 -0.965 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.615 ' O ' ' O ' ' A' ' 29' ' ' ILE . 44.2 Cg_exo -53.83 9.64 0.02 OUTLIER 'Trans proline' 0 N--CA 1.498 1.762 0 C-N-CA 122.189 1.926 . . . . 0.0 113.383 179.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.636 ' H ' ' C ' ' A' ' 27' ' ' LYS . 1.9 pp -38.01 176.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 123.703 0.627 . . . . 0.0 110.843 -178.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.453 ' ND1' ' N ' ' A' ' 30' ' ' HIS . 4.0 m80 -122.48 166.73 14.31 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 121.837 -0.539 . . . . 0.0 110.795 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.8 m -148.57 171.17 2.38 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.27 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 -179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.4 t -88.01 135.41 25.58 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.461 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.59 166.87 11.1 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.571 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.48 142.4 43.55 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.091 0.472 . . . . 0.0 110.25 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.76 178.67 4.2 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -66.8 -15.53 63.65 Favored 'General case' 0 N--CA 1.455 -0.18 0 O-C-N 122.192 -0.318 . . . . 0.0 110.906 179.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 45.3 t0 -75.94 -22.0 56.45 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.685 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.9 -7.01 67.33 Favored Glycine 0 CA--C 1.524 0.65 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 -179.79 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 12.7 p -77.2 145.12 37.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.187 0.517 . . . . 0.0 111.291 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 64.9 mt -100.4 132.89 45.53 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.857 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -141.37 138.96 33.4 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.795 -179.288 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.06 143.03 52.6 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-N 115.928 -0.578 . . . . 0.0 109.673 -178.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.533 ' NH1' ' OE1' ' A' ' 125' ' ' GLU . 0.9 OUTLIER -142.72 138.34 16.02 Favored Pre-proline 0 CA--C 1.54 0.584 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.187 -179.594 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -77.67 158.58 31.92 Favored 'Trans proline' 0 N--CA 1.494 1.508 0 C-N-CA 122.916 2.411 . . . . 0.0 112.729 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.4 t -100.73 136.07 33.97 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.359 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 29.3 m -126.95 2.06 3.84 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.589 -179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.8 t -146.33 137.07 24.19 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-N 118.922 0.783 . . . . 0.0 109.149 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.3 OUTLIER -139.32 124.17 18.64 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -138.23 146.84 43.07 Favored 'General case' 0 N--CA 1.468 0.464 0 N-CA-C 112.408 0.522 . . . . 0.0 112.408 -179.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 52.7 p-10 -113.14 140.62 47.75 Favored 'General case' 0 CA--C 1.503 -0.863 0 CA-C-O 122.027 0.918 . . . . 0.0 108.593 176.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.82 -105.5 0.35 Allowed 'General case' 0 C--N 1.313 -1.02 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.602 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -165.58 -156.43 9.24 Favored Glycine 0 C--N 1.31 -0.897 0 CA-C-N 114.332 -1.304 . . . . 0.0 112.918 -176.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 62.8 m -88.51 127.89 35.54 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.983 0.421 . . . . 0.0 111.482 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -145.8 158.65 43.84 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.627 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -76.17 140.88 41.93 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.253 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.2 m -144.1 143.72 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.141 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.121 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.56 HD11 ' CB ' ' A' ' 84' ' ' ALA . 18.9 pt -96.13 152.36 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.408 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -109.94 132.66 11.15 Favored Glycine 0 CA--C 1.522 0.487 0 N-CA-C 111.147 -0.781 . . . . 0.0 111.147 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.0 mt -110.76 112.26 24.01 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.493 ' C ' HD12 ' A' ' 61' ' ' ILE . 60.0 ttm-85 -85.81 113.24 21.81 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.972 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.694 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -104.46 149.83 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.112 -0.495 . . . . 0.0 109.806 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -50.78 139.8 16.05 Favored 'General case' 0 C--N 1.328 -0.329 0 C-N-CA 120.562 -0.455 . . . . 0.0 110.734 179.73 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 97.78 -3.31 60.72 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 96.41 -17.93 58.39 Favored Glycine 0 N--CA 1.464 0.559 0 N-CA-C 110.502 -1.039 . . . . 0.0 110.502 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.16 125.75 20.27 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.347 0.594 . . . . 0.0 109.589 -178.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.1 tt -130.76 155.96 42.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.671 -179.174 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.4 tp -142.79 124.0 14.59 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.851 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -104.52 125.19 50.46 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.9 171.11 18.29 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.144 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -78.7 155.52 78.26 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-O 120.71 0.291 . . . . 0.0 111.035 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.48 -20.51 70.76 Favored 'Trans proline' 0 N--CA 1.497 1.723 0 C-N-CA 122.675 2.25 . . . . 0.0 112.085 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.0 m-20 -89.36 -7.97 54.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.008 0.432 . . . . 0.0 110.178 179.606 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.598 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 11.5 t60 -72.66 131.17 42.06 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -87.93 132.04 34.37 Favored 'General case' 0 N--CA 1.455 -0.187 0 CA-C-O 121.153 0.501 . . . . 0.0 111.142 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.87 140.38 22.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.728 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 53.1 tp -80.99 94.7 6.6 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.701 -0.682 . . . . 0.0 110.776 -179.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 38.8 p -99.2 178.0 5.04 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 -178.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -67.03 -17.88 65.11 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 120.648 -0.421 . . . . 0.0 111.498 -179.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.474 ' O ' ' CD2' ' A' ' 79' ' ' TYR . 33.3 t80 -106.25 24.31 12.7 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 120.655 0.264 . . . . 0.0 111.35 -178.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 100.33 -142.63 15.96 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 90.8 m95 -92.78 128.85 38.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.85 0.357 . . . . 0.0 110.85 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 82.8 mtp180 -140.91 130.85 24.5 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.903 179.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.73 142.7 22.7 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.111 -179.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.56 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -61.82 -38.28 87.57 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 121.019 -0.272 . . . . 0.0 111.065 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.51 -1.23 4.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.195 -1.002 . . . . 0.0 111.902 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 72.7 tt0 -107.72 -4.04 18.56 Favored 'General case' 0 CA--C 1.528 0.134 0 CA-C-O 121.446 0.641 . . . . 0.0 110.003 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.2 mt -77.4 128.78 34.84 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 121.535 0.683 . . . . 0.0 111.259 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.523 ' O ' ' N ' ' A' ' 90' ' ' GLY . 2.3 mmm180 -129.14 147.1 50.96 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.955 -1.02 . . . . 0.0 111.1 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.2 tttm -43.55 91.46 0.0 OUTLIER 'General case' 0 N--CA 1.455 -0.212 0 CA-C-O 121.08 0.467 . . . . 0.0 110.527 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 152.71 -13.4 0.67 Allowed Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -86.46 130.38 34.52 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-O 120.858 0.361 . . . . 0.0 110.32 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.43 ' HE ' HG22 ' A' ' 107' ' ' VAL . 99.5 mtt180 -92.7 134.91 34.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.65 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 20.2 m -120.53 153.54 23.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.835 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -69.57 125.64 27.31 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.986 -179.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.469 HG22 ' O ' ' A' ' 104' ' ' ARG . 17.3 m -124.1 160.43 28.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.76 178.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.6 ttt-85 -105.2 128.88 53.62 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.784 0.325 . . . . 0.0 110.543 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.481 ' OD2' ' CZ ' ' A' ' 104' ' ' ARG . 43.0 t0 -100.11 123.3 44.19 Favored 'General case' 0 C--O 1.225 -0.231 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.399 178.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.3 p -75.16 -15.41 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.312 0 CA-C-N 118.47 0.577 . . . . 0.0 111.223 178.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.7 mm-40 -69.43 -59.13 3.19 Favored 'General case' 0 C--N 1.333 -0.134 0 C-N-CA 120.616 -0.434 . . . . 0.0 109.956 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.419 ' C ' ' H ' ' A' ' 102' ' ' GLU . 44.1 p -97.09 -11.54 24.26 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 110.281 -0.266 . . . . 0.0 110.281 179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.83 -12.51 8.5 Favored Glycine 0 C--N 1.332 0.355 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.419 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -84.45 159.69 20.72 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 120.947 0.403 . . . . 0.0 110.892 -177.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.569 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.31 140.29 36.22 Favored 'General case' 0 N--CA 1.443 -0.776 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.865 179.743 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.481 ' CZ ' ' OD2' ' A' ' 97' ' ' ASP . 32.5 mtm180 -137.83 168.79 18.98 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.58 -0.736 . . . . 0.0 109.962 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.7 m-30 -109.32 141.17 42.03 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.633 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.402 ' OG ' HG21 ' A' ' 95' ' ' VAL . 11.4 m -138.03 158.69 43.81 Favored 'General case' 0 CA--C 1.52 -0.173 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.43 HG22 ' HE ' ' A' ' 92' ' ' ARG . 65.1 t -92.1 154.3 3.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.554 0.216 . . . . 0.0 110.49 -179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.403 ' N ' HG12 ' A' ' 107' ' ' VAL . 79.1 mt -74.15 155.32 6.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.03 0.443 . . . . 0.0 110.437 178.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.4 ' N ' HG22 ' A' ' 108' ' ' ILE . 14.2 mmt180 -101.68 -45.64 5.19 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.993 -0.548 . . . . 0.0 111.038 178.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -167.44 149.88 5.95 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.427 ' C ' HD22 ' A' ' 112' ' ' LEU . 80.6 t -94.1 133.41 35.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.466 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -100.15 148.33 34.73 Favored Pre-proline 0 CA--C 1.533 0.303 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.239 -178.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -68.14 156.12 66.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 122.51 2.14 . . . . 0.0 111.095 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.461 HG23 ' H ' ' A' ' 114' ' ' THR . 1.1 p -63.63 154.74 31.9 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 -179.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.3 ptm180 -148.41 144.66 27.61 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.492 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 82.0 mtm-85 -77.38 132.02 38.34 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.184 0.516 . . . . 0.0 110.612 179.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -165.34 164.12 19.83 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.066 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 1.1 tpp85 -74.36 145.21 44.0 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.79 -0.641 . . . . 0.0 109.845 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 22.3 p -129.41 143.78 50.98 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -116.88 175.87 5.38 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.085 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -144.29 129.14 18.38 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.817 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.459 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.7 mt -122.24 171.09 9.28 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.619 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -137.94 107.17 6.07 Favored 'General case' 0 CA--C 1.517 -0.29 0 CA-C-N 116.026 -0.534 . . . . 0.0 109.623 179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.521 ' O ' ' C ' ' A' ' 125' ' ' GLU . 23.7 t -88.03 115.55 28.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 C-N-CA 120.559 -0.456 . . . . 0.0 110.068 179.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.533 ' OE1' ' NH1' ' A' ' 43' ' ' ARG . 28.1 tt0 15.54 -118.3 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 O-C-N 124.011 0.82 . . . . 0.0 111.212 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -98.64 -27.2 14.1 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.027 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 81.2 mt -84.99 87.25 7.35 Favored 'General case' 0 CA--C 1.513 -0.453 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.594 ' C ' HG22 ' A' ' 129' ' ' THR . 6.5 m170 -60.44 98.05 0.06 Allowed 'General case' 0 N--CA 1.446 -0.625 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.497 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.594 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.44 152.71 0.03 OUTLIER 'General case' 0 CA--C 1.501 -0.911 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 178.294 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.566 HD23 ' N ' ' A' ' 130' ' ' LEU . 1.4 pt? -156.04 157.85 36.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.542 0.686 . . . . 0.0 112.095 -179.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.471 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.9 p -89.08 125.47 42.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.568 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.03 123.31 24.33 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.665 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.472 ' C ' ' H ' ' A' ' 135' ' ' VAL . 77.6 mm-40 56.94 45.3 21.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.2 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.6 -19.67 0.88 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.386 179.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.472 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.4 t -90.08 152.43 3.34 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.33 0 CA-C-N 117.212 0.506 . . . . 0.0 110.773 -179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.5 t -112.93 117.75 56.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.847 179.42 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' A' ' 138' ' ' HIS . 19.1 m -147.28 139.49 18.83 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.339 0 CA-C-N 116.499 -0.318 . . . . 0.0 110.601 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.598 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 59.8 t-80 -36.17 157.5 0.01 OUTLIER 'General case' 0 C--O 1.225 -0.229 0 CA-C-N 118.043 0.383 . . . . 0.0 111.93 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.484 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 25.5 p30 . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.447 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.402 ' SG ' ' OE1' ' A' ' 51' ' ' GLN . 22.2 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 62.3 mt -110.59 134.82 52.06 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.459 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.14 161.57 25.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.833 179.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.42 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 49.3 tt0 -63.41 144.54 56.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.125 178.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.53 -16.45 31.63 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 -179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.615 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 24.7 m -68.44 122.54 18.63 Favored 'General case' 0 CA--C 1.518 -0.281 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -95.99 115.67 27.78 Favored 'General case' 0 N--CA 1.455 -0.225 0 CA-C-O 120.858 0.361 . . . . 0.0 110.35 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.4 mt -100.53 113.31 35.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.663 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.7 t80 -76.47 136.8 39.39 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 12.0 t0 -104.08 130.81 22.7 Favored Pre-proline 0 CA--C 1.539 0.522 0 N-CA-C 110.28 -0.267 . . . . 0.0 110.28 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -72.56 -29.57 13.12 Favored 'Trans proline' 0 N--CA 1.494 1.553 0 C-N-CA 122.018 1.812 . . . . 0.0 112.431 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.513 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.9 t -71.18 -55.17 14.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.042 -179.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 23.1 p -77.33 -33.58 55.48 Favored 'General case' 0 CA--C 1.516 -0.359 0 CA-C-O 120.902 0.382 . . . . 0.0 110.236 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.25 11.4 84.34 Favored Glycine 0 CA--C 1.522 0.474 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.52 -168.68 1.38 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 117.498 0.649 . . . . 0.0 109.858 -179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 90.2 m -112.79 115.87 29.19 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 121.198 0.523 . . . . 0.0 110.24 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 51.5 m170 -105.64 145.6 30.82 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.061 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -99.47 129.67 45.67 Favored 'General case' 0 C--N 1.328 -0.343 0 C-N-CA 120.982 -0.287 . . . . 0.0 110.315 178.154 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.449 HD11 HD23 ' A' ' 122' ' ' LEU . 1.0 OUTLIER -53.5 -38.64 33.89 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-O 120.885 0.374 . . . . 0.0 111.121 -178.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.8 pt-20 -60.39 -35.13 75.02 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.883 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -83.74 -40.22 19.1 Favored 'General case' 0 CA--C 1.533 0.32 0 CA-C-N 115.268 -0.878 . . . . 0.0 112.167 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 76.4 t -67.53 -42.08 86.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.614 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.538 ' CG2' HD21 ' A' ' 122' ' ' LEU . 53.4 t -74.96 -45.38 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.195 0 C-N-CA 120.848 -0.341 . . . . 0.0 111.807 -178.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.418 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 62.8 t0 -60.87 -35.52 76.81 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 120.775 0.321 . . . . 0.0 111.088 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.47 26.23 24.26 Favored Glycine 0 C--O 1.229 -0.157 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 81.3 mtt85 17.63 60.95 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.121 0 O-C-N 123.907 0.416 . . . . 0.0 109.892 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.5 mttt -86.26 133.6 40.29 Favored Pre-proline 0 N--CA 1.447 -0.619 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.959 -176.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -75.48 86.06 1.51 Allowed 'Trans proline' 0 C--N 1.313 -1.295 0 C-N-CA 121.499 1.466 . . . . 0.0 110.56 179.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.613 ' C ' HD12 ' A' ' 29' ' ' ILE . 2.4 pp -116.91 -172.81 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 120.778 0.323 . . . . 0.0 110.776 -179.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.407 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 38.2 m80 -128.37 162.57 26.79 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.449 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -146.52 170.5 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.222 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 -179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 83.8 t -90.05 134.18 29.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.343 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.99 167.43 10.26 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.71 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.76 142.78 43.01 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-O 121.04 0.448 . . . . 0.0 110.521 179.748 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.96 176.78 4.89 Favored 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.406 179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.673 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 73.4 mmtt -71.41 -13.73 61.93 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.634 0.254 . . . . 0.0 110.531 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -79.13 -16.1 57.16 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.333 179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.43 18.89 56.28 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.982 -0.847 . . . . 0.0 110.982 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 20.8 p -100.44 137.38 38.93 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.759 0.314 . . . . 0.0 111.139 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 63.2 mt -93.95 130.43 40.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.683 179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.3 m-70 -139.05 138.61 37.3 Favored 'General case' 0 C--O 1.223 -0.298 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.743 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.535 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.52 142.18 51.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.037 -0.529 . . . . 0.0 109.635 -178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.535 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 11.1 mmp_? -144.06 138.26 14.83 Favored Pre-proline 0 CA--C 1.537 0.458 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.645 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.7 Cg_endo -77.07 156.5 33.99 Favored 'Trans proline' 0 N--CA 1.489 1.226 0 C-N-CA 122.393 2.062 . . . . 0.0 112.732 179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 61.9 t -98.72 136.26 30.4 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.502 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 178.06 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 18.6 m -127.62 3.24 3.43 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.855 -179.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.7 OUTLIER -151.64 145.33 25.01 Favored 'General case' 0 N--CA 1.452 -0.364 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.345 179.089 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.583 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.92 124.23 14.65 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.148 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -139.56 145.66 38.89 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 49.0 p-10 -90.52 137.36 32.41 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 176.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.438 ' HA ' HE21 ' A' ' 51' ' ' GLN . 0.0 OUTLIER -96.95 -0.97 46.65 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.479 -179.669 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.24 -178.39 53.49 Favored Glycine 0 CA--C 1.524 0.606 0 C-N-CA 120.448 -0.882 . . . . 0.0 111.416 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.3 m -85.11 121.99 28.66 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.907 0.384 . . . . 0.0 110.214 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 -145.14 165.48 28.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.551 -179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -76.94 140.79 40.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.073 179.105 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 32.4 m -146.59 154.49 12.29 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.65 HD11 ' HB1' ' A' ' 84' ' ' ALA . 47.3 pt -107.62 160.72 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.463 179.384 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -115.67 139.71 15.63 Favored Glycine 0 N--CA 1.466 0.654 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 179.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.457 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 67.0 mt -114.23 108.53 17.07 Favored 'General case' 0 C--O 1.219 -0.526 0 CA-C-O 120.801 0.334 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.436 HH11 ' CG2' ' A' ' 66' ' ' ILE . 10.9 tpt180 -78.67 108.28 11.97 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.449 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.662 ' O ' ' N ' ' A' ' 63' ' ' GLY . 1.9 mp -94.37 132.55 38.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.518 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.624 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 23.89 33.97 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.818 0.699 . . . . 0.0 112.539 178.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.662 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 66.82 -21.24 0.19 Allowed Glycine 0 CA--C 1.531 1.088 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.202 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.624 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -52.47 -106.41 0.01 OUTLIER Glycine 0 N--CA 1.446 -0.679 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.58 171.69 7.97 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.665 HD13 ' H ' ' A' ' 66' ' ' ILE . 0.0 OUTLIER -129.19 168.75 21.77 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 CA-C-O 120.846 0.355 . . . . 0.0 110.547 -179.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 63.9 tp -130.79 115.55 16.77 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.621 0.248 . . . . 0.0 110.545 179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.2 m95 -101.64 105.36 16.28 Favored 'General case' 0 N--CA 1.463 0.209 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 178.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.44 171.22 14.81 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.144 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -76.99 157.66 81.19 Favored Pre-proline 0 C--N 1.326 -0.43 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.571 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.498 ' O ' ' N ' ' A' ' 85' ' ' GLY . 33.8 Cg_endo -62.46 -17.07 55.97 Favored 'Trans proline' 0 N--CA 1.493 1.48 0 C-N-CA 122.603 2.202 . . . . 0.0 111.869 179.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 23.6 p30 -98.07 -5.64 33.41 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.861 0.362 . . . . 0.0 110.527 179.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.555 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 9.0 t60 -72.56 131.98 43.19 Favored 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 43.0 mmtm -86.01 123.2 31.06 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 121.273 0.559 . . . . 0.0 111.082 -178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 76' ' ' LEU . 91.4 t -102.4 91.4 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 115.296 -0.865 . . . . 0.0 111.366 -179.878 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 75' ' ' VAL . 35.2 tp -32.22 95.84 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.366 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.478 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -99.75 173.62 6.61 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 -177.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -63.37 -20.0 65.15 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.042 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.413 ' CD2' ' NH2' ' A' ' 82' ' ' ARG . 63.9 m-85 -104.94 22.79 14.62 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.847 -0.16 . . . . 0.0 111.046 -179.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 102.69 -144.64 16.16 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.673 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 89.2 m95 -90.75 124.74 35.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.509 0.195 . . . . 0.0 111.157 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.413 ' NH2' ' CD2' ' A' ' 79' ' ' TYR . 88.7 mtt180 -130.23 130.03 44.1 Favored 'General case' 0 N--CA 1.464 0.225 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 178.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -69.13 141.91 54.52 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.054 -179.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.65 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -72.34 2.0 6.86 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.485 179.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -83.67 -14.52 73.0 Favored Glycine 0 CA--C 1.531 1.073 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -129.37 19.23 5.82 Favored 'General case' 0 N--CA 1.47 0.547 0 O-C-N 122.829 -0.218 . . . . 0.0 111.44 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.476 HD12 ' HA ' ' A' ' 84' ' ' ALA . 28.3 mt -82.41 136.23 34.99 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-O 121.308 0.575 . . . . 0.0 110.797 179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 58.0 mmt-85 -132.79 148.84 52.32 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.709 -179.705 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.8 ttpt -45.41 103.0 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.286 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.593 179.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.41 -15.59 1.11 Allowed Glycine 0 CA--C 1.522 0.479 0 N-CA-C 110.911 -0.876 . . . . 0.0 110.911 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 20.9 m-20 -82.31 130.28 35.06 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.791 0.329 . . . . 0.0 110.913 -179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HE ' ' CG1' ' A' ' 107' ' ' VAL . 99.5 mtt180 -91.32 129.17 37.35 Favored 'General case' 0 C--O 1.224 -0.264 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.686 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 13.4 m -109.52 143.37 19.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.986 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.418 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -63.63 125.79 25.44 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.755 -0.378 . . . . 0.0 110.579 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.434 HG22 ' O ' ' A' ' 104' ' ' ARG . 30.3 m -122.02 155.47 26.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.72 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.2 ttt85 -102.54 130.27 49.33 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.607 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -100.34 123.03 44.06 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.17 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 7.8 p -74.76 -16.65 16.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 118.056 0.389 . . . . 0.0 110.906 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.6 mm-40 -70.46 -58.87 3.24 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.09 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.431 ' C ' ' H ' ' A' ' 102' ' ' GLU . 30.0 p -96.48 -13.62 22.94 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 120.539 0.209 . . . . 0.0 110.62 179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.33 -14.43 8.7 Favored Glycine 0 C--N 1.331 0.303 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.431 ' H ' ' C ' ' A' ' 100' ' ' THR . 76.7 mt-10 -79.44 153.09 29.91 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.906 0.384 . . . . 0.0 111.185 -177.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.595 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -81.08 139.33 35.74 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.764 179.497 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.434 ' O ' HG22 ' A' ' 95' ' ' VAL . 75.2 mtp180 -138.51 174.27 10.72 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 115.559 -0.746 . . . . 0.0 109.968 -179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.478 ' OH ' ' C ' ' A' ' 77' ' ' THR . 2.4 m-85 -113.01 149.67 33.0 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.182 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 11.6 m -143.25 164.55 29.89 Favored 'General case' 0 C--O 1.221 -0.428 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.4 ' CG1' ' HE ' ' A' ' 92' ' ' ARG . 18.0 m -97.08 155.06 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.695 0.225 . . . . 0.0 110.8 -179.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 95.7 mt -86.99 121.75 38.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.202 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.211 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 67.2 mtp180 -68.55 -33.9 74.9 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -168.24 150.45 5.32 Favored 'General case' 0 N--CA 1.456 -0.163 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 71.8 t -97.15 136.38 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.474 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.2 mm? -96.22 122.38 58.06 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 120.705 -0.398 . . . . 0.0 111.082 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.64 166.0 0.16 Allowed 'Trans proline' 0 N--CA 1.498 1.776 0 C-N-CA 122.266 1.977 . . . . 0.0 111.607 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.408 ' H ' HG23 ' A' ' 114' ' ' THR . 4.5 p -66.93 151.32 47.83 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-O 121.166 0.508 . . . . 0.0 110.949 -179.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 75.5 mtp85 -134.89 -143.28 0.2 Allowed 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.81 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 36.4 mtm-85 -154.01 131.1 11.04 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.848 179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.58 171.98 3.18 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.26 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 81.3 mtp180 -74.42 145.09 43.98 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.954 178.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.1 p -123.14 142.47 50.86 Favored 'General case' 0 C--N 1.333 -0.122 0 N-CA-C 109.659 -0.496 . . . . 0.0 109.659 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -113.62 171.98 7.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.66 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.577 ' C ' HD22 ' A' ' 122' ' ' LEU . 49.6 t0 -151.85 125.8 9.13 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.896 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.577 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.6 170.16 8.52 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.207 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 42.4 tp10 -137.61 105.28 5.57 Favored 'General case' 0 CA--C 1.514 -0.406 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.33 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.4 t -88.61 118.62 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 179.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -61.85 146.04 50.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.523 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.8 tt0 69.24 -69.9 0.15 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.116 -0.947 . . . . 0.0 112.288 178.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 90.5 mt -100.44 95.8 6.98 Favored 'General case' 0 CA--C 1.514 -0.424 0 N-CA-C 110.346 -0.242 . . . . 0.0 110.346 179.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.591 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 4.8 p80 -65.83 99.73 0.5 Allowed 'General case' 0 C--N 1.318 -0.801 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 178.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.524 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.6 145.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 178.578 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.661 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.5 pp -145.62 154.05 41.7 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 121.437 0.637 . . . . 0.0 111.619 -179.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.416 ' C ' HD12 ' A' ' 130' ' ' LEU . 68.7 t -89.92 125.69 42.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 114.918 -1.037 . . . . 0.0 108.738 -179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.615 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.73 135.35 43.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.249 -178.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.621 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.2 mm-40 49.73 45.59 24.48 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.123 179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.14 22.51 55.72 Favored Glycine 0 CA--C 1.525 0.715 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.916 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.6 t -128.99 152.07 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.8 t -105.25 110.84 32.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 O-C-N 122.065 -0.397 . . . . 0.0 110.536 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' A' ' 138' ' ' HIS . 13.4 m -146.99 138.52 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.555 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 56.2 t-80 -33.93 153.73 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.752 0.311 . . . . 0.0 111.793 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 20.0 p30 . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.93 -1.033 . . . . 0.0 110.287 -179.571 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.471 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 30.3 m . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 89.0 mt -107.11 134.55 50.06 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.912 0.387 . . . . 0.0 110.406 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.32 163.61 23.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.089 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 75.4 tt0 -64.14 139.69 58.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.615 178.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 111.17 -18.66 25.67 Favored Glycine 0 C--N 1.334 0.454 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.459 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.6 m -69.78 123.93 22.69 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.719 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.505 ' NE ' HG21 ' A' ' 16' ' ' THR . 77.5 mtp85 -97.85 116.64 30.46 Favored 'General case' 0 C--O 1.231 0.088 0 CA-C-O 120.982 0.42 . . . . 0.0 110.7 -179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.462 HD11 HD13 ' A' ' 19' ' ' ILE . 18.0 mt -101.53 115.23 42.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.756 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.8 t80 -76.57 135.9 39.25 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 177.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 5.0 t70 -104.15 132.42 21.01 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 110.571 -0.159 . . . . 0.0 110.571 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 70.5 Cg_endo -74.23 -31.84 7.23 Favored 'Trans proline' 0 N--CA 1.494 1.557 0 C-N-CA 121.838 1.692 . . . . 0.0 112.462 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.58 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 74.9 t -69.89 -55.25 15.5 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.047 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 14.6 p -77.54 -35.6 53.09 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.973 0.415 . . . . 0.0 110.182 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 10.45 85.46 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.458 HG22 ' N ' ' A' ' 16' ' ' THR . 88.2 m -114.09 157.51 22.47 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 117.276 0.538 . . . . 0.0 110.09 -179.659 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.505 HG21 ' NE ' ' A' ' 7' ' ' ARG . 28.2 m -78.97 116.13 19.08 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.555 0.693 . . . . 0.0 110.897 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . 0.459 ' CG ' ' CD1' ' A' ' 29' ' ' ILE . 61.8 m-70 -104.89 144.87 31.19 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.848 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 12.9 tpp85 -98.75 128.32 44.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.304 178.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.523 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -52.8 -38.83 29.04 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.412 0 CA-C-O 120.704 0.287 . . . . 0.0 111.012 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.497 ' N ' HG23 ' A' ' 19' ' ' ILE . 9.1 pt-20 -57.03 -32.62 66.36 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.295 0.569 . . . . 0.0 110.806 -179.498 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -83.57 -37.87 22.41 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.033 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.75 -42.4 86.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 -179.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.719 HG22 HD21 ' A' ' 122' ' ' LEU . 87.5 t -73.08 -46.9 49.76 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 65.2 t0 -57.67 -36.0 71.32 Favored 'General case' 0 N--CA 1.45 -0.457 0 CA-C-O 120.836 0.351 . . . . 0.0 110.831 -178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -108.31 29.12 10.46 Favored Glycine 0 C--O 1.228 -0.254 0 CA-C-O 118.829 -0.984 . . . . 0.0 111.147 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.1 ptm180 13.08 67.91 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.488 0.644 . . . . 0.0 110.836 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.436 ' C ' ' H ' ' A' ' 29' ' ' ILE . 82.7 mttt -87.56 144.62 35.74 Favored Pre-proline 0 N--CA 1.45 -0.431 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.31 -177.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.587 ' O ' ' O ' ' A' ' 29' ' ' ILE . 57.4 Cg_endo -70.87 8.22 1.08 Allowed 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 122.057 1.838 . . . . 0.0 111.744 179.292 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.587 ' O ' ' O ' ' A' ' 28' ' ' PRO . 15.1 tt -37.1 172.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.847 -178.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.527 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 9.5 m80 -124.83 162.97 23.18 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.7 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 34.7 m -146.2 169.87 5.57 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 82.2 t -87.3 134.13 28.45 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.455 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.36 166.17 10.73 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.515 -0.311 . . . . 0.0 110.704 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.87 141.6 40.71 Favored 'General case' 0 N--CA 1.462 0.144 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.184 179.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.36 178.19 4.37 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -72.82 -12.78 61.12 Favored 'General case' 0 C--O 1.233 0.186 0 O-C-N 122.248 -0.283 . . . . 0.0 110.676 179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -78.59 -17.71 55.68 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.366 179.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.92 18.59 55.85 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 21.1 p -100.01 137.29 38.66 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.983 0.42 . . . . 0.0 111.001 178.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.7 mt -94.34 131.05 40.37 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.714 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 4.9 t-80 -139.55 138.99 36.74 Favored 'General case' 0 C--O 1.221 -0.425 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.791 -179.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.56 142.59 51.76 Favored 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 4.8 mmp_? -145.64 137.46 13.11 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.869 -179.4 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 81.4 Cg_endo -75.79 157.65 39.36 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.644 2.229 . . . . 0.0 112.401 179.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 55.6 t -90.91 127.44 43.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.8 -4.8 11.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.782 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 5.0 p -151.79 143.08 23.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 O-C-N 121.756 -0.59 . . . . 0.0 109.445 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.582 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -137.6 117.28 13.06 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.189 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -144.8 146.29 32.05 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 45.7 p-10 -90.61 138.41 31.59 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 175.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.746 ' OE1' ' O ' ' A' ' 52' ' ' GLY . 0.0 OUTLIER -103.74 7.04 37.21 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.771 -179.826 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.746 ' O ' ' OE1' ' A' ' 51' ' ' GLN . . . 92.02 -175.65 38.43 Favored Glycine 0 C--N 1.352 1.455 0 CA-C-O 121.552 0.529 . . . . 0.0 112.802 177.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.581 HG23 ' C ' ' A' ' 117' ' ' ALA . 61.3 m -100.84 131.73 46.58 Favored 'General case' 0 N--CA 1.468 0.457 0 O-C-N 121.296 -1.12 . . . . 0.0 108.981 -179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 80.5 mtp180 -148.32 172.94 13.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.32 0.581 . . . . 0.0 110.382 -179.158 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -75.54 140.34 42.68 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.622 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.6 m -140.92 158.13 23.27 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.12 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.542 HD11 ' CB ' ' A' ' 84' ' ' ALA . 46.6 pt -112.7 151.56 14.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 CA-C-O 120.848 0.356 . . . . 0.0 110.809 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.86 132.17 10.99 Favored Glycine 0 CA--C 1.523 0.554 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 49.7 mt -111.84 106.27 14.96 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.259 0.552 . . . . 0.0 109.781 179.418 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 34.3 ttm180 -86.16 117.37 24.94 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.278 -179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.403 HG22 ' N ' ' A' ' 62' ' ' ALA . 25.4 mm -110.05 156.7 10.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.461 -179.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.403 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -47.49 138.65 7.55 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.491 -0.483 . . . . 0.0 110.712 -179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . 98.47 -1.49 58.66 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 90.52 -9.99 75.91 Favored Glycine 0 N--CA 1.464 0.524 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.2 129.13 33.9 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.14 -0.624 . . . . 0.0 109.371 -177.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 8.9 tp -123.36 144.03 34.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.892 -178.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 36.5 tp -136.74 118.97 15.56 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.862 179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 99.5 m95 -103.05 127.66 50.23 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.03 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.36 170.27 20.49 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.886 -179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -76.87 155.9 82.76 Favored Pre-proline 0 CA--C 1.536 0.439 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.767 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 -18.92 64.18 Favored 'Trans proline' 0 N--CA 1.498 1.76 0 C-N-CA 122.68 2.254 . . . . 0.0 111.989 179.461 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 88.0 m-20 -95.46 -5.0 44.0 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.025 0.441 . . . . 0.0 110.022 179.353 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.561 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -69.8 130.13 41.45 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.215 179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -86.31 128.66 34.95 Favored 'General case' 0 N--CA 1.453 -0.293 0 CA-C-O 121.459 0.647 . . . . 0.0 111.446 -179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.56 144.44 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.072 -0.967 . . . . 0.0 110.185 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.469 HD13 ' C ' ' A' ' 76' ' ' LEU . 0.4 OUTLIER -82.55 94.47 7.5 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.512 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 17.0 p -100.82 175.89 5.48 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.83 -178.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.654 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 0.7 OUTLIER -60.41 -21.06 61.79 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.524 -179.32 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -106.98 24.25 13.1 Favored 'General case' 0 CA--C 1.516 -0.33 0 C-N-CA 121.303 -0.159 . . . . 0.0 111.095 -178.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 90.62 -169.39 34.08 Favored Glycine 0 CA--C 1.523 0.583 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.509 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.9 m95 -60.84 123.78 18.55 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.925 -0.638 . . . . 0.0 110.775 -178.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 60.0 ttm-85 -140.01 134.15 31.04 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.028 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.81 139.24 40.42 Favored 'General case' 0 CA--C 1.517 -0.298 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.04 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.542 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -63.21 -37.29 86.66 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 111.938 0.347 . . . . 0.0 111.938 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.28 1.87 1.85 Allowed Glycine 0 C--N 1.336 0.573 0 C-N-CA 120.521 -0.847 . . . . 0.0 112.015 -179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.421 ' H ' ' C ' ' A' ' 84' ' ' ALA . 75.8 mt-10 -110.01 3.4 20.37 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.824 0.345 . . . . 0.0 110.272 179.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.68 133.76 34.8 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.334 0.588 . . . . 0.0 111.048 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.533 ' O ' ' N ' ' A' ' 90' ' ' GLY . 10.2 tpt180 -127.88 148.66 50.48 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.599 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 36.0 ttpt -49.72 86.76 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.232 179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 159.27 -18.37 0.26 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -77.94 134.75 37.81 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 88.8 mtm180 -92.36 139.59 30.45 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.927 -178.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -132.52 154.2 39.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.285 179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -83.52 133.87 34.86 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.904 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.514 HG12 HG22 ' A' ' 135' ' ' VAL . 30.9 m -129.0 165.46 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.224 179.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 75.2 ttt180 -97.54 128.62 44.43 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.816 0.341 . . . . 0.0 111.0 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 28.1 t0 -99.64 122.64 42.96 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.982 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 13.6 p -75.33 -16.43 15.82 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 CA-C-N 118.425 0.557 . . . . 0.0 110.69 178.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 72.0 mm-40 -69.15 -58.59 3.86 Favored 'General case' 0 N--CA 1.462 0.156 0 C-N-CA 120.524 -0.471 . . . . 0.0 109.877 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.469 ' C ' ' H ' ' A' ' 102' ' ' GLU . 72.5 p -95.99 -10.78 27.75 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 179.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.98 -12.34 6.61 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.469 ' H ' ' C ' ' A' ' 100' ' ' THR . 94.0 mt-10 -89.13 161.23 16.61 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 121.269 0.557 . . . . 0.0 111.605 -177.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.552 ' H ' ' CD2' ' A' ' 103' ' ' LEU . 1.9 pt? -74.56 139.26 43.61 Favored 'General case' 0 N--CA 1.44 -0.939 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.052 179.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 37.6 ptt180 -130.98 158.05 41.31 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 179.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.654 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -104.15 135.98 44.62 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 -179.511 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 42.8 m -144.07 166.19 25.68 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 108' ' ' ILE . 94.1 t -94.84 154.44 3.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 N-CA-C 110.417 -0.216 . . . . 0.0 110.417 179.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.471 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 37.9 mt -67.42 160.2 4.45 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.087 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.471 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 74.3 ttt180 -105.64 -48.91 3.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.648 179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -164.82 142.36 6.3 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.3 t -94.37 134.74 30.86 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.429 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.8 mm? -101.8 147.16 33.48 Favored Pre-proline 0 CA--C 1.538 0.501 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.855 -179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.17 165.27 30.87 Favored 'Trans proline' 0 N--CA 1.499 1.805 0 C-N-CA 122.967 2.445 . . . . 0.0 110.938 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.4 p -69.38 157.1 37.71 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.794 -178.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttp180 -141.92 -141.75 0.13 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.377 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.405 ' H ' ' HG2' ' A' ' 115' ' ' ARG . 78.3 mtm-85 -151.89 135.23 15.99 Favored 'General case' 0 C--N 1.33 -0.243 0 O-C-N 123.471 0.482 . . . . 0.0 110.272 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . 0.581 ' C ' HG23 ' A' ' 53' ' ' THR . . . -173.17 169.45 4.56 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.141 0.496 . . . . 0.0 110.952 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 18.5 tpp180 -74.59 146.46 42.5 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.592 ' OG1' ' NE2' ' A' ' 51' ' ' GLN . 0.6 OUTLIER -136.47 154.14 50.84 Favored 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.879 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -131.53 -178.53 4.9 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.084 -0.962 . . . . 0.0 111.677 -175.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 17.0 t70 -153.74 121.56 5.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.192 179.031 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.719 HD21 HG22 ' A' ' 23' ' ' VAL . 85.4 mt -117.13 127.9 54.59 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 116.609 -0.269 . . . . 0.0 110.783 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -88.52 108.18 19.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.815 0.341 . . . . 0.0 110.36 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' N ' ' A' ' 126' ' ' GLU . 18.1 t -80.6 111.84 17.85 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.993 179.471 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 124' ' ' VAL . 2.8 tm-20 25.1 -87.63 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 112.45 0.537 . . . . 0.0 112.45 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.498 ' N ' ' O ' ' A' ' 124' ' ' VAL . 44.2 tp10 -139.25 -27.86 0.79 Allowed 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.545 179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.499 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.1 mt -80.58 66.0 5.93 Favored 'General case' 0 CA--C 1.506 -0.732 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 127' ' ' LEU . 48.3 m170 -38.9 94.96 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.579 0 CA-C-N 115.723 -0.671 . . . . 0.0 109.423 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.499 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 172.07 141.05 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.612 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.668 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.8 pp -147.56 154.79 41.15 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.46 0.648 . . . . 0.0 111.858 -179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 8' ' ' ILE . 72.7 t -91.01 126.38 43.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.77 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.459 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.91 134.09 42.23 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.397 -0.819 . . . . 0.0 110.0 -179.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.573 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 50.68 45.06 27.41 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.933 179.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 59.36 24.72 59.49 Favored Glycine 0 CA--C 1.522 0.491 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.162 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.7 t -129.69 152.47 37.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -106.49 111.31 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 118.203 0.456 . . . . 0.0 110.75 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' A' ' 138' ' ' HIS . 5.9 m -146.54 140.52 20.54 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.407 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.561 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 11.1 t60 -31.35 152.86 0.0 OUTLIER 'General case' 0 C--O 1.226 -0.149 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 17.9 p30 . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 118.016 -0.992 . . . . 0.0 110.429 -179.406 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.439 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.4 mt -117.04 132.13 56.77 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.887 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.93 161.95 26.34 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.872 179.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -63.8 147.1 52.63 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 116.175 -0.466 . . . . 0.0 109.968 178.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.31 -15.18 39.3 Favored Glycine 0 C--N 1.336 0.581 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.559 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 18.5 m -67.13 121.59 15.96 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 80.9 mtm-85 -97.39 116.66 30.02 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 120.764 0.316 . . . . 0.0 110.272 179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.422 HD11 ' HB ' ' A' ' 19' ' ' ILE . 9.0 mt -103.68 116.03 46.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.761 -179.228 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -76.13 136.04 39.82 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.544 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 11.9 t0 -103.19 130.41 23.68 Favored Pre-proline 0 CA--C 1.54 0.56 0 C-N-CA 121.187 -0.205 . . . . 0.0 110.52 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -73.05 -30.54 10.68 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.356 2.037 . . . . 0.0 112.196 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.544 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 57.8 t -72.05 -55.1 14.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.767 -179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 m -77.4 -39.98 45.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.175 0.512 . . . . 0.0 110.36 179.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 10.61 80.83 Favored Glycine 0 CA--C 1.522 0.486 0 CA-C-N 115.547 -0.751 . . . . 0.0 111.299 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 22.1 m -112.91 154.87 25.68 Favored 'General case' 0 C--O 1.232 0.162 0 CA-C-N 117.612 0.706 . . . . 0.0 109.636 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 35.8 m -79.05 117.15 19.83 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 121.265 0.555 . . . . 0.0 110.827 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -106.93 148.55 28.48 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.43 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.7 mtt85 -100.37 127.54 46.66 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.547 -0.297 . . . . 0.0 110.657 178.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.49 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.5 tt -54.09 -38.01 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.331 0 CA-C-O 120.923 0.392 . . . . 0.0 111.523 -179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.421 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.8 pt-20 -60.03 -33.12 71.59 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 121.078 0.466 . . . . 0.0 110.984 -179.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -83.79 -38.2 21.58 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.403 -0.817 . . . . 0.0 111.713 179.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 88.8 t -67.7 -41.26 85.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.245 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.697 HG22 HD21 ' A' ' 122' ' ' LEU . 60.7 t -72.99 -45.62 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 111.976 0.362 . . . . 0.0 111.976 -179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 -58.1 -34.85 70.64 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 120.696 0.284 . . . . 0.0 110.619 -178.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.76 27.34 11.26 Favored Glycine 0 C--O 1.226 -0.363 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 179.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.9 ptt-85 15.01 68.06 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.129 0.49 . . . . 0.0 109.82 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 78.2 mttt -89.8 135.27 30.69 Favored Pre-proline 0 N--CA 1.446 -0.655 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.984 -176.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -74.9 85.14 1.54 Allowed 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.848 1.699 . . . . 0.0 110.427 179.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 16.4 pt -111.92 -171.44 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 120.891 0.377 . . . . 0.0 110.963 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.45 ' CG ' HG21 ' A' ' 12' ' ' VAL . 65.7 m80 -130.44 159.62 36.49 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.454 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -146.55 170.49 4.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 98.5 t -86.61 131.52 34.56 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.626 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.6 146.66 37.01 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.396 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -117.02 143.45 45.73 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.938 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.79 176.71 4.94 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 179.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.506 ' H ' ' HD3' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -69.87 -14.43 62.73 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.772 0.32 . . . . 0.0 110.749 179.523 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' A' ' 37' ' ' ASP . 56.0 t0 -80.44 -18.34 49.08 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.177 179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.8 21.23 43.86 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 22.3 p -101.62 137.38 40.01 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.794 0.33 . . . . 0.0 111.116 178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.58 HD11 ' CD1' ' A' ' 103' ' ' LEU . 62.6 mt -91.35 126.68 36.51 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.745 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -136.76 136.71 39.14 Favored 'General case' 0 C--O 1.223 -0.331 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.579 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.548 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.51 142.02 51.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.487 -178.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.572 HH11 ' CD ' ' A' ' 125' ' ' GLU . 4.2 mmp_? -143.87 137.11 13.98 Favored Pre-proline 0 CA--C 1.537 0.473 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.672 -179.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -76.89 156.47 34.72 Favored 'Trans proline' 0 N--CA 1.493 1.475 0 C-N-CA 122.769 2.313 . . . . 0.0 112.962 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 75.2 t -96.64 134.93 32.44 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.37 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 178.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 21.7 m -126.34 -0.46 4.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.768 -178.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.7 t -146.65 136.32 23.1 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 118.535 0.607 . . . . 0.0 109.513 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.56 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.62 118.42 15.12 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.291 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -140.74 147.13 38.67 Favored 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -96.93 134.04 40.79 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 176.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.604 HE21 ' C ' ' A' ' 119' ' ' THR . 2.2 mt-30 -96.64 3.77 52.32 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.315 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.29 -178.0 49.1 Favored Glycine 0 C--N 1.34 0.78 0 C-N-CA 120.775 -0.726 . . . . 0.0 111.724 179.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -87.67 124.97 34.1 Favored 'General case' 0 CA--C 1.518 -0.264 0 CA-C-O 120.836 0.351 . . . . 0.0 110.17 179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 48.2 mmt-85 -143.35 165.04 28.61 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.727 -179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -76.05 142.45 41.79 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.256 -0.884 . . . . 0.0 109.784 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 28.6 m -145.57 149.8 16.22 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.61 HD11 ' HB1' ' A' ' 84' ' ' ALA . 46.7 pt -98.87 149.44 5.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.577 179.836 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.32 125.8 8.41 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 78.0 mt -108.58 113.37 26.32 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 121.201 0.524 . . . . 0.0 110.199 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.435 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 53.4 ttp180 -87.46 115.45 24.89 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.481 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 22.6 mm -106.09 152.47 7.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.441 -179.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -56.05 -10.1 0.75 Allowed 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.715 179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -61.87 -12.21 34.45 Favored Glycine 0 CA--C 1.523 0.569 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 89.32 -20.72 32.3 Favored Glycine 0 CA--C 1.521 0.428 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.17 172.47 8.2 Favored 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.441 HD11 ' CZ2' ' A' ' 68' ' ' TRP . 20.9 tt -118.91 143.65 29.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.11 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.7 tt -118.49 115.38 24.49 Favored 'General case' 0 CA--C 1.52 -0.204 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.363 -179.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.441 ' CZ2' HD11 ' A' ' 66' ' ' ILE . 98.0 m95 -102.68 125.51 49.44 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-N 116.162 -0.472 . . . . 0.0 109.78 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.02 170.97 19.12 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.276 -0.42 . . . . 0.0 109.879 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -83.53 157.06 65.1 Favored Pre-proline 0 CA--C 1.535 0.372 0 C-N-CA 120.739 -0.385 . . . . 0.0 110.551 179.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.442 ' O ' ' N ' ' A' ' 85' ' ' GLY . 38.3 Cg_endo -66.24 -18.7 56.17 Favored 'Trans proline' 0 N--CA 1.496 1.655 0 C-N-CA 122.549 2.166 . . . . 0.0 111.985 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -95.39 -6.29 41.32 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.874 0.368 . . . . 0.0 110.395 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.543 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 41.4 t60 -72.01 132.2 43.96 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -85.12 123.76 31.0 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-O 121.381 0.61 . . . . 0.0 111.629 -179.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.4 t -97.83 140.92 16.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.061 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 47.9 tp -81.4 92.33 6.41 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.076 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.471 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 39.3 p -98.86 173.15 7.0 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -178.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 92' ' ' ARG . 17.3 pt-20 -64.49 -17.05 63.5 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.291 -179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -105.95 24.85 11.7 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.691 0.281 . . . . 0.0 110.787 -179.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.03 -143.5 16.64 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 79.5 m95 -89.1 123.29 33.24 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.729 0.3 . . . . 0.0 111.14 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.8 tpt180 -122.88 126.06 46.57 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.026 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.45 132.0 46.77 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.784 -179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.61 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -69.36 -1.07 7.34 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.029 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.442 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -76.37 -12.93 83.85 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -134.76 27.76 3.61 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.451 HD12 ' HA ' ' A' ' 84' ' ' ALA . 13.3 mt -83.03 133.25 35.1 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.373 0.606 . . . . 0.0 111.02 179.201 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 28.8 mmt180 -133.38 148.02 51.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.615 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -47.59 106.59 0.09 Allowed 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.551 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 147.12 -17.89 1.55 Allowed Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -82.7 132.94 35.17 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.643 0.258 . . . . 0.0 110.695 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 78' ' ' GLU . 85.2 mtm180 -90.04 130.21 36.25 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 120.364 -0.535 . . . . 0.0 110.302 -179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.9 m -113.49 144.77 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.66 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -74.15 124.72 26.88 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.708 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.6 m -121.66 165.02 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.146 179.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.1 tpt180 -101.64 128.91 47.71 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.61 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.433 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 34.8 t0 -101.13 124.03 46.21 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.534 178.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.401 ' O ' HG12 ' A' ' 98' ' ' VAL . 97.1 t -74.37 -16.2 16.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 118.29 0.495 . . . . 0.0 111.065 178.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -70.3 -59.29 2.96 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 120.67 -0.412 . . . . 0.0 110.405 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.426 ' C ' ' H ' ' A' ' 102' ' ' GLU . 19.5 p -98.84 -13.93 19.88 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.627 179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.38 -14.26 6.92 Favored Glycine 0 C--N 1.333 0.408 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.426 ' H ' ' C ' ' A' ' 100' ' ' THR . 46.0 mt-10 -82.09 157.46 24.08 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 111.175 -177.22 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.58 ' CD1' HD11 ' A' ' 40' ' ' LEU . 7.8 mp -77.22 134.86 38.5 Favored 'General case' 0 N--CA 1.446 -0.635 0 CA-C-O 121.228 0.537 . . . . 0.0 110.153 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.433 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 38.9 ptt180 -132.62 165.4 24.52 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.592 179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.471 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.1 m-85 -112.04 148.55 33.61 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.048 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 65.1 m -145.15 165.84 27.14 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 57.7 t -91.81 152.31 3.41 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-O 120.62 0.248 . . . . 0.0 110.69 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.516 HG22 ' N ' ' A' ' 109' ' ' ARG . 71.9 mt -70.49 162.26 4.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.304 178.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.516 ' N ' HG22 ' A' ' 108' ' ' ILE . 37.4 mtp85 -106.04 -48.47 3.6 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.817 178.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.435 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 85.3 tt0 -167.53 149.14 5.62 Favored 'General case' 0 CA--C 1.531 0.22 0 O-C-N 121.963 -0.461 . . . . 0.0 109.853 179.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.451 ' C ' HD12 ' A' ' 112' ' ' LEU . 72.0 t -96.16 134.35 34.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.475 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -102.59 151.22 38.22 Favored Pre-proline 0 CA--C 1.534 0.333 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.168 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -67.22 159.85 50.26 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.664 2.243 . . . . 0.0 111.301 179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.493 HG22 HG22 ' A' ' 57' ' ' ILE . 81.7 p -65.75 154.19 39.69 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 120.886 -0.326 . . . . 0.0 110.431 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 81.7 mtp180 -149.8 153.36 36.67 Favored 'General case' 0 CA--C 1.507 -0.681 0 CA-C-O 121.804 0.811 . . . . 0.0 110.307 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.0 mmm180 -82.55 132.42 35.2 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 114.364 -1.289 . . . . 0.0 110.634 -179.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.81 167.63 12.9 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.973 -179.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.1 ttm180 -80.53 145.12 31.98 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.708 179.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.604 ' C ' HE21 ' A' ' 51' ' ' GLN . 41.9 p -125.95 145.01 50.46 Favored 'General case' 0 CA--C 1.521 -0.142 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.656 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.558 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 59.6 m-85 -120.5 175.09 6.16 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.42 -178.438 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.3 t0 -151.77 123.84 8.14 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.939 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.697 HD21 HG22 ' A' ' 23' ' ' VAL . 89.8 mt -122.46 124.59 43.95 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.629 0.252 . . . . 0.0 110.508 179.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tp10 -89.25 109.56 20.43 Favored 'General case' 0 C--N 1.329 -0.284 0 C-N-CA 120.67 -0.412 . . . . 0.0 109.989 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.504 ' O ' ' C ' ' A' ' 125' ' ' GLU . 18.6 t -83.6 115.78 26.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 C-N-CA 120.472 -0.491 . . . . 0.0 109.918 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.572 ' CD ' HH11 ' A' ' 43' ' ' ARG . 43.7 tt0 20.7 -92.01 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.519 0 O-C-N 123.733 0.645 . . . . 0.0 111.749 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.4 ' N ' ' O ' ' A' ' 124' ' ' VAL . 40.8 tp10 -133.22 -32.46 1.19 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.882 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.508 ' O ' ' N ' ' A' ' 129' ' ' THR . 76.8 mt -74.03 63.04 0.92 Allowed 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 -179.315 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.528 ' O ' HG23 ' A' ' 129' ' ' THR . 30.8 m170 -38.48 95.04 0.01 OUTLIER 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.528 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.33 140.84 0.02 OUTLIER 'General case' 0 C--O 1.233 0.191 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 179.1 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.6 pp -149.29 156.89 42.81 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.321 0.582 . . . . 0.0 111.796 -178.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 98.1 t -89.9 121.44 40.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.607 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.5 145.77 50.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.558 -178.429 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.529 ' O ' HG23 ' A' ' 135' ' ' VAL . 40.0 mt-10 40.8 46.5 2.32 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.155 179.063 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.32 -22.24 0.29 Allowed Glycine 0 CA--C 1.529 0.965 0 CA-C-N 115.366 -0.834 . . . . 0.0 111.658 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.4 t -90.91 152.01 3.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.274 0 C-N-CA 122.596 0.358 . . . . 0.0 110.701 179.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.3 t -108.8 115.84 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 120.757 0.313 . . . . 0.0 110.416 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 33.5 m -149.94 144.18 17.62 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.424 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.057 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.543 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 52.2 t-80 -30.01 149.95 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.128 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 179.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.429 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 22.2 p30 . . . . . 0 C--N 1.324 -0.514 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.415 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 16.0 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.415 HD11 HD11 ' A' ' 130' ' ' LEU . 68.9 mt -108.25 135.31 49.79 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.599 -179.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.85 163.22 23.58 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.732 179.7 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 65.2 tt0 -63.19 141.5 58.74 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.053 178.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.19 -19.73 31.74 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.276 -1.13 . . . . 0.0 110.276 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.3 m -67.68 124.55 23.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.261 0.077 . . . . 0.0 111.169 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 -85.32 150.1 25.0 Favored 'General case' 0 C--O 1.231 0.109 0 CA-C-O 120.992 0.425 . . . . 0.0 109.989 179.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 12.9 mt -134.47 108.99 11.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.868 -0.606 . . . . 0.0 111.191 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -76.01 125.83 29.86 Favored 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 178.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.9 129.85 25.66 Favored Pre-proline 0 CA--C 1.536 0.429 0 N-CA-C 110.195 -0.298 . . . . 0.0 110.195 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.12 -30.12 16.62 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 121.703 1.602 . . . . 0.0 112.433 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 72.2 t -73.73 -55.18 13.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.145 -179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 32.4 m -74.7 -40.34 61.4 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.472 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.32 6.64 83.85 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 111.589 -0.605 . . . . 0.0 111.589 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 85.3 m -116.92 162.0 18.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.512 0.656 . . . . 0.0 109.794 -179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 1.9 p -81.02 116.15 20.83 Favored 'General case' 0 N--CA 1.448 -0.566 0 CA-C-O 121.609 0.719 . . . . 0.0 111.301 -179.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 13.4 m80 -97.32 138.6 34.54 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.22 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -95.64 126.67 41.07 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.695 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.9 tp -53.07 -40.44 37.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 CA-C-O 120.827 0.346 . . . . 0.0 111.388 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.0 pt-20 -57.12 -36.59 70.86 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.371 0.605 . . . . 0.0 110.968 -179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.407 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.2 t0 -81.85 -36.89 27.77 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.63 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 77.2 t -67.38 -42.24 87.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.731 -0.213 . . . . 0.0 111.252 -179.502 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 91.5 t -72.2 -46.52 57.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -179.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 45.1 t0 -55.04 -37.9 67.28 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-O 120.96 0.41 . . . . 0.0 110.472 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.579 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -111.99 33.32 5.8 Favored Glycine 0 CA--C 1.52 0.374 0 CA-C-O 118.688 -1.062 . . . . 0.0 110.873 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.579 ' C ' ' O ' ' A' ' 25' ' ' GLY . 26.2 ptt180 8.97 74.63 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 117.576 0.688 . . . . 0.0 110.588 179.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.453 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.4 mttt -89.04 142.03 29.88 Favored Pre-proline 0 C--N 1.325 -0.494 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.944 -177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.514 ' O ' ' O ' ' A' ' 29' ' ' ILE . 58.4 Cg_endo -70.87 11.22 0.53 Allowed 'Trans proline' 0 N--CA 1.491 1.338 0 C-N-CA 121.832 1.688 . . . . 0.0 111.534 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.514 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.3 pp -39.78 171.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.237 -177.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.427 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 4.2 m80 -120.99 166.08 14.35 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 116.478 -0.328 . . . . 0.0 110.425 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.9 m -148.12 170.01 3.23 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 99.5 t -85.75 137.64 20.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.59 165.47 11.51 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.46 138.66 41.67 Favored 'General case' 0 N--CA 1.462 0.161 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.21 178.0 4.43 Favored 'General case' 0 N--CA 1.467 0.41 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -73.13 -14.9 61.47 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-O 120.883 0.373 . . . . 0.0 110.885 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -77.93 -18.32 56.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.331 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.38 24.97 34.76 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 23.7 p -102.87 136.4 42.77 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.649 0.262 . . . . 0.0 110.808 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.6 mt -96.97 130.84 44.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.954 0.407 . . . . 0.0 110.532 179.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -141.64 140.05 33.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.734 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -68.9 142.97 54.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 -178.437 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.4 mmp_? -146.24 137.57 12.9 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.428 -179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 89.6 Cg_endo -74.6 158.32 43.78 Favored 'Trans proline' 0 N--CA 1.497 1.697 0 C-N-CA 122.611 2.208 . . . . 0.0 112.695 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 69.2 t -100.03 136.53 30.94 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.393 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 177.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 26.1 m -127.83 2.59 3.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.49 0 CA-C-O 119.032 -0.508 . . . . 0.0 112.159 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 3.8 t -145.85 134.79 22.55 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 119.349 0.977 . . . . 0.0 108.915 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -132.89 117.6 17.91 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 177.86 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.504 ' O ' ' OE1' ' A' ' 51' ' ' GLN . 68.4 m-85 -142.81 148.73 37.61 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 112.834 0.679 . . . . 0.0 112.834 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.421 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 48.6 p-10 -97.61 135.8 38.92 Favored 'General case' 0 C--N 1.331 -0.204 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 176.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.504 ' OE1' ' O ' ' A' ' 49' ' ' PHE . 0.6 OUTLIER -97.27 8.27 44.89 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.41 -179.086 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.47 177.92 50.52 Favored Glycine 0 CA--C 1.527 0.825 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.488 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.549 ' OG1' ' NH1' ' A' ' 118' ' ' ARG . 4.3 m -87.51 127.68 35.24 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.337 -0.432 . . . . 0.0 109.87 179.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.2 mmm180 -148.51 167.49 25.24 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.049 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -73.95 141.79 45.92 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.509 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.7 m -128.88 141.22 47.17 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-O 120.905 0.383 . . . . 0.0 110.491 -179.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.788 HD13 ' H ' ' A' ' 57' ' ' ILE . 0.1 OUTLIER -100.9 139.78 21.36 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.408 0 CA-C-N 115.906 -0.588 . . . . 0.0 109.87 179.794 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.48 140.95 15.31 Favored Glycine 0 N--CA 1.443 -0.839 0 C-N-CA 121.103 -0.57 . . . . 0.0 111.846 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 27.6 mt -129.0 115.86 18.43 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-O 121.197 0.522 . . . . 0.0 109.972 -179.036 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.611 ' NH2' ' NH1' ' A' ' 109' ' ' ARG . 62.9 ttt180 -97.02 114.55 26.18 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.729 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.542 ' O ' ' N ' ' A' ' 63' ' ' GLY . 16.4 mm -100.76 123.9 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.287 -178.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.471 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 39.92 20.74 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.393 -0.821 . . . . 0.0 111.001 -178.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 75.82 -29.91 1.3 Allowed Glycine 0 CA--C 1.52 0.354 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' A' ' 63' ' ' GLY . . . -45.77 -108.77 0.01 OUTLIER Glycine 0 N--CA 1.447 -0.589 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 -177.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -81.78 167.89 18.6 Favored 'General case' 0 C--N 1.312 -1.053 0 CA-C-O 121.215 0.531 . . . . 0.0 111.174 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.425 HG21 ' CZ2' ' A' ' 68' ' ' TRP . 0.1 OUTLIER -132.07 156.81 42.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.392 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.579 -178.729 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.9 tp -146.21 123.75 11.76 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.427 -0.352 . . . . 0.0 111.723 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.425 ' CZ2' HG21 ' A' ' 66' ' ' ILE . 2.1 m95 -99.42 107.85 20.19 Favored 'General case' 0 CA--C 1.53 0.178 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 175.961 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.451 ' O ' HD13 ' A' ' 57' ' ' ILE . . . -127.51 177.14 6.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.439 -0.8 . . . . 0.0 110.158 -177.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -87.9 155.27 52.87 Favored Pre-proline 0 CA--C 1.542 0.664 0 C-N-CA 120.935 -0.306 . . . . 0.0 110.225 179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -60.44 -27.38 84.74 Favored 'Trans proline' 0 N--CA 1.504 2.112 0 C-N-CA 122.909 2.406 . . . . 0.0 112.08 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . 0.424 ' OD1' ' NZ ' ' A' ' 74' ' ' LYS . 38.7 t70 -85.9 -6.93 58.99 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.476 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.539 ' CE1' ' O ' ' A' ' 138' ' ' HIS . 6.8 t60 -70.53 126.37 29.45 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.539 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.424 ' NZ ' ' OD1' ' A' ' 72' ' ' ASP . 14.3 mptt -89.55 137.4 32.36 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.352 0.596 . . . . 0.0 110.517 -179.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.5 t -105.09 135.85 41.37 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.151 -0.932 . . . . 0.0 109.586 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 50.5 tp -76.54 100.37 5.27 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.671 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.492 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 81.8 p -98.81 174.78 6.22 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 -178.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.431 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 10.0 pt-20 -67.11 -12.75 60.84 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 120.674 -0.411 . . . . 0.0 111.438 -179.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.431 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 60.2 m-85 -112.89 22.13 14.76 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.473 0.175 . . . . 0.0 111.473 -179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 111.88 -138.01 14.67 Favored Glycine 0 N--CA 1.466 0.672 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 179.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 98.0 m95 -107.12 138.32 43.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.716 0.293 . . . . 0.0 110.387 -179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 13.8 tpt180 -137.82 130.33 29.51 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.66 141.9 36.07 Favored 'General case' 0 CA--C 1.516 -0.33 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -60.03 -40.06 88.04 Favored 'General case' 0 N--CA 1.45 -0.442 0 C-N-CA 120.718 -0.393 . . . . 0.0 111.92 -179.064 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -66.29 -3.74 20.05 Favored Glycine 0 CA--C 1.532 1.094 0 C-N-CA 119.808 -1.187 . . . . 0.0 111.893 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.83 -6.14 20.51 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 117.139 0.469 . . . . 0.0 110.382 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.0 mt -76.25 128.74 35.51 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.622 -179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.48 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.4 mmt85 -134.02 148.44 51.09 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.383 -179.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 35.8 ttmt -43.42 92.71 0.01 OUTLIER 'General case' 0 N--CA 1.455 -0.189 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.002 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.1 -17.58 0.53 Allowed Glycine 0 CA--C 1.525 0.67 0 N-CA-C 111.242 -0.743 . . . . 0.0 111.242 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -89.67 128.95 36.16 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 120.895 0.378 . . . . 0.0 111.059 -179.246 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -89.63 133.31 34.7 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.257 0.551 . . . . 0.0 110.829 -178.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 3.4 m -114.32 144.58 21.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.791 -179.62 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.59 130.55 43.38 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.251 -0.432 . . . . 0.0 111.072 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 20.5 m -128.92 161.04 38.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.416 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 78.8 ttt-85 -107.51 130.59 54.84 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.958 -179.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 34.6 t0 -100.27 123.17 44.17 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.359 179.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.0 m -75.19 -14.68 15.64 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.777 0 CA-C-N 118.534 0.606 . . . . 0.0 110.638 177.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -70.07 -58.38 3.88 Favored 'General case' 0 C--N 1.333 -0.114 0 C-N-CA 120.604 -0.438 . . . . 0.0 109.952 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.7 p -98.12 -10.68 23.82 Favored 'General case' 0 CA--C 1.52 -0.18 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.93 -12.61 6.23 Favored Glycine 0 C--N 1.334 0.423 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 93.3 mt-10 -82.32 155.62 24.69 Favored 'General case' 0 N--CA 1.45 -0.427 0 CA-C-O 120.926 0.393 . . . . 0.0 111.578 -176.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.609 ' H ' HD23 ' A' ' 103' ' ' LEU . 2.0 pt? -81.56 139.83 34.85 Favored 'General case' 0 N--CA 1.443 -0.82 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.513 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 9.4 ptm180 -140.01 178.39 7.3 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.17 179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.492 ' OH ' ' C ' ' A' ' 77' ' ' THR . 3.6 m-85 -117.36 147.9 42.21 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.028 179.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.7 m -138.28 161.35 37.13 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 178.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.413 HG22 ' N ' ' A' ' 108' ' ' ILE . 10.4 p -91.93 154.57 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 N-CA-C 110.362 -0.236 . . . . 0.0 110.362 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.413 ' N ' HG22 ' A' ' 107' ' ' VAL . 50.1 mt -75.89 151.59 6.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.19 0 N-CA-C 109.993 -0.373 . . . . 0.0 109.993 178.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.611 ' NH1' ' NH2' ' A' ' 60' ' ' ARG . 68.7 ttt180 -104.11 -42.39 5.55 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.418 -0.356 . . . . 0.0 111.579 179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.46 147.85 5.34 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.404 ' C ' HD12 ' A' ' 112' ' ' LEU . 73.4 t -94.92 133.37 36.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 178.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.461 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.0 mp -100.91 151.24 37.57 Favored Pre-proline 0 CA--C 1.537 0.475 0 CA-C-N 116.454 -0.339 . . . . 0.0 111.1 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -70.47 158.42 56.07 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.804 2.336 . . . . 0.0 111.57 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 1.6 p -67.57 156.9 35.66 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.101 0.477 . . . . 0.0 110.478 -179.035 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 82.6 mtp180 -133.77 -141.28 0.19 Allowed 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.431 -179.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 78.1 mtt85 -157.59 130.1 7.34 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.041 179.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.7 170.54 4.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.274 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.549 ' NH1' ' OG1' ' A' ' 53' ' ' THR . 64.7 mmt-85 -74.15 151.38 40.07 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.372 178.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 41.3 p -131.2 146.52 52.36 Favored 'General case' 0 CA--C 1.518 -0.261 0 CA-C-O 121.172 0.511 . . . . 0.0 109.861 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.46 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 68.6 m-85 -123.3 174.07 7.55 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.538 -0.755 . . . . 0.0 111.275 -178.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.46 ' OD1' ' O ' ' A' ' 120' ' ' PHE . 78.5 m-20 -153.62 123.26 6.73 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.71 177.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 65.5 mt -118.52 126.13 51.34 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -86.59 112.02 21.19 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-O 120.951 0.405 . . . . 0.0 110.399 -178.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.471 ' O ' ' C ' ' A' ' 125' ' ' GLU . 62.7 t -86.52 114.14 25.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.895 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.471 ' C ' ' O ' ' A' ' 124' ' ' VAL . 40.4 tp10 22.14 -115.25 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 O-C-N 123.811 0.694 . . . . 0.0 111.936 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 39.9 tp10 -109.8 -25.64 10.24 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.316 179.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 129' ' ' THR . 86.3 mt -82.83 66.68 8.56 Favored 'General case' 0 CA--C 1.505 -0.781 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.486 ' H ' ' CD2' ' A' ' 128' ' ' HIS . 2.0 p80 -41.21 98.42 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 179.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.459 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.77 142.98 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.688 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.663 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.9 pp -149.02 152.78 36.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.396 0.617 . . . . 0.0 111.961 -179.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.411 ' N ' HD12 ' A' ' 130' ' ' LEU . 97.7 t -90.96 126.58 43.67 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 CA-C-N 114.923 -1.035 . . . . 0.0 109.04 -179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.441 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.39 132.91 41.74 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.067 -179.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.557 ' O ' HG23 ' A' ' 135' ' ' VAL . 14.2 mm-40 52.01 43.71 30.13 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.542 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.62 28.13 62.23 Favored Glycine 0 CA--C 1.524 0.648 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.175 178.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.557 HG23 ' O ' ' A' ' 133' ' ' GLU . 20.8 t -129.6 151.91 36.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.967 -1.123 . . . . 0.0 107.967 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.6 t -104.38 109.6 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 CA-C-N 118.551 0.614 . . . . 0.0 110.722 179.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.431 ' O ' ' C ' ' A' ' 138' ' ' HIS . 28.8 m -147.28 139.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 179.763 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.539 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 62.7 t-80 -33.54 149.65 0.01 OUTLIER 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.853 0.359 . . . . 0.0 111.751 -179.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.349 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.445 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 4.8 m . . . . . 0 N--CA 1.489 1.515 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 85.4 mt -115.57 134.05 55.43 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.471 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.76 162.04 23.07 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.605 179.749 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.47 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 25.8 tt0 -62.62 144.42 56.24 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.939 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.13 -14.6 36.88 Favored Glycine 0 C--N 1.335 0.506 0 N-CA-C 110.243 -1.143 . . . . 0.0 110.243 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.518 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.2 m -69.22 121.46 16.85 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 121.104 -0.239 . . . . 0.0 110.785 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 86.8 mtm180 -84.55 149.89 25.6 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 120.804 0.335 . . . . 0.0 110.284 179.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' A' ' 19' ' ' ILE . 73.5 mt -133.49 107.21 10.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.301 179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -78.42 131.84 37.08 Favored 'General case' 0 C--N 1.328 -0.363 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 16.3 t0 -108.83 124.72 33.45 Favored Pre-proline 0 CA--C 1.54 0.559 0 N-CA-C 110.363 -0.236 . . . . 0.0 110.363 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.491 ' HD2' ' HD1' ' A' ' 30' ' ' HIS . 42.4 Cg_endo -68.97 -25.53 32.23 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 122.248 1.966 . . . . 0.0 111.841 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.1 t -69.95 -56.23 12.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.114 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.1 p -83.55 -38.2 22.01 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-O 121.056 0.455 . . . . 0.0 109.887 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 86.47 12.1 70.46 Favored Glycine 0 CA--C 1.519 0.331 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 41.9 m -114.75 155.37 26.82 Favored 'General case' 0 C--N 1.344 0.366 0 CA-C-N 117.963 0.882 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 17.8 m -80.59 120.65 24.81 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.311 0.577 . . . . 0.0 110.971 -179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -105.36 145.85 30.21 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.34 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.414 ' O ' HG23 ' A' ' 22' ' ' VAL . 6.6 ttm180 -97.31 123.05 41.0 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.603 ' O ' HG23 ' A' ' 23' ' ' VAL . 3.1 tt -53.99 -40.07 43.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.795 -0.362 . . . . 0.0 111.619 -179.179 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 12.7 pt-20 -60.42 -32.71 71.6 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.945 0.402 . . . . 0.0 111.202 -179.356 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -83.7 -39.07 20.62 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.672 179.454 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.488 HG11 ' CD1' ' A' ' 29' ' ' ILE . 92.8 t -67.53 -40.67 84.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 115.718 -0.674 . . . . 0.0 111.11 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.639 HG22 HD21 ' A' ' 122' ' ' LEU . 61.8 t -72.43 -46.72 55.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 C-N-CA 120.77 -0.372 . . . . 0.0 111.619 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -58.11 -34.76 70.55 Favored 'General case' 0 CA--C 1.513 -0.457 0 CA-C-O 120.65 0.262 . . . . 0.0 110.866 -178.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.556 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.81 26.7 18.66 Favored Glycine 0 CA--C 1.518 0.224 0 N-CA-C 110.768 -0.933 . . . . 0.0 110.768 179.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.556 ' C ' ' O ' ' A' ' 25' ' ' GLY . 94.1 mtt-85 17.47 64.55 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.86 -0.422 . . . . 0.0 109.86 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.419 ' O ' HG23 ' A' ' 29' ' ' ILE . 78.8 mttt -90.14 114.22 60.12 Favored Pre-proline 0 N--CA 1.448 -0.568 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.058 -176.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -55.88 86.5 0.04 OUTLIER 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.836 1.69 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.488 ' CD1' HG11 ' A' ' 22' ' ' VAL . 12.5 pt -109.24 -172.68 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 CA-C-O 120.752 0.31 . . . . 0.0 110.707 -179.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.873 ' NE2' ' HB1' ' A' ' 42' ' ' ALA . 6.3 t-80 -127.02 156.86 40.96 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.712 179.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.64 ' O ' ' CE1' ' A' ' 30' ' ' HIS . 29.2 m -148.46 169.7 3.05 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -179.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 6.3 t -89.87 134.91 27.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 O-C-N 122.115 -0.365 . . . . 0.0 110.36 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -108.1 167.18 10.19 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.799 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.44 145.3 40.75 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.261 179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.12 178.22 4.37 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.577 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.74 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 69.7 mmtt -71.4 -11.6 60.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.024 0.44 . . . . 0.0 110.458 179.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.0 p30 -80.22 -13.41 59.25 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.29 179.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 83.3 19.74 61.87 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 47.4 p -102.18 138.83 38.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.833 0.349 . . . . 0.0 111.594 178.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.3 mt -92.29 131.0 37.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.181 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 2.2 t60 -137.3 138.24 39.81 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.529 -178.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.873 ' HB1' ' NE2' ' A' ' 30' ' ' HIS . . . -69.26 136.12 51.48 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -178.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.662 ' N ' ' NE2' ' A' ' 30' ' ' HIS . 4.6 mmp_? -146.13 136.53 12.16 Favored Pre-proline 0 CA--C 1.537 0.454 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.178 -179.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.88 159.85 30.87 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 122.865 2.377 . . . . 0.0 113.118 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.9 t -101.42 139.02 23.66 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.283 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 177.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.6 m -130.68 4.56 2.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 115.738 -0.664 . . . . 0.0 112.06 -179.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 p -149.34 145.2 26.89 Favored 'General case' 0 N--CA 1.451 -0.404 0 CA-C-N 119.175 0.898 . . . . 0.0 109.025 179.276 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.612 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.26 123.76 13.98 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 108.023 -1.103 . . . . 0.0 108.023 178.51 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -136.41 145.12 44.94 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 30.3 m-20 -91.88 140.32 29.79 Favored 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.496 HE21 ' HB2' ' A' ' 121' ' ' ASP . 46.8 mm-40 -89.84 -4.19 57.72 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.338 179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 77.46 21.62 72.18 Favored Glycine 0 C--N 1.338 0.676 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.657 178.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.419 ' O ' ' CG ' ' A' ' 54' ' ' ARG . 0.4 OUTLIER 64.53 135.3 0.02 OUTLIER 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 120.836 0.35 . . . . 0.0 110.087 -179.945 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . 0.419 ' CG ' ' O ' ' A' ' 53' ' ' THR . 72.0 mtp180 -157.27 174.92 14.72 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.404 178.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . 0.443 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 50.3 t0 -73.93 139.67 45.07 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.4 m -142.13 152.73 18.42 Favored 'Isoleucine or valine' 0 CA--C 1.523 -0.09 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.726 HD11 ' HB1' ' A' ' 84' ' ' ALA . 44.6 pt -104.86 152.05 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.177 179.359 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -106.79 138.1 14.26 Favored Glycine 0 N--CA 1.464 0.555 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 63.6 mt -121.32 114.57 21.53 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 121.111 0.481 . . . . 0.0 110.365 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 54.3 ttt85 -87.0 113.78 23.05 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.888 -179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.662 ' O ' ' N ' ' A' ' 63' ' ' GLY . 15.7 mm -98.54 134.09 38.51 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.523 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.664 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 24.13 34.25 0.0 OUTLIER 'General case' 0 C--N 1.35 0.607 0 O-C-N 123.848 0.718 . . . . 0.0 112.038 179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.662 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 62.72 -18.3 0.07 OUTLIER Glycine 0 CA--C 1.535 1.281 0 N-CA-C 111.087 -0.805 . . . . 0.0 111.087 -178.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.664 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -52.9 -107.84 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 110.079 -1.208 . . . . 0.0 110.079 -178.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.23 168.91 11.01 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 120.887 0.375 . . . . 0.0 110.441 -179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 92.2 mt -122.47 150.77 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.212 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 57.9 tp -123.99 113.55 18.58 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.823 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.556 ' CG ' ' NH2' ' A' ' 115' ' ' ARG . 95.3 m95 -104.5 121.28 43.14 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -148.95 171.94 15.53 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.318 -179.384 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . 0.418 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 40.2 p -78.56 154.41 78.79 Favored Pre-proline 0 C--N 1.329 -0.294 0 C-N-CA 120.538 -0.465 . . . . 0.0 111.109 -179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -58.66 -22.15 59.23 Favored 'Trans proline' 0 N--CA 1.495 1.578 0 C-N-CA 122.027 1.818 . . . . 0.0 112.113 179.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -93.15 -7.71 44.6 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.79 0.328 . . . . 0.0 110.364 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.546 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.8 t60 -66.81 126.83 30.29 Favored 'General case' 0 C--N 1.329 -0.325 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 5.8 mptt -82.72 123.42 29.28 Favored 'General case' 0 N--CA 1.449 -0.498 0 CA-C-O 121.219 0.533 . . . . 0.0 111.395 -179.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 75.5 t -99.73 139.68 20.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.641 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.732 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 55.9 tp -78.66 95.02 5.16 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.867 -179.369 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 13.9 p -98.7 174.67 6.3 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -66.78 -14.9 63.15 Favored 'General case' 0 N--CA 1.451 -0.418 0 C-N-CA 120.665 -0.414 . . . . 0.0 111.29 -179.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 68.4 m-85 -108.05 25.22 11.86 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.483 0.183 . . . . 0.0 110.744 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 99.59 -141.15 15.35 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.74 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 92.5 m95 -94.47 129.31 41.29 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 120.966 0.412 . . . . 0.0 111.172 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 10.9 tpt180 -138.7 131.42 29.21 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.441 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -55.62 144.49 26.48 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.012 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.726 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -61.07 -37.94 84.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 120.936 -0.306 . . . . 0.0 111.613 -179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -65.77 -5.33 24.16 Favored Glycine 0 CA--C 1.528 0.9 0 C-N-CA 120.215 -0.993 . . . . 0.0 111.795 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -103.38 4.9 36.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.962 0.411 . . . . 0.0 110.432 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.5 mt -90.67 131.05 36.59 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.404 0.621 . . . . 0.0 111.122 -179.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.517 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.4 mmt180 -129.2 148.96 51.18 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.126 -0.943 . . . . 0.0 110.705 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.8 ttpt -45.27 90.83 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.464 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.846 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 153.72 -12.33 0.55 Allowed Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -84.09 130.77 34.84 Favored 'General case' 0 C--O 1.228 -0.079 0 CA-C-O 120.936 0.398 . . . . 0.0 110.672 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.411 ' HE ' HG12 ' A' ' 107' ' ' VAL . 93.9 mtt180 -92.48 141.55 28.39 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.724 -179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.51 158.98 42.06 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.282 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.6 130.35 43.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.105 -179.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.452 HG21 ' OG ' ' A' ' 106' ' ' SER . 1.4 t -130.87 132.79 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.434 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 76.9 ttt180 -84.29 125.61 32.42 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.742 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 37.5 t0 -99.81 122.62 43.04 Favored 'General case' 0 C--O 1.223 -0.322 0 CA-C-N 116.003 -0.544 . . . . 0.0 109.999 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.4 m -75.78 -17.8 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 118.35 0.523 . . . . 0.0 111.303 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.8 mm-40 -69.64 -59.74 2.77 Favored 'General case' 0 C--O 1.234 0.247 0 C-N-CA 120.517 -0.473 . . . . 0.0 109.898 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.438 ' C ' ' H ' ' A' ' 102' ' ' GLU . 33.8 p -93.1 -12.85 29.46 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 179.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.12 -14.27 6.52 Favored Glycine 0 C--N 1.331 0.278 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.438 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.5 mt-10 -83.38 157.95 22.32 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.841 0.353 . . . . 0.0 110.824 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.604 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -82.39 133.71 35.23 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.22 0.533 . . . . 0.0 109.852 179.755 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 52.4 ptt85 -138.18 137.14 37.32 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.408 -179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.3 m-30 -78.55 147.32 33.83 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.934 -177.538 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.452 ' OG ' HG21 ' A' ' 95' ' ' VAL . 3.2 m -134.98 160.44 38.31 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.575 178.478 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.431 HG22 ' H ' ' A' ' 107' ' ' VAL . 17.0 m -91.73 153.67 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.207 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.5 mm -70.23 156.33 7.2 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.084 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.443 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt85 -107.61 -46.63 3.79 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.989 178.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -166.3 145.95 6.0 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.436 ' C ' HD22 ' A' ' 112' ' ' LEU . 19.3 t -93.33 131.84 39.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.486 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.7 mm? -99.57 148.48 34.79 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.047 -178.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -68.88 160.34 50.16 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.408 2.072 . . . . 0.0 111.126 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.425 HG23 ' H ' ' A' ' 114' ' ' THR . 0.1 OUTLIER -69.26 156.67 38.36 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-O 120.999 0.428 . . . . 0.0 110.585 -179.387 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.556 ' NH2' ' CG ' ' A' ' 68' ' ' TRP . 39.3 ptt180 -139.87 -144.41 0.17 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.964 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 74.4 mtm180 -154.03 134.75 13.66 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.69 172.12 3.64 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.983 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.47 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 91.4 mtm-85 -71.45 140.54 50.07 Favored 'General case' 0 CA--C 1.514 -0.415 0 CA-C-N 115.76 -0.655 . . . . 0.0 109.519 178.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -126.1 143.01 51.28 Favored 'General case' 0 C--O 1.231 0.126 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.455 ' HB3' HG21 ' A' ' 23' ' ' VAL . 52.2 m-85 -120.61 178.02 4.84 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 115.428 -0.805 . . . . 0.0 111.719 -177.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.496 ' HB2' HE21 ' A' ' 51' ' ' GLN . 51.0 t0 -153.49 120.75 5.81 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.269 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.639 HD21 HG22 ' A' ' 23' ' ' VAL . 84.8 mt -119.57 123.53 44.15 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-O 120.744 0.307 . . . . 0.0 110.443 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -88.51 111.51 21.91 Favored 'General case' 0 CA--C 1.514 -0.441 0 C-N-CA 120.612 -0.435 . . . . 0.0 109.899 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 59.8 t -86.49 119.74 35.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 120.464 -0.495 . . . . 0.0 109.849 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 33.2 tp10 21.71 -121.05 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.596 0 O-C-N 123.961 0.788 . . . . 0.0 111.148 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -104.17 -26.81 12.39 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.916 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.431 ' O ' ' N ' ' A' ' 129' ' ' THR . 66.9 mt -81.86 70.54 8.78 Favored 'General case' 0 CA--C 1.511 -0.557 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.527 ' O ' HG23 ' A' ' 129' ' ' THR . 31.2 m170 -41.57 98.83 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 179.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.527 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.46 141.49 0.02 OUTLIER 'General case' 0 C--O 1.233 0.213 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.997 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.66 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.3 pp -146.65 155.85 42.75 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.377 0.608 . . . . 0.0 111.614 -179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 131' ' ' VAL . 8.4 p -89.8 125.48 42.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.875 -179.497 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.518 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -132.62 132.36 42.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.015 -0.993 . . . . 0.0 109.784 -179.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.618 ' O ' HG23 ' A' ' 135' ' ' VAL . 80.8 mm-40 49.7 46.49 23.8 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.22 179.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 67.39 -13.35 0.58 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.431 -0.667 . . . . 0.0 111.431 178.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.2 t -95.18 150.64 4.08 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.27 0 CA-C-N 117.061 0.43 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 91.6 t -107.97 113.52 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 120.65 0.262 . . . . 0.0 110.531 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.477 ' O ' ' O ' ' A' ' 138' ' ' HIS . 22.9 m -148.28 141.05 18.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.478 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.109 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.546 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 15.8 t60 -30.25 151.5 0.0 OUTLIER 'General case' 0 C--O 1.224 -0.254 0 CA-C-O 120.989 0.424 . . . . 0.0 112.05 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 29.6 p30 . . . . . 0 C--N 1.32 -0.683 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.674 -179.342 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.446 ' SG ' ' CD ' ' A' ' 51' ' ' GLN . 39.4 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 0.464 HD11 HD11 ' A' ' 130' ' ' LEU . 76.5 mt -109.34 136.42 48.8 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.906 0.384 . . . . 0.0 110.338 -179.636 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -83.32 162.75 21.01 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.519 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 -62.74 141.1 58.72 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.115 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 112.87 -17.67 22.5 Favored Glycine 0 C--N 1.335 0.517 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.545 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 14.4 m -68.91 120.43 14.8 Favored 'General case' 0 CA--C 1.517 -0.315 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.534 -179.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.424 ' HG2' ' HE ' ' A' ' 18' ' ' ARG . 85.9 mtm180 -94.6 114.59 26.57 Favored 'General case' 0 N--CA 1.456 -0.141 0 C-N-CA 120.607 -0.437 . . . . 0.0 110.47 179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 4.6 mp -102.37 114.87 43.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.915 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 4.6 t80 -77.16 135.41 38.53 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 9.7 t0 -102.79 132.62 21.05 Favored Pre-proline 0 CA--C 1.541 0.622 0 C-N-CA 120.832 -0.347 . . . . 0.0 110.647 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -73.22 -30.95 9.94 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 122.672 2.248 . . . . 0.0 112.37 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.512 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 47.1 t -71.31 -55.02 15.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.737 -179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 19.0 p -78.19 -37.0 46.65 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.043 0.449 . . . . 0.0 110.271 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.03 9.29 82.68 Favored Glycine 0 CA--C 1.52 0.389 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -107.23 -168.73 1.43 Allowed 'General case' 0 C--N 1.34 0.171 0 CA-C-N 117.621 0.71 . . . . 0.0 109.501 -179.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 63.7 m -113.6 117.34 31.34 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.259 179.733 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 58.9 m170 -103.46 143.59 32.51 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.341 -179.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.424 ' HE ' ' HG2' ' A' ' 7' ' ' ARG . 23.2 mmt85 -96.59 126.08 41.52 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.64 179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.457 ' CG2' ' N ' ' A' ' 20' ' ' GLU . 0.4 OUTLIER -51.4 -42.54 28.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 CA-C-O 121.213 0.53 . . . . 0.0 111.19 -177.668 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.457 ' N ' ' CG2' ' A' ' 19' ' ' ILE . 4.5 pt-20 -58.72 -32.08 68.88 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.153 -0.93 . . . . 0.0 110.823 -177.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.5 t0 -83.81 -38.49 21.19 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.236 -0.893 . . . . 0.0 112.29 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 86.6 t -64.65 -40.8 90.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.337 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 50.3 t -73.51 -44.58 53.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 112.047 0.388 . . . . 0.0 112.047 -179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 98.6 m-20 -57.52 -37.94 73.86 Favored 'General case' 0 CA--C 1.513 -0.472 0 C-N-CA 120.823 -0.351 . . . . 0.0 111.227 -177.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.568 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.2 29.37 9.27 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.568 ' C ' ' O ' ' A' ' 25' ' ' GLY . 89.1 mtt-85 16.12 65.36 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.276 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 72.7 mttt -87.31 113.99 56.5 Favored Pre-proline 0 N--CA 1.449 -0.491 0 O-C-N 123.434 0.459 . . . . 0.0 111.177 -176.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -58.6 89.43 0.06 OUTLIER 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.159 1.906 . . . . 0.0 110.414 178.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 33.6 pt -114.51 -172.32 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-O 120.867 0.365 . . . . 0.0 110.497 -179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.425 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 52.4 m80 -127.94 160.63 31.27 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.598 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.9 m -149.41 172.0 1.7 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.325 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 14.2 t -90.93 136.05 25.12 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.406 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.373 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -113.7 167.77 10.34 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.763 179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -136.0 143.24 44.69 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.325 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.01 177.7 4.55 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.938 -0.573 . . . . 0.0 109.653 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -70.0 -13.63 62.32 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 110.658 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -80.13 -18.21 50.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.453 179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.89 24.16 39.14 Favored Glycine 0 CA--C 1.522 0.475 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.6 p -103.06 136.83 42.15 Favored 'General case' 0 N--CA 1.463 0.207 0 O-C-N 122.724 -0.28 . . . . 0.0 111.281 178.436 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 68.3 mt -94.22 130.67 40.37 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.819 0.343 . . . . 0.0 110.648 179.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 7.1 t-160 -142.36 139.24 31.69 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.838 -179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.91 139.95 53.04 Favored 'General case' 0 CA--C 1.509 -0.615 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.555 -178.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.487 ' CZ ' ' OE1' ' A' ' 126' ' ' GLU . 14.5 mmt180 -142.92 140.35 17.99 Favored Pre-proline 0 CA--C 1.538 0.513 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.376 -179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -78.37 157.03 29.28 Favored 'Trans proline' 0 N--CA 1.491 1.324 0 C-N-CA 122.757 2.305 . . . . 0.0 113.019 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -99.57 134.87 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.309 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.067 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 35.8 m -125.6 0.23 4.82 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.645 -179.06 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.1 141.99 25.8 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 119.144 0.884 . . . . 0.0 108.912 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.592 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -139.39 120.74 14.93 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 107.299 -1.371 . . . . 0.0 107.299 178.398 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -139.22 145.86 39.77 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.318 -179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -89.95 133.52 34.74 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 108.045 -1.095 . . . . 0.0 108.045 176.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.545 HE21 ' HB2' ' A' ' 121' ' ' ASP . 27.3 mm-40 -92.75 -1.98 56.36 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.653 -0.249 . . . . 0.0 111.298 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.425 ' O ' ' OG1' ' A' ' 119' ' ' THR . . . 87.66 175.76 48.35 Favored Glycine 0 C--N 1.339 0.698 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 179.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 19.0 m -90.44 118.67 30.1 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -141.95 172.6 12.46 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.939 -179.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . 0.425 ' OD1' ' O ' ' A' ' 115' ' ' ARG . 99.5 m-20 -75.32 141.57 43.37 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.102 -0.953 . . . . 0.0 109.889 -179.696 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 35.1 m -141.85 157.67 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.494 ' CG2' HG22 ' A' ' 114' ' ' THR . 45.5 pt -112.79 153.47 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.206 179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.32 139.26 14.5 Favored Glycine 0 N--CA 1.465 0.577 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 38.2 mt -120.41 112.35 18.88 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.143 0.497 . . . . 0.0 110.464 -179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -89.39 111.43 22.29 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.555 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.558 ' O ' ' N ' ' A' ' 63' ' ' GLY . 16.8 mm -99.95 126.3 53.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.737 -179.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.53 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 35.98 25.6 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 O-C-N 123.879 0.737 . . . . 0.0 110.782 -178.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 70.86 -23.83 0.53 Allowed Glycine 0 CA--C 1.53 0.998 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 -179.084 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.53 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.24 -106.71 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.37 170.49 10.2 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 120.948 0.404 . . . . 0.0 110.311 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.453 HG22 ' N ' ' A' ' 67' ' ' LEU . 96.6 mt -124.89 155.01 33.2 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.462 179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.453 ' N ' HG22 ' A' ' 66' ' ' ILE . 47.1 tp -132.08 116.5 17.13 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.118 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 91.3 m95 -104.63 115.54 30.52 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 178.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.18 172.49 12.62 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -77.62 156.87 80.41 Favored Pre-proline 0 C--N 1.327 -0.401 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.901 179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 27.6 Cg_endo -61.68 -21.65 72.59 Favored 'Trans proline' 0 N--CA 1.494 1.538 0 C-N-CA 122.649 2.233 . . . . 0.0 111.826 179.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 24.5 p30 -93.09 -4.83 51.66 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 116.462 -0.335 . . . . 0.0 110.248 179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.533 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.5 t60 -72.27 129.56 38.72 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 60.8 mttm -86.19 127.47 34.74 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-O 121.277 0.56 . . . . 0.0 110.251 -179.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.827 ' O ' HG23 ' A' ' 77' ' ' THR . 91.2 t -108.26 92.39 2.06 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.117 -179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 75' ' ' VAL . 9.6 tp -31.01 93.59 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.644 0.59 . . . . 0.0 111.442 -179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.827 HG23 ' O ' ' A' ' 75' ' ' VAL . 29.9 p -98.34 177.19 5.44 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.122 -0.49 . . . . 0.0 109.747 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.524 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 6.0 pt-20 -65.05 -21.36 66.82 Favored 'General case' 0 N--CA 1.446 -0.645 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.232 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.524 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 57.8 m-85 -104.47 25.09 10.64 Favored 'General case' 0 CA--C 1.52 -0.177 0 CA-C-O 120.459 0.171 . . . . 0.0 110.905 -179.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.445 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.22 -176.07 41.73 Favored Glycine 0 C--N 1.334 0.421 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 86.3 m95 -58.62 129.68 43.24 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 115.358 -0.421 . . . . 0.0 110.696 -177.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 73.4 mtm180 -145.9 134.55 22.21 Favored 'General case' 0 C--N 1.339 0.118 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.063 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.27 141.11 24.75 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.04 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.5 -36.98 84.27 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.143 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.73 -1.44 2.7 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 120.694 -0.765 . . . . 0.0 111.672 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.7 mt-10 -108.16 6.58 26.92 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.85 0.357 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 88.9 mt -85.1 125.95 33.2 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.262 0.553 . . . . 0.0 110.975 -179.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.553 ' O ' ' N ' ' A' ' 90' ' ' GLY . 25.2 mmt85 -130.5 147.53 52.2 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.584 -179.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.1 tttm -45.89 88.22 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 120.897 0.38 . . . . 0.0 110.632 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.553 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.0 -16.82 0.37 Allowed Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -86.23 130.88 34.37 Favored 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.885 0.374 . . . . 0.0 110.419 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.67 135.25 34.03 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.467 -179.199 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 15.0 m -120.43 152.02 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.52 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -64.3 139.64 58.79 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 120.906 0.384 . . . . 0.0 111.164 -179.567 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.73 HG21 ' OG ' ' A' ' 106' ' ' SER . 26.9 m -138.55 156.7 29.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.391 178.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 61.6 ttp180 -106.09 130.65 53.95 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 120.679 0.276 . . . . 0.0 110.317 179.355 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 27.3 t0 -101.63 125.86 48.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-N 116.41 -0.359 . . . . 0.0 110.581 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.432 HG22 ' O ' ' A' ' 98' ' ' VAL . 7.4 p -73.94 -14.74 16.44 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 118.203 0.456 . . . . 0.0 111.279 178.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -67.85 -60.38 2.56 Favored 'General case' 0 C--N 1.331 -0.211 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.822 -179.106 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.571 ' HB ' ' OE1' ' A' ' 102' ' ' GLU . 53.3 m -103.39 -12.9 16.89 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.251 179.603 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 80.39 -11.19 39.35 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 120.827 -0.702 . . . . 0.0 111.995 177.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.703 ' OE1' ' N ' ' A' ' 102' ' ' GLU . 0.0 OUTLIER -77.18 158.8 30.15 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-O 121.558 0.694 . . . . 0.0 112.161 -179.149 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.52 HD21 ' HB1' ' A' ' 94' ' ' ALA . 5.9 tp -83.07 133.08 35.09 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.824 -179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.514 ' O ' HG22 ' A' ' 95' ' ' VAL . 85.0 mtp180 -133.9 172.87 12.2 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.997 -0.372 . . . . 0.0 109.997 179.615 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 8.3 m-30 -109.46 142.25 40.74 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.389 -178.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.73 ' OG ' HG21 ' A' ' 95' ' ' VAL . 6.7 m -134.43 154.39 51.41 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 7.3 p -92.37 155.15 3.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-O 120.893 0.378 . . . . 0.0 110.864 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 63.1 mt -73.44 153.05 7.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.836 178.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.8 mmm180 -108.29 -43.24 4.4 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.021 179.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -164.69 141.82 6.26 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.472 ' C ' HD22 ' A' ' 112' ' ' LEU . 16.5 t -95.13 134.09 33.74 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.034 179.419 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.472 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.3 mm? -101.97 125.46 36.78 Favored Pre-proline 0 CA--C 1.538 0.509 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.418 -179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -47.88 163.72 0.2 Allowed 'Trans proline' 0 N--CA 1.49 1.323 0 C-N-CA 122.217 1.945 . . . . 0.0 111.831 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.494 HG22 ' CG2' ' A' ' 57' ' ' ILE . 61.4 p -68.04 156.78 36.64 Favored 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 121.089 0.471 . . . . 0.0 110.812 -179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' O ' ' OD1' ' A' ' 55' ' ' ASP . 42.4 ttm-85 -139.64 -136.94 0.12 Allowed 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.974 -179.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.0 tpt180 -158.97 131.16 6.66 Favored 'General case' 0 N--CA 1.45 -0.437 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.411 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.33 172.8 3.68 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.071 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 89.0 mtm180 -76.18 145.75 39.64 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.756 -0.656 . . . . 0.0 109.871 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.425 ' OG1' ' O ' ' A' ' 52' ' ' GLY . 3.9 p -122.63 141.49 51.67 Favored 'General case' 0 N--CA 1.463 0.175 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.222 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CB ' HD12 ' A' ' 19' ' ' ILE . 83.5 m-85 -119.66 174.04 6.65 Favored 'General case' 0 CA--C 1.512 -0.517 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.215 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.545 ' HB2' HE21 ' A' ' 51' ' ' GLN . 43.2 t0 -156.18 125.72 6.29 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.709 -0.678 . . . . 0.0 111.389 179.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 76.5 mt -119.54 121.7 39.98 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 178.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -86.73 115.28 24.06 Favored 'General case' 0 CA--C 1.512 -0.491 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.127 -177.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 46.3 t -89.53 117.89 33.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.542 ' O ' ' N ' ' A' ' 127' ' ' LEU . 40.0 tt0 -58.26 156.05 10.55 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.505 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.487 ' OE1' ' CZ ' ' A' ' 43' ' ' ARG . 91.0 mt-10 56.24 -69.16 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.29 -0.868 . . . . 0.0 112.395 -179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.542 ' N ' ' O ' ' A' ' 125' ' ' GLU . 95.9 mt -98.27 101.23 12.62 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.532 ' O ' HG23 ' A' ' 129' ' ' THR . 39.6 m80 -72.3 99.61 2.44 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 178.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 166.04 143.86 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.969 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.641 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.2 pp -144.38 152.86 41.3 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 121.182 0.515 . . . . 0.0 111.293 -179.53 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.444 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.0 p -87.67 128.15 40.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -178.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.545 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.32 128.28 35.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.43 -0.804 . . . . 0.0 109.935 -179.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 72.9 mm-40 52.46 47.23 25.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.204 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.87 -18.43 0.47 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.7 t -90.59 151.02 3.56 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.209 0 CA-C-N 117.169 0.485 . . . . 0.0 110.287 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 62.1 t -106.41 112.98 41.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' A' ' 138' ' ' HIS . 17.4 m -147.77 138.23 17.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.366 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.424 179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.533 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 7.7 t60 -35.46 155.67 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.152 0 CA-C-O 120.747 0.308 . . . . 0.0 111.62 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 14.1 p30 . . . . . 0 C--N 1.322 -0.629 0 CA-C-O 118.108 -0.949 . . . . 0.0 110.659 -179.415 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.755 ' CB ' HE22 ' A' ' 51' ' ' GLN . 11.9 m . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 91.2 mt -122.72 131.85 53.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.837 -179.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -85.78 162.72 18.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.525 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -62.18 141.46 58.18 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.442 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 113.94 -15.45 21.23 Favored Glycine 0 C--N 1.338 0.657 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.495 HG23 ' HG2' ' A' ' 133' ' ' GLU . 22.6 m -71.24 120.02 16.21 Favored 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.632 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 74.3 mtm180 -93.27 115.96 28.54 Favored 'General case' 0 CA--C 1.518 -0.255 0 CA-C-O 120.908 0.385 . . . . 0.0 110.322 179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 57.5 mt -99.9 112.49 32.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.77 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 9' ' ' PHE . 3.5 t80 -77.76 135.77 38.05 Favored 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.555 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.7 t0 -102.32 131.71 22.24 Favored Pre-proline 0 CA--C 1.542 0.66 0 C-N-CA 120.793 -0.363 . . . . 0.0 111.046 179.707 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -73.43 -32.5 7.94 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.577 2.184 . . . . 0.0 112.136 179.31 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.555 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 54.0 t -69.7 -52.88 27.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.222 179.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 m -79.02 -40.01 32.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.003 0.43 . . . . 0.0 110.385 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.87 9.77 82.17 Favored Glycine 0 N--CA 1.453 -0.205 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.896 HG22 ' H ' ' A' ' 16' ' ' THR . 12.7 m -104.19 -174.5 2.56 Favored 'General case' 0 C--N 1.338 0.086 0 CA-C-N 117.68 0.74 . . . . 0.0 109.613 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.896 ' H ' HG22 ' A' ' 15' ' ' THR . 88.1 m -112.23 118.97 36.76 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.068 179.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 78.3 m-70 -113.43 151.8 30.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.477 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 66.3 mtt85 -100.27 128.77 46.27 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.607 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.423 HG23 ' N ' ' A' ' 20' ' ' GLU . 4.0 tt -52.28 -38.96 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-O 120.924 0.392 . . . . 0.0 111.2 -179.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.423 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.2 pt-20 -60.78 -34.14 74.04 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.167 0.508 . . . . 0.0 110.771 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.575 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 7.1 t70 -85.31 -38.29 18.99 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.352 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 69.0 t -69.71 -42.71 80.36 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.9 -179.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.512 ' CG2' HD21 ' A' ' 122' ' ' LEU . 34.1 t -76.14 -47.83 30.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 N-CA-C 112.328 0.492 . . . . 0.0 112.328 -178.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.578 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 33.1 p-10 -56.53 -30.77 63.45 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-O 120.987 0.423 . . . . 0.0 110.603 -177.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' N ' ' OD1' ' A' ' 24' ' ' ASP . . . -109.64 21.49 25.71 Favored Glycine 0 CA--C 1.516 0.146 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.52 ' C ' ' O ' ' A' ' 25' ' ' GLY . 43.1 ptt85 21.79 61.65 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.202 0 O-C-N 124.309 0.652 . . . . 0.0 109.324 179.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -79.02 134.65 59.52 Favored Pre-proline 0 N--CA 1.446 -0.658 0 C-N-CA 120.676 -0.41 . . . . 0.0 111.049 -177.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -76.04 81.35 2.44 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.305 2.003 . . . . 0.0 111.247 179.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.6 pt -118.33 -169.72 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.499 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.444 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 54.3 m80 -128.35 164.53 22.44 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.826 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.6 m -148.47 171.79 2.25 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.401 0 N-CA-C 109.411 -0.588 . . . . 0.0 109.411 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 74.6 t -90.81 131.6 37.55 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.488 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.11 167.83 9.45 Favored 'General case' 0 C--N 1.319 -0.726 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.205 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.62 141.81 39.12 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.912 -179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.76 177.73 4.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.225 -0.443 . . . . 0.0 109.909 179.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -70.43 -12.62 61.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 CA-C-O 120.93 0.395 . . . . 0.0 110.609 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 37' ' ' ASP . 64.6 t0 -81.32 -18.77 44.59 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.88 23.07 43.24 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 111.043 -0.823 . . . . 0.0 111.043 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.2 p -102.59 136.5 42.3 Favored 'General case' 0 C--O 1.231 0.115 0 CA-C-O 120.81 0.338 . . . . 0.0 111.012 178.526 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 77.9 mt -91.24 128.64 37.14 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.835 179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 11.3 m-70 -138.98 137.84 36.73 Favored 'General case' 0 C--O 1.219 -0.52 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.596 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.486 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -70.16 140.56 52.6 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.777 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.486 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.4 mmp_? -144.04 138.8 15.31 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.665 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -77.56 158.21 32.31 Favored 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 123.001 2.468 . . . . 0.0 113.142 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 58.3 t -101.34 136.46 33.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 16.4 m -127.89 3.01 3.31 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.745 0 CA-C-N 115.771 -0.649 . . . . 0.0 111.554 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.464 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -152.5 149.54 28.64 Favored 'General case' 0 N--CA 1.442 -0.849 0 CA-C-N 119.426 1.012 . . . . 0.0 108.585 179.732 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.503 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -149.31 127.04 11.72 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.355 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 -140.02 148.43 41.83 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.708 0.632 . . . . 0.0 112.708 -179.295 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.446 ' OD2' ' N ' ' A' ' 52' ' ' GLY . 15.1 t70 -105.84 138.58 41.8 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.755 HE22 ' CB ' ' A' ' 1' ' ' CYS . 1.4 mt-30 -101.77 2.97 39.01 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.489 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.446 ' N ' ' OD2' ' A' ' 50' ' ' ASP . . . 85.15 -165.05 39.13 Favored Glycine 0 CA--C 1.526 0.741 0 C-N-CA 120.738 -0.744 . . . . 0.0 111.415 178.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.439 HG22 ' NH2' ' A' ' 116' ' ' ARG . 20.9 m -87.16 127.72 35.14 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -148.82 160.79 42.9 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.821 -179.729 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -75.79 139.73 41.95 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.05 -179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.77 156.07 22.66 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.178 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 46.4 pt -107.8 149.37 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.359 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -102.38 142.68 15.67 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 110.711 -0.956 . . . . 0.0 110.711 179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 75.8 mt -127.9 114.73 17.56 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.2 0.524 . . . . 0.0 110.654 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 56.6 ttp180 -96.66 122.45 39.6 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.526 HG22 ' N ' ' A' ' 62' ' ' ALA . 55.1 mt -117.91 160.97 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 -179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.526 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -53.14 -27.04 19.0 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.777 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.49 -15.43 0.46 Allowed Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.751 -0.939 . . . . 0.0 110.751 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.449 ' N ' ' C ' ' A' ' 62' ' ' ALA . . . 87.28 -18.39 37.32 Favored Glycine 0 C--N 1.335 0.48 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.89 170.48 9.65 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-O 120.797 0.332 . . . . 0.0 110.117 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 95.1 mt -122.65 151.06 26.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.236 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -126.56 115.69 19.91 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.931 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 96.1 m95 -105.41 116.34 31.77 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -143.04 171.78 13.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.397 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -79.41 156.2 76.1 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.616 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -62.26 -17.48 57.27 Favored 'Trans proline' 0 N--CA 1.494 1.546 0 C-N-CA 122.597 2.198 . . . . 0.0 111.882 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -95.9 -6.71 38.58 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.742 0.306 . . . . 0.0 110.38 179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 6.4 t60 -69.03 127.46 33.23 Favored 'General case' 0 CA--C 1.519 -0.249 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 29.7 mmtp -85.97 128.19 34.79 Favored 'General case' 0 N--CA 1.451 -0.408 0 CA-C-O 121.207 0.527 . . . . 0.0 110.902 -179.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 57.6 t -103.31 141.29 19.42 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.341 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 56.3 tp -78.0 93.29 4.44 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.886 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.494 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 76.1 p -98.33 173.66 6.87 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 -178.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 21.4 pt-20 -63.7 -16.24 60.54 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-N 116.431 -0.349 . . . . 0.0 111.367 -179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 17.9 m-85 -108.06 25.65 11.34 Favored 'General case' 0 C--O 1.233 0.209 0 CA-C-O 120.616 0.246 . . . . 0.0 110.82 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 87.58 -176.1 46.1 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 111.254 -0.739 . . . . 0.0 111.254 179.551 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.7 m95 -58.64 133.12 55.61 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-O 121.206 0.527 . . . . 0.0 110.478 -177.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 92.8 mtt180 -146.11 134.73 22.17 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.666 -179.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.99 137.98 31.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.08 -179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.402 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -62.3 -37.9 87.32 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 121.057 -0.257 . . . . 0.0 111.222 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.32 -2.42 3.02 Favored Glycine 0 C--N 1.335 0.503 0 C-N-CA 120.95 -0.643 . . . . 0.0 111.734 -179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.402 ' H ' ' C ' ' A' ' 84' ' ' ALA . 79.8 mm-40 -108.17 11.51 27.41 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 120.918 0.389 . . . . 0.0 110.321 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 95.0 mt -92.93 128.15 38.7 Favored 'General case' 0 CA--C 1.519 -0.249 0 CA-C-O 121.465 0.65 . . . . 0.0 111.072 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.572 ' O ' ' N ' ' A' ' 90' ' ' GLY . 14.8 tpt180 -130.51 149.52 52.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 114.95 -1.023 . . . . 0.0 110.976 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -45.76 86.57 0.0 OUTLIER 'General case' 0 C--O 1.233 0.21 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.557 179.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.572 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 157.77 -14.83 0.29 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -85.02 131.78 34.42 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.707 -0.29 . . . . 0.0 110.29 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -89.21 130.74 35.58 Favored 'General case' 0 C--N 1.33 -0.272 0 C-N-CA 120.484 -0.487 . . . . 0.0 110.434 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.0 m -116.64 146.35 21.17 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.584 179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.452 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -71.64 137.55 47.98 Favored 'General case' 0 N--CA 1.451 -0.378 0 CA-C-O 120.704 0.288 . . . . 0.0 111.073 -179.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.17 161.92 38.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.004 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.2 ttt180 -103.5 130.98 50.99 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.526 -0.307 . . . . 0.0 110.508 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.543 ' OD2' ' NH2' ' A' ' 104' ' ' ARG . 42.5 t0 -100.62 123.96 45.54 Favored 'General case' 0 C--O 1.223 -0.332 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.491 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.33 -16.65 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.811 0 CA-C-N 118.297 0.499 . . . . 0.0 111.261 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 7.1 tm-20 -71.26 -58.27 3.7 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.139 -179.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.8 p -95.18 -15.02 23.61 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-N 116.651 -0.25 . . . . 0.0 110.34 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.99 -13.98 5.07 Favored Glycine 0 C--N 1.336 0.53 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 98.2 mt-10 -81.49 159.87 24.09 Favored 'General case' 0 CA--C 1.514 -0.418 0 CA-C-O 120.755 0.312 . . . . 0.0 110.758 -177.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.452 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.7 tp -85.32 128.79 34.83 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.163 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.543 ' NH2' ' OD2' ' A' ' 97' ' ' ASP . 16.5 ptp180 -127.24 175.81 7.88 Favored 'General case' 0 CA--C 1.519 -0.248 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.33 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.494 ' OH ' ' C ' ' A' ' 77' ' ' THR . 0.8 OUTLIER -114.68 147.26 39.88 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.835 179.877 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -144.23 163.06 34.76 Favored 'General case' 0 CA--C 1.519 -0.227 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.413 ' H ' HG22 ' A' ' 107' ' ' VAL . 9.4 m -94.79 155.85 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.267 0 CA-C-O 120.674 0.273 . . . . 0.0 110.483 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.468 HG22 ' N ' ' A' ' 109' ' ' ARG . 68.1 mt -73.08 159.43 5.75 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-O 120.97 0.414 . . . . 0.0 110.303 179.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.468 ' N ' HG22 ' A' ' 108' ' ' ILE . 24.9 mmt180 -105.26 -44.97 4.61 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.853 -0.612 . . . . 0.0 111.192 178.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 49.9 tp10 -165.23 143.55 6.27 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.497 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.9 p -96.19 134.86 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.497 HD22 ' C ' ' A' ' 111' ' ' VAL . 2.6 mm? -104.06 147.69 34.71 Favored Pre-proline 0 C--O 1.233 0.201 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.331 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.34 166.66 27.57 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 122.533 2.155 . . . . 0.0 111.357 179.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 21.8 p -66.12 151.56 46.65 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-O 121.21 0.528 . . . . 0.0 110.689 179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 22.7 ttt180 -133.86 -148.48 0.33 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.1 -0.955 . . . . 0.0 111.092 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.439 ' NH2' HG22 ' A' ' 53' ' ' THR . 25.7 mmm180 -148.88 127.62 12.52 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.147 -179.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -174.61 175.52 2.48 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.756 -178.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 84.6 mtt85 -79.48 147.03 32.4 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.928 179.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 4.2 p -121.12 140.81 51.48 Favored 'General case' 0 CA--C 1.52 -0.192 0 CA-C-O 121.1 0.476 . . . . 0.0 109.747 179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.542 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 58.3 m-85 -114.9 168.02 10.28 Favored 'General case' 0 CA--C 1.512 -0.487 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.921 -179.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.599 ' C ' HD22 ' A' ' 122' ' ' LEU . 66.4 t0 -147.47 131.16 16.91 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.219 -178.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.599 HD22 ' C ' ' A' ' 121' ' ' ASP . 4.5 mm? -114.62 163.88 14.81 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.486 -179.635 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -135.1 104.84 6.08 Favored 'General case' 0 CA--C 1.515 -0.366 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.017 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 17.4 t -91.93 120.7 41.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.418 ' O ' ' N ' ' A' ' 127' ' ' LEU . 75.7 tt0 -62.69 152.9 34.13 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.83 -179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 74.5 tt0 62.17 -70.57 0.05 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.81 179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.418 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -99.96 104.45 16.07 Favored 'General case' 0 CA--C 1.515 -0.387 0 N-CA-C 110.338 -0.245 . . . . 0.0 110.338 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.548 ' O ' HG23 ' A' ' 129' ' ' THR . 62.3 m80 -73.99 100.2 3.49 Favored 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 178.675 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 165.89 144.67 0.02 OUTLIER 'General case' 0 C--N 1.344 0.35 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.634 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.43 155.5 43.77 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-O 121.759 0.79 . . . . 0.0 111.566 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 34.8 t -84.88 125.14 40.35 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 N-CA-C 107.659 -1.238 . . . . 0.0 107.659 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.473 ' HB1' HG21 ' A' ' 6' ' ' THR . . . -131.88 125.73 32.45 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.052 -179.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.525 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 50.36 46.47 25.11 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.939 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.17 -17.24 0.43 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.525 ' H ' ' C ' ' A' ' 133' ' ' GLU . 12.1 t -92.34 150.94 3.68 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 O-C-N 122.285 -0.538 . . . . 0.0 110.727 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 99.9 t -104.19 114.35 43.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.676 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.438 ' O ' HG23 ' A' ' 137' ' ' VAL . 18.0 m -146.74 132.14 12.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.315 179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.517 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 50.2 t-80 -37.21 159.86 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.74 0.305 . . . . 0.0 111.74 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.485 ' N ' ' CG ' ' A' ' 138' ' ' HIS . 21.1 p30 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.872 -1.061 . . . . 0.0 110.388 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 61.9 m . . . . . 0 N--CA 1.489 1.504 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 73.0 mt -106.9 138.44 43.07 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.484 -0.326 . . . . 0.0 110.415 -179.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.87 164.13 20.71 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.85 -179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 17.2 tt0 -64.02 145.41 55.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.233 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 105.03 -17.6 44.43 Favored Glycine 0 CA--C 1.522 0.502 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 23.6 m -67.67 123.93 21.86 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 179.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.437 ' HE ' HG21 ' A' ' 16' ' ' THR . 61.0 mtp180 -81.62 147.78 29.4 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-O 120.829 0.347 . . . . 0.0 110.263 179.802 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.416 HD11 ' HB ' ' A' ' 19' ' ' ILE . 90.3 mt -134.46 106.4 7.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.857 179.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.4 t80 -77.52 133.5 38.52 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 178.238 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 17.1 t0 -106.49 129.62 24.2 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.44 -26.4 24.42 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.119 1.88 . . . . 0.0 112.512 -179.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.509 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 38.9 t -78.34 -53.1 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 115.934 -0.575 . . . . 0.0 111.016 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.8 p -79.97 -34.63 38.5 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 120.975 0.417 . . . . 0.0 110.134 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.94 9.5 86.64 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 111.398 -0.681 . . . . 0.0 111.398 179.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.595 HG22 ' N ' ' A' ' 16' ' ' THR . 87.8 m -113.17 166.73 11.16 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 117.873 0.836 . . . . 0.0 109.65 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.595 ' N ' HG22 ' A' ' 15' ' ' THR . 38.5 m -90.26 116.09 27.98 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.316 0.579 . . . . 0.0 111.321 -179.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -102.12 144.47 30.65 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.153 -0.931 . . . . 0.0 110.147 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 92.2 mtt-85 -98.77 129.84 45.2 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.606 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.492 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.6 tp -52.79 -40.03 33.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.721 0.296 . . . . 0.0 111.154 -179.104 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.492 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -60.56 -34.98 74.95 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.263 0.554 . . . . 0.0 110.11 -179.033 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.76 -40.45 22.64 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.741 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 83.4 t -68.47 -42.58 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 N-CA-C 111.75 0.278 . . . . 0.0 111.75 -179.25 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.4 t -72.21 -46.19 58.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.014 0.375 . . . . 0.0 112.014 -178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 66.8 t0 -58.56 -35.17 71.94 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 121.157 0.503 . . . . 0.0 110.549 -177.938 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.566 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.3 25.45 12.45 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-O 118.853 -0.971 . . . . 0.0 111.049 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.566 ' C ' ' O ' ' A' ' 25' ' ' GLY . 28.2 ptt180 14.03 72.74 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.393 0 CA-C-N 117.427 0.614 . . . . 0.0 109.523 179.219 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 85.0 mttt -87.45 137.61 32.33 Favored Pre-proline 0 N--CA 1.445 -0.705 0 O-C-N 121.673 -0.642 . . . . 0.0 110.925 -175.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -74.52 83.33 1.74 Allowed 'Trans proline' 0 C--N 1.31 -1.465 0 C-N-CA 121.311 1.341 . . . . 0.0 110.618 179.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 41.7 pt -119.51 -170.53 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.811 0.339 . . . . 0.0 110.097 -179.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.426 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 26.3 m80 -131.35 163.55 27.61 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.621 -179.837 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 17.3 m -147.42 170.96 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 85.9 t -87.16 130.88 36.31 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.563 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.239 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -105.23 166.54 10.34 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.599 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.12 141.99 40.18 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 116.23 -0.441 . . . . 0.0 109.848 179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.72 179.31 3.99 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -72.03 -13.63 61.65 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.91 0.386 . . . . 0.0 110.814 179.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.1 t70 -79.51 -21.55 45.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.402 179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 91.46 19.55 41.12 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 -179.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.4 p -99.22 135.61 40.38 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 121.098 0.475 . . . . 0.0 111.01 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.5 mt -91.65 127.72 37.21 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.269 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -137.95 138.94 39.46 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.73 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.06 142.42 50.86 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 120.384 -0.526 . . . . 0.0 109.85 -178.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.597 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.6 mmt180 -144.06 137.47 14.15 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.046 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.35 157.18 33.09 Favored 'Trans proline' 0 N--CA 1.492 1.436 0 C-N-CA 122.631 2.221 . . . . 0.0 112.73 179.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 23.1 t -98.0 135.7 31.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.57 2.88 3.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-N 115.929 -0.578 . . . . 0.0 111.647 -178.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 p -150.69 144.84 25.44 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-N 119.173 0.897 . . . . 0.0 108.844 178.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.1 OUTLIER -144.95 128.97 17.53 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 178.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 86.1 m-85 -136.41 145.03 44.83 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.242 0.544 . . . . 0.0 112.255 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 53.2 p-10 -114.43 141.22 47.95 Favored 'General case' 0 CA--C 1.5 -0.959 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . . . . . . . . . 12.2 mm-40 -110.27 -101.15 0.39 Allowed 'General case' 0 C--N 1.309 -1.168 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.002 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . -173.82 -153.13 9.47 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 114.408 -1.269 . . . . 0.0 112.951 -177.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.1 m -86.32 129.3 34.9 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.1 0.476 . . . . 0.0 111.549 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 74.6 mtm180 -150.48 162.25 40.95 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.498 179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 99.9 m-20 -78.53 138.61 38.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.309 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.1 m -141.21 141.03 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 120.828 0.347 . . . . 0.0 110.281 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.657 HD11 ' HB1' ' A' ' 84' ' ' ALA . 41.1 pt -90.41 145.64 7.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.795 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -101.97 140.53 14.91 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 15.1 mt -125.12 114.09 18.57 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.102 0.477 . . . . 0.0 110.559 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.522 ' C ' HD12 ' A' ' 61' ' ' ILE . 36.0 ttm180 -91.53 112.85 24.94 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.275 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.726 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -105.36 154.06 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.412 -179.487 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.416 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -54.89 -4.22 0.06 Allowed 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.826 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.513 ' H ' HG22 ' A' ' 61' ' ' ILE . . . -70.87 -12.75 71.44 Favored Glycine 0 CA--C 1.521 0.456 0 N-CA-C 110.569 -1.013 . . . . 0.0 110.569 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 86.87 -19.43 29.74 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.771 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.93 171.62 9.16 Favored 'General case' 0 CA--C 1.523 -0.093 0 CA-C-O 120.889 0.376 . . . . 0.0 110.25 -179.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 96.7 mt -119.13 142.0 36.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.24 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.566 HD23 ' C ' ' A' ' 67' ' ' LEU . 4.2 tt -120.41 113.08 19.8 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.197 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.555 ' N ' HD23 ' A' ' 67' ' ' LEU . 99.5 m95 -103.02 127.6 50.19 Favored 'General case' 0 C--N 1.33 -0.251 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.27 172.22 14.19 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.317 -179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -85.19 155.34 60.43 Favored Pre-proline 0 CA--C 1.535 0.38 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.353 179.696 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -63.62 -22.21 70.3 Favored 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.566 2.177 . . . . 0.0 112.012 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 22.9 t0 -91.24 -8.1 49.36 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 120.977 0.418 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.584 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.7 t60 -70.52 127.52 33.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.559 179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 22.7 mtmm -86.11 132.62 33.99 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-O 121.135 0.493 . . . . 0.0 111.159 -179.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.94 148.82 17.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.22 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 25.9 tp -85.37 92.07 8.37 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.794 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.582 ' O ' ' N ' ' A' ' 79' ' ' TYR . 0.1 OUTLIER -107.73 139.92 41.56 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-O 121.16 0.505 . . . . 0.0 110.434 -179.276 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.54 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 67.5 mm-40 60.02 -64.66 0.05 Allowed 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.134 -1.394 . . . . 0.0 111.262 178.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.582 ' N ' ' O ' ' A' ' 77' ' ' THR . 0.3 OUTLIER 179.15 55.71 0.01 OUTLIER 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -179.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 174.32 175.81 42.21 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 119.56 -1.305 . . . . 0.0 111.976 178.143 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 76.4 m95 -91.71 129.31 37.71 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.874 0.368 . . . . 0.0 110.815 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 36.7 ttm180 -145.46 138.53 26.23 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.365 179.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.89 142.74 23.4 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.144 -179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.657 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -65.24 -37.82 88.45 Favored 'General case' 0 N--CA 1.451 -0.383 0 C-N-CA 120.885 -0.326 . . . . 0.0 111.724 -179.573 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.41 5.22 0.17 Allowed Glycine 0 CA--C 1.527 0.839 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.863 -179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 84' ' ' ALA . 96.9 mt-10 -110.57 1.96 18.42 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.888 0.344 . . . . 0.0 110.259 179.298 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 61.3 mt -80.49 130.6 35.25 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 121.484 0.659 . . . . 0.0 111.127 -179.274 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.506 ' O ' ' N ' ' A' ' 90' ' ' GLY . 32.5 mmt180 -129.46 151.2 50.35 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.944 -179.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -51.91 87.19 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.538 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.27 -21.32 0.49 Allowed Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.833 -0.907 . . . . 0.0 110.833 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -73.5 135.93 44.08 Favored 'General case' 0 C--N 1.326 -0.431 0 C-N-CA 120.975 -0.29 . . . . 0.0 110.491 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.5 mtt85 -90.2 132.21 35.61 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-O 120.96 0.41 . . . . 0.0 110.248 -178.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.1 143.74 30.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.502 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.584 ' HB1' HD11 ' A' ' 103' ' ' LEU . . . -65.55 138.07 57.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 120.734 0.302 . . . . 0.0 110.52 -179.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 29.2 m -135.18 158.14 40.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.95 0.405 . . . . 0.0 110.622 179.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 73.2 ttt180 -101.93 129.0 48.09 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.581 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 31.3 t0 -99.84 120.22 39.41 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.18 179.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 42.4 t -74.62 -15.1 16.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 118.387 0.539 . . . . 0.0 110.821 178.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -69.37 -60.09 2.56 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 120.447 -0.501 . . . . 0.0 109.923 -179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.443 ' C ' ' H ' ' A' ' 102' ' ' GLU . 74.5 p -96.2 -10.47 28.02 Favored 'General case' 0 CA--C 1.519 -0.215 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.78 -12.66 5.99 Favored Glycine 0 C--N 1.332 0.332 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 179.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.443 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.7 mt-10 -83.21 158.13 22.43 Favored 'General case' 0 N--CA 1.448 -0.567 0 CA-C-O 120.792 0.33 . . . . 0.0 110.748 -177.622 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.584 HD11 ' HB1' ' A' ' 94' ' ' ALA . 5.2 tt -86.79 130.5 34.45 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.3 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 53.7 ptt85 -127.81 173.16 10.2 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.729 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.54 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.41 143.5 37.25 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.164 -179.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.2 m -141.22 164.15 31.04 Favored 'General case' 0 N--CA 1.463 0.182 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.419 HG12 ' N ' ' A' ' 108' ' ' ILE . 98.2 t -98.1 154.91 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.423 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -70.78 157.1 6.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 121.213 0.53 . . . . 0.0 109.875 179.191 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.423 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 59.8 ttt85 -101.43 -47.34 4.71 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.749 179.274 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -164.62 144.43 7.42 Favored 'General case' 0 C--N 1.341 0.197 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.425 ' C ' HD22 ' A' ' 112' ' ' LEU . 9.7 p -93.0 132.34 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 N-CA-C 110.032 -0.359 . . . . 0.0 110.032 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.425 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 2.6 mm? -102.85 148.03 34.96 Favored Pre-proline 0 N--CA 1.469 0.491 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.426 -178.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -68.71 160.2 50.53 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.606 2.204 . . . . 0.0 110.992 179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 114' ' ' THR . 1.4 p -65.96 155.01 37.81 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.061 0.458 . . . . 0.0 110.318 -178.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 17.2 ptm180 -147.99 143.69 27.44 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.002 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 11.0 mmm180 -71.92 131.01 42.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.964 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.69 168.21 14.58 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.723 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 44.4 ttp180 -81.46 149.72 28.63 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.669 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 50.6 p -133.12 144.38 49.89 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.428 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 2.8 m-85 -121.5 177.95 5.01 Favored 'General case' 0 CA--C 1.513 -0.462 0 CA-C-N 115.716 -0.674 . . . . 0.0 111.475 -178.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -144.22 149.21 36.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.947 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.408 HD11 ' CD1' ' A' ' 19' ' ' ILE . 97.3 mt -138.97 170.14 16.53 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.616 -179.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -137.29 106.66 6.09 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.926 178.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.48 ' O ' ' C ' ' A' ' 125' ' ' GLU . 48.9 t -85.72 113.55 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.708 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.48 ' C ' ' O ' ' A' ' 124' ' ' VAL . 0.3 OUTLIER 21.4 -91.11 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.66 0 O-C-N 123.816 0.698 . . . . 0.0 111.771 -179.923 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.406 ' N ' ' O ' ' A' ' 124' ' ' VAL . 9.0 tp10 -135.23 -27.97 1.18 Allowed 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.658 179.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.597 HD12 ' HE ' ' A' ' 43' ' ' ARG . 83.0 mt -82.13 67.59 8.21 Favored 'General case' 0 CA--C 1.51 -0.59 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.416 ' C ' ' O ' ' A' ' 127' ' ' LEU . 20.6 m170 -39.61 98.37 0.01 OUTLIER 'General case' 0 CA--C 1.513 -0.47 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 179.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 170.89 140.89 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.461 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 179.117 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.533 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.1 pt? -151.15 160.88 43.61 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.69 0.757 . . . . 0.0 112.386 -179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 25.2 t -90.27 124.65 43.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -135.28 124.72 24.87 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 114.788 -1.096 . . . . 0.0 109.941 -179.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.534 ' O ' HG23 ' A' ' 135' ' ' VAL . 13.5 mm-40 53.12 42.53 32.19 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 61.04 28.07 68.24 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.652 178.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -131.58 152.12 36.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 97.6 t -106.67 111.06 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 O-C-N 122.11 -0.369 . . . . 0.0 110.308 179.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.479 ' O ' ' O ' ' A' ' 138' ' ' HIS . 6.5 m -146.14 137.1 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.406 0 CA-C-N 116.638 -0.256 . . . . 0.0 110.48 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.584 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 50.4 t-80 -33.57 156.72 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.565 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.436 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 7.7 p-10 . . . . . 0 C--O 1.221 -0.416 0 CA-C-O 117.912 -1.042 . . . . 0.0 110.363 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.443 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 53.9 m . . . . . 0 N--CA 1.487 1.405 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 67.2 mt -118.38 134.68 54.85 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.728 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.4 ' HB2' ' CD1' ' A' ' 68' ' ' TRP . . . -80.59 161.7 24.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.503 179.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -63.45 145.98 54.53 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 178.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 104.55 -14.38 50.4 Favored Glycine 0 C--N 1.338 0.686 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.442 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.7 m -68.96 123.75 21.87 Favored 'General case' 0 C--O 1.234 0.278 0 O-C-N 122.652 -0.322 . . . . 0.0 110.587 -179.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 18' ' ' ARG . 10.6 mpt_? -83.67 150.62 25.75 Favored 'General case' 0 C--O 1.234 0.281 0 CA-C-O 121.238 0.542 . . . . 0.0 109.857 178.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 99.1 mt -133.89 107.74 10.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.691 179.252 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -77.25 126.57 31.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.525 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.1 t0 -104.91 129.76 24.3 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.828 -0.349 . . . . 0.0 110.982 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -71.79 -31.03 13.54 Favored 'Trans proline' 0 N--CA 1.496 1.631 0 C-N-CA 122.51 2.14 . . . . 0.0 111.989 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 71.1 t -69.13 -55.95 13.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.31 -179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 15.3 p -78.85 -37.58 40.04 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 110.059 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.27 7.99 85.92 Favored Glycine 0 CA--C 1.52 0.345 0 N-CA-C 111.047 -0.821 . . . . 0.0 111.047 179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.461 HG22 ' N ' ' A' ' 16' ' ' THR . 91.6 m -115.61 157.63 23.88 Favored 'General case' 0 C--N 1.341 0.196 0 O-C-N 121.937 -0.743 . . . . 0.0 109.756 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.461 ' N ' HG22 ' A' ' 15' ' ' THR . 15.2 m -78.91 116.95 19.56 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 121.05 0.452 . . . . 0.0 110.982 -179.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 90.5 m-70 -102.24 144.16 31.11 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.371 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.553 ' NH2' ' NH2' ' A' ' 7' ' ' ARG . 39.1 ttm180 -96.53 124.07 40.41 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.324 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.525 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.9 OUTLIER -52.67 -40.37 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 O-C-N 121.992 -0.443 . . . . 0.0 111.426 -178.433 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.525 ' N ' HG23 ' A' ' 19' ' ' ILE . 4.0 pt-20 -56.82 -35.23 68.54 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 120.984 0.421 . . . . 0.0 110.666 -179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -83.22 -39.44 20.93 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.405 -0.816 . . . . 0.0 112.125 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.8 t -66.93 -41.73 87.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.563 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.75 HG22 HD21 ' A' ' 122' ' ' LEU . 71.9 t -72.1 -46.29 59.34 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.274 0 C-N-CA 120.945 -0.302 . . . . 0.0 111.513 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 -57.87 -36.34 72.21 Favored 'General case' 0 CA--C 1.513 -0.465 0 C-N-CA 120.948 -0.301 . . . . 0.0 110.866 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.537 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -103.85 30.13 10.84 Favored Glycine 0 N--CA 1.452 -0.292 0 N-CA-C 110.536 -1.026 . . . . 0.0 110.536 179.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.537 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtt85 15.79 64.33 0.01 OUTLIER 'General case' 0 C--N 1.364 1.207 0 CA-C-N 117.418 0.609 . . . . 0.0 110.254 179.233 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.429 ' C ' ' H ' ' A' ' 29' ' ' ILE . 83.0 mttt -89.78 144.2 31.36 Favored Pre-proline 0 N--CA 1.444 -0.732 0 C-N-CA 120.883 -0.327 . . . . 0.0 110.294 -178.074 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.541 ' O ' ' O ' ' A' ' 29' ' ' ILE . 45.7 Cg_endo -70.21 10.11 0.59 Allowed 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.236 1.957 . . . . 0.0 112.33 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.616 HG22 ' N ' ' A' ' 30' ' ' HIS . 3.7 mm -37.37 168.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 O-C-N 123.718 0.636 . . . . 0.0 110.124 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.616 ' N ' HG22 ' A' ' 29' ' ' ILE . 3.7 m80 -122.68 167.27 13.65 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 120.953 0.406 . . . . 0.0 110.707 -179.607 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 33.9 m -148.63 170.73 2.49 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 21.7 t -89.52 134.65 28.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.246 0 O-C-N 121.675 -0.64 . . . . 0.0 109.624 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.48 166.91 10.61 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.785 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.27 144.99 42.99 Favored 'General case' 0 C--O 1.231 0.124 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.068 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.12 179.0 4.12 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.642 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.431 ' NZ ' ' HE1' ' A' ' 81' ' ' TRP . 68.5 mmtt -68.03 -12.57 61.05 Favored 'General case' 0 C--O 1.235 0.322 0 O-C-N 121.821 -0.549 . . . . 0.0 110.767 179.289 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 43.6 t0 -76.81 -19.41 57.59 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.346 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.04 -7.57 76.34 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.9 p -80.08 150.21 30.37 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.262 0.553 . . . . 0.0 111.203 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 61.9 mt -103.77 135.66 44.9 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.934 -179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -141.11 139.72 34.03 Favored 'General case' 0 C--O 1.223 -0.31 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.701 -179.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.36 140.74 52.22 Favored 'General case' 0 CA--C 1.506 -0.736 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.657 -178.175 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.452 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 1.0 OUTLIER -143.51 137.66 14.73 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.231 179.441 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.452 ' HD3' ' HA ' ' A' ' 43' ' ' ARG . 2.9 Cg_exo -74.78 158.27 43.13 Favored 'Trans proline' 0 N--CA 1.495 1.608 0 C-N-CA 123.105 2.537 . . . . 0.0 112.711 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 70.3 t -98.29 133.59 39.96 Favored 'Isoleucine or valine' 0 C--O 1.235 0.328 0 N-CA-C 107.875 -1.158 . . . . 0.0 107.875 177.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.6 m -125.73 0.14 4.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.215 -179.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.416 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -150.16 145.04 26.05 Favored 'General case' 0 N--CA 1.448 -0.563 0 O-C-N 121.026 -1.046 . . . . 0.0 108.676 179.411 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.584 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.06 123.2 13.68 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 178.095 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -140.94 146.73 37.76 Favored 'General case' 0 N--CA 1.467 0.382 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 50.5 t0 -87.58 133.24 33.83 Favored 'General case' 0 N--CA 1.454 -0.243 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.545 HE21 ' HB2' ' A' ' 121' ' ' ASP . 33.6 mm-40 -89.79 -0.49 57.58 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.705 -0.225 . . . . 0.0 110.86 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 82.73 174.28 50.06 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 97.4 m -91.67 127.43 37.12 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 121.031 0.443 . . . . 0.0 110.354 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.8 ptp180 -154.92 176.2 12.82 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.715 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . 0.445 ' OD1' ' N ' ' A' ' 55' ' ' ASP . 0.6 OUTLIER -74.19 136.57 42.81 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.163 -179.539 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.959 ' CG2' ' HE1' ' A' ' 68' ' ' TRP . 1.5 m -145.4 156.59 13.3 Favored 'Isoleucine or valine' 0 C--N 1.34 0.153 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.536 ' N ' HD13 ' A' ' 57' ' ' ILE . 0.0 OUTLIER -109.14 155.79 10.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 115.921 -0.582 . . . . 0.0 110.845 -178.782 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.77 121.07 5.45 Favored Glycine 0 CA--C 1.521 0.455 0 N-CA-C 110.227 -1.149 . . . . 0.0 110.227 179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 20.7 mt -102.55 116.77 33.28 Favored 'General case' 0 C--O 1.225 -0.219 0 O-C-N 122.381 -0.482 . . . . 0.0 110.133 -179.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.525 ' NH2' ' OE1' ' A' ' 110' ' ' GLU . 55.7 ttp180 -101.09 128.58 47.09 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.161 -179.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.613 HG22 ' N ' ' A' ' 62' ' ' ALA . 91.6 mt -117.63 164.22 14.12 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.613 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -60.34 139.82 57.44 Favored 'General case' 0 N--CA 1.453 -0.286 0 C-N-CA 120.653 -0.419 . . . . 0.0 110.759 -179.374 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.527 ' H ' ' NH2' ' A' ' 109' ' ' ARG . . . 99.99 -9.29 59.81 Favored Glycine 0 CA--C 1.523 0.551 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 102.49 -19.3 48.43 Favored Glycine 0 CA--C 1.525 0.701 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -54.65 119.95 6.03 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 119.915 -0.714 . . . . 0.0 109.087 -178.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.1 tt -121.12 138.79 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.82 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 42.6 tp -126.4 112.5 15.71 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.099 179.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.959 ' HE1' ' CG2' ' A' ' 56' ' ' VAL . 4.3 t-105 -107.71 125.79 51.81 Favored 'General case' 0 N--CA 1.448 -0.557 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.426 ' HB1' ' O ' ' A' ' 1' ' ' CYS . . . -154.85 175.44 13.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.233 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . 0.736 ' HA ' HG12 ' A' ' 56' ' ' VAL . 71.3 p -77.06 154.0 82.64 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.16 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -61.12 -22.21 73.97 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.649 2.233 . . . . 0.0 111.889 179.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 10.1 p30 -91.07 -6.0 54.41 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.577 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.1 t60 -70.96 128.7 36.87 Favored 'General case' 0 CA--C 1.516 -0.333 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 70.5 mmtt -85.34 128.42 34.7 Favored 'General case' 0 N--CA 1.453 -0.285 0 CA-C-O 121.01 0.433 . . . . 0.0 111.304 -179.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -102.8 139.79 22.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.59 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 54.9 tp -79.37 93.41 5.33 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.955 -179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.46 HG21 ' HE ' ' A' ' 82' ' ' ARG . 44.7 p -99.22 175.89 5.73 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -178.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.763 ' N ' ' OH ' ' A' ' 105' ' ' TYR . 3.0 pt-20 -64.94 -17.53 64.46 Favored 'General case' 0 C--N 1.325 -0.48 0 C-N-CA 120.284 -0.567 . . . . 0.0 111.268 -179.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 73.1 m-85 -105.77 25.97 10.18 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 121.125 -0.23 . . . . 0.0 110.811 -178.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.72 -141.13 15.43 Favored Glycine 0 C--N 1.334 0.465 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.431 ' HE1' ' NZ ' ' A' ' 36' ' ' LYS . 87.7 m95 -93.64 129.99 39.73 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.452 -0.374 . . . . 0.0 111.142 -179.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.46 ' HE ' HG21 ' A' ' 77' ' ' THR . 77.4 mtm180 -142.01 131.78 24.22 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.274 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.45 145.76 17.58 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.024 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . . . . . . . . . . . -62.84 -37.67 87.76 Favored 'General case' 0 CA--C 1.517 -0.29 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.124 -179.532 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.1 -2.72 2.97 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.619 -179.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -107.64 10.87 28.95 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-O 120.93 0.395 . . . . 0.0 110.378 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.1 mt -93.51 126.94 38.94 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 121.378 0.608 . . . . 0.0 111.638 -179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.589 ' O ' ' N ' ' A' ' 90' ' ' GLY . 31.6 mmt180 -132.14 151.63 51.68 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.469 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.9 tttm -47.88 85.52 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.35 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.242 -179.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.589 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 160.28 -15.97 0.2 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -84.91 130.32 34.66 Favored 'General case' 0 N--CA 1.461 0.114 0 CA-C-N 116.748 0.274 . . . . 0.0 110.304 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 89.3 mtm-85 -93.37 143.21 26.5 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.275 -178.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.4 m -135.08 158.97 41.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.593 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -75.2 131.62 40.54 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.635 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 6.4 m -129.21 132.88 66.58 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 72.6 ttp85 -74.13 125.62 28.75 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.927 -179.073 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 35.3 t0 -99.7 123.84 44.36 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.182 179.312 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 16.1 t -75.39 -16.84 15.83 Favored 'Isoleucine or valine' 0 C--O 1.236 0.373 0 O-C-N 121.653 -0.654 . . . . 0.0 111.43 178.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -68.97 -59.03 3.33 Favored 'General case' 0 C--O 1.234 0.265 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 -179.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 23.1 p -95.43 -11.97 26.72 Favored 'General case' 0 CA--C 1.514 -0.422 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.56 -13.2 6.73 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 179.305 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.8 mt-10 -87.15 162.81 17.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.942 0.401 . . . . 0.0 110.639 -177.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.623 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.8 pt? -76.35 140.08 41.28 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.173 179.055 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 75.7 mtp180 -133.18 164.32 27.32 Favored 'General case' 0 CA--C 1.515 -0.371 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.211 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.763 ' OH ' ' N ' ' A' ' 78' ' ' GLU . 0.1 OUTLIER -108.38 137.36 46.48 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.114 -178.373 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 15.7 m -144.04 163.03 34.7 Favored 'General case' 0 N--CA 1.456 -0.154 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 107' ' ' VAL . 16.9 m -90.93 154.03 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.605 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.479 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.3 mm -67.94 160.31 4.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.913 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.527 ' NH2' ' H ' ' A' ' 63' ' ' GLY . 37.9 ttm180 -106.87 -51.71 2.89 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.973 179.304 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.525 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 83.1 tt0 -166.93 147.3 5.67 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.796 -0.565 . . . . 0.0 109.739 179.415 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.471 ' C ' HD22 ' A' ' 112' ' ' LEU . 91.8 t -96.77 134.46 34.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.471 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.1 mm? -101.64 131.27 23.13 Favored Pre-proline 0 CA--C 1.538 0.504 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.555 -179.437 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -47.76 158.53 0.74 Allowed 'Trans proline' 0 N--CA 1.489 1.22 0 C-N-CA 121.956 1.771 . . . . 0.0 111.587 178.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.467 ' H ' HG23 ' A' ' 114' ' ' THR . 1.7 p -69.67 157.38 37.36 Favored 'General case' 0 N--CA 1.451 -0.39 0 C-N-CA 120.949 -0.3 . . . . 0.0 110.462 -179.31 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 43.6 mtp85 -154.71 161.62 41.46 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-O 121.789 0.804 . . . . 0.0 111.11 178.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 83.7 mtt180 -85.01 130.21 34.66 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.354 -179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -167.54 167.38 13.62 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.164 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 87.0 mtm180 -81.17 149.92 28.89 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.143 179.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 1.4 p -127.61 143.32 51.18 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.288 0.566 . . . . 0.0 109.931 179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -114.64 171.32 7.71 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.846 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.545 ' HB2' HE21 ' A' ' 51' ' ' GLN . 45.5 t0 -156.24 128.06 7.34 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.977 179.632 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.75 HD21 HG22 ' A' ' 23' ' ' VAL . 94.4 mt -126.0 125.75 43.18 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 120.751 0.31 . . . . 0.0 110.375 179.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 40.6 tp10 -86.67 112.62 21.81 Favored 'General case' 0 CA--C 1.513 -0.468 0 C-N-CA 120.339 -0.544 . . . . 0.0 109.957 -178.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' A' ' 125' ' ' GLU . 21.4 t -85.24 112.41 22.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 CA-C-N 115.987 -0.551 . . . . 0.0 109.55 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.478 ' C ' ' O ' ' A' ' 124' ' ' VAL . 52.8 tt0 24.55 -94.48 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.47 0 O-C-N 123.7 0.625 . . . . 0.0 111.578 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -130.77 -27.97 2.05 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.161 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.502 ' O ' ' N ' ' A' ' 129' ' ' THR . 88.2 mt -77.01 66.9 2.92 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.448 ' O ' HG23 ' A' ' 129' ' ' THR . 47.7 m170 -38.27 95.84 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.333 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.502 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 168.62 139.32 0.02 OUTLIER 'General case' 0 C--O 1.233 0.187 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 179.464 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.678 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.3 pp -147.29 155.61 42.19 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.659 -179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.2 p -88.66 123.19 40.87 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.016 179.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.566 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -131.58 128.78 39.93 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.75 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.537 ' O ' HG23 ' A' ' 135' ' ' VAL . 69.7 mm-40 53.87 45.79 27.04 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.799 -0.637 . . . . 0.0 110.037 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.81 -17.68 0.5 Allowed Glycine 0 CA--C 1.527 0.801 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.22 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.537 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.0 t -90.55 150.41 3.75 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.293 0 O-C-N 122.267 -0.549 . . . . 0.0 110.346 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 66.6 t -109.35 113.63 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.671 0.272 . . . . 0.0 110.423 179.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 138' ' ' HIS . 34.0 m -149.1 143.85 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.479 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.998 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.577 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 47.7 t-80 -27.53 148.86 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.087 0.403 . . . . 0.0 112.087 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.319 -0.751 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.721 -179.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 72.3 mt -112.25 136.32 51.82 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.392 -179.781 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -82.49 161.03 22.52 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.688 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 -62.82 146.22 53.15 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.832 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.66 -15.82 37.67 Favored Glycine 0 C--N 1.335 0.525 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 22.7 m -69.07 121.95 17.74 Favored 'General case' 0 C--O 1.233 0.237 0 C-N-CA 120.83 -0.348 . . . . 0.0 110.653 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -83.87 149.86 26.1 Favored 'General case' 0 N--CA 1.454 -0.252 0 CA-C-O 120.851 0.358 . . . . 0.0 110.108 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 94.4 mt -134.7 107.4 8.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.34 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 28.3 t80 -77.41 129.95 36.45 Favored 'General case' 0 CA--C 1.515 -0.396 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 178.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.634 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 3.7 t70 -103.49 133.2 20.43 Favored Pre-proline 0 CA--C 1.541 0.626 0 C-N-CA 120.741 -0.383 . . . . 0.0 110.594 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.32 -32.64 7.97 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.7 2.267 . . . . 0.0 112.236 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.634 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 68.9 t -69.22 -52.61 31.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.538 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 p -80.88 -37.74 29.26 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 110.07 -0.344 . . . . 0.0 110.07 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.03 9.74 83.85 Favored Glycine 0 C--N 1.331 0.293 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 179.662 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -108.22 -168.17 1.33 Allowed 'General case' 0 C--N 1.341 0.229 0 CA-C-N 117.725 0.763 . . . . 0.0 109.653 -179.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . . . . . . . . . 92.9 m -113.98 116.12 28.72 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.151 0.501 . . . . 0.0 110.283 179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 79.5 m-70 -105.27 147.41 28.11 Favored 'General case' 0 C--O 1.223 -0.335 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.413 -179.585 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 24.2 mmt85 -99.1 127.26 45.02 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.437 -0.347 . . . . 0.0 110.443 179.379 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.471 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.4 tt -53.02 -40.61 37.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 C-N-CA 120.738 -0.385 . . . . 0.0 111.146 -179.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.471 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.1 pt-20 -59.39 -33.83 71.69 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.672 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 67.6 t0 -84.35 -39.81 18.65 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.968 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 71.0 t -67.9 -43.01 86.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 65.2 t -73.57 -46.7 47.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 C-N-CA 120.908 -0.317 . . . . 0.0 111.647 -178.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -60.43 -35.78 76.62 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.929 0.395 . . . . 0.0 111.013 -178.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.547 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -100.25 25.17 29.3 Favored Glycine 0 C--N 1.322 -0.22 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.547 ' C ' ' O ' ' A' ' 25' ' ' GLY . 66.0 mtp180 17.14 59.73 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 109.616 -0.512 . . . . 0.0 109.616 179.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.425 ' N ' ' O ' ' A' ' 25' ' ' GLY . 80.2 mttt -86.94 135.06 35.74 Favored Pre-proline 0 N--CA 1.445 -0.677 0 CA-C-N 116.462 -0.336 . . . . 0.0 110.754 -177.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -75.36 84.89 1.64 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.222 1.948 . . . . 0.0 110.234 178.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.655 ' CG1' ' H ' ' A' ' 30' ' ' HIS . 5.2 tt -115.4 -174.5 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.994 0.426 . . . . 0.0 110.243 -179.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.655 ' H ' ' CG1' ' A' ' 29' ' ' ILE . 46.7 m80 -126.43 161.82 27.02 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.906 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.3 m -147.08 171.21 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.435 0 N-CA-C 109.481 -0.562 . . . . 0.0 109.481 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 92.2 t -89.58 133.0 32.85 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.33 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.12 166.51 11.01 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.695 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.45 145.0 42.58 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.228 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.9 177.94 4.46 Favored 'General case' 0 N--CA 1.464 0.228 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -70.8 -14.0 62.25 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-O 120.848 0.356 . . . . 0.0 110.637 179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.405 ' OD1' ' O ' ' A' ' 37' ' ' ASP . 54.5 t0 -80.03 -18.97 48.77 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.28 179.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 89.56 23.34 34.01 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 111.102 -0.799 . . . . 0.0 111.102 -179.817 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.8 p -102.31 136.11 42.72 Favored 'General case' 0 C--O 1.233 0.201 0 CA-C-O 120.854 0.359 . . . . 0.0 111.168 178.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.447 ' O ' ' CD2' ' A' ' 41' ' ' HIS . 81.2 mt -92.5 128.59 38.41 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.017 0.437 . . . . 0.0 110.607 179.605 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . 0.447 ' CD2' ' O ' ' A' ' 40' ' ' LEU . 32.7 m170 -140.01 138.49 35.49 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.772 -179.591 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -70.07 142.19 52.7 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-N 115.81 -0.632 . . . . 0.0 109.779 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -143.07 138.56 15.86 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.148 -179.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.87 157.28 34.97 Favored 'Trans proline' 0 N--CA 1.489 1.229 0 C-N-CA 122.683 2.255 . . . . 0.0 112.822 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.1 t -98.99 133.7 40.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 177.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 20.0 m -124.98 -0.27 5.28 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.806 -0.634 . . . . 0.0 111.37 -178.644 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.415 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.9 OUTLIER -151.22 146.75 26.3 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.174 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.575 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -143.45 127.51 17.47 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 178.254 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -131.22 144.6 51.45 Favored 'General case' 0 N--CA 1.469 0.479 0 CA-C-O 120.97 0.414 . . . . 0.0 111.643 -178.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.8 t0 -116.08 139.62 50.11 Favored 'General case' 0 CA--C 1.499 -1.012 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 178.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.449 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.3 mm-40 -109.2 -110.82 0.32 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 114.704 -1.134 . . . . 0.0 109.889 -178.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.449 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -162.09 -156.81 8.59 Favored Glycine 0 C--N 1.303 -1.277 0 CA-C-N 114.233 -1.348 . . . . 0.0 112.482 -177.307 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.462 ' O ' HG23 ' A' ' 53' ' ' THR . 4.5 t -98.1 126.75 43.68 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 120.868 0.366 . . . . 0.0 111.178 -179.104 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 91.4 mtt-85 -145.74 172.04 13.87 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.614 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -76.3 136.38 39.6 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.126 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.9 m -140.23 135.88 36.9 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.185 0 CA-C-O 120.942 0.401 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.676 HD11 ' HB1' ' A' ' 84' ' ' ALA . 39.3 pt -87.86 148.79 4.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.717 179.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -108.47 126.8 8.35 Favored Glycine 0 CA--C 1.522 0.507 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.0 mt -108.58 115.84 30.85 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.219 0.533 . . . . 0.0 110.938 -179.275 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 14.4 tpp180 -83.03 104.74 13.46 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.881 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.511 ' O ' ' N ' ' A' ' 63' ' ' GLY . 6.0 mm -89.93 116.31 31.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.242 -178.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.521 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 36.36 28.59 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.29 0 CA-C-N 115.617 -0.72 . . . . 0.0 110.726 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.511 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 72.36 -27.71 0.7 Allowed Glycine 0 CA--C 1.528 0.853 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.74 -106.51 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.526 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 -178.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.64 170.71 9.93 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 120.883 0.373 . . . . 0.0 110.382 -179.589 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 19.6 tt -126.87 155.64 37.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.332 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.0 tp -133.39 118.24 18.2 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.153 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.8 m95 -104.34 114.16 28.21 Favored 'General case' 0 C--N 1.332 -0.177 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 178.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -139.45 171.2 14.6 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.484 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -80.65 157.02 72.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.361 -179.645 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -63.42 -18.13 63.17 Favored 'Trans proline' 0 C--N 1.311 -1.406 0 C-N-CA 122.645 2.23 . . . . 0.0 111.9 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -94.46 -9.99 33.78 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.876 0.37 . . . . 0.0 110.309 179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.545 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.8 t60 -71.01 130.77 42.42 Favored 'General case' 0 C--N 1.331 -0.221 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -87.03 130.61 34.39 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-O 121.148 0.499 . . . . 0.0 111.144 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 61.1 t -105.36 142.29 18.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.273 -0.876 . . . . 0.0 109.875 -179.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 52.9 tp -79.91 93.17 5.63 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.691 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 12.1 p -99.02 177.67 5.17 Favored 'General case' 0 CA--C 1.52 -0.19 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 -178.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -68.09 -19.15 64.83 Favored 'General case' 0 N--CA 1.45 -0.463 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.236 -179.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -104.63 24.1 12.28 Favored 'General case' 0 CA--C 1.517 -0.319 0 CA-C-O 120.733 0.302 . . . . 0.0 110.632 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 89.69 -176.03 42.56 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.444 -0.662 . . . . 0.0 111.444 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 81.2 m95 -57.91 127.76 33.68 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.014 0.435 . . . . 0.0 110.12 -177.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 19.6 mmm-85 -142.36 133.54 26.11 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.888 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -53.44 140.01 29.01 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.675 179.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.676 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.15 -37.87 86.83 Favored 'General case' 0 C--N 1.329 -0.299 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.243 -179.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -63.01 -2.42 4.92 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.696 -0.764 . . . . 0.0 111.526 -179.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 71.0 mm-40 -106.0 -0.65 24.77 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-O 121.02 0.438 . . . . 0.0 110.418 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 89.9 mt -81.55 127.79 33.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.151 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.548 ' O ' ' N ' ' A' ' 90' ' ' GLY . 8.9 tpp180 -131.01 149.75 52.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.179 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.0 tttm -45.5 89.04 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.245 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.644 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.05 -15.72 0.43 Allowed Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 -179.826 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 -86.39 130.15 34.61 Favored 'General case' 0 CA--C 1.523 -0.085 0 CA-C-O 121.023 0.44 . . . . 0.0 110.381 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -90.73 131.3 36.49 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.37 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 26.8 m -116.93 150.35 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.227 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.39 136.09 47.58 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.004 -179.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.559 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.1 m -133.85 161.77 40.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.33 179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 67.9 ttt-85 -104.67 128.37 52.7 Favored 'General case' 0 N--CA 1.462 0.14 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 -179.829 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -100.92 123.49 45.2 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.082 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.401 ' H ' HG22 ' A' ' 98' ' ' VAL . 28.1 m -75.9 -15.4 15.34 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 CA-C-N 118.179 0.445 . . . . 0.0 110.906 179.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -69.59 -58.45 3.93 Favored 'General case' 0 C--O 1.233 0.196 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.06 -179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.437 HG23 ' H ' ' A' ' 102' ' ' GLU . 1.5 t -97.87 -12.4 22.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.269 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.35 -12.84 8.85 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.437 ' H ' HG23 ' A' ' 100' ' ' THR . 43.2 mt-10 -83.25 159.44 21.95 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.79 0.329 . . . . 0.0 110.749 -178.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.589 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -84.02 140.06 32.11 Favored 'General case' 0 N--CA 1.445 -0.704 0 CA-C-O 121.231 0.538 . . . . 0.0 109.934 179.642 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 59.4 mtp180 -137.07 171.91 13.8 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.747 -0.66 . . . . 0.0 110.218 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.8 m-30 -105.56 139.14 40.63 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.954 -178.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.559 ' OG ' HG21 ' A' ' 95' ' ' VAL . 7.9 m -135.96 155.31 50.45 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 179.125 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.406 HG22 ' N ' ' A' ' 108' ' ' ILE . 9.7 p -95.2 157.21 3.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 122.573 0.349 . . . . 0.0 111.116 -179.83 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.406 ' N ' HG22 ' A' ' 107' ' ' VAL . 42.7 mm -82.18 136.68 22.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.003 178.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 14.1 mmt85 -84.88 -38.44 19.44 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.694 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.0 tt0 -169.45 151.85 4.61 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.459 ' C ' HD22 ' A' ' 112' ' ' LEU . 84.6 t -95.31 132.08 40.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.113 0.483 . . . . 0.0 110.176 178.901 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.459 HD22 ' C ' ' A' ' 111' ' ' VAL . 4.0 mm? -100.37 131.48 23.91 Favored Pre-proline 0 N--CA 1.467 0.394 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.61 -179.273 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.37 154.63 2.5 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.129 1.886 . . . . 0.0 111.662 178.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 57' ' ' ILE . 1.3 p -68.39 158.88 32.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.022 0.439 . . . . 0.0 110.518 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 9.3 ptm180 -151.46 149.12 28.89 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.047 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 57.0 mtm180 -78.33 132.58 37.49 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.197 0.522 . . . . 0.0 110.354 179.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -166.75 158.13 12.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.43 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -67.16 142.59 56.98 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 71.4 p -124.25 141.34 52.14 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-O 121.206 0.527 . . . . 0.0 109.899 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -116.67 174.84 5.86 Favored 'General case' 0 CA--C 1.513 -0.469 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.82 -179.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -152.63 128.96 10.56 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.875 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 82.2 mt -116.1 170.79 8.24 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.667 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -137.88 107.74 6.3 Favored 'General case' 0 CA--C 1.516 -0.346 0 C-N-CA 120.604 -0.439 . . . . 0.0 110.576 179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 24.9 t -89.43 116.81 31.56 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 179.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.441 ' O ' ' N ' ' A' ' 127' ' ' LEU . 38.8 tt0 -58.39 149.88 23.69 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.757 -179.207 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 61.64 -69.13 0.05 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.254 -0.885 . . . . 0.0 112.159 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 125' ' ' GLU . 96.2 mt -98.0 95.06 7.21 Favored 'General case' 0 CA--C 1.519 -0.23 0 O-C-N 122.285 -0.259 . . . . 0.0 110.413 179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.614 ' O ' HG23 ' A' ' 129' ' ' THR . 75.5 m80 -67.04 99.84 0.69 Allowed 'General case' 0 CA--C 1.505 -0.76 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 178.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.614 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.55 144.62 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 178.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.573 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.7 pt? -144.68 154.45 42.79 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-O 121.635 0.731 . . . . 0.0 111.788 -179.156 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.76 127.25 41.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 179.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . . . . . . . . . . . -133.93 129.74 36.74 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.401 -179.076 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.527 ' C ' ' H ' ' A' ' 135' ' ' VAL . 70.6 mm-40 51.73 46.78 26.0 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.033 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.14 -21.01 0.39 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.527 ' H ' ' C ' ' A' ' 133' ' ' GLU . 8.1 t -90.4 152.42 3.34 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.172 0 O-C-N 122.27 -0.547 . . . . 0.0 110.588 -179.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -106.53 114.64 46.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.358 179.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 10.1 m -147.15 136.16 15.99 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.4 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.467 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 3.2 t60 -38.54 162.91 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.833 0.349 . . . . 0.0 111.621 -179.81 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.436 ' H ' ' CD2' ' A' ' 138' ' ' HIS . 12.6 p30 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.271 -179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.572 ' HB3' HE22 ' A' ' 51' ' ' GLN . 5.5 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -118.02 134.56 54.86 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-O 120.89 0.376 . . . . 0.0 110.391 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -86.38 163.61 17.53 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.396 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.409 ' OE2' ' CD ' ' A' ' 20' ' ' GLU . 57.7 tt0 -63.02 142.16 58.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.506 178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.85 -21.09 30.43 Favored Glycine 0 C--N 1.334 0.458 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . . . . . . . . . 25.8 m -66.04 123.48 19.96 Favored 'General case' 0 C--N 1.331 -0.202 0 C-N-CA 120.96 -0.296 . . . . 0.0 110.546 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 99.9 mtt180 -82.01 148.88 28.41 Favored 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 120.838 0.352 . . . . 0.0 110.068 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 97.5 mt -134.52 107.31 8.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.121 179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 62.8 t80 -77.4 125.19 28.94 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.625 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 4.7 t70 -101.99 132.79 21.19 Favored Pre-proline 0 CA--C 1.538 0.501 0 C-N-CA 120.951 -0.3 . . . . 0.0 110.846 -179.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -73.95 -31.61 7.94 Favored 'Trans proline' 0 N--CA 1.495 1.61 0 C-N-CA 122.619 2.213 . . . . 0.0 112.166 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.625 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 66.2 t -71.47 -54.47 17.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.694 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.9 p -77.32 -38.94 49.39 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.961 0.41 . . . . 0.0 110.171 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.31 4.62 87.91 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.474 HG22 ' N ' ' A' ' 16' ' ' THR . 55.5 m -114.18 157.63 22.39 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 117.435 0.617 . . . . 0.0 109.85 -179.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.474 ' N ' HG22 ' A' ' 15' ' ' THR . 40.2 m -78.47 116.65 19.01 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.28 0.562 . . . . 0.0 110.794 -179.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . 0.541 ' CD2' HD11 ' A' ' 29' ' ' ILE . 87.0 m-70 -103.1 146.7 27.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.452 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 63.1 mtm180 -98.52 128.12 44.73 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.971 179.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.535 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.6 tp -52.2 -40.87 31.9 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.444 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.613 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.535 ' N ' HG23 ' A' ' 19' ' ' ILE . 7.4 tt0 -57.56 -36.16 71.31 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 120.976 0.417 . . . . 0.0 110.852 -179.486 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.519 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 49.4 t0 -81.73 -35.7 29.42 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.47 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 64.7 t -67.32 -42.17 87.3 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.642 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.567 HG21 ' HB3' ' A' ' 120' ' ' PHE . 48.5 t -74.11 -46.79 44.19 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 112.299 0.481 . . . . 0.0 112.299 -177.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' A' ' 25' ' ' GLY . 0.6 OUTLIER -56.05 -37.57 69.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 C-N-CA 120.673 -0.411 . . . . 0.0 110.824 -177.869 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.561 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -106.07 32.17 7.63 Favored Glycine 0 C--O 1.227 -0.287 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.561 ' C ' ' O ' ' A' ' 25' ' ' GLY . 15.6 ptm180 12.45 65.72 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.005 0 CA-C-O 121.189 0.518 . . . . 0.0 110.307 179.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.402 ' N ' ' O ' ' A' ' 25' ' ' GLY . 78.2 mttt -85.88 141.55 35.84 Favored Pre-proline 0 N--CA 1.447 -0.579 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.811 -177.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.548 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.4 Cg_endo -71.3 7.62 1.4 Allowed 'Trans proline' 0 C--N 1.311 -1.414 0 C-N-CA 122.23 1.953 . . . . 0.0 112.224 179.371 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.548 ' O ' ' O ' ' A' ' 28' ' ' PRO . 12.8 tt -38.05 169.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 O-C-N 123.505 0.503 . . . . 0.0 110.597 -178.308 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.521 ' N ' ' CG1' ' A' ' 29' ' ' ILE . 2.2 m80 -120.16 170.61 9.16 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.341 -179.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.5 m -151.08 172.76 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.155 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 48.9 t -88.16 135.03 26.5 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -110.53 167.53 10.15 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.845 179.811 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.6 140.41 40.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.855 0.359 . . . . 0.0 110.373 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.23 179.06 4.06 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.564 178.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -68.44 -16.06 63.77 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-O 120.754 0.312 . . . . 0.0 110.764 179.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -74.8 -19.56 60.15 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.618 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.22 -11.89 69.84 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 18.0 p -74.8 148.74 40.05 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.141 0.496 . . . . 0.0 110.961 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 56.6 mt -104.78 135.09 46.81 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.802 -179.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 97.6 m-70 -141.13 138.63 33.62 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.625 -179.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.467 ' O ' ' CZ ' ' A' ' 43' ' ' ARG . . . -68.7 143.0 54.86 Favored 'General case' 0 CA--C 1.511 -0.547 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.759 -178.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.467 ' CZ ' ' O ' ' A' ' 42' ' ' ALA . 13.3 mmp_? -143.83 138.26 15.01 Favored Pre-proline 0 CA--C 1.538 0.483 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.829 -179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.93 160.06 37.42 Favored 'Trans proline' 0 N--CA 1.492 1.409 0 C-N-CA 123.058 2.505 . . . . 0.0 112.754 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 39.8 t -103.88 136.92 34.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 178.045 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 22.2 m -128.26 3.75 3.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 115.624 -0.716 . . . . 0.0 111.877 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.4 m -148.43 142.5 25.96 Favored 'General case' 0 CA--C 1.532 0.27 0 CA-C-N 118.889 0.768 . . . . 0.0 109.239 179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . . . . . . . . . 0.2 OUTLIER -144.09 123.26 12.93 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 178.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 -143.91 149.13 36.39 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 112.822 0.675 . . . . 0.0 112.822 -179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -96.51 131.85 42.7 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 108.355 -0.979 . . . . 0.0 108.355 176.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.657 HE21 ' C ' ' A' ' 119' ' ' THR . 1.9 mt-30 -95.41 4.29 53.48 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.655 -0.248 . . . . 0.0 111.075 179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 85.11 -172.09 47.11 Favored Glycine 0 C--N 1.336 0.576 0 C-N-CA 120.742 -0.742 . . . . 0.0 111.821 179.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.463 ' OG1' ' CZ ' ' A' ' 118' ' ' ARG . 67.8 m -86.82 127.44 35.01 Favored 'General case' 0 CA--C 1.517 -0.295 0 CA-C-O 120.76 0.314 . . . . 0.0 110.308 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 94.3 mtt-85 -148.18 159.6 43.78 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.605 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 -75.0 143.24 43.67 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.873 -179.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -142.01 147.11 21.91 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.117 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.513 ' N ' HD13 ' A' ' 57' ' ' ILE . 0.0 OUTLIER -100.86 148.13 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.944 -179.693 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.98 135.5 12.18 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.9 mt -119.24 114.96 23.22 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 121.254 0.549 . . . . 0.0 110.346 -179.382 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.541 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.2 tpt180 -95.95 116.81 29.5 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.776 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.9 mp -104.18 129.83 55.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-O 120.987 0.422 . . . . 0.0 111.009 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 39.93 23.25 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.561 -178.862 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 71.02 -23.81 0.55 Allowed Glycine 0 CA--C 1.53 1.002 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -46.85 -103.73 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.564 0 N-CA-C 110.614 -0.994 . . . . 0.0 110.614 -178.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.63 173.93 7.53 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.084 0.469 . . . . 0.0 110.516 -179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 18.5 tt -126.18 158.21 35.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.681 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 44.1 tp -138.61 121.73 16.85 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.429 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.1 m95 -106.06 128.96 54.21 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.96 172.39 16.33 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.411 -179.249 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . 0.434 ' OG1' ' N ' ' A' ' 1' ' ' CYS . 0.9 OUTLIER -82.65 155.98 68.21 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-O 120.814 0.34 . . . . 0.0 110.856 179.793 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.31 -24.0 75.61 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.706 2.271 . . . . 0.0 111.918 179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -87.6 -7.38 57.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.181 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 8.2 t60 -73.81 128.65 36.07 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -87.88 133.99 33.79 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.134 0.492 . . . . 0.0 111.034 -179.62 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 55.4 t -105.44 140.44 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.487 -0.778 . . . . 0.0 110.061 -179.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.614 HD23 ' CZ2' ' A' ' 81' ' ' TRP . 0.6 OUTLIER -83.39 95.29 8.18 Favored 'General case' 0 N--CA 1.451 -0.395 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.176 -179.621 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.454 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 50.1 p -98.72 179.37 4.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.493 -179.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.447 ' OE2' ' CE2' ' A' ' 79' ' ' TYR . 17.6 pt-20 -65.26 -17.61 64.64 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.521 -0.309 . . . . 0.0 111.303 -179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . 0.447 ' CE2' ' OE2' ' A' ' 78' ' ' GLU . 50.2 m-85 -107.32 25.48 11.37 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.193 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 98.47 -139.2 14.32 Favored Glycine 0 C--N 1.335 0.482 0 C-N-CA 121.082 -0.58 . . . . 0.0 111.716 179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.614 ' CZ2' HD23 ' A' ' 76' ' ' LEU . 97.5 m95 -94.47 130.13 40.96 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.329 -0.436 . . . . 0.0 111.784 -179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 15.4 tpt180 -138.13 125.92 22.41 Favored 'General case' 0 C--N 1.332 -0.157 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . 0.64 ' HB3' ' OE1' ' A' ' 86' ' ' GLU . . . -53.95 140.81 29.84 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.111 -0.495 . . . . 0.0 109.95 -179.711 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.447 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -59.97 -40.7 89.99 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 121.023 -0.271 . . . . 0.0 111.616 -178.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -58.21 -1.72 0.78 Allowed Glycine 0 CA--C 1.524 0.626 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.075 -179.275 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.64 ' OE1' ' HB3' ' A' ' 83' ' ' ALA . 57.4 mp0 -118.94 36.75 4.33 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.026 0.441 . . . . 0.0 110.612 -179.65 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 96.4 mt -110.73 124.95 52.95 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.955 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 35.7 mmt180 -131.87 145.65 51.66 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.567 -179.878 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.1 tttm -40.94 90.63 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.249 0 CA-C-O 121.01 0.433 . . . . 0.0 110.902 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.12 -13.71 0.38 Allowed Glycine 0 CA--C 1.522 0.477 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -89.99 127.75 36.11 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 120.974 0.416 . . . . 0.0 110.358 -179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 96.3 mtt180 -92.21 133.6 35.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.599 -179.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.4 m -114.57 149.24 16.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.63 128.46 36.06 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.918 0.39 . . . . 0.0 110.997 -179.297 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 25.7 m -130.8 161.74 40.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.348 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.512 ' NH2' HG11 ' A' ' 131' ' ' VAL . 25.8 ttm180 -110.29 132.9 53.77 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.993 -0.548 . . . . 0.0 110.57 179.539 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -100.98 126.11 47.61 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.251 178.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 85.3 t -74.96 -15.44 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 O-C-N 121.891 -0.506 . . . . 0.0 111.367 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -70.01 -57.41 5.03 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.145 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.1 m -100.51 -14.4 18.26 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 116.647 -0.251 . . . . 0.0 110.501 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.16 -11.93 14.5 Favored Glycine 0 C--N 1.331 0.261 0 N-CA-C 110.374 -1.09 . . . . 0.0 110.374 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.528 ' OE1' ' NH2' ' A' ' 104' ' ' ARG . 95.4 mt-10 -79.14 156.05 28.43 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 0.0 110.897 -178.144 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 2.2 pp -81.17 132.52 35.36 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-O 121.605 0.716 . . . . 0.0 110.038 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.528 ' NH2' ' OE1' ' A' ' 102' ' ' GLU . 35.9 mmt180 -132.28 -179.54 5.49 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.342 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.454 ' OH ' ' C ' ' A' ' 77' ' ' THR . 4.1 m-85 -118.63 147.28 43.92 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.681 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 28.6 m -138.57 159.0 43.19 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 178.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 13.6 p -89.55 153.09 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 120.726 0.298 . . . . 0.0 110.72 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.431 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.8 mm -72.64 156.78 6.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 121.179 0.514 . . . . 0.0 109.963 179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.431 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 2.5 tpm_? -106.69 -47.37 3.76 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.106 179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -166.56 145.56 5.57 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.562 ' C ' HD22 ' A' ' 112' ' ' LEU . 21.3 t -95.63 133.77 35.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-O 120.929 0.395 . . . . 0.0 110.072 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.755 HD22 ' N ' ' A' ' 112' ' ' LEU . 2.7 mm? -102.06 148.21 35.04 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.357 -179.195 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.99 158.52 57.01 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 122.496 2.131 . . . . 0.0 111.549 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.449 ' H ' HG23 ' A' ' 114' ' ' THR . 2.0 p -68.49 158.2 34.3 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.009 0.433 . . . . 0.0 110.66 -179.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.402 ' CG ' ' N ' ' A' ' 116' ' ' ARG . 45.2 ttp180 -153.55 153.86 33.18 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 115.528 -0.76 . . . . 0.0 111.507 179.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.402 ' N ' ' CG ' ' A' ' 115' ' ' ARG . 18.5 mmm180 -77.31 125.71 29.77 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.218 -0.901 . . . . 0.0 110.506 179.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -162.89 159.18 23.45 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.701 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.463 ' CZ ' ' OG1' ' A' ' 53' ' ' THR . 11.0 mpt_? -76.26 149.11 37.19 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.079 -0.509 . . . . 0.0 109.815 179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.657 ' C ' HE21 ' A' ' 51' ' ' GLN . 62.1 p -132.03 145.77 51.65 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 178.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.588 ' O ' ' NE2' ' A' ' 51' ' ' GLN . 63.8 m-85 -114.74 173.06 6.66 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.627 -179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -143.37 130.7 20.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.09 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.459 HD21 HG22 ' A' ' 23' ' ' VAL . 87.9 mt -123.69 170.91 10.01 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.417 179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 46.5 tp10 -135.32 106.49 6.72 Favored 'General case' 0 CA--C 1.517 -0.302 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.085 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' A' ' 125' ' ' GLU . 17.4 t -85.42 109.55 18.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.28 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.496 ' C ' ' O ' ' A' ' 124' ' ' VAL . 41.4 tp10 21.86 -108.13 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.488 0 O-C-N 123.9 0.75 . . . . 0.0 111.359 179.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 77.0 tt0 -114.41 -26.68 7.86 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.616 -0.72 . . . . 0.0 111.039 179.526 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.418 ' O ' ' N ' ' A' ' 129' ' ' THR . 91.4 mt -84.52 68.53 10.34 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 -179.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.435 ' C ' ' OG1' ' A' ' 129' ' ' THR . 9.7 m170 -41.94 99.94 0.02 OUTLIER 'General case' 0 CA--C 1.507 -0.683 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.486 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.435 ' OG1' ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 168.32 137.26 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 179.248 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.637 ' C ' HD12 ' A' ' 130' ' ' LEU . 2.2 pp -145.34 150.6 36.9 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.157 0.504 . . . . 0.0 111.237 179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.512 HG11 ' NH2' ' A' ' 96' ' ' ARG . 5.4 p -87.55 127.9 40.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.351 -0.841 . . . . 0.0 108.935 -179.127 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.4 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.9 124.86 27.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.734 -179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.502 ' O ' HG23 ' A' ' 135' ' ' VAL . 76.2 mm-40 59.21 44.63 15.4 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.287 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 71.0 -19.49 0.75 Allowed Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.502 HG23 ' O ' ' A' ' 133' ' ' GLU . 4.6 t -88.76 150.78 3.61 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.156 0 CA-C-N 117.033 0.416 . . . . 0.0 110.622 -179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 48.6 t -106.43 113.56 43.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.31 179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 138' ' ' HIS . 15.0 m -148.37 140.87 18.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.548 -179.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 60.6 t-80 -32.37 155.6 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 111.813 0.301 . . . . 0.0 111.813 179.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.429 ' O ' ' ND1' ' A' ' 138' ' ' HIS . 23.2 p30 . . . . . 0 C--N 1.324 -0.523 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.45 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.469 ' N ' ' ND1' ' A' ' 73' ' ' HIS . 28.2 m . . . . . 0 N--CA 1.489 1.489 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -111.46 139.12 47.15 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.832 0.349 . . . . 0.0 110.193 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.91 162.45 16.9 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.589 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -60.5 143.11 54.29 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.489 179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 109.14 -16.12 32.82 Favored Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.106 -1.197 . . . . 0.0 110.106 179.836 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.579 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 21.3 m -71.8 122.58 20.94 Favored 'General case' 0 N--CA 1.454 -0.237 0 O-C-N 122.707 -0.29 . . . . 0.0 111.014 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 85.6 mtt85 -82.04 148.49 28.58 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-O 120.781 0.324 . . . . 0.0 110.247 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 71.0 mt -135.62 108.21 8.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.289 -179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 49.9 t80 -79.72 129.66 34.67 Favored 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.413 ' O ' ' N ' ' A' ' 14' ' ' GLY . 55.3 t0 -109.94 113.41 57.23 Favored Pre-proline 0 CA--C 1.534 0.337 0 CA-C-N 116.813 -0.176 . . . . 0.0 110.755 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.11 -36.93 78.68 Favored 'Trans proline' 0 N--CA 1.495 1.583 0 C-N-CA 122.625 2.217 . . . . 0.0 112.082 178.629 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.4 HG21 ' CG ' ' A' ' 30' ' ' HIS . 49.1 t -61.8 -57.8 10.45 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.613 -178.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 29.9 p -78.27 -37.96 43.76 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-O 121.179 0.514 . . . . 0.0 110.126 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 85.16 5.71 85.35 Favored Glycine 0 C--O 1.23 -0.14 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 16' ' ' THR . 96.5 m -114.33 157.29 23.0 Favored 'General case' 0 C--N 1.346 0.449 0 CA-C-N 117.658 0.729 . . . . 0.0 109.837 -179.481 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.463 ' N ' HG22 ' A' ' 15' ' ' THR . 26.0 m -79.67 119.66 22.92 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.35 0.595 . . . . 0.0 110.61 -179.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 19.9 m-70 -103.31 145.34 30.11 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.385 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 29.0 ttm-85 -96.92 124.37 40.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.03 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 20' ' ' GLU . 1.6 tp -51.75 -44.14 35.47 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.667 0 C-N-CA 120.563 -0.455 . . . . 0.0 111.724 -179.056 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.617 ' N ' HG23 ' A' ' 19' ' ' ILE . 10.8 pt-20 -57.98 -34.9 70.47 Favored 'General case' 0 C--N 1.32 -0.707 0 C-N-CA 120.733 -0.387 . . . . 0.0 111.131 -178.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 42.3 t0 -82.25 -37.56 25.76 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.326 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 67.7 t -66.92 -43.24 89.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.674 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.517 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 58.3 t -72.5 -47.23 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.518 0 N-CA-C 112.038 0.384 . . . . 0.0 112.038 -178.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -57.18 -38.11 73.15 Favored 'General case' 0 N--CA 1.448 -0.56 0 C-N-CA 121.01 -0.276 . . . . 0.0 111.146 -178.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.548 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.08 29.52 12.34 Favored Glycine 0 CA--C 1.507 -0.408 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.548 ' C ' ' O ' ' A' ' 25' ' ' GLY . 90.7 mtm180 15.78 62.5 0.01 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 O-C-N 124.037 0.492 . . . . 0.0 110.045 179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 81.2 mttt -87.64 126.13 62.85 Favored Pre-proline 0 N--CA 1.44 -0.97 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.944 -177.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 55.8 Cg_endo -75.23 93.43 0.97 Allowed 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.469 2.113 . . . . 0.0 110.316 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 49.3 pt -121.21 -170.16 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.87 -179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.4 ' CG ' HG21 ' A' ' 12' ' ' VAL . 38.0 m80 -125.97 164.49 20.7 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.307 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 22.1 m -150.65 173.68 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.447 HG11 HH21 ' A' ' 96' ' ' ARG . 5.2 t -86.55 125.28 40.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.657 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -106.17 150.85 25.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.626 179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -122.22 144.12 49.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.411 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -116.26 178.26 4.39 Favored 'General case' 0 N--CA 1.472 0.664 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.8 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 25.3 mtpp -68.45 -15.25 63.48 Favored 'General case' 0 N--CA 1.453 -0.307 0 CA-C-O 120.693 0.283 . . . . 0.0 110.396 179.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -78.43 -20.3 51.37 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.083 179.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.45 -9.67 71.56 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.5 p -73.1 139.01 46.17 Favored 'General case' 0 N--CA 1.452 -0.334 0 CA-C-O 121.363 0.601 . . . . 0.0 111.297 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.616 HD13 ' NH2' ' A' ' 96' ' ' ARG . 50.6 mt -95.7 135.33 37.54 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.558 -179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -145.98 141.48 27.75 Favored 'General case' 0 C--O 1.221 -0.444 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.467 -179.438 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.39 147.54 44.2 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.663 -178.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.512 ' HD2' HD12 ' A' ' 127' ' ' LEU . 6.5 mtp180 -152.81 148.98 21.15 Favored Pre-proline 0 N--CA 1.457 -0.124 0 CA-C-N 115.916 -0.583 . . . . 0.0 111.231 179.876 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -70.6 149.55 61.71 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.557 2.172 . . . . 0.0 112.455 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 79.7 t -112.87 146.53 17.44 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.847 0 CA-C-O 121.502 0.668 . . . . 0.0 109.312 179.331 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.705 ' O ' ' CE2' ' A' ' 48' ' ' TRP . 2.1 m -139.49 -100.63 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.444 -0.746 0 CA-C-N 114.583 -1.19 . . . . 0.0 111.833 178.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.61 ' H ' HG23 ' A' ' 46' ' ' VAL . 9.3 t -19.0 113.84 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.886 0 CA-C-N 114.164 -1.38 . . . . 0.0 111.542 -175.525 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.705 ' CE2' ' O ' ' A' ' 46' ' ' VAL . 1.5 m-90 -120.3 110.89 17.1 Favored 'General case' 0 CA--C 1.512 -0.519 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 179.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.7 m-85 -138.43 147.02 42.86 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.304 -179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.441 ' OD1' ' O ' ' A' ' 50' ' ' ASP . 46.4 p-10 -91.65 134.98 34.22 Favored 'General case' 0 C--N 1.334 -0.069 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 177.04 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.561 HE21 ' HB2' ' A' ' 121' ' ' ASP . 29.8 mm-40 -92.67 -4.83 52.6 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.715 -0.22 . . . . 0.0 111.219 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.86 -179.11 48.68 Favored Glycine 0 CA--C 1.525 0.668 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 79.9 m -94.24 122.66 37.01 Favored 'General case' 0 N--CA 1.466 0.334 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 73.8 mtp85 -146.54 171.38 15.16 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.435 0.636 . . . . 0.0 110.656 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 74.9 m-20 -74.42 139.63 44.14 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.219 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -139.36 153.3 23.96 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.195 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.651 HD11 ' HB1' ' A' ' 84' ' ' ALA . 14.4 pt -108.88 155.83 9.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.183 179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.03 128.73 8.71 Favored Glycine 0 N--CA 1.465 0.631 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 28.4 mt -108.94 115.3 29.82 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.205 0.526 . . . . 0.0 110.413 -179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 15.6 tpp180 -85.81 109.29 18.57 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.055 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.547 ' O ' ' N ' ' A' ' 63' ' ' GLY . 12.8 mm -97.47 125.76 50.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.66 -179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.615 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 33.73 29.16 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.815 0.697 . . . . 0.0 110.852 -179.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.547 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 65.03 -22.62 0.11 Allowed Glycine 0 CA--C 1.532 1.139 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -178.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.615 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -48.76 -104.22 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.46 171.39 9.07 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-O 120.949 0.404 . . . . 0.0 110.462 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 20.4 tt -124.94 153.47 32.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.441 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.357 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 43.9 tp -132.75 118.72 19.39 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.337 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -105.8 118.21 36.01 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 179.134 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.96 170.97 15.12 Favored 'General case' 0 CA--C 1.514 -0.44 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.534 -179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 37.6 p -79.5 153.56 76.24 Favored Pre-proline 0 N--CA 1.45 -0.432 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.128 -179.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_exo -57.78 -30.25 88.6 Favored 'Trans proline' 0 N--CA 1.494 1.515 0 C-N-CA 122.534 2.156 . . . . 0.0 112.146 179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -80.97 -9.46 59.84 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.428 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.537 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.7 t60 -70.46 129.04 38.2 Favored 'General case' 0 CA--C 1.519 -0.246 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -86.75 131.61 34.08 Favored 'General case' 0 N--CA 1.45 -0.432 0 CA-C-O 121.399 0.619 . . . . 0.0 111.154 -179.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.6 t -103.62 139.21 25.2 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.783 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 58.7 tp -78.35 91.95 4.51 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.856 -179.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 35.9 p -97.38 -179.34 4.46 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 -178.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -69.87 -16.41 63.24 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.196 -179.162 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -106.27 26.31 9.96 Favored 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 116.627 -0.26 . . . . 0.0 110.933 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 96.88 -138.54 13.97 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -95.67 130.61 42.5 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.537 -0.331 . . . . 0.0 111.138 -179.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . 0.511 ' NH1' ' OD1' ' A' ' 91' ' ' ASP . 84.0 mtp180 -140.56 129.89 23.8 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.246 179.453 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.38 145.29 18.42 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.011 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.651 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -62.48 -40.14 95.73 Favored 'General case' 0 N--CA 1.448 -0.536 0 C-N-CA 121.249 -0.18 . . . . 0.0 111.473 -179.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.3 -3.46 3.89 Favored Glycine 0 C--N 1.337 0.614 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.757 -179.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -113.24 32.73 5.54 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.732 0.301 . . . . 0.0 110.56 179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 94.9 mt -112.7 126.81 55.8 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 121.38 0.61 . . . . 0.0 111.226 179.83 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.532 ' O ' ' N ' ' A' ' 90' ' ' GLY . 37.5 mmt180 -130.89 147.19 52.51 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.884 -179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 65.6 tttm -42.66 90.82 0.0 OUTLIER 'General case' 0 N--CA 1.452 -0.346 0 CA-C-O 120.876 0.369 . . . . 0.0 110.741 -179.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.25 -12.68 0.43 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 -179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.511 ' OD1' ' NH1' ' A' ' 82' ' ' ARG . 17.8 t70 -87.85 128.57 35.35 Favored 'General case' 0 C--O 1.227 -0.102 0 CA-C-O 121.038 0.447 . . . . 0.0 110.307 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.4 mtt85 -89.84 131.74 35.62 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.393 -179.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.6 m -118.32 150.91 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.121 -0.49 . . . . 0.0 109.797 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.47 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -66.76 134.98 53.27 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 120.955 0.407 . . . . 0.0 111.015 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.431 HG22 ' O ' ' A' ' 104' ' ' ARG . 21.4 m -134.22 159.68 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.013 179.077 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.616 ' NH2' HD13 ' A' ' 40' ' ' LEU . 52.6 ttm-85 -107.02 130.24 54.68 Favored 'General case' 0 C--N 1.334 -0.098 0 CA-C-O 120.677 0.275 . . . . 0.0 110.333 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.6 t0 -100.36 122.9 43.86 Favored 'General case' 0 CA--C 1.516 -0.348 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.365 178.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 62.3 t -76.28 -16.19 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.369 0 CA-C-N 118.133 0.424 . . . . 0.0 110.749 179.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 99' ' ' GLU . 0.5 OUTLIER -72.02 -57.26 4.44 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.849 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.449 ' C ' ' H ' ' A' ' 102' ' ' GLU . 32.3 p -94.45 -13.81 25.83 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 74.13 -14.76 3.66 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.449 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.5 mt-10 -83.56 163.53 20.34 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-O 120.981 0.42 . . . . 0.0 110.764 -177.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.47 HD21 ' HB1' ' A' ' 94' ' ' ALA . 4.6 tt -80.51 136.88 36.38 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.21 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.431 ' O ' HG22 ' A' ' 95' ' ' VAL . 45.9 mtp85 -134.42 168.81 18.25 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.099 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.0 m-30 -110.87 140.6 45.2 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.672 -179.548 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.416 ' OG ' HG21 ' A' ' 95' ' ' VAL . 23.3 m -136.49 155.39 50.05 Favored 'General case' 0 C--N 1.344 0.357 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.409 179.489 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.485 HG12 ' N ' ' A' ' 108' ' ' ILE . 58.1 t -91.33 156.68 3.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 121.008 0.432 . . . . 0.0 110.555 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.485 ' N ' HG12 ' A' ' 107' ' ' VAL . 3.5 mm -72.66 153.13 7.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.237 179.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -106.0 -45.93 4.23 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.945 179.454 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -166.05 145.36 6.08 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.457 ' C ' HD22 ' A' ' 112' ' ' LEU . 83.5 t -96.46 132.88 39.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.137 0.494 . . . . 0.0 110.163 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.484 HD22 ' N ' ' A' ' 112' ' ' LEU . 4.1 mm? -98.57 128.73 32.0 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.288 -179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -49.63 157.99 2.11 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 C-N-CA 122.384 2.056 . . . . 0.0 111.743 178.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.436 HG23 ' H ' ' A' ' 114' ' ' THR . 1.2 p -66.94 156.93 34.56 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.49 0.662 . . . . 0.0 110.685 -179.303 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -139.04 -140.1 0.14 Allowed 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.915 -179.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 80.7 mtm180 -153.66 132.6 12.46 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-O 120.902 0.382 . . . . 0.0 110.115 179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.7 173.67 3.86 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.651 -179.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 90.6 mtm180 -83.51 154.27 23.96 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.144 179.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -132.64 143.47 49.69 Favored 'General case' 0 C--N 1.339 0.147 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 179.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -112.95 174.83 5.7 Favored 'General case' 0 CA--C 1.512 -0.507 0 CA-C-N 115.483 -0.78 . . . . 0.0 111.5 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.561 ' HB2' HE21 ' A' ' 51' ' ' GLN . 26.4 t0 -148.03 128.79 14.26 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.164 -179.572 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.2 mt -132.15 123.39 27.0 Favored 'General case' 0 CA--C 1.514 -0.422 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.852 179.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -87.51 115.67 25.09 Favored 'General case' 0 N--CA 1.451 -0.402 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.144 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 125' ' ' GLU . 98.5 t -85.48 114.09 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 179.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.477 ' O ' ' N ' ' A' ' 127' ' ' LEU . 39.7 tp10 -28.2 111.92 0.06 Allowed 'General case' 0 N--CA 1.466 0.367 0 O-C-N 123.574 0.546 . . . . 0.0 111.762 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 60.49 -65.87 0.05 Allowed 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 178.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.512 HD12 ' HD2' ' A' ' 43' ' ' ARG . 86.0 mt -72.76 75.17 1.13 Allowed 'General case' 0 N--CA 1.442 -0.833 0 CA-C-O 121.041 0.448 . . . . 0.0 111.005 -177.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.629 ' O ' HG23 ' A' ' 129' ' ' THR . 31.5 m170 -56.01 98.96 0.03 OUTLIER 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 178.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.629 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 163.45 143.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 O-C-N 123.712 0.632 . . . . 0.0 109.439 178.936 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.723 ' C ' HD12 ' A' ' 130' ' ' LEU . 1.8 pp -149.23 154.1 38.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.542 0.687 . . . . 0.0 111.446 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.513 ' N ' HD12 ' A' ' 130' ' ' LEU . 85.6 t -90.01 123.69 42.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.033 -179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.649 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.08 129.16 37.65 Favored 'General case' 0 C--O 1.233 0.203 0 N-CA-C 109.886 -0.412 . . . . 0.0 109.886 -178.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.551 ' O ' HG23 ' A' ' 135' ' ' VAL . 70.2 mm-40 58.77 43.23 18.8 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.647 -0.706 . . . . 0.0 109.897 -179.566 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.76 -20.89 0.48 Allowed Glycine 0 CA--C 1.525 0.673 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.551 HG23 ' O ' ' A' ' 133' ' ' GLU . 3.9 t -89.18 151.13 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-O 120.943 0.402 . . . . 0.0 110.821 -179.361 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.403 HG21 HD11 ' A' ' 103' ' ' LEU . 2.5 t -104.69 112.78 39.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.548 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.467 ' O ' ' O ' ' A' ' 138' ' ' HIS . 11.5 m -148.3 138.65 16.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.751 0 CA-C-O 118.988 -0.529 . . . . 0.0 110.29 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.578 ' NE2' ' ND2' ' A' ' 139' ' ' ASN . 14.4 t-80 -28.41 147.63 0.0 OUTLIER 'General case' 0 C--N 1.342 0.259 0 O-C-N 123.571 0.544 . . . . 0.0 111.956 179.163 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.649 HD22 ' C ' ' A' ' 139' ' ' ASN . 0.2 OUTLIER . . . . . 0 C--N 1.321 -0.673 0 CA-C-O 117.936 -1.031 . . . . 0.0 110.895 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 76.4 mt -91.45 139.01 31.13 Favored 'General case' 0 CA--C 1.517 -0.3 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.839 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.52 161.7 28.95 Favored 'General case' 0 CA--C 1.529 0.135 0 CA-C-O 120.978 0.418 . . . . 0.0 111.262 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.533 ' OE1' ' NH2' ' A' ' 118' ' ' ARG . 77.5 tt0 -66.62 143.27 57.11 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.826 178.93 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 107.97 -18.85 33.58 Favored Glycine 0 C--N 1.336 0.561 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.512 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 26.9 m -66.05 124.97 24.01 Favored 'General case' 0 CA--C 1.519 -0.218 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.48 ' HE ' ' CD ' ' A' ' 18' ' ' ARG . 1.6 mpt_? -97.25 116.39 29.36 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-O 121.014 0.435 . . . . 0.0 110.214 -179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.47 HD11 HD13 ' A' ' 19' ' ' ILE . 15.4 mt -100.41 113.06 34.96 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.209 179.844 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -75.47 133.93 40.96 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.501 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 13.3 t0 -101.07 129.97 26.02 Favored Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 121.145 -0.222 . . . . 0.0 110.678 -179.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -71.72 -27.47 18.2 Favored 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 121.91 1.74 . . . . 0.0 112.277 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 42.7 t -76.42 -53.81 14.58 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.19 -179.324 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 3.9 p -76.94 -35.88 56.97 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.983 0.42 . . . . 0.0 110.251 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.64 10.5 85.13 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 111.345 -0.702 . . . . 0.0 111.345 179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.51 HG22 ' N ' ' A' ' 16' ' ' THR . 54.8 m -115.56 160.42 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 117.564 0.682 . . . . 0.0 109.694 -179.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.51 ' N ' HG22 ' A' ' 15' ' ' THR . 12.5 m -79.54 115.0 18.91 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.194 0.521 . . . . 0.0 110.911 -179.229 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 65.9 m-70 -101.3 143.46 31.33 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.866 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.48 ' CD ' ' HE ' ' A' ' 7' ' ' ARG . 69.3 mtm180 -99.65 128.38 45.75 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.753 -0.203 . . . . 0.0 110.574 178.247 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.509 HG23 ' N ' ' A' ' 20' ' ' GLU . 3.1 tp -53.1 -38.42 29.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.803 0.335 . . . . 0.0 110.561 -179.77 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.509 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.3 pt-20 -58.17 -35.34 71.44 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.318 0.58 . . . . 0.0 110.969 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -85.18 -38.38 19.06 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.63 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 94.2 t -69.04 -42.39 81.99 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.838 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.56 HG22 HD21 ' A' ' 122' ' ' LEU . 75.2 t -75.36 -45.89 39.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 C-N-CA 120.846 -0.342 . . . . 0.0 111.833 -178.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -57.67 -34.5 69.45 Favored 'General case' 0 CA--C 1.517 -0.315 0 CA-C-O 120.903 0.382 . . . . 0.0 110.681 -178.332 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.577 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -110.25 29.31 9.3 Favored Glycine 0 CA--C 1.519 0.298 0 CA-C-O 119.108 -0.829 . . . . 0.0 111.033 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.577 ' C ' ' O ' ' A' ' 25' ' ' GLY . 44.6 ptt85 13.62 64.92 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.45 0.643 . . . . 0.0 110.054 179.071 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 25' ' ' GLY . 81.6 mttt -84.86 139.49 37.36 Favored Pre-proline 0 N--CA 1.449 -0.503 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.369 -176.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -76.9 83.27 2.14 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.352 1.368 . . . . 0.0 110.164 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.563 ' C ' HD12 ' A' ' 29' ' ' ILE . 1.9 pp -116.27 -174.16 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.526 0 CA-C-O 120.811 0.338 . . . . 0.0 110.486 -179.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.422 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 34.7 m80 -128.65 161.95 28.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.511 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.9 m -146.96 170.47 4.06 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.251 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 89.5 t -87.97 134.98 26.56 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.358 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -107.78 166.55 10.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.534 -179.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -137.2 137.59 39.29 Favored 'General case' 0 N--CA 1.461 0.109 0 CA-C-O 120.914 0.387 . . . . 0.0 110.23 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -112.28 175.42 5.44 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 26.3 mtmm -73.02 -13.34 61.2 Favored 'General case' 0 C--O 1.232 0.163 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.865 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -78.32 -11.44 59.94 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.429 179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 84.46 17.37 64.38 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 111.009 -0.836 . . . . 0.0 111.009 -179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 19.2 p -100.81 139.34 36.64 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.767 0.318 . . . . 0.0 111.024 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 70.9 mt -98.54 131.61 44.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.655 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.7 m-70 -139.52 138.3 36.21 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.965 -179.718 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.87 142.7 52.99 Favored 'General case' 0 C--N 1.326 -0.456 0 C-N-CA 120.465 -0.494 . . . . 0.0 109.959 -178.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.526 ' HE ' HD12 ' A' ' 127' ' ' LEU . 31.7 mmt180 -145.04 138.6 14.36 Favored Pre-proline 0 N--CA 1.468 0.461 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.297 -179.156 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -77.12 157.2 33.96 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 C-N-CA 122.555 2.17 . . . . 0.0 112.424 179.905 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 59.6 t -98.84 138.17 24.14 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 177.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -126.99 2.66 3.76 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.183 -178.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 1.5 m -146.97 133.99 20.33 Favored 'General case' 0 C--O 1.231 0.125 0 C-N-CA 120.038 -0.665 . . . . 0.0 110.006 179.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.508 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -136.77 121.71 18.85 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 108.123 -1.066 . . . . 0.0 108.123 178.003 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -138.14 143.59 40.39 Favored 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.644 ' O ' ' HG2' ' A' ' 51' ' ' GLN . 29.3 t70 -88.42 125.77 34.89 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.968 -1.493 . . . . 0.0 106.968 176.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.644 ' HG2' ' O ' ' A' ' 50' ' ' ASP . 8.2 mt-30 -160.86 60.08 0.31 Allowed 'General case' 0 CA--C 1.498 -1.042 0 O-C-N 124.158 0.911 . . . . 0.0 108.55 179.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.818 ' CA ' ' H ' ' A' ' 119' ' ' THR . . . -118.62 167.06 12.98 Favored Glycine 0 C--N 1.314 -0.684 0 C-N-CA 120.676 -0.773 . . . . 0.0 111.398 -178.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.562 ' CB ' ' O ' ' A' ' 52' ' ' GLY . 33.3 m 113.99 63.53 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 O-C-N 125.436 1.315 . . . . 0.0 111.261 177.788 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.6 mtt-85 -148.78 175.72 10.99 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.634 0.254 . . . . 0.0 110.794 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -77.47 139.56 39.66 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.481 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.61 151.81 19.26 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.701 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.525 ' N ' HD13 ' A' ' 57' ' ' ILE . 0.0 OUTLIER -103.41 144.77 13.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 116.281 -0.418 . . . . 0.0 109.963 179.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -104.93 134.7 12.15 Favored Glycine 0 N--CA 1.462 0.39 0 N-CA-C 110.308 -1.117 . . . . 0.0 110.308 179.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.435 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 71.6 mt -116.78 116.34 27.3 Favored 'General case' 0 CA--C 1.521 -0.162 0 CA-C-O 121.064 0.459 . . . . 0.0 110.313 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.449 ' C ' HD12 ' A' ' 61' ' ' ILE . 9.1 tpt180 -84.75 107.73 17.09 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.103 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.754 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.6 mp -93.86 133.49 34.73 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 179.007 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.622 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 24.11 31.43 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.57 0 O-C-N 123.743 0.652 . . . . 0.0 112.756 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.696 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 65.81 -23.92 0.14 Allowed Glycine 0 CA--C 1.53 1.024 0 N-CA-C 111.171 -0.772 . . . . 0.0 111.171 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.622 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.4 -107.47 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.738 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -178.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.71 170.24 10.3 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.811 0.338 . . . . 0.0 110.503 -179.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.412 HG22 ' N ' ' A' ' 67' ' ' LEU . 95.0 mt -124.7 154.72 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.123 179.689 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.412 ' N ' HG22 ' A' ' 66' ' ' ILE . 61.9 tp -128.79 114.73 16.92 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.814 179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 95.6 m95 -103.83 109.96 21.9 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -134.2 172.32 13.02 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.198 -179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.14 156.8 69.13 Favored Pre-proline 0 CA--C 1.535 0.401 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.435 179.487 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -63.15 -17.72 61.5 Favored 'Trans proline' 0 N--CA 1.499 1.83 0 C-N-CA 122.734 2.29 . . . . 0.0 112.169 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 49.3 p-10 -97.62 -6.67 32.76 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.992 0.425 . . . . 0.0 110.185 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.552 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 13.4 t60 -71.85 129.68 39.21 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -83.57 124.07 30.4 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-O 121.375 0.607 . . . . 0.0 111.631 -179.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 73.5 t -98.14 138.35 23.07 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.058 -0.973 . . . . 0.0 109.889 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 37.9 tp -81.67 95.64 7.27 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.036 -179.524 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 58.5 p -100.28 175.87 5.57 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -67.67 -18.14 64.83 Favored 'General case' 0 N--CA 1.449 -0.513 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.459 -178.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -105.97 21.07 17.93 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.647 0.26 . . . . 0.0 110.642 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 106.89 -144.63 15.88 Favored Glycine 0 C--N 1.335 0.512 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 93.1 m95 -91.95 126.54 37.07 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.527 0.204 . . . . 0.0 110.97 -179.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 38.5 mmt180 -127.83 126.75 42.26 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 179.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -67.79 136.9 54.89 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.949 -179.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.591 ' HA ' HD12 ' A' ' 87' ' ' LEU . . . -69.78 -0.88 7.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.683 179.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -82.71 -13.78 77.22 Favored Glycine 0 CA--C 1.534 1.233 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 178.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -132.22 15.44 4.61 Favored 'General case' 0 N--CA 1.472 0.667 0 CA-C-O 120.758 0.313 . . . . 0.0 111.46 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.591 HD12 ' HA ' ' A' ' 84' ' ' ALA . 20.5 mt -80.32 141.41 35.47 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.233 0.54 . . . . 0.0 110.877 179.374 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.0 tpp85 -142.08 155.21 45.37 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.014 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 64.5 tttm -48.51 113.86 0.85 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.334 179.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 141.77 -22.33 2.5 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -83.09 130.56 35.13 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.706 0.289 . . . . 0.0 110.766 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.7 mtt180 -88.84 136.62 32.91 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.128 0.49 . . . . 0.0 110.795 -178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 29.0 m -122.02 144.05 32.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.5 -179.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -72.52 131.53 42.64 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.912 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.419 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.4 m -127.06 163.11 30.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.226 -0.443 . . . . 0.0 109.98 179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 74.5 ttt180 -100.5 128.14 46.65 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.671 -179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -100.54 124.28 45.88 Favored 'General case' 0 N--CA 1.467 0.379 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 178.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.409 ' O ' HG12 ' A' ' 98' ' ' VAL . 89.8 t -75.63 -15.81 15.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 118.24 0.473 . . . . 0.0 110.909 178.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 37.7 tp10 -69.35 -58.66 3.72 Favored 'General case' 0 C--O 1.232 0.141 0 C-N-CA 120.626 -0.43 . . . . 0.0 110.097 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.434 ' C ' ' H ' ' A' ' 102' ' ' GLU . 70.3 p -99.73 -12.18 20.2 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.756 -0.202 . . . . 0.0 110.772 179.701 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 77.32 -13.87 9.78 Favored Glycine 0 C--N 1.332 0.312 0 N-CA-C 109.804 -1.318 . . . . 0.0 109.804 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.6 mt-10 -82.05 153.84 25.93 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 120.953 0.406 . . . . 0.0 111.622 -177.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.586 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.3 OUTLIER -80.16 139.92 36.59 Favored 'General case' 0 N--CA 1.443 -0.809 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.748 179.479 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.419 ' O ' HG22 ' A' ' 95' ' ' VAL . 53.0 ptt85 -142.64 138.47 30.7 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.702 -179.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 7.9 m-30 -78.28 147.8 34.16 Favored 'General case' 0 C--N 1.32 -0.69 0 C-N-CA 120.38 -0.528 . . . . 0.0 109.998 -178.153 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 10.6 m -139.34 162.68 34.43 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 4.7 t -95.32 154.29 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 110.398 -0.223 . . . . 0.0 110.398 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 61.6 mt -73.54 154.61 6.98 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.176 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.0 ttm180 -104.75 -42.72 5.3 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.16 179.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 46.5 tt0 -167.23 147.82 5.53 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 178.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.429 ' C ' HD12 ' A' ' 112' ' ' LEU . 23.1 t -92.81 130.85 41.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.387 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.489 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.6 mp -98.99 124.93 43.69 Favored Pre-proline 0 CA--C 1.543 0.709 0 CA-C-N 116.522 -0.308 . . . . 0.0 110.973 -179.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -48.45 162.73 0.31 Allowed 'Trans proline' 0 N--CA 1.496 1.669 0 C-N-CA 122.228 1.952 . . . . 0.0 111.998 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.1 p -73.02 160.44 32.07 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 121.28 0.562 . . . . 0.0 110.823 -179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.434 ' CG ' ' H ' ' A' ' 116' ' ' ARG . 10.0 tpt180 -144.89 -132.47 0.08 Allowed 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.195 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.434 ' H ' ' CG ' ' A' ' 115' ' ' ARG . 1.5 tmm_? -155.39 134.83 12.47 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.983 179.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.17 170.77 4.27 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.072 -178.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.533 ' NH2' ' OE1' ' A' ' 4' ' ' GLU . 84.2 mtm-85 -83.87 140.36 32.04 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.843 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . 0.818 ' H ' ' CA ' ' A' ' 52' ' ' GLY . 4.2 p -128.39 148.78 50.72 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.559 177.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -122.75 179.76 4.51 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.971 -177.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -147.64 124.83 11.47 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.368 179.413 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.56 HD21 HG22 ' A' ' 23' ' ' VAL . 95.6 mt -115.84 173.08 6.75 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.444 -179.715 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -136.38 105.36 5.92 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.241 178.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.493 ' O ' ' C ' ' A' ' 125' ' ' GLU . 16.4 t -83.56 108.64 16.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.493 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.0 tt0 20.37 -89.14 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 O-C-N 123.639 0.587 . . . . 0.0 112.322 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.431 ' N ' ' O ' ' A' ' 124' ' ' VAL . 81.6 mt-10 -129.27 -39.94 1.49 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 115.36 -0.836 . . . . 0.0 111.392 179.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.526 HD12 ' HE ' ' A' ' 43' ' ' ARG . 84.3 mt -71.04 64.86 0.35 Allowed 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.183 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.438 ' O ' HG23 ' A' ' 129' ' ' THR . 39.3 m80 -41.78 94.82 0.01 OUTLIER 'General case' 0 CA--C 1.508 -0.643 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 179.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.515 ' N ' ' O ' ' A' ' 127' ' ' LEU . 0.0 OUTLIER 171.63 141.28 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 178.189 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.681 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.0 pp -147.79 155.96 42.23 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.425 0.631 . . . . 0.0 111.885 -179.417 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . . . . . . . . . 97.7 t -89.12 126.78 42.12 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.18 0 CA-C-N 114.934 -1.03 . . . . 0.0 108.582 -179.119 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.512 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -134.23 132.62 39.9 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 115.443 -0.799 . . . . 0.0 110.219 -179.099 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.583 ' O ' HG23 ' A' ' 135' ' ' VAL . 68.8 mm-40 50.64 46.23 25.95 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.156 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 58.99 23.26 56.82 Favored Glycine 0 CA--C 1.522 0.523 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.802 178.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.583 HG23 ' O ' ' A' ' 133' ' ' GLU . 21.9 t -129.75 153.69 39.18 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.436 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 2.7 t -105.32 111.9 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 O-C-N 121.944 -0.473 . . . . 0.0 110.611 179.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' A' ' 138' ' ' HIS . 26.8 m -147.38 139.33 18.59 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.349 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.884 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.552 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 55.6 t-80 -31.25 151.53 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.201 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 16.8 p30 . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 118.018 -0.992 . . . . 0.0 110.264 -179.635 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.712 ' CB ' HE22 ' A' ' 51' ' ' GLN . 6.2 m . . . . . 0 N--CA 1.488 1.47 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 80.5 mt -123.22 132.69 54.13 Favored 'General case' 0 C--N 1.34 0.189 0 CA-C-O 121.182 0.515 . . . . 0.0 110.72 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -80.09 162.26 24.89 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.39 179.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.76 146.52 52.25 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.45 -17.34 40.13 Favored Glycine 0 C--N 1.34 0.754 0 N-CA-C 109.988 -1.245 . . . . 0.0 109.988 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.477 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 25.7 m -67.03 124.76 23.95 Favored 'General case' 0 C--N 1.331 -0.197 0 C-N-CA 120.822 -0.351 . . . . 0.0 111.08 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.543 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.1 mtp180 -83.98 149.35 26.35 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 75.2 mt -134.6 107.42 8.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.81 179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -77.0 127.22 32.3 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 178.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.418 ' O ' ' N ' ' A' ' 14' ' ' GLY . 61.6 t0 -107.32 111.44 63.17 Favored Pre-proline 0 CA--C 1.539 0.552 0 C-N-CA 121.059 -0.256 . . . . 0.0 110.719 -179.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -52.07 -37.3 68.24 Favored 'Trans proline' 0 N--CA 1.494 1.551 0 C-N-CA 122.508 2.139 . . . . 0.0 111.969 178.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -61.21 -58.41 7.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 120.511 -0.476 . . . . 0.0 110.518 -179.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 30.5 p -74.88 -33.07 62.01 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.181 0.515 . . . . 0.0 109.788 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 10' ' ' ASP . . . 80.47 7.74 88.24 Favored Glycine 0 N--CA 1.451 -0.32 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.479 HG22 ' H ' ' A' ' 16' ' ' THR . 0.2 OUTLIER -110.87 -163.82 0.88 Allowed 'General case' 0 C--N 1.347 0.471 0 CA-C-N 117.727 0.764 . . . . 0.0 109.507 -179.248 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.543 HG21 ' HE ' ' A' ' 7' ' ' ARG . 87.4 m -114.71 115.7 27.49 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-O 121.516 0.674 . . . . 0.0 110.511 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -100.18 141.72 32.63 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.206 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 37.5 ttm180 -97.65 125.99 42.72 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.338 -0.392 . . . . 0.0 109.969 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.562 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -52.92 -41.01 38.82 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.615 0 C-N-CA 120.533 -0.467 . . . . 0.0 111.217 -179.333 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.562 ' N ' HG23 ' A' ' 19' ' ' ILE . 2.8 pt-20 -55.31 -35.23 64.9 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.355 0.598 . . . . 0.0 110.646 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 50.9 t0 -83.1 -36.18 25.05 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.972 . . . . 0.0 111.62 -178.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 54.1 t -66.65 -43.83 90.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 115.872 -0.604 . . . . 0.0 111.408 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 HD21 ' A' ' 122' ' ' LEU . 72.2 t -69.52 -46.11 76.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 120.834 -0.346 . . . . 0.0 111.721 -179.279 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 66.7 t0 -56.04 -36.9 68.53 Favored 'General case' 0 N--CA 1.446 -0.664 0 C-N-CA 120.946 -0.302 . . . . 0.0 110.596 -177.621 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.558 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -112.71 32.64 6.09 Favored Glycine 0 C--O 1.228 -0.257 0 CA-C-O 118.222 -1.321 . . . . 0.0 110.563 179.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.558 ' C ' ' O ' ' A' ' 25' ' ' GLY . 24.0 ptt-85 10.37 72.55 0.01 OUTLIER 'General case' 0 C--N 1.367 1.341 0 O-C-N 124.437 0.728 . . . . 0.0 110.004 179.526 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.406 ' C ' ' H ' ' A' ' 29' ' ' ILE . 74.1 mttt -90.06 144.71 31.7 Favored Pre-proline 0 N--CA 1.443 -0.791 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.716 -177.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.561 ' O ' ' O ' ' A' ' 29' ' ' ILE . 55.2 Cg_endo -71.77 9.83 0.95 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.581 2.187 . . . . 0.0 112.464 179.517 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.561 ' O ' ' O ' ' A' ' 28' ' ' PRO . 2.1 pp -38.19 171.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 O-C-N 124.087 0.867 . . . . 0.0 110.374 -178.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.557 ' ND1' ' N ' ' A' ' 30' ' ' HIS . 1.2 m80 -123.05 166.74 14.62 Favored 'General case' 0 CA--C 1.509 -0.622 0 O-C-N 122.103 -0.373 . . . . 0.0 111.057 -179.532 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 26.5 m -150.42 173.96 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.385 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.516 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 3.8 t -87.3 132.51 32.46 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.152 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -102.38 166.93 10.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 110.497 -0.186 . . . . 0.0 110.497 179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -138.79 137.08 36.34 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.074 0.464 . . . . 0.0 110.315 -179.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -114.5 177.46 4.64 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -72.76 -14.73 61.6 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-O 120.615 0.245 . . . . 0.0 110.677 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 10.5 t70 -78.98 -14.66 59.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.312 179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.7 20.46 56.1 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 16.6 p -100.82 135.29 42.49 Favored 'General case' 0 N--CA 1.462 0.174 0 CA-C-O 120.76 0.314 . . . . 0.0 110.691 178.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 53.2 mt -99.78 137.63 37.98 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.561 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -147.72 143.56 27.67 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.795 -179.674 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.86 145.01 48.86 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -178.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.641 ' HE ' HD12 ' A' ' 127' ' ' LEU . 86.6 mtt-85 -153.25 142.44 14.67 Favored Pre-proline 0 CA--C 1.54 0.587 0 O-C-N 123.813 0.696 . . . . 0.0 111.097 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -75.36 160.0 39.46 Favored 'Trans proline' 0 N--CA 1.492 1.439 0 C-N-CA 123.094 2.529 . . . . 0.0 113.267 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 60.7 t -97.89 135.76 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 177.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 9.3 m -122.24 -1.33 7.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 118.803 -0.618 . . . . 0.0 111.167 -178.705 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.8 p -148.79 141.33 24.35 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-N 119.203 0.91 . . . . 0.0 108.717 179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.509 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -142.23 121.32 12.93 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.047 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -142.1 148.23 38.03 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 112.868 0.692 . . . . 0.0 112.868 -179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -99.74 135.06 41.73 Favored 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 176.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.712 HE22 ' CB ' ' A' ' 1' ' ' CYS . 2.0 mt-30 -97.75 4.56 49.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 119.412 -0.327 . . . . 0.0 111.53 178.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 86.05 -169.73 42.49 Favored Glycine 0 C--N 1.342 0.882 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 178.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 98.0 m -88.26 128.33 35.47 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.801 0.334 . . . . 0.0 110.397 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 96.5 mtt-85 -147.17 161.59 40.6 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.544 -179.575 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -77.18 142.8 39.46 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.489 179.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 29.8 m -141.12 160.27 22.92 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.288 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.528 HD11 ' CB ' ' A' ' 84' ' ' ALA . 43.8 pt -111.89 147.29 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.316 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.257 179.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.59 137.53 13.32 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.409 ' O ' ' CD1' ' A' ' 61' ' ' ILE . 43.6 mt -120.63 111.99 18.34 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 121.403 0.62 . . . . 0.0 110.276 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.524 ' C ' HD12 ' A' ' 61' ' ' ILE . 14.4 tpt180 -87.21 109.24 19.34 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.189 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.75 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -98.99 132.61 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.079 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.636 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 32.19 28.42 0.0 OUTLIER 'General case' 0 C--N 1.343 0.303 0 O-C-N 124.052 0.845 . . . . 0.0 111.0 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.582 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 64.43 -25.88 0.1 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 111.294 -0.722 . . . . 0.0 111.294 -178.393 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.636 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -47.53 -104.91 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.752 0 N-CA-C 110.446 -1.061 . . . . 0.0 110.446 -178.293 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.22 171.93 9.15 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 120.747 0.308 . . . . 0.0 110.376 -179.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 21.2 tt -125.21 154.75 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.346 179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 54.1 tp -130.97 116.82 18.34 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.973 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 92.2 m95 -104.4 115.17 29.9 Favored 'General case' 0 N--CA 1.463 0.219 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -142.73 172.69 12.35 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.261 -179.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -78.34 156.28 78.79 Favored Pre-proline 0 C--N 1.327 -0.4 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.689 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.29 -21.44 72.63 Favored 'Trans proline' 0 N--CA 1.494 1.541 0 C-N-CA 122.794 2.33 . . . . 0.0 111.931 179.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 -92.95 -4.69 52.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.28 179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.647 ' ND1' ' N ' ' A' ' 1' ' ' CYS . 7.7 t60 -72.02 129.98 39.86 Favored 'General case' 0 C--O 1.233 0.192 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 48.9 mttp -86.86 127.58 35.04 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-O 121.51 0.672 . . . . 0.0 110.493 -179.299 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 76' ' ' LEU . 93.8 t -105.16 91.15 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 CA-C-N 115.228 -0.896 . . . . 0.0 111.602 -179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 15.3 tp -31.01 95.53 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.248 0 O-C-N 123.924 0.765 . . . . 0.0 111.123 -179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.446 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 0.2 OUTLIER -98.92 176.93 5.42 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 -177.973 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.478 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 12.8 pt-20 -63.85 -18.35 64.06 Favored 'General case' 0 N--CA 1.448 -0.537 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.291 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -107.73 24.3 13.13 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.432 0.158 . . . . 0.0 110.965 -179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 101.81 -141.37 15.26 Favored Glycine 0 C--N 1.321 -0.253 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -94.05 127.24 39.74 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.633 -0.283 . . . . 0.0 111.264 -178.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 35.3 mmm-85 -137.61 129.04 28.08 Favored 'General case' 0 N--CA 1.464 0.232 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.25 141.39 29.75 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.919 -0.582 . . . . 0.0 109.807 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.528 ' CB ' HD11 ' A' ' 57' ' ' ILE . . . -60.11 -38.58 83.41 Favored 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.164 -179.206 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -62.27 -3.2 4.86 Favored Glycine 0 C--N 1.338 0.69 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.678 -179.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 15.2 mm-40 -105.49 0.46 26.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.923 0.392 . . . . 0.0 110.179 179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 93.3 mt -80.95 127.63 32.78 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.554 0.693 . . . . 0.0 111.245 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.583 ' O ' ' N ' ' A' ' 90' ' ' GLY . 23.6 mmt85 -131.64 149.26 52.56 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.788 -179.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 66.0 tttm -44.57 86.33 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 O-C-N 123.465 0.478 . . . . 0.0 110.845 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 158.08 -15.85 0.29 Allowed Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 -179.706 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -85.39 130.1 34.67 Favored 'General case' 0 CA--C 1.52 -0.206 0 CA-C-N 117.209 0.505 . . . . 0.0 110.394 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.478 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 90.1 mtm180 -88.94 131.17 35.26 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.408 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 35.7 m -114.42 142.69 26.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.77 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.459 ' O ' HG13 ' A' ' 135' ' ' VAL . . . -67.1 131.52 45.98 Favored 'General case' 0 C--N 1.33 -0.251 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.72 -179.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.36 160.72 39.99 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.408 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.534 ' NH1' ' O ' ' A' ' 101' ' ' GLY . 9.0 tpt180 -104.6 129.63 52.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.59 -179.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' OD2' ' NH1' ' A' ' 104' ' ' ARG . 42.1 t0 -101.33 123.67 45.78 Favored 'General case' 0 C--O 1.22 -0.49 0 CA-C-O 118.996 -0.526 . . . . 0.0 110.468 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 61.4 t -77.21 -16.72 14.48 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 118.474 0.579 . . . . 0.0 111.12 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 -69.65 -58.43 3.94 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.857 -0.424 . . . . 0.0 109.857 -179.013 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.45 ' C ' ' H ' ' A' ' 102' ' ' GLU . 80.8 p -95.86 -12.65 24.88 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.105 179.303 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.534 ' O ' ' NH1' ' A' ' 96' ' ' ARG . . . 76.13 -16.05 4.88 Favored Glycine 0 C--O 1.223 -0.583 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.45 ' H ' ' C ' ' A' ' 100' ' ' THR . 97.2 mt-10 -80.78 158.05 25.59 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.614 0.245 . . . . 0.0 110.606 -177.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.572 ' H ' HD23 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -86.68 141.12 29.16 Favored 'General case' 0 N--CA 1.444 -0.751 0 CA-C-O 121.359 0.6 . . . . 0.0 110.059 179.77 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.45 ' NH1' ' OD2' ' A' ' 97' ' ' ASP . 37.6 ptt180 -139.81 178.65 7.09 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.811 -0.632 . . . . 0.0 110.214 -179.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.446 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.8 m-85 -113.31 147.74 37.03 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.801 -179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 20.2 m -139.63 160.17 40.48 Favored 'General case' 0 C--O 1.222 -0.366 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 179.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 23.6 m -90.63 153.02 3.26 Favored 'Isoleucine or valine' 0 C--O 1.233 0.225 0 CA-C-O 121.015 0.436 . . . . 0.0 110.842 179.804 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.41 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.6 mm -70.31 155.39 7.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.094 179.297 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.41 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 14.8 tpt180 -106.01 -48.31 3.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.704 179.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -166.07 145.74 6.19 Favored 'General case' 0 N--CA 1.448 -0.569 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 179.686 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 72.0 t -96.78 134.38 34.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 120.961 0.41 . . . . 0.0 110.018 179.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 mt -102.68 145.22 30.15 Favored Pre-proline 0 N--CA 1.466 0.358 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.367 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -67.16 164.06 31.75 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 122.408 2.072 . . . . 0.0 111.534 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.467 HG22 HG22 ' A' ' 57' ' ' ILE . 81.3 p -67.03 156.42 36.1 Favored 'General case' 0 N--CA 1.446 -0.627 0 CA-C-O 121.388 0.613 . . . . 0.0 110.873 179.782 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 79.3 mtp180 -139.98 -137.35 0.12 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.757 -179.689 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 26.6 ttm180 -158.04 131.31 7.58 Favored 'General case' 0 N--CA 1.451 -0.415 0 CA-C-O 121.079 0.466 . . . . 0.0 110.254 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.79 173.26 3.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.697 -0.683 . . . . 0.0 111.13 -179.07 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.3 mtp85 -78.39 145.48 35.14 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 179.509 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 2.9 p -119.5 141.08 49.51 Favored 'General case' 0 N--CA 1.463 0.21 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.155 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.62 ' C ' ' OE1' ' A' ' 51' ' ' GLN . 57.2 m-85 -118.5 168.55 10.56 Favored 'General case' 0 CA--C 1.509 -0.601 0 CA-C-N 115.57 -0.741 . . . . 0.0 111.199 -179.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -157.79 120.33 3.82 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.989 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.407 HD21 HG22 ' A' ' 23' ' ' VAL . 67.1 mt -118.04 129.52 55.62 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -87.5 109.63 19.75 Favored 'General case' 0 CA--C 1.516 -0.338 0 N-CA-C 109.851 -0.425 . . . . 0.0 109.851 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.463 HG21 ' O ' ' A' ' 129' ' ' THR . 21.6 t -83.0 113.09 21.65 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.97 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.445 ' C ' ' O ' ' A' ' 124' ' ' VAL . 73.7 tt0 29.96 -98.38 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 O-C-N 123.775 0.672 . . . . 0.0 111.1 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -123.62 -25.92 4.26 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.271 179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.641 HD12 ' HE ' ' A' ' 43' ' ' ARG . 96.4 mt -84.85 94.55 8.76 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 -179.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.62 ' C ' HG22 ' A' ' 129' ' ' THR . 29.7 m170 -60.6 98.24 0.06 Allowed 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.682 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.62 HG22 ' C ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.1 154.77 0.03 OUTLIER 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.941 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.608 HD23 ' N ' ' A' ' 130' ' ' LEU . 1.2 pt? -162.83 161.49 26.06 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 121.796 0.808 . . . . 0.0 112.369 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 136' ' ' VAL . 9.3 t -86.2 126.15 40.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 N-CA-C 108.068 -1.086 . . . . 0.0 108.068 179.42 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.477 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.88 123.78 25.32 Favored 'General case' 0 C--O 1.234 0.263 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.757 -179.851 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.602 ' O ' HG23 ' A' ' 135' ' ' VAL . 77.8 mm-40 54.29 44.66 28.68 Favored 'General case' 0 CA--C 1.515 -0.395 0 CA-C-N 115.681 -0.69 . . . . 0.0 109.682 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 62.0 28.1 69.88 Favored Glycine 0 CA--C 1.523 0.587 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 179.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.602 HG23 ' O ' ' A' ' 133' ' ' GLU . 5.2 t -132.67 151.3 34.27 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 CA-C-N 118.155 0.977 . . . . 0.0 108.681 -179.751 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.428 HG22 HG22 ' A' ' 131' ' ' VAL . 89.9 t -108.9 112.34 40.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 118.232 0.469 . . . . 0.0 110.239 178.841 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' A' ' 138' ' ' HIS . 29.4 m -146.63 136.72 17.51 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.406 0 CA-C-O 119.086 -0.483 . . . . 0.0 110.021 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.545 ' O ' ' CE1' ' A' ' 73' ' ' HIS . 37.4 t-80 -31.54 152.08 0.0 OUTLIER 'General case' 0 C--O 1.223 -0.295 0 O-C-N 123.577 0.548 . . . . 0.0 111.36 179.597 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.521 ' OD1' ' CE1' ' A' ' 138' ' ' HIS . 49.2 p30 . . . . . 0 C--N 1.325 -0.464 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.74 179.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.9 m . . . . . 0 N--CA 1.489 1.523 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 70.0 mt -101.16 143.72 30.91 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.365 -179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -88.18 162.41 16.71 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.637 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.431 ' OE2' ' OE1' ' A' ' 20' ' ' GLU . 59.8 tt0 -60.37 142.69 54.54 Favored 'General case' 0 CA--C 1.52 -0.179 0 CA-C-O 120.786 0.327 . . . . 0.0 110.466 178.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 115.98 -21.66 12.08 Favored Glycine 0 C--N 1.333 0.376 0 N-CA-C 110.507 -1.037 . . . . 0.0 110.507 179.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.577 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 23.0 m -69.01 120.03 14.24 Favored 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 120.868 -0.333 . . . . 0.0 110.11 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.508 ' NE ' HG21 ' A' ' 16' ' ' THR . 74.7 mtp85 -95.15 112.63 24.31 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 120.752 -0.379 . . . . 0.0 110.91 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.6 mt -99.17 113.29 33.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.621 -179.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.7 t80 -76.48 137.79 39.88 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 178.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' A' ' 12' ' ' VAL . 10.2 t0 -106.31 132.64 20.73 Favored Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 121.25 -0.18 . . . . 0.0 110.622 -179.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -73.03 -30.88 10.36 Favored 'Trans proline' 0 N--CA 1.497 1.722 0 C-N-CA 122.187 1.925 . . . . 0.0 112.433 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.533 ' N ' ' OD1' ' A' ' 10' ' ' ASP . 24.9 t -72.98 -53.89 17.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.868 -179.497 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.8 p -77.64 -36.79 51.2 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.136 0.493 . . . . 0.0 110.159 -179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 81.23 6.9 89.01 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 179.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.447 HG22 ' N ' ' A' ' 16' ' ' THR . 48.1 m -111.55 156.53 21.6 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 117.769 0.785 . . . . 0.0 109.717 -179.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.508 HG21 ' NE ' ' A' ' 7' ' ' ARG . 27.0 m -80.49 116.77 20.71 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.146 0.498 . . . . 0.0 110.976 -179.154 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -107.32 150.29 26.86 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.302 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 78.5 mtm180 -101.43 132.74 46.86 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.914 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.548 HG23 ' N ' ' A' ' 20' ' ' GLU . 2.8 tp -52.69 -40.21 33.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 120.764 0.316 . . . . 0.0 111.077 -179.775 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.548 ' N ' HG23 ' A' ' 19' ' ' ILE . 6.9 tt0 -58.51 -36.25 73.51 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.191 0.519 . . . . 0.0 110.483 -179.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -82.18 -38.36 24.76 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.615 179.853 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 73.6 t -69.51 -43.76 80.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 112.214 0.45 . . . . 0.0 112.214 -179.127 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.589 HG22 HD21 ' A' ' 122' ' ' LEU . 72.5 t -73.82 -46.73 46.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 111.784 0.29 . . . . 0.0 111.784 -178.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' A' ' 24' ' ' ASP . 67.9 t0 -60.85 -36.4 79.05 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.019 0.437 . . . . 0.0 110.813 -178.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.559 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -101.36 24.55 31.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.559 ' C ' ' O ' ' A' ' 25' ' ' GLY . 83.3 mtm180 17.22 62.73 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.119 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . . . . . . . . . 79.2 mttt -86.57 131.96 44.11 Favored Pre-proline 0 N--CA 1.449 -0.486 0 C-N-CA 121.098 -0.241 . . . . 0.0 110.869 -176.438 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 63.3 Cg_endo -75.07 87.21 1.35 Allowed 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 121.491 1.461 . . . . 0.0 110.41 178.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 29' ' ' ILE . 30.1 pt -120.67 -172.01 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-O 120.917 0.389 . . . . 0.0 110.491 -179.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.43 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 16.5 m80 -127.21 162.88 25.13 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.747 -179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 29.0 m -148.46 171.24 2.44 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.237 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 18.0 t -89.01 136.33 23.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -115.27 164.33 14.4 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.67 -0.241 . . . . 0.0 110.414 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -130.84 142.97 50.42 Favored 'General case' 0 C--O 1.233 0.187 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -113.36 177.66 4.55 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 50.7 mtmt -72.74 -16.33 61.66 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 122.101 -0.375 . . . . 0.0 111.105 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -78.71 -16.46 57.22 Favored 'General case' 0 N--CA 1.447 -0.581 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.336 179.288 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.97 22.85 40.45 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.49 ' C ' HD22 ' A' ' 40' ' ' LEU . 33.1 p -102.11 133.84 46.31 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 120.676 0.274 . . . . 0.0 111.052 178.13 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.776 HD22 ' N ' ' A' ' 40' ' ' LEU . 2.2 mm? -94.57 133.05 38.63 Favored 'General case' 0 N--CA 1.448 -0.546 0 CA-C-O 121.069 0.461 . . . . 0.0 111.128 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -143.66 139.87 29.8 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.661 -0.699 . . . . 0.0 110.569 -179.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.2 144.86 49.99 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.127 -0.488 . . . . 0.0 109.969 -178.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.488 ' HE ' ' HB3' ' A' ' 125' ' ' GLU . 15.7 mtp85 -147.81 138.91 13.36 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.181 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -74.94 158.1 42.64 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.7 2.267 . . . . 0.0 112.831 -179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 18.9 t -93.82 131.85 39.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 177.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.0 t -119.24 -3.1 9.64 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.334 -0.393 . . . . 0.0 111.387 -177.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . 0.442 ' C ' ' CD2' ' A' ' 48' ' ' TRP . 0.3 OUTLIER -155.06 149.01 25.7 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.612 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.571 ' N ' ' CE3' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -144.84 131.02 19.48 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.701 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -134.64 144.56 47.92 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 121.379 0.609 . . . . 0.0 111.899 -179.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.414 ' OD1' ' N ' ' A' ' 51' ' ' GLN . 58.1 t0 -112.76 139.21 48.57 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 177.224 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.448 ' HB2' ' H ' ' A' ' 52' ' ' GLY . 2.8 mm-40 -105.15 -106.46 0.3 Allowed 'General case' 0 N--CA 1.436 -1.162 0 CA-C-N 114.328 -1.305 . . . . 0.0 108.854 -178.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.448 ' H ' ' HB2' ' A' ' 51' ' ' GLN . . . -167.24 -156.1 9.59 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 114.457 -1.247 . . . . 0.0 112.354 -177.26 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.457 HG22 ' HG3' ' A' ' 116' ' ' ARG . 0.5 OUTLIER -94.58 119.56 33.45 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 121.077 0.465 . . . . 0.0 111.2 -179.264 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -138.31 164.66 28.7 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.51 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 38.1 m-20 -76.98 140.9 40.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.3 m -140.12 159.61 26.1 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.164 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.596 HD11 ' HB1' ' A' ' 84' ' ' ALA . 32.7 pt -112.58 151.26 14.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-O 120.966 0.412 . . . . 0.0 109.991 179.353 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.16 131.68 10.76 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.874 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 32.2 mt -113.16 113.19 25.02 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.897 0.38 . . . . 0.0 110.044 -179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.467 ' C ' HD12 ' A' ' 61' ' ' ILE . 12.6 tpt180 -87.75 107.06 18.47 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.355 -179.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.742 HD12 ' N ' ' A' ' 61' ' ' ILE . 1.7 mp -96.69 127.79 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.929 -179.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.578 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 35.02 27.2 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.165 -0.925 . . . . 0.0 111.072 -179.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.546 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 68.22 -26.31 0.26 Allowed Glycine 0 CA--C 1.531 1.066 0 N-CA-C 111.397 -0.681 . . . . 0.0 111.397 -178.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.578 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -47.51 -104.78 0.01 OUTLIER Glycine 0 N--CA 1.448 -0.513 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 -178.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.95 171.82 9.02 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.105 0.479 . . . . 0.0 110.726 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.448 HD13 ' HE1' ' A' ' 68' ' ' TRP . 19.1 tt -125.38 152.06 31.78 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.711 -0.677 . . . . 0.0 110.34 179.64 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 68' ' ' TRP . 2.2 tt -127.63 114.91 17.98 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.496 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.57 ' N ' HD23 ' A' ' 67' ' ' LEU . 81.3 m95 -102.93 120.04 39.92 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -151.85 171.09 18.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.158 -179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 20.4 p -76.91 154.71 83.04 Favored Pre-proline 0 CA--C 1.531 0.232 0 C-N-CA 120.584 -0.447 . . . . 0.0 111.227 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_exo -58.89 -24.09 70.8 Favored 'Trans proline' 0 N--CA 1.499 1.849 0 C-N-CA 122.096 1.864 . . . . 0.0 112.211 178.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -84.75 -8.64 58.76 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.853 0.359 . . . . 0.0 110.813 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.573 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 7.2 t60 -72.8 132.66 43.86 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 46.5 mttp -90.44 131.73 36.04 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.183 0.516 . . . . 0.0 110.348 -178.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.726 ' O ' HG23 ' A' ' 77' ' ' THR . 92.5 t -107.37 89.59 1.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-N 115.375 -0.83 . . . . 0.0 111.117 -179.431 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 75' ' ' VAL . 55.7 tp -29.12 97.17 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.355 0 O-C-N 123.508 0.505 . . . . 0.0 111.717 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.726 HG23 ' O ' ' A' ' 75' ' ' VAL . 38.5 p -98.68 177.21 5.37 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.531 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.548 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.8 pt-20 -66.45 -17.56 64.86 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.341 -179.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 1.3 t80 -108.07 22.22 16.25 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-O 120.745 0.307 . . . . 0.0 111.117 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 105.76 -141.09 15.34 Favored Glycine 0 N--CA 1.462 0.431 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 97.0 m95 -97.38 130.91 44.47 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.724 -0.238 . . . . 0.0 110.924 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 78.8 mtp85 -139.7 131.12 26.9 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -54.43 144.73 20.09 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.449 -0.341 . . . . 0.0 110.084 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.596 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -63.11 -38.88 92.93 Favored 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.753 -0.379 . . . . 0.0 111.576 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -61.7 -1.75 2.91 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.622 -0.799 . . . . 0.0 111.428 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.408 ' H ' ' C ' ' A' ' 84' ' ' ALA . 72.3 mm-40 -107.49 -2.99 19.9 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.941 0.4 . . . . 0.0 110.184 179.761 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 85.7 mt -76.88 125.59 29.56 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.91 -0.587 . . . . 0.0 110.917 -179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.558 ' O ' ' N ' ' A' ' 90' ' ' GLY . 7.1 tpt180 -132.1 148.42 52.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.501 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 85.2 tttt -43.34 88.83 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.932 0.396 . . . . 0.0 110.693 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 155.97 -16.57 0.45 Allowed Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -87.21 129.79 34.82 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 120.728 0.299 . . . . 0.0 110.771 -179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.548 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 87.1 mtm180 -90.19 131.06 36.23 Favored 'General case' 0 CA--C 1.522 -0.119 0 CA-C-O 121.083 0.468 . . . . 0.0 110.586 -178.617 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 27.3 m -113.15 143.32 23.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.391 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -63.13 131.78 49.64 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.833 0.349 . . . . 0.0 110.923 -178.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.451 HG22 ' O ' ' A' ' 104' ' ' ARG . 25.8 m -129.57 157.81 42.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.368 179.453 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 71.7 ttt180 -106.98 130.28 54.65 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.458 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 42.5 t0 -100.53 121.9 42.34 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.373 179.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 57.6 t -75.01 -15.44 15.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 O-C-N 122.081 -0.387 . . . . 0.0 110.648 178.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 5.2 tm-20 -70.75 -58.03 4.06 Favored 'General case' 0 C--O 1.232 0.154 0 C-N-CA 120.485 -0.486 . . . . 0.0 109.927 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.442 ' C ' ' H ' ' A' ' 102' ' ' GLU . 45.9 p -96.79 -12.56 23.48 Favored 'General case' 0 CA--C 1.519 -0.241 0 CA-C-N 116.751 -0.204 . . . . 0.0 110.562 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 75.53 -13.72 6.17 Favored Glycine 0 C--N 1.333 0.379 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.442 ' H ' ' C ' ' A' ' 100' ' ' THR . 95.4 mt-10 -81.74 157.1 24.67 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.972 0.415 . . . . 0.0 111.078 -177.794 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.629 ' H ' HD23 ' A' ' 103' ' ' LEU . 1.9 pt? -78.48 140.4 38.61 Favored 'General case' 0 N--CA 1.442 -0.87 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.49 179.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.451 ' O ' HG22 ' A' ' 95' ' ' VAL . 52.5 mtm180 -139.55 174.51 10.44 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 178.809 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.47 ' OH ' ' C ' ' A' ' 77' ' ' THR . 1.9 m-85 -115.3 146.09 41.84 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.222 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.44 ' OG ' HG21 ' A' ' 95' ' ' VAL . 14.8 m -139.78 161.44 37.54 Favored 'General case' 0 N--CA 1.463 0.212 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 179.033 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.3 t -94.35 154.75 3.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.667 0.27 . . . . 0.0 110.467 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . . . . . . . . . 97.0 mt -76.38 149.96 6.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 178.735 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 74.1 ttt-85 -99.16 -41.77 7.36 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.613 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -165.74 146.81 6.97 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.444 ' C ' HD12 ' A' ' 112' ' ' LEU . 71.9 t -97.63 134.43 35.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.507 ' CD1' ' N ' ' A' ' 112' ' ' LEU . 5.1 mp -98.67 148.78 35.02 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.074 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.79 162.03 44.03 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.796 2.331 . . . . 0.0 111.436 179.398 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 114' ' ' THR . 2.9 p -62.49 149.38 43.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.981 0.419 . . . . 0.0 110.742 -179.694 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.405 ' HG2' ' H ' ' A' ' 116' ' ' ARG . 30.9 ttt85 -132.3 -141.24 0.21 Allowed 'General case' 0 N--CA 1.462 0.167 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.663 -179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . 0.457 ' HG3' HG22 ' A' ' 53' ' ' THR . 12.8 tpt180 -157.06 129.98 7.71 Favored 'General case' 0 N--CA 1.449 -0.491 0 CA-C-N 115.762 -0.653 . . . . 0.0 110.322 -179.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -172.19 170.5 5.16 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.087 -179.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 95.5 mtm-85 -75.57 149.29 38.34 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.868 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 59.2 p -128.78 142.7 50.9 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.069 0.461 . . . . 0.0 109.764 179.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' A' ' 120' ' ' PHE . 9.2 m-85 -120.85 176.4 5.56 Favored 'General case' 0 CA--C 1.512 -0.488 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.897 -178.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -148.76 153.54 38.31 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.594 -0.73 . . . . 0.0 110.855 179.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.589 HD21 HG22 ' A' ' 23' ' ' VAL . 90.8 mt -140.18 171.14 14.59 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.681 -179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -135.17 106.11 6.61 Favored 'General case' 0 CA--C 1.518 -0.252 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.498 ' O ' ' C ' ' A' ' 125' ' ' GLU . 7.9 t -86.89 111.74 22.05 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.108 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.498 ' C ' ' O ' ' A' ' 124' ' ' VAL . 5.2 tp10 20.79 -116.57 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 O-C-N 123.657 0.598 . . . . 0.0 111.685 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -106.74 -26.14 11.43 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.277 179.31 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 58.9 mt -89.21 69.84 8.26 Favored 'General case' 0 CA--C 1.507 -0.708 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.498 ' O ' HG23 ' A' ' 129' ' ' THR . 28.9 m170 -42.92 104.88 0.04 OUTLIER 'General case' 0 CA--C 1.511 -0.528 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.498 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.0 OUTLIER 167.4 139.59 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.451 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.675 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.569 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.3 pt? -147.14 156.73 43.23 Favored 'General case' 0 C--O 1.232 0.175 0 CA-C-O 121.509 0.671 . . . . 0.0 112.122 179.542 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 131' ' ' VAL . 9.0 p -89.02 125.35 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.577 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.8 126.59 30.9 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.947 -179.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.503 ' C ' ' H ' ' A' ' 135' ' ' VAL . 15.4 mm-40 53.81 46.78 25.07 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.982 -179.791 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 70.33 -22.06 0.51 Allowed Glycine 0 CA--C 1.524 0.649 0 N-CA-C 111.421 -0.672 . . . . 0.0 111.421 179.267 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.503 ' H ' ' C ' ' A' ' 133' ' ' GLU . 4.1 t -89.01 152.56 3.32 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.306 0 CA-C-N 117.121 0.461 . . . . 0.0 110.66 -179.411 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -110.44 115.55 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.416 179.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.423 ' O ' ' O ' ' A' ' 138' ' ' HIS . 12.3 m -147.31 137.69 17.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.528 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.573 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 53.1 t-80 -36.52 156.79 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.529 ' OXT' ' ND1' ' A' ' 138' ' ' HIS . 16.1 p30 . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.468 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 7.6 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.5 mt -105.12 141.49 36.58 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-O 120.938 0.399 . . . . 0.0 110.543 -179.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -84.35 161.42 20.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.463 179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 63.8 tt0 -61.68 146.03 50.45 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.367 -0.378 . . . . 0.0 110.381 179.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 106.57 -16.4 40.81 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.633 HG23 ' HG3' ' A' ' 133' ' ' GLU . 26.3 m -68.47 124.16 22.81 Favored 'General case' 0 C--N 1.327 -0.376 0 C-N-CA 120.977 -0.289 . . . . 0.0 110.789 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.472 ' HE ' HG21 ' A' ' 16' ' ' THR . 81.0 mtp180 -85.03 149.82 25.31 Favored 'General case' 0 N--CA 1.456 -0.157 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 179.162 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 56.2 mt -134.13 108.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.271 179.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.413 ' HB3' HH22 ' A' ' 96' ' ' ARG . 43.9 t80 -76.94 126.7 31.4 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 178.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -96.06 131.2 29.37 Favored Pre-proline 0 CA--C 1.538 0.483 0 C-N-CA 120.725 -0.39 . . . . 0.0 111.094 -179.335 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.05 -33.17 4.73 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 122.33 2.02 . . . . 0.0 111.8 179.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.426 HG21 ' CG ' ' A' ' 30' ' ' HIS . 73.6 t -73.31 -54.27 16.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.159 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.64 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.5 m -75.17 -38.09 61.01 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.163 0.506 . . . . 0.0 110.065 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.23 7.36 85.18 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 111.059 -0.816 . . . . 0.0 111.059 -179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 16' ' ' THR . 3.0 t -106.9 -167.22 1.25 Allowed 'General case' 0 C--N 1.338 0.09 0 CA-C-N 117.652 0.726 . . . . 0.0 109.895 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.472 HG21 ' HE ' ' A' ' 7' ' ' ARG . 93.3 m -115.0 115.28 26.6 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.547 179.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . . . . . . . . . 14.8 m-70 -100.68 140.75 34.51 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.744 -179.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 10.7 tpp85 -97.27 127.2 43.02 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.538 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.671 HD12 HD11 ' A' ' 122' ' ' LEU . 3.1 tp -51.57 -40.3 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.303 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.771 -178.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.541 ' N ' HG23 ' A' ' 19' ' ' ILE . 14.3 tt0 -53.74 -35.29 61.06 Favored 'General case' 0 C--N 1.325 -0.49 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.961 179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -79.72 -34.13 40.31 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.695 -179.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.662 ' O ' ' O ' ' A' ' 26' ' ' ARG . 85.1 t -64.83 -45.61 94.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 120.807 0.337 . . . . 0.0 111.122 179.916 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.925 HG21 ' CD1' ' A' ' 120' ' ' PHE . 87.9 t -66.54 -45.16 89.49 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 O-C-N 121.186 -0.946 . . . . 0.0 111.951 -178.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -55.41 -42.41 74.04 Favored 'General case' 0 C--N 1.325 -0.473 0 C-N-CA 120.958 -0.297 . . . . 0.0 111.741 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -124.75 33.49 3.72 Favored Glycine 0 CA--C 1.529 0.95 0 N-CA-C 111.449 -0.66 . . . . 0.0 111.449 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.662 ' O ' ' O ' ' A' ' 22' ' ' VAL . 82.4 mtp180 58.14 -100.58 0.11 Allowed 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.638 ' C ' ' H ' ' A' ' 29' ' ' ILE . 40.7 mttt 79.94 82.65 0.09 OUTLIER Pre-proline 0 C--N 1.299 -1.604 0 C-N-CA 122.898 0.479 . . . . 0.0 110.388 -178.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.7 ' O ' ' O ' ' A' ' 29' ' ' ILE . 34.1 Cg_exo -59.52 19.76 0.03 OUTLIER 'Trans proline' 0 N--CA 1.496 1.665 0 C-N-CA 122.745 2.297 . . . . 0.0 112.577 179.514 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.7 ' O ' ' O ' ' A' ' 28' ' ' PRO . 20.3 pt -35.41 -178.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 O-C-N 124.041 0.838 . . . . 0.0 111.189 -178.258 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.426 ' CG ' HG21 ' A' ' 12' ' ' VAL . 56.6 m80 -119.78 163.33 17.63 Favored 'General case' 0 C--N 1.326 -0.455 0 O-C-N 121.43 -0.794 . . . . 0.0 110.891 179.546 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 27.8 m -149.1 171.33 1.97 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.298 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.9 t -91.03 135.13 27.58 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.387 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -111.47 168.09 9.81 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.82 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -135.06 142.67 46.39 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.216 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -115.39 177.93 4.48 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.785 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -70.54 -13.9 62.29 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.92 0.39 . . . . 0.0 110.656 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -81.34 -18.53 45.35 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.279 179.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.9 24.91 36.28 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 -179.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 13.6 p -103.11 135.18 45.25 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-O 120.7 0.286 . . . . 0.0 111.203 178.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 65.4 mt -92.59 131.24 37.86 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.434 -0.348 . . . . 0.0 110.654 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 8.2 t-160 -142.82 139.82 31.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.483 -179.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.5 ' O ' ' NE ' ' A' ' 43' ' ' ARG . . . -70.55 141.95 51.82 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.794 -178.51 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.5 ' NE ' ' O ' ' A' ' 42' ' ' ALA . 5.1 mmp_? -143.85 138.21 14.95 Favored Pre-proline 0 CA--C 1.535 0.398 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.898 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -77.8 158.81 31.46 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 C-N-CA 122.86 2.373 . . . . 0.0 112.727 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 45.9 t -100.32 135.42 36.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 178.243 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 34.9 m -124.9 1.05 5.06 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.543 -178.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 2.9 t -144.34 133.68 23.16 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 118.548 0.613 . . . . 0.0 109.792 179.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.531 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -132.68 117.26 17.65 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 178.106 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . . . . . . . . . 51.4 m-85 -141.24 146.55 37.0 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.3 t0 -89.2 132.83 34.67 Favored 'General case' 0 C--N 1.33 -0.246 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 176.642 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.434 ' HA ' HE21 ' A' ' 51' ' ' GLN . 0.0 OUTLIER -92.17 -0.64 57.42 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.186 179.967 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.36 -179.6 51.66 Favored Glycine 0 CA--C 1.525 0.692 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.31 179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.8 m -91.74 126.6 36.89 Favored 'General case' 0 CA--C 1.519 -0.244 0 CA-C-O 120.945 0.402 . . . . 0.0 110.39 179.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 78.1 mtp85 -150.25 170.48 18.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.798 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -75.45 141.83 43.07 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.041 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -142.44 156.46 18.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.466 ' CG2' HG22 ' A' ' 114' ' ' THR . 37.7 pt -110.75 154.4 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.278 0 CA-C-O 120.978 0.418 . . . . 0.0 110.258 179.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -105.84 132.73 11.26 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 21.0 mt -115.26 114.29 25.0 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 121.104 0.478 . . . . 0.0 110.222 -179.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 68.3 ttt180 -99.19 122.75 42.81 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.648 -0.705 . . . . 0.0 109.968 179.58 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 63' ' ' GLY . 94.4 mt -111.37 143.56 20.98 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.465 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 -179.692 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.633 ' C ' ' H ' ' A' ' 64' ' ' GLY . . . 29.04 30.62 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 O-C-N 123.831 0.707 . . . . 0.0 111.517 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.629 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 64.1 -20.26 0.09 OUTLIER Glycine 0 CA--C 1.533 1.184 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.672 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.633 ' H ' ' C ' ' A' ' 62' ' ' ALA . . . -49.38 -109.13 0.01 OUTLIER Glycine 0 N--CA 1.445 -0.74 0 N-CA-C 110.941 -0.864 . . . . 0.0 110.941 -178.094 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -92.28 172.89 8.11 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 120.994 0.426 . . . . 0.0 110.553 -178.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . 0.508 HG22 ' N ' ' A' ' 67' ' ' LEU . 97.1 mt -125.89 158.64 34.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.524 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.508 ' N ' HG22 ' A' ' 66' ' ' ILE . 42.5 tp -132.68 117.43 17.85 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.582 179.45 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . . . . . . . . . 81.6 m95 -102.79 115.74 31.19 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.087 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -147.13 171.74 14.86 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.368 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 75.9 p -77.09 152.52 82.19 Favored Pre-proline 0 C--N 1.327 -0.394 0 C-N-CA 120.457 -0.497 . . . . 0.0 111.35 -179.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -57.19 -28.8 81.01 Favored 'Trans proline' 0 N--CA 1.498 1.768 0 C-N-CA 122.214 1.943 . . . . 0.0 112.336 179.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -83.21 -5.66 59.2 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.899 0.38 . . . . 0.0 110.563 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 6.9 t60 -71.64 130.02 40.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.43 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.422 ' HD2' ' H ' ' A' ' 74' ' ' LYS . 0.0 OUTLIER -85.64 127.26 34.43 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.236 0.541 . . . . 0.0 110.737 -179.464 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.451 ' O ' ' N ' ' A' ' 77' ' ' THR . 91.5 t -109.6 93.75 2.7 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.619 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.117 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.448 HD13 ' CH2' ' A' ' 81' ' ' TRP . 6.4 tp -31.42 93.6 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.677 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.451 ' N ' ' O ' ' A' ' 75' ' ' VAL . 0.9 OUTLIER -97.25 177.86 5.42 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 -178.236 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' OE1' ' NE ' ' A' ' 92' ' ' ARG . 18.2 pt-20 -64.68 -22.84 67.07 Favored 'General case' 0 N--CA 1.448 -0.573 0 CA-C-N 116.01 -0.541 . . . . 0.0 111.262 -179.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -104.59 26.39 9.11 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 121.235 -0.186 . . . . 0.0 110.99 -179.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.415 ' O ' ' OG1' ' A' ' 77' ' ' THR . . . 90.18 -177.88 43.01 Favored Glycine 0 CA--C 1.52 0.387 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.448 ' CH2' HD13 ' A' ' 76' ' ' LEU . 83.1 m95 -57.01 130.74 47.38 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 120.977 0.418 . . . . 0.0 110.335 -177.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -146.38 135.26 22.42 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.383 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -52.78 144.5 14.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.146 -0.479 . . . . 0.0 109.917 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.462 ' C ' ' H ' ' A' ' 86' ' ' GLU . . . -64.25 -38.76 92.21 Favored 'General case' 0 N--CA 1.451 -0.402 0 CA-C-N 116.627 -0.26 . . . . 0.0 111.488 -179.014 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -59.51 1.02 0.52 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.449 -0.881 . . . . 0.0 111.76 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.462 ' H ' ' C ' ' A' ' 84' ' ' ALA . 19.9 tp10 -107.66 5.43 26.83 Favored 'General case' 0 CA--C 1.531 0.229 0 CA-C-O 121.159 0.504 . . . . 0.0 110.049 179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . . . . . . . . . 91.4 mt -83.29 123.19 29.37 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.226 0.536 . . . . 0.0 111.018 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . 0.536 ' O ' ' N ' ' A' ' 90' ' ' GLY . 33.1 mmt180 -132.47 149.76 52.28 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.803 -179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 62.4 tttm -48.02 87.89 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.977 0.418 . . . . 0.0 110.657 -179.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' A' ' 88' ' ' ARG . . . 156.73 -20.0 0.44 Allowed Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.911 -0.875 . . . . 0.0 110.911 -179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 61.3 t0 -84.18 129.48 34.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.83 0.348 . . . . 0.0 110.582 -179.769 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.411 ' NE ' ' OE1' ' A' ' 78' ' ' GLU . 88.2 mtm180 -90.68 132.38 35.82 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.142 -179.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.6 m -119.93 152.14 22.61 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.823 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.442 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -68.69 137.36 54.07 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.491 -179.422 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.436 HG21 ' OG ' ' A' ' 106' ' ' SER . 30.0 m -137.19 162.34 33.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.465 178.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.709 HH21 HG11 ' A' ' 131' ' ' VAL . 12.2 ttm180 -106.58 129.45 54.51 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.535 179.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.439 ' O ' ' N ' ' A' ' 101' ' ' GLY . 45.9 t0 -100.97 123.77 45.67 Favored 'General case' 0 C--O 1.224 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.426 178.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 43.4 t -74.24 -15.73 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 118.184 0.447 . . . . 0.0 111.12 179.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -72.45 -55.18 7.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.01 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.467 ' C ' ' H ' ' A' ' 102' ' ' GLU . 3.2 m -99.44 -16.27 18.43 Favored 'General case' 0 N--CA 1.462 0.142 0 CA-C-N 116.735 -0.211 . . . . 0.0 110.632 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 97' ' ' ASP . . . 73.84 -14.32 3.67 Favored Glycine 0 C--N 1.334 0.453 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.467 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.3 mt-10 -80.71 160.4 24.97 Favored 'General case' 0 CA--C 1.514 -0.438 0 CA-C-O 120.781 0.324 . . . . 0.0 110.64 -177.651 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.442 HD21 ' HB1' ' A' ' 94' ' ' ALA . 7.5 tp -79.03 126.59 30.9 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.616 -0.434 . . . . 0.0 110.027 -179.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.408 ' O ' HG22 ' A' ' 95' ' ' VAL . 65.8 mtp85 -126.81 168.17 14.8 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.956 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 6.9 m-30 -110.32 142.72 41.58 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.5 -179.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . 0.436 ' OG ' HG21 ' A' ' 95' ' ' VAL . 12.7 m -137.94 158.44 44.33 Favored 'General case' 0 C--O 1.232 0.179 0 CA-C-N 115.666 -0.697 . . . . 0.0 109.331 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 9.0 p -89.85 152.82 3.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.919 0.39 . . . . 0.0 110.737 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.43 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.9 mm -67.46 156.7 6.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.989 -0.551 . . . . 0.0 109.844 179.502 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.43 ' N ' ' CG2' ' A' ' 108' ' ' ILE . 17.2 tpt180 -108.39 -52.33 2.78 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.01 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -165.56 144.47 6.27 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 70.0 t -95.09 133.29 36.49 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.087 0.47 . . . . 0.0 110.037 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.62 127.02 32.39 Favored Pre-proline 0 CA--C 1.536 0.432 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.518 -179.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -47.88 161.64 0.33 Allowed 'Trans proline' 0 N--CA 1.494 1.517 0 C-N-CA 122.206 1.937 . . . . 0.0 112.021 179.274 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.466 HG22 ' CG2' ' A' ' 57' ' ' ILE . 80.6 p -64.99 153.82 39.53 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.0 0.429 . . . . 0.0 110.699 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 31.8 ttp180 -134.98 -140.8 0.17 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.586 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.8 mtm-85 -156.79 130.44 8.19 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.855 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -173.11 172.82 3.8 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.979 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 22.6 mmt85 -77.51 147.03 36.03 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.971 179.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 18.5 p -125.13 142.9 51.21 Favored 'General case' 0 CA--C 1.52 -0.181 0 N-CA-C 109.77 -0.456 . . . . 0.0 109.77 179.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . 0.925 ' CD1' HG21 ' A' ' 23' ' ' VAL . 75.6 m-85 -118.93 175.54 5.71 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.821 -179.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -153.47 120.51 5.74 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.553 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.671 HD11 HD12 ' A' ' 19' ' ' ILE . 75.1 mt -120.03 123.95 44.7 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.066 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -87.58 118.41 27.04 Favored 'General case' 0 CA--C 1.514 -0.442 0 C-N-CA 120.808 -0.357 . . . . 0.0 111.209 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 50.5 t -90.42 115.23 29.38 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 179.078 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -58.1 149.28 24.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.715 -179.261 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 70.9 tt0 63.85 -69.73 0.08 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.295 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 94.6 mt -99.82 100.79 11.78 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 110.43 -0.211 . . . . 0.0 110.43 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.55 ' O ' HG23 ' A' ' 129' ' ' THR . 72.4 m-70 -69.73 100.28 1.47 Allowed 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.437 -1.32 . . . . 0.0 107.437 178.161 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.55 HG23 ' O ' ' A' ' 128' ' ' HIS . 0.1 OUTLIER 164.15 144.37 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.558 HD23 ' H ' ' A' ' 130' ' ' LEU . 1.5 pt? -145.33 157.02 44.13 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.636 0.732 . . . . 0.0 112.011 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.709 HG11 HH21 ' A' ' 96' ' ' ARG . 8.9 p -92.35 120.56 41.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.089 -0.959 . . . . 0.0 108.832 178.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.604 ' HB1' ' CG2' ' A' ' 6' ' ' THR . . . -133.89 126.45 30.46 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 116.206 -0.452 . . . . 0.0 109.891 -179.261 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.633 ' HG3' HG23 ' A' ' 6' ' ' THR . 8.9 mt-10 59.86 45.33 12.64 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 121.222 0.534 . . . . 0.0 110.029 -179.475 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 69.41 -24.7 0.35 Allowed Glycine 0 CA--C 1.522 0.524 0 CA-C-N 115.489 -0.778 . . . . 0.0 111.28 178.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.533 ' H ' ' C ' ' A' ' 133' ' ' GLU . 10.3 t -90.25 151.21 3.53 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.145 0 O-C-N 122.485 -0.42 . . . . 0.0 110.68 -179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . . . . . . . . . 59.3 t -108.89 115.84 50.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.68 179.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 138' ' ' HIS . 20.9 m -147.28 136.67 16.34 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.302 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.434 -179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.557 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 17.9 t-80 -34.99 154.36 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 112.089 0.403 . . . . 0.0 112.089 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.5 p30 . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.277 -179.861 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . . . . . . . . . 69.6 mt -108.97 137.53 46.74 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.341 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -81.4 161.46 23.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.687 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -62.36 145.91 52.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.092 179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 108.56 -17.65 33.3 Favored Glycine 0 C--N 1.337 0.63 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' THR . . . . . 0.544 ' CG2' ' HB1' ' A' ' 132' ' ' ALA . 20.8 m -66.89 122.4 17.63 Favored 'General case' 0 CA--C 1.516 -0.336 0 C-N-CA 120.765 -0.374 . . . . 0.0 110.224 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -98.35 115.72 29.06 Favored 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 120.833 -0.347 . . . . 0.0 110.143 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 131' ' ' VAL . 3.6 mt -102.59 117.33 47.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.734 -179.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -75.84 133.23 40.66 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASP . . . . . 0.823 ' OD1' HG22 ' A' ' 13' ' ' THR . 4.1 t70 -104.0 134.93 19.45 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.526 -179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -76.52 -32.51 3.71 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 C-N-CA 122.512 2.142 . . . . 0.0 112.321 179.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 24.3 t -64.07 -59.6 4.02 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.24 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.417 -178.504 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.823 HG22 ' OD1' ' A' ' 10' ' ' ASP . 1.9 t -76.9 -34.21 57.74 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.97 12.84 76.11 Favored Glycine 0 N--CA 1.449 -0.45 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.648 ' H ' HG23 ' A' ' 13' ' ' THR . 75.5 m -116.94 161.6 19.1 Favored 'General case' 0 C--N 1.343 0.317 0 CA-C-N 117.977 0.888 . . . . 0.0 109.753 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' THR . . . . . 0.523 ' N ' HG22 ' A' ' 15' ' ' THR . 43.0 m -79.71 115.83 19.54 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.278 0.561 . . . . 0.0 110.713 -179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' HIS . . . . . 0.669 ' NE2' HG21 ' A' ' 13' ' ' THR . 24.8 m-70 -101.84 147.07 26.94 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.206 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.1 mtt180 -101.23 125.53 47.87 Favored 'General case' 0 CA--C 1.516 -0.358 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.004 178.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.512 HG23 ' N ' ' A' ' 20' ' ' GLU . 0.6 OUTLIER -53.46 -39.32 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.541 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.265 -179.234 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.512 ' N ' HG23 ' A' ' 19' ' ' ILE . 5.2 pt-20 -58.55 -33.72 70.23 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.792 179.914 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . 0.43 ' OD1' ' O ' ' A' ' 21' ' ' ASP . 68.4 t0 -83.97 -37.22 22.52 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.596 179.611 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 78.4 t -66.39 -42.74 91.02 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.601 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.27 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.447 HG22 HD21 ' A' ' 122' ' ' LEU . 75.9 t -69.51 -44.81 79.56 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 C-N-CA 121.093 -0.243 . . . . 0.0 111.428 -179.697 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -54.15 -36.32 63.19 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 121.036 -0.266 . . . . 0.0 110.761 -178.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.578 ' O ' ' C ' ' A' ' 26' ' ' ARG . . . -117.25 33.31 5.07 Favored Glycine 0 N--CA 1.462 0.375 0 N-CA-C 110.642 -0.983 . . . . 0.0 110.642 179.571 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ARG . . . . . 0.578 ' C ' ' O ' ' A' ' 25' ' ' GLY . 0.0 OUTLIER 12.42 74.95 0.01 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 124.056 0.504 . . . . 0.0 109.9 179.859 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LYS . . . . . 0.652 ' C ' ' H ' ' A' ' 29' ' ' ILE . 64.0 mttt -91.29 117.74 68.04 Favored Pre-proline 0 N--CA 1.442 -0.862 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 -178.201 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.68 ' O ' ' O ' ' A' ' 29' ' ' ILE . 52.5 Cg_exo -52.67 7.54 0.02 OUTLIER 'Trans proline' 0 N--CA 1.493 1.485 0 C-N-CA 122.964 2.442 . . . . 0.0 113.005 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.68 ' O ' ' O ' ' A' ' 28' ' ' PRO . 1.3 pp -37.05 -178.66 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 O-C-N 123.949 0.781 . . . . 0.0 110.722 -178.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' HIS . . . . . 0.506 ' O ' ' OD2' ' A' ' 10' ' ' ASP . 2.4 m80 -126.49 168.14 14.65 Favored 'General case' 0 C--N 1.321 -0.658 0 O-C-N 121.404 -0.81 . . . . 0.0 111.247 -179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 31.1 m -148.12 171.78 2.5 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.264 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 -179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 130' ' ' LEU . 62.9 t -88.11 131.11 36.53 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.641 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -109.07 149.72 28.86 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.055 -179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ALA . . . . . . . . . . . . . . . -119.69 140.79 50.1 Favored 'General case' 0 N--CA 1.464 0.243 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.933 179.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.485 ' HB3' ' OD1' ' A' ' 37' ' ' ASP . . . -113.69 174.31 5.99 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.006 -0.543 . . . . 0.0 109.771 179.867 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -68.42 -14.62 63.13 Favored 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.651 0.263 . . . . 0.0 110.648 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.485 ' OD1' ' HB3' ' A' ' 35' ' ' ALA . 38.4 p30 -81.79 -15.71 53.31 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.328 -0.396 . . . . 0.0 110.488 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.43 ' N ' ' OD1' ' A' ' 37' ' ' ASP . . . 87.04 22.64 44.45 Favored Glycine 0 C--N 1.335 0.507 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 -179.953 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.42 ' OG1' ' OD1' ' A' ' 37' ' ' ASP . 22.0 p -102.87 137.29 41.27 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-O 120.622 0.249 . . . . 0.0 111.108 178.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 74.7 mt -94.79 130.18 41.45 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.884 0.374 . . . . 0.0 110.47 179.544 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -141.48 138.7 33.01 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.404 -179.073 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.74 139.9 53.4 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.609 -178.806 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . . . . . . . . . 28.7 mmt-85 -143.38 137.97 15.1 Favored Pre-proline 0 CA--C 1.535 0.373 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.897 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -76.73 156.34 35.37 Favored 'Trans proline' 0 C--N 1.316 -1.177 0 C-N-CA 122.783 2.322 . . . . 0.0 112.969 -179.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.9 t -93.86 130.75 42.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.186 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 178.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.6 t -118.11 -5.02 11.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.527 -178.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' SER . . . . . . . . . . . . . 4.1 t -145.97 134.73 22.35 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.203 179.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' TRP . . . . . 0.557 ' N ' ' CD2' ' A' ' 48' ' ' TRP . 0.0 OUTLIER -134.02 116.28 15.32 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.359 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 0.514 ' O ' ' OD1' ' A' ' 121' ' ' ASP . 47.5 m-85 -140.94 150.71 43.48 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -179.063 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 47.6 t0 -93.54 133.16 37.13 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 176.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.694 HE21 ' CB ' ' A' ' 121' ' ' ASP . 26.1 mm-40 -92.17 -0.35 57.43 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.544 -0.298 . . . . 0.0 111.202 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . 84.5 179.73 51.48 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 111.148 -0.781 . . . . 0.0 111.148 179.555 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 32.0 m -91.41 123.07 34.55 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.239 -0.282 . . . . 0.0 110.239 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 17.9 mmt180 -143.79 169.97 16.76 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.915 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -76.99 142.71 39.83 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.971 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.7 m -147.15 157.59 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.113 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.629 HD11 ' HB1' ' A' ' 84' ' ' ALA . 45.9 pt -108.12 159.05 7.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.238 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -112.83 139.55 15.75 Favored Glycine 0 N--CA 1.464 0.545 0 N-CA-C 111.028 -0.829 . . . . 0.0 111.028 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 56.7 mt -118.53 112.04 19.39 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.148 0.499 . . . . 0.0 109.689 179.648 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.735 ' NE ' ' HE ' ' A' ' 109' ' ' ARG . 56.8 ttp180 -98.94 126.17 44.55 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.595 -0.729 . . . . 0.0 111.001 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.733 HD12 ' N ' ' A' ' 61' ' ' ILE . 2.2 mp -106.28 160.79 5.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.448 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.546 ' N ' HG22 ' A' ' 61' ' ' ILE . . . -34.84 92.85 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 O-C-N 123.303 0.377 . . . . 0.0 111.256 -179.482 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 61' ' ' ILE . . . 40.46 20.84 0.03 OUTLIER Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 -179.774 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.522 ' N ' ' O ' ' A' ' 62' ' ' ALA . . . -89.61 -149.1 20.59 Favored Glycine 0 N--CA 1.439 -1.15 0 N-CA-C 110.173 -1.171 . . . . 0.0 110.173 -179.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.17 169.21 16.05 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-N 115.069 -0.565 . . . . 0.0 110.556 -179.12 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ILE . . . . . . . . . . . . . 93.5 mt -120.89 135.55 60.73 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.397 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.222 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 38.7 tp -112.53 111.0 21.51 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.798 -179.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' TRP . . . . . 0.515 ' CE3' ' NH2' ' A' ' 115' ' ' ARG . 97.9 m95 -103.73 105.71 16.0 Favored 'General case' 0 N--CA 1.464 0.272 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -144.25 172.47 12.87 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.549 -179.059 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' THR . . . . . . . . . . . . . 1.1 p -72.76 156.24 90.11 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.759 -179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.419 ' O ' ' N ' ' A' ' 85' ' ' GLY . 31.4 Cg_endo -64.3 -19.36 65.59 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 C-N-CA 122.644 2.229 . . . . 0.0 111.866 179.228 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASP . . . . . . . . . . . . . 39.6 p-10 -90.99 -4.98 56.0 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.126 179.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' HIS . . . . . 0.534 ' NE2' ' O ' ' A' ' 138' ' ' HIS . 10.6 t60 -71.88 132.09 43.91 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -85.19 124.65 32.09 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-O 121.442 0.639 . . . . 0.0 111.386 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 69.8 t -99.03 143.01 13.95 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.159 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . . . . . . . . . 57.4 tp -82.83 89.87 6.86 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.699 -179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.473 ' C ' ' OH ' ' A' ' 105' ' ' TYR . 30.0 p -97.86 176.25 5.86 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -67.39 -20.03 65.49 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.117 -179.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' TYR . . . . . . . . . . . . . 62.2 m-85 -101.73 24.35 9.98 Favored 'General case' 0 CA--C 1.519 -0.225 0 CA-C-O 120.656 0.265 . . . . 0.0 110.825 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 97.09 -144.71 17.5 Favored Glycine 0 C--N 1.332 0.306 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . . . . . . . . . 82.0 m95 -86.88 121.88 29.97 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.732 0.301 . . . . 0.0 111.289 -179.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ARG . . . . . . . . . . . . . 14.7 mmt85 -122.56 125.8 46.45 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.089 179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ALA . . . . . . . . . . . . . . . -68.54 129.84 41.11 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.507 -179.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.629 ' HB1' HD11 ' A' ' 57' ' ' ILE . . . -66.83 -0.03 2.75 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.799 179.85 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 71' ' ' PRO . . . -75.55 -13.13 83.22 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -136.97 30.84 2.74 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.914 0.387 . . . . 0.0 111.378 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LEU . . . . . 0.455 HD12 ' HA ' ' A' ' 84' ' ' ALA . 10.9 mt -82.88 131.81 35.18 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 121.403 0.62 . . . . 0.0 111.007 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 83.2 mmt-85 -133.62 148.38 51.55 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.082 -0.963 . . . . 0.0 111.346 179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -46.37 97.92 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.547 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 158.48 -16.52 0.28 Allowed Glycine 0 CA--C 1.525 0.677 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 31.7 t0 -88.29 129.91 35.25 Favored 'General case' 0 C--N 1.328 -0.336 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 94.6 mtt180 -88.57 129.74 35.41 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.36 -178.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 32.9 m -108.9 141.86 23.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.046 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . 0.465 ' HB1' HD21 ' A' ' 103' ' ' LEU . . . -72.08 120.71 18.06 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.722 -179.167 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' VAL . . . . . 0.406 ' O ' HG23 ' A' ' 95' ' ' VAL . 33.2 m -121.85 131.28 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.945 0.402 . . . . 0.0 110.07 179.09 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 69.9 ttp85 -67.73 132.05 46.72 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.848 -179.413 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 48.7 t0 -101.77 122.9 44.81 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 119.297 -0.382 . . . . 0.0 110.443 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 10.5 p -75.22 -16.87 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.359 0 CA-C-N 118.427 0.558 . . . . 0.0 111.323 179.101 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.75 -58.49 3.59 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.436 -179.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . 0.439 ' C ' ' H ' ' A' ' 102' ' ' GLU . 48.8 p -98.58 -14.89 19.72 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.456 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 76.37 -17.22 4.26 Favored Glycine 0 CA--C 1.52 0.405 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.439 ' H ' ' C ' ' A' ' 100' ' ' THR . 96.4 mt-10 -78.38 157.75 28.97 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 120.865 0.364 . . . . 0.0 110.91 -177.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.494 HD11 HG21 ' A' ' 136' ' ' VAL . 2.1 tp -75.06 135.18 41.24 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.314 -179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 32.5 ptt180 -135.04 167.46 20.91 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.216 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.473 ' OH ' ' C ' ' A' ' 77' ' ' THR . 5.0 m-85 -117.12 152.83 33.9 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.029 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' SER . . . . . . . . . . . . . 18.1 m -146.2 165.21 29.85 Favored 'General case' 0 CA--C 1.516 -0.348 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 18.8 t -89.2 150.37 3.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.257 0 CA-C-O 120.775 0.321 . . . . 0.0 110.769 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ILE . . . . . 0.491 ' CG2' ' N ' ' A' ' 109' ' ' ARG . 3.2 mm -69.83 160.75 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.211 179.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.735 ' HE ' ' NE ' ' A' ' 60' ' ' ARG . 12.6 ttp85 -107.67 -49.32 3.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.533 179.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLU . . . . . 0.527 ' OE1' ' NH2' ' A' ' 60' ' ' ARG . 74.8 tt0 -166.78 146.66 5.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.473 ' C ' HD22 ' A' ' 112' ' ' LEU . 1.0 OUTLIER -94.09 134.58 31.18 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.238 0.542 . . . . 0.0 110.019 179.688 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.521 ' N ' ' CD2' ' A' ' 112' ' ' LEU . 3.0 mm? -97.86 145.48 29.82 Favored Pre-proline 0 C--N 1.331 -0.227 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.157 -179.208 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.47 160.18 50.78 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 122.568 2.179 . . . . 0.0 111.468 179.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 81.7 p -64.88 154.12 38.22 Favored 'General case' 0 N--CA 1.45 -0.468 0 CA-C-O 121.146 0.498 . . . . 0.0 110.655 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.515 ' NH2' ' CE3' ' A' ' 68' ' ' TRP . 74.4 mtm180 -140.95 -138.82 0.12 Allowed 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.657 -179.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 95.2 mtm-85 -155.58 132.01 10.31 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.236 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ALA . . . . . . . . . . . . . . . -171.13 173.03 5.15 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.764 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -77.77 140.24 39.43 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.779 179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' THR . . . . . . . . . . . . . 3.1 p -114.98 140.46 49.01 Favored 'General case' 0 CA--C 1.522 -0.117 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' PHE . . . . . . . . . . . . . 58.9 m-85 -119.59 171.59 8.26 Favored 'General case' 0 CA--C 1.514 -0.411 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.24 -179.197 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.694 ' CB ' HE21 ' A' ' 51' ' ' GLN . 43.6 p-10 -160.72 120.31 2.71 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 115.559 -0.746 . . . . 0.0 111.089 179.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.447 HD21 HG22 ' A' ' 23' ' ' VAL . 69.9 mt -117.38 131.67 56.73 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 120.72 0.295 . . . . 0.0 110.63 179.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -87.71 110.18 20.25 Favored 'General case' 0 CA--C 1.517 -0.3 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 -179.391 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.568 ' O ' ' N ' ' A' ' 126' ' ' GLU . 21.6 t -81.04 109.49 15.46 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.467 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.074 179.796 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.488 ' C ' ' O ' ' A' ' 124' ' ' VAL . 1.6 tm-20 24.14 -85.53 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 123.815 0.697 . . . . 0.0 111.435 179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . 0.568 ' N ' ' O ' ' A' ' 124' ' ' VAL . 79.8 tt0 -136.87 -36.44 0.68 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.157 -0.928 . . . . 0.0 111.141 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.481 ' O ' ' N ' ' A' ' 129' ' ' THR . 74.0 mt -72.4 67.69 0.74 Allowed 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 109.973 -0.38 . . . . 0.0 109.973 -179.019 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' HIS . . . . . 0.58 ' O ' HG23 ' A' ' 129' ' ' THR . 35.4 m80 -40.82 95.92 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.823 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.631 ' C ' HD21 ' A' ' 139' ' ' ASN . 0.0 OUTLIER 166.5 136.36 0.01 OUTLIER 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.611 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.685 ' C ' HD12 ' A' ' 130' ' ' LEU . 3.5 pp -144.99 154.37 42.47 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.449 0.642 . . . . 0.0 111.679 -178.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' VAL . . . . . 0.478 ' O ' HG23 ' A' ' 8' ' ' ILE . 97.2 t -87.81 123.99 40.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ALA . . . . . 0.603 ' HB2' HD11 ' A' ' 130' ' ' LEU . . . -133.51 142.22 48.13 Favored 'General case' 0 C--O 1.227 -0.106 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.444 -178.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.581 ' O ' HG23 ' A' ' 135' ' ' VAL . 71.1 mm-40 40.23 49.79 2.52 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.196 179.76 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 68.45 -25.32 0.27 Allowed Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.446 -0.662 . . . . 0.0 111.446 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 133' ' ' GLU . 2.7 t -89.12 152.24 3.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.394 0 O-C-N 122.48 -0.423 . . . . 0.0 110.689 -179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' VAL . . . . . 0.494 HG21 HD11 ' A' ' 103' ' ' LEU . 2.7 t -109.87 117.64 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.437 179.643 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' VAL . . . . . 0.451 ' O ' ' O ' ' A' ' 138' ' ' HIS . 20.5 m -149.87 141.01 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.531 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.492 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' HIS . . . . . 0.534 ' O ' ' NE2' ' A' ' 73' ' ' HIS . 54.3 t-80 -31.42 150.31 0.01 OUTLIER 'General case' 0 N--CA 1.462 0.173 0 O-C-N 123.209 0.318 . . . . 0.0 111.741 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.631 HD21 ' C ' ' A' ' 129' ' ' THR . 1.5 m120 . . . . . 0 N--CA 1.444 -0.733 0 CA-C-O 118.056 -0.973 . . . . 0.0 110.628 -179.467 . . . . . . . . 1 1 . 1 stop_ save_